<SEC-DOCUMENT>0001804220-23-000016.txt : 20230504
<SEC-HEADER>0001804220-23-000016.hdr.sgml : 20230504
<ACCEPTANCE-DATETIME>20230504071454
ACCESSION NUMBER:		0001804220-23-000016
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		70
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230504
DATE AS OF CHANGE:		20230504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REGENERON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000872589
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133444607
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19034
		FILM NUMBER:		23886439

	BUSINESS ADDRESS:	
		STREET 1:		777 OLD SAW MILL RIVER ROAD
		CITY:			TARRYTOWN
		STATE:			NY
		ZIP:			10591
		BUSINESS PHONE:		9148477000

	MAIL ADDRESS:	
		STREET 1:		777 OLD SAW MILL RIVER ROAD
		CITY:			TARRYTOWN
		STATE:			NY
		ZIP:			10591

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	REGENERON PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>regn-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:22cd9e9c-8c6e-43d9-ac99-edd9ddfa2dcd,g:8ddcabf6-ffb8-41b1-9a90-14e4490a05f1,d:d4c1ef3770fb4cfcadf88c3685e610eb--><html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:regn="http://www.regeneron.com/20230331" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>regn-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80L2ZyYWc6MWU4NTg5MjY0MTA5NGIxMTljM2JhZDg3YTdmYmI3OGMvdGFibGU6MTU4YmMzM2U2MzBhNDBmZjhjZTNjZjI3NGEzMzEwMzEvdGFibGVyYW5nZToxNThiYzMzZTYzMGE0MGZmOGNlM2NmMjc0YTMzMTAzMV80LTEtMS0xLTIyMTU2OA_006f4281-06c6-4fb7-a611-8728e5f3faac">0000872589</ix:nonNumeric><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80L2ZyYWc6MWU4NTg5MjY0MTA5NGIxMTljM2JhZDg3YTdmYmI3OGMvdGFibGU6MTU4YmMzM2U2MzBhNDBmZjhjZTNjZjI3NGEzMzEwMzEvdGFibGVyYW5nZToxNThiYzMzZTYzMGE0MGZmOGNlM2NmMjc0YTMzMTAzMV81LTEtMS0xLTIyMTU2OA_8fb17fa8-eeb0-4dd4-a404-7d1b00b33ffa">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80L2ZyYWc6MWU4NTg5MjY0MTA5NGIxMTljM2JhZDg3YTdmYmI3OGMvdGFibGU6MTU4YmMzM2U2MzBhNDBmZjhjZTNjZjI3NGEzMzEwMzEvdGFibGVyYW5nZToxNThiYzMzZTYzMGE0MGZmOGNlM2NmMjc0YTMzMTAzMV85LTEtMS0xLTIyMTU2OA_4c71bfbb-1aab-4a68-99c1-502d204630b2">2023</ix:nonNumeric><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80L2ZyYWc6MWU4NTg5MjY0MTA5NGIxMTljM2JhZDg3YTdmYmI3OGMvdGFibGU6MTU4YmMzM2U2MzBhNDBmZjhjZTNjZjI3NGEzMzEwMzEvdGFibGVyYW5nZToxNThiYzMzZTYzMGE0MGZmOGNlM2NmMjc0YTMzMTAzMV8xMC0xLTEtMS0yMjE1Njg_b8e4e60c-6af9-4042-9fbc-606ee3d2b561">Q1</ix:nonNumeric><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80L2ZyYWc6MWU4NTg5MjY0MTA5NGIxMTljM2JhZDg3YTdmYmI3OGMvdGFibGU6MTU4YmMzM2U2MzBhNDBmZjhjZTNjZjI3NGEzMzEwMzEvdGFibGVyYW5nZToxNThiYzMzZTYzMGE0MGZmOGNlM2NmMjc0YTMzMTAzMV8xMS0xLTEtMS0yMjE1Njg_5904549f-ec4f-432b-9e5f-cb1eb00ca8f9">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="regn-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52501e7fdeda4b63b53fa2c38deee3ba_I20230411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i95399a66c34747c7ae8a30809bebb551_I20230411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ia687c58bde834c42ab9a8d978528b6c1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i6b8134b6a41640a59debc09f522f7159_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic62e60ebc7424784abaf7166a92b5115_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad84cd28f95b42f29a3715741068591b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b7c4d8560fb43119f17d189a9cc1ec6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89d2806ddfda4899b23a4e2a27b639ee_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cd61146d31845f7aa0a400c1de8c9af_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e96d85f6116487bb808133461cb06a1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i322b8ce5df5b4c60ad8cc95df009f249_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i375b286d61df4bd4851e798baea9fbed_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7d1404e1f794d79bf92b04d446901cf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e0ca86da19f48e88d9bf110de7b69c2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bf386a54cb94d3693610866086baa33_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if30714371f9e46528af3d8f6681b15c7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee31f7d64fe049c7a439d288ec9486d5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f33b378dd044be2997a03a26a5d3b48_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i464958bff30b4da893895a523da36762_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fa0f967adc9439caf372e79f15e9e65_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica431963a44548bd8c3c65e67df71293_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5c88fce876d4566b4cbbac88f11de2b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i015fc10968404f9596294e54195211db_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i185b612165b347b2b4aa073de182131b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5afdea61952c4451a233ed8c133cf438_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfb86f8ed7f34a63aa1ea7aa30866925_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ccec8fe40c04d699a63e2967214f0b4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcec73dff80346e1895f9d7262e1ea33_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e41e273a91b4f7080ff818a13fe99be_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icef282f2e36944018a2590dcf58321d6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46042c6680c54f40880fde0d8f818288_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib287cdc989b242ed899986d4cbe3af11_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic23d397894814b2486b54d92fc4b1a6d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97aac951375a4b61997b83f703090509_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a88badb1d6e4841ab079e4f443a7e4c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38ccce571fef4b90bc060bfc54280e73_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcb31e106e34471ea566f05963a75c5e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80bf6dc29204481a9c4efae367ed366e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6c18de361b24fb9a6ed97dcb156b4ac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6b622c0a75c4abf85767c76eeb3eb23_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12fb29cdd4ea4b8b919c34781498d6c1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bfc42c5e2314ceda9b705bf6f75c36e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64fe108807dd4be4af7e9ea5f30001e4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5bc7a6419f1432ca3b84fea5414f7a3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i936952c9103a4c52811822936c6feffb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i763f240b37e34f9e97c13b9647d2763e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7292cbbd4824b5b8b48cd9b81256747_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39ca18ca3a794b3c9cc3567ecaf855ed_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide8d66252aa645be98653f0b578cbb44_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia23f7613df634004b007e3599b0e97f9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7298587e584844a686de7edf412eb7a2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c137cb80c2348b6b72faccb7cba8e93_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EyleaNetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb40dc2b4e6d4ddc9267422ed2896f2b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EyleaNetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d3ca332ac7b44e7afd08a842efc7831_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1493138d25f94132897d582fa5633635_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i539fd4a3ebc04eee85f11898f58b8e50_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">regn:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d4c5cb7b7d440c39db96ce2e6fcdf63_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">regn:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97633ca31aaf4a5494aff1cd47af72b6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:PraluentNetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6180931ab3794a16a3d092c67267848f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:PraluentNetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i170bf04d3efb4e2ba2dbc70f34869ad4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EvkeezaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7a13e46bf874e5d863afd595bc4af6a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EvkeezaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ee16d3d639e46f8a41fb5fef9f9301a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:InmazebMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0510a432e77041dca5a54640cff8ad6f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:InmazebMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8a607a3e56c41779c0e4d7f40f3276c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddde8724f2d94806b024d0d0b38bb09c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66be2d5d13e14c65a79a0cd9a1fdba09_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:BesseMedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="iffa15815bae94096ae1f51c8a0ecfdf8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:BesseMedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1c2ae76df8543b98e4b8e032206851d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:McKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5edea8b3603449e90ce4d1565b6ee02_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:McKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2f2c59d2425478cb9a759cbb016a8e3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3e3b5297b2d4da18d1e8bf81c32ed78_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a2817fbcc324c0dace63bfa58aa3472_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SalesBasedMilestoneEarnedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i496ebaf3b22440b2b2d69aab06cd1a36_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SalesBasedMilestoneEarnedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cadf695465b4d2c823616dee5674384_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea1238f837994a0a8d152d9ed98974c4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied6deae52c5a4fddbad0b5bb2c2d457d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic09e4f946d7f4b20bff8285f40f649f9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id88f78210881451481543b0e7df5322b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83fd3849cf8b49c990d30ebab1b52082_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9bce6102ed54468900a9f32c759ef8c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied033f1452834cc0b77499b012220842_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d4d7003a52c48d286f50a758bf9d9fb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfExCommercialSuppliesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id312ecfecca44b6cad64d0a4dead7154_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfExCommercialSuppliesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b748b8781634cf7bad7b7c57fea08bc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifeba37fd20ba4aa5aa90737cd4da0556_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie398e6bd3f1649b1b129db816c08a863_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba78c9e3c2b14c9f8c6d4c4c6903cefe_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b3cda38a64e4813ba22059700b5a833_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfCommercialExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13a2eb4e3a324853b0f3388887ed2b2c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfCommercialExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf4bf1050794419cbf96df94e7e5a822_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CostOfGoodsSoldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofisShareofLibtayoU.S.GrossProfitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fd3f28a70a64843aab800c66e3727dd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CostOfGoodsSoldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofisShareofLibtayoU.S.GrossProfitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cfd4128aea7458a926f5ef7dc7d8228_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1807e85b9a734966b305aebfce1a2b3e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93a73ef5b43a4b719c774ecb420922ef_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa0640ad68f44c88a2dbc0ebca2b3b73_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76483ad7f52e40cab4a22bb58eb53286_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38436edb47124f8fb19121d45a1874e7_D20220630-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4de45f3331e49d0bc3791fd059ee5a4_D20220701-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd392818c90b43539fc9c9768bb1ca18_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:MilestoneTypeAxis">regn:SalesMilestoneThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd80951ec63945c1a0f004821f556950_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="regn:MilestoneTypeAxis">regn:SalesMilestoneFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78bee0b457e64f8ca4716924e360fafb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="regn:MilestoneTypeAxis">regn:SalesMilestoneFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50cbbeeb8ba0490fb582afb27330f7db_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaea9b652c53d4a4c82b1a7b4ea756d8c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia67b58013e1b4eb9829600ae26b049f1_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib05c9a4e748542a39f0ded000f62b58a_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:MilestoneTypeAxis">regn:RegulatoryMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i157885e3534940e6bbf0c1712c537758_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:MilestoneTypeAxis">regn:SalesBasedMilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51a33fff830d49e2836b1dcc69fd8e6d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:MilestoneTypeAxis">regn:SalesBasedMilestoneTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfc4183c9b684d69800dbe32f7df3f9c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="regn:MilestoneTypeAxis">regn:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28142adb16bf44cd9637c180668c9386_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb424b76bb944bb487058cb7b71b5478_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:NetProfitInConnectionWithCommercializationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba893ed59b6f4ef9b1de82284a9c172b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:NetProfitInConnectionWithCommercializationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0252272660b2483c9bdc58226cbd09da_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idde62877d41141df8937d3435f4c3667_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf1d66b82008486885a981ea123058f2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:OneTimePaymentInConnectionWithChangeInJapanArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia020696b0d3c4162aea4b7989e504a75_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:OneTimePaymentInConnectionWithChangeInJapanArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a5fff795cfe4c74b86bc4bd5174db81_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:ResearchAndDevelopmentExpensesAndReductionOfResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsObligationOfResearchAndDevelopmentExpensesNetOfReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie08517bc56f64a56855dedc1fd282413_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:ResearchAndDevelopmentExpensesAndReductionOfResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsObligationOfResearchAndDevelopmentExpensesNetOfReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9e294aebc65480da80f32f7028adbb2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i102f804ba9484132ae7196bde6f74767_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64841568e706401985fc84aa04b36f1e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RonapreveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29f6f63a87914141b95f4f2c48ff1364_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RonapreveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38fd75f0c02644a59d387c1d665dac3e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e796f5592204aff856a0effed5d30f5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c9892adbc9444b2ba40d227075a443b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:SonomaBiotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6c0a3e1eb3f4fa4b60c33bacffd2f52_D20230401-20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SonomaBiotherapeuticsIncCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3456908093f4728b4a4f17cb0d3cd19_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="regn:MilestoneTypeAxis">regn:DevelopmentMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:SonomaBiotherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SonomaBiotherapeuticsIncCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b0f6d873f2441d7890447099c7468ad_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i899f0e7929c744418d1f315d17e1594a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i084af335d0d14bb79b9fc2db8159a242_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2be78b3922ff4f9196bd6708075600e8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aef696237bd4fa2bb67d81627a03291_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic57e069f15ea4d1eb588c09adef593ba_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8903a1b5844542cfbc9e394aa701aed8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdb936c554134642a68368b066e9f82a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdb70d5f062d4e928b605b2f2599a47d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9bf0ce9cab24153b67d76ba77f2f319_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i418c3363911e44aba24f1ae219890db8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab279394f6cf43de9deae81fa065d878_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf94038a80c74b0d9edbcbeccb24dde9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8a4bb9880684a74adbfbf4815ad715c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a32793eceeb4ea687e38aa30fc6de37_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31e5c62bbe8047b78e6c3041593ef2fe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d7998c008a645b497664f16dfdf9c3e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i076e28d6501548bba1781c8d95c229c1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42bb7405dae2448892d28fe5254d753b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69a16600ec214325aa04a3be1bcacc1a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccd0b582761d43a79ac5b665419222c1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ed1181d127f48eeae6cc93827001b60_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d138ebcdd8d4f6f9da1861a1980e8fe_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a4637e5ee1a4615bd9757cfde09d5ed_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib78b4e7f93bf4cb2b480289b8085219d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2861028cb0f04545abad3da8e9947ae3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d31ef08646d47068b930b62221f25c5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bb4ac30d7174141bd68e0e5165503a4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27a37895006f481b99b894294d32f453_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45e1a224580a4ab4a851ce1cd380e58b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic48dc13ed46549c38aa86d1646750b7e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc9d4a9ec68c46a2a1444ba0c21c58d1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2532a7ae6c44f0183a1a72036a1dbd2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2c1cf62b52f4290802d97ca8e3f7314_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07b68bd2a55e4e4e98087d12385f43b6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i924a1104d72e45899f48ce68164557a6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6c8f015a8c6464c939619f06315efe8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i319e916558384549ac07e82dc579d15f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i407aae8d570145af8c0266b54d98beec_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50f8bc3a2ad94180966f9ebe0be125f0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb363b73e6244abcb656ed2ab62f8f78_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i923780b5c4714bd0b32f8a52e41383bd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b2c64ec3f6040309efed4a34a2e340c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e1656e9d1074b078faaced1a79a540d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96714fa1a4ef4fbea15e01d83966c0d7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd6e5891198641dc82ba047fab579cec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i906a5a8877744181bffbf220eeea0a73_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaba3655e9756414b9e6fd04ad3ee2f24_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25b7eaabac2f458b96618bac777bd2ca_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0fce717fc9443019cee095389f2baf5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c5fb90e07b84a9a87b35eaaf73fad05_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc7e444572ae46a385283f8406b98c84_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0392b26a3fbc4c43a64deca654005f83_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a3f2f6efec84786af7fd186d6c5c4c9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if32b8d821f0642acafbc9612834c9293_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b5bb5d7a78a4a57b46ccf314f728939_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b9fc3319f5841518dd67e46c582c888_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdc9ce269439490ab1af63a29b885fa0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia11171f0e5db4eed91923c0534566b26_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d989b03e30442ce8a9b3481c7124765_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2536f989b03944a4b9a0d7e8f56ea080_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85985f6f1c3c4f01b858acc29e09e5ca_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1da2e40825b44fd59ead3dde06e37600_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i442be721ac15405da1349485e18c28ac_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2bcc6312921492999cec875c39d9b73_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c67c7b931244e59af10a080716aafec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f2bd6363aa141e7a2a47119609b54b9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4849fbe85bf94052b4be3ec967ec493f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib961b996c000420b839a622c158db724_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a829313946c4d029d2545a0b99636f6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57cc71aadf054c0aa6efa5f790dfbd1e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i551685f126c4400481a7132a780426b0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c8af3a2f8cb4400af2f7e31cff2cfb3_I20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramNovember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e3a527460f44b9181602c95f95e6612_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramJanuary2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffc0c76d2e7c4dffaaaad5977285af04_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64798e076fa64db2b5de1538f7e77d5f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d8a843a06e446c69b2ab4242c134351_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EYLEAAfliberceptInjectionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A226PatentAnd992PatentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="request"><xbrli:measure>regn:request</xbrli:measure></xbrli:unit><xbrli:context id="i1194a9d0d6454fd98015eb8688e54523_I20211209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A338PatentAnd069PatentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:CelltrionIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>regn:claim</xbrli:measure></xbrli:unit><xbrli:context id="ice77d20fb98c4a08910e2616a45f1fbd_I20211209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:ApotexIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A338PatentAnd069PatentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b0615f9b30640a6aff828894aee0920_I20200716"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A631PatentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-16</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_1"></div><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGV4dHJlZ2lvbjoyNzI0ZjBiZmVhYTM0ZDQzODQ4NDU3MTlmNjY3ZDY3Ml80MjE_3e4f8a7f-8242-4f52-9014-0e1651241925">10-Q</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:1.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Mark One)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6NzdiZTk2NDU4MjJmNGY1YTg5MGEzZWY1YWU0OTUyY2MvdGFibGVyYW5nZTo3N2JlOTY0NTgyMmY0ZjVhODkwYTNlZjVhZTQ5NTJjY18xLTAtMS0xLTIyMTU2OA_d0c3f146-20a9-4edd-adc9-0f1289a28c19">&#9746;</ix:nonNumeric></span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">For the quarterly period ended <ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6NzdiZTk2NDU4MjJmNGY1YTg5MGEzZWY1YWU0OTUyY2MvdGFibGVyYW5nZTo3N2JlOTY0NTgyMmY0ZjVhODkwYTNlZjVhZTQ5NTJjY18yLTEtMS0xLTIyMTU2OC90ZXh0cmVnaW9uOmZiYzM5MWM3ZDdmZTQwODA4MjliMjA3NjYwNTBiMzRhXzM1_9ee2ebe6-3874-4354-b1ba-350c61adcdeb">March 31, 2023</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">OR</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6NzdiZTk2NDU4MjJmNGY1YTg5MGEzZWY1YWU0OTUyY2MvdGFibGVyYW5nZTo3N2JlOTY0NTgyMmY0ZjVhODkwYTNlZjVhZTQ5NTJjY180LTAtMS0xLTIyMTU2OA_fa7851fd-8659-4522-84bd-013fba9e9bde">&#9744;</ix:nonNumeric></span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">For the transition period from __________ to __________</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.725%"><tr><td style="width:1.0%"></td><td style="width:28.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.776%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commission File Number: <ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6MGY3YzVkN2RkYjZlNDMyYmEyYTQ1NTBjMmNkMDE5YWUvdGFibGVyYW5nZTowZjdjNWQ3ZGRiNmU0MzJiYTJhNDU1MGMyY2QwMTlhZV8wLTEtMS0xLTIyMTU2OC90ZXh0cmVnaW9uOjk2ZDUzZWFhY2MwMTQzYzQ5Zjc0NjY4MTYzYjc3NDAzXzI5_3e6a7380-1daa-40ec-b998-7fffbe691ccf">000-19034</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGV4dHJlZ2lvbjoyNzI0ZjBiZmVhYTM0ZDQzODQ4NDU3MTlmNjY3ZDY3Ml80MjI_453202d6-28b2-4915-8827-4bdbfdd75daf">REGENERON PHARMACEUTICALS, INC.</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6OGI0Y2M4OGEyMzNmNDM1Nzk4ZTIyNzI1NGJlNWYyMDUvdGFibGVyYW5nZTo4YjRjYzg4YTIzM2Y0MzU3OThlMjI3MjU0YmU1ZjIwNV8wLTAtMS0xLTIyMTU2OA_ff236772-933e-4c88-88fa-3adc5b8b047d">New York</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6OGI0Y2M4OGEyMzNmNDM1Nzk4ZTIyNzI1NGJlNWYyMDUvdGFibGVyYW5nZTo4YjRjYzg4YTIzM2Y0MzU3OThlMjI3MjU0YmU1ZjIwNV8wLTItMS0xLTIyMTU2OA_5df7b15d-da11-4d8d-ad16-4a62580eeb27">13-3444607</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.479%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6ZjU4MmVkYzkzZjFkNDAwNmFmMzk2MzdhMmE1M2Q4ZWYvdGFibGVyYW5nZTpmNTgyZWRjOTNmMWQ0MDA2YWYzOTYzN2EyYTUzZDhlZl8wLTAtMS0xLTIyMTU2OC90ZXh0cmVnaW9uOjc3NGViZjAzYjczZDRlMzRhM2Q2NDlhNjczM2IwMTBkXzQ_2cd2660f-cdeb-438a-89f7-9f3c259c6dc2">777 Old Saw Mill River Road</ix:nonNumeric>, <ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6ZjU4MmVkYzkzZjFkNDAwNmFmMzk2MzdhMmE1M2Q4ZWYvdGFibGVyYW5nZTpmNTgyZWRjOTNmMWQ0MDA2YWYzOTYzN2EyYTUzZDhlZl8wLTAtMS0xLTIyMTU2OC90ZXh0cmVnaW9uOjc3NGViZjAzYjczZDRlMzRhM2Q2NDlhNjczM2IwMTBkXzg_2f013d3e-a063-4d76-8eb2-f7fcebe1041a">Tarrytown</ix:nonNumeric>, <ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6ZjU4MmVkYzkzZjFkNDAwNmFmMzk2MzdhMmE1M2Q4ZWYvdGFibGVyYW5nZTpmNTgyZWRjOTNmMWQ0MDA2YWYzOTYzN2EyYTUzZDhlZl8wLTAtMS0xLTIyMTU2OC90ZXh0cmVnaW9uOjc3NGViZjAzYjczZDRlMzRhM2Q2NDlhNjczM2IwMTBkXzEy_78345745-bd6c-47c0-9d99-8db4da2ac9a1">New York</ix:nonNumeric> <ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6ZjU4MmVkYzkzZjFkNDAwNmFmMzk2MzdhMmE1M2Q4ZWYvdGFibGVyYW5nZTpmNTgyZWRjOTNmMWQ0MDA2YWYzOTYzN2EyYTUzZDhlZl8wLTAtMS0xLTIyMTU2OC90ZXh0cmVnaW9uOjc3NGViZjAzYjczZDRlMzRhM2Q2NDlhNjczM2IwMTBkXzE1_e3ac042a-ab0d-4e40-ac67-d72facdef692">10591-6707</ix:nonNumeric></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Address of principal executive offices, including zip code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGV4dHJlZ2lvbjoyNzI0ZjBiZmVhYTM0ZDQzODQ4NDU3MTlmNjY3ZDY3Ml80MjM_9ba0c02b-58db-49e6-91ec-f0fd274f075c">914</ix:nonNumeric>) <ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGV4dHJlZ2lvbjoyNzI0ZjBiZmVhYTM0ZDQzODQ4NDU3MTlmNjY3ZDY3Ml80MjQ_ac4f15a6-aee4-4ea6-a211-4a55f22ab0a2">847-7000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Registrant's telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.619%"><tr><td style="width:1.0%"></td><td style="width:41.314%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.071%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.315%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6YjgzNTRiNzBjNTAxNDc0ZThmMmIyODIwYmFkYWYwNGUvdGFibGVyYW5nZTpiODM1NGI3MGM1MDE0NzRlOGYyYjI4MjBiYWRhZjA0ZV8xLTAtMS0xLTIyMTU2OA_4d4538b7-f514-49dd-855a-9cbf81e3b7e8">Common Stock - par value $.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6YjgzNTRiNzBjNTAxNDc0ZThmMmIyODIwYmFkYWYwNGUvdGFibGVyYW5nZTpiODM1NGI3MGM1MDE0NzRlOGYyYjI4MjBiYWRhZjA0ZV8xLTEtMS0xLTIyMTU2OA_cea02312-3c88-4610-bb81-53fa39d261bf">REGN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6YjgzNTRiNzBjNTAxNDc0ZThmMmIyODIwYmFkYWYwNGUvdGFibGVyYW5nZTpiODM1NGI3MGM1MDE0NzRlOGYyYjI4MjBiYWRhZjA0ZV8xLTItMS0xLTIyMTU2OA_9e514baa-2c25-4fc1-bd34-7bc10bc3826c">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:87.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6MjlkODJlYzdlODNiNDAxZDg5NThkYmE1ZWJhNzg1ZTEvdGFibGVyYW5nZToyOWQ4MmVjN2U4M2I0MDFkODk1OGRiYTVlYmE3ODVlMV8wLTEtMS0xLTIyMTU2OA_758940c9-be8a-42de-bfd8-b182694cbd5b">Yes</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6MjlkODJlYzdlODNiNDAxZDg5NThkYmE1ZWJhNzg1ZTEvdGFibGVyYW5nZToyOWQ4MmVjN2U4M2I0MDFkODk1OGRiYTVlYmE3ODVlMV8yLTEtMS0xLTIyMTU2OA_6d3f36c1-1e2a-4f2c-92e8-054f896f100d">Yes</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"><tr><td style="width:1.0%"></td><td style="width:13.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6ZTU0ZjAwYmZhZWU0NGIwMzkzMTJkY2ViOTEzZjBiMGIvdGFibGVyYW5nZTplNTRmMDBiZmFlZTQ0YjAzOTMxMmRjZWI5MTNmMGIwYl8wLTAtMS0xLTIyMTU2OA_cf0819cc-38bd-4c43-a21f-ea76c274cf3f">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6ZTU0ZjAwYmZhZWU0NGIwMzkzMTJkY2ViOTEzZjBiMGIvdGFibGVyYW5nZTplNTRmMDBiZmFlZTQ0YjAzOTMxMmRjZWI5MTNmMGIwYl8wLTEwLTEtMS0yMjE1Njg_136b47ea-4b60-44c2-baca-8ce1df8da497">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6ZTU0ZjAwYmZhZWU0NGIwMzkzMTJkY2ViOTEzZjBiMGIvdGFibGVyYW5nZTplNTRmMDBiZmFlZTQ0YjAzOTMxMmRjZWI5MTNmMGIwYl8wLTEzLTEtMS0yMjE1Njg_21e6de52-33a3-4f78-8ba8-d8ec468775c2">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:86.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.379%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6YTFmNGVkYWQzZmNkNDY3M2E3YmMxYjIyNmI2YWY2NWEvdGFibGVyYW5nZTphMWY0ZWRhZDNmY2Q0NjczYTdiYzFiMjI2YjZhZjY1YV8yLTQtMS0xLTIyMTU2OA_118c78f3-d3a6-4228-abbd-037f22499493">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="text-align:justify;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares outstanding of each of the registrant's classes of common stock as of April&#160;11, 2023:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.526%"><tr><td style="width:1.0%"></td><td style="width:47.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.002%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Class of Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of Shares</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Class A Stock, $.001 par value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52501e7fdeda4b63b53fa2c38deee3ba_I20230411" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6ZWRlYzUwYjMzZDY2NGYxYWEyNTlhYjFlNzY1NzhkMmYvdGFibGVyYW5nZTplZGVjNTBiMzNkNjY0ZjFhYTI1OWFiMWU3NjU3OGQyZl8xLTItMS0xLTIyMTU2OA_e6b41b46-5a33-4551-a1de-53fb4e651bd0">1,818,146</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Stock, $.001 par value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i95399a66c34747c7ae8a30809bebb551_I20230411" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6ZWRlYzUwYjMzZDY2NGYxYWEyNTlhYjFlNzY1NzhkMmYvdGFibGVyYW5nZTplZGVjNTBiMzNkNjY0ZjFhYTI1OWFiMWU3NjU3OGQyZl8yLTItMS0xLTIyMTU2OA_941415e6-e901-4079-bcc6-3c08b5735b17">107,892,108</ix:nonFraction></span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT ON FORM 10-Q</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.888%"><tr><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.998%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.198%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page Numbers</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_10">PART I</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_10">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_13">Item 1.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_13">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_13">2</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_16">Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_16">2</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_19">Condensed Consolidated Statements of Operations and Comprehensive Income for the Three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_19">Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_19">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_19"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_19">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_19">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_19">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_19"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_19">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_19">2</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_19">3</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_22">Condensed Consolidated Statements of Stockholders' Equity for the Three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_22"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_22">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_22"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_22">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_22">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_22">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_22"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_22">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_22">2</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_22">4</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_25">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_25">Three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_25"> Months Ended</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_25"> March 31</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_25">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_25">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_25"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_25">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_25">2</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_25">5</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_28">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_28">6</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_73">Item 2.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_73">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_73">21</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_97">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_97">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_97">42</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_100">Item 4.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_100">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_100">42</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_103">PART II</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_103">OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_106">Item 1.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_106">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_106">42</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_109">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_109">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_109">43</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_112">Item 2.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_112">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_112">77</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_115">Item 6.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_115">Exhibits</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_115">78</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_118">SIGNATURE PAGE</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_118">79</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">"Altibodies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "ARCALYST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "Evkeeza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "Inmazeb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">" (in the United States), "REGEN-COV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "Regeneron</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "Regeneron Genetics Center</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "RGC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Veloci-Bi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VelociGene</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VelociHum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VelociMab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VelocImmune</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VelociMouse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VelociSuite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VelociT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," and "ZALTRAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">" are trademarks of Regeneron Pharmaceuticals, Inc. Trademarks and trade names of other companies appearing in this report are, to the knowledge of Regeneron Pharmaceuticals, Inc., the property of their respective owners. This report refers to products of Regeneron Pharmaceuticals, Inc., its collaborators, and other parties. Consult the product label in each territory for specific information about such products.</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_13"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements</span></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_16"></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(In millions, except per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.524%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfNC0xLTEtMS0yMjE1Njg_f176381c-39db-406a-9db1-d0521f8c4a9b">3,916.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfNC0zLTEtMS0yMjE1Njg_12d91e70-c31c-40ad-a49b-6c3430644e2d">3,105.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfNS0xLTEtMS0yMjE1Njg_cef106e5-9350-4f44-a18a-44c8a5da12a6">5,043.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfNS0zLTEtMS0yMjE1Njg_7730cdd0-e960-4340-af60-5b4addc804c8">4,636.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfNi0xLTEtMS0yMjE1Njg_8b570119-2942-498a-8efa-704adf3d4c74">5,118.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfNi0zLTEtMS0yMjE1Njg_00c993eb-9100-427f-91de-2794cd9d0af3">5,328.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfNy0xLTEtMS0yMjE1Njg_2fa9af6a-702a-49d5-ad5e-563bc1632469">2,424.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfNy0zLTEtMS0yMjE1Njg_506e644d-e7db-4b35-9340-806044046a6a">2,401.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfOC0xLTEtMS0yMjE1Njg_84d9b22e-3140-4d79-bec8-a804f9e02928">406.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfOC0zLTEtMS0yMjE1Njg_a6d528b3-357f-41c6-b721-b7dcf5c341db">411.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfOS0xLTEtMS0yMjE1Njg_8cd67c76-0527-4c01-a323-afd48c1b04f5">16,909.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfOS0zLTEtMS0yMjE1Njg_8573151a-646c-4201-ab5f-a1cfe1ba8819">15,884.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMTEtMS0xLTEtMjIxNTY4_5c53d441-2631-4fbb-b81d-8cd1e18044da">6,066.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMTEtMy0xLTEtMjIxNTY4_00bece50-b741-4267-a866-8c750a83c51f">6,591.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMTItMS0xLTEtMjIxNTY4_75abcb14-7fbd-4085-a085-eb7126a86906">3,880.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMTItMy0xLTEtMjIxNTY4_5c640a00-0aff-4b89-9c0b-e97a0d99f659">3,763.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMTMtMS0xLTEtMjIxNTY4_eb767ba0-41c7-4aac-814d-9ccfa93547ec">928.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMTMtMy0xLTEtMjIxNTY4_ebfc990f-e1a8-478f-9b36-58f9105769e6">915.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMTQtMS0xLTEtMjIxNTY4_cfb391a9-a2d6-44b1-b5a2-992b17df5055">1,924.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMTQtMy0xLTEtMjIxNTY4_2ccb98ea-c91f-4fb6-9ddd-d9980af6133c">1,723.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMTUtMS0xLTEtMjIxNTY4_04b92b05-be39-4678-863b-a6700018b31b">349.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMTUtMy0xLTEtMjIxNTY4_74fc2af6-d89e-4eb7-8a33-92f36f031433">336.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMTYtMS0xLTEtMjIxNTY4_0093e000-9222-4d13-8b59-dc34f0658bae">30,059.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMTYtMy0xLTEtMjIxNTY4_9a7646b9-d083-46dd-8656-325646525316">29,214.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjAtMS0xLTEtMjIxNTY4_0bfc9715-328b-41ff-af0f-c92dd754424a">599.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjAtMy0xLTEtMjIxNTY4_150200b4-f64e-42bf-a285-741b8f886458">589.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjEtMS0xLTEtMjIxNTY4_ae66def1-a622-4ad1-bcbc-024572200d25">2,074.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjEtMy0xLTEtMjIxNTY4_24f720a6-8a5c-4407-a475-6944f9bf66d5">2,074.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjMtMS0xLTEtMjIxNTY4_51d9c472-7ecb-41c6-84ce-eb76d869032a">426.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjMtMy0xLTEtMjIxNTY4_94762ce9-d3c0-416c-9a10-f8bd1cc5264b">477.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjQtMS0xLTEtMjIxNTY4_97a7c68e-2e59-4080-8cf1-bde85205dfb6">3,100.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjQtMy0xLTEtMjIxNTY4_1f94b7df-b320-4cff-8721-08efff1030e5">3,141.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjYtMS0xLTEtMjIxNTY4_c18dcfd4-6799-4d86-8dfa-1013974e82b5">1,981.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjYtMy0xLTEtMjIxNTY4_9be9d421-cb48-400d-b95d-a4b2c87ca403">1,981.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjctMS0xLTEtMjIxNTY4_9c3c41d8-fd5d-4e95-a9fe-541fcb324b82">720.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjctMy0xLTEtMjIxNTY4_040ea0de-1b66-49f9-b5dc-c25142c65f42">720.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjgtMS0xLTEtMjIxNTY4_ae78f857-059a-4ba7-81eb-145a4b086ef0">85.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjgtMy0xLTEtMjIxNTY4_cd4e3222-c5a5-4be4-a2ef-78bfd0496c29">69.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjktMS0xLTEtMjIxNTY4_20232dc2-a833-4c19-a99d-c7d8956febd3">677.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjktMy0xLTEtMjIxNTY4_3d33a747-2b97-47ff-af5c-f70a7c794dc8">638.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzAtMS0xLTEtMjIxNTY4_c4f527e8-dae4-41a6-980d-33ce8999fe1a">6,564.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzAtMy0xLTEtMjIxNTY4_2471eb97-a4cd-43ad-a201-36ac94e63f7f">6,550.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzMtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246OWY2ZmE3NTdlM2M1NDBlMTkxZTRlMTM4NmNlYmFhOTlfMzE_1478c81f-0c4f-4122-a651-ee68fc688945"><ix:nonFraction unitRef="usdPerShare" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzMtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246OWY2ZmE3NTdlM2M1NDBlMTkxZTRlMTM4NmNlYmFhOTlfMzE_6ae6dd97-5aae-476b-9596-2d23e306c553">.01</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzMtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246OWY2ZmE3NTdlM2M1NDBlMTkxZTRlMTM4NmNlYmFhOTlfNDU_716cfe69-54ff-4245-be0a-a8207f12dc3c"><ix:nonFraction unitRef="shares" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzMtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246OWY2ZmE3NTdlM2M1NDBlMTkxZTRlMTM4NmNlYmFhOTlfNDU_804bc133-afb5-4602-862c-57ab92fdb97d">30.0</ix:nonFraction></ix:nonFraction> shares authorized; issued and outstanding - <ix:nonFraction unitRef="shares" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzMtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246OWY2ZmE3NTdlM2M1NDBlMTkxZTRlMTM4NmNlYmFhOTlfOTI_073eb672-b4a4-40f9-936c-f44825088f40"><ix:nonFraction unitRef="shares" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzMtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246OWY2ZmE3NTdlM2M1NDBlMTkxZTRlMTM4NmNlYmFhOTlfOTI_65c772be-eb7e-4364-a4a6-f35ba83d77a5"><ix:nonFraction unitRef="shares" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzMtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246OWY2ZmE3NTdlM2M1NDBlMTkxZTRlMTM4NmNlYmFhOTlfOTI_7144f1e0-bf56-41e9-81c5-b5d2fc31e288"><ix:nonFraction unitRef="shares" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzMtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246OWY2ZmE3NTdlM2M1NDBlMTkxZTRlMTM4NmNlYmFhOTlfOTI_a134cdbd-d8d0-4087-8e06-8b9a88dcad43">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>ne</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzMtMS0xLTEtMjIxNTY4_bdb0b4e9-8c44-465f-a3fb-5f2333fbd836">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzMtMy0xLTEtMjIxNTY4_9b9e5294-6900-40cf-8659-a867723c5e71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A Stock, convertible, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i6b8134b6a41640a59debc09f522f7159_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzQtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MGVkZTY5NWQ1M2FjNGQ2MTliYTI5Mjk0MjZlODJlN2FfNDI_42479e7b-a05e-4058-b76f-d03e0702b270"><ix:nonFraction unitRef="usdPerShare" contextRef="ic62e60ebc7424784abaf7166a92b5115_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzQtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MGVkZTY5NWQ1M2FjNGQ2MTliYTI5Mjk0MjZlODJlN2FfNDI_b6329031-d39a-4235-8ce7-f234ac9568f3">.001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="ic62e60ebc7424784abaf7166a92b5115_I20230331" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzQtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MGVkZTY5NWQ1M2FjNGQ2MTliYTI5Mjk0MjZlODJlN2FfNTY_1fcea8c6-286c-4328-8207-a5b5c85a7826"><ix:nonFraction unitRef="shares" contextRef="i6b8134b6a41640a59debc09f522f7159_I20221231" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzQtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MGVkZTY5NWQ1M2FjNGQ2MTliYTI5Mjk0MjZlODJlN2FfNTY_c75c8ed6-627d-4892-b586-fd1a57475c49">40.0</ix:nonFraction></ix:nonFraction> shares authorized; shares issued and outstanding - <ix:nonFraction unitRef="shares" contextRef="i6b8134b6a41640a59debc09f522f7159_I20221231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzQtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MGVkZTY5NWQ1M2FjNGQ2MTliYTI5Mjk0MjZlODJlN2FfMTEw_1850ab07-d381-4193-b17b-4ca54df71ba2"><ix:nonFraction unitRef="shares" contextRef="ic62e60ebc7424784abaf7166a92b5115_I20230331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzQtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MGVkZTY5NWQ1M2FjNGQ2MTliYTI5Mjk0MjZlODJlN2FfMTEw_bcc44fae-1bee-4f1f-96c3-ab35ce752cef"><ix:nonFraction unitRef="shares" contextRef="i6b8134b6a41640a59debc09f522f7159_I20221231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzQtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MGVkZTY5NWQ1M2FjNGQ2MTliYTI5Mjk0MjZlODJlN2FfMTEw_ce341e73-6a9d-4876-9adb-f5a2c8549047"><ix:nonFraction unitRef="shares" contextRef="ic62e60ebc7424784abaf7166a92b5115_I20230331" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzQtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MGVkZTY5NWQ1M2FjNGQ2MTliYTI5Mjk0MjZlODJlN2FfMTEw_f3a8befd-2481-4251-a1c9-554b575205f4">1.8</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> in 2023 and 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62e60ebc7424784abaf7166a92b5115_I20230331" decimals="-5" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzQtMS0xLTEtMjIxNTY4_cbc61bce-fb9b-43f0-a0b6-f11af4684fb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b8134b6a41640a59debc09f522f7159_I20221231" decimals="-5" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzQtMy0xLTEtMjIxNTY4_44c7af5b-f070-448d-b5b8-113c6c195982">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="iad84cd28f95b42f29a3715741068591b_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzUtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MzNhZmQyMzViNmE5NDhhMzgxNTExYTM2MGNhMzBiOGFfMjg_072f5a26-e0ed-4895-a326-bed3e4167bab"><ix:nonFraction unitRef="usdPerShare" contextRef="i7b7c4d8560fb43119f17d189a9cc1ec6_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzUtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MzNhZmQyMzViNmE5NDhhMzgxNTExYTM2MGNhMzBiOGFfMjg_b870d173-12fa-49a6-90c7-ff23895699fe">.001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="i7b7c4d8560fb43119f17d189a9cc1ec6_I20230331" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzUtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MzNhZmQyMzViNmE5NDhhMzgxNTExYTM2MGNhMzBiOGFfNDI_686a77f4-4c5e-4255-a21d-688fe9a4e20d"><ix:nonFraction unitRef="shares" contextRef="iad84cd28f95b42f29a3715741068591b_I20221231" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzUtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MzNhZmQyMzViNmE5NDhhMzgxNTExYTM2MGNhMzBiOGFfNDI_cb09a7df-ceff-40f8-8553-ae17f2c5609d">320.0</ix:nonFraction></ix:nonFraction> shares authorized; shares issued - <ix:nonFraction unitRef="shares" contextRef="i7b7c4d8560fb43119f17d189a9cc1ec6_I20230331" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzUtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MzNhZmQyMzViNmE5NDhhMzgxNTExYTM2MGNhMzBiOGFfODA_559a8622-7891-4838-ab9e-2c695fb4ac2a">131.4</ix:nonFraction> in 2023 and <ix:nonFraction unitRef="shares" contextRef="iad84cd28f95b42f29a3715741068591b_I20221231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzUtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MzNhZmQyMzViNmE5NDhhMzgxNTExYTM2MGNhMzBiOGFfOTU_0241bd9c-01d0-418e-9187-6c663472fb51">130.4</ix:nonFraction> in 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b7c4d8560fb43119f17d189a9cc1ec6_I20230331" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzUtMS0xLTEtMjIxNTY4_17c1f7ca-c1c9-4470-adef-ec9dd0d8ceee">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad84cd28f95b42f29a3715741068591b_I20221231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzUtMy0xLTEtMjIxNTY4_9dd3d959-c73c-4236-8782-24255707092d">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzYtMS0xLTEtMjIxNTY4_4783ffae-ba69-4b7e-bd09-28d70ab35747">10,597.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzYtMy0xLTEtMjIxNTY4_53ac3299-5c92-4ba8-ad5e-4cba6653a34a">9,949.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzctMS0xLTEtMjIxNTY4_1dd96bd2-a3af-4737-bbdc-5a0acb209399">24,124.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzctMy0xLTEtMjIxNTY4_7a7b7821-7dff-4e31-9511-8604b6d0a333">23,306.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzgtMS0xLTEtMjIxNTY4_6d6ebba8-bb36-4775-967d-89fff00a0303">181.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzgtMy0xLTEtMjIxNTY4_9fab1c75-e80c-4e67-9480-59a2dbd1d6bb">238.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Stock, at cost; <ix:nonFraction unitRef="shares" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzktMC0xLTEtMjIxNTY4L3RleHRyZWdpb246ZWI2ZjhhZWRjNjJiNDY4Nzg1YjA3OGFkM2FiNTE0NTdfMjk_94a08668-2290-4808-9293-db322264afb4">23.5</ix:nonFraction> shares in 2023 and <ix:nonFraction unitRef="shares" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzktMC0xLTEtMjIxNTY4L3RleHRyZWdpb246ZWI2ZjhhZWRjNjJiNDY4Nzg1YjA3OGFkM2FiNTE0NTdfNTE_bac98e47-41a2-4798-96fd-407c598002fc">22.6</ix:nonFraction> shares in 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzktMS0xLTEtMjIxNTY4_806de7eb-7816-4d4e-879b-d204cd2a0a05">11,045.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzktMy0xLTEtMjIxNTY4_4b65e88a-ceda-4410-b800-93d38d42725f">10,353.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfNDAtMS0xLTEtMjIxNTY4_819cdb89-f625-4fdb-bd59-ddc3e6173868">23,495.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfNDAtMy0xLTEtMjIxNTY4_fd0e9625-1992-474b-b8fa-6864ed8ae83f">22,664.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfNDEtMS0xLTEtMjIxNTY4_562a1166-0a7f-48c3-a86c-74165b5eabe1">30,059.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfNDEtMy0xLTEtMjIxNTY4_f76ac8ff-3590-48aa-9626-d051ecef94d0">29,214.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 13.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The accompanying notes are an integral part of the financial statements.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(In millions, except per share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:71.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.007%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statements of Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89d2806ddfda4899b23a4e2a27b639ee_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNC02LTEtMS0yMjE1Njg_3fcad1af-c965-42a8-b8a8-d7e432006069">1,668.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cd61146d31845f7aa0a400c1de8c9af_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNC04LTEtMS0yMjE1Njg_34a56638-08f8-44fb-89ea-deeda3db1c4b">1,638.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e96d85f6116487bb808133461cb06a1_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNS02LTEtMS0yMjE1Njg_4f417908-8883-4dc5-ba6a-bb591529de7d">1,378.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i322b8ce5df5b4c60ad8cc95df009f249_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNS04LTEtMS0yMjE1Njg_40de85d7-1570-4cd8-8dbf-0c18f6e3d7e5">1,232.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i375b286d61df4bd4851e798baea9fbed_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNi02LTEtMS0yMjE1Njg_91302d3c-6928-4f9f-843c-269c75ddf84b">116.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7d1404e1f794d79bf92b04d446901cf_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNi04LTEtMS0yMjE1Njg_1d275220-7bd9-4136-9fcb-8406b144a762">94.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNy02LTEtMS0yMjE1Njg_263b8a92-6351-428c-841d-59656365bea7">3,162.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNy04LTEtMS0yMjE1Njg_a0482dc8-0c3e-4811-a588-b4e0c7cc9418">2,965.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTAtNi0xLTEtMjIxNTY4_50854ab9-66ca-4c4c-8404-ac9503abe377">1,101.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTAtOC0xLTEtMjIxNTY4_8fa50eca-acd8-4e90-b9f1-f3aa836e8d8d">843.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="regn:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTEtNi0xLTEtMjIxNTY4_90287ee7-0f49-4d5b-a9fa-e7e03a829ae2">56.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="regn:AcquiredInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTEtOC0xLTEtMjIxNTY4_c4dc90c9-68d5-4208-9360-8865f0cdf258">28.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTItNi0xLTEtMjIxNTY4_934ceaaa-fdaf-421c-86e7-c1c3ef0a20df">601.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTItOC0xLTEtMjIxNTY4_23ebe79b-b564-43bf-a4d2-4e20011af565">450.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89d2806ddfda4899b23a4e2a27b639ee_D20230101-20230331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTMtNi0xLTEtMjIxNTY4_5b7476f4-09ac-4efd-b040-9c27ed465d6f">208.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cd61146d31845f7aa0a400c1de8c9af_D20220101-20220331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTMtOC0xLTEtMjIxNTY4_385d2a22-8efc-4d2d-ab0c-c187ebfecaa0">207.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of collaboration and contract manufacturing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0ca86da19f48e88d9bf110de7b69c2_D20230101-20230331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTQtNi0xLTEtMjIxNTY4_6f0df168-0fac-4256-9874-8574d73b79a8">249.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bf386a54cb94d3693610866086baa33_D20220101-20220331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTQtOC0xLTEtMjIxNTY4_c2883fff-2edb-4b32-8b6a-122e3888918b">197.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTUtNi0xLTEtMjIxNTY4_ea0130a6-0af0-4df2-88de-17dac7312324">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTUtOC0xLTEtMjIxNTY4_0f237ce9-8111-4a05-bc38-21bd314033f9">20.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTYtNi0xLTEtMjIxNTY4_af830f8b-1f14-4652-8e2d-6507952f6278">2,215.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTYtOC0xLTEtMjIxNTY4_0fb60a82-fb47-4411-97b6-3946bf7a7421">1,706.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTgtNi0xLTEtMjIxNTY4_69a85f62-b8d6-46e5-ae4f-b6fefbe1f6b2">946.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTgtOC0xLTEtMjIxNTY4_50b5688d-2a6f-447b-a5b8-d43c814d0bfd">1,258.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMjEtNi0xLTEtMjIxNTY4_f6b117bf-3684-4b81-85a1-5a753cc61e82">70.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMjEtOC0xLTEtMjIxNTY4_e6989d07-02f4-43a3-a411-df32bc2f2ce4">183.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMjItNi0xLTEtMjIxNTY4_8fe19550-1a2d-49e7-bdae-9a1aa6d02dc6">18.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMjItOC0xLTEtMjIxNTY4_d8087f8a-e932-4b21-9af3-c4770090d05b">13.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMjMtNi0xLTEtMjIxNTY4_aaeeb356-c1b0-4978-91d8-f6ddf36e48e8">88.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMjMtOC0xLTEtMjIxNTY4_a55502cb-3bf7-40bc-8873-c543a8e691c2">197.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMjUtNi0xLTEtMjIxNTY4_090923c6-23f9-4287-b7be-c564d4f02b53">858.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMjUtOC0xLTEtMjIxNTY4_f4ec7491-815c-44bd-a996-84096b3b0701">1,061.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMjctNi0xLTEtMjIxNTY4_98fd03d2-c7d5-4e00-bb86-7a09395f58ed">40.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMjctOC0xLTEtMjIxNTY4_5faf3f5b-cc9e-4e87-92bb-57f76aaa70e4">87.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMjktNi0xLTEtMjIxNTY4_37fb1fac-2f92-48b2-ba24-a07ce40f3a85">817.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMjktOC0xLTEtMjIxNTY4_6583963b-4705-4b82-9c69-3259c57f2c4a">973.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMzEtNi0xLTEtMjIxNTY4_b567779a-a8bc-441f-bd6d-392c26f51085">7.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMzEtOC0xLTEtMjIxNTY4_1501ba35-80a0-4995-a08c-1918aac9a3e9">9.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMzItNi0xLTEtMjIxNTY4_a6117a81-11fb-48b1-9865-c236e3dd9c02">7.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMzItOC0xLTEtMjIxNTY4_15f5ef34-69dd-497d-b932-b3b766ade013">8.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMzQtNi0xLTEtMjIxNTY4_68ef17e2-6e01-472c-9def-c4fce0d1c77d">107.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMzQtOC0xLTEtMjIxNTY4_3e9f1b2b-8c4e-4996-a070-2ae1167fc6d8">106.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMzUtNi0xLTEtMjIxNTY4_c9e4eefb-1ca5-44cc-ba01-4ba52a9780a1">114.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMzUtOC0xLTEtMjIxNTY4_57d765b8-5c29-425e-af2f-d0bf17dec38c">113.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statements of Comprehensive Income </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMzgtNi0xLTEtMjIxNTY4_a4f55dff-0f4c-4e39-9490-4e5f5b2be00b">817.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMzgtOC0xLTEtMjIxNTY4_834433c9-6ddc-4529-9f9e-4313d5a8090f">973.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNDAtNi0xLTEtMjIxNTY4_b151c779-eb0d-431e-96da-79b4a7372c1d">57.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNDAtOC0xLTEtMjIxNTY4_b5424e6a-6e10-4a8b-bad3-5b030ff24b89">144.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNDEtNi0xLTEtMjIxNTY4_e97f35e1-e9a7-4d51-b18b-3aceff41e319">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNDEtOC0xLTEtMjIxNTY4_60f2093b-8039-477a-aae7-6bea30e1ee85">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNDItNi0xLTEtMjIxNTY4_4532eb3b-a958-4c60-a5ce-abab9ade0051">875.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNDItOC0xLTEtMjIxNTY4_627bdd75-4118-4f4a-ad3f-c4533d760b4e">829.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="15" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The accompanying notes are an integral part of the financial statements.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.414%"><tr><td style="width:1.0%"></td><td style="width:33.774%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.824%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.849%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Class A Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Stockholders' Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if30714371f9e46528af3d8f6681b15c7_I20221231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMi0yLTEtMS0yMjE1Njg_4e6653cb-9122-4f75-8f26-3763a35cc7a2">1.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if30714371f9e46528af3d8f6681b15c7_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMi00LTEtMS0yMjE1Njg_c04a01f8-3578-4e67-a7fe-f7588ac2424f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee31f7d64fe049c7a439d288ec9486d5_I20221231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMi02LTEtMS0yMjE1Njg_d1d44564-4125-4d90-8a73-72f8d27662a3">130.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee31f7d64fe049c7a439d288ec9486d5_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMi04LTEtMS0yMjE1Njg_5a3db6f5-4138-484d-ac68-572e2f7f8e3d">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f33b378dd044be2997a03a26a5d3b48_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMi0xMC0xLTEtMjIxNTY4_4798fa36-065e-4f51-b4cb-8625bce4ea40">9,949.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i464958bff30b4da893895a523da36762_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMi0xMi0xLTEtMjIxNTY4_b07b2325-88f8-4ca3-af9d-267a75141f6f">23,306.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fa0f967adc9439caf372e79f15e9e65_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMi0xNC0xLTEtMjIxNTY4_8655af7f-b597-4011-9a3a-86f9f8314c64">238.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ica431963a44548bd8c3c65e67df71293_I20221231" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMi0xNi0xLTEtMjIxNTY4_899c14ac-c486-49ad-aa2e-d3f1b29521aa">22.6</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica431963a44548bd8c3c65e67df71293_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMi0xOC0xLTEtMjIxNTY4_7bab9f58-0680-4dc2-ab75-93b92e27d271">10,353.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMi0yMC0xLTEtMjIxNTY4_3c9b729c-f0b5-430b-9c4b-c7a5c85ecbc0">22,664.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Common Stock for equity awards granted under long-term incentive plans</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5c88fce876d4566b4cbbac88f11de2b_D20230101-20230331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMy02LTEtMS0yMjE1Njg_bee991ac-6535-407b-808d-67f6006eeeec">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015fc10968404f9596294e54195211db_D20230101-20230331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMy0xMC0xLTEtMjIxNTY4_bbf4d0f8-d3a6-474e-b245-20a7524568d2">491.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMy0yMC0xLTEtMjIxNTY4_a773d6d6-fa8b-4c2a-87bd-c4bcafb45ef7">491.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib5c88fce876d4566b4cbbac88f11de2b_D20230101-20230331" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfNC02LTEtMS0yMjE1Njg_944285e0-4464-464f-b62a-14439d10a523">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i015fc10968404f9596294e54195211db_D20230101-20230331" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfNC0xMC0xLTEtMjIxNTY4_27caf7ba-1613-45ff-886a-33d8ca2cf4eb">99.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfNC0yMC0xLTEtMjIxNTY4_c0ae7685-0f55-4086-b0eb-881c412a9c91">99.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance/distribution of Common Stock for 401(k) Savings Plan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015fc10968404f9596294e54195211db_D20230101-20230331" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfNS0xMC0xLTEtMjIxNTY4_ecc4673b-ecfe-4fde-9fcd-dfe752d3f621">18.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i185b612165b347b2b4aa073de182131b_D20230101-20230331" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfNS0xOC0xLTEtMjIxNTY4_d03d09d9-7fb2-4cf2-862a-313ef58ec774">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfNS0yMC0xLTEtMjIxNTY4_261417f5-0f3f-493e-a091-bd5ff9b37fd1">20.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of Common Stock</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i185b612165b347b2b4aa073de182131b_D20230101-20230331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfNi0xNi0xLTEtMjIxNTY4_42f698f3-3665-4c07-8564-20c9867c9c04">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i185b612165b347b2b4aa073de182131b_D20230101-20230331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfNi0xOC0xLTEtMjIxNTY4_65438d08-7519-4e97-bcc3-55259403234f">693.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfNi0yMC0xLTEtMjIxNTY4_f57f53ff-76fc-4cf3-9f31-8d99a1a33f8e">693.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015fc10968404f9596294e54195211db_D20230101-20230331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfNy0xMC0xLTEtMjIxNTY4_ccad5ecd-a541-4980-8c75-64a2ad4ae0fd">237.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfNy0yMC0xLTEtMjIxNTY4_1ff22945-8f32-44b6-933a-5be5ebe6426e">237.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5afdea61952c4451a233ed8c133cf438_D20230101-20230331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfOC0xMi0xLTEtMjIxNTY4_d60cce47-1263-4ed1-bb99-a84aad7ccd80">817.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfOC0yMC0xLTEtMjIxNTY4_97025a76-0b13-4bb4-b6db-98e414a69831">817.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfb86f8ed7f34a63aa1ea7aa30866925_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfOS0xNC0xLTEtMjIxNTY4_2e02fa4f-be81-49f3-9faa-c3b8ea12df6a">57.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfOS0yMC0xLTEtMjIxNTY4_4cc0695d-b42d-4dfe-8b7c-6b38d9411d47">57.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2ccec8fe40c04d699a63e2967214f0b4_I20230331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMTAtMi0xLTEtMjIxNTY4_9fafc18f-315e-4abf-a8d4-3e0f20644f53">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ccec8fe40c04d699a63e2967214f0b4_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMTAtNC0xLTEtMjIxNTY4_4667be44-ab8a-47e0-a0cb-f53b2da377b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibcec73dff80346e1895f9d7262e1ea33_I20230331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMTAtNi0xLTEtMjIxNTY4_1fd52ef1-7f0a-4551-bd57-90b43ec5e655">131.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcec73dff80346e1895f9d7262e1ea33_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMTAtOC0xLTEtMjIxNTY4_711001e9-3bdd-4dc2-a599-9020b51a76b3">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e41e273a91b4f7080ff818a13fe99be_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMTAtMTAtMS0xLTIyMTU2OA_f843a63e-c399-4f3a-ba8a-fb13f034d333">10,597.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef282f2e36944018a2590dcf58321d6_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMTAtMTItMS0xLTIyMTU2OA_3765b211-7596-4fbb-8d01-2b3cc964e413">24,124.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46042c6680c54f40880fde0d8f818288_I20230331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMTAtMTQtMS0xLTIyMTU2OA_015bd7c0-5ea6-4154-aa27-adde610caabd">181.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib287cdc989b242ed899986d4cbe3af11_I20230331" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMTAtMTYtMS0xLTIyMTU2OA_10b2ce3f-0625-42e9-b066-c444d1e3ac50">23.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib287cdc989b242ed899986d4cbe3af11_I20230331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMTAtMTgtMS0xLTIyMTU2OA_b1e2b5b9-2498-4def-a1a1-9ad8d48723c8">11,045.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMTAtMjAtMS0xLTIyMTU2OA_06a6992c-b9e5-4b30-982c-ff8c5bc0badf">23,495.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic23d397894814b2486b54d92fc4b1a6d_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzEtMi0xLTEtMjIxNTY4_1badbc87-b12d-4d8c-94f2-4d61e6abadc6">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic23d397894814b2486b54d92fc4b1a6d_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzEtNC0xLTEtMjIxNTY4_cac7688d-40c6-4dae-b6d5-2e8e8cae62c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i97aac951375a4b61997b83f703090509_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzEtNi0xLTEtMjIxNTY4_6f01066f-3798-4619-bceb-c44dfe2ec842">126.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aac951375a4b61997b83f703090509_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzEtOC0xLTEtMjIxNTY4_c0b2554e-ccea-4afb-b3e7-a0fa5c1a7c74">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a88badb1d6e4841ab079e4f443a7e4c_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzEtMTAtMS0xLTIyMTU2OA_a44b8f9c-0087-4ddb-b525-d54f1708d8a0">8,087.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ccce571fef4b90bc060bfc54280e73_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzEtMTItMS0xLTIyMTU2OA_1dfe3ab5-79bc-4a42-99be-0c1e3c9f56b0">18,968.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcb31e106e34471ea566f05963a75c5e_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzEtMTQtMS0xLTIyMTU2OA_bd9166d8-2e1e-444d-91b7-6c4640e41deb">26.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i80bf6dc29204481a9c4efae367ed366e_I20211231" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzEtMTYtMS0xLTIyMTU2OA_833ad5bc-f5d1-45fc-8c97-84eb32f317be">19.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80bf6dc29204481a9c4efae367ed366e_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzEtMTgtMS0xLTIyMTU2OA_09d90b14-8c30-485c-88d5-e4ccedc34f8c">8,260.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c18de361b24fb9a6ed97dcb156b4ac_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzEtMjAtMS0xLTIyMTU2OA_b9ebd7b9-022a-460b-b7cb-9ec7e4bad935">18,768.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Common Stock for equity awards granted under long-term incentive plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if6b622c0a75c4abf85767c76eeb3eb23_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzItNi0xLTEtMjIxNTY4_8e0efcd6-1adc-4a91-9bea-b472fd2c206f">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12fb29cdd4ea4b8b919c34781498d6c1_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzItMTAtMS0xLTIyMTU2OA_3b9f3df7-3c5a-4675-9e02-72a154de6714">593.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzItMjAtMS0xLTIyMTU2OA_43252183-3cc9-4165-a4e0-cc35e9194f2e">593.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if6b622c0a75c4abf85767c76eeb3eb23_D20220101-20220331" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzMtNi0xLTEtMjIxNTY4_4a5e0317-19c8-4a71-889f-980adaa5c298">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12fb29cdd4ea4b8b919c34781498d6c1_D20220101-20220331" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzMtMTAtMS0xLTIyMTU2OA_d80b1950-8fe4-45ac-94c8-6b1d6c3dc817">105.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzMtMjAtMS0xLTIyMTU2OA_c3981e66-bb37-4f3f-bce7-3a489344ca72">105.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance/distribution of Common Stock for 401(k) Savings Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12fb29cdd4ea4b8b919c34781498d6c1_D20220101-20220331" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzQtMTAtMS0xLTIyMTU2OA_19b7a026-d3b9-4c67-ab44-68b266fac813">12.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bfc42c5e2314ceda9b705bf6f75c36e_D20220101-20220331" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzQtMTgtMS0xLTIyMTU2OA_a6c56bae-46ad-4f96-b8da-43ded4915364">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzQtMjAtMS0xLTIyMTU2OA_95df147c-71ab-4474-8313-7ca7c5d1f179">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of Common Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6bfc42c5e2314ceda9b705bf6f75c36e_D20220101-20220331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzUtMTYtMS0xLTIyMTU2OA_05a15310-b773-4bba-9a93-2d6a80f2fc0f">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bfc42c5e2314ceda9b705bf6f75c36e_D20220101-20220331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzUtMTgtMS0xLTIyMTU2OA_5b66e771-5e64-40df-b2e5-9f80533f5661">352.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzUtMjAtMS0xLTIyMTU2OA_7d9c0bba-5a01-4d38-974c-4980c69bea09">352.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12fb29cdd4ea4b8b919c34781498d6c1_D20220101-20220331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzYtMTAtMS0xLTIyMTU2OA_68d4e5f4-a2c6-4c4a-9ecb-c2703e7b40af">165.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzYtMjAtMS0xLTIyMTU2OA_c7319959-4b77-4113-930d-8caf5f09057d">165.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64fe108807dd4be4af7e9ea5f30001e4_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzctMTItMS0xLTIyMTU2OA_37fc974e-a271-4985-a4fe-ac8110b4511c">973.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzctMjAtMS0xLTIyMTU2OA_2c270ae6-cb1d-483e-921b-789e0a502918">973.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5bc7a6419f1432ca3b84fea5414f7a3_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzgtMTQtMS0xLTIyMTU2OA_e1325fd9-c4e4-4029-9a3e-8aa70fa2ad5d">143.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzgtMjAtMS0xLTIyMTU2OA_d1ed6080-99b6-4928-9f81-d175a5c1733d">143.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i936952c9103a4c52811822936c6feffb_I20220331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzktMi0xLTEtMjIxNTY4_48565f52-3b33-45c3-be63-2c27fbf20792">1.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i936952c9103a4c52811822936c6feffb_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzktNC0xLTEtMjIxNTY4_ead0ea3f-0884-4243-bcd2-2b106f26ba2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i763f240b37e34f9e97c13b9647d2763e_I20220331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzktNi0xLTEtMjIxNTY4_10c4676f-94f3-40ad-add1-89807b505b8b">127.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i763f240b37e34f9e97c13b9647d2763e_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzktOC0xLTEtMjIxNTY4_635c7d9d-72dd-4b6f-a587-b860a0476ba7">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7292cbbd4824b5b8b48cd9b81256747_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzktMTAtMS0xLTIyMTU2OA_eab5df00-7ad4-4f81-b1b0-7049ba1edd5a">8,754.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39ca18ca3a794b3c9cc3567ecaf855ed_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzktMTItMS0xLTIyMTU2OA_fdc4e9e1-da52-4bde-979e-5db5deb11775">19,941.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide8d66252aa645be98653f0b578cbb44_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzktMTQtMS0xLTIyMTU2OA_e6ca388b-6eef-4aa8-9b39-b37eb3531342">170.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia23f7613df634004b007e3599b0e97f9_I20220331" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzktMTYtMS0xLTIyMTU2OA_426829ca-436e-4179-a5b8-f8dcc744e498">19.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia23f7613df634004b007e3599b0e97f9_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzktMTgtMS0xLTIyMTU2OA_06720d2b-c10c-4435-a8ac-bb33a9b23374">8,611.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7298587e584844a686de7edf412eb7a2_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzktMjAtMS0xLTIyMTU2OA_36069bf5-ddc6-4e44-b195-1b13d1bfb574">19,914.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="63" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The accompanying notes are an integral part of the financial statements.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:71.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.939%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMy0yLTEtMS0yMjE1Njg_fa7cf586-c2f9-4aec-a591-9c373d2be169">817.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMy00LTEtMS0yMjE1Njg_9a8e43e4-8a9b-4938-aa27-d82913a089a6">973.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfNS0yLTEtMS0yMjE1Njg_1e7b5780-ddd8-4679-b139-db4ea228b604">99.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfNS00LTEtMS0yMjE1Njg_b958c1fd-19ff-4d01-841d-5731c7ec0792">74.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfNi0yLTEtMS0yMjE1Njg_076ed5c7-a811-40f8-9b55-920e46e896f5">238.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfNi00LTEtMS0yMjE1Njg_ae153679-096b-48d4-b67a-c092f29bb217">166.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Losses on marketable and other securities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" sign="-" name="regn:MarketableAndOtherSecuritiesGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfNy0yLTEtMS0yMjE1Njg_70670848-1dba-48c6-b365-5427166c8ffa">166.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" sign="-" name="regn:MarketableAndOtherSecuritiesGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfNy00LTEtMS0yMjE1Njg_f7df926c-9ca3-4c8e-88b1-481f55ad3ab9">204.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash items, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfOC0yLTEtMS0yMjE1Njg_c6b3ad47-12c5-4309-a87e-792cabe01874">20.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfOC00LTEtMS0yMjE1Njg_2ce555dd-94c1-43fc-8ea4-c6f45adb9072">84.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfOS0yLTEtMS0yMjE1Njg_bbb24f30-bd6a-48b9-aa47-0ea01171f716">216.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfOS00LTEtMS0yMjE1Njg_08a4e4b0-9c5b-4cd8-b739-61a5187ea8be">225.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTItMi0xLTEtMjIxNTY4_84147ecf-4f4c-45d0-a500-245270905fd4">210.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTItNC0xLTEtMjIxNTY4_855d72d4-e8ca-4852-973a-974878c103f9">1,197.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTMtMi0xLTEtMjIxNTY4_7e71bb44-f58f-47ca-9f35-8d9696e7827e">46.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTMtNC0xLTEtMjIxNTY4_46cb6aa8-433c-4ab2-a971-e1da1df6f2ac">88.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTQtMi0xLTEtMjIxNTY4_fa9aca57-ede3-497c-b6e6-0a582a22e772">5.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTQtNC0xLTEtMjIxNTY4_860feb04-4c37-4f05-8bb4-803d0dc6d165">44.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Decrease) increase in deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTUtMi0xLTEtMjIxNTY4_d08e0afd-e401-4576-90fd-427335f3a7d9">35.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTUtNC0xLTEtMjIxNTY4_bdd54621-fca8-4482-b8b3-59f6534b8141">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in accounts payable, accrued expenses, and other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTYtMi0xLTEtMjIxNTY4_508dc007-d17f-4662-a657-710b2e8e0dfa">119.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTYtNC0xLTEtMjIxNTY4_073eca43-03da-49fe-a3b2-5857bb8cb44f">250.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTctMi0xLTEtMjIxNTY4_21154cb1-d9d2-4687-9ea4-7f4defe51c19">549.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTctNC0xLTEtMjIxNTY4_d639ac58-e678-45e7-9907-cfaaccbc42fa">1,128.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTgtMi0xLTEtMjIxNTY4_1f2bfa1a-8189-4740-acfc-f0b7d1bfee86">1,367.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTgtNC0xLTEtMjIxNTY4_b77d4301-3f53-4cb6-ac81-49cc79344677">2,101.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable and other securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMjEtMi0xLTEtMjIxNTY4_07fa5934-a212-412e-ba90-ef3b8c44ce1b">1,749.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMjEtNC0xLTEtMjIxNTY4_412b9e79-c5b9-45c0-a8d5-c46be4953232">2,309.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales or maturities of marketable and other securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMjItMi0xLTEtMjIxNTY4_ece95c41-25eb-4998-933c-7d9a3ffd9600">1,792.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMjItNC0xLTEtMjIxNTY4_e165257c-2c86-4b13-aaa2-3bf59e1bab31">746.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMjMtMi0xLTEtMjIxNTY4_bd7acd66-0321-4b20-879a-94218f242604">178.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMjMtNC0xLTEtMjIxNTY4_9fc3e378-5063-4bf8-8447-6897bf0cb1ea">141.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for Libtayo intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="regn:PaymentsToAcquireIntangibleAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMjQtMi0xLTEtMjIxNTY4_a3ea2b2b-dd69-4704-8d67-31bf9e306379">100.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="regn:PaymentsToAcquireIntangibleAssets1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMjQtNC0xLTEtMjIxNTY4_95a3cc53-2cb1-401e-bf11-f19eb755c574">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMjYtMi0xLTEtMjIxNTY4_148a8080-6f86-406e-8e04-fdaaabce1ada">235.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMjYtNC0xLTEtMjIxNTY4_b785eb7b-a4d0-4ac6-8473-4fab0bb4528c">1,705.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMjktMi0xLTEtMjIxNTY4_38252a7f-f57a-42f3-a08e-4550c80f3d83">485.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMjktNC0xLTEtMjIxNTY4_a05df068-1d5c-4160-a05e-29027685bb7c">521.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments in connection with Common Stock tendered for employee tax obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMzAtMi0xLTEtMjIxNTY4_ac7911d5-6a54-44a0-af43-8f66b4f39c30">97.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMzAtNC0xLTEtMjIxNTY4_71065a1b-38ab-4bc2-a613-05a98649560f">98.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMzEtMi0xLTEtMjIxNTY4_569da2a9-367a-4b1a-83b5-dae2bf88a3a1">710.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMzEtNC0xLTEtMjIxNTY4_cc71736b-4c32-4ecd-bccf-139877b1c521">358.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMzItMi0xLTEtMjIxNTY4_be084511-1ad2-40d5-be31-537893691a93">322.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMzItNC0xLTEtMjIxNTY4_cf7b2c7c-d631-4187-a2eb-f0c7357c59ed">64.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMzQtMi0xLTEtMjIxNTY4_32854c38-01d9-479d-b8b1-c928a6bf18e4">809.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMzQtNC0xLTEtMjIxNTY4_8906683b-0b98-4c33-97ea-73ab4d912d37">461.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMzYtMi0xLTEtMjIxNTY4_bb41c3f3-38b5-47a3-84eb-8d383c38dd0c">3,119.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c18de361b24fb9a6ed97dcb156b4ac_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMzYtNC0xLTEtMjIxNTY4_86f904a3-401d-40c2-81fd-0b2fdc75ee00">2,898.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMzgtMi0xLTEtMjIxNTY4_8e1df0a7-8069-4134-b33e-75a0a09ac0bb">3,928.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7298587e584844a686de7edf412eb7a2_I20220331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMzgtNC0xLTEtMjIxNTY4_0737db13-256d-426f-8448-df84f1728177">3,359.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="15" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The accompanying notes are an integral part of the financial statements.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_28"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div></div><div><span><br/></span></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_31"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zMS9mcmFnOmJjNDM5ZDMzMmI1MzQ4NTU4NWZmZGY1NGQ1NWFlZWM1L3RleHRyZWdpb246YmM0MzlkMzMyYjUzNDg1NTg1ZmZkZjU0ZDU1YWVlYzVfMjA3OQ_04595932-8fb7-47e1-9549-935c23c34869" continuedAt="i001dc76bcc3448cca86b524459bec36f" escape="true">Interim Financial Statements</ix:nonNumeric></span></div><ix:continuation id="i001dc76bcc3448cca86b524459bec36f"><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zMS9mcmFnOmJjNDM5ZDMzMmI1MzQ4NTU4NWZmZGY1NGQ1NWFlZWM1L3RleHRyZWdpb246YmM0MzlkMzMyYjUzNDg1NTg1ZmZkZjU0ZDU1YWVlYzVfMjA3MA_9bce019f-c803-49c8-ae5b-bfeeb26856ca" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Condensed Consolidated Financial Statements of Regeneron Pharmaceuticals, Inc. and its subsidiaries ("Regeneron," "Company," "we," "us," and "our") have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and disclosures necessary for a presentation of the Company's financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, these financial statements reflect all normal recurring adjustments and accruals necessary for a fair statement of the Company's condensed consolidated financial statements for such periods. The results of operations for any interim period are not necessarily indicative of the results for the full year. The December&#160;31, 2022 Condensed Consolidated Balance Sheet data were derived from audited financial statements, but do not include all disclosures required by accounting principles generally accepted in the United States of America. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior period amounts to conform with the current period's presentation.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RleHRyZWdpb246N2E2NWI1ZDA3NjU4NDc0NGE4MjdlNTNiYzBlMTk2NzdfNTI5_a85d46c4-b85c-4b48-a766-d36c10e189e3" continuedAt="ic2edbe5f5ec54a12ac4c96bdd1f74f90" escape="true">Product Sales</ix:nonNumeric></span></div><ix:continuation id="ic2edbe5f5ec54a12ac4c96bdd1f74f90"><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RleHRyZWdpb246N2E2NWI1ZDA3NjU4NDc0NGE4MjdlNTNiYzBlMTk2NzdfNTE2_991a8a6e-363f-4334-b882-ea0cdb8d1fad" continuedAt="ic16fba774e59403286ef47408d1e0234" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.140%"><tr><td style="width:1.0%"></td><td style="width:42.910%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.347%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.102%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.868%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.102%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c137cb80c2348b6b72faccb7cba8e93_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfMi03LTEtMS0yMjE1Njg_58eb9abc-b2a4-4071-b2ae-8b8fdfd4dbd6">1,433.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb40dc2b4e6d4ddc9267422ed2896f2b_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfMi05LTEtMS0yMjE1Njg_14a56ded-65e0-47e7-b2de-c86759322ffa">1,517.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(a) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3ca332ac7b44e7afd08a842efc7831_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfMy03LTEtMS0yMjE1Njg_0c13c6bb-123c-4b52-b13b-92270f79d64d">109.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1493138d25f94132897d582fa5633635_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfMy05LTEtMS0yMjE1Njg_017cc011-54fc-46b7-b080-94307dcbff7d">78.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539fd4a3ebc04eee85f11898f58b8e50_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfNC03LTEtMS0yMjE1Njg_a27b931a-5f03-4a75-a020-e14bb9f771b9">67.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4c5cb7b7d440c39db96ce2e6fcdf63_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfNC05LTEtMS0yMjE1Njg_f8a7aab3-d388-490b-a1b4-f3a05baf2bf3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97633ca31aaf4a5494aff1cd47af72b6_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfNS03LTEtMS0yMjE1Njg_165addcc-861c-4611-b95a-fe37ed236714">40.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6180931ab3794a16a3d092c67267848f_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfNS05LTEtMS0yMjE1Njg_0dbbd23f-c13f-4a09-9b08-81c2e4e16171">33.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evkeeza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i170bf04d3efb4e2ba2dbc70f34869ad4_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfNy03LTEtMS0yMjE1Njg_a92b7b9f-8c87-4647-9188-4026e6cd6776">14.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a13e46bf874e5d863afd595bc4af6a_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfNy05LTEtMS0yMjE1Njg_87b07a80-7d81-4d23-935b-d79924fc3846">8.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inmazeb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ee16d3d639e46f8a41fb5fef9f9301a_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfOC03LTEtMS0yMjE1Njg_8c55f97b-af4a-4d7f-82c1-db62036f2dac">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0510a432e77041dca5a54640cff8ad6f_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfOC05LTEtMS0yMjE1Njg_fc0508d1-7ca3-451a-afa7-69000bbb40ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89d2806ddfda4899b23a4e2a27b639ee_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfMTAtNy0xLTEtMjIxNTY4_6c4dd142-e616-4e77-b88b-069864e7bcdc">1,668.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cd61146d31845f7aa0a400c1de8c9af_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfMTAtOS0xLTEtMjIxNTY4_1cb3ab6b-2ec1-4177-87a0-4f71b6b3d1e0">1,638.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Prior to July 1, 2022, Regeneron recorded net product sales of Libtayo in the United States and Sanofi recorded net product sales of Libtayo outside the United States. Effective July 1, 2022, the Company records global net product sales of Libtayo. See Note 3 for further details.</span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of world ("ROW")</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="ib8a607a3e56c41779c0e4d7f40f3276c_I20230331" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RleHRyZWdpb246N2E2NWI1ZDA3NjU4NDc0NGE4MjdlNTNiYzBlMTk2NzdfMjE5OTAyMzI1NjE4NQ_f673a450-a306-480c-b863-b7322d3c6303">3.578</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="iddde8724f2d94806b024d0d0b38bb09c_I20221231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RleHRyZWdpb246N2E2NWI1ZDA3NjU4NDc0NGE4MjdlNTNiYzBlMTk2NzdfMTA4_35d2db18-6074-4a0f-8dce-9e2dc4a18419">3.586</ix:nonFraction>&#160;billion, respectively, of trade accounts receivable that were recorded within Accounts receivable, net.</span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had product sales to certain customers that accounted for more than 10% of total gross product revenue for the three months ended March&#160;31, 2023 and 2022. <ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RleHRyZWdpb246N2E2NWI1ZDA3NjU4NDc0NGE4MjdlNTNiYzBlMTk2NzdfNDg1_970527fe-2ca9-41c4-ac2d-21bda264f738" continuedAt="i964d474c74304efc863c8d9117f70ca2" escape="true">Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><ix:continuation id="i964d474c74304efc863c8d9117f70ca2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.210%"><tr><td style="width:1.0%"></td><td style="width:62.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.939%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Besse Medical, a subsidiary of AmerisourceBergen Corporation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i66be2d5d13e14c65a79a0cd9a1fdba09_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOjQxOTY4MGUwNWY0MjRiNGQ5NDU0NjU1NTUzYTcyNTZmL3RhYmxlcmFuZ2U6NDE5NjgwZTA1ZjQyNGI0ZDk0NTQ2NTU1NTNhNzI1NmZfMi02LTEtMS0yMjE1Njg_33cec460-8c4f-4462-8670-c665ae915de6">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iffa15815bae94096ae1f51c8a0ecfdf8_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOjQxOTY4MGUwNWY0MjRiNGQ5NDU0NjU1NTUzYTcyNTZmL3RhYmxlcmFuZ2U6NDE5NjgwZTA1ZjQyNGI0ZDk0NTQ2NTU1NTNhNzI1NmZfMi04LTEtMS0yMjE1Njg_b4345235-bdc5-41eb-ac2e-022188770201">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1c2ae76df8543b98e4b8e032206851d_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOjQxOTY4MGUwNWY0MjRiNGQ5NDU0NjU1NTUzYTcyNTZmL3RhYmxlcmFuZ2U6NDE5NjgwZTA1ZjQyNGI0ZDk0NTQ2NTU1NTNhNzI1NmZfMy02LTEtMS0yMjE1Njg_de9fa14a-7cfd-4acb-80d2-6735e765107b">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id5edea8b3603449e90ce4d1565b6ee02_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOjQxOTY4MGUwNWY0MjRiNGQ5NDU0NjU1NTUzYTcyNTZmL3RhYmxlcmFuZ2U6NDE5NjgwZTA1ZjQyNGI0ZDk0NTQ2NTU1NTNhNzI1NmZfMy04LTEtMS0yMjE1Njg_88c2ad48-8f35-4b27-b303-478220a1b6dc">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfMTM0MjM_e7794623-d4f5-4690-96f3-ab0ddae71c47" continuedAt="i7e8ce525d6074524babc11632f0231a0" escape="true">Collaboration, License, and Other Agreements</ix:nonNumeric></span></div><ix:continuation id="i7e8ce525d6074524babc11632f0231a0" continuedAt="ic81034a76850462f9b94892d666f0ce5"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">a. Sanofi</span></div><ix:continuation id="ic16fba774e59403286ef47408d1e0234" continuedAt="i337d61af07574f3d9e48a32728343979"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in our Statements of Operations in connection with our collaborations with Sanofi are detailed below:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.888%"><tr><td style="width:1.0%"></td><td style="width:44.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.265%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antibody:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of antibodies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2f2c59d2425478cb9a759cbb016a8e3_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMy04LTEtMS0yMjE1Njg_a6b27af3-f11c-4e98-b54b-6999d126d5a9">636.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3e3b5297b2d4da18d1e8bf81c32ed78_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMy0xMC0xLTEtMjIxNTY4_38a94c32-ea6f-4f0e-9f23-a628aa413540">415.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-based milestones earned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a2817fbcc324c0dace63bfa58aa3472_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfNC04LTEtMS0yMjE1Njg_7b1a98cd-bef9-4382-b706-d785f884badf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i496ebaf3b22440b2b2d69aab06cd1a36_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfNC0xMC0xLTEtMjIxNTY4_911e654c-c8ff-4865-8b17-2638402b086b">50.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cadf695465b4d2c823616dee5674384_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfNS04LTEtMS0yMjE1Njg_c5c37a27-f934-4a5d-b44f-6f4881a54e4e">161.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea1238f837994a0a8d152d9ed98974c4_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfNS0xMC0xLTEtMjIxNTY4_82bc67c5-0dec-4a48-b87c-b4fbec26841d">160.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Sanofi R&amp;D expenses, net of reimbursement of R&amp;D expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(R&amp;D expense)/Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied6deae52c5a4fddbad0b5bb2c2d457d_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfNy04LTEtMS0yMjE1Njg_962e7a11-1f73-43ac-8927-db4d816167b5">26.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic09e4f946d7f4b20bff8285f40f649f9_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfNy0xMC0xLTEtMjIxNTY4_fe77eab0-6e0f-4463-9f86-013e537e1837">26.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of SG&amp;A expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id88f78210881451481543b0e7df5322b_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfOC04LTEtMS0yMjE1Njg_bcdf27e7-5157-4fc4-84a3-9939748ecb9c">117.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83fd3849cf8b49c990d30ebab1b52082_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfOC0xMC0xLTEtMjIxNTY4_ced57a6a-e326-46a4-bf25-986496d66ec8">91.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immuno-oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of Libtayo outside the United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9bce6102ed54468900a9f32c759ef8c_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTEtOC0xLTEtMjIxNTY4_3e2ffba4-3930-4c41-b382-4d1ea612377a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied033f1452834cc0b77499b012220842_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTEtMTAtMS0xLTIyMTU2OA_f0adabba-2ebe-4b7b-b411-9e7967571623">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of ex-U.S. commercial supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4d7003a52c48d286f50a758bf9d9fb_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTItOC0xLTEtMjIxNTY4_c4706a8c-fada-41e4-b7fc-b0b86fd3122d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id312ecfecca44b6cad64d0a4dead7154_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTItMTAtMS0xLTIyMTU2OA_fe4c3114-3f3c-4a61-96c8-27a7af6e86f7">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of R&amp;D expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b748b8781634cf7bad7b7c57fea08bc_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTMtOC0xLTEtMjIxNTY4_a14beb3b-bcff-497c-9dc7-cad364687baf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeba37fd20ba4aa5aa90737cd4da0556_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTMtMTAtMS0xLTIyMTU2OA_cfbb2cc9-79c2-4171-9c2c-e47a5ee3a4ae">21.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of SG&amp;A expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie398e6bd3f1649b1b129db816c08a863_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTQtOC0xLTEtMjIxNTY4_33a75d67-1c57-4e6e-9480-3a1e5aa6e3f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba78c9e3c2b14c9f8c6d4c4c6903cefe_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTQtMTAtMS0xLTIyMTU2OA_9d33f2ee-4d64-4b8a-b556-37f407652151">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Sanofi commercial expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&amp;A expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b3cda38a64e4813ba22059700b5a833_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTUtOC0xLTEtMjIxNTY4_35af6322-b784-46a3-b37a-9e87af6eb082">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13a2eb4e3a324853b0f3388887ed2b2c_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTUtMTAtMS0xLTIyMTU2OA_5b5695bf-55a8-46ba-9dc6-853038b193da">9.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf4bf1050794419cbf96df94e7e5a822_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTYtOC0xLTEtMjIxNTY4_e50036cd-86e4-426f-97a6-0deb3f788295">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fd3f28a70a64843aab800c66e3727dd_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTYtMTAtMS0xLTIyMTU2OA_3080010b-c104-4c09-8d1f-f899b68f5a95">32.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in connection with up-front payments received</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cfd4128aea7458a926f5ef7dc7d8228_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTctOC0xLTEtMjIxNTY4_3d9ff175-c1f5-4fbe-a0b8-49d24ecda86d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1807e85b9a734966b305aebfce1a2b3e_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTctMTAtMS0xLTIyMTU2OA_53d55dc7-0a2f-48f0-a379-98876a316be1">18.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As described within the "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Immuno-Oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">" section below, effective July 1, 2022, the Company obtained the exclusive right to develop, commercialize, and manufacture Libtayo worldwide.</span></div></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Contents</a></span></div></div><ix:continuation id="ic81034a76850462f9b94892d666f0ce5" continuedAt="ic659d31458c2478896d713b84d0bd9fa"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antibody</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a global, strategic collaboration with Sanofi to research, develop, and commercialize fully human monoclonal antibodies (the "Antibody Collaboration"), which currently consists of Dupixent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (dupilumab), Kevzara</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sarilumab), and itepekimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Antibody License and Collaboration Agreement (the "LCA"), Sanofi is generally responsible for funding <ix:nonFraction unitRef="number" contextRef="i93a73ef5b43a4b719c774ecb420922ef_D20230101-20230331" decimals="2" name="regn:PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfNTc0_e2cfb571-0cfb-43de-8514-af97e4e76cbd">80</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="iaa0640ad68f44c88a2dbc0ebca2b3b73_D20230101-20230331" decimals="2" name="regn:PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfNTgw_c05e1c59-0f9b-42e9-a1d7-7b432a1430c3">100</ix:nonFraction>% of agreed-upon development costs. The Company is obligated to reimburse Sanofi for <ix:nonFraction unitRef="number" contextRef="i93a73ef5b43a4b719c774ecb420922ef_D20230101-20230331" decimals="2" name="regn:PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfNjU4_e8a8c446-b532-444c-ad4a-9c44d9fc63ee">30</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="iaa0640ad68f44c88a2dbc0ebca2b3b73_D20230101-20230331" decimals="2" name="regn:PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfNjY0_00ae7ff2-ab7c-4130-be67-db8ee84dcc7d">50</ix:nonFraction>% of worldwide development expenses that were funded by Sanofi based on the Company's share of collaboration profits from commercialization of collaboration products. Under the terms of the LCA, the Company was required to apply <ix:nonFraction unitRef="number" contextRef="i76483ad7f52e40cab4a22bb58eb53286_D20230101-20230331" decimals="2" name="regn:PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfOTE3_cb1a95f7-7b3a-4fe4-9843-a36af4d43dba">10</ix:nonFraction>% of its share of the profits from the Antibody Collaboration in any calendar quarter to reimburse Sanofi for these development costs. On July 1, 2022, an amendment to the LCA became effective, pursuant to which the percentage of the Company's share of profits used to reimburse Sanofi for such development costs increased from <ix:nonFraction unitRef="number" contextRef="i38436edb47124f8fb19121d45a1874e7_D20220630-20220630" decimals="2" name="regn:PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfMTI4NQ_d78291f1-1111-4557-bfe6-f143abcc2e10">10</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ia4de45f3331e49d0bc3791fd059ee5a4_D20220701-20220701" decimals="2" name="regn:PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfMTI5MQ_cfb68af1-906f-49b2-90c1-64882d7b0783">20</ix:nonFraction>%. A portion of the value associated with the increase in reimbursement percentage was deemed to be contingent consideration attributable to the Company's acquisition of the Libtayo (cemiplimab) rights described within the "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immuno-Oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" section below; this portion will be recorded as an increase to the Libtayo intangible asset over time as the Company repays such development costs to Sanofi. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanofi leads commercialization activities for products under the Antibody Collaboration, subject to the Company's right to co-commercialize such products. In addition to profit and loss sharing, the Company is entitled to receive sales milestone payments from Sanofi. During the three months ended March 31, 2022, the Company earned a $<ix:nonFraction unitRef="usd" contextRef="icd392818c90b43539fc9c9768bb1ca18_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfMjAxNA_a6671463-dfa5-4501-b415-c28923dee220">50.0</ix:nonFraction>&#160;million sales-based milestone from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $<ix:nonFraction unitRef="usd" contextRef="icd392818c90b43539fc9c9768bb1ca18_D20220101-20220331" decimals="-8" name="regn:LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfMjE1MQ_e1cfd003-6f79-492e-8b80-47acbc78691a">2.0</ix:nonFraction>&#160;billion on a rolling <ix:nonNumeric contextRef="icd392818c90b43539fc9c9768bb1ca18_D20220101-20220331" name="regn:PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfMTMzNTM_e6c36bb8-96cd-4687-8538-e56d960f7c0e">twelve-month</ix:nonNumeric> basis. The Company is entitled to receive the final sales milestone payment of $<ix:nonFraction unitRef="usd" contextRef="idd80951ec63945c1a0f004821f556950_I20230331" decimals="-5" name="regn:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfMjQ3Mg_f9fba110-cac5-4d62-b96a-c3088b801497">50.0</ix:nonFraction>&#160;million when such sales outside the United States exceed $<ix:nonFraction unitRef="usd" contextRef="i78bee0b457e64f8ca4716924e360fafb_D20230101-20230331" decimals="-8" name="regn:LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfMjY1MQ_b88032ed-9ee8-4548-9cff-564c0267246f">3.0</ix:nonFraction>&#160;billion on a rolling <ix:nonNumeric contextRef="i78bee0b457e64f8ca4716924e360fafb_D20230101-20230331" name="regn:PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfMTMzNjc_d4c7d913-5e2c-48aa-938d-f2b025479670">twelve-month</ix:nonNumeric> basis.</span></div><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfMTM0MDI_2f716675-ead5-40f7-b7ab-3c6f9665c33f" continuedAt="i09b3f15b033743cfa267748b9404e239" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Company's Antibody Collaboration with Sanofi:</span></div><div style="margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.502%"><tr><td style="width:1.0%"></td><td style="width:49.268%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.487%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.489%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cbbeeb8ba0490fb582afb27330f7db_I20230331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjA1ZjczYWUzYTZiYjRiZmM4YmU3ZjdlMTk4MDllMTg3L3RhYmxlcmFuZ2U6MDVmNzNhZTNhNmJiNGJmYzhiZTdmN2UxOTgwOWUxODdfMi0yLTEtMS0yMjE1Njg_33cc13e5-348f-4fdf-b349-282f5bbb73bc">731.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea9b652c53d4a4c82b1a7b4ea756d8c_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjA1ZjczYWUzYTZiYjRiZmM4YmU3ZjdlMTk4MDllMTg3L3RhYmxlcmFuZ2U6MDVmNzNhZTNhNmJiNGJmYzhiZTdmN2UxOTgwOWUxODdfMi00LTEtMS0yMjE1Njg_bfec8a9d-2b14-4eb8-aa5d-53e823e97c6f">692.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cbbeeb8ba0490fb582afb27330f7db_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjA1ZjczYWUzYTZiYjRiZmM4YmU3ZjdlMTk4MDllMTg3L3RhYmxlcmFuZ2U6MDVmNzNhZTNhNmJiNGJmYzhiZTdmN2UxOTgwOWUxODdfMy0yLTEtMS0yMjE1Njg_9b2c17a8-e3a8-4813-a342-5f7ee32dd064">377.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea9b652c53d4a4c82b1a7b4ea756d8c_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjA1ZjczYWUzYTZiYjRiZmM4YmU3ZjdlMTk4MDllMTg3L3RhYmxlcmFuZ2U6MDVmNzNhZTNhNmJiNGJmYzhiZTdmN2UxOTgwOWUxODdfMy00LTEtMS0yMjE1Njg_5c5e7459-a964-45df-a1a8-dc3540af4c7f">415.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immuno-Oncology</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was previously a party to a collaboration with Sanofi for antibody-based cancer treatments in the field of immuno-oncology (the "IO Collaboration"). Under the terms of the Immuno-oncology License and Collaboration Agreement, the parties were co-developing and co-commercializing Libtayo. The parties shared equally, on an ongoing basis, development and commercialization expenses for Libtayo. The Company had principal control over the development of Libtayo and led commercialization activities in the United States, while Sanofi led commercialization activities outside of the United States. The parties shared equally in profits and losses in connection with the commercialization of Libtayo.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective July 1, 2022, the Company obtained the exclusive right to develop, commercialize, and manufacture Libtayo worldwide under an Amended and Restated Immuno-oncology License and Collaboration Agreement with Sanofi (the "A&amp;R IO LCA"). In connection with the A&amp;R IO LCA, in 2022, the Company made a $<ix:nonFraction unitRef="usd" contextRef="ia67b58013e1b4eb9829600ae26b049f1_D20220701-20221231" decimals="-5" name="regn:UpFrontPaymentToCollaboratingParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfNjA0NzMxMzk3ODU4OQ_268b540f-4d63-44e1-bf9d-d023f6b7d2d8">900.0</ix:nonFraction>&#160;million up-front payment to Sanofi, as well as a $<ix:nonFraction unitRef="usd" contextRef="ib05c9a4e748542a39f0ded000f62b58a_D20220701-20221231" decimals="-5" name="regn:UpFrontPaymentToCollaboratingParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfMzg4MQ_54b856f0-93a0-4be3-95d5-78c3790ad5fd">100.0</ix:nonFraction>&#160;million regulatory milestone payment. In addition, Sanofi earned a $<ix:nonFraction unitRef="usd" contextRef="i157885e3534940e6bbf0c1712c537758_D20220701-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfNjA0NzMxMzk3ODU0NA_ed88d6b7-4fa2-42ec-8274-f3236c94eaf4">65.0</ix:nonFraction>&#160;million sales-based milestone upon the achievement of a specified amount of worldwide net product sales of Libtayo in 2022 and is eligible to receive an additional $<ix:nonFraction unitRef="usd" contextRef="i51a33fff830d49e2836b1dcc69fd8e6d_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfNjA0NzMxMzk3ODU1OQ_a94084a8-a9b4-4873-9509-848f591f801d">35.0</ix:nonFraction>&#160;million sales-based milestone upon the achievement of a specified amount of worldwide net product sales of Libtayo in 2023 (aggregate of $<ix:nonFraction unitRef="usd" contextRef="idfc4183c9b684d69800dbe32f7df3f9c_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfMzkzMQ_28e11216-732e-4b54-8243-d42486d0146d">100.0</ix:nonFraction>&#160;million in sales-based milestones eligible to be earned under the terms of the A&amp;R IO LCA). The Company also pays Sanofi an <ix:nonFraction unitRef="number" contextRef="i28142adb16bf44cd9637c180668c9386_D20230101-20230331" decimals="2" name="regn:RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfNDA4Mw_1d0d9c20-8555-48de-982b-b764d58c96e1">11</ix:nonFraction>% royalty on net product sales of Libtayo through March 31, 2034. The transaction was accounted for as an asset acquisition and amounts paid to Sanofi in connection with obtaining the worldwide rights to Libtayo, including the up-front payment and any contingent consideration, are recorded as an intangible asset.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Contents</a></span></div></div><ix:continuation id="ic659d31458c2478896d713b84d0bd9fa" continuedAt="ic227d8854f5843969fe9d3b7ff821a3d"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">b. Bayer </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a license and collaboration agreement with Bayer for the global development and commercialization of EYLEA (aflibercept) and aflibercept 8 mg outside the United States. Agreed-upon development expenses incurred by the Company and Bayer are generally shared equally. Bayer markets EYLEA outside the United States, and the companies share equally in profits and losses from such sales.</span></div><ix:continuation id="i337d61af07574f3d9e48a32728343979" continuedAt="i9ae7b7ddf33c4a77b656b7ebfed56bae"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Statements of Operations in connection with its Bayer collaboration are as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"></td><td style="width:49.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.931%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.934%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of EYLEA outside the United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb424b76bb944bb487058cb7b71b5478_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjM5M2FiMzQ4ZTNlOTRiNDM5NGE1YmI4ZDRjZmUxMTNiL3RhYmxlcmFuZ2U6MzkzYWIzNDhlM2U5NGI0Mzk0YTViYjhkNGNmZTExM2JfMi04LTEtMS0yMjE1Njg_9bb2ce4b-34d7-443b-b651-56598d7a20e8">331.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba893ed59b6f4ef9b1de82284a9c172b_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjM5M2FiMzQ4ZTNlOTRiNDM5NGE1YmI4ZDRjZmUxMTNiL3RhYmxlcmFuZ2U6MzkzYWIzNDhlM2U5NGI0Mzk0YTViYjhkNGNmZTExM2JfMi0xMC0xLTEtMjIxNTY4_dcb56e6f-de6d-42a5-8b7d-b21ebf656117">338.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of ex-U.S. commercial supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0252272660b2483c9bdc58226cbd09da_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjM5M2FiMzQ4ZTNlOTRiNDM5NGE1YmI4ZDRjZmUxMTNiL3RhYmxlcmFuZ2U6MzkzYWIzNDhlM2U5NGI0Mzk0YTViYjhkNGNmZTExM2JfMy04LTEtMS0yMjE1Njg_401a3c42-684b-4ed7-b904-4fe45a32a6e5">25.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idde62877d41141df8937d3435f4c3667_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjM5M2FiMzQ4ZTNlOTRiNDM5NGE1YmI4ZDRjZmUxMTNiL3RhYmxlcmFuZ2U6MzkzYWIzNDhlM2U5NGI0Mzk0YTViYjhkNGNmZTExM2JfMy0xMC0xLTEtMjIxNTY4_4b50ce66-2c0a-4311-bd07-43ff4744ccd7">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One-time payment in connection with change in Japan arrangement</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf1d66b82008486885a981ea123058f2_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjM5M2FiMzQ4ZTNlOTRiNDM5NGE1YmI4ZDRjZmUxMTNiL3RhYmxlcmFuZ2U6MzkzYWIzNDhlM2U5NGI0Mzk0YTViYjhkNGNmZTExM2JfNC04LTEtMS0yMjE1Njg_1d336e48-11af-4833-b805-4462644723cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia020696b0d3c4162aea4b7989e504a75_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjM5M2FiMzQ4ZTNlOTRiNDM5NGE1YmI4ZDRjZmUxMTNiL3RhYmxlcmFuZ2U6MzkzYWIzNDhlM2U5NGI0Mzk0YTViYjhkNGNmZTExM2JfNC0xMC0xLTEtMjIxNTY4_f5fed62b-2755-4863-937f-450e7c2166c6">21.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Bayer R&amp;D expenses, net of reimbursement of R&amp;D expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(R&amp;D expense)/Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a5fff795cfe4c74b86bc4bd5174db81_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjM5M2FiMzQ4ZTNlOTRiNDM5NGE1YmI4ZDRjZmUxMTNiL3RhYmxlcmFuZ2U6MzkzYWIzNDhlM2U5NGI0Mzk0YTViYjhkNGNmZTExM2JfNS00LTEtMS0yNDg0Mjc_09d88d9e-e7c5-48cd-a39d-3856eaf6900c">13.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 16.75pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie08517bc56f64a56855dedc1fd282413_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjM5M2FiMzQ4ZTNlOTRiNDM5NGE1YmI4ZDRjZmUxMTNiL3RhYmxlcmFuZ2U6MzkzYWIzNDhlM2U5NGI0Mzk0YTViYjhkNGNmZTExM2JfNS02LTEtMS0yNDg0Mjc_1796e1ff-913d-4030-b8e5-f98c94c412e8">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:continuation id="i09b3f15b033743cfa267748b9404e239" continuedAt="ice992a8bcef5441097454bc90ad37ea3"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Company's Bayer collaboration:</span></div><div style="margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.795%"><tr><td style="width:1.0%"></td><td style="width:49.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9e294aebc65480da80f32f7028adbb2_I20230331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjM3MTZlNGM5ZDA3NjQwYTc4YzIwZjUxNmE1ZDJkZmI0L3RhYmxlcmFuZ2U6MzcxNmU0YzlkMDc2NDBhNzhjMjBmNTE2YTVkMmRmYjRfMi0yLTEtMS0yMjE1Njg_8fde4bc4-d7a0-4854-ad44-5a0da62f4095">356.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i102f804ba9484132ae7196bde6f74767_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjM3MTZlNGM5ZDA3NjQwYTc4YzIwZjUxNmE1ZDJkZmI0L3RhYmxlcmFuZ2U6MzcxNmU0YzlkMDc2NDBhNzhjMjBmNTE2YTVkMmRmYjRfMi00LTEtMS0yMjE1Njg_55365a9b-1266-448f-b46a-04775c0d5e3b">348.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9e294aebc65480da80f32f7028adbb2_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjM3MTZlNGM5ZDA3NjQwYTc4YzIwZjUxNmE1ZDJkZmI0L3RhYmxlcmFuZ2U6MzcxNmU0YzlkMDc2NDBhNzhjMjBmNTE2YTVkMmRmYjRfMy0yLTEtMS0yMjE1Njg_df10e486-ce15-4214-bdb8-67f73b131e1b">134.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i102f804ba9484132ae7196bde6f74767_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjM3MTZlNGM5ZDA3NjQwYTc4YzIwZjUxNmE1ZDJkZmI0L3RhYmxlcmFuZ2U6MzcxNmU0YzlkMDc2NDBhNzhjMjBmNTE2YTVkMmRmYjRfMy00LTEtMS0yMjE1Njg_f6eb2663-106d-49d0-8cdd-03999a8de43a">131.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">c. Roche</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to a collaboration agreement (the "Roche Collaboration Agreement") with Roche to develop, manufacture, and distribute the casirivimab and imdevimab antibody cocktail (known as REGEN-COV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States and Ronapreve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in other countries). Under the terms of the collaboration agreement, the parties jointly fund certain studies, and the Company has the right to distribute the product in the United States while Roche has the right to distribute the product outside of the United States. The parties share gross profits from worldwide sales based on a pre-specified formula, depending on the amount of manufactured product supplied by each party to the market. </span></div><ix:continuation id="i9ae7b7ddf33c4a77b656b7ebfed56bae"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Statements of Operations in connection with the Roche Collaboration Agreement are as follows:</span></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.818%"><tr><td style="width:1.0%"></td><td style="width:48.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global gross profit payment from Roche in connection with sales of Ronapreve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64841568e706401985fc84aa04b36f1e_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOmRmMTc3ZTg0ZmMxZDRkYTJiZTgxYmNjN2I5YjdiMjJlL3RhYmxlcmFuZ2U6ZGYxNzdlODRmYzFkNGRhMmJlODFiY2M3YjliN2IyMmVfMi04LTEtMS0yMjE1Njg_5d7445d1-a256-473f-a19a-c5bc68d2f474">222.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f6f63a87914141b95f4f2c48ff1364_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOmRmMTc3ZTg0ZmMxZDRkYTJiZTgxYmNjN2I5YjdiMjJlL3RhYmxlcmFuZ2U6ZGYxNzdlODRmYzFkNGRhMmJlODFiY2M3YjliN2IyMmVfMi0xMC0xLTEtMjIxNTY4_fd234a02-d748-43ea-848b-2b6661e9638b">216.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement of research and development expenses from Roche was not material for the three months ended March&#160;31, 2023 and 2022.</span></div><ix:continuation id="ice992a8bcef5441097454bc90ad37ea3"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Roche Collaboration Agreement:</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.368%"><tr><td style="width:1.0%"></td><td style="width:58.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.296%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38fd75f0c02644a59d387c1d665dac3e_I20230331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjQ3ZWI4N2VjNmYwYzQwYTk5ZjA1ODM3YTAyMDhjNjBlL3RhYmxlcmFuZ2U6NDdlYjg3ZWM2ZjBjNDBhOTlmMDU4MzdhMDIwOGM2MGVfMi0yLTEtMS0yMjE1Njg_ade58d72-a45f-4cda-9686-e323a96c51ea">220.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e796f5592204aff856a0effed5d30f5_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjQ3ZWI4N2VjNmYwYzQwYTk5ZjA1ODM3YTAyMDhjNjBlL3RhYmxlcmFuZ2U6NDdlYjg3ZWM2ZjBjNDBhOTlmMDU4MzdhMDIwOGM2MGVfMi00LTEtMS0yMjE1Njg_fd332cd6-e279-41bb-ac19-95bdddbe187b">396.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="ic227d8854f5843969fe9d3b7ff821a3d" continuedAt="i9548e376710d4de493c9e1529d79ec3b">d. Sonoma Biotherapeutics, Inc.</ix:continuation></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><ix:continuation id="i9548e376710d4de493c9e1529d79ec3b" continuedAt="idc9d8d39a91d4de88e31fcbf3525f535"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company and Sonoma Biotherapeutics, Inc. entered into a license and collaboration agreement to bring together the Company's </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VelociSuite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technologies with Sonoma's technology platform for the discovery, development, and commercialization of novel regulatory T cell (T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">reg</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idc9d8d39a91d4de88e31fcbf3525f535">) therapies for autoimmune diseases. In connection with the agreement, the Company made a $<ix:nonFraction unitRef="usd" contextRef="i9c9892adbc9444b2ba40d227075a443b_D20230101-20230331" decimals="-5" name="regn:UpFrontPaymentToCollaboratingParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfOTg5NTYwNDY4Mzc5OA_38e1373c-afb4-4400-9d49-a3f5862e232e">45.0</ix:nonFraction>&#160;million up-front payment (which was recorded to Acquired in-process research and development expense in the first quarter of 2023) and, in April 2023, the Company purchased an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ib6c0a3e1eb3f4fa4b60c33bacffd2f52_D20230401-20230430" decimals="-5" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfOTg5NTYwNDY4MzkyOA_cb39d3e8-3b8a-4914-8387-46be2a7c58ce">30.0</ix:nonFraction>&#160;million of Sonoma preferred stock. Sonoma is also eligible to receive a $<ix:nonFraction unitRef="usd" contextRef="id3456908093f4728b4a4f17cb0d3cd19_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfOTg5NTYwNDY4Mzk0Mw_97c4dc4d-898e-4df7-a40c-3d91e576e8d7">45.0</ix:nonFraction>&#160;million development milestone payment. The Company and Sonoma will co-fund research and development activities and share equally any future commercial expenses and profits. The Company will have the option to lead late-stage development and commercialization on all products globally, with Sonoma retaining rights to co-promote all such products in the United States.</ix:continuation> </span></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_40"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RleHRyZWdpb246Y2UyODgyY2NmMTIyNGY0OWFlYzZmNWU0MmJkYjFkYjJfNzU1_6a6cb5e2-ac58-4d98-b560-81560a1992e6" continuedAt="i91c8ac3e1cfb4612bea653867818bc81" escape="true">Net Income Per Share </ix:nonNumeric></span></div><ix:continuation id="i91c8ac3e1cfb4612bea653867818bc81"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share is computed by dividing net income by the weighted average number of shares of Common Stock and Class A Stock outstanding. Net income per share is presented on a combined basis, inclusive of Common Stock and Class A Stock outstanding, as each class of stock has equivalent economic rights. Diluted net income per share includes the potential dilutive effect of other securities as if such securities were converted or exercised during the period, when the effect is dilutive. <ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RleHRyZWdpb246Y2UyODgyY2NmMTIyNGY0OWFlYzZmNWU0MmJkYjFkYjJfNzYz_8b918097-4edf-430e-b337-c2b44c4a5ecc" continuedAt="if8bac74ff3c44bbc9e74a3c91faa4298" escape="true">The calculations of basic and diluted net income per share are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><ix:continuation id="if8bac74ff3c44bbc9e74a3c91faa4298"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.304%"><tr><td style="width:1.0%"></td><td style="width:64.719%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.838%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfMi02LTEtMS0yMjE1Njg_fa7cf586-c2f9-4aec-a591-9c373d2be169">817.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfMi04LTEtMS0yMjE1Njg_9a8e43e4-8a9b-4938-aa27-d82913a089a6">973.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfNC02LTEtMS0yMjE1Njg_68ef17e2-6e01-472c-9def-c4fce0d1c77d">107.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfNC04LTEtMS0yMjE1Njg_3e9f1b2b-8c4e-4996-a070-2ae1167fc6d8">106.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b0f6d873f2441d7890447099c7468ad_D20230101-20230331" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfNi02LTEtMS0yMjE1Njg_f04ddb55-c0d3-480c-ab17-f1f1d3e35ab4">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i899f0e7929c744418d1f315d17e1594a_D20220101-20220331" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfNi04LTEtMS0yMjE1Njg_34ebd9b0-a2a3-4241-8f10-bab2bcdf5dc9">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards and restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i084af335d0d14bb79b9fc2db8159a242_D20230101-20230331" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfNy02LTEtMS0yMjE1Njg_44b875f0-536e-4460-98a4-f4b296c56bb9">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2be78b3922ff4f9196bd6708075600e8_D20220101-20220331" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfNy04LTEtMS0yMjE1Njg_8d13b272-993a-4e09-b449-181bf32f6034">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfOC02LTEtMS0yMjE1Njg_7270f1a6-b17c-46b8-a4c8-480d71c7f234">114.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfOC04LTEtMS0yMjE1Njg_ba6b35b1-2a2a-4504-866d-c467e69297af">113.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfMTAtNi0xLTEtMjIxNTY4_b567779a-a8bc-441f-bd6d-392c26f51085">7.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfMTAtOC0xLTEtMjIxNTY4_1501ba35-80a0-4995-a08c-1918aac9a3e9">9.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfMTEtNi0xLTEtMjIxNTY4_a6117a81-11fb-48b1-9865-c236e3dd9c02">7.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfMTEtOC0xLTEtMjIxNTY4_15f5ef34-69dd-497d-b932-b3b766ade013">8.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RleHRyZWdpb246Y2UyODgyY2NmMTIyNGY0OWFlYzZmNWU0MmJkYjFkYjJfNzYx_04545c16-bbca-4885-837e-6de7ba5905ff" escape="true"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from diluted per share amounts because their effect would have been antidilutive include the following:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.298%"><tr><td style="width:1.0%"></td><td style="width:54.015%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Shares in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7aef696237bd4fa2bb67d81627a03291_D20230101-20230331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjQwMDhjYjJlMmVhMDQzMjg4MjBkYzcwMjM1MmY4NjY1L3RhYmxlcmFuZ2U6NDAwOGNiMmUyZWEwNDMyODgyMGRjNzAyMzUyZjg2NjVfMi02LTEtMS0yMjE1Njg_291fa9d4-3d64-48f0-a82b-e2104e503f6f">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic57e069f15ea4d1eb588c09adef593ba_D20220101-20220331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjQwMDhjYjJlMmVhMDQzMjg4MjBkYzcwMjM1MmY4NjY1L3RhYmxlcmFuZ2U6NDAwOGNiMmUyZWEwNDMyODgyMGRjNzAyMzUyZjg2NjVfMi04LTEtMS0yMjE1Njg_8324bb97-d01f-4e62-8a1e-c5c75fff177a">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_43"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RleHRyZWdpb246YzE3YjdmZGZkNjEwNDJiNjhiM2Q1OGVjZDdmYjhkMzZfMTI1Nw_b00369ad-46a3-4189-ad45-c5ce9d8c0089" continuedAt="i1478eb70d1264383b947463cb564b2ac" escape="true">Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="i1478eb70d1264383b947463cb564b2ac" continuedAt="i003f8d0d1cbe4b88b36ee35b3f5e75b8"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities as of March&#160;31, 2023 and December&#160;31, 2022 consist of both available-for-sale debt securities of investment grade issuers (see below and Note 6) as well as equity securities of publicly traded companies (see Note 6).</span></div><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RleHRyZWdpb246YzE3YjdmZGZkNjEwNDJiNjhiM2Q1OGVjZDdmYjhkMzZfMTI4NA_4942d177-dd00-458a-b89f-fa6d7a4f21a4" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's investments in available-for-sale debt securities:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:46.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of March&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8903a1b5844542cfbc9e394aa701aed8_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMi0yLTEtMS0yMjE1Njg_b998f3f9-8729-455c-b3ce-8a279cdbc31e">6,819.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8903a1b5844542cfbc9e394aa701aed8_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMi00LTEtMS0yMjE1Njg_74990bc7-5883-41f5-9bdd-66e82167008f">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8903a1b5844542cfbc9e394aa701aed8_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMi02LTEtMS0yMjE1Njg_2ca19163-ba05-4733-b29e-075d872773b0">231.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8903a1b5844542cfbc9e394aa701aed8_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMi04LTEtMS0yMjE1Njg_9aa2e0d0-71c6-481e-8314-96860cbbbd35">6,592.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb936c554134642a68368b066e9f82a_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMy0yLTEtMS0yMjE1Njg_14ba1c64-18ae-4376-a562-a3dceede6c78">2,902.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb936c554134642a68368b066e9f82a_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMy00LTEtMS0yMjE1Njg_a846bbc2-8bc2-407b-bbfd-0a7c19628e61">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifdb936c554134642a68368b066e9f82a_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMy02LTEtMS0yMjE1Njg_db2ec1be-43ce-47b2-9a19-9d89d1b6838f">4.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb936c554134642a68368b066e9f82a_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMy04LTEtMS0yMjE1Njg_55b2cc14-5645-4402-bdce-2c21c3557854">2,903.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb70d5f062d4e928b605b2f2599a47d_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNC0yLTEtMS0yMjE1Njg_5f3da1df-2928-4934-b709-0554ee8a2d0d">72.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb70d5f062d4e928b605b2f2599a47d_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNC00LTEtMS0yMjE1Njg_78bded6c-e12c-427b-a3c6-34903822b4ea">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifdb70d5f062d4e928b605b2f2599a47d_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNC02LTEtMS0yMjE1Njg_5cfe9b65-2145-4480-81f9-5a165f32c016">2.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb70d5f062d4e928b605b2f2599a47d_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNC04LTEtMS0yMjE1Njg_731976b3-0841-46a9-8e73-8525f78fcf85">70.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9bf0ce9cab24153b67d76ba77f2f319_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNS0yLTEtMS0yMjE1Njg_e584501d-e995-4a72-9090-e127028ce819">279.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9bf0ce9cab24153b67d76ba77f2f319_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNS00LTEtMS0yMjE1Njg_ba8c364b-5009-42db-851f-9fcbcdab4b59">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9bf0ce9cab24153b67d76ba77f2f319_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNS02LTEtMS0yMjE1Njg_44ddf870-5a9f-4219-ae4b-e96b063a2c17">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9bf0ce9cab24153b67d76ba77f2f319_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNS04LTEtMS0yMjE1Njg_04162509-121f-4dcb-8202-3bb5ddb498d9">279.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i418c3363911e44aba24f1ae219890db8_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNi0yLTEtMS0yMjE1Njg_d579b79d-50d8-4371-9a26-9027061a787b">153.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i418c3363911e44aba24f1ae219890db8_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNi00LTEtMS0yMjE1Njg_4387965d-9216-43cf-b04b-34b8f1cf767d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i418c3363911e44aba24f1ae219890db8_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNi02LTEtMS0yMjE1Njg_9600e0e1-e09f-428a-b211-6090271b2bf3">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i418c3363911e44aba24f1ae219890db8_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNi04LTEtMS0yMjE1Njg_6e2bab55-633a-48f7-8222-13967e05879e">153.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab279394f6cf43de9deae81fa065d878_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNy0yLTEtMS0yMjE1Njg_1636660b-8ee2-4d0e-ae5e-00bc2ea2f5fb">53.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab279394f6cf43de9deae81fa065d878_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNy00LTEtMS0yMjE1Njg_70bc3b7c-a91b-4dfd-9946-f7d92214cafa">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab279394f6cf43de9deae81fa065d878_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNy02LTEtMS0yMjE1Njg_04ae6f45-190d-42df-9c1d-82ff1eb5d5d1">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab279394f6cf43de9deae81fa065d878_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNy04LTEtMS0yMjE1Njg_5a70aaba-6bc2-4b2d-9373-ec516b53e16b">52.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfOC0yLTEtMS0yMjE1Njg_7e818f4c-69c1-4dda-bf98-223ed0d290ad">10,280.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfOC00LTEtMS0yMjE1Njg_1751fb13-df6f-43ce-a86a-9da874eaa7f6">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfOC02LTEtMS0yMjE1Njg_ed0bc025-2ae6-46ad-97f7-280ca5f48492">240.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfOC04LTEtMS0yMjE1Njg_6b1ba3c3-ceff-4ae1-9de6-b72cd5fbda96">10,051.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf94038a80c74b0d9edbcbeccb24dde9_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTEtMi0xLTEtMjIxNTY4_8882fbb2-0cfc-4f07-9e11-724bd3c06de5">6,975.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf94038a80c74b0d9edbcbeccb24dde9_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTEtNC0xLTEtMjIxNTY4_7598b910-e5ba-416d-ad0c-656d240960ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf94038a80c74b0d9edbcbeccb24dde9_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTEtNi0xLTEtMjIxNTY4_b824d8ee-a585-4583-8975-d67a034225fe">291.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf94038a80c74b0d9edbcbeccb24dde9_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTEtOC0xLTEtMjIxNTY4_7d2b4526-f541-450f-af1a-86030f2f77d7">6,684.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8a4bb9880684a74adbfbf4815ad715c_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTItMi0xLTEtMjIxNTY4_7811fd27-0580-43ef-aaea-382747e77894">2,945.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8a4bb9880684a74adbfbf4815ad715c_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTItNC0xLTEtMjIxNTY4_0de1ba83-24d0-457a-adc3-016d25cfd3c0">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8a4bb9880684a74adbfbf4815ad715c_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTItNi0xLTEtMjIxNTY4_1cde2c36-c5f9-44e7-8a77-86a091e7b467">6.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8a4bb9880684a74adbfbf4815ad715c_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTItOC0xLTEtMjIxNTY4_3b6ca285-9a54-4557-9180-30f59943c87f">2,939.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a32793eceeb4ea687e38aa30fc6de37_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTMtMi0xLTEtMjIxNTY4_53ae7634-291c-4ff8-ab5f-a78915f4a845">67.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a32793eceeb4ea687e38aa30fc6de37_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTMtNC0xLTEtMjIxNTY4_3cce665c-bc7e-4b05-a430-097a2bb913df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a32793eceeb4ea687e38aa30fc6de37_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTMtNi0xLTEtMjIxNTY4_17a8ec7f-aea2-4071-97f3-3eb797a21002">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a32793eceeb4ea687e38aa30fc6de37_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTMtOC0xLTEtMjIxNTY4_df1976f8-698f-4fe0-966d-7987db735d31">64.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31e5c62bbe8047b78e6c3041593ef2fe_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTQtMi0xLTEtMjIxNTY4_d1b0d336-bc35-47c9-9705-872ac58cd3c8">121.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31e5c62bbe8047b78e6c3041593ef2fe_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTQtNC0xLTEtMjIxNTY4_d2ba7a50-224c-4b80-ba8c-5886e55c64db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31e5c62bbe8047b78e6c3041593ef2fe_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTQtNi0xLTEtMjIxNTY4_6cde1173-89a4-4ef6-839d-073728ec7a2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31e5c62bbe8047b78e6c3041593ef2fe_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTQtOC0xLTEtMjIxNTY4_ec9a2dd7-9e76-4a73-b81d-6e62fa1bb219">121.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d7998c008a645b497664f16dfdf9c3e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTUtMi0xLTEtMjIxNTY4_3b9dc8b2-2a2d-476c-ac61-04005321dd08">182.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d7998c008a645b497664f16dfdf9c3e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTUtNC0xLTEtMjIxNTY4_511ee6e7-2a08-40ad-910b-9362f6449766">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d7998c008a645b497664f16dfdf9c3e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTUtNi0xLTEtMjIxNTY4_361b0c42-1778-4fb4-af40-90c814119f01">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d7998c008a645b497664f16dfdf9c3e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTUtOC0xLTEtMjIxNTY4_5643898e-f966-424d-83e7-2113506a6167">182.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076e28d6501548bba1781c8d95c229c1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTYtMi0xLTEtMjIxNTY4_38594c31-d232-4549-839b-55956d6d2752">28.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076e28d6501548bba1781c8d95c229c1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTYtNC0xLTEtMjIxNTY4_4210fcbd-8af2-4a58-84d7-26b03dbce2a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i076e28d6501548bba1781c8d95c229c1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTYtNi0xLTEtMjIxNTY4_e672f188-bae1-4dfc-a9a4-559a52b24861">1.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076e28d6501548bba1781c8d95c229c1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTYtOC0xLTEtMjIxNTY4_db93bc6a-e075-4fe9-b054-0da07ba76b4b">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTctMi0xLTEtMjIxNTY4_c4a0fd19-5d7a-43f8-9bd3-29b730443547">10,320.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTctNC0xLTEtMjIxNTY4_2fdad84c-8518-4cd9-8384-28dcb84c3175">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTctNi0xLTEtMjIxNTY4_1847e3f1-183e-4786-8b0a-e17d734cb070">302.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTctOC0xLTEtMjIxNTY4_16200ac0-ad13-4e96-8a1d-5dd062fd4ff5">10,018.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its investments in available-for-sale debt securities based on their contractual maturity dates. The available-for-sale debt securities as of March&#160;31, 2023 mature at various dates through August 2028. <ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RleHRyZWdpb246YzE3YjdmZGZkNjEwNDJiNjhiM2Q1OGVjZDdmYjhkMzZfMTI3MQ_54d498e8-3891-4f25-ba09-265f87994ec0" continuedAt="ic715e43ecdaf481ca95081e56d621776" escape="true">The fair values of available-for-sale debt securities by contractual maturity consist of the following:</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center;text-indent:13.5pt"><ix:continuation id="ic715e43ecdaf481ca95081e56d621776"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.473%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.933%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.933%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjU2YTVjNmVhNjBkNzRhNGJiOGQ0ZWY5Mjk5NmQ4YjhjL3RhYmxlcmFuZ2U6NTZhNWM2ZWE2MGQ3NGE0YmI4ZDRlZjkyOTk2ZDhiOGNfMi0yLTEtMS0yMjE1Njg_e7a37f73-3b3a-4fa6-9427-629fd647deed">5,043.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjU2YTVjNmVhNjBkNzRhNGJiOGQ0ZWY5Mjk5NmQ4YjhjL3RhYmxlcmFuZ2U6NTZhNWM2ZWE2MGQ3NGE0YmI4ZDRlZjkyOTk2ZDhiOGNfMi00LTEtMS0yMjE1Njg_0dc21fbe-6092-49d0-9af2-f2b65440619d">4,636.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjU2YTVjNmVhNjBkNzRhNGJiOGQ0ZWY5Mjk5NmQ4YjhjL3RhYmxlcmFuZ2U6NTZhNWM2ZWE2MGQ3NGE0YmI4ZDRlZjkyOTk2ZDhiOGNfMy0yLTEtMS0yMjE1Njg_28326190-b643-419b-88b0-fb3630c8d917">4,996.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjU2YTVjNmVhNjBkNzRhNGJiOGQ0ZWY5Mjk5NmQ4YjhjL3RhYmxlcmFuZ2U6NTZhNWM2ZWE2MGQ3NGE0YmI4ZDRlZjkyOTk2ZDhiOGNfMy00LTEtMS0yMjE1Njg_a55437fb-7fe9-4a32-9f38-6b83eb21b0e9">5,381.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities after five years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="regn:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjU2YTVjNmVhNjBkNzRhNGJiOGQ0ZWY5Mjk5NmQ4YjhjL3RhYmxlcmFuZ2U6NTZhNWM2ZWE2MGQ3NGE0YmI4ZDRlZjkyOTk2ZDhiOGNfNC0yLTEtMS0yMjU2MDY_d68e720d-d795-4166-ab6c-ced4ace238fe">11.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="regn:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjU2YTVjNmVhNjBkNzRhNGJiOGQ0ZWY5Mjk5NmQ4YjhjL3RhYmxlcmFuZ2U6NTZhNWM2ZWE2MGQ3NGE0YmI4ZDRlZjkyOTk2ZDhiOGNfNC00LTEtMS0yMjU2MDY_39234e90-bf05-44f4-9267-8c1a36c0942c">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjU2YTVjNmVhNjBkNzRhNGJiOGQ0ZWY5Mjk5NmQ4YjhjL3RhYmxlcmFuZ2U6NTZhNWM2ZWE2MGQ3NGE0YmI4ZDRlZjkyOTk2ZDhiOGNfNC0yLTEtMS0yMjE1Njg_3d14aaa3-09f9-42a7-9adf-b8cb0d37b080">10,051.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjU2YTVjNmVhNjBkNzRhNGJiOGQ0ZWY5Mjk5NmQ4YjhjL3RhYmxlcmFuZ2U6NTZhNWM2ZWE2MGQ3NGE0YmI4ZDRlZjkyOTk2ZDhiOGNfNC00LTEtMS0yMjE1Njg_cbf63a22-075c-4063-a5fb-5a6dd89e6a11">10,018.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Contents</a></span></div></div><ix:continuation id="i003f8d0d1cbe4b88b36ee35b3f5e75b8"><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RleHRyZWdpb246YzE3YjdmZGZkNjEwNDJiNjhiM2Q1OGVjZDdmYjhkMzZfMTI2MQ_e0f3e3ff-43d1-447e-80a7-3e8b1f01b1ec" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the fair value of the Company's available-for-sale debt securities&#160;that have unrealized losses, aggregated by investment category and length of time that the individual securities have been in a continuous loss position.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.590%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of March&#160;31, 2023</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8903a1b5844542cfbc9e394aa701aed8_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMi0xLTEtMS0yMjE1Njg_4f09dd90-25ce-424b-b91d-2474afeaf582">707.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8903a1b5844542cfbc9e394aa701aed8_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMi0zLTEtMS0yMjE1Njg_198c9dc0-24de-45d3-9c61-1bac85fa71ec">8.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8903a1b5844542cfbc9e394aa701aed8_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMi01LTEtMS0yMjE1Njg_f6d167cb-498f-445d-91e2-57012cf073fa">5,293.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8903a1b5844542cfbc9e394aa701aed8_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMi03LTEtMS0yMjE1Njg_36b72479-d5ea-45d8-9f2d-802123a01a5f">223.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8903a1b5844542cfbc9e394aa701aed8_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMi05LTEtMS0yMjE1Njg_ad44f3c7-a2d3-4b63-8eac-753a6e5e2686">6,000.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8903a1b5844542cfbc9e394aa701aed8_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMi0xMS0xLTEtMjIxNTY4_976b7dec-d32c-45e9-b1e1-66b99704decf">231.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb936c554134642a68368b066e9f82a_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMy0xLTEtMS0yMjE1Njg_46fec0d5-626f-432c-b1a1-09b8bbfccc98">228.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifdb936c554134642a68368b066e9f82a_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMy0zLTEtMS0yMjE1Njg_20488778-efed-47b9-8ddc-850f29d39649">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb936c554134642a68368b066e9f82a_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMy01LTEtMS0yMjE1Njg_25bdee4e-0bf0-4403-993e-57fe04f60b81">79.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifdb936c554134642a68368b066e9f82a_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMy03LTEtMS0yMjE1Njg_21b86220-14da-417b-be09-88c99e8546b1">4.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb936c554134642a68368b066e9f82a_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMy05LTEtMS0yMjE1Njg_191808e4-2ecc-4837-8bb5-7bcca80a9574">307.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifdb936c554134642a68368b066e9f82a_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMy0xMS0xLTEtMjIxNTY4_5981b94c-1f61-4f51-a5d1-52ab246f9e47">4.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb70d5f062d4e928b605b2f2599a47d_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNC0xLTEtMS0yMjE1Njg_10fc6ec1-28e4-48f6-9137-e449c1f2a1f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb70d5f062d4e928b605b2f2599a47d_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNC0zLTEtMS0yMjE1Njg_3d74254d-4604-46a0-a605-442bc1d509bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb70d5f062d4e928b605b2f2599a47d_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNC01LTEtMS0yMjE1Njg_94e9291e-19b2-4db7-8d7a-13bfb1347703">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifdb70d5f062d4e928b605b2f2599a47d_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNC03LTEtMS0yMjE1Njg_76abb273-6ae9-4c11-8b52-b88b0b00bb81">2.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb70d5f062d4e928b605b2f2599a47d_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNC05LTEtMS0yMjE1Njg_2d4101b3-1e89-4314-8622-4892661e856d">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifdb70d5f062d4e928b605b2f2599a47d_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNC0xMS0xLTEtMjIxNTY4_47717a9b-1976-42f6-9fc6-7e580aab0bcf">2.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9bf0ce9cab24153b67d76ba77f2f319_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNS0xLTEtMS0yMjE1Njg_767e3a28-bd0c-4343-b85a-482c483a8e24">212.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9bf0ce9cab24153b67d76ba77f2f319_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNS0zLTEtMS0yMjE1Njg_7704be7b-b231-4193-b128-e911e68b9e13">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9bf0ce9cab24153b67d76ba77f2f319_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNS01LTEtMS0yMjE1Njg_8d93d9ff-5e15-4b45-a043-8a02742275a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9bf0ce9cab24153b67d76ba77f2f319_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNS03LTEtMS0yMjE1Njg_350bd0cb-4808-438e-aefc-1184ac606a71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9bf0ce9cab24153b67d76ba77f2f319_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNS05LTEtMS0yMjE1Njg_e4206c7a-9c53-471b-abf6-b791bc37069b">212.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9bf0ce9cab24153b67d76ba77f2f319_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNS0xMS0xLTEtMjIxNTY4_563ff237-595e-4c3c-9d81-1794b0552cd5">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i418c3363911e44aba24f1ae219890db8_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNi0xLTEtMS0yMjE1Njg_d8036948-a1e1-4187-b8e1-ba3eb8b84ef3">74.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i418c3363911e44aba24f1ae219890db8_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNi0zLTEtMS0yMjE1Njg_a63f242a-44fe-4a39-87d9-df489f09f843">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i418c3363911e44aba24f1ae219890db8_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNi01LTEtMS0yMjE1Njg_5e8ff423-cc88-44b8-9972-911e1be08579">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i418c3363911e44aba24f1ae219890db8_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNi03LTEtMS0yMjE1Njg_c3cdb74f-b6b8-44a9-a9f6-5ebcb85555ac">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i418c3363911e44aba24f1ae219890db8_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNi05LTEtMS0yMjE1Njg_e45f0586-974a-4360-a6e1-d1c2be7dc631">77.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i418c3363911e44aba24f1ae219890db8_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNi0xMS0xLTEtMjIxNTY4_c940a884-b9b2-4d94-8b5b-575f01a9e349">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab279394f6cf43de9deae81fa065d878_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNy0xLTEtMS0yMjE1Njg_0fe0859c-7381-4313-a3ad-91cfa651cd6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab279394f6cf43de9deae81fa065d878_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNy0zLTEtMS0yMjE1Njg_6beec839-f9fe-4697-8c82-e71d3bd78184">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab279394f6cf43de9deae81fa065d878_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNy01LTEtMS0yMjE1Njg_43c351fd-cb0e-4676-84be-9fe0d9966cb4">24.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab279394f6cf43de9deae81fa065d878_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNy03LTEtMS0yMjE1Njg_016b935a-873a-4853-8562-8795ecddfed9">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab279394f6cf43de9deae81fa065d878_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNy05LTEtMS0yMjE1Njg_c9a84038-ac4e-4e51-b6f0-18c7b6c3303c">24.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab279394f6cf43de9deae81fa065d878_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNy0xMS0xLTEtMjIxNTY4_81dd018d-856f-45e1-99c7-9a32a3ec2b44">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfOC0xLTEtMS0yMjE1Njg_c8370dce-df5b-4206-9182-58051c41d7c0">1,222.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfOC0zLTEtMS0yMjE1Njg_63b69e9d-2fb8-4139-9a8e-b771aeb8ea6f">8.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfOC01LTEtMS0yMjE1Njg_0d4880d8-cea7-450e-aa75-0ee6b9d4c71b">5,464.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfOC03LTEtMS0yMjE1Njg_07d493dd-fee6-45c8-9f02-02b2eeb8ed1a">231.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfOC05LTEtMS0yMjE1Njg_675932f6-6615-4659-8760-3b2c9deea901">6,687.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfOC0xMS0xLTEtMjIxNTY4_8dd9de3e-8526-472a-a5c3-8301bd6c6d96">240.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf94038a80c74b0d9edbcbeccb24dde9_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTEtMS0xLTEtMjIxNTY4_0cafb543-0241-46ec-be80-76f95c6b3aea">2,445.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf94038a80c74b0d9edbcbeccb24dde9_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTEtMy0xLTEtMjIxNTY4_94933aef-da5a-48d7-83e9-d241dffd49a0">73.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf94038a80c74b0d9edbcbeccb24dde9_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTEtNS0xLTEtMjIxNTY4_38b81f4d-ab4a-4683-b47d-f14106ae5f32">4,200.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf94038a80c74b0d9edbcbeccb24dde9_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTEtNy0xLTEtMjIxNTY4_29816d6d-32d6-49d2-a8b6-d72ab41c9d82">218.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf94038a80c74b0d9edbcbeccb24dde9_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTEtOS0xLTEtMjIxNTY4_f0638f8e-5149-4b79-b21d-194528959707">6,645.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf94038a80c74b0d9edbcbeccb24dde9_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTEtMTEtMS0xLTIyMTU2OA_f932d441-e410-4f08-9257-0d31950033d3">291.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8a4bb9880684a74adbfbf4815ad715c_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTItMS0xLTEtMjIxNTY4_2d4a6d2b-c082-49fb-8699-9c4eda3c249b">785.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8a4bb9880684a74adbfbf4815ad715c_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTItMy0xLTEtMjIxNTY4_3b2c9607-066f-4280-8451-43d3c920055f">2.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8a4bb9880684a74adbfbf4815ad715c_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTItNS0xLTEtMjIxNTY4_2e7ee07b-8f27-4b63-a050-c4dcbb7a9597">71.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8a4bb9880684a74adbfbf4815ad715c_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTItNy0xLTEtMjIxNTY4_3bddf6a1-a754-491c-a561-0ddb2b691930">4.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8a4bb9880684a74adbfbf4815ad715c_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTItOS0xLTEtMjIxNTY4_6dfc32fb-6527-4d81-b14c-7cdcca84fd55">856.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8a4bb9880684a74adbfbf4815ad715c_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTItMTEtMS0xLTIyMTU2OA_6836ede5-3527-4ab7-840b-4aa5ccee9671">6.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a32793eceeb4ea687e38aa30fc6de37_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTMtMS0xLTEtMjIxNTY4_de2d2cff-7679-4244-abc8-28de93d0245f">18.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a32793eceeb4ea687e38aa30fc6de37_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTMtMy0xLTEtMjIxNTY4_dcef1af4-b5ee-42ca-9dfe-083092cc1503">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a32793eceeb4ea687e38aa30fc6de37_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTMtNS0xLTEtMjIxNTY4_3cea1529-5150-438c-819c-f7364e9d1d07">45.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a32793eceeb4ea687e38aa30fc6de37_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTMtNy0xLTEtMjIxNTY4_c8379f4e-ebe4-4b47-9c9d-670657a5ba08">1.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a32793eceeb4ea687e38aa30fc6de37_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTMtOS0xLTEtMjIxNTY4_cb5c5973-0aff-4895-ac2a-fc056f9043a0">64.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a32793eceeb4ea687e38aa30fc6de37_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTMtMTEtMS0xLTIyMTU2OA_f2e953d7-0d33-4aed-a055-1f84d2762b7f">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d7998c008a645b497664f16dfdf9c3e_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTUtMS0xLTEtMjIxNTY4_299ab533-1706-4cbd-b36c-19f48c1731a1">40.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d7998c008a645b497664f16dfdf9c3e_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTUtMy0xLTEtMjIxNTY4_dad73754-1d98-443d-baba-4badd41f7896">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d7998c008a645b497664f16dfdf9c3e_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTUtNS0xLTEtMjIxNTY4_578ba941-6ae5-4daf-9f28-779d4e048e78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d7998c008a645b497664f16dfdf9c3e_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTUtNy0xLTEtMjIxNTY4_bfa1faa7-cf01-46af-86d0-b93b55b84b74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d7998c008a645b497664f16dfdf9c3e_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTUtOS0xLTEtMjIxNTY4_d412b30f-b422-4859-8f21-fb055ff5a075">40.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d7998c008a645b497664f16dfdf9c3e_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTUtMTEtMS0xLTIyMTU2OA_6b54bf62-d01f-42ac-9660-291cc0157efe">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076e28d6501548bba1781c8d95c229c1_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTYtMS0xLTEtMjIxNTY4_368560c6-87d3-4cbc-b388-c1c2353ef1f2">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i076e28d6501548bba1781c8d95c229c1_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTYtMy0xLTEtMjIxNTY4_2de5578f-4446-4899-8fb8-c4d06bd39423">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076e28d6501548bba1781c8d95c229c1_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTYtNS0xLTEtMjIxNTY4_5a8f30d4-30cd-4399-8bbd-70d26c9195b8">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i076e28d6501548bba1781c8d95c229c1_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTYtNy0xLTEtMjIxNTY4_c3f5f2e5-9874-4391-9b69-720102e6b945">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076e28d6501548bba1781c8d95c229c1_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTYtOS0xLTEtMjIxNTY4_1937588c-b71a-49a0-874a-fae20faf1c98">26.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i076e28d6501548bba1781c8d95c229c1_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTYtMTEtMS0xLTIyMTU2OA_0926143e-5e64-4861-af13-d5ee28d24c20">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTctMS0xLTEtMjIxNTY4_1fc4e3c4-31d3-46cb-b585-5ab26456b90e">3,300.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTctMy0xLTEtMjIxNTY4_62111bf0-8b6d-457c-a97b-d702af61cb68">76.9</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTctNS0xLTEtMjIxNTY4_4e2c0767-9427-4463-b031-97e3e7516418">4,332.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTctNy0xLTEtMjIxNTY4_c34d2470-48ca-4b11-9b16-5e5f40bb3bc3">225.9</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTctOS0xLTEtMjIxNTY4_8cae2399-fdb3-4469-83fa-ef16f0106e1e">7,633.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTctMTEtMS0xLTIyMTU2OA_154a3667-59f4-4ad3-ba1e-9718da4baab2">302.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrealized losses on corporate bonds as of March 31, 2023 were primarily driven by increases in interest rates. The Company has reviewed its portfolio of available-for-sale debt securities and determined that the decline in fair value below cost did not result from credit-related factors. In addition, the Company does not intend to sell, and it is not more likely than not that the Company will be required to sell, such securities before recovery of their amortized cost bases.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to marketable securities, for the three months ended March&#160;31, 2023 and 2022, amounts reclassified from Accumulated other comprehensive loss into Other (expense) income, net were related to realized gains and losses on sales of available-for-sale debt securities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023 and 2022, realized gains and losses on sales of marketable securities were not material.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RleHRyZWdpb246OGI4M2VkYjU5NDVhNDJlOTgxNjY5YmQ3MDkzOWRiN2ZfMTU1Mw_5317ee1c-ffbd-4ca8-b8ba-096542acc374" continuedAt="i41737199aed44d4a939244b5ba127e3b" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i41737199aed44d4a939244b5ba127e3b"><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RleHRyZWdpb246OGI4M2VkYjU5NDVhNDJlOTgxNjY5YmQ3MDkzOWRiN2ZfMTU2Mg_744e7f8f-22b8-4975-b739-f2092b768ff5" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company's assets which are measured at fair value on a recurring basis. The following fair value hierarchy is used to classify assets, based on inputs to valuation techniques utilized to measure fair value:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Quoted prices in active markets for identical assets</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Significant other observable inputs, such as quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuations in which significant inputs used are observable</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Significant other unobservable inputs</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"></td><td style="width:49.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.781%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of March&#160;31, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42bb7405dae2448892d28fe5254d753b_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMy0xLTEtMS0yNDI2ODM_6300a0ae-ae4a-4ec2-9a82-e1cbf05df41d">1,422.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a16600ec214325aa04a3be1bcacc1a_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMy0zLTEtMS0yNDI2ODM_a9434102-093a-4f73-9b90-7a200c577985">154.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccd0b582761d43a79ac5b665419222c1_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMy01LTEtMS0yNDI2ODM_70ee2acd-7cdd-44e9-8fa1-cd050c0e62a9">1,268.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ed1181d127f48eeae6cc93827001b60_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMy0xLTEtMS0yMjE1Njg_2afa656f-96c1-4499-be52-e0395920653d">6,592.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d138ebcdd8d4f6f9da1861a1980e8fe_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMy0zLTEtMS0yMjE1Njg_907a29d0-7b28-4b74-aab8-cf24b64a9e93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4637e5ee1a4615bd9757cfde09d5ed_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMy01LTEtMS0yMjE1Njg_dc016eca-adbd-441e-8cff-9a21acc5ee09">6,592.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib78b4e7f93bf4cb2b480289b8085219d_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfNC0xLTEtMS0yMjE1Njg_d9d7cfee-54be-4e54-829a-ec0365c60667">2,903.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2861028cb0f04545abad3da8e9947ae3_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfNC0zLTEtMS0yMjE1Njg_dfd14a29-ae3e-4ab7-83de-7de4cf933339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d31ef08646d47068b930b62221f25c5_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfNC01LTEtMS0yMjE1Njg_d1d61ead-6711-4952-b123-7feea5a3679b">2,903.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bb4ac30d7174141bd68e0e5165503a4_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfNS0xLTEtMS0yMjE1Njg_c1ec6deb-0474-4c10-9412-25f4f6753c94">70.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27a37895006f481b99b894294d32f453_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfNS0zLTEtMS0yMjE1Njg_fe041058-83f1-429a-a9ca-0610055ce560">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45e1a224580a4ab4a851ce1cd380e58b_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfNS01LTEtMS0yMjE1Njg_54e93644-9090-413b-b053-1c140635d9d2">70.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic48dc13ed46549c38aa86d1646750b7e_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfNi0xLTEtMS0yMjE1Njg_bae6c4b6-191e-45b3-a88b-f1ec3573e76b">279.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc9d4a9ec68c46a2a1444ba0c21c58d1_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfNi0zLTEtMS0yMjE1Njg_0caadf70-dcea-4070-841e-ce5677b7050b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2532a7ae6c44f0183a1a72036a1dbd2_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfNi01LTEtMS0yMjE1Njg_450cf43f-a6ef-4662-803c-3c4e268ec7be">279.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2c1cf62b52f4290802d97ca8e3f7314_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfNy0xLTEtMS0yMjE1Njg_f4e42a63-ea9e-4e5c-8a39-9229a1cf5d4b">153.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b68bd2a55e4e4e98087d12385f43b6_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfNy0zLTEtMS0yMjE1Njg_68ce4da5-2232-452c-87b8-4369cf5a561e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i924a1104d72e45899f48ce68164557a6_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfNy01LTEtMS0yMjE1Njg_8e6cc02c-840a-45be-b573-2c7795500080">153.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c8f015a8c6464c939619f06315efe8_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfOC0xLTEtMS0yMjE1Njg_a20d7746-70f1-42e1-ac39-8e837669a572">52.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i319e916558384549ac07e82dc579d15f_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfOC0zLTEtMS0yMjE1Njg_42cf0347-049e-41d9-8ce6-90fbb70595db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i407aae8d570145af8c0266b54d98beec_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfOC01LTEtMS0yMjE1Njg_2003fa35-cbd1-4e46-ad26-4a8ac59f9020">52.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (unrestricted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f8bc3a2ad94180966f9ebe0be125f0_I20230331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfOS0xLTEtMS0yMjE1Njg_73483734-08d5-4aa1-9d00-0f789eee06a1">20.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb363b73e6244abcb656ed2ab62f8f78_I20230331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfOS0zLTEtMS0yMjE1Njg_3e574906-0726-4254-a1bd-245f1e16de92">20.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i923780b5c4714bd0b32f8a52e41383bd_I20230331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfOS01LTEtMS0yMjE1Njg_84ed7f6f-fafa-4666-9f2f-88c3275dc03a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (restricted)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b2c64ec3f6040309efed4a34a2e340c_I20230331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTAtMS0xLTEtMjIxNTY4_bde2c5d2-73a1-43ca-9693-f2e7133a7189">1,038.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1656e9d1074b078faaced1a79a540d_I20230331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTAtMy0xLTEtMjIxNTY4_ee606183-ed26-42d7-ba2e-707785c92abd">1,028.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96714fa1a4ef4fbea15e01d83966c0d7_I20230331" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTAtNS0xLTEtMjIxNTY4_e6ecb1c6-c869-4660-97fe-1dc2785302bc">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42bb7405dae2448892d28fe5254d753b_I20230331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTMtMS0xLTEtMjQxNzkz_3a58a5ec-2b23-4c1b-a1f5-002c3e515e1e">12,532.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a16600ec214325aa04a3be1bcacc1a_I20230331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTMtMy0xLTEtMjQxNzkz_ccf9ea07-e8f5-4b88-9a0a-d7ff0149e6ad">1,203.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccd0b582761d43a79ac5b665419222c1_I20230331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTMtNS0xLTEtMjQxNzkz_6afabb6c-25ab-43bd-81f2-7f508f34598d">11,329.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6e5891198641dc82ba047fab579cec_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjAtMS0xLTEtMjQyNjg1_95382e7a-f66d-47db-873d-1b3d554a05b5">1,662.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i906a5a8877744181bffbf220eeea0a73_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjAtMy0xLTEtMjQyNjg1_a2057f0e-a0f6-46d8-8d61-5285d16d3db8">88.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba3655e9756414b9e6fd04ad3ee2f24_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjAtNS0xLTEtMjQyNjg1_00638480-83ab-4d7d-9550-16e57c69f0c5">1,574.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25b7eaabac2f458b96618bac777bd2ca_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTUtMS0xLTEtMjIxNTY4_8f412dfa-8ab4-420c-9584-eab2aa41fd11">6,684.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0fce717fc9443019cee095389f2baf5_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTUtMy0xLTEtMjIxNTY4_ab72dffb-5d7d-49ee-b4df-17ceb30e33f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c5fb90e07b84a9a87b35eaaf73fad05_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTUtNS0xLTEtMjIxNTY4_d0f44e14-0e61-4ffd-986a-e8815a3d2827">6,684.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc7e444572ae46a385283f8406b98c84_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTYtMS0xLTEtMjIxNTY4_9d94e348-aee9-439c-b7f9-9b618c14ce5e">2,939.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0392b26a3fbc4c43a64deca654005f83_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTYtMy0xLTEtMjIxNTY4_1812874a-9f93-4b89-9b61-8f63d816f5a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a3f2f6efec84786af7fd186d6c5c4c9_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTYtNS0xLTEtMjIxNTY4_45932b31-e240-46fa-9c81-3693437830ba">2,939.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if32b8d821f0642acafbc9612834c9293_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTctMS0xLTEtMjIxNTY4_2a6c8634-2148-4211-895f-5806d14069db">64.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b5bb5d7a78a4a57b46ccf314f728939_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTctMy0xLTEtMjIxNTY4_7afe3665-1d7a-4031-a524-ed5c47093c64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b9fc3319f5841518dd67e46c582c888_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTctNS0xLTEtMjIxNTY4_1ffbf06c-ab22-4b9a-88a9-98f1d321ac1d">64.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdc9ce269439490ab1af63a29b885fa0_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTgtMS0xLTEtMjIxNTY4_9eb51f9a-66bc-4a5a-87d3-e2c2191cc041">121.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11171f0e5db4eed91923c0534566b26_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTgtMy0xLTEtMjIxNTY4_a129b632-8ff6-4341-be5a-d0379c247b4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d989b03e30442ce8a9b3481c7124765_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTgtNS0xLTEtMjIxNTY4_76cc9ad5-03aa-4289-99f0-e8caf039465b">121.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2536f989b03944a4b9a0d7e8f56ea080_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTktMS0xLTEtMjIxNTY4_bfce9630-545f-4910-b2d5-e964667e8cf8">182.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85985f6f1c3c4f01b858acc29e09e5ca_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTktMy0xLTEtMjIxNTY4_919a5acc-9b3d-4bcc-9fa5-4581cd79031e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1da2e40825b44fd59ead3dde06e37600_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTktNS0xLTEtMjIxNTY4_c76c200c-c54a-4d7c-8b26-3b04f871af91">182.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i442be721ac15405da1349485e18c28ac_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjAtMS0xLTEtMjIxNTY4_5e6a4cb4-f3b7-49ca-992e-a85baf1daecc">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2bcc6312921492999cec875c39d9b73_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjAtMy0xLTEtMjIxNTY4_55164cae-2be4-4304-98cc-9ee6d8acb06f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c67c7b931244e59af10a080716aafec_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjAtNS0xLTEtMjIxNTY4_099b385e-def5-4970-9f46-6d23360b25c5">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (unrestricted)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f2bd6363aa141e7a2a47119609b54b9_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjEtMS0xLTEtMjIxNTY4_47321a5f-ed9a-4864-a790-a1b1e3ee49de">24.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4849fbe85bf94052b4be3ec967ec493f_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjEtMy0xLTEtMjIxNTY4_9141bc03-3b40-4b7b-a689-53f118c524a6">24.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib961b996c000420b839a622c158db724_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjEtNS0xLTEtMjIxNTY4_0751b667-0358-4ace-88da-ce97627991ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (restricted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a829313946c4d029d2545a0b99636f6_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjItMS0xLTEtMjIxNTY4_b284411f-e7e9-43a0-aaec-f0eb1dff9b21">1,185.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57cc71aadf054c0aa6efa5f790dfbd1e_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjItMy0xLTEtMjIxNTY4_c0f0a0ec-b9ba-46ff-a2ae-71b5772c475a">1,185.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551685f126c4400481a7132a780426b0_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjItNS0xLTEtMjIxNTY4_95643b76-300d-4234-8b3f-5a17b13fcb13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6e5891198641dc82ba047fab579cec_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjMtMS0xLTEtMjIxNTY4_eabf07bf-3c4a-4b46-b874-e3a1ed9301fb">12,891.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i906a5a8877744181bffbf220eeea0a73_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjMtMy0xLTEtMjIxNTY4_922ab22e-a67c-4851-97a7-f4fc9d8c6f48">1,298.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaba3655e9756414b9e6fd04ad3ee2f24_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjMtNS0xLTEtMjIxNTY4_c0564e1d-8f43-431f-bd79-c362695c2236">11,592.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held certain restricted equity securities as of March&#160;31, 2023 which are subject to transfer restrictions that expire at various dates through 2024. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, we recorded $<ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RleHRyZWdpb246OGI4M2VkYjU5NDVhNDJlOTgxNjY5YmQ3MDkzOWRiN2ZfODY1_b8a74b7f-bec5-438d-86a1-0a4c2f8520e8">164.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RleHRyZWdpb246OGI4M2VkYjU5NDVhNDJlOTgxNjY5YmQ3MDkzOWRiN2ZfNDM5ODA0NjUxMjg5OQ_17aa9871-7966-4ec1-bbbe-f053da74356a">211.2</ix:nonFraction>&#160;million of net unrealized losses, respectively, on equity securities in Other (expense) income, net.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the investments summarized in the table above, as of both March&#160;31, 2023 and December&#160;31, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RleHRyZWdpb246OGI4M2VkYjU5NDVhNDJlOTgxNjY5YmQ3MDkzOWRiN2ZfMTIyNg_49373a58-b1e2-4f63-b322-42b2b9ce015c"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RleHRyZWdpb246OGI4M2VkYjU5NDVhNDJlOTgxNjY5YmQ3MDkzOWRiN2ZfMTIyNg_9906d7c6-413c-41dd-ac87-ed3e4ab7327c">48.3</ix:nonFraction></ix:nonFraction>&#160;million in equity investments that do not have a readily determinable fair value. These investments are recorded within Other noncurrent assets.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term debt, which was determined based on Level 2 inputs, was estimated to be $<ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-6" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RleHRyZWdpb246OGI4M2VkYjU5NDVhNDJlOTgxNjY5YmQ3MDkzOWRiN2ZfNDM5ODA0NjUxNDg2Ng_386c0eb6-787f-4773-9ede-a79a4377b564">1.516</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-6" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RleHRyZWdpb246OGI4M2VkYjU5NDVhNDJlOTgxNjY5YmQ3MDkzOWRiN2ZfNDM5ODA0NjUxNDkxOA_74c3cdf0-7a48-4749-80aa-85d604dd9196">1.443</ix:nonFraction>&#160;billion as of March&#160;31, 2023 and December&#160;31, 2022, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_49"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RleHRyZWdpb246MmU5MTlmZjFiMDFmNDhkY2IzMzk2ZjA3OGU3NzFlOGFfNTEx_95edc051-5188-4106-8fa2-5a4344bda172" continuedAt="ia34c9375030f4a46ae6ebf8b70b293d1" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="ia34c9375030f4a46ae6ebf8b70b293d1"><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RleHRyZWdpb246MmU5MTlmZjFiMDFmNDhkY2IzMzk2ZjA3OGU3NzFlOGFfNTE0_69b81c5b-ff57-4ad1-8e70-fcc85ca17ed8" escape="true"><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.555%"><tr><td style="width:1.0%"></td><td style="width:47.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RhYmxlOmU4ODI0OTIxNzhhNDQ1NjhiZDY0MDQ1OGNjZWY2ZDAxL3RhYmxlcmFuZ2U6ZTg4MjQ5MjE3OGE0NDU2OGJkNjQwNDU4Y2NlZjZkMDFfMi0xLTEtMS0yMjE1Njg_db13622d-c8ca-44d9-9b2b-e646b280b6e3">844.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RhYmxlOmU4ODI0OTIxNzhhNDQ1NjhiZDY0MDQ1OGNjZWY2ZDAxL3RhYmxlcmFuZ2U6ZTg4MjQ5MjE3OGE0NDU2OGJkNjQwNDU4Y2NlZjZkMDFfMi0zLTEtMS0yMjE1Njg_9354569a-f3e7-4656-8208-d4ccbb4ff520">818.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RhYmxlOmU4ODI0OTIxNzhhNDQ1NjhiZDY0MDQ1OGNjZWY2ZDAxL3RhYmxlcmFuZ2U6ZTg4MjQ5MjE3OGE0NDU2OGJkNjQwNDU4Y2NlZjZkMDFfMy0xLTEtMS0yMjE1Njg_11b5b113-5ecd-43c6-915a-82ac656990df">855.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RhYmxlOmU4ODI0OTIxNzhhNDQ1NjhiZDY0MDQ1OGNjZWY2ZDAxL3RhYmxlcmFuZ2U6ZTg4MjQ5MjE3OGE0NDU2OGJkNjQwNDU4Y2NlZjZkMDFfMy0zLTEtMS0yMjE1Njg_d520b9ca-6119-4159-8b9b-2a176944ee50">963.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RhYmxlOmU4ODI0OTIxNzhhNDQ1NjhiZDY0MDQ1OGNjZWY2ZDAxL3RhYmxlcmFuZ2U6ZTg4MjQ5MjE3OGE0NDU2OGJkNjQwNDU4Y2NlZjZkMDFfNC0xLTEtMS0yMjE1Njg_de4efdd2-e301-4241-b1f9-765709cecd2e">169.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RhYmxlOmU4ODI0OTIxNzhhNDQ1NjhiZDY0MDQ1OGNjZWY2ZDAxL3RhYmxlcmFuZ2U6ZTg4MjQ5MjE3OGE0NDU2OGJkNjQwNDU4Y2NlZjZkMDFfNC0zLTEtMS0yMjE1Njg_de92b731-0d6b-4f1e-b647-bebbfdcadb55">98.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:OtherInventoryNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RhYmxlOmU4ODI0OTIxNzhhNDQ1NjhiZDY0MDQ1OGNjZWY2ZDAxL3RhYmxlcmFuZ2U6ZTg4MjQ5MjE3OGE0NDU2OGJkNjQwNDU4Y2NlZjZkMDFfNS0xLTEtMS0yMjE1Njg_f9b42ebd-9114-43e9-be3d-f65553b428c9">555.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:OtherInventoryNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RhYmxlOmU4ODI0OTIxNzhhNDQ1NjhiZDY0MDQ1OGNjZWY2ZDAxL3RhYmxlcmFuZ2U6ZTg4MjQ5MjE3OGE0NDU2OGJkNjQwNDU4Y2NlZjZkMDFfNS0zLTEtMS0yMjE1Njg_bddf06d4-83c9-4580-976c-b2de1b79e9db">521.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RhYmxlOmU4ODI0OTIxNzhhNDQ1NjhiZDY0MDQ1OGNjZWY2ZDAxL3RhYmxlcmFuZ2U6ZTg4MjQ5MjE3OGE0NDU2OGJkNjQwNDU4Y2NlZjZkMDFfNi0xLTEtMS0yMjE1Njg_99c0832b-f26b-4602-bee1-70cf5b78ce61">2,424.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RhYmxlOmU4ODI0OTIxNzhhNDQ1NjhiZDY0MDQ1OGNjZWY2ZDAxL3RhYmxlcmFuZ2U6ZTg4MjQ5MjE3OGE0NDU2OGJkNjQwNDU4Y2NlZjZkMDFfNi0zLTEtMS0yMjE1Njg_2e9b16d9-f63d-4e90-80b5-362a307305eb">2,401.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory balances in the table above are net of reserves of $<ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RleHRyZWdpb246MmU5MTlmZjFiMDFmNDhkY2IzMzk2ZjA3OGU3NzFlOGFfMjE5OTAyMzI1Njk5NQ_c26b9809-92bb-40f5-80b2-05c354c34e78">752.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RleHRyZWdpb246MmU5MTlmZjFiMDFmNDhkY2IzMzk2ZjA3OGU3NzFlOGFfMjE5OTAyMzI1NzAwNg_5a5c478e-e8b8-4d24-a9ea-65f3622dd4a6">720.7</ix:nonFraction> million as of March&#160;31, 2023 and December&#160;31, 2022, respectively. Deferred costs represent the costs of product manufactured and shipped to the Company's collaborators for which recognition of revenue has been deferred.</span></div></ix:continuation><div id="id4c1ef3770fb4cfcadf88c3685e610eb_61"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82MS9mcmFnOmI4ZWRmNGZlN2ZhNTQxZWZiMGFlNTFjMDk1N2Y0NmRmL3RleHRyZWdpb246YjhlZGY0ZmU3ZmE1NDFlZmIwYWU1MWMwOTU3ZjQ2ZGZfMTIxMA_57a4af48-57a8-4d99-88de-031fe0c2bca0" continuedAt="ib6c93a9d1ca94781889fbcae37a83a9c" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="ib6c93a9d1ca94781889fbcae37a83a9c"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal, state, and foreign income taxes. The Company's effective tax rate was <ix:nonFraction unitRef="number" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82MS9mcmFnOmI4ZWRmNGZlN2ZhNTQxZWZiMGFlNTFjMDk1N2Y0NmRmL3RleHRyZWdpb246YjhlZGY0ZmU3ZmE1NDFlZmIwYWU1MWMwOTU3ZjQ2ZGZfMTk3_6b1f7e5b-93cc-4a33-abcf-e92ad468baee">4.7</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82MS9mcmFnOmI4ZWRmNGZlN2ZhNTQxZWZiMGFlNTFjMDk1N2Y0NmRmL3RleHRyZWdpb246YjhlZGY0ZmU3ZmE1NDFlZmIwYWU1MWMwOTU3ZjQ2ZGZfMjA0_a4332ddf-28b7-407d-bc89-8f4c0e52ced7">8.3</ix:nonFraction>% for the three months ended March&#160;31, 2023 and 2022, respectively. The Company's effective tax rate for the three months ended March&#160;31, 2023 was positively impacted, compared to the U.S. federal statutory rate, primarily by stock-based compensation and income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Inflation Reduction Act of 2022 ("IRA") was signed into law in the United States. The IRA created a new corporate alternative minimum tax of 15% on adjusted financial statement income and an excise tax of 1% of the value of certain stock repurchases. The provisions of the IRA became effective for periods beginning after December&#160;31, 2022.&#160;The IRA had no impact on the Company's financial statements for the three months ended March 31, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's effective tax rate for the three months ended March&#160;31, 2022 was positively impacted, compared to the U.S. federal statutory rate, primarily by income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate and stock-based compensation.</span></div></ix:continuation><div id="id4c1ef3770fb4cfcadf88c3685e610eb_64"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82NC9mcmFnOjYzYjNmYWU2MmE2NjQzMDRiOGI0OTRkMzRmOTc0MTViL3RleHRyZWdpb246NjNiM2ZhZTYyYTY2NDMwNGI4YjQ5NGQzNGY5NzQxNWJfMTU5Ng_429d2079-16bd-45da-b607-9c9a88b3b60f" continuedAt="i7fd1669fd834498dbf5d2127c7049f44" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="i7fd1669fd834498dbf5d2127c7049f44"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Programs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, our board of directors authorized a share repurchase program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i1c8af3a2f8cb4400af2f7e31cff2cfb3_I20211130" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82NC9mcmFnOjYzYjNmYWU2MmE2NjQzMDRiOGI0OTRkMzRmOTc0MTViL3RleHRyZWdpb246NjNiM2ZhZTYyYTY2NDMwNGI4YjQ5NGQzNGY5NzQxNWJfMjE5OTAyMzI1ODUwNg_c7920216-af8a-49a2-99c0-6ab248484ae8">3.0</ix:nonFraction> billion of our Common Stock. The share repurchase program permits the Company to make repurchases through a variety of methods, including open-market transactions (including pursuant to a trading plan adopted in accordance with Rule 10b5-1 of the Exchange Act), privately negotiated transactions, accelerated share repurchases, block trades, and other transactions in compliance with Rule 10b-18 of the Exchange Act. Repurchases may be made from time to time at management&#8217;s discretion, and the timing and amount of any such repurchases will be determined based on share price, market conditions, legal requirements, and other relevant factors. The program has no time limit and can be discontinued at any time. There can be no assurance as to the timing or number of shares of any repurchases in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, our board of directors authorized an additional share repurchase program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i5e3a527460f44b9181602c95f95e6612_I20230131" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82NC9mcmFnOjYzYjNmYWU2MmE2NjQzMDRiOGI0OTRkMzRmOTc0MTViL3RleHRyZWdpb246NjNiM2ZhZTYyYTY2NDMwNGI4YjQ5NGQzNGY5NzQxNWJfNTQ5NzU1ODE2MjA2_4a919bfc-200a-40c1-8717-87d653f0d497">3.0</ix:nonFraction>&#160;billion of our Common Stock. The share repurchase program was approved under terms substantially similar to the share repurchase program described above. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-6" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82NC9mcmFnOjYzYjNmYWU2MmE2NjQzMDRiOGI0OTRkMzRmOTc0MTViL3RleHRyZWdpb246NjNiM2ZhZTYyYTY2NDMwNGI4YjQ5NGQzNGY5NzQxNWJfNTQ5NzU1ODE2NzA2_0dc8448b-a325-426f-9481-86feab0db059">3.051</ix:nonFraction> billion remained available for share repurchases under the Company's share repurchase programs.</span></div><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="us-gaap:ScheduleOfTreasuryStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82NC9mcmFnOjYzYjNmYWU2MmE2NjQzMDRiOGI0OTRkMzRmOTc0MTViL3RleHRyZWdpb246NjNiM2ZhZTYyYTY2NDMwNGI4YjQ5NGQzNGY5NzQxNWJfMTYwMg_bf8d50f4-acca-41e5-8b33-3351ef188762" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the shares of our Common Stock we repurchased and the cost of the shares, which were recorded as Treasury Stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.432%"><tr><td style="width:1.0%"></td><td style="width:61.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82NC9mcmFnOjYzYjNmYWU2MmE2NjQzMDRiOGI0OTRkMzRmOTc0MTViL3RhYmxlOjhhZTUyNTA0MTVmYzRjM2I4ZTM1ZDFmMzdlOWQyM2EzL3RhYmxlcmFuZ2U6OGFlNTI1MDQxNWZjNGMzYjhlMzVkMWYzN2U5ZDIzYTNfMi01LTEtMS0yMjE1Njg_9d0110ee-c6be-475c-b6a3-8577f60b3bec">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82NC9mcmFnOjYzYjNmYWU2MmE2NjQzMDRiOGI0OTRkMzRmOTc0MTViL3RhYmxlOjhhZTUyNTA0MTVmYzRjM2I4ZTM1ZDFmMzdlOWQyM2EzL3RhYmxlcmFuZ2U6OGFlNTI1MDQxNWZjNGMzYjhlMzVkMWYzN2U5ZDIzYTNfMi03LTEtMS0yMjE1Njg_796ea0c9-864f-4e10-b4ab-88a45ba7491b">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of shares </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82NC9mcmFnOjYzYjNmYWU2MmE2NjQzMDRiOGI0OTRkMzRmOTc0MTViL3RhYmxlOjhhZTUyNTA0MTVmYzRjM2I4ZTM1ZDFmMzdlOWQyM2EzL3RhYmxlcmFuZ2U6OGFlNTI1MDQxNWZjNGMzYjhlMzVkMWYzN2U5ZDIzYTNfMy01LTEtMS0yMjE1Njg_fa1e076f-d0c6-4b33-aa0f-9e5b6fe74b2c">693.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82NC9mcmFnOjYzYjNmYWU2MmE2NjQzMDRiOGI0OTRkMzRmOTc0MTViL3RhYmxlOjhhZTUyNTA0MTVmYzRjM2I4ZTM1ZDFmMzdlOWQyM2EzL3RhYmxlcmFuZ2U6OGFlNTI1MDQxNWZjNGMzYjhlMzVkMWYzN2U5ZDIzYTNfMy03LTEtMS0yMjE1Njg_443a6232-b39e-40d0-9a59-a9f33090ad7f">352.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RleHRyZWdpb246MzE2OGU5ZjMxMDgxNDc4N2I2ZmYzZDc3MjNiZTUwYzdfNDYy_594dc7f5-1eef-406f-89b0-6401657c862b" continuedAt="ic825e992f99941c58667ae8bfd2214c2" escape="true">Statement of Cash Flows</ix:nonNumeric></span></div><ix:continuation id="ic825e992f99941c58667ae8bfd2214c2"><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RleHRyZWdpb246MzE2OGU5ZjMxMDgxNDc4N2I2ZmYzZDc3MjNiZTUwYzdfNDU4_35569009-7b97-49e1-bb67-8ff56bace723" escape="true"><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RleHRyZWdpb246MzE2OGU5ZjMxMDgxNDc4N2I2ZmYzZDc3MjNiZTUwYzdfNDY3_de40c4fe-9717-409b-a989-527e0b3e04fa" escape="true"><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheet to the total of the same such amounts shown in the Condensed Consolidated Statement of Cash Flows:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.210%"><tr><td style="width:1.0%"></td><td style="width:58.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.170%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.172%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjc4OTQ4ZDEwNDQwNTRkYzdhMjQ4ZjlmYjYxNDhlYjZhL3RhYmxlcmFuZ2U6Nzg5NDhkMTA0NDA1NGRjN2EyNDhmOWZiNjE0OGViNmFfMi0yLTEtMS0yMjE1Njg_f176381c-39db-406a-9db1-d0521f8c4a9b">3,916.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7298587e584844a686de7edf412eb7a2_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjc4OTQ4ZDEwNDQwNTRkYzdhMjQ4ZjlmYjYxNDhlYjZhL3RhYmxlcmFuZ2U6Nzg5NDhkMTA0NDA1NGRjN2EyNDhmOWZiNjE0OGViNmFfMi00LTEtMS0yMjE1Njg_806c0754-ad35-4b17-9695-b65cf8bd0c36">3,345.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in Other noncurrent assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjc4OTQ4ZDEwNDQwNTRkYzdhMjQ4ZjlmYjYxNDhlYjZhL3RhYmxlcmFuZ2U6Nzg5NDhkMTA0NDA1NGRjN2EyNDhmOWZiNjE0OGViNmFfMy0yLTEtMS0yMjE1Njg_7847a7bb-4e61-4176-b806-627e786a6320">12.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7298587e584844a686de7edf412eb7a2_I20220331" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjc4OTQ4ZDEwNDQwNTRkYzdhMjQ4ZjlmYjYxNDhlYjZhL3RhYmxlcmFuZ2U6Nzg5NDhkMTA0NDA1NGRjN2EyNDhmOWZiNjE0OGViNmFfMy00LTEtMS0yMjE1Njg_99256a3d-6d03-4871-8927-635b58cf9aa8">13.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjc4OTQ4ZDEwNDQwNTRkYzdhMjQ4ZjlmYjYxNDhlYjZhL3RhYmxlcmFuZ2U6Nzg5NDhkMTA0NDA1NGRjN2EyNDhmOWZiNjE0OGViNmFfNC0yLTEtMS0yMjE1Njg_a2a204c1-f613-4c1f-96bd-c589c5c6d95c">3,928.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7298587e584844a686de7edf412eb7a2_I20220331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjc4OTQ4ZDEwNDQwNTRkYzdhMjQ4ZjlmYjYxNDhlYjZhL3RhYmxlcmFuZ2U6Nzg5NDhkMTA0NDA1NGRjN2EyNDhmOWZiNjE0OGViNmFfNC00LTEtMS0yMjE1Njg_e5fdd641-a6d7-44dc-a16a-a4ebc085a426">3,359.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists of amounts held by financial institutions pursuant to contractual arrangements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental disclosure of non-cash investing and financing activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RleHRyZWdpb246MzE2OGU5ZjMxMDgxNDc4N2I2ZmYzZDc3MjNiZTUwYzdfNDU2_8a5c6acf-6305-4d4c-8c82-be83bef29664" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:31.200%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued capital expenditures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjI1NTBjMDhmYjdlMjRmZDRhMGVlYjBlNWNjYTA2ZmNjL3RhYmxlcmFuZ2U6MjU1MGMwOGZiN2UyNGZkNGEwZWViMGU1Y2NhMDZmY2NfMi0xLTEtMS0yMjE1Njg_27694601-0e68-4320-9adc-3cf250f3888a">90.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc0c76d2e7c4dffaaaad5977285af04_D20220101-20221231" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjI1NTBjMDhmYjdlMjRmZDRhMGVlYjBlNWNjYTA2ZmNjL3RhYmxlcmFuZ2U6MjU1MGMwOGZiN2UyNGZkNGEwZWViMGU1Y2NhMDZmY2NfMi0zLTEtMS0yMjE1Njg_c5ef1358-35c9-49b1-a642-89ec2ba45160">70.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjI1NTBjMDhmYjdlMjRmZDRhMGVlYjBlNWNjYTA2ZmNjL3RhYmxlcmFuZ2U6MjU1MGMwOGZiN2UyNGZkNGEwZWViMGU1Y2NhMDZmY2NfMi01LTEtMS0yMjE1Njg_8603272a-d937-4909-b20d-6c04bf988361">80.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64798e076fa64db2b5de1538f7e77d5f_D20210101-20211231" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjI1NTBjMDhmYjdlMjRmZDRhMGVlYjBlNWNjYTA2ZmNjL3RhYmxlcmFuZ2U6MjU1MGMwOGZiN2UyNGZkNGEwZWViMGU1Y2NhMDZmY2NfMi03LTEtMS0yMjE1Njg_8c22ffdd-81df-4a94-a235-c2f2ab597c64">74.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued contingent consideration for Libtayo intangible asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" decimals="-5" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjI1NTBjMDhmYjdlMjRmZDRhMGVlYjBlNWNjYTA2ZmNjL3RhYmxlcmFuZ2U6MjU1MGMwOGZiN2UyNGZkNGEwZWViMGU1Y2NhMDZmY2NfMy0xLTEtMS0yMjE1Njg_2630ac4a-f598-445f-8999-4b1bbb42422b">55.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc0c76d2e7c4dffaaaad5977285af04_D20220101-20221231" decimals="-5" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjI1NTBjMDhmYjdlMjRmZDRhMGVlYjBlNWNjYTA2ZmNjL3RhYmxlcmFuZ2U6MjU1MGMwOGZiN2UyNGZkNGEwZWViMGU1Y2NhMDZmY2NfMy0zLTEtMS0yMjE1Njg_78c1c7d4-6ca6-4533-acf1-c866b72caf0d">135.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331" decimals="-5" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjI1NTBjMDhmYjdlMjRmZDRhMGVlYjBlNWNjYTA2ZmNjL3RhYmxlcmFuZ2U6MjU1MGMwOGZiN2UyNGZkNGEwZWViMGU1Y2NhMDZmY2NfMy01LTEtMS0yMjE1Njg_46da2239-a3b5-4a3e-a0a8-a7f8bf26c825">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64798e076fa64db2b5de1538f7e77d5f_D20210101-20211231" decimals="-5" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjI1NTBjMDhmYjdlMjRmZDRhMGVlYjBlNWNjYTA2ZmNjL3RhYmxlcmFuZ2U6MjU1MGMwOGZiN2UyNGZkNGEwZWViMGU1Y2NhMDZmY2NfMy03LTEtMS0yMjE1Njg_f0037bd2-f238-4dcb-be85-2990fc2bd12b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div id="id4c1ef3770fb4cfcadf88c3685e610eb_70"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl83MC9mcmFnOmExYjBmZTBkM2E1NDQxNTk5MzY1ZDVhOGMwZTllYjhiL3RleHRyZWdpb246YTFiMGZlMGQzYTU0NDE1OTkzNjVkNWE4YzBlOWViOGJfMjU2Njg_37f440bd-d741-4442-b6eb-4edb8176c7bb" continuedAt="i6d021ee9cff948e99962e5b569d57ca8" escape="true">Legal Matters</ix:nonNumeric></span></div><ix:continuation id="i6d021ee9cff948e99962e5b569d57ca8" continuedAt="ic6978cf9ac9c4cdeab3aacf19bd5fc8f"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is a party to legal proceedings in the course of the Company's business. The outcome of any such proceedings, regardless of the merits, is inherently uncertain. If the Company were unable to prevail in any such proceedings, its consolidated financial position, results of operations, and future cash flows may be materially impacted. <ix:nonNumeric contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331" name="us-gaap:LegalCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl83MC9mcmFnOmExYjBmZTBkM2E1NDQxNTk5MzY1ZDVhOGMwZTllYjhiL3RleHRyZWdpb246YTFiMGZlMGQzYTU0NDE1OTkzNjVkNWE4YzBlOWViOGJfNjA0NzMxNDAzMjk4MA_2b72728b-d483-4464-9531-f51ebcd22481" escape="true">Costs associated with the Company's involvement in legal proceedings are expensed as incurred.</ix:nonNumeric> The Company recognizes accruals for loss contingencies associated with such proceedings when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. As of March&#160;31, 2023 and December&#160;31, 2022, the Company's accruals for loss contingencies were not material. There are certain loss contingencies that the Company deems reasonably possible for which the possible loss or range of possible loss is not estimable at this time. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to Praluent (alirocumab) Injection</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described below, the Company is currently a party to patent infringement actions initiated by Amgen Inc. (and/or its affiliated entities) against the Company and/or Sanofi (and/or the Company's and Sanofi's respective affiliated entities) in a number of jurisdictions relating to Praluent. In addition, as described below, the Company filed a lawsuit against Amgen alleging that Amgen engaged in an anticompetitive bundling scheme which was designed to exclude Praluent from the market in violation of federal and state laws.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United States</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, Amgen has asserted claims of U.S. Patent Nos. 8,829,165 (the "'165 Patent") and 8,859,741 (the "'741 Patent"), and sought a permanent injunction to prevent the Company and the Sanofi defendants from commercial manufacturing, using, offering to sell, or selling within the United States (as well as importing into the United States) (collectively, "Commercializing") Praluent. Amgen also seeks a judgment of patent infringement of the asserted patents, monetary damages (together with interest), costs and expenses of the lawsuits, and attorneys' fees. As previously reported, on February 11, 2021, the United States Court of Appeals for the Federal Circuit (the "Federal Circuit") affirmed the lower court's decision that certain of Amgen's asserted patent claims are invalid based on lack of enablement. On April 14, 2021, Amgen filed a petition for a rehearing en banc with the Federal Circuit, which was denied on June 21, 2021. On November 4, 2022, the United States Supreme Court granted Amgen's petition for writ of certiorari. An oral hearing was held on March 27, 2023.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Contents</a></span></div></div><ix:continuation id="ic6978cf9ac9c4cdeab3aacf19bd5fc8f" continuedAt="i4bb8fa7429194d4daeaf0970cca25182"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2022, the Company filed a lawsuit against Amgen in the United States District Court for the District of Delaware, alleging that, beginning in 2020, Amgen engaged in an anticompetitive bundling scheme which was designed to exclude Praluent from the market in violation of federal and state laws. The lawsuit seeks damages for harm caused by the alleged scheme, as well as injunctive relief restraining Amgen from continuing its alleged anticompetitive conduct. On August 1, 2022, Amgen filed a motion to dismiss the complaint. On August 11, 2022, Amgen filed a motion to stay these proceedings pending resolution of the patent litigation described in the preceding paragraph. An oral hearing on Amgen's motion to dismiss and motion to stay was held on January 6, 2023. On February 10, 2023, the court denied Amgen's motion to stay; and on March 21, 2023, the court denied Amgen's motion to dismiss. A trial has been scheduled to begin in November 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Europe</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen has asserted European Patent No. 2,215,124 (the "'124 Patent"), which pertains to PCSK9 monoclonal antibodies, in certain countries in Europe. In October 2020, the '124 Patent claims directed to compositions of matter and medical use relevant to Praluent were ruled invalid based on a lack of inventive step by the Technical Board of Appeal (the "TBA") of the European Patent Office (the "EPO"). Following the EPO's decision, each of the '124 Patent infringement proceedings initiated by Amgen against the Company and certain of Sanofi's affiliated entities in these countries was dismissed, including in Germany. The dismissal in Germany followed an earlier finding of infringement and granting of an injunction, both of which were subsequently overturned. As a result of the overturned injunction in Germany, the Company and/or certain of Sanofi's affiliated entities are seeking damages caused by Amgen's enforcement of the injunction. As part of its opposition to these damages claims, on March 23, 2022, Amgen filed a counterclaim that asserted the German designation of European Patent No. 2,641,917 (the "'917 Patent") and seeks, among other things, a judgment of patent infringement, injunctive relief, and monetary damages. The '917 Patent is a divisional patent of the '124 Patent discussed above (i.e., a patent that shares the same priority date, disclosure, and patent term of the parent '124 Patent but contains claims to a different invention). The '917 Patent is also subject to opposition proceedings in the EPO, which were initiated by Sanofi on May 5, 2021. An oral hearing before the EPO was held on February 21, 2023, at which the '917 Patent was revoked. Amgen filed a notice to appeal to the TBA of the EPO on February 27, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to EYLEA (aflibercept) Injection</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company's patents pertaining to EYLEA are subject to post-grant proceedings before the United States Patent and Trademark Office ("USPTO"), EPO, or other comparable foreign authorities, including those described in greater detail below. In addition, the Company has filed patent infringement lawsuits in several jurisdictions alleging infringement of certain Company patents pertaining to EYLEA, including those described in greater detail below. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United States</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 11, 2020, anonymous parties filed <ix:nonFraction unitRef="request" contextRef="i9d8a843a06e446c69b2ab4242c134351_I20200211" decimals="INF" name="regn:LossContingencyExParteReexaminationFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl83MC9mcmFnOmExYjBmZTBkM2E1NDQxNTk5MzY1ZDVhOGMwZTllYjhiL3RleHRyZWdpb246YTFiMGZlMGQzYTU0NDE1OTkzNjVkNWE4YzBlOWViOGJfNzU5Nw_3d0c9bfb-22b2-46f2-b020-d246ac9bb05e">two</ix:nonFraction> requests for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex parte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reexamination of the Company's U.S. Patent Nos. 10,406,226 (the "'226 Patent") and 10,464,992 (the "'992 Patent"), and the USPTO has granted both requests.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2021, Mylan Pharmaceuticals Inc. filed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review ("IPR") petitions in the USPTO against the Company's U.S. Patent Nos. 9,254,338 (the "'338 Patent") and 9,669,069 (the "'069 Patent") seeking declarations of invalidity of the '338 Patent and the '069 Patent. On November 10, 2021, the USPTO issued a decision instituting both IPR proceedings. On December 9, 2021, Apotex Inc. and Celltrion, Inc. each filed <ix:nonFraction unitRef="claim" contextRef="i1194a9d0d6454fd98015eb8688e54523_I20211209" decimals="INF" name="regn:NumberOfInterPartiesReviewIPRPetitionsFiled" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl83MC9mcmFnOmExYjBmZTBkM2E1NDQxNTk5MzY1ZDVhOGMwZTllYjhiL3RleHRyZWdpb246YTFiMGZlMGQzYTU0NDE1OTkzNjVkNWE4YzBlOWViOGJfODIwMg_03d14199-b4f1-4bb3-bc8d-ed89acf5f9e4"><ix:nonFraction unitRef="claim" contextRef="ice77d20fb98c4a08910e2616a45f1fbd_I20211209" decimals="INF" name="regn:NumberOfInterPartiesReviewIPRPetitionsFiled" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl83MC9mcmFnOmExYjBmZTBkM2E1NDQxNTk5MzY1ZDVhOGMwZTllYjhiL3RleHRyZWdpb246YTFiMGZlMGQzYTU0NDE1OTkzNjVkNWE4YzBlOWViOGJfODIwMg_136cabe1-e7ab-4707-bd76-88559a3cc990">two</ix:nonFraction></ix:nonFraction> separate IPR petitions against the Company's '338 and '069 Patents requesting that their IPRs be instituted and joined with the IPR proceedings initiated by Mylan concerning the '338 and '069 Patents, which petitions were granted on February 9, 2022. An oral hearing was held on August 10, 2022. On November 9, 2022, the USPTO issued final written decisions finding that the claims of the '338 and '069 Patents are unpatentable and, therefore, invalid. On January 10, 2023, the Company filed notices of appeal of the USPTO written decisions concerning the '338 and '069 Patents with the Federal Circuit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, Mylan filed IPR petitions against the Company's U.S. Patent Nos. 10,130,681 (the "'681 Patent") and 10,888,601 (the "'601 Patent") (each filed July 1, 2022) and 10,857,205 (the "'205 Patent") (filed October 28, 2022) seeking declarations of invalidity of each of these patents. On January 11, 2023, the USPTO instituted IPR proceedings concerning the '681 Patent and the '601 Patent. On February 21, 2023, the Company filed a Notice of Disclaimer with the USPTO, disclaiming all claims of the '205 Patent; and, as a result, on March 1, 2023, the USPTO denied institution of Mylan's IPR petition against the '205 Patent. On January 6, 2023 and March 26, 2023, Samsung Bioepis Co., Ltd. filed separate IPR petitions against the Company's '681 Patent and '601 Patent, respectively, seeking declarations of invalidity of such patents.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 9, 2022, Apotex filed an IPR petition against the Company's U.S. Patent No. 11,253,572 (the "'572 Patent") seeking a declaration of invalidity of the '572 Patent. On March 10, 2023, the USPTO declined to institute an IPR proceeding concerning the '572 Patent. On April 27, 2023, Samsung Bioepis Co., Ltd. filed a separate IPR petition against the '572 Patent seeking a declaration of invalidity of the '572 Patent.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Contents</a></span></div></div><ix:continuation id="i4bb8fa7429194d4daeaf0970cca25182" continuedAt="i03c2d40ed00b497ebe0ead77576c142c"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 17, 2023 and February 28, 2023, Celltrion filed IPR petitions against the '992 Patent and the '226 Patent, respectively, seeking declarations of invalidity of such patents.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2022, the Company filed a patent infringement lawsuit against Mylan in the United States District Court for the Northern District of West Virginia alleging that Mylan's filing for a U.S. Food and Drug Administration approval of an aflibercept biosimilar infringes certain Company patents. On April 20, 2023, Mylan filed a motion for summary judgment or partial summary judgment concerning four of the asserted patents. On April 26, 2023, the Company filed a stipulation accepting summary judgment of noninfringement of all asserted claims of the Company's U.S. Patent No. 11,104,715. A trial has been scheduled to begin on June 12, 2023 concerning certain claims of the '601 Patent, the '572 Patent, and the Company's U.S. Patent No. 11,084,865.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Europe</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 26 and October 27, 2021, anonymous parties initiated opposition proceedings in the EPO against the Company's European Patent No. 2,944,306 (the "'306 Patent") seeking revocation of the '306 Patent in its entirety.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Canada</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, July 15, August 30, and October 4, 2022, the Company and Bayer Inc. filed patent infringement lawsuits against BGP Pharma ULC d.b.a Viatris Canada ("Viatris Canada") in the Federal Court of Canada seeking a declaration that the making, constructing, using, or selling of an aflibercept biosimilar would directly or indirectly infringe one or more claims of the Company's Canadian Patent Nos. 2,654,510 (the "'510 Patent) and 3,007,276 (the "'276 Patent") (in the lawsuit filed on June 15, 2022); the Company's Canadian Patent No. 2,965,495 (the "'495 Patent") (in the lawsuit filed on July 15, 2022); the Company's Canadian Patent No. 2,906,768 (the "'768 Patent") (in the lawsuit filed on August 30, 2022, which has been joined with the lawsuit filed on July 15, 2022); and the Company's Canadian Patent No. 3,129,193 (the "'193 Patent") (in the lawsuit filed on October 4, 2022). A trial for the lawsuit concerning the '510 Patent and the '276 Patent has been scheduled for March 2024; a trial for the lawsuit concerning the '193 Patent has been scheduled for May 2024; and a trial for the lawsuit concerning the '495 Patent and the '768 Patent has been scheduled for November/December 2024. The filing of the lawsuit concerning the '510 Patent and the '276 Patent resulted in a statutory 24-month stay of regulatory approval of Viatris Canada's aflibercept biosimilar in Canada unless the lawsuit is resolved earlier. On March 27, 2023, in light of the transfer of the New Drug Submission ("NDS") discussed below, the Company filed a motion in the Federal Court of Canada seeking termination of the Viatris Canada action relating to the '510 Patent and the '276 Patent in the Federal Court of Canada.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2023, following the transfer of Viatris Canada's NDS of its aflibercept biosimilar to Biosimilar Collaborations Ireland Limited ("BCIL"), the Company and Bayer Inc. filed a patent infringement lawsuit against BCIL in the Federal Court of Canada seeking a declaration that the making, constructing, using, or selling of an aflibercept biosimilar would directly or indirectly infringe one or more claims of the Company's '510 and '276 Patents. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">South Korea</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2022 and December 13, 2022, Samsung Bioepis Co., Ltd. initiated invalidation proceedings before the Intellectual Property Trial</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Appeal Board of the Korean Intellectual Property Office against the Company's Korean Patent Nos. 1131429 and 1406811, respectively, seeking revocation of each of such patents in its entirety.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 16, 2023, the Company filed patent infringement lawsuits against Samsung Bioepis Co., Ltd. and its parent Samsung Biologics Co., Ltd. before the Seoul Central District Court seeking a declaration that the making, constructing, using, or selling of an aflibercept biosimilar would infringe one or more claims of Company's Korean Patent No. 659477 (the "'477 Patent").</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 2, 2023, the Company filed an affirmative scope confirmation action against Samsung Bioepis Co., Ltd. before the Intellectual Property Tribunal and Appeal Board of the Korean Intellectual Property Office seeking a ruling that Samsung Bioepis's aflibercept biosimilar is covered by the claims of the '477 Patent. On March 7, 2023, the action was designated for expedited proceedings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Proceedings Relating to EYLEA (aflibercept) Injection Pre-filled Syringe</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2020, Novartis Pharma AG, Novartis Pharmaceuticals Corporation, and Novartis Technology LLC (collectively, "Novartis") filed a patent infringement lawsuit (as amended on August 2, 2021) in the U.S. District Court for the Northern District of New York asserting claims of Novartis's U.S. Patent No. 9,220,631 (the "'631 Patent") and seeking preliminary and permanent injunctions to prevent the Company from continuing to infringe the '631 Patent. Novartis also seeks a judgment of patent infringement of the '631 Patent, monetary damages (together with interest), an order of willful infringement of the '631 Patent (which would allow the court in its discretion to award damages up to three times the amount assessed), costs and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Contents</a></span></div></div><ix:continuation id="i03c2d40ed00b497ebe0ead77576c142c" continuedAt="i3554e392221d4c3ab9a1000c6037ec14"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses of the lawsuits, and attorneys' fees. On November 7, 2022, the Company and Novartis entered into a stipulation staying the lawsuit in light of the decision in the IPR proceeding discussed below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 16, 2020, the Company initiated <ix:nonFraction unitRef="claim" contextRef="i6b0615f9b30640a6aff828894aee0920_I20200716" decimals="INF" name="regn:NumberOfInterPartiesReviewIPRPetitionsFiled" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl83MC9mcmFnOmExYjBmZTBkM2E1NDQxNTk5MzY1ZDVhOGMwZTllYjhiL3RleHRyZWdpb246YTFiMGZlMGQzYTU0NDE1OTkzNjVkNWE4YzBlOWViOGJfMTM4OTA_7734b002-47b7-41f6-999c-4eac6f9e35a2">two</ix:nonFraction> IPR petitions in the USPTO seeking a declaration of invalidity of the '631 Patent on two separate grounds. On October 26, 2021, the USPTO issued a decision instituting the IPR proceeding. An oral hearing was held on July 21, 2022. On October 25, 2022, the Patent Trial and Appeal Board ("PTAB") of the USPTO issued a final written decision invalidating all claims of the '631 Patent. On December 23, 2022, Novartis filed a notice of appeal of the PTAB's decision to the Federal Circuit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 17, 2020, the Company filed an antitrust lawsuit against Novartis and Vetter Pharma International Gmbh ("Vetter") in the United States District Court for the Southern District of New York seeking a declaration that the '631 Patent is unenforceable and a judgment that the defendants' conduct violates Sections 1 and 2 of the Sherman Antitrust Act of 1890, as amended (the "Sherman Antitrust Act"). The Company is also seeking injunctive relief and treble damages. On September 4, 2020, Novartis filed, and Vetter moved to join, a motion to dismiss the complaint, to transfer the lawsuit to the Northern District of New York, or to stay the suit; and on October 19, 2020, Novartis filed, and Vetter moved to join, a second motion to dismiss the complaint on different grounds. On January 25, 2021, the Company filed an amended complaint seeking a judgment that Novartis's conduct violates Section 2 of the Sherman Antitrust Act based on additional grounds, as well as a judgment of tortious interference with contract. On February 22, 2021, Novartis filed, and Vetter moved to join, a motion to dismiss the amended complaint. On September 21, 2021, the court granted Novartis and Vetter's motion to transfer this lawsuit to the Northern District of New York. As a result, this lawsuit was transferred to the same judge that had been assigned to the patent infringement lawsuit discussed above. On November 5, 2021, the Company filed a motion to stay these proceedings in light of the pending IPR proceeding discussed above. On January 31, 2022, the court denied the Company's motion to stay these proceedings and granted Novartis and Vetter's motion to dismiss the amended complaint. On June 10, 2022, the Company filed an appeal of the District Court's decision to dismiss the amended complaint with the U.S. Court of Appeals for the Second Circuit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to REGEN-COV (casirivimab and imdevimab)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 5, 2020, Allele Biotechnology and Pharmaceuticals, Inc. ("Allele") filed a lawsuit (as amended on April 8, 2021 and December 12, 2022) against the Company in the United States District Court for the Southern District of New York, asserting infringement of U.S. Patent No. 10,221,221 (the "'221 Patent").</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allele seeks a judgment of patent infringement of the '221 Patent, an award of monetary damages (together with interest), an order of willful infringement of the '221 Patent (which would allow the court in its discretion to award damages up to three times the amount assessed), costs and expenses of the lawsuit, and attorneys' fees. On July 16, 2021, the Company filed a motion to dismiss the complaint, which motion was denied on March 2, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting documents relating to its support of 501(c)(3) organizations that provide financial assistance to patients; documents concerning its provision of financial assistance to patients with respect to products sold or developed by Regeneron (including EYLEA, Praluent, ARCALYST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and ZALTRAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); and certain other related documents and communications. On June 24, 2020, the U.S. Attorney's Office for the District of Massachusetts filed a civil complaint in the U.S. District Court for the District of Massachusetts alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law. On August 24, 2020, the Company filed a motion to dismiss the complaint in its entirety. On December 4, 2020, the court denied the motion to dismiss. On December 28, 2022, the U.S. Attorney&#8217;s Office for the District of Massachusetts filed a motion for partial summary judgment. On January 31, 2023, the Company filed a motion for summary judgment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company and Regeneron Healthcare Solutions, Inc., a wholly-owned subsidiary of the Company, each received a civil investigative demand ("CID") from the U.S. Department of Justice pursuant to the federal False Claims Act relating to remuneration paid to physicians in the form of consulting fees, advisory boards, speaker fees, and payment or reimbursement for travel and entertainment allegedly in violation of the federal Anti-Kickback Statute. The CIDs relate to EYLEA, Praluent, Dupixent, ZALTRAP, ARCALYST, and Kevzara and cover the period from January 2015 to the present. On June 3, 2021, the United States District Court for the Central District of California unsealed a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaint filed against the Company, Regeneron Healthcare Solutions, Inc., and Sanofi-Aventis U.S. LLC by two </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plaintiffs (known as relators) purportedly on behalf of the United States and various states (the "State Plaintiffs"), asserting causes of action under the federal False Claims Act and state law. Also on June 3, 2021, the United States and the State Plaintiffs notified the court of their decision to decline to intervene in the case. On October 29, 2021, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plaintiffs filed an amended complaint in this matter. On January 14, 2022, the Company filed a motion to dismiss the amended complaint in its entirety.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Contents</a></span></div></div><ix:continuation id="i3554e392221d4c3ab9a1000c6037ec14" continuedAt="i197993adf2e54dfa9b019678111e39e9"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company received a CID from the U.S. Department of Justice pursuant to the federal False Claims Act. The CID states that the investigation concerns allegations that the Company (i) violated the False Claims Act by paying kickbacks to distributors and ophthalmology practices to induce purchase of EYLEA, including through discounts, rebates, credit card fees, free units of EYLEA, and inventory management systems; and (ii) inflated reimbursement rates for EYLEA by excluding applicable discounts, rebates, and benefits from the average sales price reported to the Centers for Medicare &amp; Medicaid Services. The CID covers the period from January 2011 through June 2021. The Company is cooperating with this investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Department of Insurance Subpoena</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Company received a subpoena from the Insurance Commissioner for the State of California pursuant to the California Insurance Code. The subpoena seeks information relating to the marketing, sale, and distribution of EYLEA, including (i) discounts, rebates, credit card fees, and inventory management systems; (ii) Regeneron's relationships with distributors; (iii) price reporting; (iv) speaker programs; and (v) patient support programs. The subpoena covers the period from January 1, 2014 through August 1, 2021. The Company is cooperating with this investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Initiated by Other Payors Relating to Patient Assistance Organization Support</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to several lawsuits relating to the conduct alleged in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. These lawsuits were filed by UnitedHealthcare Insurance Company and United Healthcare Services, Inc. (collectively, "UHC") and Humana Inc. ("Humana") in the United States District Court for the Southern District of New York on December 17, 2020 and July 22, 2021, respectively; and by Blue Cross and Blue Shield of Massachusetts, Inc. and Blue Cross and Blue Shield of Massachusetts HMO Blue, Inc. (collectively, "BCBS"), Medical Mutual of Ohio ("MMO"), Horizon Healthcare Services, Inc. d/b/a Horizon Blue Cross Blue Shield of New Jersey ("Horizon"), and Local 464A United Food and Commercial Workers Union Welfare Service Benefit Fund ("Local 464A") in the U.S. District Court for the District of Massachusetts on December 20, 2021, February 23, 2022, April 4, 2022, and June 17, 2022, respectively. These lawsuits allege causes of action under state law and the federal Racketeer Influenced and Corrupt Organizations Act and seek monetary damages and equitable relief. The MMO and Local 464A lawsuits are putative class action lawsuits. On December 29, 2021, the lawsuits filed by UHC and Humana were stayed by the United States District Court for the Southern District of New York pending resolution of the proceedings before the U.S. District Court for the District of Massachusetts discussed under "Department of Justice Matters" above. On September 27, 2022, the lawsuits filed by BCBS, MMO, and Horizon were stayed by the U.S. District Court for the District of Massachusetts pending resolution of the proceedings before the same court discussed under "Department of Justice Matters" above; and, in light of these stays, the parties to the Local 464A action have also agreed to stay that matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Proceedings Relating to Shareholder Derivative Complaint</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i197993adf2e54dfa9b019678111e39e9">On June 29, 2021, an alleged shareholder filed a shareholder derivative complaint in the New York Supreme Court, naming the current and certain former members of the Company's board of directors and certain current and former executive officers of the Company as defendants and Regeneron as a nominal defendant. The complaint asserts that the individual defendants breached their fiduciary duties in relation to the allegations in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. The complaint seeks an award of damages allegedly sustained by the Company; an order requiring Regeneron to take all necessary actions to reform and improve its corporate governance and internal procedures; disgorgement from the individual defendants of all profits and benefits obtained by them resulting from their sales of Regeneron stock; and costs and disbursements of the action, including attorneys' fees. On July 28, 2021, the defendants filed a notice of removal, removing the case from the New York Supreme Court to the U.S. District Court for the Southern District of New York. On September 23, 2021, the plaintiff moved to remand the case to the New York Supreme Court. Also on September 23, 2021, the individual defendants moved to dismiss the complaint in its entirety. On December 19, 2022, the U.S. District Court for the Southern District of New York denied the plaintiff's motion to remand the case and granted a motion to stay the case pending resolution of the proceedings before the U.S. District Court for the District of Massachusetts discussed under "Department of Justice Matters" above. As a result of the stay, the court also terminated the Company's motion to dismiss the complaint without prejudice. The Company can therefore renew the motion to dismiss upon conclusion of the stay.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_76"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (where applicable, together with its subsidiaries, "Regeneron," "Company," "we," "us," and "our"), and actual events or results may differ materially from these forward-looking statements.&#160;Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words.&#160;These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Products") and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Product Candidates") and research and clinical programs now underway or planned, including without limitation EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;(aflibercept) Injection, Dupixent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;(dupilumab) Injection, Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(cemiplimab) Injection, Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;(alirocumab) Injection, Kevzara</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;(sarilumab) Injection, Evkeeza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (evinacumab), aflibercept 8 mg, pozelimab, odronextamab, itepekimab, fianlimab, garetosmab, linvoseltamab, REGN5713-5714-5715, Regeneron's other oncology programs (including its costimulatory bispecific portfolio), Regeneron's and its collaborators' earlier-stage programs, and the use of human genetics in Regeneron's research programs; the likelihood and timing of achieving any of our anticipated development milestones referenced in this report; safety issues resulting from the administration of Regeneron's Products and Regeneron's Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron's Products and Regeneron's Product Candidates in clinical trials; the likelihood, timing, and scope of possible regulatory approval and commercial launch of our late-stage product candidates and new indications for Regeneron's Products, including without limitation those listed above; the extent to which the results from the research and development programs conducted by us and/or our collaborators may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; determinations by regulatory and administrative governmental authorities which may delay or restrict our ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron's Products and Regeneron's Product Candidates; uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) or recommendations and guidelines from governmental authorities and other third parties on the commercial success of Regeneron's Products and Regeneron's Product Candidates; our ability to manufacture and manage supply chains for multiple products and product candidates; the ability of our collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; the availability and extent of reimbursement of Regeneron's Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; unanticipated expenses; the costs of developing, producing, and selling products; our ability to meet any of our financial projections or guidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 11 to our Condensed Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 11 to our Condensed Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition.&#160;These statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any such statements.&#160;In evaluating such statements, shareholders and potential investors should specifically consider the various factors identified under Part II, Item 1A. "Risk Factors," which could cause actual events and results to differ materially from those indicated by such forward-looking statements. We do not undertake any obligation to update (publicly or otherwise) any forward-looking statement, whether as a result of new information, future events, or otherwise.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases. Our products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases.   </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our core business strategy is to maintain a strong foundation in basic scientific research and discovery-enabling technologies, and to build on that foundation with our clinical development, manufacturing, and commercial capabilities. Our objective is to continue to advance as an integrated, multi-product biotechnology company that provides patients and medical professionals with important medicines for preventing and treating human diseases.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected financial information is summarized as follows:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.923%"><tr><td style="width:1.0%"></td><td style="width:60.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,162.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,965.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">973.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this report, references to our products encompass products marketed or otherwise commercialized by us and/or our collaborators or licensees and references to our product candidates encompass product candidates in development by us and/or our collaborators or licensees (in the case of collaborated or licensed products or product candidates under the terms of the applicable collaboration or license agreements), unless otherwise stated or required by the context.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Products</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products that have received marketing approval are summarized in the table below.</span></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:28.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.391%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EU</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Japan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROW</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA (aflibercept) Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neovascular age-related macular degeneration ("wet AMD")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetic macular edema ("DME")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Macular edema following retinal vein occlusion ("RVO"), which includes macular edema following central retinal vein occlusion ("CRVO") and macular edema following branch retinal vein occlusion ("BRVO")</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Myopic choroidal neovascularization ("mCNV")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetic retinopathy ("DR")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neovascular glaucoma ("NVG")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retinopathy of prematurity ("ROP")</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent (dupilumab) Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atopic dermatitis (in adults and adolescents)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atopic dermatitis (in pediatrics 6&#8211;11 years of age)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atopic dermatitis (in pediatrics 6 months&#8211;5 years of age)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asthma (in adults and adolescents)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asthma (in pediatrics 6&#8211;11 years of age)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic rhinosinusitis with nasal polyposis ("CRSwNP")</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:28.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.391%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EU</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Japan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROW</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent (dupilumab) Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eosinophilic esophagitis ("EoE") (in adults and adolescents)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prurigo nodularis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo (cemiplimab) Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic or locally advanced first-line non-small cell lung cancer ("NSCLC")</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic or locally advanced first-line NSCLC (in combination with chemotherapy)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic or locally advanced basal cell carcinoma ("BCC")</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic or locally advanced cutaneous squamous cell carcinoma ("CSCC")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic or recurrent second-line cervical cancer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent (alirocumab) Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LDL-lowering in heterozygous familial hypercholesterolemia ("HeFH") or clinical atherosclerotic cardiovascular disease ("ASCVD")</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular risk reduction in patients with established cardiovascular disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Homozygous familial hypercholesterolemia ("HoFH")</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGEN-COV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(f)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevzara (sarilumab) Solution for Subcutaneous Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rheumatoid arthritis ("RA")</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Polymyalgia rheumatica ("PMR")</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evkeeza (evinacumab) Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HoFH (in adults and adolescents)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HoFH (in pediatrics 5&#8211;11 years of age)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inmazeb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (atoltivimab, maftivimab, and odesivimab-ebgn) Injection</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infection caused by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zaire ebolavirus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARCALYST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (rilonacept) Injection for Subcutaneous Use</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cryopyrin-associated periodic syndromes ("CAPS"), including familial cold auto-inflammatory syndrome ("FCAS") and Muckle-Wells syndrome ("MWS") (in adults and adolescents)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deficiency of interleukin-1 receptor antagonist ("DIRA") (in adults and pediatrics)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recurrent pericarditis (in adults and adolescents)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZALTRAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ziv-aflibercept) Injection for Intravenous Infusion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic colorectal cancer ("mCRC")</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Note: Refer to table below (net product sales of Regeneron-discovered products) for information regarding whether net product sales for a particular product are recorded by us or others. In addition, unless otherwise noted, products in the table above are generally approved for use in adults in the above-referenced diseases.</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In collaboration with Bayer outside the United States</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In collaboration with Sanofi</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:28.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.391%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In collaboration with Sanofi prior to July 2022. Effective July 2022, the Company is solely responsible for the development, commercialization, and manufacturing of Libtayo. Refer to "Collaboration, License, and Other Agreements" section below for further details.</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> The Company is solely responsible for the development and commercialization of Praluent in the United States, and Sanofi is solely responsible for the development and commercialization of Praluent outside of the United States.</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Rest of world ("ROW"). A checkmark in this column indicates that the product has received marketing approval in at least one country outside of the United States, European Union ("EU"), or Japan.</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Known as REGEN-COV in the United States and Ronapreve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> in other countries. </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> The Company is solely responsible for the development and commercialization of Evkeeza in the United States and Ultragenyx is responsible for the development and commercialization of Evkeeza outside of the United States.</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kiniksa is solely responsible for the development and commercialization of ARCALYST.</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Sanofi is solely responsible for the development and commercialization of ZALTRAP.</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales of Regeneron-discovered products consist of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.608%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Total Sales)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,433.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,280.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,386.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,898.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,485.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,810.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGEN-COV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevzara</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="45" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Regeneron records net product sales of EYLEA in the United States. Bayer records net product sales of EYLEA outside the United States. The Company records its share of profits/losses in connection with sales of EYLEA outside the United States. </span></div></td></tr><tr><td colspan="45" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Sanofi records global net product sales of Dupixent and Kevzara. The Company records its share of profits/losses in connection with global sales of Dupixent and Kevzara.</span></div></td></tr><tr><td colspan="45" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Prior to July 1, 2022, Regeneron recorded net product sales of Libtayo in the United States and Sanofi recorded net product sales of Libtayo outside the United States. The parties equally shared profits/losses in connection with global sales of Libtayo. Effective July 1, 2022, the Company began recording net product sales of Libtayo outside the United States and pays Sanofi a royalty on global sales. Refer to "Collaboration, License, and Other Agreements" section below for further details. Included in this line item is approximately $6&#160;million of net product sales recorded by Sanofi in the first quarter of 2023 in connection with sales in certain markets outside the United States (Sanofi records net product sales in such markets during a transition period until inventory on hand as of July 1, 2022 is sold through to the end customers).</span></div></td></tr><tr><td colspan="45" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Regeneron records net product sales of Praluent in the United States. Sanofi records net product sales of Praluent outside the United States and pays the Company a royalty on such sales.</span></div></td></tr><tr><td colspan="45" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Regeneron records net product sales of REGEN-COV in the United States and Roche records net product sales of Ronapreve outside the United States. The parties share gross profits from global sales of REGEN-COV and Ronapreve based on a pre-specified formula.</span></div></td></tr><tr><td colspan="45" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in this line item are products which are sold by the Company and others. Refer to "Results of Operations - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">" below for a complete listing of net product sales recorded by the Company. Not included in this line item are net product sales of ARCALYST, which are recorded by Kiniksa; net product sales of ARCALYST were $40&#160;million for the fourth quarter of 2022.</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Programs in Clinical Development</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product candidates in clinical development, which are being developed by us and/or our collaborators, are summarized in the table below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous uncertainties associated with drug development, including uncertainties related to safety and efficacy data from each phase of drug development (including any post-approval studies), uncertainties related to the enrollment and performance of clinical trials, changes in regulatory requirements, changes to drug pricing and reimbursement regulations and requirements, and changes in the competitive landscape affecting a product candidate. The planning, execution, and results of our clinical programs are significant factors that can affect our operating and financial results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Part II, Item 1A. "Risk Factors" for a description of risks and uncertainties that may affect our clinical programs. Any of such risks and uncertainties may, among other matters, negatively impact the development timelines set forth in the table below.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Program</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory Review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023 Events to Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Select Upcoming Milestones</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#acacac;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ophthalmology</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EYLEA (aflibercept)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Approved by U.S. Food and Drug Administration ("FDA") for ROP</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aflibercept 8 mg</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Wet AMD</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;DME</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Wet AMD and DME (U.S., EU, and Japan)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;DR (U.S.)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;FDA decision on BLA for wet AMD, DME, and DR (target action date of June 27, 2023)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;European Commission ("EC") and Ministry of Health, Labour and Welfare ("MHLW") decision on regulatory submissions for wet AMD and DME (first half 2024)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Report two-year data from Phase 3 studies in wet AMD and DME (third quarter 2023)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#acacac;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology &amp; Inflammation</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dupixent (dupilumab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to IL-4R alpha subunit</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Ulcerative colitis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Eosinophilic gastroenteritis (Phase 2/3)</span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;EoE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">in pediatrics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Chronic obstructive pulmonary disease ("COPD")</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Bullous pemphigoid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Chronic spontaneous urticaria ("CSU")</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Chronic pruritus of unknown origin </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Atopic dermatitis in pediatrics and adolescents (6 months&#8211;14 years of age) (Japan)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Prurigo nodularis (Japan)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;CSU in adults and adolescents (U.S. and Japan)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Approved by EC for atopic dermatitis in pediatrics (6 months&#8211;5 years of age)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Approved by EC for EoE in adults and adolescents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Reported that Phase 3 trial in COPD with evidence of type 2 inflammation met its primary and all key secondary endpoints</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Phase 3 trial in chronic cold induced urticaria did not meet its required efficacy endpoints</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;MHLW decision on regulatory submission for atopic dermatitis in pediatrics and adolescents (6 months&#8211;14 years of age) in Japan (second half 2023)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Submit sBLA for EoE in pediatrics (mid-2023)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Report results from replicate Phase 3 trial in COPD (mid-2024)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;FDA decision on sBLA (target action date of October 22, 2023) and MHLW decision on regulatory submission (first half 2024) for CSU in adults and adolescents </span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Program </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory Review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023 Events to Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Select Upcoming Milestones</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dupixent (dupilumab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(continued)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Discontinued further clinical development in allergic fungal rhinosinusitis and chronic rhinosinusitis without nasal polyposis</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kevzara (sarilumab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to IL-6R</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Polyarticular-course juvenile idiopathic arthritis ("pcJIA") (pivotal study)<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Systemic juvenile idiopathic arthritis ("sJIA") (pivotal study)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Approved by FDA for PMR</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Submit sBLA and regulatory application in the EU for pcJIA (second half 2023)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Itepekimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(REGN3500)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to IL-33</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;COPD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Report results from Phase 3 study in COPD (2025)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5713-5714-5715</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Multi-antibody therapy to Bet v 1</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Birch allergy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#acacac;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Solid Organ Oncology</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Libtayo (cemiplimab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(g)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to PD-1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;First-line NSCLC, BNT116 combination</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Neoadjuvant CSCC</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Second-line cervical cancer, ISA101b combination</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Adjuvant CSCC</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Approved by EC for first-line NSCLC, chemotherapy combination </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fianlimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(REGN3767)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to LAG-3 </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Solid tumors and advanced hematologic malignancies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;First-line advanced NSCLC (Phase 2/3) (pivotal study)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;First-line metastatic melanoma<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;First-line adjuvant melanoma</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Initiate Phase 3 study (in combination with Libtayo) in perioperative melanoma (second half 2023) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Initiate Phase 2 study (in combination with Libtayo) in perioperative NSCLC (second half 2023) </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vidutolimod</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Immune activator targeting TLR9</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Solid tumors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Initiate Phase 2 study in melanoma </span></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Program </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory Review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023 Events to Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Select Upcoming Milestones</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ubamatamab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(REGN4018)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting MUC16 and CD3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Platinum-resistant ovarian cancer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Report results from Phase 1/2 study (in combination with Libtayo) in platinum-resistant ovarian cancer (second half 2023)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5668</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(n)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting MUC16 and CD28</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Platinum-resistant ovarian cancer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5678</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting PSMA and CD28</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Prostate cancer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Report additional results from Phase 1/2 study (in combination with Libtayo) in prostate cancer (second half 2023/first half 2024)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN4336</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting PSMA and CD3</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Prostate cancer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5093</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting two distinct MET epitopes</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;MET-altered advanced NSCLC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5093-M114</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody-drug conjugate targeting two distinct MET epitopes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;MET overexpressing advanced cancer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN6569</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to GITR</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Solid tumors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN7075</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting EGFR and CD28</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Solid tumors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#acacac;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hematology</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Odronextamab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> (REGN1979)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting CD20 and CD3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Certain B-cell malignancies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)(m)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;B-cell non-Hodgkin lymphoma</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;("B-NHL")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(m)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (pivotal study)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Initiate Phase 3 studies in follicular lymphoma ("FL") and diffuse large B-cell lymphoma ("DLBCL"), including earlier lines of therapy (second quarter 2023)</span></div></td></tr><tr style="height:50pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Program </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory Review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023 Events to Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Select Upcoming Milestones</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Odronextamab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> (REGN1979)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Submit BLA and Marketing Authorization Application ("MAA") for relapsed/refractory FL and DLBCL (second half 2023)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5837</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(p)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting CD22 and CD28</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;B-NHL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Linvoseltamab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(REGN5458)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting BCMA and CD3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Multiple myeloma</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Multiple myeloma (pivotal study)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Initiate Phase 3 study in multiple myeloma, including earlier lines of therapy (mid-2023) <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Submit BLA for relapsed/refractory multiple myeloma (second half 2023)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5459</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting BCMA and CD3</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Transplant desensitization in patients with chronic kidney disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pozelimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(REGN3918)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to C5; studied as monotherapy and in combination with cemdisiran</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;CD55-deficient protein-losing enteropathy ("CHAPLE"), monotherapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (potentially pivotal study)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Myasthenia gravis, cemdisiran combination</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(k)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Paroxysmal nocturnal hemoglobinuria ("PNH"), cemdisiran combination</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)(k)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;CHAPLE, monotherapy (adults and children aged 1 year and older) (U.S.)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;FDA decision on BLA for CHAPLE, monotherapy (target action date of August 20, 2023)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN7257</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to IL2Rg</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Aplastic anemia</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NTLA-2001</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(j)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">TTR gene knockout using CRISPR/Cas9</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Transthyretin ("ATTR") amyloidosis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN9933</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to Factor XI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Thrombosis<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN7508</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to Factor XI</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Thrombosis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN7999</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to TMPRSS6</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Transfusion dependent iron overload</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Program </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory Review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023 Events to Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Select Upcoming Milestones</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#acacac;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General Medicine</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">"Next Generation" Covid Antibodies</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibodies to SARS-CoV-2 variants</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Initiate clinical development of "next generation" antibody (mid-2023)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Praluent (alirocumab)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to PCSK9</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;HeFH in pediatrics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Submit sBLA for HeFH in pediatrics (mid-2023)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evkeeza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(evinacumab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)(l)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to ANGPTL3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Approved by FDA for HoFH in pediatrics (5&#8211;11 years of age)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Garetosmab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(REGN2477)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to Activin A</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Fibrodysplasia ossificans progressiva </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">("FOP")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)(d)(e)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mibavademab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(REGN4461)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Agonist antibody to leptin receptor ("LEPR")</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Generalized lipodystrophy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Partial lipodystrophy</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5381/REGN9035</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Agonist antibody to NPR1/reversal agent to REGN5381</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Reversal agent in healthy volunteers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Heart failure</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Report initial data in healthy volunteers (2023)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALN-HSD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(o)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">RNAi therapeutic targeting HSD17B13</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Nonalcoholic steatohepatitis<br/>("NASH")</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;NASH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALN-PNP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(k)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">RNAi therapeutic targeting PNPLA3</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;NASH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALN-APP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(k)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">RNAi therapeutic targeting APP</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Early-onset Alzheimer&#8217;s disease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(q)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Reported positive interim data from single dose part of Phase 1 trial in early-onset Alzheimer&#8217;s disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.893%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Note: For purposes of the table above, a program is classified in Phase 1, 2, or 3 clinical development after recruitment for the corresponding study or studies has commenced.</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In collaboration with Bayer outside the United States</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In collaboration with Sanofi</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> FDA granted orphan drug designation</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> FDA granted Breakthrough Therapy designation</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> FDA granted Fast Track designation</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Sanofi did not opt-in to or elected not to continue to co-develop the product candidate. Under the terms of our agreement, Sanofi is entitled to receive royalties on sales of the product, if any.</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Studied as monotherapy and in combination with other antibodies and treatments</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Information in this column relates to U.S., EU, and Japan regulatory submissions only</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In collaboration with Zai Lab in mainland China, Hong Kong, Taiwan, and Macau</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(j)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In collaboration with Intellia</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(k)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In collaboration with Alnylam</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(l)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In collaboration with Ultragenyx outside the United States</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(m)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> FDA granted Fast Track designation for follicular lymphoma and diffuse large B-cell lymphoma</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(n)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Studied in combination with ubamatamab</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(o)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Alnylam elected to opt-out of the product candidate. Under the terms of our agreement, Alnylam is entitled to receive royalties on sales of the product, if any.</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(p)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Studied in combination with odronextamab</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(q)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Part B of the study (multi-dose regimen) has been placed on partial clinical hold in the U.S. by the FDA due to findings observed in prior non-clinical chronic toxicology studies.</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Information - Clinical Development Programs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dupixent</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company and Sanofi announced that the primary and all key secondary endpoints were met in the BOREAS trial (the first of two Phase 3 trials) in adults currently on maximal standard-of-care inhaled therapy (triple therapy) with uncontrolled COPD and evidence of type 2 inflammation. In this trial, patients receiving Dupixent experienced a 30% reduction in moderate or severe acute COPD exacerbations (rapid and acute worsening of respiratory symptoms) over 52 weeks, while also demonstrating significant improvements in lung function, quality of life, and COPD respiratory symptoms. The safety results were generally consistent with the known safety profile of Dupixent in its approved indications. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration, License, and Other Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antibody</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are collaborating with Sanofi on the global development and commercialization of Dupixent, Kevzara, and itepekimab (the "Antibody Collaboration"). Under the terms of the Antibody License and Collaboration Agreement (the "LCA"), Sanofi is generally responsible for funding 80% to 100% of agreed-upon development costs. We are obligated to reimburse Sanofi for 30% to 50% of worldwide development expenses that were funded by Sanofi based on our share of collaboration profits from commercialization of collaboration products; as of December 31, 2022, the total amount of our contingent reimbursement obligation to Sanofi in connection with such development expenses was approximately $2.9&#160;billion. Under the terms of the LCA, we were required to apply 10% of our share of the profits from the Antibody Collaboration in any calendar quarter to reimburse Sanofi for these development costs. On July 1, 2022, an amendment to the LCA became effective, pursuant to which the percentage of Regeneron&#8217;s share of profits used to reimburse Sanofi for such development costs increased from 10% to 20%. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our collaboration agreement, Sanofi records product sales for commercialized products, and Regeneron has the right to co-commercialize such products on a country-by-country basis. We co-commercialize Dupixent in the United States and in certain countries outside the United States. We supply certain commercial bulk product to Sanofi. We and Sanofi equally share profits and losses from sales within the United States. We and Sanofi share profits outside the United States on a sliding scale based on sales starting at 65% (Sanofi)/35% (us) and ending at 55% (Sanofi)/45% (us), and share losses outside the United States at 55% (Sanofi)/45% (us). In each of 2020 and 2021, we earned a $50.0 million sales-based milestone from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $1.0 billion and $1.5 billion, respectively, on a rolling twelve-month basis. In 2022, we earned two additional $50.0&#160;million sales-based milestones, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $2.0&#160;billion and $2.5 billion, respectively, on a rolling twelve-month basis. We are entitled to receive the final sales milestone payment of $50.0&#160;million when such sales outside the United States exceed $3.0&#160;billion on a rolling twelve-month basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immuno-Oncology</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously collaborated with Sanofi for antibody-based cancer treatments in the field of immuno-oncology (the "IO Collaboration"). Under the terms of the Immuno-oncology License and Collaboration Agreement, the parties were co-developing and co-commercializing Libtayo. The parties shared equally, on an ongoing basis, development and commercialization expenses for Libtayo. We had principal control over the development of Libtayo and led commercialization activities in the United States, while Sanofi led commercialization activities outside of the United States. The parties shared equally in profits and losses in connection with the commercialization of Libtayo.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective July 1, 2022, the Company obtained the exclusive right to develop, commercialize, and manufacture Libtayo worldwide under an Amended and Restated Immuno-oncology License and Collaboration Agreement with Sanofi (the "A&amp;R IO LCA"). In connection with the A&amp;R IO LCA, in 2022, the Company made a $900.0&#160;million up-front payment to Sanofi, as well as a $100.0&#160;million regulatory milestone payment. In addition, Sanofi earned a $65.0 million sales-based milestone upon the achievement of a specified amount of worldwide net product sales of Libtayo in 2022 and is eligible to receive an additional $35.0 million sales-based milestone upon the achievement of a specified amount of worldwide net product sales of Libtayo in 2023. We also pay Sanofi an 11% royalty on net product sales of Libtayo through March 31, 2034. The parties have also entered into a transition services agreement, a transitional distribution agreement, and a manufacturing services agreement, pursuant to which, during certain transitional periods, Sanofi will perform for Regeneron certain transition, distribution, and manufacturing services, respectively.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Amended and Restated Immuno-oncology Discovery and Development Agreement, we were obligated to reimburse Sanofi for half of the development costs it funded that were attributable to clinical development of product candidates from our share of profits from commercialized IO Collaboration products. Under the A&amp;R IO LCA, the amount of development costs incurred under the IO Collaboration for which we are obligated to reimburse Sanofi was $35.0&#160;million as of the effective date of the A&amp;R IO LCA, and we pay Sanofi a 0.5% royalty on net product sales of Libtayo until all such development costs have been reimbursed by us.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bayer </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Bayer are parties to a license and collaboration agreement for the global development and commercialization of EYLEA and aflibercept 8 mg outside the United States. Agreed-upon development expenses incurred by the Company and Bayer are generally shared equally. Bayer markets EYLEA outside the United States, and the companies share equally in profits and losses from such sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to reimburse Bayer for 50% of the development costs that it has incurred under the agreement from our share of the collaboration profits. The reimbursement payment in any quarter will equal 5% of the then outstanding repayment obligation, but never more than our share of the collaboration profits in the quarter unless we elect to reimburse Bayer at a faster rate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the United States, we retain exclusive commercialization rights and are entitled to all profits from such sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Alnylam</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we and Alnylam Pharmaceuticals, Inc. entered into a collaboration to discover RNA interference ("RNAi") therapeutics for NASH and potentially other related diseases, as well as to research, co-develop and commercialize any therapeutic product candidates that emerge from these discovery efforts (including ALN-HSD, which is currently in clinical development). Under the terms of the collaboration agreement, the parties share development costs equally. During the fourth quarter of 2022, Alnylam elected to opt-out of further development activities related to ALN-HSD; as a result, we retain the exclusive right to develop and commercialize such product and Alnylam will receive a royalty on sales, if any.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we and Alnylam entered into a global, strategic collaboration to discover, develop, and commercialize RNAi therapeutics for a broad range of diseases by addressing therapeutic disease targets expressed in the eye and central nervous system ("CNS"), in addition to a select number of targets expressed in the liver. In connection with the collaboration, the Company made an up-front payment of $400.0&#160;million to Alnylam, and also purchased shares of Alnylam common stock for $400.0&#160;million. For each program, we provide Alnylam with a specified amount of funding at program initiation and at lead candidate designation, and Alnylam is eligible to receive two $100.0 million clinical proof-of-principle milestones for each of the eye and CNS programs (an aggregate of $200.0&#160;million in development milestones).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the collaboration, the parties plan to perform discovery research until designation of lead candidates. Following designation of a lead candidate, the parties may further advance such lead candidate under either a co-development/co-commercialization collaboration agreement ("Co-Co Collaboration Agreement") (under which the parties are advancing ALN-APP and ALN-PNP, which are currently in clinical development) or a license agreement ("License Agreement") structure. The initial target nomination and discovery period is five years (which may under certain situations automatically be extended for up to seven years in the aggregate) (the "Research Term"). In addition, we have an option to extend the Research Term for an additional five-year period for a research extension fee of $300.0 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the stage of designation of a lead candidate for CNS programs and liver programs, the parties have alternating rights to be a lead party for collaboration products. At the stage of designation of a lead candidate for eye programs, we have the sole right to take the product forward as a licensee. The lead party is required to take the program forward under the License Agreement structure unless the other party exercises its rights to opt-in to a Co-Co Collaboration Agreement as a participating party, in which case the lead party is required to take the program forward under the Co-Co Collaboration Agreement structure. Alnylam does not have rights to opt-in to a Co-Co Collaboration Agreement for eye programs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under a License Agreement, the lead party is designated as the licensee and has the right to develop and commercialize the collaboration product under such program. The licensee will be responsible for its own costs and expenses incurred in connection with the development and commercialization of the collaboration products under the License Agreement. The licensee will pay to the licensor certain development and/or commercialization milestone payments, as well as certain tiered royalty payments to the licensor based on the aggregate annual net sales of the collaboration product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For CNS programs and liver programs, under a Co-Co Collaboration Agreement, the party designated as the lead party will lead development and commercialization of the program and the parties will split profits and share costs equally, subject to certain co-funding opt-outs at specified clinical trial phases or under other conditions. If a party exercises its co-funding opt-out right, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the lead party will be required to make certain tiered royalty payments to the other party based on the aggregate annual net sales of the collaboration product and the timing of the exercise of the co-funding opt-out right.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the collaboration, when we are the licensee under a License Agreement or the lead party under a Co-Co Collaboration Agreement, Alnylam will be responsible for the manufacture and supply of the product to us for Phase 1 and Phase 2 clinical trials.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, during 2019, the parties entered into a Co-Co Collaboration Agreement for cemdisiran, a small interfering RNA ("siRNA") therapeutic targeting the C5 component of the human complement pathway being developed by Alnylam, with Alnylam as the lead party, and a License Agreement for a combination consisting of cemdisiran and pozelimab, with us as the licensee. Under the C5 siRNA Co-Co Collaboration Agreement, the parties shared costs equally, and under the License Agreement, we as the licensee are responsible for our own costs and expenses. The C5 siRNA License Agreement contains a flat low double-digit royalty payable to Alnylam on potential future net sales of the combination only subject to customary reductions, as well as up to $325.0 million in sales milestones.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2022, we elected to opt-out of further development activities pursuant to the Co-Co Collaboration Agreement for cemdisiran as a monotherapy; as a result, Alnylam retains the right to develop and commercialize such product and we will receive a royalty on sales (if any).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellia</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we entered into a license and collaboration agreement with Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development. NTLA-2001, which is in clinical development, is subject to a co-development and co-commercialization arrangement pursuant to which Intellia will lead development and commercialization activities and the parties share an agreed-upon percentage of development expenses and profits (if commercialized).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we expanded our existing collaboration with Intellia to provide us with rights to develop products for additional in vivo CRISPR/Cas9-based therapeutic targets and for the companies to jointly develop potential products for the treatment of hemophilia A and B, with Regeneron leading development and commercialization activities. In addition, we also received non-exclusive rights to independently develop and commercialize ex vivo gene edited products. In connection with the 2020 agreement, we made a $70.0 million up-front payment to Intellia. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to generate profits and to generate positive cash flow from operations over the next several years depends significantly on the continued success in commercializing EYLEA and Dupixent, as well as on whether we are able to obtain regulatory approval for aflibercept 8 mg and are successful in commercializing it. We expect to continue to incur substantial expenses related to our research and development activities, a portion of which we expect to be reimbursed by our collaborators. In addition, our research and development activities and related costs which are not reimbursed are expected to expand and require additional resources. We also expect to incur substantial costs related to the commercialization of our marketed products. Our financial results may fluctuate from quarter to quarter and will depend on, among other factors, the net sales of our products; the scope and progress of our research and development efforts; the timing of certain expenses; the continuation of our collaborations, in particular with Sanofi and Bayer, including our share of collaboration profits from sales of commercialized products and the amount of reimbursement of our research and development expenses that we receive from collaborators; and the amount of income tax expense we incur, which is partly dependent on the profits or losses we earn in each of the countries in which we operate. We cannot predict whether or when new products or new indications for marketed products will receive regulatory approval or, if any such approval is received, whether we will be able to successfully commercialize such product(s) and whether or when they may become profitable.</span></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_85"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in the State of New York in 1988 and publicly listed in 1991. Our principal executive offices are located at 777 Old Saw Mill River Road, Tarrytown, New York 10591, and our telephone number at that address is (914) 847-7000. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available free of charge on or through our Internet website (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://www.regeneron.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and, if applicable, amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission ("SEC"). </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors and other interested parties should note that we use our media and investor relations website (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://newsroom.regeneron.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and our social media channels to publish important information about Regeneron, including information that may be deemed material to investors. We encourage investors and other interested parties to review the information we may publish through our media and investor relations website and the social media channels listed on our media and investor relations website, in addition to our SEC filings, press releases, conference calls, and webcasts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained on our websites and social media channels is not included as a part of, or incorporated by reference into, this report.</span></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_88"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Three Months Ended March&#160;31, 2023 and 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.157%"><tr><td style="width:1.0%"></td><td style="width:63.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.874%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,162.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,965.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,215.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,706.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,061.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">973.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.619%"><tr><td style="width:1.0%"></td><td style="width:48.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.931%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.510%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.931%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.510%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.931%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.514%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA - U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,433.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo - U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo - ROW</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:9pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent - U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evkeeza - U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inmazeb - U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,638.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayer </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Roche</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,162.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,965.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Not meaningful</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Product Sales</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales of EYLEA in the United States decreased for the three months ended March&#160;31, 2023, compared to the same period in 2022, primarily due to an increase in sales-related deductions, partly offset by higher sales volume.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in "Collaboration, License, and Other Agreements - Sanofi - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immuno-Oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" above, effective July 1, 2022, the Company became solely responsible for the research, development, and commercialization of Libtayo worldwide and began recording net product sales of Libtayo outside the United States. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sanofi Collaboration Revenue</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.181%"><tr><td style="width:1.0%"></td><td style="width:65.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antibody:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of antibodies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-based milestones earned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Antibody</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Immuno-oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Corresponding costs incurred by the Company in connection with such production is recorded within Cost of collaboration and contract manufacturing.</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global net product sales of Dupixent and Kevzara are recorded by Sanofi in connection with the Antibody Collaboration. As described above under "Collaboration, License, and Other Agreements - Sanofi - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antibody</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">", on July 1, 2022, an amendment to the LCA became effective, pursuant to which the percentage of Regeneron's share of profits in any calendar quarter used to reimburse Sanofi for development costs which were funded by Sanofi increased from 10% to 20%. The increase in our share of profits in connection with commercialization of antibodies during the three months ended March&#160;31, 2023, compared to the same period in 2022, was driven by profits associated with higher Dupixent sales, partly offset by the impact of the amendment to the LCA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regeneron's share of profits in connection with the commercialization of Dupixent and Kevzara is summarized below: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"><tr><td style="width:1.0%"></td><td style="width:71.507%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent and Kevzara net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,563.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,916.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of collaboration profits  </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of development expenses incurred by Sanofi in accordance with Regeneron's payment obligation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74.9)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.9)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of antibodies </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415.3</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of collaboration profits as a percentage of Dupixent and Kevzara net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, the Company earned a $50.0 million sales-based milestone from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $2.0&#160;billion on a rolling twelve-month basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the A&amp;R IO LCA became effective July 1, 2022, the three months ended June 30, 2022 was the last period in which Sanofi collaboration revenue was recognized in connection with the IO Collaboration.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Bayer Collaboration Revenue</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.029%"><tr><td style="width:1.0%"></td><td style="width:68.419%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.096%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of EYLEA outside the United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of ex-U.S. commercial supplies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One-time payment in connection with change in Japan arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Bayer collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Corresponding costs incurred by the Company in connection with such production is recorded within Cost of collaboration and contract manufacturing.</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Effective January 1, 2022, the Company and Bayer commenced sharing equally in profits and losses based on sales from Bayer to its distributor in Japan. Previously, the Company received from Bayer a tiered percentage of sales based on sales by Bayer's distributor in Japan.</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bayer records net product sales of EYLEA outside the United States. Regeneron's share of profits in connection with commercialization of EYLEA outside the United States is summarized below:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.538%"><tr><td style="width:1.0%"></td><td style="width:69.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA net product sales outside the United States </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of collaboration profit from sales outside the United States</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of development expenses incurred by Bayer in accordance with Regeneron's payment obligation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.0)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of EYLEA outside the United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338.4</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits as a percentage of EYLEA net product sales outside the United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Roche Collaboration Revenue</span></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.538%"><tr><td style="width:1.0%"></td><td style="width:69.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global gross profit payment from Roche in connection with sales of Ronapreve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Roche distributes and records net product sales of Ronapreve outside the United States, and the parties share gross profits from worldwide sales. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expenses</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.608%"><tr><td style="width:1.0%"></td><td style="width:59.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.113%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.113%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.116%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except headcount data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of collaboration and contract manufacturing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,215.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,706.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average headcount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Includes costs incurred net of any cost reimbursements from collaborators who are not deemed to be our customers</span></div></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Cost of collaboration and contract manufacturing includes costs we incur in connection with producing commercial drug supplies for collaborators and others.</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses included a total of $238.7 million and $166.9 million for the three months ended March&#160;31, 2023 and 2022, respectively, of stock-based compensation expense related to equity awards granted under our long-term incentive plans. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our estimates of direct research and development expenses by clinical development program and other significant categories of research and development expenses. Direct research and development expenses are comprised primarily of costs paid to third parties for clinical and product development activities, including costs related to preclinical research activities, clinical trials, and the portion of research and development expenses incurred by our collaborators that we are obligated to reimburse. Indirect research and development expenses have not been allocated directly to each program, and primarily consist of costs to compensate personnel, overhead and infrastructure costs to maintain our facilities, and other costs related to activities that benefit multiple projects. Clinical manufacturing costs primarily consist of costs to manufacture bulk drug product for clinical development purposes as well as related drug filling, packaging, and labeling costs. Clinical manufacturing costs also includes pre-launch commercial supplies which did not meet the criteria to be capitalized as inventory. The table below also includes reimbursements of research and development expenses by collaborators, as when we are entitled to reimbursement of all or a portion of such expenses that we incur under a collaboration, we record those reimbursable amounts in the period in which such costs are incurred.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.052%"><tr><td style="width:1.0%"></td><td style="width:53.838%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.828%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.891%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.828%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.891%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.828%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.896%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct research and development expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent (dupilumab)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fianlimab</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo (cemiplimab)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aflibercept 8 mg</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Odronextamab</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Linvoseltamab</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other product candidates in clinical development and other research programs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total direct research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indirect research and development expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab supplies and other research and development costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy and other operating costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total indirect research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical manufacturing costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses by collaborators</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Certain prior year amounts have been reclassified to conform to the current year's presentation.</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development expenses increased for the three months ended March 31, 2023, compared to the same period in 2022, partially due to the impact of the amendments to the Sanofi collaboration agreements (which were effective July 1, 2022) described under the "Collaboration, License, and Other Agreements" section above, as (i) Sanofi is no longer reimbursing us for 50% of Libtayo development costs and (ii) we recognize our 50% share of research and development expenses in connection with the Sanofi Antibody Collaboration.</span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses included stock-based compensation expense of $139.5 million and $92.4 million for the three months ended March&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous uncertainties associated with drug development, including uncertainties related to safety and efficacy data from each phase of drug development, uncertainties related to the enrollment and performance of clinical trials, changes in regulatory requirements, changes in the competitive landscape affecting a product candidate, and other risks and uncertainties described in Part II, Item 1A. "Risk Factors." There is also variability in the duration and costs necessary to develop a pharmaceutical product, potential opportunities and/or uncertainties related to future indications to be studied, and the estimated cost and scope of the projects. The lengthy process of seeking FDA and other applicable approvals, and subsequent compliance with applicable statutes and regulations, require the expenditure of substantial resources. Any failure by us to obtain, or delay in obtaining, regulatory approvals could materially adversely affect our business. We are unable to reasonably estimate if our product candidates in clinical development will generate material product revenues and net cash inflows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-process Research and Development ("IPR&amp;D")</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D for the three months ended March&#160;31, 2023 included a $45.0&#160;million up-front payment in connection with our collaboration agreement with Sonoma Biotherapeutics, Inc. Acquired IPR&amp;D for the three months ended March 31, 2022 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included a $20.0 million opt-in payment in connection with a product candidate under our collaboration agreement with Adicet Bio, Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General, and Administrative Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative expenses increased for the three months ended March&#160;31, 2023, compared to the same period in 2022, primarily due to an increase in commercialization-related expenses for Libtayo outside the United States (as effective July 1, 2022, the Company became solely responsible for the commercialization of Libtayo worldwide), higher headcount and headcount-related costs, and higher contributions to an independent not-for-profit patient assistance organization. These increases were partly offset by a decrease in commercialization-related expenses for EYLEA. Selling, general, and administrative expenses also included stock-based compensation expense of $76.8 million and $60.7 million for the three months ended March&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Collaboration and Contract Manufacturing</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of collaboration and contract manufacturing increased for the three months ended March 31, 2023, compared to the same period in 2022, primarily due to the recognition of costs in connection with manufacturing commercial supplies for Sanofi related to Praluent outside the United States and Dupixent globally.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Operating (Income) Expense</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating (income) expense, net, for the three months ended March 31, 2022 included recognition of amounts previously deferred in connection with up-front and development milestone payments, as applicable, received in connection with our Sanofi IO, Teva, and MTPC collaborative arrangements. As the A&amp;R IO LCA became effective July 1, 2022, the three months ended June 30, 2022 was the last period in which such amounts were recognized in connection with our Sanofi IO Collaboration. In addition, during the three months ended September 30, 2022, the Company discontinued further clinical development of fasinumab, and, as a result, we deemed our obligation to provide development services in connection with the Teva and MTPC collaborative arrangements to be complete.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) consists of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:49.5pt;padding-right:49.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.257%"><tr><td style="width:1.0%"></td><td style="width:64.055%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.130%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (losses) gains on equity securities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.087%"><tr><td style="width:1.0%"></td><td style="width:63.863%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except effective tax rate)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's effective tax rate for the three months ended March&#160;31, 2023 was positively impacted, compared to the U.S. federal statutory rate, primarily by stock-based compensation and income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate. The effective tax rate for the three months ended March 31, 2023 was positively impacted, compared to the same period in 2022, primarily by stock-based compensation. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition is summarized as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.853%"><tr><td style="width:1.0%"></td><td style="width:44.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,916.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,105.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities - current </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,043.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,636.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities - noncurrent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,066.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,591.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(525.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,026.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,334.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,909.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,884.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,100.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,141.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,809.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,742.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings and finance lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,981.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,981.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we also had borrowing availability of $750.0 million under a revolving credit facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources and Uses of Cash for the Three Months Ended March&#160;31, 2023 and 2022</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.818%"><tr><td style="width:1.0%"></td><td style="width:48.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.083%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.083%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,367.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,101.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(734.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in investing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,705.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,469.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows (used in) provided by financing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(387.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures during the three months ended March&#160;31, 2023 included costs incurred in connection with the expansion of our Tarrytown, New York campus, as well costs associated with the expansion of our manufacturing facilities in Rensselaer, New York (including the ongoing construction of a fill/finish facility and related equipment). We expect to incur capital expenditures of $800 million to $900 million for the full year of 2023 primarily in connection with the continued expansion of our research, preclinical manufacturing, and support facilities at our Tarrytown campus and our Rensselaer manufacturing facility (including the fill/finish facility).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments for Libtayo intangible asset of $100.9 million during the three months ended March&#160;31, 2023 were related to contingent consideration in connection with our acquisition of the exclusive right to develop, commercialize, and manufacture Libtayo worldwide (as described in "Collaboration, License, and Other Agreements - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sanofi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immuno-Oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" above).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from issuances of Common Stock, in connection with exercises of employee stock options, were&#160;$485.2 million during the three months ended March&#160;31, 2023, compared to&#160;$521.6 million&#160;during the three months ended March&#160;31, 2022. For information related to repurchases of Common Stock, see "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchase Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" section below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Programs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, our board of directors authorized a share repurchase program to repurchase up to $3.0 billion of our Common Stock. The share repurchase program permits the Company to make repurchases through a variety of methods, including open-market transactions (including pursuant to a trading plan adopted in accordance with Rule 10b5-1 of the Exchange Act), privately negotiated transactions, accelerated share repurchases, block trades, and other transactions in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compliance with Rule 10b-18 of the Exchange Act. Share repurchases may be made from time to time at management's discretion, and the timing and amount of any such repurchases will be determined based on share price, market conditions, legal requirements, and other relevant factors. The program has no time limit and can be discontinued at any time. There can be no assurance as to the timing or number of shares of any repurchases in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, our board of directors authorized an additional share repurchase program to repurchase up to an additional $3.0&#160;billion of our Common Stock. The share repurchase program was approved under terms substantially similar to the share repurchase program above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, an aggregate of $3.051 billion remained available for share repurchases under the programs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the shares of our Common Stock we repurchased and the cost of the shares, which were recorded as Treasury Stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.432%"><tr><td style="width:1.0%"></td><td style="width:61.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of shares </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_94"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of critical accounting estimates is presented in Part II, Item&#160;7. "Management's Discussion and Analysis of Financial Condition and Results of Operations" of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022 (filed February 6, 2023).&#160;There have been no material changes to critical accounting estimates during the three months ended March&#160;31, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future Impact of Recently Issued Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the future adoption of recently issued accounting standards is not expected to have a material impact on the Company's financial position or results of operations.</span></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_97"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our market risks, and the way we manage them, are summarized in Part II, Item 7A, "Quantitative and Qualitative Disclosures About Market Risk" of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022 (filed February 6, 2023). There have been no material changes to our market risks or to our management of such risks as of March&#160;31, 2023.</span></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_100"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.  Controls and Procedures </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")), as of the end of the period covered by this report. Based on this evaluation, our principal executive officer and principal financial officer each concluded that, as of the end of such period, our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported on a timely basis, and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosures.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) or 15d-15(f) under the Exchange Act) during the quarter ended March&#160;31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_103"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_106"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.  Legal Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this item is incorporated herein by reference to the information set forth in Note 11 to our Condensed Consolidated Financial Statements included in this report.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in an environment that involves a number of significant risks and uncertainties. We caution you to read the following risk factors, which have affected, and/or in the future could affect, our business, prospects, operating results, and financial condition. The risks described below include forward-looking statements, and actual events and our actual results may differ materially from these forward-looking statements. Additional risks and uncertainties not currently known to us or that we currently deem immaterial may also impair our business, prospects, operating results, and financial condition. Furthermore, additional risks and uncertainties are described under other captions in this report and should also be considered by our investors. For purposes of this section (as well as this report in general), references to our products encompass products marketed or otherwise commercialized by us and/or our collaborators or licensees; and references to our product candidates encompass product candidates in development by us and/or our collaborators or licensees (in the case of collaborated or licensed products or product candidates under the terms of the applicable collaboration or license agreements), unless otherwise stated or required by the context. In this section, we first provide a summary of the more significant risks and uncertainties we face and then provide a full set of risk factors and discuss them in greater detail.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Summary of Risk Factors</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As noted above, we are subject to a number of risks that if realized could materially harm our business, prospects, operating results, and financial condition. Some of the more significant risks and uncertainties we face include those summarized below. The summary below is not exhaustive and is qualified by reference to the full set of risk factors set forth in this "Risk Factors" section. Please carefully consider all of the information in this Form 10-Q, including the full set of risks set forth in this "Risk Factors" section, and in our other filings with the SEC before making an investment decision regarding Regeneron.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization Risks </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are substantially dependent on the success of EYLEA and Dupixent. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sales of our products are dependent on the availability and extent of reimbursement from third-party payors, including private payors and government programs such as Medicare and Medicaid, which could change due to various factors such as drug price control measures that have been or may be enacted or introduced in the United States by various federal and state authorities.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The commercial success of our products is subject to significant competition from products or product candidates that may be superior to, or more cost effective than, our products or product candidates.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and our collaborators on which we rely to commercialize some of our marketed products may be unable to continue to successfully commercialize or co-commercialize our products, both in the United States and abroad.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory and Development Risks</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Drug development and obtaining and maintaining regulatory approval for drug products is costly, time-consuming, and highly uncertain.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Serious complications or side effects in connection with the use or development of our products or product candidates could cause our regulatory approvals to be revoked or limited or lead to delay or discontinuation of development of our product candidates or new indications for our marketed products.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unable to formulate or manufacture our product candidates in a way that is suitable for clinical or commercial use, which would delay or prevent continued development of such candidates and/or receipt of regulatory approval or commercial sale.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Many of our products are intended to be used in combination with drug-delivery devices, which may result in additional regulatory, commercialization, and other risks.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property and Market Exclusivity Risks</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to protect the confidentiality of our trade secrets, and our patents or other means of defending our intellectual property may be insufficient to protect our proprietary rights.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patents or proprietary rights of others may restrict our development, manufacturing, and/or commercialization efforts and subject us to patent litigation and other proceedings that could find us liable for damages.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Loss or limitation of patent rights, and regulatory pathways for biosimilar competition, could reduce the duration of market exclusivity for our products, including EYLEA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Supply Risks</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on limited internal and contracted manufacturing and supply chain capacity, which could adversely affect our ability to commercialize our products and to advance our clinical pipeline. As we increase our production in response to higher product demand or in anticipation of a potential regulatory approval, our current manufacturing capacity will </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">likely not be sufficient, and our dependence on our collaborators and/or contract manufacturers may increase, to produce adequate quantities of drug material for both commercial and clinical purposes.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expanding our manufacturing capacity and establishing fill/finish capabilities will be costly and we may be unsuccessful in doing so in a timely manner, which could delay or prevent the launch and successful commercialization of our products approved for marketing and could jeopardize our clinical development programs.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to manufacture products may be impaired if any of our or our collaborators' manufacturing activities, or the activities of other third parties involved in our manufacture and supply chain, are found to infringe patents of others.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If sales of our marketed products do not meet the levels currently expected, or if the launch of any of our product candidates is delayed or unsuccessful, we may face costs related to excess inventory or unused capacity at our manufacturing facilities and at the facilities of third parties or our collaborators.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third-party service or supply failures, failures at our manufacturing facilities in Rensselaer, New York and Limerick, Ireland, or failures at the facilities of any other party participating in the supply chain would adversely affect our ability to supply our products.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our or our collaborators' failure to meet the stringent requirements of governmental regulation in the manufacture of drug products or product candidates could result in incurring substantial remedial costs, delays in the development or approval of our product candidates or new indications for our marketed products and/or in their commercial launch if regulatory approval is obtained, and a reduction in sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Regulatory and Litigation Risks</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the testing or use of our products harms people, or is perceived to harm them even when such harm is unrelated to our products, we could be subject to costly and damaging product liability claims.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business activities have been, and may in the future be, challenged under U.S. federal or state and foreign healthcare laws, which may subject us to civil or criminal proceedings, investigations, or penalties.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions, and fines.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face risks from the improper conduct of our employees, agents, contractors, or collaborators, including those relating to potential non-compliance with relevant laws and regulations such as the Foreign Corrupt Practices Act and the U.K. Bribery Act.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operations are subject to environmental, health, and safety laws and regulations, including those governing the use of hazardous materials.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in laws and regulations affecting the healthcare industry could adversely affect our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tax liabilities and risks associated with our operations outside of the United States could adversely affect our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face risks related to the personal data we collect, process, and share.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on or Transactions with Third Parties</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our collaborations with Sanofi or Bayer or other third parties are terminated or breached, our ability to develop, manufacture, and commercialize certain of our products and product candidates in the time expected, or at all, would be materially harmed.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our collaborators and service providers may fail to perform adequately in their efforts to support the development, manufacture, and commercialization of our drug candidates and current and future products.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have undertaken and may in the future undertake strategic acquisitions, and any difficulties from integrating such acquisitions could adversely affect our business, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Risks Related to Our Business and Our Common Stock</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business is dependent on our key personnel and will be harmed if we cannot recruit and retain leaders in our research, development, manufacturing, and commercial organizations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Significant disruptions of information technology systems or breaches of data security could adversely affect our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) have adversely affected and may in the future adversely affect our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may need additional funding in the future, which may not be available to us, and which may force us to delay, reduce, or eliminate our product development programs or commercialization efforts.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our indebtedness could adversely impact our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our stock price is extremely volatile.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our existing shareholders may be able to exert substantial influence over matters requiring shareholder approval and over our management.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*       *       *</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on the success of EYLEA and Dupixent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EYLEA net product sales represent a substantial portion of our revenues and this concentration of our net sales in a single product makes us substantially dependent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on that product. For the three months ended March&#160;31, 2023 and 2022, EYLEA net product sales in the United States represented 45% and 51% of our total revenues, respectively. For the three months ended March 31, 2023, EYLEA global net product sales decreased by 4%, compared to the same period in 2022, as discussed in Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations - Results of Operations." If we were to experience difficulty with the commercialization of EYLEA in the United States or if Bayer were to experience any difficulty with the commercialization of EYLEA outside the United States, if EYLEA net product sales experience a sustained decline in or outside the United States, or if we and Bayer are unable to maintain current marketing approvals of EYLEA, we may experience a reduction in revenue and may not be able to stay profitable at the levels we previously achieved or at all, and our business, prospects, operating results, and financial condition may be materially harmed. In the United States, the regulatory exclusivity period for EYLEA (i.e., the period during which no biosimilar product can be approved by the FDA) will expire after May 17, 2024. See "Risks Related to Intellectual Property and Market Exclusivity - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss or limitation of patent rights, and regulatory pathways for biosimilar competition, could reduce the duration of market exclusivity for our products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" below. As a result, we face the risk of lower EYLEA net product sales due to biosimilar competition following such expiration, which may have a material adverse impact on our results of operations. While we have submitted a BLA for aflibercept 8 mg with the FDA, the degree to which any future net product sales of aflibercept 8 mg (if approved) may offset any potential decrease in EYLEA net product sales, resulting from the factors discussed above or otherwise, is highly uncertain.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are dependent on our share of profits from the commercialization of Dupixent under our Antibody Collaboration with Sanofi. If we or Sanofi were to experience any difficulty with the commercialization of Dupixent or if we or Sanofi are unable to maintain current marketing approvals of Dupixent, we may experience a reduction in revenue and our business, prospects, operating results, and financial condition may be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our collaborators are unable to continue to successfully commercialize our products, our business, prospects, operating results, and financial condition will be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that the degree of commercial success of our marketed products will continue to depend on many factors, including the following (as applicable):</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectiveness of the commercial strategy in and outside the United States for the marketing of our products, including pricing strategy;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sufficient coverage of, and reimbursement for, our marketed products by third-party payors, including Medicare and Medicaid in the United States and other government and private payors in the United States and foreign jurisdictions, as well as U.S. and foreign payor restrictions on eligible patient populations and the reimbursement process (including drug price control measures that have been or may be enacted or introduced in the United States by various federal and state authorities);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability and our collaborators' ability to maintain sales of our marketed products in the face of competitive products and to differentiate our marketed products from competitive products, including as applicable product candidates currently in clinical development (such as aflibercept 8 mg); and, in the case of EYLEA, the existing and potential new branded and biosimilar competition for EYLEA (discussed further under "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The commercial success of our products and product candidates is subject to significant competition - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketed Products" below) and the willingness of retinal specialists and patients to start or continue treatment with EYLEA or to switch from another product to EYLEA;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of existing and new health care laws and regulations currently being considered or implemented in the United States, including measures requiring the U.S. government in the future to negotiate the prices of certain drugs and price reporting and other disclosure requirements and the potential impact of such requirements on physician prescribing practices and payor coverage;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">serious complications or side effects in connection with the use of our marketed products, as discussed under "Risks Related to Maintaining Approval of Our Marketed Products and the Development and Obtaining Approval of Our Product Candidates and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Serious complications or side effects in connection with the use of our products and in clinical trials for our product candidates and new indications for our marketed products could cause our regulatory approvals to be revoked or limited or lead to delay or discontinuation of development of our product candidates or new indications for our marketed products, which could severely harm our business, prospects, operating results, and financial condition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" below;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining and successfully monitoring commercial manufacturing arrangements for our marketed products with third parties who perform fill/finish or other steps in the manufacture of such products to ensure that they meet our standards and those of regulatory authorities, including the FDA, which extensively regulate and monitor pharmaceutical manufacturing facilities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to meet the demand for commercial supplies of our marketed products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of the pending proceedings relating to EYLEA, Praluent, and REGEN-COV (described further in Note 11 to our Condensed Consolidated Financial Statements included in this report), as well as other risks relating to our marketed products and product candidates associated with intellectual property of other parties and pending or future litigation relating thereto (as discussed under "Risks Related to Intellectual Property and Market Exclusivity" below);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of the pending government proceedings and investigations and other matters described in Note 11 to our Condensed Consolidated Financial Statements included in this report (including the civil complaint filed against us on June 24, 2020 in the U.S. District Court for the District of Massachusetts by the U.S. Attorney's Office for the District of Massachusetts); and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of post-approval studies, whether conducted by us or by others and whether mandated by regulatory agencies or voluntary, and studies of other products that could implicate an entire class of products or are perceived to do so.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More detailed information about the risks related to the commercialization of our marketed products is provided in the risk factors below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators are subject to significant ongoing regulatory obligations and oversight with respect to the products we or our collaborators commercialize. If we or our collaborators fail to maintain regulatory compliance for any of such products, the applicable marketing approval may be withdrawn, which would materially harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators are subject to significant ongoing regulatory obligations and oversight with respect to the products we or they commercialize for the products' currently approved indications in the United States, EU, and other countries where such products are approved. If we or our collaborators fail to maintain regulatory compliance or satisfy other obligations for such products' currently approved indications (including because the product does not meet the relevant endpoints of any required post-approval studies (such as those required under an accelerated approval by the FDA or other similar type of approval), or for any of the reasons discussed below under "Risks Related to Maintaining Approval of Our Marketed Products and the Development and Obtaining Approval of Our Product Candidates and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Obtaining and maintaining regulatory approval for drug products is costly, time-consuming, and highly uncertain</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"), the applicable marketing approval may be withdrawn, which would materially harm our business, prospects, operating results, and financial condition. Failure to comply may also subject us to sanctions, product recalls, or withdrawals of previously approved marketing applications. See also "Risks Related to Manufacturing and Supply - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our or our collaborators' failure to meet the stringent requirements of governmental regulation in the manufacture of drug products or product candidates could result in incurring substantial remedial costs, delays in the development or approval of our product candidates or new indications for our marketed products and/or in their commercial launch if regulatory approval is obtained, and a reduction in sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of our marketed products are dependent on the availability and extent of reimbursement from third-party payors, and changes to such reimbursement may materially harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our marketed products in the United States are dependent, in large part, on the availability and extent of reimbursement from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies ("PBMs"), and government programs such as Medicare and Medicaid. Sales of our marketed products in other countries are dependent, in large part, on similar reimbursement mechanisms and programs in those countries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future revenues and profitability will be adversely affected in a material manner if such third-party payors do not adequately defray or reimburse the cost of our marketed products. If these entities do not provide coverage and reimbursement with respect to our marketed products or provide an insufficient level of coverage and reimbursement, such products may be too costly for many patients to afford them, and physicians may not prescribe them. Many third-party payors cover only selected drugs, or may prefer selected drugs, making drugs that are not covered or preferred by such payors more expensive for patients. Third-party payors may also require prior authorization for reimbursement, or require failure on another type of treatment before covering a particular drug, particularly with respect to higher-priced drugs. As our currently marketed products and most of our product candidates are biologics, bringing them to market may cost more than bringing traditional, small-molecule drugs to market due to the complexity associated with the research, development, production, supply, and regulatory review of such products. Given cost sensitivities in many health care systems, our currently marketed products and product candidates are </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">likely to be subject to continued pricing pressures, which may have an adverse impact on our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in order for private insurance and governmental payors (such as Medicare and Medicaid in the United States) to reimburse the cost of our marketed products, we must maintain, among other things, our FDA registration and our National Drug Code, formulary approval by PBMs, and recognition by insurance companies and the Centers for Medicare &amp; Medicaid Services ("CMS"). There is no certainty that we will be able to obtain or maintain the applicable requirements for reimbursement (including relevant formulary coverage, as discussed further below) of our current and future marketed products, which may have a material adverse effect on our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government and other third-party payors (including PBMs) are challenging the prices charged for healthcare products and increasingly limiting, and attempting to limit, both coverage and level of reimbursement for prescription drugs, such as by requiring outcomes-based or other pay-for-performance pricing arrangements. They are also imposing restrictions on eligible patient populations and the reimbursement process, including by means of required prior authorizations and utilization management criteria, such as step therapy (i.e., requiring the use of less costly medications before more costly medications are approved for coverage). Some states are also considering legislation that would control the prices and reimbursement of prescription drugs, and state Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any prescription drug for which supplemental rebates are not being paid. It is likely that federal and state legislatures and health agencies will continue to focus on additional health care reform measures in the future that will impose additional constraints on prices and reimbursements for our marketed products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, there have been several recent U.S. Congressional inquiries and recently approved or proposed federal and state legislation and policies (in addition to those already in effect) designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the out-of-pocket cost of prescription drugs, and reform government program reimbursement methodologies for drugs. Notably, the U.S. Congress recently passed the Inflation Reduction Act ("IRA"), which includes, among other items, provisions regarding the following:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Implementation of a Medicare Drug Price Negotiation Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the "Medicare Drug Price Negotiation Program").  The Medicare Drug Price Negotiation Program requires the government to set prices for select high-expenditure drugs covered under Medicare Parts B and D. In the first two years, only Part D drugs are eligible for inclusion in the Medicare Drug Price Negotiation Program. Starting in 2026, the government is authorized to select both Part B and Part D drugs for inclusion in the Medicare Drug Price Negotiation Program, with established prices for selected drugs to go into effect in 2028 absent certain disqualifying events. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Medicare Inflation Based Rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The IRA includes measures penalizing manufacturers that raise prices of drugs covered under Medicare Parts B and D at a rate that exceeds the rate of inflation. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Medicare Part D Program Redesign</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The IRA implements changes to the Medicare Part D benefits to limit patient out-of-pocket drug costs and shift program liabilities from patients to other stakeholders, including health plans, manufacturers, and the government.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While enacted into law, it is currently unclear how many of the provisions of the IRA (including the Medicare Drug Price Negotiation Program with respect to Part B drugs and biologics) will be implemented and the extent to which the policy changes will ultimately impact reimbursement levels of our marketed products, including those covered under Medicare Part B (such as EYLEA) or our product candidates that may be covered under Medicare Part B (such as aflibercept 8 mg) or Medicare Part D in the future. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures are becoming increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and price and marketing cost disclosure and transparency measures. In some cases, these measures are designed to encourage importation from other countries and bulk purchasing. A reduction in the availability or extent of reimbursement from U.S. government programs (including as a result of the legislation, proposals, initiatives, and developments described above) could have a material adverse effect on the sales of EYLEA or our other marketed products. Economic pressure on state budgets may also have a similar impact. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, PBMs and other managed-care organizations often develop formularies to reduce their cost for medications. The breadth of the products covered by formularies varies considerably from one PBM to another. Failure to be included in such formularies or to achieve favorable formulary status may negatively impact the utilization and market share of our marketed products. If our marketed products are not included within an adequate number of formularies, adequate reimbursement levels are not provided, the eligible insured patient population for our products is limited, or a key payor refuses to provide reimbursement for our products in a particular jurisdiction altogether, this could have a material adverse effect on our and our collaborators' ability to commercialize the applicable product.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many foreign countries, pricing, coverage, and level of reimbursement of prescription drugs are subject to governmental control, and we and our collaborators may be unable to obtain coverage, pricing, and/or reimbursement on terms that are favorable to us or necessary for us or our collaborators to successfully commercialize our marketed products in those countries. In some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country, and may take into account the clinical effectiveness, cost, and service impact of existing, new, and emerging drugs and treatments. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Our results of operations may suffer if we or our collaborators are unable to market our products in foreign countries or if coverage and reimbursement for our marketed products in foreign countries is limited or delayed. As discussed below under "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to establish commercial capabilities outside the United States for Libtayo, Dupixent, or any other products we intend to commercialize or co-commercialize outside the United States, our business, prospects, operating results, and financial condition may be adversely affected,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" we will need to manage these and other commercialization-related risks in order for us to successfully develop commercial capabilities outside the United States (including those necessary for our successful commercialization and co-commercialization of Libtayo and Dupixent, respectively).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercial success of our products and product candidates is subject to significant competition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marketed Products</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is substantial competition in the biotechnology and pharmaceutical industries from biotechnology, pharmaceutical, and chemical companies. Many of our competitors have substantially greater research, preclinical and clinical product development and manufacturing capabilities, as well as financial, marketing, and human resources, than we do. Our competitors, regardless of their size, may also enhance their competitive position if they acquire or discover patentable inventions, form collaborative arrangements, or merge with other pharmaceutical or biotechnology companies. There is significant actual and potential future competition for each of our marketed products.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EYLEA and (if approved) aflibercept 8 mg.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EYLEA faces and, if approved, aflibercept 8 mg will face, significant competition in the marketplace. For example, EYLEA competes in one or more of its approved indications with other VEGF inhibitors, including Genentech/Roche's Vabysmo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (faricimab-svoa) and Susvimo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ranibizumab ocular implant), Novartis and Genentech/Roche's Lucentis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ranibizumab), and Novartis' Beovu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brolucizumab), as well as biosimilar versions of Lucentis commercialized in the United States by Biogen Inc. and Coherus BioSciences, Inc. Ophthalmologists are also using off-label, third-party repackaged versions of Genentech/Roche's approved VEGF antagonist, bevacizumab, for the treatment of certain of EYLEA's indications, and we are aware of another company developing an ophthalmic formulation of such product. In DME and RVO, EYLEA also competes with intravitreal implants of corticosteroids. We are also aware of a number of companies working on the development of product candidates and extended delivery devices for the potential treatment of one or more of EYLEA's indications, including those that act by blocking VEGF and VEGF receptors (including therapies designed to extend the treatment interval) and/or other targets. In addition, we are aware of several companies developing biosimilar versions of EYLEA and other approved anti-VEGF treatments. Other potentially competitive products in development include products for use in combination with EYLEA and/or other anti-VEGF treatments, small-molecule tyrosine kinase inhibitors, gene therapies, and other eye-drop formulations, devices, and oral therapies. There also is a risk that third parties repackage ZALTRAP for off-label use and sale for the treatment of diseases of the eye, even though ZALTRAP has not been manufactured and formulated for use in intravitreal injections. We are aware of claims by third parties, including those based on published clinical data, alleging that ZALTRAP may be safely administered to the eye. If approved, we expect that aflibercept 8 mg will be entering a highly competitive environment; and our success in potentially commercializing aflibercept 8 mg will depend on a number of factors, including the extent to which we and our collaborators are able to differentiate aflibercept 8 mg from competitive products and the applicability of any restrictions imposed by payors at the time, such as step therapy. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dupixent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The market for Dupixent's current and potential future indications is also increasingly competitive. In atopic dermatitis, there are topical and systemic JAK inhibitors and an antibody against IL-13 approved for atopic dermatitis and others are in development. In addition, a number of companies are developing antibodies against IL-4Ra, IL-13Ra1, OX40(L), and/or IL-31R that may compete with Dupixent in atopic dermatitis and other indications (including asthma and/or prurigo nodularis), as applicable. In asthma, competitors to Dupixent include antibodies against the IL-5 ligand or the IL-5 receptor, immunoglobulin E, or thymic stromal lymphopoietin ("TSLP"); and some of these antibodies are either approved or in development for indications that also compete or may compete in the future with Dupixent in CRSwNP and EoE. There are several other potentially competitive products in development that may compete with Dupixent in asthma, as well as potential future indications, including antibodies against the IL-33 ligand or receptor. Dupixent also faces competition from inhaled products in asthma and potential future indications.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Libtayo.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Libtayo also faces significant competition. There are several competitors that are marketing and/or developing antibodies against PD-1 and/or PDL-1 (some of which were approved in the relevant indications and commercialized before Libtayo), including Merck's Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab), Bristol-Myers Squibb's Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (nivolumab), Roche's Tecentriq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (atezolizumab), and AstraZeneca's Imfinzi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (durvalumab).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other marketed products.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also significant actual and potential future competition for other products marketed or otherwise commercialized by us and/or our collaborators under our collaboration agreements with them. For example, there are several companies that are marketing and/or developing antibodies or other molecules (such as small interfering RNA molecules, or siRNAs) against PCSK9, ANGPTL3 and IL-6 and/or IL-6R, which currently (or, for product candidates in development, may in the future if approved) compete with Praluent, Evkeeza, and Kevzara, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Candidates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VelocImmune</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology, other antibody generation technologies, and late-stage and earlier-stage clinical candidates face competition from many pharmaceutical and biotechnology companies using various technologies, including antibody generation technologies and other approaches such as RNAi, chimeric antigen receptor T cell (CAR-T cell), and gene therapy technologies. For example, we are aware of other pharmaceutical and biotechnology companies actively engaged in the research and development of antibody-based products against targets that are also the targets of our early- and late-stage product candidates. We are also aware of other companies developing or marketing small molecules or other treatments that may compete with our antibody-based product candidates in various indications, if such product candidates obtain regulatory approval in those indications. If any of these or other competitors announces a successful clinical study involving a product that may be competitive with one of our product candidates or the grant of marketing approval by a regulatory agency for a competitive product, such developments may have an adverse effect on our business or future prospects. In addition, the first product to reach the market in a therapeutic area is often at a significant competitive advantage relative to later entrants to the market. Accordingly, the relative speed with which we, or our collaborators, can develop our product candidates, complete the clinical trials and approval processes, and, if such product candidates are approved for marketing and sale, supply commercial quantities to the market is expected to continue to be an important competitive factor. Due to the uncertainties associated with developing biopharmaceutical products, we may not be the first to obtain marketing approval for a product against any particular target, which may have a material adverse effect on our business or future prospects.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on our collaborations with Bayer and Sanofi for commercializing some of our marketed products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have established our own sales and marketing organization for EYLEA in the United States for its currently approved indications, we have no sales, marketing, commercial, or distribution capabilities for EYLEA outside the United States. Under the terms of our license and collaboration agreement with Bayer (which is terminable by Bayer at any time upon six or twelve months' advance notice, depending on the circumstances giving rise to termination), we rely on Bayer (and, in Japan, Santen pursuant to a Co-Promotion and Distribution Agreement with Bayer's Japanese affiliate) for sales, marketing, and distribution of EYLEA (and, if approved, will rely on Bayer for such activities relating to aflibercept 8 mg) in countries outside the United States.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the terms of our Antibody Collaboration, we and Sanofi co-commercialize Dupixent in the United States and, as further discussed below, certain jurisdictions outside the United States. As a result, we rely in part on Sanofi's sales and marketing organization for Dupixent. If we and Sanofi fail to coordinate our sales and marketing efforts effectively, sales of Dupixent may be materially affected. Sanofi also maintains other important responsibilities relating to Dupixent. For example, Sanofi records product sales for Dupixent in the United States and leads negotiations with payors relating to this product. We also rely on Sanofi for sales, marketing, and distribution of Dupixent in countries outside the United States. While we exercised our option under the Antibody Collaboration to co-commercialize Dupixent in certain jurisdictions outside the United States, we will continue to rely in part on Sanofi's sales and marketing organization in such jurisdictions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we and our collaborators are unsuccessful in continuing to commercialize the marketed products subject to such collaborations, or if Bayer or Sanofi terminate their respective collaborations with us, our business, prospects, operating results, and financial condition would be materially impaired. We have limited commercial capabilities outside the United States and would have to develop or outsource these capabilities. Therefore, termination of the Bayer collaboration agreement or our Antibody Collaboration would create substantial new and additional risks to the successful commercialization of the applicable products, particularly outside the United States. For additional information regarding our collaborations with Bayer and Sanofi, see "Risks Related to Our Reliance on or Transactions with Third Parties - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If our collaboration with Bayer for EYLEA is terminated, or Bayer materially breaches its obligations thereunder, our business, prospects, operating results, and financial condition, and our ability to continue to commercialize EYLEA outside the United States would be materially harmed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" below and "Risks Related to Our Reliance on or Transactions with Third Parties - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If our Antibody Collaboration with Sanofi is terminated, or Sanofi materially breaches its obligations thereunder, our business, prospects, operating results, and financial </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">condition, and our ability to develop, manufacture, and commercialize certain of our products and product candidates in the time expected, or at all, would be materially harmed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of our marketed products recorded by us and our collaborators could be reduced by imports from countries where such products may be available at lower prices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales of products we commercialize in the United States and our collaborators' sales of products they commercialize or co-commercialize with us under our collaboration agreements with them in the United States and other countries (which impact our share of any profits or losses from the commercialization of these products under the relevant collaboration agreements and, therefore, our results of operations) may be reduced if the applicable product is imported into those countries from lower priced markets, whether legally or illegally (a practice known as parallel trading or reimportation). Parallel traders (who may repackage or otherwise alter the original product or sell it through alternative channels such as mail order or the Internet) take advantage of the price differentials between markets arising from factors including sales costs, market conditions (such as intermediate trading stages), tax rates, or national regulation of prices. Under our arrangement with Bayer, pricing and reimbursement for EYLEA outside the United States is the responsibility of Bayer. Similarly, under our Antibody Collaboration with Sanofi, pricing and reimbursement for the products commercialized or co-commercialized thereunder outside the United States are the responsibility of Sanofi. Prices for our marketed products in jurisdictions outside the United States are based on local market economics and competition and are likely to differ from country to country. In the United States, prices for pharmaceuticals are generally higher than in the bordering nations of Canada and Mexico and sales of our marketed products in the United States may be reduced if the applicable product marketed in those bordering nations is imported into the United States. In addition, there are proposals to legalize the import of pharmaceuticals from outside the United States into the United States. If such proposals were implemented, our future revenues derived from sales of our marketed products could be reduced. Parallel-trading practices also are of particular relevance to the EU, where they have been encouraged by the current regulatory framework. These types of imports may exert pressure on the pricing of our marketed products in a particular market or reduce sales recorded by us or our collaborators, thereby adversely affecting our results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unsuccessful in continuing the commercialization of our marketed products or in commercializing our product candidates or new indications for our marketed products, if approved, which would materially and adversely affect our business, profitability, and future prospects.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if clinical trials demonstrate the safety and effectiveness of any of our product candidates for a specific disease and the necessary regulatory approvals are obtained, the commercial success of any of our product candidates or new indications for our marketed products will depend upon, among other things, their acceptance by patients, the medical community, and third-party payors and on our and our collaborators' ability to successfully manufacture, market, and distribute those products in substantial commercial quantities or to establish and manage the required infrastructure to do so, including large-scale information technology systems and a large-scale distribution network. Establishing and maintaining sales, marketing, and distribution capabilities are expensive and time-consuming. Even if we obtain regulatory approval for our product candidates or new indications, if they are not successfully commercialized, we will not be able to recover the significant investment we have made in developing such products and our business, prospects, operating results, and financial condition would be severely harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of our products may also be adversely affected by guidelines or recommendations to healthcare providers, administrators, payors, and patient communities that result in decreased use of our products. Such guidelines or recommendations may be published not only by governmental agencies, but also professional societies, practice management groups, private foundations, and other interested parties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are delivered either by intravenous infusion or by intravitreal or subcutaneous injections, which are generally less well received by patients than tablet or capsule delivery and this could adversely affect the commercial success of those products if they receive marketing approval.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent upon a small number of customers for a significant portion of our revenue, and the loss of or significant reduction in sales to these customers would adversely affect our results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our marketed products for which we record net product sales in the United States to several distributors and specialty pharmacies, as applicable, which generally sell the product directly to healthcare providers or other pharmacies (as applicable). For the three months ended March&#160;31, 2023 and 2022, our gross product sales of such products to two customers accounted on a combined basis for 77% and 85% of our total gross product revenue, respectively. We expect significant customer concentration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to continue for the foreseeable future. Our ability to generate and grow sales of these products will depend, in part, on the extent to which our distributors and specialty pharmacies are able to provide adequate distribution of these products to healthcare providers. Although we believe we can find additional distributors, if necessary, our revenue during any period of disruption could suffer and we might incur additional costs. In addition, these customers are responsible for a significant portion </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our net trade accounts receivable balances. The loss of any large customer, a significant reduction in sales we make to them, any cancellation of orders they have made with us, or any failure to pay for the products we have shipped to them could adversely affect our results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish commercial capabilities outside the United States for Libtayo, Dupixent, and any other products we intend to commercialize or co-commercialize outside the United States, our business, prospects, operating results, and financial condition may be adversely affected.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited commercial capabilities outside the United States and do not currently have a fully established organization for the sales, marketing, and distribution of marketed products outside the United States. We will need to establish some or all of these capabilities outside the United States for any product we decide to independently commercialize or co-commercialize outside the United States. For example, in 2022, we and Sanofi amended the IO Collaboration to transfer all rights to develop, commercialize, and manufacture Libtayo exclusively to our Company, on a worldwide basis, over the course of a defined transition period, and we will need to establish certain sales, marketing, distribution, and manufacturing capabilities for Libtayo to support certain markets outside the United States. We will also need to obtain and/or maintain regulatory approvals for Libtayo in many jurisdictions outside of the United States. In addition, following the exercise of our option under the Antibody Collaboration to co-commercialize Dupixent in certain jurisdictions outside the United States, we have established certain commercial capabilities for Dupixent in some of these jurisdictions and are in the process of establishing these capabilities in others. There may be other circumstances in which we need to establish commercial capabilities outside the United States, including because we decide to commercialize a particular product independently; we are unable to find an appropriate collaborator; or an existing collaborator decides to opt out or breaches its obligations to us with respect to a particular product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to commercialize or co-commercialize any products outside the United States, we must build our sales, marketing, distribution, regulatory, managerial, and other capabilities in the relevant markets or make arrangements with third parties to perform these services, any of which will likely be expensive and time consuming and could delay product launch or the co-commercialization of a product in one or more markets outside the United States. We cannot be certain that we will be able to successfully develop commercial capabilities outside the United States (including as it relates to Libtayo and Dupixent) within an acceptable time frame, without incurring substantial expenses, or at all. These and other difficulties relating to commercializing our products outside the United States may harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Maintaining Approval of Our Marketed Products and the Development and Obtaining Approval of Our Product Candidates and New Indications for Our Marketed Products</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our collaborators do not maintain regulatory approval for our marketed products, and obtain regulatory approval for our product candidates or new indications for our marketed products, we will not be able to market or sell them, which would materially and negatively impact our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot sell or market products without regulatory approval or other authorization. If we or our collaborators do not maintain regulatory approval for our marketed products, and obtain regulatory approval for our product candidates or new indications of our marketed products (or are materially delayed in doing so), the value of our Company and our business, prospects, operating results, and financial condition may be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining regulatory approval for drug products is costly, time-consuming, and highly uncertain.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we (which, for purposes of this risk factor, includes our collaborators, unless otherwise stated or required by the context) must obtain and maintain approval from the FDA for each drug we intend to sell. Obtaining FDA approval for a new drug or indication is typically a lengthy and expensive process, and approval is highly uncertain. We cannot predict with certainty if or when we might submit for regulatory approval for any of our product candidates currently under development. Any approvals we may obtain may not cover all of the clinical indications for which we are seeking approval. Also, an approval might contain significant limitations in the form of narrow indications, warnings, precautions, or contra-indications with respect to conditions of use. Additionally, the FDA may determine that a Risk Evaluation and Mitigation Strategy ("REMS") is necessary to ensure that the benefits of a new product outweigh its risks, and the product can therefore be approved. A REMS may include various elements, ranging from a medication guide or patient package insert to limitations on who may prescribe or dispense the drug, depending on what the FDA considers necessary for the safe use of the drug. The FDA has substantial discretion in the approval process (including with respect to setting specific conditions for submission) and may either refuse to accept an application for substantive review or may form the opinion after review of an application that the application is insufficient to allow approval of a product candidate. If the FDA does not accept our application for review or approve our application, it may require that we conduct additional clinical, preclinical, or manufacturing validation studies and submit the data before it will reconsider our application. Depending on the extent of these or any other studies that might be required, approval of any applications that we submit may be delayed significantly, or we may be required to expend more resources. It is </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">also possible that any such additional studies, if performed and completed, may not be considered sufficient by the FDA to make our applications approvable. If any of these outcomes occur, we may be forced to delay or abandon our applications for approval.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain instances (such as when we use a biomarker-based test to identify and enroll specific patients in a clinical trial), regulatory approval of a companion diagnostic to our therapeutic product candidate may be required as a condition to regulatory approval of the therapeutic product candidate. We may need to rely on third parties to provide companion diagnostics for use with our product candidates. Such third parties may be unable or unwilling on terms acceptable to us to provide such companion diagnostics or to obtain timely regulatory approval of or product labeling updates for such companion diagnostics, which could negatively impact regulatory approval of our product candidates or may result in increased development costs or delays.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also require us to conduct additional clinical trials after granting approval of a product. The FDA has the explicit authority to require post-marketing studies (also referred to as post-approval or Phase 4 studies), labeling changes based on new safety information, and compliance with FDA-approved risk evaluation and mitigation strategies. Post-approval studies, whether conducted by us or by others and whether mandated by regulatory agencies or voluntary, and other data about our marketed products (or data about products similar to our marketed products that implicate an entire class of products or are perceived to do so) may result in changes in product labeling, restrictions on use, product withdrawal or recall, loss of approval, or lower sales of our products. Obligations equivalent in scope, but which can vary widely in application, apply in foreign countries.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the FDA policies under the Prescription Drug User Fee Act, the FDA system of review times for new drugs includes standard review and priority review. The FDA's goal for a standard review is to review the application within a 10-month time frame from the time the application is filed by the FDA (filing date), which typically occurs approximately 60 days following submission of the application by the applicant. The FDA has stated the goal to act on 90% of standard new molecular entity ("NME") New Drug Application ("NDA") and original BLA submissions within 10 months of the filing date. A priority review designation is given to drugs that treat a serious condition and offer major advances in treatment, or provide a treatment where no adequate therapy exists, and may also be afforded to a human drug application based on a priority review voucher. The FDA has stated the goal to act on 90% of priority NME NDA and original BLA submissions within six months of the filing date. However, the FDA's review goals are subject to change and the duration of the FDA's review depends on a number of factors, including the number and types of other applications that are submitted to the FDA around the same time period or are pending, and may be delayed for reasons beyond our control. For example, in 2022, an FDA travel complication related to scheduling a routine clinical trial site inspection in eastern Europe delayed by nearly two months the FDA's approval of our sBLA for the combination treatment of Libtayo with chemotherapy in NSCLC. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we believe we meet eligibility requirements, we may apply for various regulatory incentives in the United States, such as breakthrough therapy designation, fast track designation, accelerated approval, or priority review, where available, that serve to expedite drug development and/or review, and we may also seek similar designations elsewhere in the world. Often, regulatory agencies have broad discretion in determining whether or not product candidates qualify for such regulatory incentives and benefits, and we cannot guarantee we would be successful in obtaining beneficial regulatory designations by the FDA or other regulatory agencies. Even if obtained, such designations may not result in faster development processes, reviews, or approvals compared to drugs considered for approval under conventional FDA procedures. In addition, the FDA may later decide that any of our development programs no longer meets the conditions for a beneficial regulatory designation (including due to factors beyond our control, such as intervening competitive developments) or decide that the time period for FDA review or approval will not be shortened.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and comparable foreign regulatory authorities enforce Good Clinical Practice requirements ("GCPs") and other regulations and legal requirements through periodic inspections of trial sponsors, clinical research organizations ("CROs"), principal investigators, and trial sites. If we or any of the third parties conducting our clinical studies are determined to have failed to fully comply with GCPs, the study protocol or applicable regulations, the clinical data generated in those studies may be deemed unreliable. This and similar instances of non-compliance with GCPs could result in non-approval of our product candidates by the FDA or foreign regulatory authorities such as the EC, or we or the FDA or such other regulatory authorities may decide to conduct additional inspections or require additional clinical studies, which would delay our development programs, require us to incur additional costs, and could substantially harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a new drug or biologic product, the FDA and such comparable foreign regulatory authorities require that the facilities at which the product will be manufactured or advanced through the supply chain be in compliance with current Good Manufacturing Practices, or cGMP, requirements and regulations governing the manufacture, shipment, and storage of the product. Additionally, manufacturers of biological products and their facilities are subject to payment of substantial user fees </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and adherence to any commitments made in the applicable BLA. These cGMP requirements and regulations are not prescriptive instructions on how to manufacture products, but rather a series of principles that must be observed during manufacturing; as a result, their implementation may not be clearly delineated and may present a challenging task. Manufacturing product candidates in compliance with these regulatory requirements is complex, time-consuming, and expensive. To be successful, our products must be manufactured in compliance with regulatory requirements, and at competitive costs. If we or any of our third-party manufacturers, product packagers, labelers, or other parties performing steps in the supply chain are unable to maintain regulatory compliance with cGMP, the FDA and comparable foreign regulatory authorities can impose monetary penalties or other civil or criminal sanctions, including, among other things, refusal to approve a pending application for a new drug or biologic product, or revocation of a pre-existing approval. For additional information, see "Risks Related to Manufacturing and Supply - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our or our collaborators' failure to meet the stringent requirements of governmental regulation in the manufacture of drug products or product candidates could result in incurring substantial remedial costs, delays in the development or approval of our product candidates or new indications for our marketed products and/or in their commercial launch if regulatory approval is obtained, and a reduction in sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" Our business, prospects, operating results, and financial condition may be materially harmed as a result of noncompliance with the requirements and regulations described in this paragraph.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to ongoing requirements imposed by the FDA and comparable foreign regulatory authorities governing the labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, record-keeping, and reporting of safety and other post-marketing information. The holder of an approved BLA or foreign equivalent is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. The holder of an approved BLA or foreign equivalent must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing process. Advertising and promotional materials must comply with FDA regulations and those of foreign regulatory authorities and may be subject to other potentially applicable federal and state laws. The applicable regulations in countries outside the U.S. grant similar powers to the competent authorities and impose similar obligations on companies.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the standard drug approval process, the Secretary of the U.S. Department of Health and Human Services ("HHS") may authorize the issuance of, and the FDA Commissioner may issue, an EUA to allow an unapproved medical product to be used in an emergency based on criteria established by the Food, Drug, and Cosmetic Act, including that the product at issue may be effective in diagnosing, treating, or preventing serious or life-threatening diseases when there are no adequate, approved, and available alternatives. An EUA terminates when the emergency determination underlying the EUA terminates. The FDA may also revoke, revise, or restrict an EUA for a variety of reasons, including where it is determined that the underlying health emergency no longer exists or warrants such authorization or the medical product is no longer effective in diagnosing, treating, or preventing the underlying health emergency. For example, in January 2022, the FDA revised the EUA previously granted for REGEN-COV to exclude its use in geographic regions (currently including all U.S. states, territories, and jurisdictions) where, based on available information including variant susceptibility and regional variant frequency, infection or exposure is likely due to a variant such as an Omicron-lineage variant that is not susceptible to the treatment. Any such termination, revocation, or revision of an EUA could adversely impact our business in a variety of ways, including by having to absorb related manufacturing and overhead costs as well as potential inventory write-offs if regulatory approval is not obtained timely or at all. For example, during each of the years ended December 31, 2022 and 2021, we recorded a charge to write down inventory related to REGEN-COV.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the FDA and other regulatory agency regulations in the United States, we are subject to a variety of foreign regulatory requirements governing human clinical trials, manufacturing, marketing and approval of drugs, and commercial sale and distribution of drugs in foreign countries. The foreign regulatory approval process is similarly a lengthy and expensive process, the result of which is highly uncertain, and foreign regulatory requirements include all of the risks associated with FDA approval as well as country specific regulations. We and our collaborators must maintain regulatory compliance for the products we or they commercialize in foreign jurisdictions.&#160;From time to time, we may hold a product's marketing approval in a jurisdiction outside the United States where we may have less experience and where our regulatory capabilities may be more limited.&#160;In addition, actions by a regulatory agency in a country or region with respect to a product candidate may have an impact on the approval process for that product candidate in another country or region. Foreign regulatory authorities may ask for additional data in order to begin a clinical study, including Phase 3 clinical trials required to submit a MAA in the EU. In addition, such authorities often have the authority to require post-approval studies, such as a post-authorization safety study ("PASS") and/or post-authorization efficacy study ("PAES"), which involve various risks similar to those described above. Whether or not we obtain FDA approval for a product in the United States, we must obtain approval of the product by the comparable regulatory authorities in foreign countries before we can market that product or any other product in those countries.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we are subject to pharmacovigilance reporting and other pharmacovigilance requirements, which may differ in the numerous countries in which we conduct clinical trials or commercialize a product. Failure to comply with any such requirements may result in the premature closure of the clinical trials and other enforcement actions by the relevant regulatory authorities. For example, if we do not manage to retain a Qualified Person Responsible for Pharmacovigilance ("QPPV"), to maintain a Pharmacovigilance System Master File ("PSMF"), or to comply with other pharmacovigilance obligations in the European Economic Area ("EEA"), we may be at risk of our clinical trials being closed prematurely, our marketing authorization being suspended, and we may be subject to other enforcement actions by the national competent authorities of the EEA or the EC. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and clinical studies required for our product candidates and new indications of our marketed products are expensive and time-consuming, and their outcome is highly uncertain. If any such studies are delayed or yield unfavorable results, regulatory approval for our product candidates or new indications of our marketed products may be delayed or become unobtainable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, we must conduct extensive testing of our product candidates and new indications of our marketed products before we can obtain regulatory approval to market and sell them. We need to conduct both preclinical animal testing and human clinical trials. Conducting such studies is a lengthy, time-consuming, and expensive process. These tests and trials may not achieve favorable results for many reasons, including, among others, failure of the product candidate to demonstrate safety or efficacy, the development of serious or life-threatening adverse events (or side effects) caused by or connected with exposure to the product candidate (or prior or concurrent exposure to other products or product candidates), difficulty in enrolling and maintaining subjects in a clinical trial, clinical trial design that may not make it possible to enroll or retain a sufficient number of patients to achieve a statistically significant result or the desired level of statistical significance for the endpoint in question, lack of sufficient supplies of the product candidate or comparator drug, and the failure of clinical investigators, trial monitors, contractors, consultants, or trial subjects to comply with the trial plan, protocol, or applicable regulations related to the FDA's Good Laboratory Practice requirements ("GLPs") or GCPs. A clinical trial may also fail because the dose(s) of the investigational drug included in the trial were either too low or too high to determine the optimal effect of the investigational drug in the disease setting.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, conducting clinical trials in foreign countries presents additional risks, including political and economic risks that are not present in the United States, such as armed conflict and economic embargoes or boycotts. For example, we and our collaborators are currently conducting and may in the future conduct or initiate clinical trials with sites in Russia and/or Ukraine. While we currently do not expect the conflict between Russia and Ukraine and related developments to have a significant impact on our ability to obtain results from clinical trials conducted by us or our collaborators, actions taken by Russia or potentially other countries in Ukraine and surrounding areas may adversely affect our ability to adequately conduct certain clinical trials and maintain compliance with relevant protocols due to, among other reasons, the prioritization of hospital resources away from clinical trials, reallocation or evacuation of site staff and subjects, or as a result of government-imposed curfews, warfare, violence, or other governmental action or other events that restrict movement. These developments may also result in our inability to access sites for monitoring or to obtain data from affected sites or patients going forward. We could also experience disruptions in our supply chain or limits to our ability to provide sufficient investigational materials in Ukraine and surrounding regions. Clinical trial sites may suspend or terminate the trials being conducted and patients could be forced to evacuate or choose to relocate, making them unavailable for initial or further participation in such trials. Alternative sites in these areas may not be available and we may need to find other countries to conduct the relevant trials. Furthermore, military action may prevent the FDA or other regulatory agencies from inspecting clinical sites in these countries. Such interruptions may delay our plans for clinical development and approvals for our product candidates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to reevaluate any drug candidate that does not test favorably and either conduct new studies, which are expensive and time consuming, or abandon that drug development program. If preclinical testing yields unfavorable results, product candidates may not advance to clinical trials. The failure of clinical trials to demonstrate the safety and effectiveness of our clinical candidates for the desired indication(s) would preclude the successful development of those candidates for such indication(s), in which event our business, prospects, operating results, and financial condition may be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, some of our products and product candidates (such as Libtayo) are studied in combination with agents and treatments developed by us or our collaborators. There may be additional risks and unforeseen safety issues resulting from such combined administration, any of which may materially adversely impact clinical development of these product candidates and our ability to obtain regulatory approval.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some jurisdictions such as the EU, initiating Phase 3 clinical trials and clinical trials in the pediatric population is subject to a requirement to obtain approval or a waiver from the competent authorities of the EU Member States and/or the European Medicines Agency ("EMA"). If we do not obtain such approval, our ability to conduct clinical trials and obtain marketing authorizations or approvals may be severely impaired and our business may be adversely impacted.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our research and development activities are conducted at our existing facilities primarily located in Tarrytown, New York. As we continue to expand, we may lease, operate, purchase, or construct additional facilities to expand our research and development capabilities in the future. Expanding our research and laboratory facilities may require significant time and resources. Further, we may be unable to pursue our research and development efforts if the relevant facility were to cease operations due to fire, climate change, natural disasters, acts of war or terrorism, or other disruptions. Any related delays may interfere with our research and development efforts and our business may be adversely impacted.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Successful development of our current and future product candidates is uncertain.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Only a small minority of all research and development programs ultimately result in commercially successful drugs. Clinical trials may not demonstrate statistically sufficient effectiveness and safety to obtain the requisite regulatory approvals for these product candidates in these indications. Many companies in the biopharmaceutical industry, including our Company, have suffered significant setbacks in clinical trials, even after promising results had been obtained in earlier trials. In a number of instances, we have terminated the development of product candidates due to a lack of or only modest effectiveness and/or safety concerns, and clinical trials evaluating our product candidates have failed to meet the relevant endpoints. Moreover, even if we obtain positive results from preclinical testing or clinical trials, we may not achieve the same success in future trials, or the FDA and analogous foreign regulatory authorities may deem the results insufficient for an approval. If concerns arise about the safety of a product candidate or non-compliance with the protocol or applicable regulatory requirements, the FDA or other regulatory authorities can delay or suspend a clinical trial by placing it on a full or partial "clinical hold" pending receipt of additional data or the satisfaction of other conditions. A clinical hold may require us to spend significant resources to address the underlying causes of the clinical hold and may result in a delay in the clinical program, which may be significant. In addition, if we are not able to successfully address such underlying causes or our response is not deemed adequate to lift the clinical hold, the clinical program may have to be terminated. Any such clinical program delays or terminations may adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our clinical trials are conducted under the oversight of Independent Data Monitoring Committees ("IDMCs"). These independent oversight bodies are made up of external experts who review the progress of ongoing clinical trials, including available safety and efficacy data, and make recommendations concerning a trial's continuation, modification, or termination based on interim, unblinded data. Any of our ongoing clinical trials may be discontinued or amended in response to recommendations made by responsible IDMCs based on their review of such interim trial results. For example, we previously discontinued actively treating patients with fasinumab following a recommendation from the responsible IDMC that the program be terminated based on available evidence at that time; and we later discontinued further clinical development of fasinumab. The recommended termination or material modification of any of our ongoing late-stage clinical trials by an IDMC could negatively impact the future development of our product candidate(s), and our business, prospects, operating results, and financial condition may be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are studying our product candidates in a wide variety of indications in clinical trials. Many of these trials are exploratory studies designed to evaluate the safety profile of these compounds and to identify what diseases and uses, if any, are best suited for these product candidates. These product candidates may not demonstrate the requisite efficacy and/or safety profile to support continued development for some or all of the indications that are being, or are planned to be, studied, which would diminish our clinical "pipeline" and could negatively affect our future prospects and the value of our Company.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Serious complications or side effects in connection with the use of our products and in clinical trials for our product candidates and new indications for our marketed products could cause our regulatory approvals to be revoked or limited or lead to delay or discontinuation of development of our product candidates or new indications for our marketed products, which could severely harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries, and discomforts, to their study doctor. Often, it is not possible to determine whether or not the drug candidate being studied caused these conditions. Various illnesses, injuries, and discomforts have been reported from time-to-time during clinical trials of our product candidates and new indications for our marketed products. It is possible that as we test our drug candidates or new indications in larger, longer, and more extensive clinical programs, or as use of these drugs becomes more widespread if they receive regulatory approval, illnesses, injuries, and discomforts that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. Many times, side effects are only detectable after investigational drugs are tested in large-scale, Phase 3 clinical trials or, in some cases, after they are made available to patients after approval. If additional clinical experience indicates that any of our product candidates or new indications for our marketed products has many side effects or causes serious or life-threatening side effects, the development of the product candidate may be delayed or fail, or, if the product candidate has received regulatory approval, such approval may be revoked, which would severely harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to EYLEA and aflibercept 8 mg, there are many potential safety concerns associated with significant blockade of VEGF that may limit our ability to further successfully commercialize EYLEA and to obtain regulatory approval for aflibercept </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 mg. These serious and potentially life-threatening risks, based on clinical and preclinical experience of VEGF inhibitors, include bleeding, intestinal perforation, hypertension, proteinuria, congestive heart failure, heart attack, and stroke. Other VEGF blockers have reported side effects that became evident only after large-scale trials or after marketing approval when large numbers of patients were treated. There are risks inherent in the intravitreal administration of drugs like aflibercept (such as intraocular inflammation ("IOI"), sterile and culture positive endophthalmitis, corneal decomposition, retinal detachment, and retinal tear), which can cause injury to the eye and other complications. The side effects previously reported for aflibercept include conjunctival hemorrhage, macular degeneration, eye pain, retinal hemorrhage, and vitreous floaters. There is no guarantee that we will be able to successfully obtain regulatory approval for aflibercept 8 mg. In addition, commercialization of EYLEA or our other products and potential future commercialization of aflibercept 8 mg or our other product candidates may be impacted by actions of third parties on which we rely, such as manufacturers of syringes or other devices used in the administration of our products. These and other complications or issues or side effects could harm further development and/or commercialization of EYLEA as well as further development and potential future commercialization of aflibercept 8 mg. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dupixent and Libtayo are being studied in additional indications, as shown in the table under Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations - Overview - Programs in Clinical Development." There is no guarantee that regulatory approval of Dupixent or Libtayo (as applicable) in any of these indications will be successfully obtained. The side effects previously reported for Dupixent include hypersensitivity reactions, eye problems (including conjunctivitis and keratitis), injection-site reactions, eye and eyelid inflammation, cold sores, oropharyngeal pain, eosinophilia, insomnia, toothache, gastritis, joint pain (arthralgia), parasitic (helminth) infections, and facial rash or redness; and the side effects previously reported for Libtayo include certain immune-mediated adverse reactions that may occur in any organ system or tissue, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and dermatologic reactions, as well as infusion-related reactions, cellulitis, sepsis, pneumonia, urinary tract infection, fatigue, rash, and diarrhea. These and other complications or side effects could harm further development and/or commercialization of Dupixent and Libtayo (as applicable).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There also are risks inherent in subcutaneous injections (which are used for administering most of our antibody-based products and product candidates), such as injection-site reactions (including redness, itching, swelling, pain, and tenderness) and other side effects. In addition, there are risks inherent in intravenous administration (which are used for some of our antibody-based products and product candidates), such as infusion-related reactions (including nausea, pyrexia, rash, and dyspnea). These and other complications or side effects could harm further development and/or commercialization of our antibody-based products and product candidates utilizing this method of administration.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Many of our product candidates in development are recombinant proteins that could cause an immune response, resulting in the creation of harmful or neutralizing antibodies against the therapeutic protein.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the safety, efficacy, manufacturing, and regulatory hurdles faced by our product candidates, the administration of recombinant proteins frequently causes an immune response, sometimes resulting in the creation of antibodies against the therapeutic protein. The antibodies can have no effect or can totally neutralize the effectiveness of the protein, or require that higher doses be used to obtain a therapeutic effect. In some cases, the antibody can cross-react with the patient's own proteins, resulting in an "auto-immune" type disease. Whether antibodies will be created can often not be predicted from preclinical or clinical experiments, and their detection or appearance is often delayed, so neutralizing antibodies may be detected at a later date, in some cases even after pivotal clinical trials have been completed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to formulate or manufacture our product candidates in a way that is suitable for clinical or commercial use, which would delay or prevent continued development of such candidates and/or receipt of regulatory approval or commercial sale, which could materially harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to continue to develop suitable product formulations or manufacturing processes to support large-scale clinical testing of our product candidates, including our antibody-based product candidates, we may be unable to supply necessary materials for our clinical trials, which would delay or prevent the development of our product candidates. Similarly, if we are unable, directly or through our collaborators or third parties, to supply sufficient quantities of our products or develop formulations of our product candidates suitable for commercial use, we will be unable to obtain regulatory approval for those product candidates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Many of our products are intended to be used and, if approved, our product candidates may be used in combination with drug-delivery devices, which may result in additional regulatory, commercialization, and other risks.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our products are used and some of our products and product candidates may be used, if approved, in combination with a drug-delivery device, including a pre-filled syringe, patch pump, auto-injector, or other delivery system. For example, in the United States and the EU, EYLEA is approved in the 2mg pre-filled syringe. The success of our products and product candidates may depend to a significant extent on the performance of such devices, some of which may be novel or comprised of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">complex components. Given the increased complexity of the review process when approval of the product and device is sought under a single marketing application and the additional risks resulting from a product candidate's designation as a combination product discussed below, our product candidates used with such drug-delivery devices may be substantially delayed in receiving regulatory approval or may not be approved at all. The FDA review process and criteria for such applications are not well established, which could also lead to delays in the approval process. In addition, some of these drug-delivery devices may be provided by single-source, third-party providers or our collaborators. In any such case, we may be dependent on the sustained cooperation of those third-party providers or collaborators to supply and manufacture the devices; to conduct the studies and prepare related documentation required for approval or clearance by the applicable regulatory agencies; and to continue to meet the applicable regulatory and other requirements to maintain approval or clearance once it has been received. In addition, other parties may allege that our drug-delivery devices infringe patents or other intellectual property rights. For example, we are currently party to patent infringement and other proceedings relating to the EYLEA pre-filled syringe, as described in Note 11 to our Condensed Consolidated Financial Statements. Failure to successfully develop or supply the devices, delays in or failure of the studies conducted by us, our collaborators, or third-party providers, or failure of our Company, our collaborators, or the third-party providers to obtain or maintain regulatory approval or clearance of the devices could result in increased development costs, delays in or failure to obtain regulatory approval, and associated delays in a product or product candidate reaching the market. Loss of regulatory approval or clearance of a device that is used with our product may also result in the removal of our product from the market. Further, failure to successfully develop or supply and manufacture these devices, or to gain or maintain their approval, could adversely affect sales of the related products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, each component of a combination product is subject to the requirements established by the FDA for that type of component, whether a drug, biologic, or device. The determination whether a product is a combination product or two separately regulated products is made by the FDA on a case-by-case basis. Although a single marketing application is generally sufficient for the approval, clearance, or licensure of a combination product, the FDA may determine that separate marketing applications are necessary. In addition, submitting separate marketing applications may be necessary to receive some benefit that accrues only from approval under a particular type of application. This could significantly increase the resources and time required to bring a particular combination product to market.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property and Market Exclusivity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this subsection, references to our intellectual property (including patents, trademarks, copyrights, and trade secrets) include that of our collaborators and licensees, unless otherwise stated or required by the context.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot protect the confidentiality of our trade secrets, or our patents or other means of defending our intellectual property are insufficient to protect our proprietary rights, our business and competitive position will be harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business requires using sensitive and proprietary technology and other information that we protect as trade secrets. We seek to prevent improper disclosure of these trade secrets through confidentiality agreements and other means. If our trade secrets are improperly disclosed, by our current or former employees, our collaborators, or otherwise, it could help our competitors and adversely affect our business. We will be able to protect our proprietary rights only to the extent that our proprietary technologies and other information are covered by valid and enforceable patents or are effectively maintained as trade secrets. The patent position of biotechnology companies, including our Company, involves complex legal and factual questions and, therefore, enforceability cannot be predicted with certainty. Our patents may be challenged, invalidated, held to be unenforceable, or circumvented. For example, certain of our U.S. patents (including those pertaining to our key products, such as EYLEA) have been and may in the future be challenged by parties who file a request for post-grant review or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review under the America Invents Act of 2011 or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex parte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reexamination, as described in Note 11 to our Condensed Consolidated Financial Statements included in this report. Post-grant proceedings are increasingly common in the United States and are costly to defend. In addition, patent applications filed outside the United States may be challenged by other parties, for example, by filing pre-grant third-party observations that argue against patentability or a post-grant opposition. Such opposition proceedings are increasingly common in Europe and are costly to defend. For example, in 2021, anonymous parties initiated opposition proceedings in the European Patent Office ("EPO") against our European Patent No. 2,944,306 (which concerns pre-filled syringes comprising ophthalmic formulations containing VEGF antagonists such as aflibercept for intravitreal administration), as described in Note 11 to our Condensed Consolidated Financial Statements included in this report. We have pending patent applications in the United States Patent and Trademark Office (the "USPTO"), the EPO, and the patent offices of other foreign jurisdictions, and it is likely that we will need to defend patents from challenges by others from time to time in the future. Our patent rights may not provide us with a proprietary position or competitive advantages against competitors. Furthermore, even if the outcome is favorable to us, the enforcement of our intellectual property rights can be extremely expensive and time consuming.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions or our ability to obtain, maintain, and enforce our intellectual property rights. Any such changes could </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">also affect the value of our intellectual property or narrow the scope of our patents. We cannot be certain that our intellectual property rights related to any current or future product or product candidate or technology would not be eliminated, narrowed, or weakened by any such change or other rulemaking.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the United States and other government actions related to Russia's invasion of Ukraine may limit or prevent filing, prosecution, and maintenance of patent applications in Russia. These actions could result in abandonment or lapse of our patents or patent applications, resulting in partial or complete loss of patent rights in Russia. Further, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patent holders from the United States without consent or compensation. Consequently, we would not be able to prevent third parties from practicing our inventions in Russia or from selling or importing products made using our inventions in and into Russia.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also currently hold issued trademark registrations and have trademark applications pending in the United States and other jurisdictions, any of which may be the subject of a governmental or third-party objection, which could prevent the maintenance or issuance of the trademark. As our products mature, our reliance on our&#160;trademarks&#160;to differentiate us from our competitors increases and as a result, if we are unable to prevent third parties from adopting, registering, or using&#160;trademarks that infringe, dilute or otherwise violate our trademark rights, our business could be adversely affected.&#160;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be restricted in our development, manufacturing, and/or commercialization activities by patents or other proprietary rights of others, and could be subject to awards of damages if we are found to have infringed such patents or rights.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of others (including those relating to trademarks, copyrights, and trade secrets). Other parties may allege that they own blocking patents to our products in clinical development or even to products that have received regulatory approval and are being or have been commercialized, either because they claim to hold proprietary rights to the composition of a product or the way it is manufactured or the way it is used. Moreover, other parties may allege that they have blocking patents to antibody-based products made using our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VelocImmune</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology, or any other of our technologies, either because of the way the antibodies are discovered or produced or because of a proprietary composition covering an antibody or the antibody's target.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been in the past, are currently, and may in the future be involved in patent litigation and other proceedings involving patents and other intellectual property. For example, we and/or Sanofi are currently party to patent infringement proceedings initiated by Amgen against us and/or Sanofi relating to Praluent, as described in Note 11 to our Condensed Consolidated Financial Statements. In addition, we are currently party to patent infringement and other proceedings relating to EYLEA and REGEN-COV, as described in Note 11 to our Condensed Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of patents and pending patent applications owned by others that claim compositions and methods of treatment relating to targets and conditions that we are also pursuing with our products and/or product candidates. Although we do not believe that any of our products or our late-stage antibody-based product candidates infringe any valid claim in these patents or patent applications,</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these other parties could initiate lawsuits for patent infringement and assert that their patents are valid and cover our products or our late-stage antibody-based product candidates, similar to the patent infringement proceedings referred to above. Further, we are aware of a number of patent applications of others that, if granted with claims as currently drafted, may cover our current or planned activities. It could be determined that our products and/or actions in manufacturing or selling our products or product candidates infringe such patents.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent holders could assert claims against us for damages and seek to prevent us from manufacturing, selling, or developing our products or product candidates, and a court may find that we are infringing validly issued patents of others. In the event that the manufacture, use, or sale of any of our products or product candidates infringes on the patents or violates other proprietary rights of others, we may be prevented from pursuing product development, manufacturing, and commercialization of those drugs and may be required to pay costly damages. In addition, in the event that we assert our patent rights against other parties that we believe are infringing our patent rights, such parties may challenge the validity of our patents and we may become the target of litigation, which may result in an outcome that is unfavorable to us. Any of these adverse developments may materially harm our business, prospects, operating results, and financial condition. In any event, legal disputes are likely to be costly and time consuming to defend.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to obtain licenses to patents when, in our judgment, such licenses are needed or advisable. For example, in 2018, we and Sanofi entered into a license agreement with Bristol-Myers Squibb, E. R. Squibb &amp; Sons, and Ono Pharmaceutical to obtain a license under certain patents owned and/or exclusively licensed by one or more of these parties that includes the right to develop and sell Libtayo. If any licenses are required, we may not be able to obtain such licenses on commercially reasonable terms, if at all. The failure to obtain any such license could prevent us from developing or commercializing any one or more of our products or product candidates, which could severely harm our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other parties may have regulatory exclusivity in the United States or foreign jurisdictions for products relating to targets or conditions we are also pursuing, which could prevent or delay our ability to apply for or obtain regulatory approval for our product candidates in such jurisdictions. For example, in the EU, a designated orphan drug is provided up to 10 years of market exclusivity in the orphan indication, during which time the EMA is generally precluded from accepting a MAA for a similar medicinal product unless it can be demonstrated that it is safer, more effective, or otherwise clinically superior to the original orphan medicinal product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss or limitation of patent rights, and regulatory pathways for biosimilar competition, could reduce the duration of market exclusivity for our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the pharmaceutical and biotechnology industries, the majority of an innovative product's commercial value is usually realized during the period in which it has market exclusivity. In the United States and some other countries, when market exclusivity expires and generic versions of a product are approved and marketed, there usually are very substantial and rapid declines in the product's sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our late-stage product candidates or other clinical candidates are approved for marketing in the United States or elsewhere, market exclusivity for those products will generally be based upon patent rights and/or certain regulatory forms of exclusivity. As described above under "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we cannot protect the confidentiality of our trade secrets, or our patents or other means of defending our intellectual property are insufficient to protect our proprietary rights, our business and competitive position will be harmed,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" the scope and enforceability of our patent rights may vary from country to country. The failure to obtain patent and other intellectual property rights, or limitations on the use, or the loss, of such rights could materially harm us. Absent patent protection or regulatory exclusivity for our products, it is possible, both in the United States and elsewhere, that generic, biosimilar, and/or interchangeable versions of those products may be approved and marketed, which would likely result in substantial and rapid reductions in revenues from sales of those products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the federal Patient Protection and Affordable Care Act ("PPACA"), there is an abbreviated path in the United States for regulatory approval of products that are demonstrated to be "biosimilar" or "interchangeable" with an FDA-approved biological product. The PPACA provides a regulatory mechanism that allows for FDA approval of biologic drugs that are similar to innovative drugs on the basis of less extensive data than is required by a full BLA. Under this regulation, an application for approval of a biosimilar may be filed four years after approval of the innovator product. However, qualified innovative biological products receive 12 years of regulatory exclusivity, meaning that the FDA may not approve a biosimilar version until 12 years after the innovative biological product was first approved by the FDA. However, the term of regulatory exclusivity may not remain at 12 years in the United States and could be shortened if, for example, the PPACA is amended.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of jurisdictions outside of the United States have also established abbreviated pathways for regulatory approval of biological products that are biosimilar to earlier versions of biological products. For example, the EU has had an established regulatory pathway for biosimilars since 2005.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increased likelihood of biosimilar competition has increased the risk of loss of innovators' market exclusivity. It is also not possible to predict changes in United States regulatory law that might reduce biological product regulatory exclusivity. Due to this risk, and uncertainties regarding patent protection, it is not possible to predict the length of market exclusivity for any particular product we currently or may in the future commercialize with certainty based solely on the expiration of the relevant patent(s) or the current forms of regulatory exclusivity. We are aware of several companies developing biosimilar versions of EYLEA, as discussed further under "Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The commercial success of our products and product candidates is subject to significant competition - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketed Products" above. In the United States, the regulatory exclusivity period for EYLEA (i.e., the period during which no biosimilar product can be approved by the FDA) extends through May 17, 2024 following the pediatric exclusivity granted by the FDA. The loss of market exclusivity for a product (such as EYLEA) would likely materially and negatively affect revenues from product sales of that product and thus our financial results and condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Manufacturing and Supply</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on limited internal and contracted manufacturing and supply chain capacity, which could adversely affect our ability to commercialize our marketed products and, if approved, our product candidates and to advance our clinical pipeline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have large-scale manufacturing operations in Rensselaer, New York and Limerick, Ireland. Manufacturing facilities operated by us and by third-party contract manufacturers engaged by us would be inadequate to produce the active pharmaceutical ingredients of our current marketed products and our product candidates in sufficient clinical quantities if our clinical pipeline advances as planned or if there is greater demand than currently expected for our marketed products. In addition to expanding our internal capacity, we intend to continue to rely on our collaborators, and may also rely on contract </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturers, to produce commercial quantities of drug material needed for commercialization of our products. As we increase our production in anticipation of potential regulatory approval for our product candidates, our current manufacturing capacity will likely not be sufficient, and our dependence on our collaborators and/or contract manufacturers may increase, to produce adequate quantities of drug material for both commercial and clinical purposes. The COVID-19 pandemic has exacerbated and may in the future further exacerbate certain of these risks. For example, the impact of prioritizing certain manufacturing-related resources for our COVID-19 monoclonal antibodies has included and may in the future include, among other things, drawing down inventory safety stock levels for certain of our other products (including Dupixent and EYLEA). Depending on the demand for our products, our ability to re-establish successfully our customary manufacturing cadence, and other relevant factors, we may not be able to replenish our inventory safety stock to the levels we deem prudent or supply our products and product candidates in sufficient quantities to satisfy our commercial and development needs. We also rely entirely on other parties and our collaborators for filling and finishing services. Generally, in order for other parties to perform any step in the manufacturing and supply chain, we must transfer technology to the other party, which can be time consuming and may not be successfully accomplished without considerable cost and expense, or at all. We will have to depend on these other parties to perform effectively on a timely basis and to comply with regulatory requirements. If for any reason they are unable to do so, and as a result we are unable to directly or through other parties manufacture and supply sufficient commercial and clinical quantities of our products on acceptable terms, or if we should encounter delays or other difficulties with our collaborators, contract manufacturers, warehouses, shipping, testing laboratories, or other parties involved in our supply chain which adversely affect the timely manufacture and supply of our products or product candidates, our business, prospects, operating results, and financial condition may be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expanding our manufacturing capacity and establishing fill/finish capabilities will be costly and we may be unsuccessful in doing so in a timely manner, which could delay or prevent the launch and successful commercialization of our marketed products and product candidates or other indications for our marketed products if they are approved for marketing and could jeopardize our current and future clinical development programs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our existing manufacturing facilities in Rensselaer, New York and Limerick, Ireland, we may lease, operate, purchase, or construct additional facilities to conduct expanded manufacturing or other related activities in the future. Expanding our manufacturing capacity to supply commercial quantities of the active pharmaceutical ingredients for our marketed products and our product candidates if they are approved for marketing, and to supply clinical drug material to support the continued growth of our clinical programs, will require substantial additional expenditures, time, and various regulatory approvals and permits. This also holds true for establishing fill/finish capabilities in the future, for which we are in the process of constructing fill/finish facilities (refer to Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations &#8211; Liquidity and Capital Resources" for information about expected capital expenditures relating to this and other projects). In addition, we may need to develop or acquire additional manufacturing capabilities to the extent we or our collaborators pursue the development of drugs generated by means other than our existing "Trap" or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VelociSuite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technologies, such as siRNA gene silencing, genome editing, and targeted viral-based gene delivery and expression. Further, we will need to hire and train significant numbers of employees and managerial personnel to staff our expanding manufacturing and supply chain operations, as well as any future fill/finish activities. Start-up costs can be large, and scale-up entails significant risks related to process development and manufacturing yields. In addition, we may face difficulties or delays in developing or acquiring the necessary production equipment and technology to manufacture sufficient quantities of our product candidates at reasonable costs and in compliance with applicable regulatory requirements. The FDA and analogous foreign regulatory authorities must determine that our existing and any expanded manufacturing facilities and any future fill/finish activities comply, or continue to comply, with cGMP requirements for both clinical and commercial production and license them, or continue to license them, accordingly, and such facilities must also comply with applicable environmental, safety, and other governmental permitting requirements. We may not successfully expand or establish sufficient manufacturing or any future fill/finish capabilities or manufacture our products economically or in compliance with cGMPs and other regulatory requirements, and we and our collaborators may not be able to build or procure additional capacity in the required timeframe to meet commercial demand for our product candidates if they receive regulatory approval, and to continue to meet the requirements of our clinical programs. This would interfere with our efforts to successfully commercialize our marketed products, and it could also delay or require us to discontinue one or more of our clinical development programs. As a result, our business, prospects, operating results, and financial condition could be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to manufacture products may be impaired if any of our or our collaborators' manufacturing activities, or the activities of other third parties involved in our manufacture and supply chain, are found to infringe patents of others.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue to manufacture products in our Rensselaer, New York and Limerick, Ireland facilities and at additional facilities (if any) in the future (including our ability to conduct any fill/finish activities in the future), the ability of our collaborators to manufacture products at their facilities, and our ability to utilize other third parties to produce our products, to supply raw materials or other products, or to perform fill/finish services or other steps in our manufacture and supply chain, depends on our and their ability to operate without infringing the patents or other intellectual property rights of others. Other </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">parties may allege that our or our collaborators' manufacturing activities, or the activities of other third parties involved in our manufacture and supply chain (which may be located in jurisdictions outside the United States), infringe patents or other intellectual property rights. For example, we are currently party to patent infringement and other proceedings relating to the EYLEA pre-filled syringe, as described in Note 11 to our Condensed Consolidated Financial Statements. A judicial or regulatory decision in favor of one or more parties making such allegations could directly or indirectly preclude the manufacture of our products to which those intellectual property rights apply on a temporary or permanent basis, which could materially harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If sales of our marketed products do not meet the levels currently expected, or if the launch of any of our product candidates is delayed or unsuccessful, we may face costs related to excess inventory or unused capacity at our manufacturing facilities and at the facilities of third parties or our collaborators.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our manufacturing facilities primarily to produce bulk product for commercial supply of our marketed products and clinical and preclinical candidates for ourselves and our collaborations. We also plan to use such facilities to produce bulk product for commercial supply of new indications of our marketed products and new product candidates if they are approved for marketing or otherwise authorized for use. If our clinical candidates are discontinued or their clinical development is delayed, if the launch of new indications for our marketed products or new product candidates is delayed or does not occur, or if such products are launched and the launch is unsuccessful or the product is subsequently recalled or marketing approval is rescinded, we may have to absorb one hundred percent of related overhead costs and inefficiencies, as well as similar costs of third-party contract manufacturers performing services for us. In addition, if we or our collaborators experience excess inventory, it may be necessary to write down or write off such excess inventory or incur an impairment charge with respect to the facility where such product is manufactured, which could adversely affect our operating results. For example, during each of the years ended December 31, 2022 and 2021, we recorded a charge to write down inventory related to REGEN-COV.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party service or supply failures, or other failures, business interruptions, or other disasters affecting our manufacturing facilities in Rensselaer, New York and Limerick, Ireland, the manufacturing facilities of our collaborators, or the facilities of any other party participating in the supply chain, would adversely affect our ability to supply our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bulk drug materials are currently manufactured at our manufacturing facilities in Rensselaer, New York and Limerick, Ireland, as well as at our collaborators' facilities. We and our collaborators would be unable to manufacture these materials if the relevant facility were to cease production due to regulatory requirements or actions, business interruptions, labor shortages or disputes, supply chain interruptions or constraints (including with respect to natural gas and other raw materials), contaminations, fire, climate change, natural disasters, acts of war or terrorism, or other problems.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our products and product candidates are very difficult to manufacture. As our products and most of our product candidates are biologics, they require processing steps that are more difficult than those required for many other chemical pharmaceuticals. Accordingly, multiple steps are needed to control the manufacturing processes. Problems with these manufacturing processes, even minor deviations from the normal process or from the materials used in the manufacturing process (which may not be detectable by us or our collaborators in a timely manner), could lead to product defects or manufacturing failures, resulting in lot failures, product recalls, product liability claims, and insufficient inventory. Also, the complexity of our manufacturing process may make it difficult, time-consuming, and expensive to transfer our technology to our collaborators or contract manufacturers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain raw materials or other products necessary for the manufacture and formulation of our marketed products and product candidates, some of which are difficult to source, are provided by single-source unaffiliated third-party suppliers. In addition, we rely on certain third parties or our collaborators to perform filling, finishing, distribution, laboratory testing, and other services related to the manufacture of our marketed products and product candidates, and to supply various raw materials and other products. We would be unable to obtain these raw materials, other products, or services for an indeterminate period of time if any of these third parties were to cease or interrupt production or otherwise fail to supply these materials, products, or services to us for any reason, including due to regulatory requirements or actions (including recalls), adverse financial developments at or affecting the supplier, failure by the supplier to comply with cGMPs, contaminations, business interruptions, or labor shortages or disputes (in each case, including as a result of the COVID-19 pandemic and Russia's invasion of Ukraine, which have exacerbated many of these issues). In any such circumstances, we may not be able to engage a backup or alternative supplier or service provider in a timely manner or at all. This, in turn, could materially and adversely affect our or our collaborators' ability to manufacture or supply marketed products and product candidates, which could materially and adversely affect our business and future prospects.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the raw materials required in the manufacture and testing of our products and product candidates may be derived from biological sources, including mammalian tissues, bovine serum, and human serum albumin. There are certain regulatory restrictions on using these biological source materials. If we or our collaborators are required to substitute for these sources to comply with such regulatory requirements, our clinical development or commercial activities may be delayed or interrupted.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our or our collaborators' failure to meet the stringent requirements of governmental regulation in the manufacture of drug products or product candidates could result in incurring substantial remedial costs, delays in the development or approval of our product candidates or new indications for our marketed products and/or in their commercial launch if regulatory approval is obtained, and a reduction in sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators and other third-party providers are required to maintain compliance with cGMPs, and are subject to inspections by the FDA or comparable agencies in other jurisdictions to confirm such compliance. Changes of suppliers or modifications of methods of manufacturing may require amending our application(s) to the FDA or such comparable foreign agencies and acceptance of the change by the FDA or such comparable foreign agencies prior to release of product(s). Because we produce multiple products and product candidates at our facilities in Rensselaer, New York and Limerick, Ireland, there are increased risks associated with cGMP compliance. Our inability, or the inability of our collaborators and third-party fill/finish or other service providers, to demonstrate ongoing cGMP compliance could require us to engage in lengthy and expensive remediation efforts, withdraw or recall product, halt or interrupt clinical trials, and/or interrupt commercial supply of any marketed products, and could also delay or prevent our obtaining regulatory approval for our product candidates or new indications for our marketed products. Any delay, interruption, or other issue that arises in the manufacture, fill/finish, packaging, or storage of any drug product or product candidate as a result of a failure of our facilities or the facilities or operations of our collaborators or other third parties to pass any regulatory agency inspection or maintain cGMP compliance could significantly impair our ability to develop, obtain approval for, and successfully commercialize our products, which would substantially harm our business, prospects, operating results, and financial condition. Any finding of non-compliance could also increase our costs, cause us to delay the development of our product candidates, result in delay in our obtaining, or our not obtaining, regulatory approval of product candidates or new indications for our marketed products, and cause us to lose revenue from any marketed products, which could be seriously detrimental to our business, prospects, operating results, and financial condition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Regulatory and Litigation Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the testing or use of our products harms people, or is perceived to harm them even when such harm is unrelated to our products, we could be subject to costly and damaging product liability claims.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The testing, manufacturing, marketing, and sale of drugs for use in people expose us to product liability risk. Any informed consent or waivers obtained from people who enroll in our clinical trials may not protect us from liability or the cost of litigation. We may also be subject to claims by patients who use our approved products, or our product candidates if those product candidates receive regulatory approval and become commercially available, that they have been injured by a side effect associated with the drug. Even in a circumstance in which we do not believe that an adverse event is related to our products or product candidates, the related investigation may be time consuming or inconclusive and may have a negative impact on our reputation or business. We may face product liability claims and be found responsible even if injury arises from the acts or omissions of third parties who provide fill/finish or other services. To the extent we maintain product liability insurance in relevant periods, such insurance may not cover all potential liabilities or may not completely cover any liability arising from any such litigation. Moreover, in the future we may not have access to liability insurance or be able to maintain our insurance on acceptable terms.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business activities have been, and may in the future be, challenged under U.S. federal or state and foreign healthcare laws, which may subject us to civil or criminal proceedings, investigations, or penalties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA regulates the marketing and promotion of our products, which must comply with the Food, Drug, and Cosmetic Act and applicable FDA implementing standards. The FDA's review of promotional activities includes healthcare provider-directed and direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities, and sales representatives' communications. Failure to comply with applicable FDA requirements and restrictions in this area may subject a company to adverse enforcement action by the FDA, the Department of Justice, or the Office of the Inspector General of the HHS, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes a drug. Any such failures could also cause significant reputational harm. The FDA may take enforcement action for promoting unapproved uses of a product or other violations of its advertising laws and regulations. The applicable regulations in countries outside the U.S. grant similar powers to the competent authorities and impose similar obligations on companies.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to FDA and related regulatory requirements, we are subject to health care "fraud and abuse" laws, such as the federal civil False Claims Act, the anti-kickback provisions of the federal Social Security Act, and other state and federal laws and regulations. The U.S. federal healthcare program anti-kickback statute (the "AKS") prohibits, among other things, knowingly and willfully offering, paying, soliciting, or receiving payments or other remuneration, directly or indirectly, to induce or reward someone to purchase, prescribe, endorse, arrange for, or recommend a product or service that is reimbursed under federal healthcare programs such as Medicare or Medicaid. If we provide payments or other remuneration to a healthcare professional to induce the prescribing of our products, we could face liability under state and federal anti-kickback laws. The Bipartisan Budget Act of 2018 has increased the criminal and civil penalties that can be imposed for violating certain federal health care laws, including the federal anti-kickback statute.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal civil False Claims Act prohibits any person from, among other things, knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to get a false claim paid. The False Claims Act also permits a private individual acting as a "whistleblower" to bring actions on behalf of the federal government alleging violations of the statute and to share in any monetary recovery. Pharmaceutical companies have been investigated and/or prosecuted under these laws for a variety of alleged promotional and marketing activities, such as allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in promotion for uses that the FDA has not approved, known as off-label uses, that caused claims to be submitted to Medicaid for non-covered off-label uses; and submitting inflated best price information to the Medicaid Rebate program. Pharmaceutical and other healthcare companies also are subject to other federal false claims laws, including, among others, federal criminal fraud and false statement statutes that extend to non-government health benefit programs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of states also have statutes or regulations similar to the federal anti-kickback law and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Sanctions under these federal and state laws may include civil monetary penalties, damages, exclusion of a manufacturer's products from reimbursement under government programs, criminal fines, and imprisonment for individuals and the curtailment or restructuring of operations. Even if it is determined that we have not violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which would harm our business, prospects, operating results, and financial condition. Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business activities could be challenged under one or more of such laws. As described further in Note 11 to our Condensed Consolidated Financial Statements included in this report, we are party to civil litigation initiated in 2020 by the U.S. Attorney's Office for the District of Massachusetts concerning our support of a 501(c)(3) organization that provides financial assistance to patients; and we are cooperating with pending government investigations concerning certain other business activities. Any adverse decision, finding, allegation, or exercise of enforcement or regulatory discretion in any such proceedings or investigations could harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the PPACA, the federal government requires that pharmaceutical manufacturers record any "transfers of value" made to U.S. licensed physicians and teaching hospitals as well as ownership and investment interests held by physicians and their immediate family members. Information provided by companies is aggregated and posted annually on an "Open Payments" website, which is managed by CMS, the agency responsible for implementing these disclosure requirements. Applicable manufacturers also are required to report information regarding payments and transfers of value provided to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants, and certified nurse-midwives. We also have similar reporting obligations in other countries based on laws, regulations, and/or industry trade association requirements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to dedicate significant resources to comply with these requirements and need to be prepared to comply with additional reporting obligations outside the United States that may apply in the future. In addition, several states have legislation requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports with the state, or make periodic public disclosures on sales, marketing, pricing, clinical trials, and other activities; restrict when pharmaceutical companies may provide meals or gifts to prescribers or engage in other marketing-related activities; require identification or licensing of sales representatives; and restrict the ability of manufacturers to offer co-pay support to patients for certain prescription drugs. Many of these requirements and standards are new or uncertain, and the penalties for failure to comply with these requirements may be unclear. If we are found not to be in full compliance with these laws, we could face enforcement actions, fines, and other penalties, and could receive adverse publicity, which would harm our business, prospects, operating results, and financial condition. Additionally, access to such data by fraud-and-abuse investigators and industry critics may draw scrutiny to our collaborations with reported entities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations, and future prospects.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in the Medicaid Drug Rebate program, the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public Health Service's 340B drug pricing program (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"340B program") (which is administered by the Health Resources and Services Administration ("HRSA")), the U.S. Department of Veterans Affairs ("VA") Federal Supply Schedule ("FSS") pricing program, and the Tricare Retail Pharmacy Program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by us, governmental or regulatory agencies, and the courts. Such interpretation can change and evolve over time. In the case of our Medicaid pricing data, if we become aware that our reporting for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, we are obligated to resubmit the corrected data for up to three years after those data originally were due. Such restatements and recalculations increase our costs for complying with the laws and regulations governing the Medicaid Drug Rebate program and could result in an overage or underage in our rebate liability for past quarters. Price recalculations also may affect the ceiling price at which we are required to offer our products under the 340B program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Civil monetary penalties can be applied if we are found to have knowingly submitted any false price or product information to the government, if we are found to have made a misrepresentation in the reporting of our average sales price, if we fail to submit the required price data on a timely basis, or if we are found to have charged 340B covered entities more than the statutorily mandated ceiling price. CMS could also decide to terminate our Medicaid drug rebate agreement, or HRSA could decide to terminate our 340B program participation agreement, in which case federal payments may not be available under Medicaid or Medicare Part B for our covered outpatient drugs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to comply with our reporting and payment obligations under the Medicaid Drug Rebate program and other governmental programs could negatively impact our financial results. The final regulation governing the Medicaid Drug Rebate program issued by CMS has increased and will continue to increase our costs and the complexity of compliance, has been and will continue to be time-consuming to implement, and could have a material adverse effect on our results of operations, particularly if CMS challenges the approach we have taken in our implementation of the final regulation. Other regulations and coverage expansion by various governmental agencies relating to the Medicaid Drug Rebate program may have a similar impact.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the final regulation issued by HRSA regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities has affected our obligations and potential liability under the 340B program. We are also required to report the 340B ceiling prices for our covered outpatient drugs to HRSA, which then publishes them to 340B covered entities. Any charge by HRSA that we have violated the requirements of the program or the regulation could negatively impact our financial results. Moreover, under a final regulation effective January 13, 2021, HRSA established an ADR process for claims by covered entities that a manufacturer has engaged in overcharging, and by manufacturers that a covered entity violated the prohibitions against diversion or duplicate discounts. Such claims are to be resolved through an ADR panel of government officials rendering a decision that could be appealed only in federal court. An ADR proceeding could subject us to onerous procedural requirements and could result in additional liability. On November 30, 2022, HRSA issued a notice of proposed rulemaking that proposes several changes to the ADR process. Further, any additional future changes to the definition of average manufacturer price and the Medicaid rebate amount under the PPACA or otherwise could affect our 340B ceiling price calculations and negatively impact our results of operations.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obligations to report the average sales price for certain of our drugs to the Medicare program. Statutory or regulatory changes or CMS guidance could affect the average sales price calculations for our products and the resulting Medicare payment rate, and could negatively impact our results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in 2023, manufacturers must pay refunds to Medicare for single-source drugs or biological products, or biosimilar biological products, reimbursed under Medicare Part B and packaged in single-dose containers or single-use packages for units of discarded drug reimbursed by Medicare Part B in excess of 10 percent of total allowed charges under Medicare Part B for that drug. Manufacturers that fail to pay refunds could be subject to civil monetary penalties of 125 percent of the refund amount.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to applicable law, knowing provision of false information in connection with price reporting or contract&#8209;based requirements under the VA/FSS and/or Tricare programs can subject a manufacturer to civil monetary penalties. These program and contract-based obligations also contain extensive disclosure and certification requirements. If we overcharge the government in connection with our arrangements with FSS or Tricare, we are required to refund the difference to the government. Failure to make necessary disclosures or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations. Unexpected refunds to the government, and/or response to a government </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investigation or enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations, and future prospects.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks from the improper conduct of employees, agents, contractors, or collaborators could adversely affect our reputation and our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot ensure that our compliance controls, policies, and procedures will in every instance protect us from acts committed by our employees, agents, contractors, or collaborators that would violate the laws or regulations of the jurisdictions in which we operate, including, without limitation, healthcare, employment, foreign corrupt practices, trade restrictions and sanctions, environmental, competition, and privacy laws and regulations. Such improper actions could subject us to civil or criminal investigations, and monetary and injunctive penalties, and could adversely impact our ability to conduct business, operating results, and reputation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, our business activities outside the United States (which have recently increased, and are expected to continue to increase, due to, in part, our efforts to establish our commercialization and co-commercialization capabilities in certain jurisdictions outside the United States) are subject to the Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate, including the U.K. Bribery Act. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. Recently the SEC and Department of Justice have increased their FCPA enforcement activities with respect to pharmaceutical companies. There is no certainty that all of our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our ability to expand internationally, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations are subject to environmental, health, and safety laws and regulations, including those governing the use of hazardous materials. Compliance with these laws and regulations is costly, and we may incur substantial liability arising from our activities involving the use of hazardous materials.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a fully integrated biotechnology company with significant research and development and manufacturing operations, we are subject to extensive environmental, health, and safety laws and regulations, including those governing the use of hazardous materials. Our research and development and manufacturing activities involve the controlled use of chemicals, infectious agents (such as viruses, bacteria, and fungi), radioactive compounds, and other hazardous materials. The cost of compliance with environmental, health, and safety regulations is substantial. If an accident involving these materials or an environmental discharge were to occur, we could be held liable for any resulting damages, or face regulatory actions, which could exceed our resources or insurance coverage.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to increasingly complex corporate governance, public disclosure, and accounting requirements and regulations that could adversely affect our business, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to changing rules and regulations of various federal and state governmental authorities as well as the stock exchange on which our Common Stock is listed. These entities, including the SEC and The NASDAQ Stock Market LLC, have issued a significant number of new and increasingly complex requirements and regulations over the course of the last several years and continue to develop additional requirements and regulations. For example, in March 2022, the SEC proposed new rules for extensive and prescriptive climate-related disclosure in annual reports and registration statements, which would also require inclusion of certain climate-related financial metrics in companies' audited financial statements. Also in March 2022, the SEC proposed rules that are intended to enhance and standardize disclosures regarding cybersecurity risk management, strategy, and governance, as well as cybersecurity incident reporting, by public companies. Our efforts to comply with these requirements and regulations (as well as corporate governance and disclosure expectations of investors and other stakeholders) have resulted in, and are likely to continue to result in, an increase in expenses and a diversion of management's time from other business activities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in laws and regulations affecting the healthcare industry could adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All aspects of our business, including research and development, manufacturing, marketing, pricing, sales, intellectual property rights, and the framework for dispute resolution and asserting our rights against others, are subject to extensive legislation and regulation. Changes in applicable federal and state laws and agency regulations could have a materially negative impact on our business. These include:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the FDA and foreign regulatory processes for new therapeutics that may delay or prevent the approval of any of our current or future product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new laws, regulations, or judicial decisions related to prescription drugs or other healthcare products, healthcare availability, or the payment for healthcare products and services, including prescription drugs, that would make it more difficult for us to market and sell products once they are approved by the FDA or foreign regulatory agencies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in FDA and foreign regulations that may require additional safety monitoring prior to or after the introduction of new products to market, which could materially increase our costs of doing business; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in FDA and foreign cGMP requirements that may make it more difficult and costly for us to maintain regulatory compliance and/or manufacture our marketed product and product candidates in accordance with cGMPs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, the PPACA and potential regulations thereunder easing the entry of competing follow-on biologics into the marketplace, other new legislation or implementation of existing statutory provisions on importation of lower-cost competing drugs from other jurisdictions, and legislation on comparative effectiveness research are examples of previously enacted and possible future changes in laws that could adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal or state governments could carry out other significant changes in legislation, regulation, or government policy, including with respect to government reimbursement changes or drug price control measures (such as those discussed above under "Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales of our marketed products are dependent on the availability and extent of reimbursement from third-party payors, and changes to such reimbursement may materially harm our business, prospects, operating results, and financial condition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">") or the PPACA or other healthcare reform laws. While it is not possible to predict whether and when any such changes will occur, changes in the laws, regulations, and policies governing the development and approval of our product candidates and the commercialization, importation, and reimbursement of our products could adversely affect our business. In addition, our development and commercialization activities could be harmed or delayed by a shutdown of the U.S. government, including the FDA. For example, a prolonged shutdown may significantly delay the FDA's ability to timely review and process any submissions we have filed or may file or cause other regulatory delays, which could materially and adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks associated with our operations outside the United States could adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operations and conduct business in several countries outside the United States and we plan to significantly expand the scope of these activities in existing and/or additional countries. For example, as discussed above, we will need to establish commercial capabilities related to Libtayo in certain markets outside the United States following the amendment to the IO Collaboration; and we perform co-commercialization activities under the Antibody Collaboration related to Dupixent in certain jurisdictions outside the United States. Consequently, we are, and will continue to be, subject to risks related to operating in foreign countries, particularly those in which we have not previously established operations, and many of these risks will increase as we expand our activities in such jurisdictions. These risks include:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfamiliar foreign laws or regulatory requirements or unexpected changes to those laws or requirements, including those with which we and/or our collaborators must comply in order to maintain our marketing authorizations outside the United States;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other laws and regulatory and industry trade association requirements to which our business activities abroad are subject, such as the FCPA and the U.K. Bribery Act (discussed in greater detail above under "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks from the improper conduct of employees, agents, contractors, or collaborators could adversely affect our reputation and our business, prospects, operating results, and financial condition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">");</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the political or economic condition of a specific country or region, including as a result of Russia's invasion of Ukraine;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in the value of foreign currency versus the U.S. dollar;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">tariffs, trade protection measures, import or export licensing requirements, trade embargoes, and sanctions (including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury), and other trade barriers; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in attracting and retaining qualified personnel; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cultural differences in the conduct of business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have large-scale manufacturing operations in Limerick, Ireland and have also established offices in the United Kingdom, Germany, and other countries outside the United States. Changes impacting our ability to conduct business in the those countries, or changes to the regulatory regime applicable to our operations in those countries (such as with respect to the approval of our product candidates), may materially and adversely impact our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may incur additional tax liabilities related to our operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income tax in the United States and foreign jurisdictions in which we operate. Significant judgment is required in determining our worldwide tax liabilities, and our effective tax rate is derived from the applicable statutory tax rates and relative earnings in each taxing jurisdiction. We record liabilities for uncertain tax positions that involve significant management judgment as to the application of law. Domestic or foreign taxing authorities have previously disagreed, and may in the future disagree, with our interpretation of tax law as applied to the operations of Regeneron and its subsidiaries or with the positions we may take with respect to particular tax issues on our tax returns. Consequently, tax assessments or judgments in excess of accrued amounts that we have estimated in preparing our financial statements may materially and adversely affect our reported effective tax rate or our cash flows. Further, other factors may adversely affect our effective tax rate, including changes in the mix of our profitability from country to country, changes in tax laws and regulations, and tax effects of the accounting for stock-based compensation (which depend in part on the price of our stock and, therefore, are beyond our control). For example, the IRA has created a corporate alternative minimum tax of 15% on adjusted financial statement income and an excise tax of 1% of the value of certain stock repurchases that apply to certain corporations for tax years beginning after December 31, 2022. Further, actions taken by the Organization for Economic Co-operation and Development and the EC could also influence tax laws in countries in which we operate, including the implementation of a global minimum tax. Changes to these or other laws and regulations or their interpretations could materially adversely impact our effective tax rate or cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face risks related to the personal data we collect, process, and share.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to conduct our business is significantly dependent on the data that we collect, process, and share in discovering, developing, and commercializing drug products. These data are often considered personal data and are therefore regulated by data privacy laws in applicable jurisdictions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities outside the U.S., including clinical trial programs and research collaborations (such as our consortium with a group of companies to fund the generation of genetic exome sequence data from the UK Biobank health resource), implicate non-U.S. data protection laws, including the EU's General Data Protection Regulations ("GDPR"). The GDPR has a wide range of compliance obligations, including increased transparency requirements and data subject rights. Violations of the GDPR carry significant financial penalties for noncompliance (including possible fines of up to 4% of global annual turnover for the preceding financial year or &#8364;20 million (whichever is higher)). In addition to the GDPR, certain EU Member States have issued or will be issuing their own implementation legislation. In June 2021, the EC introduced new standard contractual clauses required to be incorporated into certain new and existing agreements within prescribed timeframes in order to continue to lawfully transfer personal data outside the EU. Compliance with these requirements has been and is expected to continue to be costly and time consuming.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct clinical trials in many countries around the world, which have new or evolving data privacy laws that have resulted in increased liability in the management of clinical trial data, and additional contractual and due-diligence obligations that could lead to a delay in clinical trial site start-up. There is an increase of enforcement activities in various EU countries that require evidence of compliance with local data privacy requirements. While we continue to monitor these developments, there remains some uncertainty surrounding the legal and regulatory environment for these evolving privacy and data protection laws. Complying with varying jurisdictional requirements could increase the costs and complexity of compliance, including the risk of substantial financial penalties for insufficient notice and consent, failure to respond to data subject rights requests, lack of a legal basis for the transfer of personal information out of the EU, or improper processing of personal data under the GDPR. Failure by our collaborators to comply with the strict rules on the transfer of personal data outside the EU into the U.S. may result in the imposition of criminal and administrative sanctions on such collaborators or impact the flow of personal data outside the EU, which could adversely affect our business and could create liability for us. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most U.S. health care providers, including research institutions from which we or our collaborators obtain clinical trial data, are subject to privacy and security regulations promulgated under HIPAA. For example, as part of our human genetics initiative, our wholly-owned subsidiary, Regeneron Genetics Center LLC, has entered into collaborations with many research institutions, which are subject to HIPAA. Regeneron is not a covered entity or business associate under HIPAA and thus is not subject to its requirements. However, we could be subject to criminal penalties if we, our affiliates, or our agents knowingly receive PHI in a manner that is not permitted under HIPAA. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive PHI from a health care provider or research institution that has not satisfied HIPAA's requirements for its disclosure. There are instances where we collect and maintain personal data, which may include </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">health information that is outside the scope of HIPAA but within the scope of state health privacy laws or similar state level privacy legislation. This information may be received throughout the clinical trial process, in the course of our research collaborations, directly from individuals who enroll in our patient assistance programs, and from our own employees in a pandemic response process (such as in connection with the COVID-19 pandemic).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consumer protection laws impact the manner in which we develop and maintain processes to support our patient assistance programs, product marketing activities, and the sharing of employee and clinical data for internal and third-party commercial activities. Several U.S. states have proposed and passed consumer privacy laws, which were modeled after the California Consumer Privacy Act of 2018 ("CCPA") and influenced by the GDPR. The CCPA is a consumer protection law that establishes requirements for data use and sharing transparency and provides California residents with personal data privacy rights regarding the use, disclosure, and retention of their personal data. Amendments to the CCPA have, among other things, imposed new obligations to provide notice where personal data will be de-identified. Failure to comply with the CCPA may result in, among other things, significant civil penalties and injunctive relief, or statutory or actual damages. In addition, California residents have the right to bring a private right of action in connection with data privacy incidents involving certain elements of personal data. These claims may result in significant liability and damages. These laws and regulations are constantly evolving and may impose limitations on our business activities. Several other U.S. states have introduced similar consumer protection laws, some of which are set to go into effect in the near future. At the federal level, Section 5 of the FTC Act is a consumer protection law that bars unfair and deceptive acts and practices and requires, among other things, companies to notify individuals that they will safeguard their personal data and that they will fulfil the commitments made in their privacy notices. The FTC has brought legal actions against organizations that have violated consumers' privacy rights or have misled them by failing to maintain appropriate security.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, health privacy laws, data breach notification laws, consumer protection laws, data localization laws, and genetic privacy laws may apply directly to our operations and/or those of our collaborators and may impose restrictions on our collection, use, and dissemination of individuals' health and other personal data. New state level genetic privacy and consumer protection laws in the United States may require additional transparency and permissions in our informed consent forms. Moreover, individuals about whom we or our collaborators obtain health or other personal data, as well as the providers and third parties who share this information with us, may have statutory or contractual limits that impact our ability to use and disclose the information. We are likely to be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws both inside and outside the United States. Many of these laws differ from each other in significant ways and have different effects. Many of the state laws enable a state attorney general to bring actions and provide private rights of action to consumers as enforcement mechanisms. Compliance with these laws requires a flexible privacy framework as they are constantly evolving. Failure to comply with these laws and regulations could result in government enforcement actions and create liability for us (which could include civil and/or criminal penalties), private litigation, and/or adverse publicity. Federal regulators, state attorneys general, and plaintiffs' attorneys have been active in this space. Claims that we have violated individuals' privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or any collaborators fail to comply with applicable federal, state, local, or foreign regulatory requirements, we could be subject to a range of regulatory actions that could affect our or any collaborators' ability to commercialize our products and could harm, prevent, or substantially increase the cost of marketing and sales of any affected products that we are able to commercialize. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increasing use of social media could give rise to liability, breaches of data security, or reputational damage.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our employees are increasingly utilizing social media tools as a means of communication both internally and externally. Despite our efforts to monitor evolving social media communication guidelines and comply with applicable rules, there is a risk that the use of social media by us or our employees to communicate about our products or business may cause us to be found in violation of applicable requirements. In addition, our employees may knowingly or inadvertently make use of social media in ways that may not comply with our social media policy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or other legal or contractual requirements, which may give rise to liability, lead to the loss of trade secrets or other intellectual property, or result in public exposure of personal data of our employees, clinical trial patients, customers, and others. Furthermore, negative posts or comments about us or our products in social media could seriously damage our reputation, brand image, and goodwill.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could have a material adverse effect on our business, prospects, operating results, and financial condition and could adversely affect the price of our Common Stock.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on or Transactions with Third Parties</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our Antibody Collaboration with Sanofi is terminated, or Sanofi materially breaches its obligations thereunder, our business, prospects, operating results, and financial condition, and our ability to develop, manufacture, and commercialize certain of our products and product candidates in the time expected, or at all, would be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on support from Sanofi to develop, manufacture, and commercialize certain of our products and product candidates. With respect to the products that we are co-developing with Sanofi under our Antibody Collaboration (currently consisting of Dupixent, Kevzara, and itepekimab), Sanofi funds a significant portion of development expenses incurred in connection with the development of these products. In addition, we rely on Sanofi to lead much of the clinical development efforts, assist with or lead efforts to obtain and maintain regulatory approvals, and lead the commercialization efforts for these products and product candidates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Sanofi terminates the Antibody Collaboration or fails to comply with its payment obligations under any of our collaborations, our business, prospects, operating results, and financial condition would be materially harmed. We would be required to either expend substantially more resources than we have anticipated to support our research and development efforts, which could require us to seek additional funding that might not be available on favorable terms or at all, or materially cut back on such activities. If Sanofi does not perform its obligations with respect to the product candidates it is co-developing with us, our ability to develop, manufacture, and commercialize these product candidates will be significantly adversely affected. We have limited commercial capabilities outside the United States and would have to develop or outsource these capabilities for products commercialized under our Antibody Collaboration (see also "Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to establish commercial capabilities outside the United States for Libtayo, Dupixent, or any other products we intend to commercialize or co-commercialize outside the United States, our business, prospects, operating results, and financial condition may be adversely affected</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" above). Termination of the Antibody Collaboration would create substantial new and additional risks to the successful development and commercialization of the products subject to such collaborations, particularly outside the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our collaboration with Bayer for EYLEA is terminated, or Bayer materially breaches its obligations thereunder, our business, prospects, operating results, and financial condition, and our ability to continue to commercialize EYLEA outside the United States would be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely heavily on Bayer with respect to the commercialization of EYLEA outside the United States (and, if approved, will rely on Bayer with respect to any potential future commercialization of aflibercept 8 mg outside the United States, including the activities discussed below). Bayer is responsible for obtaining and maintaining regulatory approval outside the United States, as well as providing all sales, marketing, and commercial support for the product outside the United States. In particular, Bayer has responsibility for selling EYLEA outside the United States using its sales force and, in Japan, in cooperation with Santen pursuant to a Co-Promotion and Distribution Agreement with Bayer's Japanese affiliate. If Bayer and, in Japan, Santen do not perform their obligations in a timely manner, or at all, our ability to commercialize EYLEA outside the United States will be significantly adversely affected. Bayer has the right to terminate its collaboration agreement with us at any time upon six or twelve months' advance notice, depending on the circumstances giving rise to termination. If Bayer were to terminate its collaboration agreement with us, we may not have the resources or skills to replace those of our collaborator, which could require us to seek another collaboration that might not be available on favorable terms or at all, and could cause significant issues for the commercialization of EYLEA outside the United States and result in substantial additional costs and/or lower revenues to us. We have limited commercial capabilities outside the United States and would have to develop or outsource these capabilities (see also "Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to establish commercial capabilities outside the United States for Libtayo, Dupixent, or any other products we intend to commercialize or co-commercialize outside the United States, our business, prospects, operating results, and financial condition may be adversely affected</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" above). Termination of the Bayer collaboration agreement would create substantial new and additional risks to the successful commercialization of EYLEA and, if approved, any potential future commercialization of aflibercept 8 mg outside the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our collaborators and service providers may fail to perform adequately in their efforts to support the development, manufacture, and commercialization of our drug candidates and current and future products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend upon third-party collaborators, including Sanofi and Bayer, and service providers such as CROs, outside testing laboratories, clinical investigator sites, third-party manufacturers, fill/finish providers, and product packagers and labelers, to assist us in the manufacture and preclinical and clinical development of our product candidates. We also depend, or will depend, on some of these or other third parties in connection with the commercialization of our marketed products and our product candidates and new indications for our marketed products if they are approved for marketing. If any of our existing collaborators or service providers breaches or terminates its agreement with us or does not perform its development or manufacturing services under an agreement in a timely manner (including as a result of its inability to perform due to financial </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or other relevant constraints, such as due to Russia's invasion of Ukraine) or in compliance with applicable GMPs, GLPs, or GCP standards, we could experience additional costs, delays, and difficulties in the manufacture or development of, or in obtaining approval by regulatory authorities for, or successfully commercializing our product candidates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators rely on third-party service providers to support the distribution of our marketed products and for many other related activities in connection with the commercialization of these marketed products. Despite our or our collaborators' arrangements with them, these third parties may not perform adequately. If these service providers do not perform their services adequately, sales of our marketed products will suffer.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have undertaken and may in the future undertake strategic acquisitions, and any difficulties from integrating such acquisitions could adversely affect our business, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire companies, businesses, products, or product candidates that complement or augment our existing business. For example, in May 2022, we completed our acquisition of Checkmate Pharmaceuticals, Inc. The process of proposing, negotiating, completing, and integrating any such acquisition is lengthy and complex. Other companies may compete with us for such acquisitions. In addition, we may not be able to integrate any acquired business successfully or operate any acquired business profitably. Integrating any newly acquired business could be expensive and time consuming. Integration efforts often take a significant amount of time, place a significant strain on managerial, operational, and financial resources, result in a loss of key personnel of the acquired business, and could prove to be more difficult or expensive than we predict. The diversion of our management&#8217;s attention and any delay or difficulties encountered in connection with any acquisitions we may consummate could result in the disruption of our ongoing business or inconsistencies in standards and controls that could negatively affect our ability to maintain third-party relationships. Moreover, we may need to raise additional funds through public or private debt or equity financing to acquire any businesses, products, or product candidates, which may result in dilution for shareholders or the incurrence of indebtedness.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our efforts to acquire companies, businesses, products, or product candidates or to enter into other significant transactions, we will conduct business, legal, and financial due diligence with the goal of identifying and evaluating material risks involved in the transaction. Despite our efforts, we ultimately may be unsuccessful in ascertaining or evaluating all such risks and, as a result, might not realize the intended advantages of the transaction. If we fail to realize the expected benefits from acquisitions we have consummated or may consummate in the future, whether as a result of unidentified risks or liabilities, integration difficulties, regulatory setbacks, litigation with current or former employees and other events, our business, operating results, and financial condition could be adversely affected. For any acquired product candidates, we will also need to make certain assumptions about, among other things, development costs, the likelihood of receiving regulatory approval, and the market for any such product candidates. Our assumptions may prove to be incorrect, which could cause us to fail to realize the anticipated benefits of these transactions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may experience significant charges to earnings in connection with our efforts, if any, to consummate acquisitions. For transactions that are ultimately not consummated, these charges may include fees and expenses for investment bankers, attorneys, accountants, and other advisors in connection with our efforts. Even if our efforts are successful, we may incur, as part of a transaction, substantial charges for closure costs associated with elimination of duplicate operations and facilities and acquired in-process research and development charges. In either case, the incurrence of these charges could adversely affect our operating results for particular periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Risks Related to Our Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on our key personnel and if we cannot recruit and retain leaders in our research, development, manufacturing, and commercial organizations, our business will be harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on certain of our executive officers and other key members of our senior management team. If we are not able to retain (or for any other reason lose the services of) any of these persons, our business may suffer. In particular, we depend on the services of Leonard S. Schleifer, M.D., Ph.D., our President and Chief Executive Officer, and George D. Yancopoulos, M.D., Ph.D., our President and Chief Scientific Officer. We are also highly dependent on the expertise and services of other senior management members leading our research, development, manufacturing, and commercialization efforts. There is intense competition in the biotechnology industry for qualified scientists and managerial personnel in the research, development, manufacture, and commercialization of drugs. We may not be able to continue to attract and retain the qualified personnel necessary to continue to advance our business and achieve our strategic objectives.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant disruptions of information technology systems or breaches of data security could adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is increasingly dependent on critical, complex, and interdependent information technology systems, including Internet-based systems, to support business processes as well as internal and external communications. These systems are also critical to enable remote working arrangements, which have been growing in importance. The size and complexity of our computer systems make us potentially vulnerable to IT system breakdowns, internal and external malicious intrusion, and computer viruses and ransomware, which may impact product production and key business processes. We also have outsourced significant elements of our information technology infrastructure and operations to third parties, which may allow them to access our confidential information and may also make our systems vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by such third parties or others.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our systems are potentially vulnerable to data security breaches - whether by employees or others - which may expose sensitive data to unauthorized persons. Data security breaches could lead to the loss of trade secrets or other intellectual property, result in demands for ransom or other forms of blackmail, or lead to the public exposure of personal information (including sensitive personal information) of our employees, clinical trial patients, customers, and others. Such attacks are of ever-increasing levels of sophistication and are made by groups and individuals with a wide range of motives (including industrial espionage or extortion) and expertise, including by organized criminal groups, "hacktivists," nation states, and others. As a company with an increasingly global presence, our systems are subject to frequent attacks. There is the potential that our systems may be directly or indirectly affected as nation-states conduct global cyberwarfare, including in connection with the current Russia-Ukraine hostilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of some of these attacks, there is a risk that an attack may remain undetected for a period of time. While we continue to make investments to improve the protection of data and information technology, and to oversee and monitor the security measures of our suppliers and/or service providers, there can be no assurance that our efforts will prevent service interruptions or security breaches. In addition, we depend in part on third-party security measures over which we do not have full control to protect against data security breaches.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our suppliers and/or service providers fail to maintain or protect our information technology systems and data security effectively and in compliance with U.S. and foreign laws, or fail to anticipate, plan for, or manage significant disruptions to these systems, we or our suppliers and/or service providers could have difficulty preventing, detecting, or controlling such disruptions or security breaches, which could result in legal proceedings, liability under U.S. and foreign laws that protect the privacy of personal information, disruptions to our operations, government investigations, breach of contract claims, and damage to our reputation (in each case in the U.S. or globally), which could have a material adverse effect on our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) have adversely affected and may in the future adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic previously adversely affected, and the COVID-19 pandemic or other actual or threatened public health outbreaks, epidemics, or pandemics may in the future adversely affect, among other things, the economic and financial markets and labor resources of the countries in which we operate; our manufacturing and supply chain operations, research and development efforts, commercial operations and sales force, administrative personnel, third-party service providers, and business partners and customers; and the demand for our marketed products. These and other adverse effects may result from various developments including the following</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The imposition of various restrictions and mandates to reduce the spread of outbreaks, epidemics, or pandemics, including governmental orders that direct individuals to shelter at their places of residence, direct businesses and governmental agencies to cease non-essential operations at physical locations, prohibit certain non-essential gatherings, maintain social distancing, order cessation of non-essential travel, and require proof of vaccination and/or negative test results. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Negative impacts on productivity, disruptions to our business, and delays to our clinical programs and development timelines caused by the imposition of various government-imposed or private-sector measures relating to outbreaks, epidemics, or pandemics. Such restrictions and limitations could also negatively impact our access to regulatory authorities (which may be affected, among other things, by travel restrictions and may be delayed in responding to inquiries, reviewing filings, and conducting inspections); our ability to perform regularly scheduled quality checks and maintenance; and our ability to obtain services from third-party specialty vendors and other providers or to access their expertise as fully and timely as needed. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The loss of key personnel, either temporarily or permanently. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Negative impacts to our sales and marketing efforts due to the postponement or cancellation of face-to-face meetings and restrictions on access by non-essential personnel to hospitals or clinics to the extent such measures slow down adoption or further commercialization of our marketed products. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reduced demand for some or all of our marketed products due to, among other factors, shelter-in-place, social distancing, or similar orders. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Supply chain strains or disruptions (such as port closures and government or other restrictions or limitations, whether resulting from a public health outbreak, epidemic, pandemic, or otherwise, such as those that may be imposed under the Defense Production Act) that result in reduced availability or increased cost of materials produced by or purchased from our suppliers or other third parties on which we rely. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Microbial, viral, or other contamination of our products, product candidates, the materials used for their production, or in our facilities (or in the facilities of our collaborators, third-party contract manufacturers, or other providers or suppliers), which could result in the closure of or other impact to the affected facilities for an extended period of time, or could result in other delays or disruptions in our direct or indirect supply chain.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Disruptions to the healthcare and healthcare regulatory systems, which could among other matters, divert healthcare resources away from, or materially delay, regulatory review and potential approval of our product candidates and new indications for our marketed products. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pricing pressures, rebates, clawbacks, and other changes in reimbursement policies and programs resulting from the financial strain of a public health outbreak, epidemic, or pandemic on government-funded healthcare systems.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risks related to any therapies we may have developed or be in the process of developing in response to any such public health outbreak, epidemic, or pandemic (such as REGEN-COV and our "next generation" monoclonal antibodies targeting SARS-CoV-2), including heightened regulatory scrutiny; restrictions on administration that limit widespread and timely access to any such therapies; fluctuations in, or elimination of, demand for any such therapies (including due to the availability of superior or competitive therapies or preventative measures); mutations of the disease-causing pathogen impacting efficacy; and revocations of or restrictions on any emergency use authorizations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Impacts on our clinical trials due to delays in site initiation and patient enrollment as a result of prioritization of hospital resources to address the public health outbreak, epidemic, or pandemic, patients' inability to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services, and restrictions on trial initiations imposed by hospitals and other trial sites. Similarly, our ability to recruit and retain patients and principal investigators and site staff could be delayed or disrupted. Any such disruptions could negatively impact the progress of our clinical trials, including the readouts of trial results, the timing of regulatory review, and any anticipated program milestones.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Significant disruption to the global financial markets or economy, which may make it more difficult for us to access capital if needed. In addition, a recession or market correction resulting from a public health outbreak, epidemic, or pandemic could materially affect the value of our Common Stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and similar, and perhaps more severe, disruptions in our operations may materially adversely impact our business, prospects, operating results, and financial condition. To the extent a public health outbreak, epidemic, or pandemic adversely affects our business, prospects, operating results, or financial condition, it may also have the effect of heightening many of the other risks described in this "Risk Factors" section.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need additional funding in the future, which may not be available to us, and which may force us to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expend substantial resources for research and development, including costs associated with clinical testing of our product candidates and new indications of our marketed products, the commercialization of products, and capital expenditures. We believe our existing capital resources and borrowing availability under our revolving credit facility, together with funds generated by our current and anticipated EYLEA net product sales and funding we are entitled to receive under our collaboration agreements and other similar agreements (including our share of profits in connection with commercialization of EYLEA and Dupixent under our collaboration agreements with Bayer and Sanofi, respectively), will enable us to meet our anticipated operating needs for the foreseeable future. However, one or more of our collaboration agreements may terminate, our revenues may fall short of our projections or be delayed, or our expenses may increase, any of which could result in our capital being consumed significantly faster than anticipated. Our expenses may increase for many reasons, including expenses in connection with the commercialization of our marketed products and the potential commercial launches of our product candidates and new indications for our marketed products, manufacturing scale-up, expenses related to clinical trials testing of product candidates we are developing on our own (without a collaborator), and expenses for which we are responsible in accordance with the terms of our collaboration agreements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that our existing capital resources and our current and anticipated revenues will be sufficient to meet our operating needs. We may require additional financing in the future and we may not be able to raise additional funds on acceptable terms or at all. For example, there is no guarantee that we will have the ability to pay the principal amount due on </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our senior unsecured notes at maturity or redeem, repurchase, or refinance the notes prior to maturity on acceptable terms or at all. In addition, in March 2022, we completed an extension of the $720.0 million lease financing for our existing corporate headquarters and other rentable area consisting of approximately 150 acres of predominately office buildings and laboratory space located in Tarrytown, New York, which is set to expire in March 2027. Our ability to refinance or to obtain additional financing could be adversely affected if there is a significant decline in the demand for our products or other significantly unfavorable changes in economic conditions. Volatility in the financial markets could increase borrowing costs or affect our ability to raise capital. If additional financing is necessary and we obtain it through the sale of equity securities, such sales will likely be dilutive to our shareholders. Debt financing arrangements may require us to pledge certain assets or enter into covenants that would restrict our business activities or our ability to incur further indebtedness and may be at interest rates and contain other terms that are not favorable to our shareholders. Should we require and be unable to raise sufficient funds (i) to complete the development of our product candidates, (ii) to successfully commercialize our product candidates or new indications for our marketed products if they obtain regulatory approval, and (iii) to continue our manufacturing and marketing of our marketed products, we may face delay, reduction, or elimination of our research and development or preclinical or clinical programs and our commercialization activities, which would significantly limit our potential to generate revenue.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our indebtedness could adversely impact our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain indebtedness and contingent liabilities, including milestone and royalty payment obligations. As of March 31, 2023, we had an aggregate of $2.702 billion of outstanding indebtedness under our senior unsecured notes and the lease financing facility. We may also incur additional debt in the future. Any such indebtedness could:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit our ability to access capital markets and incur additional debt in the future;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development efforts, research and development, and mergers and acquisitions; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a competitive disadvantage compared to competitors that have less debt.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in foreign currency exchange rates could have a material adverse effect on our operating results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue from outside the United States will increase as our products, whether marketed or otherwise commercialized by us or our collaborators, gain marketing approval in such jurisdictions. Our primary foreign currency exposure relates to movements in the Japanese yen, euro, British pound sterling, Canadian dollar, Chinese yuan, and Australian dollar. If the U.S. dollar weakens against a specific foreign currency, our revenues will increase, having a positive impact on net income, but our overall expenses will increase, having a negative impact. Conversely, if the U.S. dollar strengthens against a specific foreign currency, our revenues will decrease, having a negative impact on net income, but our overall expenses will decrease, having a positive impact. Therefore, significant changes in foreign exchange rates can impact our operating results and the financial condition of our Company. For example, as previously reported, the amount of our share of profits we earned in connection with commercialization of antibodies outside the United States was adversely impacted in 2022 by the U.S. dollar strengthening against foreign currencies, including the Japanese yen and the euro.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investments are subject to risks and other external factors that may result in losses or affect the liquidity of these investments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had $3.916 billion in cash and cash equivalents and $11.110 billion in marketable securities (including $1.059 billion in equity securities). Our investments consist primarily of debt securities, including investment-grade corporate bonds. These fixed-income investments are subject to external factors that may adversely affect their market value or liquidity, such as interest rate, liquidity, market, and issuer credit risks, including actual or anticipated changes in credit ratings. The equity securities we hold may experience significant volatility and may decline in value or become worthless if the issuer experiences an adverse development. Furthermore, our equity investments could be subject to dilution (and decline in value) as a result of the issuance of additional equity interests by the applicable issuer. If any of our investments suffer market price declines, such declines may have an adverse effect on our financial condition and operating results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price is extremely volatile.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been significant volatility in our stock price and generally in the market prices of biotechnology companies' securities. Various factors and events may have a significant impact on the market price of our Common Stock. These factors include, by way of example:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">net product sales of our marketed products (as recorded by us or our collaborators), in particular EYLEA, Dupixent, and Libtayo, as well as our overall operating results;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if any of our product candidates (such as aflibercept 8 mg) or our new indications for our marketed products receive regulatory approval, net product sales of, and profits from, these product candidates and new indications;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market acceptance of, and the market share for, our marketed products, especially EYLEA, Dupixent, and Libtayo;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether our net product sales and net profits underperform, meet, or exceed the expectations of investors or analysts;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement of actions by the FDA or foreign regulatory authorities or their respective advisory committees regarding our, or our collaborators', or our competitors', currently pending or future application(s) for regulatory approval of product candidate(s) or new indications for marketed products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement of submission of an application for regulatory approval of one or more of our, or our competitors', product candidates or new indications for marketed products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">progress, delays, or results in clinical trials of our or our competitors' product candidates or new indications for marketed products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">announcement of technological innovations or product candidates by us or competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">claims by others that our products or technologies infringe their patents;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges by others to our patents in the EPO and in the USPTO;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern as to the safety or effectiveness of any of our marketed products or product candidates or new indications for our marketed products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing or reimbursement actions, decisions, or recommendations by government authorities, insurers, or other organizations (such as health maintenance organizations and PBMs) affecting the coverage, reimbursement, or use of any of our marketed products or competitors' products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise additional capital as needed on favorable terms;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in our relationships with collaborators or key customers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in the biotechnology industry or in government regulation of healthcare, including those relating to compounding (i.e., a practice in which a pharmacist, a physician, or, in the case of an outsourcing facility, a person under the supervision of a pharmacist, combines, mixes, or alters ingredients of a drug to create a medication tailored to the needs of an individual patient);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">large sales of our Common Stock by our executive officers or other employees, directors, or significant shareholders (or the expectation of any such sales);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in tax rates, laws, or interpretation of tax laws;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">arrivals and departures of key personnel; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general market conditions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to repurchase our Common Stock under any share repurchase program on favorable terms or at all;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading activity that results from the rebalancing of stock indices in which our Common Stock is included, or the inclusion or exclusion of our Common Stock from such indices; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors identified in these "Risk Factors"; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perception by the investment community or our shareholders of any of the foregoing factors.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our Common Stock has been, and could continue to be, subject to wide fluctuations in response to these and other factors, including the sale or attempted sale of a large amount of our Common Stock in the market. As discussed in greater detail under "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future sales of our Common Stock by our significant shareholders or us may depress our stock price and impair our ability to raise funds in new share offerings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" below, a large percentage of our Common Stock is owned by a small number of our principal shareholders. As a result, the public float of our Common Stock (i.e., the portion of our Common Stock held by public investors, as opposed to the Common Stock held by our directors, officers, and principal shareholders) may be lower than the public float of other large public companies with broader public ownership. Therefore, the trading price of our Common Stock may fluctuate significantly more than the stock market as a whole. These factors may exacerbate the volatility in the trading price of our Common Stock and may negatively impact your ability to liquidate your investment in Regeneron at the time you wish at a price you consider satisfactory. Broad market fluctuations may also adversely affect the market price of our Common Stock. In the past, securities class action litigation has often been initiated against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs and divert our management's attention and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resources, and could also require us to make substantial payments to satisfy judgments or to settle litigation, which may harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales of our Common Stock by our significant shareholders or us may depress our stock price and impair our ability to raise funds in new share offerings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A small number of our shareholders beneficially own a substantial amount of our Common Stock. As of April&#160;11, 2023, our five largest shareholders plus Dr. Schleifer, our Chief Executive Officer, beneficially owned approximately 40.4% of our outstanding shares of Common Stock, assuming, in the case of our Chief Executive Officer, the conversion of his Class A Stock into Common Stock and the exercise of all options held by him which are exercisable within 60 days of April&#160;11, 2023. If our significant shareholders or we sell substantial amounts of our Common Stock in the public market, or there is a perception that such sales may occur, the market price of our Common Stock could fall. Sales of Common Stock by our significant shareholders also might make it more difficult for us to raise funds by selling equity or equity-related securities in the future at a time and price that we deem appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There can be no assurance that we will repurchase shares of our Common Stock or that we will repurchase shares at favorable prices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, our board of directors authorized a share repurchase program to repurchase up to $3.0 billion of our Common Stock; and, in January 2023, our board of directors authorized an additional $3.0&#160;billion for share repurchases (of which $3.051 billion remained available in the aggregate as of March&#160;31, 2023). There can be no assurance of any future share repurchases or share repurchase program authorizations. Any share repurchases will depend upon, among other factors, our cash balances and potential future capital requirements, our results of operations and financial condition, the price of our Common Stock on the NASDAQ Global Select Market, and other factors that we may deem relevant. We can provide no assurance that we will repurchase shares of our Common Stock at favorable prices, if at all.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our existing shareholders may be able to exert substantial influence over matters requiring shareholder approval and over our management.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Class A Stock, who are generally the shareholders who purchased their stock from us before our initial public offering, are entitled to ten votes per share, while holders of Common Stock are entitled to one vote per share. As of April&#160;11, 2023, holders of Class A Stock held 14.4% of the combined voting power of all shares of Common Stock and Class A Stock then outstanding. These shareholders, if acting together, would be in a position to substantially influence the election of our directors and the vote on certain corporate transactions that require majority or supermajority approval of the combined classes, including mergers and other business combinations. This may result in our taking corporate actions that other shareholders may not consider to be in their best interest and may affect the price of our Common Stock. As of April&#160;11, 2023:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our current executive officers and directors beneficially owned 7.0% of our outstanding shares of Common Stock, assuming conversion of their Class A Stock into Common Stock and the exercise of all options held by such persons which are exercisable within 60 days of April&#160;11, 2023, and 18.4% of the combined voting power of our outstanding shares of Common Stock and Class A Stock, assuming the exercise of all options held by such persons which are exercisable within 60 days of April&#160;11, 2023; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our five largest shareholders plus Dr. Schleifer, our Chief Executive Officer, beneficially owned approximately 40.4% of our outstanding shares of Common Stock, assuming, in the case of our Chief Executive Officer, the conversion of his Class A Stock into Common Stock and the exercise of all options held by him which are exercisable within 60 days of April&#160;11, 2023. In addition, these five shareholders plus our Chief Executive Officer held approximately 47.4% of the combined voting power of our outstanding shares of Common Stock and Class A Stock, assuming the exercise of all options held by our Chief Executive Officer which are exercisable within 60 days of April&#160;11, 2023.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The anti-takeover effects of provisions of our charter, by-laws, and of New York corporate law, as well as the contractual provisions in our investor and collaboration agreements and certain provisions of our compensation plans and agreements, could deter, delay, or prevent an acquisition or other "change of control" of us and could adversely affect the price of our Common Stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation, our by-laws, and the New York Business Corporation Law contain various provisions that could have the effect of delaying or preventing a change in control of our Company or our management that shareholders may consider favorable or beneficial. Some of these provisions could discourage proxy contests and make it more difficult for shareholders to elect directors and take other corporate actions. These provisions could also limit the price that investors might be willing to pay in the future for shares of our Common Stock. These provisions include:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorization to issue "blank check" preferred stock, which is preferred stock that can be created and issued by the board of directors without prior shareholder approval, with rights senior to those of our Common Stock and Class A Stock;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a staggered board of directors, so that it would take three successive annual shareholder meetings to replace all of our directors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement that removal of directors may only be effected for cause and only upon the affirmative vote of at least eighty percent (80%) of the outstanding shares entitled to vote for directors, as well as a requirement that any vacancy on the board of directors may be filled only by the remaining directors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a provision whereby any action required or permitted to be taken at any meeting of shareholders may be taken without a meeting, only if, prior to such action, all of our shareholders consent, the effect of which is to require that shareholder action may only be taken at a duly convened meeting;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement that any shareholder seeking to bring business before an annual meeting of shareholders must provide timely notice of this intention in writing and meet various other requirements; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">under the New York Business Corporation Law, in addition to certain restrictions which may apply to "business combinations" involving our Company and an "interested shareholder," a plan of merger or consolidation of our Company must be approved by two-thirds of the votes of all outstanding shares entitled to vote thereon. See the risk factor above captioned "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our existing shareholders may be able to exert substantial influence over matters requiring shareholder approval and over our management.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, certain of our collaborators are currently bound by "standstill" provisions under their respective agreements with us. These include the January 2014 amended and restated investor agreement between us and Sanofi, as amended, and our 2016 ANG2 license and collaboration agreement with Bayer, which contractually prohibit Sanofi and Bayer, respectively, from seeking to directly or indirectly exert control of our Company or acquiring more than a specified percentage of our Class A Stock and Common Stock, taken together (30% in the case of Sanofi and 20% in the case of Bayer). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our Change in Control Severance Plan and the employment agreement with our Chief Executive Officer, each as amended and restated, provide for severance benefits in the event of termination as a result of a change in control of our Company. Also, equity awards issued under our long-term incentive plans may become fully vested in connection with a "change in control" of our Company, as defined in the plans. These contractual provisions may also have the effect of deterring, delaying, or preventing an acquisition or other change in control.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reflects shares of Common Stock we repurchased under our share repurchase programs, as well as Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock granted under one of our long-term incentive plans, during the three months ended March&#160;31, 2023. Refer to Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations &#8211; Liquidity and Capital Resources" for further details of the share repurchase programs.</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.320%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Price Paid per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approximate Dollar Value of Shares that May Yet Be Purchased Under the Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/1/2023&#8211;1/31/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366,315&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722.22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,482.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/1/2023&#8211;2/28/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,274.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2023&#8211;3/31/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,051.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">930,242&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The difference between the total number of shares purchased and the total number of shares purchased as part of a publicly announced programs relates to Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock granted under one of our long-term incentive plans.</span></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In January 2023, our board of directors authorized an additional share repurchase program to repurchase up to $3.0 billion of our Common Stock. See Part I, Item 2. "Liquidity and Capital Resources - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Share Repurchase Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">" for further details.</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.380%"><tr><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.942%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="regn-ex_101x3312023x10q.htm">First Amendment to the Regeneron Pharmaceuticals, Inc. Cash Incentive Bonus Plan.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465923038299/tm2310647d1_ex10-1.htm">Third Amended and Restated Participation Agreement, dated as of March 27, 2023, by and among Old Saw Mill Holdings LLC, as lessee, Bank of America, N.A., as administrative agent, BA Leasing BSC, LLC, as lessor, and the rent assignees party thereto from time to time. (Incorporated by reference from the Form 8-K for Regeneron Pharmaceuticals, Inc. (the "Registrant"), filed March 29, 2023.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465923038299/tm2310647d1_ex10-2.htm">Third Amended and Restated Lease and Remedies Agreement, dated as of March 27, 2023, between Old Saw Mill Holdings LLC, as lessee, and BA Leasing BSC, LLC, as lessor. (Incorporated by reference from the Form 8-K for the Registrant, filed March 29, 2023.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465923038299/tm2310647d1_ex10-3.htm">Third Amended and Restated Guaranty, dated as of March 27, 2023, made by the Registrant, Regeneron Healthcare Solutions, Inc., and Regeneron Genetics Center LLC, as guarantors. (Incorporated by reference from the Form 8-K for the Registrant, filed March 29, 2023.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="regn-ex_311x3312022x10q.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="regn-ex_312x3312022x10q.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="regn-ex_32x3312022x10q.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interactive Data Files pursuant to Rule 405 of Regulation S-T formatted in Inline Extensible Business Reporting Language ("Inline XBRL"): (i) the Registrant's Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022; (ii) the Registrant's Condensed Consolidated Statements of Operations and Comprehensive Income for the three months ended March 31, 2023 and 2022; (iii) the Registrant's Condensed Consolidated Statements of Stockholders&#8217; Equity for the three months ended March 31, 2023 and 2022; (iv) the Registrant's Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022; and (v) the notes to the Registrant's Condensed Consolidated Financial Statements.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Indicates a management contract or compensatory plan or arrangement.</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Certain of the exhibits and/or schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Registrant agrees to furnish supplementally a copy of all omitted exhibits and schedules to the Securities and Exchange Commission upon its request.</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="id4c1ef3770fb4cfcadf88c3685e610eb_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id4c1ef3770fb4cfcadf88c3685e610eb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.572%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGENERON PHARMACEUTICALS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Robert E. Landry</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert E. Landry</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Finance and </span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Duly Authorized Officer)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>regn-ex_101x3312023x10q.htm
<DESCRIPTION>FIRST AMENDMENT TO CASH INCENTIVE BONUS PLAN
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i3b3294969a724083ad01a1681a640def_1"></div><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">FIRST AMENDMENT TO THE REGENERON PHARMACEUTICALS, INC. CASH INCENTIVE BONUS PLAN</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">THIS AMENDMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> (this &#8220;Amendment&#8221;) is made as of March 22, 2023 by Regeneron Pharmaceuticals, Inc., a New York corporation (the &#8220;Company&#8221;). </font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">, the Company has heretofore established and maintains the Regeneron Pharmaceuticals, Inc. Cash Incentive Bonus Plan (the &#8220;Plan&#8221;)&#59;</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">, pursuant to Section 5.6 of the Plan, the Compensation Committee of the Board of Directors of the Company (the &#8220;Committee&#8221;) has the authority to amend the Plan&#59; and </font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">, the Committee has determined that it is in the best interests of the Company to amend the Plan as provided in this Amendment. </font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">NOW, THEREFORE, BE IT RESOLVED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">, that the Plan is hereby amended in the following respects, effective as of March 22, 2023&#58; </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt">A new Section 4.5 is added to the Plan, as follows&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;4.5&#160;&#160;&#160;&#160;Without limitation of the authority of the Committee hereunder, the Committee is specifically authorized to add new Participants to the Plan during any Performance Period, to adjust the Performance Goals applicable to any such new Participant in such manner as the Committee may determine to be necessary or appropriate under the circumstances, to reserve a portion of any pool otherwise established for payment of Awards hereunder for allocation to new Participants should they be added during a Performance Period, and to take such other actions as the Committee deems necessary or appropriate to integrate new Participants into an ongoing Performance Period.&#8221;</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt">The Plan is amended in its entirety to remove those provisions which were required in order to permit the Plan to comply, in form or operation, with the performance-based compensation exception previously available under Section 162(m) of the Internal Revenue Code of 1986, as amended (&#8220;Section 162(m)&#8221;), including, without limitation, provisions requiring shareholder approval related to Section 162(m) as well as any limitation on the duration of the Plan&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the maximum payout that an individual Participant may receive as set forth in Section 4.3 of the Plan shall continue to be in effect. </font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-top:1.6pt;padding-left:40pt;padding-right:3.1pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>regn-ex_311x3312022x10q.htm
<DESCRIPTION>CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ifdc2093fea14433e8b66cddaa1386aa5_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.1 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Executive Officer Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rule 13a-14(a) under the Securities Exchange Act</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of 1934, as Adopted Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Leonard S. Schleifer, certify that&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Regeneron Pharmaceuticals, Inc.&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:5.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.134%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;text-decoration:underline">&#47;s&#47; Leonard S. Schleifer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leonard S. Schleifer, M.D., Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #666666;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>regn-ex_312x3312022x10q.htm
<DESCRIPTION>CERTIFICATION OF CFO PURSUANT TO RULE 13A-14(A)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id8859e7399184db18e7bd6a88aefc54c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.2 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Financial Officer Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rule 13a-14(a) under the Securities Exchange Act</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of 1934, as Adopted Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Robert E. Landry, certify that&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Regeneron Pharmaceuticals, Inc.&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:5.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.134%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;text-decoration:underline">&#47;s&#47; Robert E. Landry</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert E. Landry</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Finance and Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>5
<FILENAME>regn-ex_32x3312022x10q.htm
<DESCRIPTION>CERTIFICATION OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib6cec3fd93f64398b19048838c13c467_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 32 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. Section 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 906 of the Sarbanes-Oxley Act of 2002 </font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Regeneron Pharmaceuticals, Inc. (the &#34;Company&#34;) on Form 10-Q for the quarterly period ended March&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), Leonard S. Schleifer, M.D., Ph.D., as Principal Executive Officer of the Company, and Robert E. Landry, as Principal Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that&#58; </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:32.309%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Leonard S. Schleifer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leonard S. Schleifer, M.D., Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Robert E. Landry</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert E. Landry</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Finance and Chief Financial Officer </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2023</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>regn-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:22cd9e9c-8c6e-43d9-ac99-edd9ddfa2dcd,g:8ddcabf6-ffb8-41b1-9a90-14e4490a05f1-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:regn="http://www.regeneron.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.regeneron.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="regn-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="regn-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="regn-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="regn-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.regeneron.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited">
        <link:definition>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical">
        <link:definition>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited" roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited">
        <link:definition>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited">
        <link:definition>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited">
        <link:definition>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterimFinancialStatements" roleURI="http://www.regeneron.com/role/InterimFinancialStatements">
        <link:definition>0000007 - Disclosure - Interim Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSales" roleURI="http://www.regeneron.com/role/ProductSales">
        <link:definition>0000008 - Disclosure - Product Sales</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreements" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements">
        <link:definition>0000009 - Disclosure - Collaboration, License, and Other Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShare" roleURI="http://www.regeneron.com/role/NetIncomePerShare">
        <link:definition>0000010 - Disclosure - Net Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://www.regeneron.com/role/MarketableSecurities">
        <link:definition>0000011 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.regeneron.com/role/FairValueMeasurements">
        <link:definition>0000012 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.regeneron.com/role/Inventories">
        <link:definition>0000013 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.regeneron.com/role/IncomeTaxes">
        <link:definition>0000014 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.regeneron.com/role/StockholdersEquity">
        <link:definition>0000015 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashFlows" roleURI="http://www.regeneron.com/role/CashFlows">
        <link:definition>0000016 - Disclosure - Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalMatters" roleURI="http://www.regeneron.com/role/LegalMatters">
        <link:definition>0000017 - Disclosure - Legal Matters</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterimFinancialStatementsPolicies" roleURI="http://www.regeneron.com/role/InterimFinancialStatementsPolicies">
        <link:definition>0000018 - Disclosure - Interim Financial Statements (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSalesTables" roleURI="http://www.regeneron.com/role/ProductSalesTables">
        <link:definition>0000019 - Disclosure - Product Sales (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsTables" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables">
        <link:definition>0000020 - Disclosure - Collaboration, License, and Other Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareTables" roleURI="http://www.regeneron.com/role/NetIncomePerShareTables">
        <link:definition>0000021 - Disclosure - Net Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://www.regeneron.com/role/MarketableSecuritiesTables">
        <link:definition>0000022 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.regeneron.com/role/FairValueMeasurementsTables">
        <link:definition>0000023 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.regeneron.com/role/InventoriesTables">
        <link:definition>0000024 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.regeneron.com/role/StockholdersEquityTables">
        <link:definition>0000025 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashFlowsTables" roleURI="http://www.regeneron.com/role/CashFlowsTables">
        <link:definition>0000026 - Disclosure - Cash Flows (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSalesScheduleofNetProductSalesDetails" roleURI="http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails">
        <link:definition>0000027 - Disclosure - Product Sales - Schedule of Net Product Sales (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSalesNarrativeDetails" roleURI="http://www.regeneron.com/role/ProductSalesNarrativeDetails">
        <link:definition>0000028 - Disclosure - Product Sales - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails" roleURI="http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails">
        <link:definition>0000029 - Disclosure - Product Sales - Schedule of Concentration of Risk, by Risk Factor (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails">
        <link:definition>0000030 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized In Statement of Operations with Sanofi (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails">
        <link:definition>0000031 - Disclosure - Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails">
        <link:definition>0000032 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Antibody Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails">
        <link:definition>0000033 - Disclosure - Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails">
        <link:definition>0000034 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Bayer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails">
        <link:definition>0000035 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Bayer Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails">
        <link:definition>0000036 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Roche (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheDetails">
        <link:definition>0000037 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances - Roche (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails">
        <link:definition>0000038 - Disclosure - Collaboration, License, and Other Agreements - Sonoma Biotherapeutics, Inc. Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails">
        <link:definition>0000039 - Disclosure - Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails" roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails">
        <link:definition>0000040 - Disclosure - Net Income Per Share - Schedule of Antidilutive Securities Excluded From Computation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails">
        <link:definition>0000041 - Disclosure - Marketable Securities - Schedule of Investments in Available For Sale Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails" roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails">
        <link:definition>0000042 - Disclosure - Marketable Securities - Schedule of Debt Securities Based on Contractual Maturity Dates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails">
        <link:definition>0000043 - Disclosure - Marketable Securities - Schedule of Fair Value and Unrealized Losses of Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>0000044 - Disclosure - Fair Value Measurements - Schedule of Assets Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>0000045 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesScheduleofInventoriesDetails" roleURI="http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails">
        <link:definition>0000046 - Disclosure - Inventories - Schedule of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNarrativeDetails" roleURI="http://www.regeneron.com/role/InventoriesNarrativeDetails">
        <link:definition>0000047 - Disclosure - Inventories - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.regeneron.com/role/IncomeTaxesDetails">
        <link:definition>0000048 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.regeneron.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>0000049 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofShareRepurchasesDetails" roleURI="http://www.regeneron.com/role/StockholdersEquityScheduleofShareRepurchasesDetails">
        <link:definition>0000050 - Disclosure - Stockholders' Equity - Schedule of Share Repurchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.regeneron.com/role/CashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>0000051 - Disclosure - Cash Flows - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails" roleURI="http://www.regeneron.com/role/CashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails">
        <link:definition>0000052 - Disclosure - Cash Flows - Summary of Non-cash Investing and Financing Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalMattersDetails" roleURI="http://www.regeneron.com/role/LegalMattersDetails">
        <link:definition>0000053 - Disclosure - Legal Matters (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="regn_BayerCollaborationAgreementMember" abstract="true" name="BayerCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ClassificationOfInvestmentDomain" abstract="true" name="ClassificationOfInvestmentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_DevelopmentMilestoneMember" abstract="true" name="DevelopmentMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SanofiCollaborationAgreementAntibodyMember" abstract="true" name="SanofiCollaborationAgreementAntibodyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SalesMilestoneThreeMember" abstract="true" name="SalesMilestoneThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_PaymentsToAcquireIntangibleAssets1" abstract="false" name="PaymentsToAcquireIntangibleAssets1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_RegeneronsShareOfCommercialExpensesMember" abstract="true" name="RegeneronsShareOfCommercialExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" abstract="false" name="StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_A631PatentMember" abstract="true" name="A631PatentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ClassificationOfInvestmentAxis" abstract="true" name="ClassificationOfInvestmentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="regn_InmazebMember" abstract="true" name="InmazebMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SalesBasedMilestoneOneMember" abstract="true" name="SalesBasedMilestoneOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ReimbursementOfCommercializationRelatedExpensesMember" abstract="true" name="ReimbursementOfCommercializationRelatedExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_MilestoneTypeAxis" abstract="true" name="MilestoneTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="regn_SonomaBiotherapeuticsIncCollaborationAgreementMember" abstract="true" name="SonomaBiotherapeuticsIncCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_CollaborationRevenueMember" abstract="true" name="CollaborationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_EvkeezaMember" abstract="true" name="EvkeezaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_CostOfGoodsSoldMember" abstract="true" name="CostOfGoodsSoldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_EyleaNetProductSalesMember" abstract="true" name="EyleaNetProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived" abstract="false" name="LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_SanofisShareofLibtayoU.S.GrossProfitsMember" abstract="true" name="SanofisShareofLibtayoU.S.GrossProfitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SanofiMember" abstract="true" name="SanofiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_GrossProductRevenueMember" abstract="true" name="GrossProductRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SalesBasedMilestoneEarnedMember" abstract="true" name="SalesBasedMilestoneEarnedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember" abstract="true" name="ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_NumberOfInterPartiesReviewIPRPetitionsFiled" abstract="false" name="NumberOfInterPartiesReviewIPRPetitionsFiled" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_RegulatoryMilestoneMember" abstract="true" name="RegulatoryMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales" abstract="false" name="RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts" abstract="false" name="PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_SalesMilestoneFiveMember" abstract="true" name="SalesMilestoneFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_EYLEAAfliberceptInjectionMember" abstract="true" name="EYLEAAfliberceptInjectionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_LossContingencyExParteReexaminationFiledNumber" abstract="false" name="LossContingencyExParteReexaminationFiledNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="regn_CelltrionIncMember" abstract="true" name="CelltrionIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_LIBTAYONetProductSalesMember" abstract="true" name="LIBTAYONetProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_A338PatentAnd069PatentMember" abstract="true" name="A338PatentAnd069PatentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_AcquiredInProcessResearchAndDevelopment" abstract="false" name="AcquiredInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_ReimbursementOfResearchAndDevelopmentExpensesMember" abstract="true" name="ReimbursementOfResearchAndDevelopmentExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ApotexIncMember" abstract="true" name="ApotexIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_PraluentNetProductSalesMember" abstract="true" name="PraluentNetProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_RegeneronsObligationOfResearchAndDevelopmentExpensesNetOfReimbursementOfResearchAndDevelopmentExpensesMember" abstract="true" name="RegeneronsObligationOfResearchAndDevelopmentExpensesNetOfReimbursementOfResearchAndDevelopmentExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ShareOfProfitLossesInConnectionWithCommercializationMember" abstract="true" name="ShareOfProfitLossesInConnectionWithCommercializationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts" abstract="false" name="PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_ReimbursementForManufacturingOfCommercialSuppliesMember" abstract="true" name="ReimbursementForManufacturingOfCommercialSuppliesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ShareRepurchaseProgramJanuary2023Member" abstract="true" name="ShareRepurchaseProgramJanuary2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_UpFrontPaymentToCollaboratingParty" abstract="false" name="UpFrontPaymentToCollaboratingParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_RestOfWorldMember" abstract="true" name="RestOfWorldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember" abstract="true" name="OneTimePaymentInConnectionWithChangeInJapanArrangementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ShareRepurchaseProgramNovember2021Member" abstract="true" name="ShareRepurchaseProgramNovember2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_BesseMedicalMember" abstract="true" name="BesseMedicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SalesBasedMilestonesMember" abstract="true" name="SalesBasedMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_RestrictedMember" abstract="true" name="RestrictedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_SanofiCollaborationAgreementImmunooncologyMember" abstract="true" name="SanofiCollaborationAgreementImmunooncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" abstract="true" name="AmountsRecognizedInConnectionWithUpFrontPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ResearchAndDevelopmentExpensesAndReductionOfResearchAndDevelopmentExpenseMember" abstract="true" name="ResearchAndDevelopmentExpensesAndReductionOfResearchAndDevelopmentExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_UnrestrictedMember" abstract="true" name="UnrestrictedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" abstract="false" name="PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="regn_RocheCollaborationAgreementMember" abstract="true" name="RocheCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_CollaborationandContractManufacturingMember" abstract="true" name="CollaborationandContractManufacturingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_McKessonCorporationMember" abstract="true" name="McKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_A226PatentAnd992PatentMember" abstract="true" name="A226PatentAnd992PatentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SonomaBiotherapeuticsIncMember" abstract="true" name="SonomaBiotherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_NetProfitInConnectionWithCommercializationMember" abstract="true" name="NetProfitInConnectionWithCommercializationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SalesBasedMilestoneTwoMember" abstract="true" name="SalesBasedMilestoneTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_MilestoneTypeDomain" abstract="true" name="MilestoneTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_RonapreveMember" abstract="true" name="RonapreveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" abstract="false" name="PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_MarketableAndOtherSecuritiesGainLoss" abstract="false" name="MarketableAndOtherSecuritiesGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_ReimbursementForManufacturingOfExCommercialSuppliesMember" abstract="true" name="ReimbursementForManufacturingOfExCommercialSuppliesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>regn-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:22cd9e9c-8c6e-43d9-ac99-edd9ddfa2dcd,g:8ddcabf6-ffb8-41b1-9a90-14e4490a05f1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="simple" xlink:href="regn-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ec8c109a-3455-4f06-8f79-d6fab3f0e49c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1bf62c01-9bb9-4bf6-ad5c-ad0f23e7d99f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ec8c109a-3455-4f06-8f79-d6fab3f0e49c" xlink:to="loc_us-gaap_Liabilities_1bf62c01-9bb9-4bf6-ad5c-ad0f23e7d99f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_59dffd81-463b-4dda-ae60-1817e8a77a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ec8c109a-3455-4f06-8f79-d6fab3f0e49c" xlink:to="loc_us-gaap_StockholdersEquity_59dffd81-463b-4dda-ae60-1817e8a77a7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d84a2d32-ad21-4e8c-8ac8-6aa109747732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_423b9c11-df53-4e66-b7f1-63f2d1b817be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d84a2d32-ad21-4e8c-8ac8-6aa109747732" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_423b9c11-df53-4e66-b7f1-63f2d1b817be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_6ce13e11-16a6-4361-9f77-acb948a32d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d84a2d32-ad21-4e8c-8ac8-6aa109747732" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_6ce13e11-16a6-4361-9f77-acb948a32d48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2fce18bf-aed7-44c4-8046-6a14dcb2f174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d84a2d32-ad21-4e8c-8ac8-6aa109747732" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2fce18bf-aed7-44c4-8046-6a14dcb2f174" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_13c4afe4-ea09-4b63-8f4f-773a001ff35a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d84a2d32-ad21-4e8c-8ac8-6aa109747732" xlink:to="loc_us-gaap_InventoryNet_13c4afe4-ea09-4b63-8f4f-773a001ff35a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c5bed64d-e510-4070-864d-012945d5de06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d84a2d32-ad21-4e8c-8ac8-6aa109747732" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c5bed64d-e510-4070-864d-012945d5de06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_95c89ffc-2d15-43e9-a1f0-dc936521443a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d8524b40-d08b-491f-bf01-0f53151e9e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_95c89ffc-2d15-43e9-a1f0-dc936521443a" xlink:to="loc_us-gaap_AccountsPayableCurrent_d8524b40-d08b-491f-bf01-0f53151e9e5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_a604a734-2ab9-4aed-98ff-e173b1c09449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_95c89ffc-2d15-43e9-a1f0-dc936521443a" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_a604a734-2ab9-4aed-98ff-e173b1c09449" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b50f0345-269b-4e6b-bf1d-38aad69e2c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_95c89ffc-2d15-43e9-a1f0-dc936521443a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b50f0345-269b-4e6b-bf1d-38aad69e2c7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7e67cb41-a9a8-4be3-bf08-f8dc1f5333da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4da02ae4-ada5-4309-b1d9-544677a94921" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7e67cb41-a9a8-4be3-bf08-f8dc1f5333da" xlink:to="loc_us-gaap_CommonStockValue_4da02ae4-ada5-4309-b1d9-544677a94921" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_60f72b60-842f-42f3-9e67-127d6f546dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7e67cb41-a9a8-4be3-bf08-f8dc1f5333da" xlink:to="loc_us-gaap_TreasuryStockCommonValue_60f72b60-842f-42f3-9e67-127d6f546dec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_e6f24b36-390e-4a16-9b0d-e1ebe521a8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7e67cb41-a9a8-4be3-bf08-f8dc1f5333da" xlink:to="loc_us-gaap_AdditionalPaidInCapital_e6f24b36-390e-4a16-9b0d-e1ebe521a8d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_34558b5c-8b87-4fea-b795-d710ad34596b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7e67cb41-a9a8-4be3-bf08-f8dc1f5333da" xlink:to="loc_us-gaap_PreferredStockValue_34558b5c-8b87-4fea-b795-d710ad34596b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_df959c54-7da2-437e-af76-f8b4bed18d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7e67cb41-a9a8-4be3-bf08-f8dc1f5333da" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_df959c54-7da2-437e-af76-f8b4bed18d14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_de6a314f-8569-4129-9d3a-3bf320383bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7e67cb41-a9a8-4be3-bf08-f8dc1f5333da" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_de6a314f-8569-4129-9d3a-3bf320383bb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c4f19752-9218-43fa-bb76-d3767fa31a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9b8cb3a7-c1e2-4d1b-bf30-c43807608199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c4f19752-9218-43fa-bb76-d3767fa31a89" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9b8cb3a7-c1e2-4d1b-bf30-c43807608199" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1c353214-8e35-4f8e-9306-0cfeee877ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c4f19752-9218-43fa-bb76-d3767fa31a89" xlink:to="loc_us-gaap_AssetsCurrent_1c353214-8e35-4f8e-9306-0cfeee877ab9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_a1454507-17c2-4ce9-9145-6bb8d04f5064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c4f19752-9218-43fa-bb76-d3767fa31a89" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_a1454507-17c2-4ce9-9145-6bb8d04f5064" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c2fd7f5c-fc54-4209-9404-d904802326c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c4f19752-9218-43fa-bb76-d3767fa31a89" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c2fd7f5c-fc54-4209-9404-d904802326c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_35124a66-fcb7-4b87-af32-bdbbd8ff5d87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c4f19752-9218-43fa-bb76-d3767fa31a89" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_35124a66-fcb7-4b87-af32-bdbbd8ff5d87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5f4fa925-31ca-492a-99d4-e6ad10a8f6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c4f19752-9218-43fa-bb76-d3767fa31a89" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5f4fa925-31ca-492a-99d4-e6ad10a8f6f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e19608cd-a656-48ac-85b9-4048a572562e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_84deace6-9fd5-4df1-8283-db437b126021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e19608cd-a656-48ac-85b9-4048a572562e" xlink:to="loc_us-gaap_LiabilitiesCurrent_84deace6-9fd5-4df1-8283-db437b126021" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_df68fed6-93de-45a5-b6d9-8c9887d23ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e19608cd-a656-48ac-85b9-4048a572562e" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_df68fed6-93de-45a5-b6d9-8c9887d23ee7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_9d822c6d-db05-484a-b9b5-d0c84234dd8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e19608cd-a656-48ac-85b9-4048a572562e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_9d822c6d-db05-484a-b9b5-d0c84234dd8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2322229d-c117-412c-9ca7-22d3fb6fa332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e19608cd-a656-48ac-85b9-4048a572562e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2322229d-c117-412c-9ca7-22d3fb6fa332" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f5d6f7ff-9214-4a6e-b437-549401889d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e19608cd-a656-48ac-85b9-4048a572562e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f5d6f7ff-9214-4a6e-b437-549401889d25" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited" xlink:type="simple" xlink:href="regn-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_240e6ef3-c543-45a5-84be-31901cfff6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_ab5f953f-176f-4241-b557-fadad772987c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_240e6ef3-c543-45a5-84be-31901cfff6fb" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_ab5f953f-176f-4241-b557-fadad772987c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_295ca804-1555-48d5-a4f7-7ece75a00158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_240e6ef3-c543-45a5-84be-31901cfff6fb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_295ca804-1555-48d5-a4f7-7ece75a00158" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AcquiredInProcessResearchAndDevelopment_aab3c59a-dac0-44d7-9dc2-51b1cb3140c8" xlink:href="regn-20230331.xsd#regn_AcquiredInProcessResearchAndDevelopment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_240e6ef3-c543-45a5-84be-31901cfff6fb" xlink:to="loc_regn_AcquiredInProcessResearchAndDevelopment_aab3c59a-dac0-44d7-9dc2-51b1cb3140c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f5e95538-6512-4796-91c6-a9c40c1eebac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_240e6ef3-c543-45a5-84be-31901cfff6fb" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f5e95538-6512-4796-91c6-a9c40c1eebac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f984112c-28f7-4bde-bcfd-22fce2522374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_240e6ef3-c543-45a5-84be-31901cfff6fb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f984112c-28f7-4bde-bcfd-22fce2522374" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bc563ddb-ba72-4449-a9f6-a6704b69850d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_96dd07fe-de93-4aff-a488-cc787b95e778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bc563ddb-ba72-4449-a9f6-a6704b69850d" xlink:to="loc_us-gaap_OperatingIncomeLoss_96dd07fe-de93-4aff-a488-cc787b95e778" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ad2fc2f0-995b-4add-9a03-1bc26a134308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bc563ddb-ba72-4449-a9f6-a6704b69850d" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_ad2fc2f0-995b-4add-9a03-1bc26a134308" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_dde039bf-2360-4fd5-a26f-e9fa5e4b078b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a137c6fd-429c-4729-be75-a0eb25542c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_dde039bf-2360-4fd5-a26f-e9fa5e4b078b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a137c6fd-429c-4729-be75-a0eb25542c1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8fa55a01-5d8e-407e-b1da-69b7d6668e71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_dde039bf-2360-4fd5-a26f-e9fa5e4b078b" xlink:to="loc_us-gaap_InterestExpense_8fa55a01-5d8e-407e-b1da-69b7d6668e71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_00bb40fc-2fc3-477e-94b6-3196a8eec5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_af562bdb-1688-4a6c-bcf8-e2d49383fd67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_00bb40fc-2fc3-477e-94b6-3196a8eec5f2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_af562bdb-1688-4a6c-bcf8-e2d49383fd67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f1077d0c-9d3d-4727-87d4-e1800536eeeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_00bb40fc-2fc3-477e-94b6-3196a8eec5f2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f1077d0c-9d3d-4727-87d4-e1800536eeeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9ae5c3cb-5ab6-45d1-994c-d8b7e81fd03b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b29ed25c-2c4f-4a09-8561-fb09298a8ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9ae5c3cb-5ab6-45d1-994c-d8b7e81fd03b" xlink:to="loc_us-gaap_NetIncomeLoss_b29ed25c-2c4f-4a09-8561-fb09298a8ea3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_045196f6-1008-4041-ab38-831b07b8fd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9ae5c3cb-5ab6-45d1-994c-d8b7e81fd03b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_045196f6-1008-4041-ab38-831b07b8fd2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_105595e7-e875-4eb0-b5b0-62653f693706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9ae5c3cb-5ab6-45d1-994c-d8b7e81fd03b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_105595e7-e875-4eb0-b5b0-62653f693706" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_49fd817e-f152-43ff-849f-2d8902303349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ef662534-0a3d-4e4b-97d6-34d353cb7b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_49fd817e-f152-43ff-849f-2d8902303349" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ef662534-0a3d-4e4b-97d6-34d353cb7b32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_087698c0-6f5a-4b5e-b101-55b4d1c499cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_49fd817e-f152-43ff-849f-2d8902303349" xlink:to="loc_us-gaap_CostsAndExpenses_087698c0-6f5a-4b5e-b101-55b4d1c499cc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="simple" xlink:href="regn-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0998eb71-8766-4729-9b66-14be52cef46e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f7967b67-533c-44d9-a036-ff5d8f77466c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0998eb71-8766-4729-9b66-14be52cef46e" xlink:to="loc_us-gaap_NetIncomeLoss_f7967b67-533c-44d9-a036-ff5d8f77466c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_6fd97139-c31e-4149-94e8-62e5eac14b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0998eb71-8766-4729-9b66-14be52cef46e" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_6fd97139-c31e-4149-94e8-62e5eac14b5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8177c236-94f0-4e27-a861-23eb7879405d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08849c9f-4069-4dc1-8830-19e2e6e7d8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8177c236-94f0-4e27-a861-23eb7879405d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08849c9f-4069-4dc1-8830-19e2e6e7d8e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_72c51ffb-61c0-48bc-a7e3-d4d56e8c1809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8177c236-94f0-4e27-a861-23eb7879405d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_72c51ffb-61c0-48bc-a7e3-d4d56e8c1809" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ac62dde-ff62-411e-acc0-1c8b0668854a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8177c236-94f0-4e27-a861-23eb7879405d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ac62dde-ff62-411e-acc0-1c8b0668854a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_27890a7c-4ed6-4ef9-810c-84bd5d431100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_6abb9142-e6fc-4f01-81d3-3eb63f2811da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_27890a7c-4ed6-4ef9-810c-84bd5d431100" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_6abb9142-e6fc-4f01-81d3-3eb63f2811da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_74ac5be9-91a4-4c65-b7e4-e5fe4d212d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_27890a7c-4ed6-4ef9-810c-84bd5d431100" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_74ac5be9-91a4-4c65-b7e4-e5fe4d212d4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PaymentsToAcquireIntangibleAssets1_df4ff4c5-501e-46b6-9b97-766776213a61" xlink:href="regn-20230331.xsd#regn_PaymentsToAcquireIntangibleAssets1"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_27890a7c-4ed6-4ef9-810c-84bd5d431100" xlink:to="loc_regn_PaymentsToAcquireIntangibleAssets1_df4ff4c5-501e-46b6-9b97-766776213a61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_50e5c59e-900d-49ae-9387-c112d62b5aff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_27890a7c-4ed6-4ef9-810c-84bd5d431100" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_50e5c59e-900d-49ae-9387-c112d62b5aff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6a451833-82c9-4684-8a19-dd4bf8e0b547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9a6cf307-97e5-4e36-a0d3-443a82ad7c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6a451833-82c9-4684-8a19-dd4bf8e0b547" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9a6cf307-97e5-4e36-a0d3-443a82ad7c6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_301aa5a3-553d-45b7-b4e4-26b9f3b17c72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6a451833-82c9-4684-8a19-dd4bf8e0b547" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_301aa5a3-553d-45b7-b4e4-26b9f3b17c72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_2f707486-7b15-499b-a41c-1fd1828c4b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6a451833-82c9-4684-8a19-dd4bf8e0b547" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_2f707486-7b15-499b-a41c-1fd1828c4b7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_fd76fc34-85c5-4359-b993-5503fe3581bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_212906b2-6e2a-4a2e-845f-8faef5554f53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_fd76fc34-85c5-4359-b993-5503fe3581bc" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_212906b2-6e2a-4a2e-845f-8faef5554f53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_e4eb4e5e-ff54-4f51-9f98-4247ffaf3c20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_fd76fc34-85c5-4359-b993-5503fe3581bc" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_e4eb4e5e-ff54-4f51-9f98-4247ffaf3c20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_c74bde1b-dddf-41d2-af4b-354f69b39274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_fd76fc34-85c5-4359-b993-5503fe3581bc" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_c74bde1b-dddf-41d2-af4b-354f69b39274" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_eaddc620-86d5-4dc2-8b6a-95f1bee6542d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_fd76fc34-85c5-4359-b993-5503fe3581bc" xlink:to="loc_us-gaap_ShareBasedCompensation_eaddc620-86d5-4dc2-8b6a-95f1bee6542d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_36bf24df-92de-4c8b-92f9-6652ca52f3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_fd76fc34-85c5-4359-b993-5503fe3581bc" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_36bf24df-92de-4c8b-92f9-6652ca52f3c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fdec24f8-6c3e-431a-9f81-4064854adaab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_fd76fc34-85c5-4359-b993-5503fe3581bc" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fdec24f8-6c3e-431a-9f81-4064854adaab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7e44b2e7-16ce-410a-8af0-121cf3ef6a60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_fd76fc34-85c5-4359-b993-5503fe3581bc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7e44b2e7-16ce-410a-8af0-121cf3ef6a60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MarketableAndOtherSecuritiesGainLoss_b4fbe25d-0238-4432-a94f-455164325057" xlink:href="regn-20230331.xsd#regn_MarketableAndOtherSecuritiesGainLoss"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_fd76fc34-85c5-4359-b993-5503fe3581bc" xlink:to="loc_regn_MarketableAndOtherSecuritiesGainLoss_b4fbe25d-0238-4432-a94f-455164325057" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_93025f7b-808c-4364-8b63-35f607c1d786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_fd76fc34-85c5-4359-b993-5503fe3581bc" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_93025f7b-808c-4364-8b63-35f607c1d786" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b0a0aef3-126c-479a-b510-240e85377a24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_fd76fc34-85c5-4359-b993-5503fe3581bc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b0a0aef3-126c-479a-b510-240e85377a24" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_609ccb4b-7161-40be-93c3-a1787ca5a91b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_613f1dc8-7d02-44a3-a0ca-32456b71dee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_609ccb4b-7161-40be-93c3-a1787ca5a91b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_613f1dc8-7d02-44a3-a0ca-32456b71dee2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_b69b97c8-9533-4927-90b7-68e5dd14e6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_609ccb4b-7161-40be-93c3-a1787ca5a91b" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_b69b97c8-9533-4927-90b7-68e5dd14e6f9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4282d49e-25a0-4b74-9ba2-578ffabd6c39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_aa949a9d-d9b6-46bd-b92b-d0631a325d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4282d49e-25a0-4b74-9ba2-578ffabd6c39" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_aa949a9d-d9b6-46bd-b92b-d0631a325d90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c53fef9f-1b59-4b2c-b623-1f091526caf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4282d49e-25a0-4b74-9ba2-578ffabd6c39" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c53fef9f-1b59-4b2c-b623-1f091526caf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_21a57773-e682-4a88-8c21-391e3f7d7a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4282d49e-25a0-4b74-9ba2-578ffabd6c39" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_21a57773-e682-4a88-8c21-391e3f7d7a5e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ce2c819c-d289-4ff4-9b5b-4c30293cb6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_aada5f0d-8da5-48c3-96d5-7ec514a88757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ce2c819c-d289-4ff4-9b5b-4c30293cb6b0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_aada5f0d-8da5-48c3-96d5-7ec514a88757" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_fe290648-b090-4ba3-9563-68cfa3c1c922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ce2c819c-d289-4ff4-9b5b-4c30293cb6b0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_fe290648-b090-4ba3-9563-68cfa3c1c922" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_79259699-f875-4985-809a-c32486fc3238" xlink:href="regn-20230331.xsd#regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ce2c819c-d289-4ff4-9b5b-4c30293cb6b0" xlink:to="loc_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_79259699-f875-4985-809a-c32486fc3238" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_e32bc94f-110b-4336-bbad-06cfaf15dda8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_cbaf612d-6826-4cb1-87de-1e4d99c110b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_e32bc94f-110b-4336-bbad-06cfaf15dda8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_cbaf612d-6826-4cb1-87de-1e4d99c110b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_2e8e9b1d-5316-4198-8441-76fbf6c5cb96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_e32bc94f-110b-4336-bbad-06cfaf15dda8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_2e8e9b1d-5316-4198-8441-76fbf6c5cb96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_cfddf38d-e56a-451e-ab6c-1a0e9e0e5a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_d015b983-9f03-4649-a79f-e8be310279c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_cfddf38d-e56a-451e-ab6c-1a0e9e0e5a76" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_d015b983-9f03-4649-a79f-e8be310279c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_0b93b266-0bdf-44f8-a1cc-ad29b364f0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_cfddf38d-e56a-451e-ab6c-1a0e9e0e5a76" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_0b93b266-0bdf-44f8-a1cc-ad29b364f0d8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6403f00c-1217-4afb-873d-979ca09d6d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5cc194fe-50d8-4eb3-8f3a-2f298a3e5df1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_6403f00c-1217-4afb-873d-979ca09d6d1a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5cc194fe-50d8-4eb3-8f3a-2f298a3e5df1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_a82b869b-952c-4830-abad-614dadd41246" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_6403f00c-1217-4afb-873d-979ca09d6d1a" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_a82b869b-952c-4830-abad-614dadd41246" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d7f373c1-fda9-412b-8157-cfdddaf16b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_6403f00c-1217-4afb-873d-979ca09d6d1a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d7f373c1-fda9-412b-8157-cfdddaf16b6d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_db9a20be-ae28-48df-991a-0f2ae4b4563c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_0187afa5-a4c5-4941-8b1c-d18f92748481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_db9a20be-ae28-48df-991a-0f2ae4b4563c" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_0187afa5-a4c5-4941-8b1c-d18f92748481" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_11a67099-af1d-4a52-b1ae-4bba8e049d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_db9a20be-ae28-48df-991a-0f2ae4b4563c" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_11a67099-af1d-4a52-b1ae-4bba8e049d77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_33b5d725-db27-4559-8c45-4dc24772c191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_db9a20be-ae28-48df-991a-0f2ae4b4563c" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_33b5d725-db27-4559-8c45-4dc24772c191" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryNetOfReserves_7bea72e9-8cfe-428d-9e78-635d07a279a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryNetOfReserves"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_db9a20be-ae28-48df-991a-0f2ae4b4563c" xlink:to="loc_us-gaap_OtherInventoryNetOfReserves_7bea72e9-8cfe-428d-9e78-635d07a279a7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#CashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_088a83d1-ca55-4db2-823a-907347591523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_fa349e14-ed00-4a59-b611-46c0a7a9f8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_088a83d1-ca55-4db2-823a-907347591523" xlink:to="loc_us-gaap_RestrictedCash_fa349e14-ed00-4a59-b611-46c0a7a9f8b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_beb8dd7b-57e4-4e17-bc89-aa03cbe75b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_088a83d1-ca55-4db2-823a-907347591523" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_beb8dd7b-57e4-4e17-bc89-aa03cbe75b63" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>regn-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:22cd9e9c-8c6e-43d9-ac99-edd9ddfa2dcd,g:8ddcabf6-ffb8-41b1-9a90-14e4490a05f1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/Cover" xlink:type="simple" xlink:href="regn-20230331.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/Cover" xlink:type="extended" id="if167d9fe5fcc44219d84bdb4b2b5b723_Cover">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f3af2d66-8c27-412a-aed6-9600025a5558" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_DocumentType_f3af2d66-8c27-412a-aed6-9600025a5558" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_07e25a5a-6212-42d1-a4e0-3e726c5d0ef2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_DocumentQuarterlyReport_07e25a5a-6212-42d1-a4e0-3e726c5d0ef2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3ee56e72-c21c-4768-ad59-2547f4bb08bf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_DocumentPeriodEndDate_3ee56e72-c21c-4768-ad59-2547f4bb08bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_057a6116-bf2a-4937-b5e8-45384e0d6944" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_DocumentTransitionReport_057a6116-bf2a-4937-b5e8-45384e0d6944" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4790cb6d-7c76-4561-9150-f8fdaa683256" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityFileNumber_4790cb6d-7c76-4561-9150-f8fdaa683256" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_733f20c4-0c77-44ef-9a47-0b5d796cd4b5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityRegistrantName_733f20c4-0c77-44ef-9a47-0b5d796cd4b5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_dc9d3916-19d8-4c07-9801-4311cb5afdc5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_dc9d3916-19d8-4c07-9801-4311cb5afdc5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_16200ddb-9b41-40fd-97c4-5b964b433f10" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityTaxIdentificationNumber_16200ddb-9b41-40fd-97c4-5b964b433f10" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ee0e7500-6234-47e6-a4c9-c3055b21a2e8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityAddressAddressLine1_ee0e7500-6234-47e6-a4c9-c3055b21a2e8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b7bd8688-6b13-4cd4-abee-e670ccde7c2d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityAddressCityOrTown_b7bd8688-6b13-4cd4-abee-e670ccde7c2d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_dc8c03a7-ddf5-474f-83f8-a4441e76f075" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityAddressStateOrProvince_dc8c03a7-ddf5-474f-83f8-a4441e76f075" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bcec20ae-3d6e-41fd-b6dc-0fe128f47425" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityAddressPostalZipCode_bcec20ae-3d6e-41fd-b6dc-0fe128f47425" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_62549b0c-60a7-4dfa-9e40-d41ee0d083e4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_CityAreaCode_62549b0c-60a7-4dfa-9e40-d41ee0d083e4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_18d10d1d-8946-4290-92fd-642ccd3e6b41" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_LocalPhoneNumber_18d10d1d-8946-4290-92fd-642ccd3e6b41" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_449c6be3-f411-4a79-a0d0-43b8630b5797" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_Security12bTitle_449c6be3-f411-4a79-a0d0-43b8630b5797" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_925bbec9-6d68-46ae-882c-365b06cad1fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_TradingSymbol_925bbec9-6d68-46ae-882c-365b06cad1fa" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d87a5f05-a909-4ea7-abe7-eeb0d05e539f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_SecurityExchangeName_d87a5f05-a909-4ea7-abe7-eeb0d05e539f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_be5f9dcb-cf21-4f8d-ad33-2c1fcc69275a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityCurrentReportingStatus_be5f9dcb-cf21-4f8d-ad33-2c1fcc69275a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_3f1e2acb-5e27-48fa-86bd-d7e84bb58ce9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityInteractiveDataCurrent_3f1e2acb-5e27-48fa-86bd-d7e84bb58ce9" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_13d00516-6ec1-4bf7-a4ae-7a3d93031d1d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityFilerCategory_13d00516-6ec1-4bf7-a4ae-7a3d93031d1d" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_a3bab69e-9954-42bb-9518-b1bb42823b9b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntitySmallBusiness_a3bab69e-9954-42bb-9518-b1bb42823b9b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_02f093bd-a170-4522-af38-e408870f98ae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityEmergingGrowthCompany_02f093bd-a170-4522-af38-e408870f98ae" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_fec84fc8-6843-4407-b02c-d2ee01000890" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityShellCompany_fec84fc8-6843-4407-b02c-d2ee01000890" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ef1a1c68-380a-47ea-968d-c63984fcb24f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ef1a1c68-380a-47ea-968d-c63984fcb24f" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3d228664-9784-4c85-afe2-d73a77c265b3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityCentralIndexKey_3d228664-9784-4c85-afe2-d73a77c265b3" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_031cd6be-e76d-42a0-8c78-2a377a30e265" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_CurrentFiscalYearEndDate_031cd6be-e76d-42a0-8c78-2a377a30e265" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_65c4ea65-af7f-4d8c-bad6-c40996013398" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_DocumentFiscalYearFocus_65c4ea65-af7f-4d8c-bad6-c40996013398" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_856e3ba9-0805-4395-a395-3fa9b0054b9b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_DocumentFiscalPeriodFocus_856e3ba9-0805-4395-a395-3fa9b0054b9b" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e5bf54a1-ae3e-4f8e-9e09-0f7f58ea9fec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_AmendmentFlag_e5bf54a1-ae3e-4f8e-9e09-0f7f58ea9fec" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_96833a31-d7a4-429e-a178-443587ae80a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntitiesTable_96833a31-d7a4-429e-a178-443587ae80a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b9aad427-58bd-4cd0-98e5-f1b3d37d4175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_96833a31-d7a4-429e-a178-443587ae80a9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b9aad427-58bd-4cd0-98e5-f1b3d37d4175" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b9aad427-58bd-4cd0-98e5-f1b3d37d4175_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b9aad427-58bd-4cd0-98e5-f1b3d37d4175" xlink:to="loc_us-gaap_ClassOfStockDomain_b9aad427-58bd-4cd0-98e5-f1b3d37d4175_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_12f7bd10-b54a-46b9-aee9-732b1257e2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b9aad427-58bd-4cd0-98e5-f1b3d37d4175" xlink:to="loc_us-gaap_ClassOfStockDomain_12f7bd10-b54a-46b9-aee9-732b1257e2bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_d9c3ce79-fb27-4c78-9978-393d9d050cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_12f7bd10-b54a-46b9-aee9-732b1257e2bb" xlink:to="loc_us-gaap_CommonClassAMember_d9c3ce79-fb27-4c78-9978-393d9d050cf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e1e73ad2-d318-4203-acf6-a2eae40da926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_12f7bd10-b54a-46b9-aee9-732b1257e2bb" xlink:to="loc_us-gaap_CommonStockMember_e1e73ad2-d318-4203-acf6-a2eae40da926" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="simple" xlink:href="regn-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="extended" id="i665fdeb00e964df2981e5a16630c6dd6_CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3259dab4-a88a-4e96-9cd8-0fe57c76722e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ba0f6de1-5796-40c7-8a03-42a2950e0c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3259dab4-a88a-4e96-9cd8-0fe57c76722e" xlink:to="loc_us-gaap_AssetsAbstract_ba0f6de1-5796-40c7-8a03-42a2950e0c1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_a444c82b-0a00-43b0-bdc3-ca93333f430a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ba0f6de1-5796-40c7-8a03-42a2950e0c1e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_a444c82b-0a00-43b0-bdc3-ca93333f430a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_05f0f9ed-e269-4d08-9e06-624341b352b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a444c82b-0a00-43b0-bdc3-ca93333f430a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_05f0f9ed-e269-4d08-9e06-624341b352b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_e870d5fa-3212-418d-a1d6-22bb760553f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a444c82b-0a00-43b0-bdc3-ca93333f430a" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_e870d5fa-3212-418d-a1d6-22bb760553f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e8a224d1-e7b6-435a-9533-0e752fbd5763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a444c82b-0a00-43b0-bdc3-ca93333f430a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e8a224d1-e7b6-435a-9533-0e752fbd5763" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7f692899-a027-4ae6-ac3b-5430c99264ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a444c82b-0a00-43b0-bdc3-ca93333f430a" xlink:to="loc_us-gaap_InventoryNet_7f692899-a027-4ae6-ac3b-5430c99264ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_668328fd-4dd1-4ef8-90ad-6c4fbc0a13d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a444c82b-0a00-43b0-bdc3-ca93333f430a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_668328fd-4dd1-4ef8-90ad-6c4fbc0a13d9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_27d6090b-2b95-480e-a95b-7473a931a53a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a444c82b-0a00-43b0-bdc3-ca93333f430a" xlink:to="loc_us-gaap_AssetsCurrent_27d6090b-2b95-480e-a95b-7473a931a53a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_9636bc15-ac64-4f5e-89f5-5fd12abaf39c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ba0f6de1-5796-40c7-8a03-42a2950e0c1e" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_9636bc15-ac64-4f5e-89f5-5fd12abaf39c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_8904a0bc-1647-4298-b234-91b785fc2127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ba0f6de1-5796-40c7-8a03-42a2950e0c1e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_8904a0bc-1647-4298-b234-91b785fc2127" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_39b4a721-0101-408d-aefe-1a35310fbdd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ba0f6de1-5796-40c7-8a03-42a2950e0c1e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_39b4a721-0101-408d-aefe-1a35310fbdd2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_2a3d20c9-2af8-41e0-bd4d-439482c37300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ba0f6de1-5796-40c7-8a03-42a2950e0c1e" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_2a3d20c9-2af8-41e0-bd4d-439482c37300" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_cb44d157-8306-4ece-8702-c6f038613e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ba0f6de1-5796-40c7-8a03-42a2950e0c1e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_cb44d157-8306-4ece-8702-c6f038613e8b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0c9ac63a-d8bb-4ae5-86d0-18f5d0bdfbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ba0f6de1-5796-40c7-8a03-42a2950e0c1e" xlink:to="loc_us-gaap_Assets_0c9ac63a-d8bb-4ae5-86d0-18f5d0bdfbc7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a89dc8e5-4168-4425-9526-381eca8cd2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3259dab4-a88a-4e96-9cd8-0fe57c76722e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a89dc8e5-4168-4425-9526-381eca8cd2b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5e8fa7e8-8ea4-48e1-ab9f-b88b0227df1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a89dc8e5-4168-4425-9526-381eca8cd2b8" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_5e8fa7e8-8ea4-48e1-ab9f-b88b0227df1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2166f841-1683-470b-a36d-5c4a1cbe6d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5e8fa7e8-8ea4-48e1-ab9f-b88b0227df1c" xlink:to="loc_us-gaap_AccountsPayableCurrent_2166f841-1683-470b-a36d-5c4a1cbe6d66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_2866c967-6145-4f89-bf79-3cb68eb27f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5e8fa7e8-8ea4-48e1-ab9f-b88b0227df1c" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_2866c967-6145-4f89-bf79-3cb68eb27f6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8d3e31e3-5ef6-4e53-ae14-4d200970b272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5e8fa7e8-8ea4-48e1-ab9f-b88b0227df1c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8d3e31e3-5ef6-4e53-ae14-4d200970b272" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_26365d64-32e3-46b1-ab6a-51e09a9c481f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5e8fa7e8-8ea4-48e1-ab9f-b88b0227df1c" xlink:to="loc_us-gaap_LiabilitiesCurrent_26365d64-32e3-46b1-ab6a-51e09a9c481f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_09e44681-c6b1-4019-ba50-860adfb770dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a89dc8e5-4168-4425-9526-381eca8cd2b8" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_09e44681-c6b1-4019-ba50-860adfb770dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_64bb5498-70d4-44c0-ba1c-052e0ebf094f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a89dc8e5-4168-4425-9526-381eca8cd2b8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_64bb5498-70d4-44c0-ba1c-052e0ebf094f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ccb2b7a7-7f1b-477a-87a4-e7fd8d164e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a89dc8e5-4168-4425-9526-381eca8cd2b8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ccb2b7a7-7f1b-477a-87a4-e7fd8d164e4d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e6811cf4-77f0-4939-9a7d-c595812a0e61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a89dc8e5-4168-4425-9526-381eca8cd2b8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e6811cf4-77f0-4939-9a7d-c595812a0e61" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_658bc223-27cc-4caf-82d7-885a7a419cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a89dc8e5-4168-4425-9526-381eca8cd2b8" xlink:to="loc_us-gaap_Liabilities_658bc223-27cc-4caf-82d7-885a7a419cd3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_69b25dc7-5b5c-4c7d-a4be-640e98f1f870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a89dc8e5-4168-4425-9526-381eca8cd2b8" xlink:to="loc_us-gaap_StockholdersEquityAbstract_69b25dc7-5b5c-4c7d-a4be-640e98f1f870" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_df5759ab-416a-4518-bce6-280958828db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_69b25dc7-5b5c-4c7d-a4be-640e98f1f870" xlink:to="loc_us-gaap_PreferredStockValue_df5759ab-416a-4518-bce6-280958828db8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_54cf2c96-2343-4713-bfe1-1c9fa113fe6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_69b25dc7-5b5c-4c7d-a4be-640e98f1f870" xlink:to="loc_us-gaap_CommonStockValue_54cf2c96-2343-4713-bfe1-1c9fa113fe6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_951dcc3b-ed21-46e3-8665-f33021926718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_69b25dc7-5b5c-4c7d-a4be-640e98f1f870" xlink:to="loc_us-gaap_AdditionalPaidInCapital_951dcc3b-ed21-46e3-8665-f33021926718" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_da81c001-0ec2-4040-8510-5ae2ea9762cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_69b25dc7-5b5c-4c7d-a4be-640e98f1f870" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_da81c001-0ec2-4040-8510-5ae2ea9762cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_47b002b4-ee01-4707-b406-67266e0f985e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_69b25dc7-5b5c-4c7d-a4be-640e98f1f870" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_47b002b4-ee01-4707-b406-67266e0f985e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_9b7a1dc6-64cf-478a-aadc-82bd46ccfbd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_69b25dc7-5b5c-4c7d-a4be-640e98f1f870" xlink:to="loc_us-gaap_TreasuryStockCommonValue_9b7a1dc6-64cf-478a-aadc-82bd46ccfbd9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c4f7618b-d09a-4881-94a8-53122d025e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_69b25dc7-5b5c-4c7d-a4be-640e98f1f870" xlink:to="loc_us-gaap_StockholdersEquity_c4f7618b-d09a-4881-94a8-53122d025e2c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_eaac56f7-6377-4524-99a6-3098d6b14488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a89dc8e5-4168-4425-9526-381eca8cd2b8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_eaac56f7-6377-4524-99a6-3098d6b14488" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ffea5c4c-c5fa-4065-ac78-fef41de0ceb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3259dab4-a88a-4e96-9cd8-0fe57c76722e" xlink:to="loc_us-gaap_StatementTable_ffea5c4c-c5fa-4065-ac78-fef41de0ceb0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a36c06c8-15fa-4d4e-9d87-5953a7c38488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ffea5c4c-c5fa-4065-ac78-fef41de0ceb0" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a36c06c8-15fa-4d4e-9d87-5953a7c38488" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a36c06c8-15fa-4d4e-9d87-5953a7c38488_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a36c06c8-15fa-4d4e-9d87-5953a7c38488" xlink:to="loc_us-gaap_ClassOfStockDomain_a36c06c8-15fa-4d4e-9d87-5953a7c38488_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_15ae93b7-099b-4d7f-bfd7-f7821ec7f90c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a36c06c8-15fa-4d4e-9d87-5953a7c38488" xlink:to="loc_us-gaap_ClassOfStockDomain_15ae93b7-099b-4d7f-bfd7-f7821ec7f90c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_d977c095-f604-49af-9b22-d5119d634496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_15ae93b7-099b-4d7f-bfd7-f7821ec7f90c" xlink:to="loc_us-gaap_CommonClassAMember_d977c095-f604-49af-9b22-d5119d634496" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_11435938-98ce-497a-bc2b-50592685f900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_15ae93b7-099b-4d7f-bfd7-f7821ec7f90c" xlink:to="loc_us-gaap_CommonStockMember_11435938-98ce-497a-bc2b-50592685f900" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="simple" xlink:href="regn-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="extended" id="i168ad1d53dba4c6c9d359ffbbf5d590f_CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6f4c0940-d036-4dc0-ada2-f3ebfb918d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a3d6adc-e47a-463a-b22d-30ad0e8e3396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f4c0940-d036-4dc0-ada2-f3ebfb918d79" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a3d6adc-e47a-463a-b22d-30ad0e8e3396" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1313698e-d0b2-40be-b9ac-432226cf549d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a3d6adc-e47a-463a-b22d-30ad0e8e3396" xlink:to="loc_us-gaap_StockholdersEquityAbstract_1313698e-d0b2-40be-b9ac-432226cf549d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_69de9250-97fd-4910-92c2-b3a424f57230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1313698e-d0b2-40be-b9ac-432226cf549d" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_69de9250-97fd-4910-92c2-b3a424f57230" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ffd5c891-d4ca-416f-a89d-d3af0afa7691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1313698e-d0b2-40be-b9ac-432226cf549d" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ffd5c891-d4ca-416f-a89d-d3af0afa7691" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b9d7fdbe-d4e5-492c-9d5d-3b1ba178da9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1313698e-d0b2-40be-b9ac-432226cf549d" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b9d7fdbe-d4e5-492c-9d5d-3b1ba178da9d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f39b92e3-c31b-439e-9253-df03acf7326b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1313698e-d0b2-40be-b9ac-432226cf549d" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f39b92e3-c31b-439e-9253-df03acf7326b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_137b0a39-d208-4415-9c69-bd21f0dd2710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1313698e-d0b2-40be-b9ac-432226cf549d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_137b0a39-d208-4415-9c69-bd21f0dd2710" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b3a50189-c7a6-4783-b872-51c97e931535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1313698e-d0b2-40be-b9ac-432226cf549d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b3a50189-c7a6-4783-b872-51c97e931535" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_509442f8-52cd-471f-b86b-e522d388d81f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1313698e-d0b2-40be-b9ac-432226cf549d" xlink:to="loc_us-gaap_CommonStockSharesIssued_509442f8-52cd-471f-b86b-e522d388d81f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b445c5d9-c201-4df2-97eb-e1247e908000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1313698e-d0b2-40be-b9ac-432226cf549d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b445c5d9-c201-4df2-97eb-e1247e908000" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_4cfec303-93ef-45cd-9d51-373b0543a00d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1313698e-d0b2-40be-b9ac-432226cf549d" xlink:to="loc_us-gaap_TreasuryStockCommonShares_4cfec303-93ef-45cd-9d51-373b0543a00d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ab7c624c-eadd-4ecb-8407-00efe6082cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6f4c0940-d036-4dc0-ada2-f3ebfb918d79" xlink:to="loc_us-gaap_StatementTable_ab7c624c-eadd-4ecb-8407-00efe6082cbd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ba7130ce-b549-4990-a573-f70f5fdd6721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ab7c624c-eadd-4ecb-8407-00efe6082cbd" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ba7130ce-b549-4990-a573-f70f5fdd6721" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ba7130ce-b549-4990-a573-f70f5fdd6721_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ba7130ce-b549-4990-a573-f70f5fdd6721" xlink:to="loc_us-gaap_ClassOfStockDomain_ba7130ce-b549-4990-a573-f70f5fdd6721_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3cd1080e-5e7f-45d1-adb2-7dcf4fec88c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ba7130ce-b549-4990-a573-f70f5fdd6721" xlink:to="loc_us-gaap_ClassOfStockDomain_3cd1080e-5e7f-45d1-adb2-7dcf4fec88c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_bf7e74a0-dd8b-439a-af33-71b38ac21655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3cd1080e-5e7f-45d1-adb2-7dcf4fec88c9" xlink:to="loc_us-gaap_CommonClassAMember_bf7e74a0-dd8b-439a-af33-71b38ac21655" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_603a180d-2220-4cf8-83db-f27a625fda96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3cd1080e-5e7f-45d1-adb2-7dcf4fec88c9" xlink:to="loc_us-gaap_CommonStockMember_603a180d-2220-4cf8-83db-f27a625fda96" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited" xlink:type="simple" xlink:href="regn-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited" xlink:type="extended" id="ic67eb444da194d3c95270c632c7901a3_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dce0f452-6617-4acf-bdfb-39c5f5abe1db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_160b1531-671d-4ff5-81ee-8cb3f8dae7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dce0f452-6617-4acf-bdfb-39c5f5abe1db" xlink:to="loc_us-gaap_IncomeStatementAbstract_160b1531-671d-4ff5-81ee-8cb3f8dae7f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_1bdf288f-e8a1-4ec8-98df-e1677baf29f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_160b1531-671d-4ff5-81ee-8cb3f8dae7f4" xlink:to="loc_us-gaap_RevenuesAbstract_1bdf288f-e8a1-4ec8-98df-e1677baf29f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_213a8f7f-81bf-443e-9015-fafd86d4ed3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1bdf288f-e8a1-4ec8-98df-e1677baf29f3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_213a8f7f-81bf-443e-9015-fafd86d4ed3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_aa73266e-8c0b-4897-bb97-e3ddfd12cfaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_160b1531-671d-4ff5-81ee-8cb3f8dae7f4" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_aa73266e-8c0b-4897-bb97-e3ddfd12cfaf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4e78fc33-2e3c-44b1-9888-44aa97f0e7be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_aa73266e-8c0b-4897-bb97-e3ddfd12cfaf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4e78fc33-2e3c-44b1-9888-44aa97f0e7be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AcquiredInProcessResearchAndDevelopment_c1218fff-0b63-4b5f-8aee-696c4d3e2058" xlink:href="regn-20230331.xsd#regn_AcquiredInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_aa73266e-8c0b-4897-bb97-e3ddfd12cfaf" xlink:to="loc_regn_AcquiredInProcessResearchAndDevelopment_c1218fff-0b63-4b5f-8aee-696c4d3e2058" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fdd0f44d-82e6-4bed-a6fa-07dc5122c3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_aa73266e-8c0b-4897-bb97-e3ddfd12cfaf" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fdd0f44d-82e6-4bed-a6fa-07dc5122c3cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6345c00b-fbcc-4518-b3ab-a48777350130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_aa73266e-8c0b-4897-bb97-e3ddfd12cfaf" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6345c00b-fbcc-4518-b3ab-a48777350130" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_2aeb0e8f-e93d-46ac-a4c2-f1682dddb0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_aa73266e-8c0b-4897-bb97-e3ddfd12cfaf" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_2aeb0e8f-e93d-46ac-a4c2-f1682dddb0c1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ae75f08b-4278-4f7e-9e67-c2103e8971a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_aa73266e-8c0b-4897-bb97-e3ddfd12cfaf" xlink:to="loc_us-gaap_CostsAndExpenses_ae75f08b-4278-4f7e-9e67-c2103e8971a8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8a18ea6a-c4c7-4de3-ac5b-970e10ab0e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_160b1531-671d-4ff5-81ee-8cb3f8dae7f4" xlink:to="loc_us-gaap_OperatingIncomeLoss_8a18ea6a-c4c7-4de3-ac5b-970e10ab0e96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d165deb9-806c-4f95-a839-14aef6d28548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_160b1531-671d-4ff5-81ee-8cb3f8dae7f4" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d165deb9-806c-4f95-a839-14aef6d28548" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_18e193d5-fe0e-46e4-a1e0-e8c5238f5ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d165deb9-806c-4f95-a839-14aef6d28548" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_18e193d5-fe0e-46e4-a1e0-e8c5238f5ae2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_c96d3a8b-1450-4250-81fb-b76767f898ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d165deb9-806c-4f95-a839-14aef6d28548" xlink:to="loc_us-gaap_InterestExpense_c96d3a8b-1450-4250-81fb-b76767f898ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_cd220ec6-129a-4387-827c-1d9031e030df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d165deb9-806c-4f95-a839-14aef6d28548" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_cd220ec6-129a-4387-827c-1d9031e030df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_97125950-a568-47f7-bc5e-d6b9730d8160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_160b1531-671d-4ff5-81ee-8cb3f8dae7f4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_97125950-a568-47f7-bc5e-d6b9730d8160" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b6214a3d-5377-42b9-8d1e-40e47764aadc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_160b1531-671d-4ff5-81ee-8cb3f8dae7f4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b6214a3d-5377-42b9-8d1e-40e47764aadc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ff527fcf-d34d-44de-98e1-728f179a3cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_160b1531-671d-4ff5-81ee-8cb3f8dae7f4" xlink:to="loc_us-gaap_NetIncomeLoss_ff527fcf-d34d-44de-98e1-728f179a3cfd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6412e64d-2149-4e2b-a411-fbf2ad62a44c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_160b1531-671d-4ff5-81ee-8cb3f8dae7f4" xlink:to="loc_us-gaap_EarningsPerShareBasic_6412e64d-2149-4e2b-a411-fbf2ad62a44c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2b966a66-ddd5-49ca-949f-f5ebf9ce10c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_160b1531-671d-4ff5-81ee-8cb3f8dae7f4" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2b966a66-ddd5-49ca-949f-f5ebf9ce10c9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fb50d5ee-8b38-4e3c-8eae-17f006847d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_160b1531-671d-4ff5-81ee-8cb3f8dae7f4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fb50d5ee-8b38-4e3c-8eae-17f006847d7f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_eaecbc47-6dd9-473e-b0d2-868c35a1446f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_160b1531-671d-4ff5-81ee-8cb3f8dae7f4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_eaecbc47-6dd9-473e-b0d2-868c35a1446f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_b563009c-4080-442f-9d8e-d7c276d01d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dce0f452-6617-4acf-bdfb-39c5f5abe1db" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_b563009c-4080-442f-9d8e-d7c276d01d7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_74bd62f4-7eb6-4f1c-9c0e-39642525863d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_fbc02748-bb71-4560-bbea-fa225c9823b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_b563009c-4080-442f-9d8e-d7c276d01d7b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_fbc02748-bb71-4560-bbea-fa225c9823b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2cb6600f-d416-4f92-b49f-00d7c528c463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_fbc02748-bb71-4560-bbea-fa225c9823b3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2cb6600f-d416-4f92-b49f-00d7c528c463" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_ffcdb886-2276-4190-b39b-e465634524cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_fbc02748-bb71-4560-bbea-fa225c9823b3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_ffcdb886-2276-4190-b39b-e465634524cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_be3bf7ea-a9e1-446c-8c9d-e21b7ab05e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_b563009c-4080-442f-9d8e-d7c276d01d7b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_be3bf7ea-a9e1-446c-8c9d-e21b7ab05e2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_af299f61-5d01-4ba5-bbc2-34ce60b48fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_dce0f452-6617-4acf-bdfb-39c5f5abe1db" xlink:to="loc_us-gaap_StatementTable_af299f61-5d01-4ba5-bbc2-34ce60b48fbe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a01d2b97-b648-46b6-9a52-2bb0caed040a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_af299f61-5d01-4ba5-bbc2-34ce60b48fbe" xlink:to="loc_srt_ProductOrServiceAxis_a01d2b97-b648-46b6-9a52-2bb0caed040a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a01d2b97-b648-46b6-9a52-2bb0caed040a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a01d2b97-b648-46b6-9a52-2bb0caed040a" xlink:to="loc_srt_ProductsAndServicesDomain_a01d2b97-b648-46b6-9a52-2bb0caed040a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3014acf5-9448-4b27-863b-c581729f5f75" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a01d2b97-b648-46b6-9a52-2bb0caed040a" xlink:to="loc_srt_ProductsAndServicesDomain_3014acf5-9448-4b27-863b-c581729f5f75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_ad01a960-2e12-427d-bd42-4fc3ab80432b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3014acf5-9448-4b27-863b-c581729f5f75" xlink:to="loc_us-gaap_ProductMember_ad01a960-2e12-427d-bd42-4fc3ab80432b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationRevenueMember_7e1c250d-3777-49a4-966e-64b579c1f98d" xlink:href="regn-20230331.xsd#regn_CollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3014acf5-9448-4b27-863b-c581729f5f75" xlink:to="loc_regn_CollaborationRevenueMember_7e1c250d-3777-49a4-966e-64b579c1f98d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_76cf8b66-bbd4-41d8-8ec1-ae64f5d4b508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3014acf5-9448-4b27-863b-c581729f5f75" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_76cf8b66-bbd4-41d8-8ec1-ae64f5d4b508" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationandContractManufacturingMember_7902e244-0f78-4fe8-bcc3-3934e2bd1652" xlink:href="regn-20230331.xsd#regn_CollaborationandContractManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3014acf5-9448-4b27-863b-c581729f5f75" xlink:to="loc_regn_CollaborationandContractManufacturingMember_7902e244-0f78-4fe8-bcc3-3934e2bd1652" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="simple" xlink:href="regn-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="extended" id="i869d879f4695439e924beca253248519_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_56eed85a-ab81-48d0-a00e-cc862228406a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_56eed85a-ab81-48d0-a00e-cc862228406a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1c8cd69d-1382-4d81-97c9-c98881fcee52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1c8cd69d-1382-4d81-97c9-c98881fcee52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_e8dd59cc-a066-485f-91c5-00c4f395598b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_us-gaap_TreasuryStockCommonShares_e8dd59cc-a066-485f-91c5-00c4f395598b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5cbbb9f3-fdd8-4c11-8ecc-3647d7e5054a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_us-gaap_StockholdersEquity_5cbbb9f3-fdd8-4c11-8ecc-3647d7e5054a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_cdcd8300-8f22-4a7c-9579-378a17dcba20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_cdcd8300-8f22-4a7c-9579-378a17dcba20" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_765b78f9-1251-413d-b84b-a4e192807794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_765b78f9-1251-413d-b84b-a4e192807794" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_f72da5d1-e4fd-4c6d-ad39-3b135951f563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_f72da5d1-e4fd-4c6d-ad39-3b135951f563" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_97f1c7d1-f5ee-45a7-ad08-dc4f81eb8b84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_97f1c7d1-f5ee-45a7-ad08-dc4f81eb8b84" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_82004cbb-59e7-4538-8fab-9b60901d7d8b" xlink:href="regn-20230331.xsd#regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_82004cbb-59e7-4538-8fab-9b60901d7d8b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_ddcda904-d229-48bc-ba31-0f845af75833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_ddcda904-d229-48bc-ba31-0f845af75833" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_b88c2bf7-33e2-43fe-a4dd-eb5922d9d02a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_b88c2bf7-33e2-43fe-a4dd-eb5922d9d02a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_10b7f029-cbcd-4569-89d7-2a197149341f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_10b7f029-cbcd-4569-89d7-2a197149341f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5aa85eb9-9eb4-4e7f-ab10-43a59a8251ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_us-gaap_NetIncomeLoss_5aa85eb9-9eb4-4e7f-ab10-43a59a8251ef" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4041ac40-fc9e-4863-a47c-7a7d3b3b9c87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4041ac40-fc9e-4863-a47c-7a7d3b3b9c87" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_93c58235-1bca-4678-86da-6df62479290d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_d7da822b-82a9-43a3-a7d6-25e1aa6fb555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fc42af2f-87e7-40aa-8be6-169de863901e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_74140cc1-b547-4d61-80cf-1adb4da44cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_56eed85a-ab81-48d0-a00e-cc862228406a" xlink:to="loc_us-gaap_StatementTable_74140cc1-b547-4d61-80cf-1adb4da44cda" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bb677f32-6280-4005-af91-455b65500b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_74140cc1-b547-4d61-80cf-1adb4da44cda" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bb677f32-6280-4005-af91-455b65500b34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bb677f32-6280-4005-af91-455b65500b34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bb677f32-6280-4005-af91-455b65500b34" xlink:to="loc_us-gaap_ClassOfStockDomain_bb677f32-6280-4005-af91-455b65500b34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e0bac490-3e08-4784-81aa-07abc47a3646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bb677f32-6280-4005-af91-455b65500b34" xlink:to="loc_us-gaap_ClassOfStockDomain_e0bac490-3e08-4784-81aa-07abc47a3646" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_43d3d76c-257c-41b8-ab6b-440ed496fb95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e0bac490-3e08-4784-81aa-07abc47a3646" xlink:to="loc_us-gaap_CommonClassAMember_43d3d76c-257c-41b8-ab6b-440ed496fb95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_576a0a97-867a-4396-b0f9-14ccc5576a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_74140cc1-b547-4d61-80cf-1adb4da44cda" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_576a0a97-867a-4396-b0f9-14ccc5576a3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_576a0a97-867a-4396-b0f9-14ccc5576a3e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_576a0a97-867a-4396-b0f9-14ccc5576a3e" xlink:to="loc_us-gaap_EquityComponentDomain_576a0a97-867a-4396-b0f9-14ccc5576a3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c7e94e2e-d9d6-4f78-a13b-203d878f847c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_576a0a97-867a-4396-b0f9-14ccc5576a3e" xlink:to="loc_us-gaap_EquityComponentDomain_c7e94e2e-d9d6-4f78-a13b-203d878f847c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c9d66002-382c-4b78-9f6c-b207d89e938a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c7e94e2e-d9d6-4f78-a13b-203d878f847c" xlink:to="loc_us-gaap_CommonStockMember_c9d66002-382c-4b78-9f6c-b207d89e938a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_cbbfc990-baa5-461a-ae1d-05de85a3a2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c7e94e2e-d9d6-4f78-a13b-203d878f847c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_cbbfc990-baa5-461a-ae1d-05de85a3a2b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9930c60b-fe09-4dff-85c9-f4f16216b008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c7e94e2e-d9d6-4f78-a13b-203d878f847c" xlink:to="loc_us-gaap_RetainedEarningsMember_9930c60b-fe09-4dff-85c9-f4f16216b008" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_27183498-feef-41e0-a7e4-6e2c023b20b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c7e94e2e-d9d6-4f78-a13b-203d878f847c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_27183498-feef-41e0-a7e4-6e2c023b20b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_58516a29-368e-47a3-a563-53bbd470bce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c7e94e2e-d9d6-4f78-a13b-203d878f847c" xlink:to="loc_us-gaap_TreasuryStockCommonMember_58516a29-368e-47a3-a563-53bbd470bce0" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#ProductSalesScheduleofNetProductSalesDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails" xlink:type="extended" id="i47a9f615cf504c8f890771811a72f59e_ProductSalesScheduleofNetProductSalesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_849009af-40a2-4c89-9fc8-4448f92e3d30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c8a1574c-003d-401c-97f8-1fbf2f3ddea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_849009af-40a2-4c89-9fc8-4448f92e3d30" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c8a1574c-003d-401c-97f8-1fbf2f3ddea2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_27b92d0a-4ba4-46ab-acad-e2b4b7fb70c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_849009af-40a2-4c89-9fc8-4448f92e3d30" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_27b92d0a-4ba4-46ab-acad-e2b4b7fb70c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4d6fc976-e1e9-427f-9cfd-e872a9f669d4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_27b92d0a-4ba4-46ab-acad-e2b4b7fb70c5" xlink:to="loc_srt_StatementGeographicalAxis_4d6fc976-e1e9-427f-9cfd-e872a9f669d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4d6fc976-e1e9-427f-9cfd-e872a9f669d4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4d6fc976-e1e9-427f-9cfd-e872a9f669d4" xlink:to="loc_srt_SegmentGeographicalDomain_4d6fc976-e1e9-427f-9cfd-e872a9f669d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cfc0b1a0-e14f-4abe-a3fe-9ce0dc0c6283" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4d6fc976-e1e9-427f-9cfd-e872a9f669d4" xlink:to="loc_srt_SegmentGeographicalDomain_cfc0b1a0-e14f-4abe-a3fe-9ce0dc0c6283" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_145fe1e3-83d8-4ba8-b2c4-4a9ed4c3bd66" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cfc0b1a0-e14f-4abe-a3fe-9ce0dc0c6283" xlink:to="loc_country_US_145fe1e3-83d8-4ba8-b2c4-4a9ed4c3bd66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RestOfWorldMember_e2b9fd72-fdfa-4ed8-95f4-57fe7fddc0ed" xlink:href="regn-20230331.xsd#regn_RestOfWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cfc0b1a0-e14f-4abe-a3fe-9ce0dc0c6283" xlink:to="loc_regn_RestOfWorldMember_e2b9fd72-fdfa-4ed8-95f4-57fe7fddc0ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_223324f2-cd81-438a-8d0d-89deab6d351b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_27b92d0a-4ba4-46ab-acad-e2b4b7fb70c5" xlink:to="loc_srt_ProductOrServiceAxis_223324f2-cd81-438a-8d0d-89deab6d351b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_223324f2-cd81-438a-8d0d-89deab6d351b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_223324f2-cd81-438a-8d0d-89deab6d351b" xlink:to="loc_srt_ProductsAndServicesDomain_223324f2-cd81-438a-8d0d-89deab6d351b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0d3177cb-efb4-403a-99bb-f41b5d44a531" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_223324f2-cd81-438a-8d0d-89deab6d351b" xlink:to="loc_srt_ProductsAndServicesDomain_0d3177cb-efb4-403a-99bb-f41b5d44a531" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_d41f2f9d-e4d5-4fef-b79e-7246469bd300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0d3177cb-efb4-403a-99bb-f41b5d44a531" xlink:to="loc_us-gaap_ProductMember_d41f2f9d-e4d5-4fef-b79e-7246469bd300" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EyleaNetProductSalesMember_b55ed30c-867e-4ca2-81d0-48cce122ffd6" xlink:href="regn-20230331.xsd#regn_EyleaNetProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_d41f2f9d-e4d5-4fef-b79e-7246469bd300" xlink:to="loc_regn_EyleaNetProductSalesMember_b55ed30c-867e-4ca2-81d0-48cce122ffd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LIBTAYONetProductSalesMember_5773b224-8189-40af-bd09-3e29a2fb8475" xlink:href="regn-20230331.xsd#regn_LIBTAYONetProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_d41f2f9d-e4d5-4fef-b79e-7246469bd300" xlink:to="loc_regn_LIBTAYONetProductSalesMember_5773b224-8189-40af-bd09-3e29a2fb8475" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PraluentNetProductSalesMember_95190dc3-351e-4fc4-b5e3-483511810001" xlink:href="regn-20230331.xsd#regn_PraluentNetProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_d41f2f9d-e4d5-4fef-b79e-7246469bd300" xlink:to="loc_regn_PraluentNetProductSalesMember_95190dc3-351e-4fc4-b5e3-483511810001" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EvkeezaMember_4c1ecdc8-7030-46bd-b823-84e606d10687" xlink:href="regn-20230331.xsd#regn_EvkeezaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_d41f2f9d-e4d5-4fef-b79e-7246469bd300" xlink:to="loc_regn_EvkeezaMember_4c1ecdc8-7030-46bd-b823-84e606d10687" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_InmazebMember_5408412f-9064-43b4-b1d7-d71e37f50f07" xlink:href="regn-20230331.xsd#regn_InmazebMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_d41f2f9d-e4d5-4fef-b79e-7246469bd300" xlink:to="loc_regn_InmazebMember_5408412f-9064-43b4-b1d7-d71e37f50f07" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesNarrativeDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#ProductSalesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/ProductSalesNarrativeDetails" xlink:type="extended" id="i7f2ec4bfd4d543a8b4e113b4ee146821_ProductSalesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_26886fbd-7dee-423c-b61f-76923fd52e04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7a69596e-530c-42b6-b6f8-521e29ad15ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_26886fbd-7dee-423c-b61f-76923fd52e04" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7a69596e-530c-42b6-b6f8-521e29ad15ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_dba7a20a-3db1-45fa-aff3-7fd850ad45aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_26886fbd-7dee-423c-b61f-76923fd52e04" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_dba7a20a-3db1-45fa-aff3-7fd850ad45aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_e77cae1e-104d-45bc-a43a-a9a0231fe608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_dba7a20a-3db1-45fa-aff3-7fd850ad45aa" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_e77cae1e-104d-45bc-a43a-a9a0231fe608" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_e77cae1e-104d-45bc-a43a-a9a0231fe608_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_e77cae1e-104d-45bc-a43a-a9a0231fe608" xlink:to="loc_us-gaap_ReceivableTypeDomain_e77cae1e-104d-45bc-a43a-a9a0231fe608_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_c69f0aba-9f61-481c-9abd-7977d888ee3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_e77cae1e-104d-45bc-a43a-a9a0231fe608" xlink:to="loc_us-gaap_ReceivableTypeDomain_c69f0aba-9f61-481c-9abd-7977d888ee3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_48a7c0eb-ceff-4987-a5c3-33dcc465fbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_c69f0aba-9f61-481c-9abd-7977d888ee3f" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_48a7c0eb-ceff-4987-a5c3-33dcc465fbb6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails" xlink:type="extended" id="i61fcf0c48708460db44281d2a688a685_ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_51f7730f-a261-4b7c-90ff-42fa9bb23123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_7511195d-391f-4c58-a845-0488d06a2f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_51f7730f-a261-4b7c-90ff-42fa9bb23123" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_7511195d-391f-4c58-a845-0488d06a2f52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_cd86a27d-3cfa-405a-a874-0cb0a9e58f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_51f7730f-a261-4b7c-90ff-42fa9bb23123" xlink:to="loc_us-gaap_ConcentrationRiskTable_cd86a27d-3cfa-405a-a874-0cb0a9e58f0e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e72171df-12ce-4492-8c81-83198d3c9ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_cd86a27d-3cfa-405a-a874-0cb0a9e58f0e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e72171df-12ce-4492-8c81-83198d3c9ffa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e72171df-12ce-4492-8c81-83198d3c9ffa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e72171df-12ce-4492-8c81-83198d3c9ffa" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e72171df-12ce-4492-8c81-83198d3c9ffa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7034b8e5-f7f2-434e-8e75-e054a4d65b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e72171df-12ce-4492-8c81-83198d3c9ffa" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7034b8e5-f7f2-434e-8e75-e054a4d65b30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_GrossProductRevenueMember_c4db9256-b164-4c55-971c-03876b1dc537" xlink:href="regn-20230331.xsd#regn_GrossProductRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7034b8e5-f7f2-434e-8e75-e054a4d65b30" xlink:to="loc_regn_GrossProductRevenueMember_c4db9256-b164-4c55-971c-03876b1dc537" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_3fb78fdd-45b4-4542-a4f4-7e9945edc35b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_cd86a27d-3cfa-405a-a874-0cb0a9e58f0e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_3fb78fdd-45b4-4542-a4f4-7e9945edc35b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3fb78fdd-45b4-4542-a4f4-7e9945edc35b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3fb78fdd-45b4-4542-a4f4-7e9945edc35b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3fb78fdd-45b4-4542-a4f4-7e9945edc35b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_82074d7c-44fe-4d6a-bc66-8f8d616bd452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3fb78fdd-45b4-4542-a4f4-7e9945edc35b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_82074d7c-44fe-4d6a-bc66-8f8d616bd452" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_0a4f8acd-634c-4b68-86ee-7ab4950da66e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_82074d7c-44fe-4d6a-bc66-8f8d616bd452" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_0a4f8acd-634c-4b68-86ee-7ab4950da66e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_cf528978-7b6b-4801-a222-0c2b7467fe8a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_cd86a27d-3cfa-405a-a874-0cb0a9e58f0e" xlink:to="loc_srt_MajorCustomersAxis_cf528978-7b6b-4801-a222-0c2b7467fe8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_cf528978-7b6b-4801-a222-0c2b7467fe8a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_cf528978-7b6b-4801-a222-0c2b7467fe8a" xlink:to="loc_srt_NameOfMajorCustomerDomain_cf528978-7b6b-4801-a222-0c2b7467fe8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e8eacb6e-4e7e-4645-9499-7fa90e1118f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_cf528978-7b6b-4801-a222-0c2b7467fe8a" xlink:to="loc_srt_NameOfMajorCustomerDomain_e8eacb6e-4e7e-4645-9499-7fa90e1118f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BesseMedicalMember_66a25973-1f2c-458c-9f37-856da4a8ec28" xlink:href="regn-20230331.xsd#regn_BesseMedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e8eacb6e-4e7e-4645-9499-7fa90e1118f2" xlink:to="loc_regn_BesseMedicalMember_66a25973-1f2c-458c-9f37-856da4a8ec28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_McKessonCorporationMember_e11c7e88-7006-45db-9365-2a10cd54a690" xlink:href="regn-20230331.xsd#regn_McKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e8eacb6e-4e7e-4645-9499-7fa90e1118f2" xlink:to="loc_regn_McKessonCorporationMember_e11c7e88-7006-45db-9365-2a10cd54a690" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails" xlink:type="extended" id="i8891ef7a686b4b35b5610630cebc58b9_CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d55af94f-5528-4040-8535-5569fe9c4965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a0452ad1-7596-47a8-a57d-c97037fbe073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d55af94f-5528-4040-8535-5569fe9c4965" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a0452ad1-7596-47a8-a57d-c97037fbe073" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_cef21ad3-5518-46a8-b516-05615eb69602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d55af94f-5528-4040-8535-5569fe9c4965" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_cef21ad3-5518-46a8-b516-05615eb69602" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_55ab6572-8fda-4360-9da0-1106f50b3e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cef21ad3-5518-46a8-b516-05615eb69602" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_55ab6572-8fda-4360-9da0-1106f50b3e1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_55ab6572-8fda-4360-9da0-1106f50b3e1f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_55ab6572-8fda-4360-9da0-1106f50b3e1f" xlink:to="loc_us-gaap_ProjectMember_55ab6572-8fda-4360-9da0-1106f50b3e1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_d7632b8a-30b0-4cbf-bd40-c8366507b7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_55ab6572-8fda-4360-9da0-1106f50b3e1f" xlink:to="loc_us-gaap_ProjectMember_d7632b8a-30b0-4cbf-bd40-c8366507b7ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember_3ed29f98-d4cd-4412-994f-a6fbd9a88121" xlink:href="regn-20230331.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_d7632b8a-30b0-4cbf-bd40-c8366507b7ef" xlink:to="loc_regn_SanofiCollaborationAgreementAntibodyMember_3ed29f98-d4cd-4412-994f-a6fbd9a88121" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_f2a50643-85e9-4a35-b662-efa09aafb46e" xlink:href="regn-20230331.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_d7632b8a-30b0-4cbf-bd40-c8366507b7ef" xlink:to="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_f2a50643-85e9-4a35-b662-efa09aafb46e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_eb4825aa-c1be-466c-9fad-63252abadf62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cef21ad3-5518-46a8-b516-05615eb69602" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_eb4825aa-c1be-466c-9fad-63252abadf62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_eb4825aa-c1be-466c-9fad-63252abadf62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_eb4825aa-c1be-466c-9fad-63252abadf62" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_eb4825aa-c1be-466c-9fad-63252abadf62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_876b0799-42c8-424c-a5b7-e7796bfdc477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_eb4825aa-c1be-466c-9fad-63252abadf62" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_876b0799-42c8-424c-a5b7-e7796bfdc477" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationRevenueMember_14968896-342b-4e64-a23c-ae6e2a3c534c" xlink:href="regn-20230331.xsd#regn_CollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_876b0799-42c8-424c-a5b7-e7796bfdc477" xlink:to="loc_regn_CollaborationRevenueMember_14968896-342b-4e64-a23c-ae6e2a3c534c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_22ff9367-3ba7-4f79-a5c6-16b3a7792f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_876b0799-42c8-424c-a5b7-e7796bfdc477" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_22ff9367-3ba7-4f79-a5c6-16b3a7792f4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6b693d86-462a-4805-9c22-873b3e5c4782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_876b0799-42c8-424c-a5b7-e7796bfdc477" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6b693d86-462a-4805-9c22-873b3e5c4782" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CostOfGoodsSoldMember_def0e25b-c579-4934-8ec8-7e5dd5bd9600" xlink:href="regn-20230331.xsd#regn_CostOfGoodsSoldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_876b0799-42c8-424c-a5b7-e7796bfdc477" xlink:to="loc_regn_CostOfGoodsSoldMember_def0e25b-c579-4934-8ec8-7e5dd5bd9600" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_fbc85b9e-351a-4c87-b6dc-67b5dd565181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_876b0799-42c8-424c-a5b7-e7796bfdc477" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_fbc85b9e-351a-4c87-b6dc-67b5dd565181" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b819f0e0-da6c-41d2-9d6f-6d011024d6ab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cef21ad3-5518-46a8-b516-05615eb69602" xlink:to="loc_srt_ProductOrServiceAxis_b819f0e0-da6c-41d2-9d6f-6d011024d6ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b819f0e0-da6c-41d2-9d6f-6d011024d6ab_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b819f0e0-da6c-41d2-9d6f-6d011024d6ab" xlink:to="loc_srt_ProductsAndServicesDomain_b819f0e0-da6c-41d2-9d6f-6d011024d6ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d2080893-b3b1-4364-92ed-92038cc407d6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b819f0e0-da6c-41d2-9d6f-6d011024d6ab" xlink:to="loc_srt_ProductsAndServicesDomain_d2080893-b3b1-4364-92ed-92038cc407d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareOfProfitLossesInConnectionWithCommercializationMember_c5848b29-647c-4b29-8a1f-9efcd1e289b8" xlink:href="regn-20230331.xsd#regn_ShareOfProfitLossesInConnectionWithCommercializationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d2080893-b3b1-4364-92ed-92038cc407d6" xlink:to="loc_regn_ShareOfProfitLossesInConnectionWithCommercializationMember_c5848b29-647c-4b29-8a1f-9efcd1e289b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestoneEarnedMember_73379881-8a51-4b80-9d08-cf24b47d84b1" xlink:href="regn-20230331.xsd#regn_SalesBasedMilestoneEarnedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d2080893-b3b1-4364-92ed-92038cc407d6" xlink:to="loc_regn_SalesBasedMilestoneEarnedMember_73379881-8a51-4b80-9d08-cf24b47d84b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_e552143c-668b-4f4b-b4b9-cb141b2ff67c" xlink:href="regn-20230331.xsd#regn_ReimbursementForManufacturingOfCommercialSuppliesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d2080893-b3b1-4364-92ed-92038cc407d6" xlink:to="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_e552143c-668b-4f4b-b4b9-cb141b2ff67c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember_e5412dfb-67c5-4864-aa83-b82c83d2c043" xlink:href="regn-20230331.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d2080893-b3b1-4364-92ed-92038cc407d6" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember_e5412dfb-67c5-4864-aa83-b82c83d2c043" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementForManufacturingOfExCommercialSuppliesMember_a1039828-be16-4fc9-a8f4-99516e7fbd3d" xlink:href="regn-20230331.xsd#regn_ReimbursementForManufacturingOfExCommercialSuppliesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d2080893-b3b1-4364-92ed-92038cc407d6" xlink:to="loc_regn_ReimbursementForManufacturingOfExCommercialSuppliesMember_a1039828-be16-4fc9-a8f4-99516e7fbd3d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_35a2a64a-c81d-4a2f-97be-cfb1bba12afd" xlink:href="regn-20230331.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d2080893-b3b1-4364-92ed-92038cc407d6" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_35a2a64a-c81d-4a2f-97be-cfb1bba12afd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfCommercializationRelatedExpensesMember_ac7da540-d451-422c-8879-5233ce8f7a3f" xlink:href="regn-20230331.xsd#regn_ReimbursementOfCommercializationRelatedExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d2080893-b3b1-4364-92ed-92038cc407d6" xlink:to="loc_regn_ReimbursementOfCommercializationRelatedExpensesMember_ac7da540-d451-422c-8879-5233ce8f7a3f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegeneronsShareOfCommercialExpensesMember_36094e31-0a97-4bef-9391-b7f61813cd69" xlink:href="regn-20230331.xsd#regn_RegeneronsShareOfCommercialExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d2080893-b3b1-4364-92ed-92038cc407d6" xlink:to="loc_regn_RegeneronsShareOfCommercialExpensesMember_36094e31-0a97-4bef-9391-b7f61813cd69" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofisShareofLibtayoU.S.GrossProfitsMember_981e118a-159d-4468-90c8-58e9ca1d49b4" xlink:href="regn-20230331.xsd#regn_SanofisShareofLibtayoU.S.GrossProfitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d2080893-b3b1-4364-92ed-92038cc407d6" xlink:to="loc_regn_SanofisShareofLibtayoU.S.GrossProfitsMember_981e118a-159d-4468-90c8-58e9ca1d49b4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_10dbc159-a0d1-4a63-9c64-1ac5c4329c7e" xlink:href="regn-20230331.xsd#regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d2080893-b3b1-4364-92ed-92038cc407d6" xlink:to="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_10dbc159-a0d1-4a63-9c64-1ac5c4329c7e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_61821607-dff8-4137-a624-d923883b7098" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cef21ad3-5518-46a8-b516-05615eb69602" xlink:to="loc_srt_StatementGeographicalAxis_61821607-dff8-4137-a624-d923883b7098" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_61821607-dff8-4137-a624-d923883b7098_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_61821607-dff8-4137-a624-d923883b7098" xlink:to="loc_srt_SegmentGeographicalDomain_61821607-dff8-4137-a624-d923883b7098_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_888bdfc0-0272-4cda-9822-d9beaa9cff41" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_61821607-dff8-4137-a624-d923883b7098" xlink:to="loc_srt_SegmentGeographicalDomain_888bdfc0-0272-4cda-9822-d9beaa9cff41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_feb1044f-af33-4214-82f2-685e04c4cf40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_888bdfc0-0272-4cda-9822-d9beaa9cff41" xlink:to="loc_us-gaap_NonUsMember_feb1044f-af33-4214-82f2-685e04c4cf40" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails" xlink:type="extended" id="ice0bb375b020455ab791a2a3e9c89208_CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_dc3b3348-37af-463c-93c4-3004585c730a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty_9874afe6-8bc6-47b1-b3f7-484abee03ab4" xlink:href="regn-20230331.xsd#regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_dc3b3348-37af-463c-93c4-3004585c730a" xlink:to="loc_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty_9874afe6-8bc6-47b1-b3f7-484abee03ab4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts_388a6fe6-f471-4297-86ef-7d5a425b4ec6" xlink:href="regn-20230331.xsd#regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_dc3b3348-37af-463c-93c4-3004585c730a" xlink:to="loc_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts_388a6fe6-f471-4297-86ef-7d5a425b4ec6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts_2d5e91e5-2747-462e-ba39-997e3165b460" xlink:href="regn-20230331.xsd#regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_dc3b3348-37af-463c-93c4-3004585c730a" xlink:to="loc_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts_2d5e91e5-2747-462e-ba39-997e3165b460" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93214353-7814-4771-9540-d60b39718126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_dc3b3348-37af-463c-93c4-3004585c730a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93214353-7814-4771-9540-d60b39718126" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived_761b4bf4-e809-49d2-b173-b2cb5c2386ed" xlink:href="regn-20230331.xsd#regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_dc3b3348-37af-463c-93c4-3004585c730a" xlink:to="loc_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived_761b4bf4-e809-49d2-b173-b2cb5c2386ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_9a12dc82-5d77-4d0d-b87e-8eafbef5b624" xlink:href="regn-20230331.xsd#regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_dc3b3348-37af-463c-93c4-3004585c730a" xlink:to="loc_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_9a12dc82-5d77-4d0d-b87e-8eafbef5b624" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount_116a51fe-0cc7-4aa9-83ed-498004f0680d" xlink:href="regn-20230331.xsd#regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_dc3b3348-37af-463c-93c4-3004585c730a" xlink:to="loc_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount_116a51fe-0cc7-4aa9-83ed-498004f0680d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4f2d1e6e-2926-4586-b749-7b9e5abed953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_dc3b3348-37af-463c-93c4-3004585c730a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4f2d1e6e-2926-4586-b749-7b9e5abed953" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_0d363c0b-ede5-4a17-b73d-3540708b0cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4f2d1e6e-2926-4586-b749-7b9e5abed953" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_0d363c0b-ede5-4a17-b73d-3540708b0cf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_0d363c0b-ede5-4a17-b73d-3540708b0cf0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_0d363c0b-ede5-4a17-b73d-3540708b0cf0" xlink:to="loc_us-gaap_ProjectMember_0d363c0b-ede5-4a17-b73d-3540708b0cf0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_4aaa9814-1482-41ff-a996-3bfe305f105d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_0d363c0b-ede5-4a17-b73d-3540708b0cf0" xlink:to="loc_us-gaap_ProjectMember_4aaa9814-1482-41ff-a996-3bfe305f105d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember_9f406ea2-651d-4a69-bfe7-22629dfe0069" xlink:href="regn-20230331.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_4aaa9814-1482-41ff-a996-3bfe305f105d" xlink:to="loc_regn_SanofiCollaborationAgreementAntibodyMember_9f406ea2-651d-4a69-bfe7-22629dfe0069" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3a758c49-a2ff-442a-a5df-890a43d43c48" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4f2d1e6e-2926-4586-b749-7b9e5abed953" xlink:to="loc_srt_RangeAxis_3a758c49-a2ff-442a-a5df-890a43d43c48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3a758c49-a2ff-442a-a5df-890a43d43c48_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3a758c49-a2ff-442a-a5df-890a43d43c48" xlink:to="loc_srt_RangeMember_3a758c49-a2ff-442a-a5df-890a43d43c48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a87cf70a-6bd1-49e5-b58d-7cb1b1998a1c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3a758c49-a2ff-442a-a5df-890a43d43c48" xlink:to="loc_srt_RangeMember_a87cf70a-6bd1-49e5-b58d-7cb1b1998a1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a3a6f95a-5552-4708-a537-16a890f69bc0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a87cf70a-6bd1-49e5-b58d-7cb1b1998a1c" xlink:to="loc_srt_MinimumMember_a3a6f95a-5552-4708-a537-16a890f69bc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_65ecf91c-d356-477c-86e1-2fc8dfa7c60d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a87cf70a-6bd1-49e5-b58d-7cb1b1998a1c" xlink:to="loc_srt_MaximumMember_65ecf91c-d356-477c-86e1-2fc8dfa7c60d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MilestoneTypeAxis_90d6c14c-22ea-4d6b-ae35-5550ee4d2723" xlink:href="regn-20230331.xsd#regn_MilestoneTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4f2d1e6e-2926-4586-b749-7b9e5abed953" xlink:to="loc_regn_MilestoneTypeAxis_90d6c14c-22ea-4d6b-ae35-5550ee4d2723" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MilestoneTypeDomain_90d6c14c-22ea-4d6b-ae35-5550ee4d2723_default" xlink:href="regn-20230331.xsd#regn_MilestoneTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_regn_MilestoneTypeAxis_90d6c14c-22ea-4d6b-ae35-5550ee4d2723" xlink:to="loc_regn_MilestoneTypeDomain_90d6c14c-22ea-4d6b-ae35-5550ee4d2723_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MilestoneTypeDomain_95e0caa1-cb35-477b-836f-c1b46fe30522" xlink:href="regn-20230331.xsd#regn_MilestoneTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_regn_MilestoneTypeAxis_90d6c14c-22ea-4d6b-ae35-5550ee4d2723" xlink:to="loc_regn_MilestoneTypeDomain_95e0caa1-cb35-477b-836f-c1b46fe30522" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestoneThreeMember_8b51460d-d69e-4e28-ba6a-b9af90436bf9" xlink:href="regn-20230331.xsd#regn_SalesMilestoneThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_MilestoneTypeDomain_95e0caa1-cb35-477b-836f-c1b46fe30522" xlink:to="loc_regn_SalesMilestoneThreeMember_8b51460d-d69e-4e28-ba6a-b9af90436bf9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestoneFiveMember_cefe6212-45dd-4a87-ab94-8312d3916e06" xlink:href="regn-20230331.xsd#regn_SalesMilestoneFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_MilestoneTypeDomain_95e0caa1-cb35-477b-836f-c1b46fe30522" xlink:to="loc_regn_SalesMilestoneFiveMember_cefe6212-45dd-4a87-ab94-8312d3916e06" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails" xlink:type="extended" id="ia717b3c21ba54eeba40a6f05cf23fe0e_CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_229832ec-f097-4a61-9b74-f354fa03896d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8ab5a4eb-d688-47ea-8eb2-5561ae124987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_229832ec-f097-4a61-9b74-f354fa03896d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8ab5a4eb-d688-47ea-8eb2-5561ae124987" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f4bd8682-5b03-484c-99bb-e803f23baccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_229832ec-f097-4a61-9b74-f354fa03896d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_f4bd8682-5b03-484c-99bb-e803f23baccb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_adf9e0e0-167a-407a-8367-97e73dc6cf9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_229832ec-f097-4a61-9b74-f354fa03896d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_adf9e0e0-167a-407a-8367-97e73dc6cf9e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ac55740a-1e64-4c46-924a-9773d2a3fa10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_adf9e0e0-167a-407a-8367-97e73dc6cf9e" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ac55740a-1e64-4c46-924a-9773d2a3fa10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_ac55740a-1e64-4c46-924a-9773d2a3fa10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ac55740a-1e64-4c46-924a-9773d2a3fa10" xlink:to="loc_us-gaap_ProjectMember_ac55740a-1e64-4c46-924a-9773d2a3fa10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_66a93705-bc3a-431e-bc23-e19ed1861f86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ac55740a-1e64-4c46-924a-9773d2a3fa10" xlink:to="loc_us-gaap_ProjectMember_66a93705-bc3a-431e-bc23-e19ed1861f86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember_1da42d39-53db-459f-b0a9-2b4573f3a5ea" xlink:href="regn-20230331.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_66a93705-bc3a-431e-bc23-e19ed1861f86" xlink:to="loc_regn_SanofiCollaborationAgreementAntibodyMember_1da42d39-53db-459f-b0a9-2b4573f3a5ea" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails" xlink:type="extended" id="ib70a9756749e4759a50e90dccf638ba3_CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ad6b1ccf-aa00-4812-b8bc-cb4e0fccea39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UpFrontPaymentToCollaboratingParty_7a6343c0-9dbf-4856-ae86-c22c844d3db4" xlink:href="regn-20230331.xsd#regn_UpFrontPaymentToCollaboratingParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ad6b1ccf-aa00-4812-b8bc-cb4e0fccea39" xlink:to="loc_regn_UpFrontPaymentToCollaboratingParty_7a6343c0-9dbf-4856-ae86-c22c844d3db4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_39ac9540-6332-4dc0-b90a-76d890aff4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ad6b1ccf-aa00-4812-b8bc-cb4e0fccea39" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_39ac9540-6332-4dc0-b90a-76d890aff4dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales_755bfcb4-f459-43c2-a63f-0666b45e19f0" xlink:href="regn-20230331.xsd#regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ad6b1ccf-aa00-4812-b8bc-cb4e0fccea39" xlink:to="loc_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales_755bfcb4-f459-43c2-a63f-0666b45e19f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ab766e4e-ad3f-495c-a9af-16a7f62a5981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ad6b1ccf-aa00-4812-b8bc-cb4e0fccea39" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ab766e4e-ad3f-495c-a9af-16a7f62a5981" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ca4856bd-f52a-4067-ba97-febea009507c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ab766e4e-ad3f-495c-a9af-16a7f62a5981" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ca4856bd-f52a-4067-ba97-febea009507c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_ca4856bd-f52a-4067-ba97-febea009507c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ca4856bd-f52a-4067-ba97-febea009507c" xlink:to="loc_us-gaap_ProjectMember_ca4856bd-f52a-4067-ba97-febea009507c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_9cbb8f44-4fd7-4632-b6ac-b5f9169aa0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ca4856bd-f52a-4067-ba97-febea009507c" xlink:to="loc_us-gaap_ProjectMember_9cbb8f44-4fd7-4632-b6ac-b5f9169aa0e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_3d7b4701-9595-43e7-90ac-fa8813229250" xlink:href="regn-20230331.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_9cbb8f44-4fd7-4632-b6ac-b5f9169aa0e8" xlink:to="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_3d7b4701-9595-43e7-90ac-fa8813229250" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MilestoneTypeAxis_27aa1db7-343c-4350-a73b-b9ab0759b6bd" xlink:href="regn-20230331.xsd#regn_MilestoneTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ab766e4e-ad3f-495c-a9af-16a7f62a5981" xlink:to="loc_regn_MilestoneTypeAxis_27aa1db7-343c-4350-a73b-b9ab0759b6bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MilestoneTypeDomain_27aa1db7-343c-4350-a73b-b9ab0759b6bd_default" xlink:href="regn-20230331.xsd#regn_MilestoneTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_regn_MilestoneTypeAxis_27aa1db7-343c-4350-a73b-b9ab0759b6bd" xlink:to="loc_regn_MilestoneTypeDomain_27aa1db7-343c-4350-a73b-b9ab0759b6bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MilestoneTypeDomain_783b5ad7-78b0-4269-9c36-cb9f0d858bbe" xlink:href="regn-20230331.xsd#regn_MilestoneTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_regn_MilestoneTypeAxis_27aa1db7-343c-4350-a73b-b9ab0759b6bd" xlink:to="loc_regn_MilestoneTypeDomain_783b5ad7-78b0-4269-9c36-cb9f0d858bbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegulatoryMilestoneMember_4ea85cda-86fc-4078-9f69-a8eb847d02eb" xlink:href="regn-20230331.xsd#regn_RegulatoryMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_MilestoneTypeDomain_783b5ad7-78b0-4269-9c36-cb9f0d858bbe" xlink:to="loc_regn_RegulatoryMilestoneMember_4ea85cda-86fc-4078-9f69-a8eb847d02eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestoneOneMember_dceddb0e-896c-43b7-afc5-671e777aeb45" xlink:href="regn-20230331.xsd#regn_SalesBasedMilestoneOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_MilestoneTypeDomain_783b5ad7-78b0-4269-9c36-cb9f0d858bbe" xlink:to="loc_regn_SalesBasedMilestoneOneMember_dceddb0e-896c-43b7-afc5-671e777aeb45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestoneTwoMember_df502265-22cf-4bf6-a12d-6babc0843040" xlink:href="regn-20230331.xsd#regn_SalesBasedMilestoneTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_MilestoneTypeDomain_783b5ad7-78b0-4269-9c36-cb9f0d858bbe" xlink:to="loc_regn_SalesBasedMilestoneTwoMember_df502265-22cf-4bf6-a12d-6babc0843040" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestonesMember_34a5d5d6-56fb-4db3-9340-bb79ed7d3b13" xlink:href="regn-20230331.xsd#regn_SalesBasedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_MilestoneTypeDomain_783b5ad7-78b0-4269-9c36-cb9f0d858bbe" xlink:to="loc_regn_SalesBasedMilestonesMember_34a5d5d6-56fb-4db3-9340-bb79ed7d3b13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_b6e563de-24eb-4b84-a2bc-1cabd002c11a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ab766e4e-ad3f-495c-a9af-16a7f62a5981" xlink:to="loc_dei_LegalEntityAxis_b6e563de-24eb-4b84-a2bc-1cabd002c11a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b6e563de-24eb-4b84-a2bc-1cabd002c11a_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_b6e563de-24eb-4b84-a2bc-1cabd002c11a" xlink:to="loc_dei_EntityDomain_b6e563de-24eb-4b84-a2bc-1cabd002c11a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_be601c87-2278-42f6-a5a5-db32b3ac4d2c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_b6e563de-24eb-4b84-a2bc-1cabd002c11a" xlink:to="loc_dei_EntityDomain_be601c87-2278-42f6-a5a5-db32b3ac4d2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiMember_65e391a4-b06a-4305-b76c-6477495e29df" xlink:href="regn-20230331.xsd#regn_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_be601c87-2278-42f6-a5a5-db32b3ac4d2c" xlink:to="loc_regn_SanofiMember_65e391a4-b06a-4305-b76c-6477495e29df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2fd42750-0a3d-429c-ae9d-e38fdd537f79" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ab766e4e-ad3f-495c-a9af-16a7f62a5981" xlink:to="loc_srt_CounterpartyNameAxis_2fd42750-0a3d-429c-ae9d-e38fdd537f79" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2fd42750-0a3d-429c-ae9d-e38fdd537f79_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2fd42750-0a3d-429c-ae9d-e38fdd537f79" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2fd42750-0a3d-429c-ae9d-e38fdd537f79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93e30dc6-807a-4173-aed2-89dad1b8a463" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2fd42750-0a3d-429c-ae9d-e38fdd537f79" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93e30dc6-807a-4173-aed2-89dad1b8a463" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiMember_079c8ed8-05cd-4c5c-8c14-b9944b32c721" xlink:href="regn-20230331.xsd#regn_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93e30dc6-807a-4173-aed2-89dad1b8a463" xlink:to="loc_regn_SanofiMember_079c8ed8-05cd-4c5c-8c14-b9944b32c721" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails" xlink:type="extended" id="i2867dab9ca544d9d823c789eabd77b4b_CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4dbc01aa-f839-4cbd-abf1-73ff13ef91fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_908a5820-d2c6-4c9e-abae-eedfa03f01c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4dbc01aa-f839-4cbd-abf1-73ff13ef91fd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_908a5820-d2c6-4c9e-abae-eedfa03f01c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a691b55d-246f-4237-a5a4-f37e56194ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4dbc01aa-f839-4cbd-abf1-73ff13ef91fd" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a691b55d-246f-4237-a5a4-f37e56194ebe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_52579fae-62a7-4512-a9ff-c3a472957955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a691b55d-246f-4237-a5a4-f37e56194ebe" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_52579fae-62a7-4512-a9ff-c3a472957955" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_52579fae-62a7-4512-a9ff-c3a472957955_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_52579fae-62a7-4512-a9ff-c3a472957955" xlink:to="loc_us-gaap_ProjectMember_52579fae-62a7-4512-a9ff-c3a472957955_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_6a87be91-5a27-475d-9bf1-178971c75dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_52579fae-62a7-4512-a9ff-c3a472957955" xlink:to="loc_us-gaap_ProjectMember_6a87be91-5a27-475d-9bf1-178971c75dfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_f960d4b9-5ce1-4d5a-baff-1ec0062b10f6" xlink:href="regn-20230331.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_6a87be91-5a27-475d-9bf1-178971c75dfb" xlink:to="loc_regn_BayerCollaborationAgreementMember_f960d4b9-5ce1-4d5a-baff-1ec0062b10f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_be0fa605-62de-4571-ad19-331d54e4573e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a691b55d-246f-4237-a5a4-f37e56194ebe" xlink:to="loc_srt_StatementGeographicalAxis_be0fa605-62de-4571-ad19-331d54e4573e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_be0fa605-62de-4571-ad19-331d54e4573e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_be0fa605-62de-4571-ad19-331d54e4573e" xlink:to="loc_srt_SegmentGeographicalDomain_be0fa605-62de-4571-ad19-331d54e4573e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0ff34008-36e8-4b26-a0c3-4be77e0dd7c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_be0fa605-62de-4571-ad19-331d54e4573e" xlink:to="loc_srt_SegmentGeographicalDomain_0ff34008-36e8-4b26-a0c3-4be77e0dd7c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_067201ea-4ab0-43fe-801d-e4d48a3d5d40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0ff34008-36e8-4b26-a0c3-4be77e0dd7c1" xlink:to="loc_us-gaap_NonUsMember_067201ea-4ab0-43fe-801d-e4d48a3d5d40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1e3d1dd7-92e8-425d-95d5-397090b8fad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a691b55d-246f-4237-a5a4-f37e56194ebe" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1e3d1dd7-92e8-425d-95d5-397090b8fad9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1e3d1dd7-92e8-425d-95d5-397090b8fad9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1e3d1dd7-92e8-425d-95d5-397090b8fad9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1e3d1dd7-92e8-425d-95d5-397090b8fad9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fe332a3e-3ee2-4a0b-b4a3-3c3d4f2b6be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1e3d1dd7-92e8-425d-95d5-397090b8fad9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fe332a3e-3ee2-4a0b-b4a3-3c3d4f2b6be3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationRevenueMember_53e0e164-f6f4-4ca8-bbe8-5c479448897f" xlink:href="regn-20230331.xsd#regn_CollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fe332a3e-3ee2-4a0b-b4a3-3c3d4f2b6be3" xlink:to="loc_regn_CollaborationRevenueMember_53e0e164-f6f4-4ca8-bbe8-5c479448897f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchAndDevelopmentExpensesAndReductionOfResearchAndDevelopmentExpenseMember_8cf1484a-707e-4cb0-9bb5-a3fef3fb8ebb" xlink:href="regn-20230331.xsd#regn_ResearchAndDevelopmentExpensesAndReductionOfResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fe332a3e-3ee2-4a0b-b4a3-3c3d4f2b6be3" xlink:to="loc_regn_ResearchAndDevelopmentExpensesAndReductionOfResearchAndDevelopmentExpenseMember_8cf1484a-707e-4cb0-9bb5-a3fef3fb8ebb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_85e1900d-0ce8-49de-8e46-0c7bfab93285" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a691b55d-246f-4237-a5a4-f37e56194ebe" xlink:to="loc_srt_ProductOrServiceAxis_85e1900d-0ce8-49de-8e46-0c7bfab93285" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_85e1900d-0ce8-49de-8e46-0c7bfab93285_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_85e1900d-0ce8-49de-8e46-0c7bfab93285" xlink:to="loc_srt_ProductsAndServicesDomain_85e1900d-0ce8-49de-8e46-0c7bfab93285_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_235c6842-d09d-4e83-901f-bda9af31d176" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_85e1900d-0ce8-49de-8e46-0c7bfab93285" xlink:to="loc_srt_ProductsAndServicesDomain_235c6842-d09d-4e83-901f-bda9af31d176" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_NetProfitInConnectionWithCommercializationMember_5b9ca3eb-1c03-419e-adfd-7434151bdf38" xlink:href="regn-20230331.xsd#regn_NetProfitInConnectionWithCommercializationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_235c6842-d09d-4e83-901f-bda9af31d176" xlink:to="loc_regn_NetProfitInConnectionWithCommercializationMember_5b9ca3eb-1c03-419e-adfd-7434151bdf38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_fc26cba5-6ec4-4a95-836b-13663e4ddf85" xlink:href="regn-20230331.xsd#regn_ReimbursementForManufacturingOfCommercialSuppliesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_235c6842-d09d-4e83-901f-bda9af31d176" xlink:to="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_fc26cba5-6ec4-4a95-836b-13663e4ddf85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember_efb8a243-cee5-4f65-8910-a10a7534135a" xlink:href="regn-20230331.xsd#regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_235c6842-d09d-4e83-901f-bda9af31d176" xlink:to="loc_regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember_efb8a243-cee5-4f65-8910-a10a7534135a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegeneronsObligationOfResearchAndDevelopmentExpensesNetOfReimbursementOfResearchAndDevelopmentExpensesMember_18c65e67-9d0a-4272-a457-8319ea90bb12" xlink:href="regn-20230331.xsd#regn_RegeneronsObligationOfResearchAndDevelopmentExpensesNetOfReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_235c6842-d09d-4e83-901f-bda9af31d176" xlink:to="loc_regn_RegeneronsObligationOfResearchAndDevelopmentExpensesNetOfReimbursementOfResearchAndDevelopmentExpensesMember_18c65e67-9d0a-4272-a457-8319ea90bb12" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails" xlink:type="extended" id="i473bea7aa72b4ea682c6b72fa1a7d307_CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_bad81ce4-3d5f-469f-a4b7-050e04c9929f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5604f21e-2e7c-4e11-bf33-1afe2a2b05ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bad81ce4-3d5f-469f-a4b7-050e04c9929f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5604f21e-2e7c-4e11-bf33-1afe2a2b05ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_d8381753-9748-468c-a606-6f080125e1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bad81ce4-3d5f-469f-a4b7-050e04c9929f" xlink:to="loc_us-gaap_ContractWithCustomerLiability_d8381753-9748-468c-a606-6f080125e1a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_aaec540f-ebf8-49ad-a960-d933a09f0102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bad81ce4-3d5f-469f-a4b7-050e04c9929f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_aaec540f-ebf8-49ad-a960-d933a09f0102" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_96795e93-a1d2-4813-9d31-233f107c8504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_aaec540f-ebf8-49ad-a960-d933a09f0102" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_96795e93-a1d2-4813-9d31-233f107c8504" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_96795e93-a1d2-4813-9d31-233f107c8504_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_96795e93-a1d2-4813-9d31-233f107c8504" xlink:to="loc_us-gaap_ProjectMember_96795e93-a1d2-4813-9d31-233f107c8504_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_8d17a6db-6329-4fa2-b828-17603833ea5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_96795e93-a1d2-4813-9d31-233f107c8504" xlink:to="loc_us-gaap_ProjectMember_8d17a6db-6329-4fa2-b828-17603833ea5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_106583d0-233d-4592-b1d3-7bf6e35bcbbf" xlink:href="regn-20230331.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_8d17a6db-6329-4fa2-b828-17603833ea5c" xlink:to="loc_regn_BayerCollaborationAgreementMember_106583d0-233d-4592-b1d3-7bf6e35bcbbf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails" xlink:type="extended" id="i5e9c1093cfe346f48031bd20540e314f_CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_56a2a69a-d15c-4d4a-a805-78ff7461d7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ae2172d4-923f-4d5e-be0b-4717c1d36e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_56a2a69a-d15c-4d4a-a805-78ff7461d7c2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ae2172d4-923f-4d5e-be0b-4717c1d36e6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_c12c175a-96e4-4ce5-9994-a2b2dd7a34be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_56a2a69a-d15c-4d4a-a805-78ff7461d7c2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_c12c175a-96e4-4ce5-9994-a2b2dd7a34be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ec50b96c-5374-4609-b0b0-b36fc99b57b9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c12c175a-96e4-4ce5-9994-a2b2dd7a34be" xlink:to="loc_srt_ProductOrServiceAxis_ec50b96c-5374-4609-b0b0-b36fc99b57b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ec50b96c-5374-4609-b0b0-b36fc99b57b9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ec50b96c-5374-4609-b0b0-b36fc99b57b9" xlink:to="loc_srt_ProductsAndServicesDomain_ec50b96c-5374-4609-b0b0-b36fc99b57b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_357c5e8f-b093-4b29-a37e-1e6897dae5cb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ec50b96c-5374-4609-b0b0-b36fc99b57b9" xlink:to="loc_srt_ProductsAndServicesDomain_357c5e8f-b093-4b29-a37e-1e6897dae5cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RonapreveMember_efb0674f-b7d6-48b0-b437-f372a8527849" xlink:href="regn-20230331.xsd#regn_RonapreveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_357c5e8f-b093-4b29-a37e-1e6897dae5cb" xlink:to="loc_regn_RonapreveMember_efb0674f-b7d6-48b0-b437-f372a8527849" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cf138e1c-698c-495f-bb13-933cc6f0d6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c12c175a-96e4-4ce5-9994-a2b2dd7a34be" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cf138e1c-698c-495f-bb13-933cc6f0d6c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_cf138e1c-698c-495f-bb13-933cc6f0d6c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cf138e1c-698c-495f-bb13-933cc6f0d6c4" xlink:to="loc_us-gaap_ProjectMember_cf138e1c-698c-495f-bb13-933cc6f0d6c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_e180a0c2-78e0-496e-a8b4-5ecc5ef88438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cf138e1c-698c-495f-bb13-933cc6f0d6c4" xlink:to="loc_us-gaap_ProjectMember_e180a0c2-78e0-496e-a8b4-5ecc5ef88438" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RocheCollaborationAgreementMember_255da977-2ffa-4014-9528-70edafd9fb93" xlink:href="regn-20230331.xsd#regn_RocheCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_e180a0c2-78e0-496e-a8b4-5ecc5ef88438" xlink:to="loc_regn_RocheCollaborationAgreementMember_255da977-2ffa-4014-9528-70edafd9fb93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1d668305-3585-486b-9f99-a9ae03e68d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c12c175a-96e4-4ce5-9994-a2b2dd7a34be" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1d668305-3585-486b-9f99-a9ae03e68d9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1d668305-3585-486b-9f99-a9ae03e68d9f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1d668305-3585-486b-9f99-a9ae03e68d9f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1d668305-3585-486b-9f99-a9ae03e68d9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1b079972-3655-4331-9ece-ba4432c1bdc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1d668305-3585-486b-9f99-a9ae03e68d9f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1b079972-3655-4331-9ece-ba4432c1bdc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationRevenueMember_2976b3af-e3d7-469a-9ae0-43ca2ebd8c1e" xlink:href="regn-20230331.xsd#regn_CollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1b079972-3655-4331-9ece-ba4432c1bdc0" xlink:to="loc_regn_CollaborationRevenueMember_2976b3af-e3d7-469a-9ae0-43ca2ebd8c1e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheDetails" xlink:type="extended" id="ic19942d4c12b4688a1246a4159964297_CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_70c3a879-36cb-443d-83a9-62da24a0211d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_34e56eaf-f6d5-4ab0-ab1d-be77a503b417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_70c3a879-36cb-443d-83a9-62da24a0211d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_34e56eaf-f6d5-4ab0-ab1d-be77a503b417" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a6654264-78d4-41d5-ac4d-d562ec8dcaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_70c3a879-36cb-443d-83a9-62da24a0211d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a6654264-78d4-41d5-ac4d-d562ec8dcaa0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1db80afa-8846-4234-82ed-842e89071954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a6654264-78d4-41d5-ac4d-d562ec8dcaa0" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1db80afa-8846-4234-82ed-842e89071954" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_1db80afa-8846-4234-82ed-842e89071954_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1db80afa-8846-4234-82ed-842e89071954" xlink:to="loc_us-gaap_ProjectMember_1db80afa-8846-4234-82ed-842e89071954_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_35039296-ad3f-49cc-9a97-86fe58ffcf3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1db80afa-8846-4234-82ed-842e89071954" xlink:to="loc_us-gaap_ProjectMember_35039296-ad3f-49cc-9a97-86fe58ffcf3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RocheCollaborationAgreementMember_83180a73-df2a-4045-b56e-4f7bcd0767b2" xlink:href="regn-20230331.xsd#regn_RocheCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_35039296-ad3f-49cc-9a97-86fe58ffcf3f" xlink:to="loc_regn_RocheCollaborationAgreementMember_83180a73-df2a-4045-b56e-4f7bcd0767b2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails" xlink:type="extended" id="iaeae599aa8e340e89097900de9f80fb8_CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f6f6f69e-3808-44f8-be13-60416aed3e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UpFrontPaymentToCollaboratingParty_e3b03028-8b43-45a5-9572-d68edd6df8a7" xlink:href="regn-20230331.xsd#regn_UpFrontPaymentToCollaboratingParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f6f6f69e-3808-44f8-be13-60416aed3e2f" xlink:to="loc_regn_UpFrontPaymentToCollaboratingParty_e3b03028-8b43-45a5-9572-d68edd6df8a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_4af97b0a-c7cb-4c0d-89df-db1627a8d8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f6f6f69e-3808-44f8-be13-60416aed3e2f" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_4af97b0a-c7cb-4c0d-89df-db1627a8d8b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97fb21d2-b2bf-40a0-9cb4-150ae46364eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f6f6f69e-3808-44f8-be13-60416aed3e2f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97fb21d2-b2bf-40a0-9cb4-150ae46364eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_68032f0c-bd5a-4cf5-83d8-fd5741a24c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f6f6f69e-3808-44f8-be13-60416aed3e2f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_68032f0c-bd5a-4cf5-83d8-fd5741a24c01" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_90d70b21-3579-4db6-afb2-14e277a4cf82" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_68032f0c-bd5a-4cf5-83d8-fd5741a24c01" xlink:to="loc_srt_CounterpartyNameAxis_90d70b21-3579-4db6-afb2-14e277a4cf82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90d70b21-3579-4db6-afb2-14e277a4cf82_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_90d70b21-3579-4db6-afb2-14e277a4cf82" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90d70b21-3579-4db6-afb2-14e277a4cf82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88c252a7-e961-4b06-8c51-3c4aba345b30" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_90d70b21-3579-4db6-afb2-14e277a4cf82" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88c252a7-e961-4b06-8c51-3c4aba345b30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SonomaBiotherapeuticsIncMember_17ec5dc4-0741-426a-a38b-d4b9dbdc857f" xlink:href="regn-20230331.xsd#regn_SonomaBiotherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88c252a7-e961-4b06-8c51-3c4aba345b30" xlink:to="loc_regn_SonomaBiotherapeuticsIncMember_17ec5dc4-0741-426a-a38b-d4b9dbdc857f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_c23b8adb-1368-4187-80b0-86762d762cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_68032f0c-bd5a-4cf5-83d8-fd5741a24c01" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_c23b8adb-1368-4187-80b0-86762d762cbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_c23b8adb-1368-4187-80b0-86762d762cbe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_c23b8adb-1368-4187-80b0-86762d762cbe" xlink:to="loc_us-gaap_ProjectMember_c23b8adb-1368-4187-80b0-86762d762cbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_0523c1b3-d094-4cd9-8551-687b62949df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_c23b8adb-1368-4187-80b0-86762d762cbe" xlink:to="loc_us-gaap_ProjectMember_0523c1b3-d094-4cd9-8551-687b62949df7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SonomaBiotherapeuticsIncCollaborationAgreementMember_e3070733-c9bc-4a99-bd83-4ace8bf0a6bc" xlink:href="regn-20230331.xsd#regn_SonomaBiotherapeuticsIncCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_0523c1b3-d094-4cd9-8551-687b62949df7" xlink:to="loc_regn_SonomaBiotherapeuticsIncCollaborationAgreementMember_e3070733-c9bc-4a99-bd83-4ace8bf0a6bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MilestoneTypeAxis_f142b492-bfb4-4a1b-879e-3c1dc119516a" xlink:href="regn-20230331.xsd#regn_MilestoneTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_68032f0c-bd5a-4cf5-83d8-fd5741a24c01" xlink:to="loc_regn_MilestoneTypeAxis_f142b492-bfb4-4a1b-879e-3c1dc119516a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MilestoneTypeDomain_f142b492-bfb4-4a1b-879e-3c1dc119516a_default" xlink:href="regn-20230331.xsd#regn_MilestoneTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_regn_MilestoneTypeAxis_f142b492-bfb4-4a1b-879e-3c1dc119516a" xlink:to="loc_regn_MilestoneTypeDomain_f142b492-bfb4-4a1b-879e-3c1dc119516a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MilestoneTypeDomain_8e700fa2-7637-4847-b66b-99880d8cc79e" xlink:href="regn-20230331.xsd#regn_MilestoneTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_regn_MilestoneTypeAxis_f142b492-bfb4-4a1b-879e-3c1dc119516a" xlink:to="loc_regn_MilestoneTypeDomain_8e700fa2-7637-4847-b66b-99880d8cc79e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DevelopmentMilestoneMember_34b8255c-888d-4fab-8ec1-a453de637556" xlink:href="regn-20230331.xsd#regn_DevelopmentMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_MilestoneTypeDomain_8e700fa2-7637-4847-b66b-99880d8cc79e" xlink:to="loc_regn_DevelopmentMilestoneMember_34b8255c-888d-4fab-8ec1-a453de637556" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f24dc9d7-8754-42fc-9210-5b3e52e98759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_68032f0c-bd5a-4cf5-83d8-fd5741a24c01" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f24dc9d7-8754-42fc-9210-5b3e52e98759" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f24dc9d7-8754-42fc-9210-5b3e52e98759_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f24dc9d7-8754-42fc-9210-5b3e52e98759" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f24dc9d7-8754-42fc-9210-5b3e52e98759_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1cfc0721-fba8-4a63-89e9-b6644f683d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f24dc9d7-8754-42fc-9210-5b3e52e98759" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1cfc0721-fba8-4a63-89e9-b6644f683d2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_017acdbe-60b3-4c6f-b7c1-40da58fdba72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1cfc0721-fba8-4a63-89e9-b6644f683d2d" xlink:to="loc_us-gaap_SubsequentEventMember_017acdbe-60b3-4c6f-b7c1-40da58fdba72" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended" id="ie3ac56867794444398c26ef0d833c466_NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_5b33c64a-6864-42bc-915f-f113fd1af11e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_62b1c140-2a34-4b73-ac40-d207c0737e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_5b33c64a-6864-42bc-915f-f113fd1af11e" xlink:to="loc_us-gaap_NetIncomeLoss_62b1c140-2a34-4b73-ac40-d207c0737e7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9db6cab9-2c33-46da-b17a-9579598ae822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_5b33c64a-6864-42bc-915f-f113fd1af11e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9db6cab9-2c33-46da-b17a-9579598ae822" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ef29ef8f-9a24-44a5-b02e-ed1b96b06653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_5b33c64a-6864-42bc-915f-f113fd1af11e" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ef29ef8f-9a24-44a5-b02e-ed1b96b06653" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_16a26f97-6913-4e5c-b779-b70260621c94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_5b33c64a-6864-42bc-915f-f113fd1af11e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_16a26f97-6913-4e5c-b779-b70260621c94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_237e6702-6383-4891-93c6-b02e47c51849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_5b33c64a-6864-42bc-915f-f113fd1af11e" xlink:to="loc_us-gaap_EarningsPerShareBasic_237e6702-6383-4891-93c6-b02e47c51849" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c60bf1b7-31a9-4153-bbfe-0bef3824ad60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_5b33c64a-6864-42bc-915f-f113fd1af11e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c60bf1b7-31a9-4153-bbfe-0bef3824ad60" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_405a770c-ab29-4cf5-a52a-16a355357829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_5b33c64a-6864-42bc-915f-f113fd1af11e" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_405a770c-ab29-4cf5-a52a-16a355357829" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7f7f5e4e-b178-4a70-9356-c80cba52153e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_405a770c-ab29-4cf5-a52a-16a355357829" xlink:to="loc_us-gaap_AwardTypeAxis_7f7f5e4e-b178-4a70-9356-c80cba52153e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7f7f5e4e-b178-4a70-9356-c80cba52153e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7f7f5e4e-b178-4a70-9356-c80cba52153e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7f7f5e4e-b178-4a70-9356-c80cba52153e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d7295a8-d944-41fd-b588-dd7b781db06c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7f7f5e4e-b178-4a70-9356-c80cba52153e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d7295a8-d944-41fd-b588-dd7b781db06c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1409c73e-5b40-41c8-85fa-adbd231cd677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d7295a8-d944-41fd-b588-dd7b781db06c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1409c73e-5b40-41c8-85fa-adbd231cd677" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e2a59c35-9e1d-4757-89d7-543ca378db62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d7295a8-d944-41fd-b588-dd7b781db06c" xlink:to="loc_us-gaap_RestrictedStockMember_e2a59c35-9e1d-4757-89d7-543ca378db62" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails" xlink:type="extended" id="i722bb8a4c3ac4f699895935b69bf7849_NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_dd5a6645-afce-4a94-82ea-25bf106d7e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7608ce0d-608f-4503-8883-944a0c56f3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_dd5a6645-afce-4a94-82ea-25bf106d7e0f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7608ce0d-608f-4503-8883-944a0c56f3b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_257c3e15-7467-4901-a084-1d1529ce9e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_dd5a6645-afce-4a94-82ea-25bf106d7e0f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_257c3e15-7467-4901-a084-1d1529ce9e0a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_049f48f5-cf30-4c9f-ba27-8aad94dcaf13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_257c3e15-7467-4901-a084-1d1529ce9e0a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_049f48f5-cf30-4c9f-ba27-8aad94dcaf13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_049f48f5-cf30-4c9f-ba27-8aad94dcaf13_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_049f48f5-cf30-4c9f-ba27-8aad94dcaf13" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_049f48f5-cf30-4c9f-ba27-8aad94dcaf13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5a181cef-733b-47d0-983d-65401ddc824e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_049f48f5-cf30-4c9f-ba27-8aad94dcaf13" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5a181cef-733b-47d0-983d-65401ddc824e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3a3797bd-c75a-4939-8ee9-186659305229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5a181cef-733b-47d0-983d-65401ddc824e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3a3797bd-c75a-4939-8ee9-186659305229" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" xlink:type="extended" id="i652c548ed0a744389bbeb28cef37ee8a_MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_86c67bde-9398-4695-ae5a-404085ad52eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c9e0831e-c4e3-4de7-9b32-71411341c326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_86c67bde-9398-4695-ae5a-404085ad52eb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c9e0831e-c4e3-4de7-9b32-71411341c326" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4d7c63e9-6655-4bae-b345-5f118325f53c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_86c67bde-9398-4695-ae5a-404085ad52eb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4d7c63e9-6655-4bae-b345-5f118325f53c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_16c97e34-60c1-443e-8da9-151c1b5e1308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_86c67bde-9398-4695-ae5a-404085ad52eb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_16c97e34-60c1-443e-8da9-151c1b5e1308" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_286b4d87-b45d-44c3-a4ba-f550a2d9c0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_86c67bde-9398-4695-ae5a-404085ad52eb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_286b4d87-b45d-44c3-a4ba-f550a2d9c0cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d8aeadad-7651-4631-ae5a-d7dae67eb1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_86c67bde-9398-4695-ae5a-404085ad52eb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d8aeadad-7651-4631-ae5a-d7dae67eb1cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_599e0781-30b3-416e-ae67-90d89f6da31f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d8aeadad-7651-4631-ae5a-d7dae67eb1cf" xlink:to="loc_us-gaap_FinancialInstrumentAxis_599e0781-30b3-416e-ae67-90d89f6da31f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_599e0781-30b3-416e-ae67-90d89f6da31f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_599e0781-30b3-416e-ae67-90d89f6da31f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_599e0781-30b3-416e-ae67-90d89f6da31f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_40090e1b-3d53-4c88-821d-6f3d2e243054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_599e0781-30b3-416e-ae67-90d89f6da31f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_40090e1b-3d53-4c88-821d-6f3d2e243054" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_0869baca-7554-44dc-a14d-98f57dff387a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_40090e1b-3d53-4c88-821d-6f3d2e243054" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_0869baca-7554-44dc-a14d-98f57dff387a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_b428071e-7bc2-4a92-a5e7-2248d163ff29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_40090e1b-3d53-4c88-821d-6f3d2e243054" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_b428071e-7bc2-4a92-a5e7-2248d163ff29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_476c8c66-e7ce-4f69-85ba-e5d848170c10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_40090e1b-3d53-4c88-821d-6f3d2e243054" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_476c8c66-e7ce-4f69-85ba-e5d848170c10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_53b6e601-8edb-4e8c-a859-bf511a7f1922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_40090e1b-3d53-4c88-821d-6f3d2e243054" xlink:to="loc_us-gaap_CommercialPaperMember_53b6e601-8edb-4e8c-a859-bf511a7f1922" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_a80f9651-8063-4ed1-a9d9-0e0d1699098b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_40090e1b-3d53-4c88-821d-6f3d2e243054" xlink:to="loc_us-gaap_CertificatesOfDepositMember_a80f9651-8063-4ed1-a9d9-0e0d1699098b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_bc004e59-8cfc-4752-bfc4-71ca383960f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_40090e1b-3d53-4c88-821d-6f3d2e243054" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_bc004e59-8cfc-4752-bfc4-71ca383960f5" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" xlink:type="extended" id="i35fffec7efcc415eb216c8481c060754_MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_681316fc-1ba3-4d8b-95c9-ecfeeae80deb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_33767d06-ebb7-4a99-9e4a-74da2b8e6aef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_681316fc-1ba3-4d8b-95c9-ecfeeae80deb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_33767d06-ebb7-4a99-9e4a-74da2b8e6aef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_5e85ad07-b47d-4d91-af4c-9ed1e2602060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_681316fc-1ba3-4d8b-95c9-ecfeeae80deb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_5e85ad07-b47d-4d91-af4c-9ed1e2602060" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_7cdb3492-ad55-449a-abe5-7ed5e1f91151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_681316fc-1ba3-4d8b-95c9-ecfeeae80deb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_7cdb3492-ad55-449a-abe5-7ed5e1f91151" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3b335e40-e60b-42d8-a22d-884aaefc4c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_681316fc-1ba3-4d8b-95c9-ecfeeae80deb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3b335e40-e60b-42d8-a22d-884aaefc4c5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_ddebf0bf-e92d-4776-94dd-0a096ea77887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_681316fc-1ba3-4d8b-95c9-ecfeeae80deb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_ddebf0bf-e92d-4776-94dd-0a096ea77887" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_b55567e6-1b98-47bf-a79e-fb18702816e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_681316fc-1ba3-4d8b-95c9-ecfeeae80deb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_b55567e6-1b98-47bf-a79e-fb18702816e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f92646c6-d525-4b83-ba8b-6f4b637ed90f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_681316fc-1ba3-4d8b-95c9-ecfeeae80deb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f92646c6-d525-4b83-ba8b-6f4b637ed90f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c292354f-91b3-4ffc-a36c-9c8d4deee405" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f92646c6-d525-4b83-ba8b-6f4b637ed90f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c292354f-91b3-4ffc-a36c-9c8d4deee405" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c292354f-91b3-4ffc-a36c-9c8d4deee405_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c292354f-91b3-4ffc-a36c-9c8d4deee405" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c292354f-91b3-4ffc-a36c-9c8d4deee405_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_62c19203-51bf-48fa-aeee-2e3a03f7b2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c292354f-91b3-4ffc-a36c-9c8d4deee405" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_62c19203-51bf-48fa-aeee-2e3a03f7b2fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_d9112525-6aac-4980-b479-47136e167dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_62c19203-51bf-48fa-aeee-2e3a03f7b2fe" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_d9112525-6aac-4980-b479-47136e167dab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_64525ecf-bf12-45fa-be5e-9fef1bdd507f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_62c19203-51bf-48fa-aeee-2e3a03f7b2fe" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_64525ecf-bf12-45fa-be5e-9fef1bdd507f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_7681cb99-8343-4e73-a792-e8e86ef1417c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_62c19203-51bf-48fa-aeee-2e3a03f7b2fe" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_7681cb99-8343-4e73-a792-e8e86ef1417c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_0b0865dc-92ac-4e39-ab4b-53f925268479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_62c19203-51bf-48fa-aeee-2e3a03f7b2fe" xlink:to="loc_us-gaap_CommercialPaperMember_0b0865dc-92ac-4e39-ab4b-53f925268479" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_b42d25aa-2532-4883-8707-b4ab3780028b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_62c19203-51bf-48fa-aeee-2e3a03f7b2fe" xlink:to="loc_us-gaap_CertificatesOfDepositMember_b42d25aa-2532-4883-8707-b4ab3780028b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_a127f877-c354-476e-b108-9dd9e1291f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_62c19203-51bf-48fa-aeee-2e3a03f7b2fe" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_a127f877-c354-476e-b108-9dd9e1291f4b" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="i587c69e0cbfc45e38f1b56e564b5ed19_FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d663a8d1-bdfa-4f42-b678-6b3e3f59b862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9ee0dde1-9f30-415b-9751-59a44f9e0aec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d663a8d1-bdfa-4f42-b678-6b3e3f59b862" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9ee0dde1-9f30-415b-9751-59a44f9e0aec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_84aef472-6b4b-437c-bac2-292af42efa61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d663a8d1-bdfa-4f42-b678-6b3e3f59b862" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_84aef472-6b4b-437c-bac2-292af42efa61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_d36abc49-3415-42c1-a228-37a11d196c35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d663a8d1-bdfa-4f42-b678-6b3e3f59b862" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_d36abc49-3415-42c1-a228-37a11d196c35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_72fb9d0c-26ec-4d37-8f95-20eb4d1d1ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d663a8d1-bdfa-4f42-b678-6b3e3f59b862" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_72fb9d0c-26ec-4d37-8f95-20eb4d1d1ea5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29aafef5-7e48-4fcf-a027-84e69925c126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d663a8d1-bdfa-4f42-b678-6b3e3f59b862" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29aafef5-7e48-4fcf-a027-84e69925c126" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5637f780-bf38-49ef-b2dc-f382c4f4aed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29aafef5-7e48-4fcf-a027-84e69925c126" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5637f780-bf38-49ef-b2dc-f382c4f4aed0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5637f780-bf38-49ef-b2dc-f382c4f4aed0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5637f780-bf38-49ef-b2dc-f382c4f4aed0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5637f780-bf38-49ef-b2dc-f382c4f4aed0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9aa7de7d-2108-419e-9344-0c71678ca62c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5637f780-bf38-49ef-b2dc-f382c4f4aed0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9aa7de7d-2108-419e-9344-0c71678ca62c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_01d6981c-d302-4677-a3c5-1e89c65b2039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9aa7de7d-2108-419e-9344-0c71678ca62c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_01d6981c-d302-4677-a3c5-1e89c65b2039" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_df9a1066-17d4-484f-a4a4-c8dff252b247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29aafef5-7e48-4fcf-a027-84e69925c126" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_df9a1066-17d4-484f-a4a4-c8dff252b247" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_df9a1066-17d4-484f-a4a4-c8dff252b247_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_df9a1066-17d4-484f-a4a4-c8dff252b247" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_df9a1066-17d4-484f-a4a4-c8dff252b247_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f33fda03-ea80-430f-9b62-dfcfb2545881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_df9a1066-17d4-484f-a4a4-c8dff252b247" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f33fda03-ea80-430f-9b62-dfcfb2545881" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_76da1bd0-9961-48a3-9866-d6b6ee329812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f33fda03-ea80-430f-9b62-dfcfb2545881" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_76da1bd0-9961-48a3-9866-d6b6ee329812" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4cc31212-0ce8-40b3-a201-90b8c933de77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f33fda03-ea80-430f-9b62-dfcfb2545881" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4cc31212-0ce8-40b3-a201-90b8c933de77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4f5c2751-d0e8-4a26-9eba-7fbdc7cced2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29aafef5-7e48-4fcf-a027-84e69925c126" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4f5c2751-d0e8-4a26-9eba-7fbdc7cced2e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4f5c2751-d0e8-4a26-9eba-7fbdc7cced2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4f5c2751-d0e8-4a26-9eba-7fbdc7cced2e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4f5c2751-d0e8-4a26-9eba-7fbdc7cced2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4acdd16-61b3-4a28-8954-d58fb9921e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4f5c2751-d0e8-4a26-9eba-7fbdc7cced2e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4acdd16-61b3-4a28-8954-d58fb9921e30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_4216533c-4bed-40b1-9285-c6b05a82c546" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4acdd16-61b3-4a28-8954-d58fb9921e30" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_4216533c-4bed-40b1-9285-c6b05a82c546" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_c594c65a-8e8d-457b-95b7-7d94f970fa2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4acdd16-61b3-4a28-8954-d58fb9921e30" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_c594c65a-8e8d-457b-95b7-7d94f970fa2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_169cc162-31cc-4107-a710-4be65f0ad580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4acdd16-61b3-4a28-8954-d58fb9921e30" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_169cc162-31cc-4107-a710-4be65f0ad580" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_3608dd25-e5e7-4826-9df2-3a6151789411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4acdd16-61b3-4a28-8954-d58fb9921e30" xlink:to="loc_us-gaap_CommercialPaperMember_3608dd25-e5e7-4826-9df2-3a6151789411" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_dd10178f-d75c-4aa2-8212-bbd20a89e271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4acdd16-61b3-4a28-8954-d58fb9921e30" xlink:to="loc_us-gaap_CertificatesOfDepositMember_dd10178f-d75c-4aa2-8212-bbd20a89e271" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_8ce92c22-cc59-4b06-9ab6-17d098d42338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4acdd16-61b3-4a28-8954-d58fb9921e30" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_8ce92c22-cc59-4b06-9ab6-17d098d42338" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentAxis_818f4851-09c8-4d0c-8dca-310021bfdbbe" xlink:href="regn-20230331.xsd#regn_ClassificationOfInvestmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29aafef5-7e48-4fcf-a027-84e69925c126" xlink:to="loc_regn_ClassificationOfInvestmentAxis_818f4851-09c8-4d0c-8dca-310021bfdbbe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentDomain_818f4851-09c8-4d0c-8dca-310021bfdbbe_default" xlink:href="regn-20230331.xsd#regn_ClassificationOfInvestmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_regn_ClassificationOfInvestmentAxis_818f4851-09c8-4d0c-8dca-310021bfdbbe" xlink:to="loc_regn_ClassificationOfInvestmentDomain_818f4851-09c8-4d0c-8dca-310021bfdbbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentDomain_7a1aa4ac-3a0b-470e-a462-328ce7c9e9b4" xlink:href="regn-20230331.xsd#regn_ClassificationOfInvestmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_regn_ClassificationOfInvestmentAxis_818f4851-09c8-4d0c-8dca-310021bfdbbe" xlink:to="loc_regn_ClassificationOfInvestmentDomain_7a1aa4ac-3a0b-470e-a462-328ce7c9e9b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UnrestrictedMember_93c698b5-f0b7-4029-bbd4-14298609fef9" xlink:href="regn-20230331.xsd#regn_UnrestrictedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_ClassificationOfInvestmentDomain_7a1aa4ac-3a0b-470e-a462-328ce7c9e9b4" xlink:to="loc_regn_UnrestrictedMember_93c698b5-f0b7-4029-bbd4-14298609fef9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RestrictedMember_ca1afcc6-ae06-4714-a3f4-cb2d2039675c" xlink:href="regn-20230331.xsd#regn_RestrictedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_ClassificationOfInvestmentDomain_7a1aa4ac-3a0b-470e-a462-328ce7c9e9b4" xlink:to="loc_regn_RestrictedMember_ca1afcc6-ae06-4714-a3f4-cb2d2039675c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i4f9e9815f5b8493da27c9e3cf5db0591_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_35bd0f55-1b38-4cc9-8b5d-84f470f7e4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d3d53f84-a377-45e5-b829-f90692775dad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_35bd0f55-1b38-4cc9-8b5d-84f470f7e4e4" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d3d53f84-a377-45e5-b829-f90692775dad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_837011bf-6740-48df-ab34-2aba02be5802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_35bd0f55-1b38-4cc9-8b5d-84f470f7e4e4" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_837011bf-6740-48df-ab34-2aba02be5802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_30bb35ae-f8ed-4fdf-8d98-eba154fdbc06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_35bd0f55-1b38-4cc9-8b5d-84f470f7e4e4" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_30bb35ae-f8ed-4fdf-8d98-eba154fdbc06" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_4fafad40-4b6a-49c7-adb8-21c4e1054f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_30bb35ae-f8ed-4fdf-8d98-eba154fdbc06" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_4fafad40-4b6a-49c7-adb8-21c4e1054f10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_4fafad40-4b6a-49c7-adb8-21c4e1054f10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_4fafad40-4b6a-49c7-adb8-21c4e1054f10" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_4fafad40-4b6a-49c7-adb8-21c4e1054f10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_dd8f1aba-511b-4ed1-8a4c-f2f91441fa0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_4fafad40-4b6a-49c7-adb8-21c4e1054f10" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_dd8f1aba-511b-4ed1-8a4c-f2f91441fa0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgramNovember2021Member_86dd76d1-d20a-486d-bc4a-c9ea5953cb01" xlink:href="regn-20230331.xsd#regn_ShareRepurchaseProgramNovember2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_dd8f1aba-511b-4ed1-8a4c-f2f91441fa0a" xlink:to="loc_regn_ShareRepurchaseProgramNovember2021Member_86dd76d1-d20a-486d-bc4a-c9ea5953cb01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgramJanuary2023Member_b9160e71-0421-4e57-baae-08241642f030" xlink:href="regn-20230331.xsd#regn_ShareRepurchaseProgramJanuary2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_dd8f1aba-511b-4ed1-8a4c-f2f91441fa0a" xlink:to="loc_regn_ShareRepurchaseProgramJanuary2023Member_b9160e71-0421-4e57-baae-08241642f030" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/LegalMattersDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#LegalMattersDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/LegalMattersDetails" xlink:type="extended" id="iceb99f9b32bf4d0ba9bee29477dc9558_LegalMattersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_732502bd-63d2-44e3-8287-b1d08eebeb98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LossContingencyExParteReexaminationFiledNumber_0fcfddea-07c3-4b1e-9cce-f4f8d1adba4e" xlink:href="regn-20230331.xsd#regn_LossContingencyExParteReexaminationFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_732502bd-63d2-44e3-8287-b1d08eebeb98" xlink:to="loc_regn_LossContingencyExParteReexaminationFiledNumber_0fcfddea-07c3-4b1e-9cce-f4f8d1adba4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_NumberOfInterPartiesReviewIPRPetitionsFiled_93f091db-8411-489c-ba95-17a9616e06dc" xlink:href="regn-20230331.xsd#regn_NumberOfInterPartiesReviewIPRPetitionsFiled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_732502bd-63d2-44e3-8287-b1d08eebeb98" xlink:to="loc_regn_NumberOfInterPartiesReviewIPRPetitionsFiled_93f091db-8411-489c-ba95-17a9616e06dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_bb5cd0fb-e4dc-4599-8767-2876075120d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_732502bd-63d2-44e3-8287-b1d08eebeb98" xlink:to="loc_us-gaap_LossContingenciesTable_bb5cd0fb-e4dc-4599-8767-2876075120d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_df6e9843-689f-4345-976c-2f3ed8fca970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_bb5cd0fb-e4dc-4599-8767-2876075120d4" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_df6e9843-689f-4345-976c-2f3ed8fca970" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_df6e9843-689f-4345-976c-2f3ed8fca970_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_df6e9843-689f-4345-976c-2f3ed8fca970" xlink:to="loc_us-gaap_LossContingencyNatureDomain_df6e9843-689f-4345-976c-2f3ed8fca970_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_366a787a-1952-4fa3-acfb-8e1a9094bd53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_df6e9843-689f-4345-976c-2f3ed8fca970" xlink:to="loc_us-gaap_LossContingencyNatureDomain_366a787a-1952-4fa3-acfb-8e1a9094bd53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A226PatentAnd992PatentMember_c88489bf-0173-48db-934d-b949b42ea62e" xlink:href="regn-20230331.xsd#regn_A226PatentAnd992PatentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_366a787a-1952-4fa3-acfb-8e1a9094bd53" xlink:to="loc_regn_A226PatentAnd992PatentMember_c88489bf-0173-48db-934d-b949b42ea62e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A338PatentAnd069PatentMember_5c5e21f6-b729-4b34-8f52-6b53de2d3a37" xlink:href="regn-20230331.xsd#regn_A338PatentAnd069PatentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_366a787a-1952-4fa3-acfb-8e1a9094bd53" xlink:to="loc_regn_A338PatentAnd069PatentMember_5c5e21f6-b729-4b34-8f52-6b53de2d3a37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A631PatentMember_3e6f396f-6ed7-43b5-b721-216331a1a0b7" xlink:href="regn-20230331.xsd#regn_A631PatentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_366a787a-1952-4fa3-acfb-8e1a9094bd53" xlink:to="loc_regn_A631PatentMember_3e6f396f-6ed7-43b5-b721-216331a1a0b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0de13f45-0634-49fd-953e-55592dfb8d4f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_bb5cd0fb-e4dc-4599-8767-2876075120d4" xlink:to="loc_srt_ProductOrServiceAxis_0de13f45-0634-49fd-953e-55592dfb8d4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0de13f45-0634-49fd-953e-55592dfb8d4f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0de13f45-0634-49fd-953e-55592dfb8d4f" xlink:to="loc_srt_ProductsAndServicesDomain_0de13f45-0634-49fd-953e-55592dfb8d4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f9d0fb77-fa03-408e-982e-4aef96b1a83a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0de13f45-0634-49fd-953e-55592dfb8d4f" xlink:to="loc_srt_ProductsAndServicesDomain_f9d0fb77-fa03-408e-982e-4aef96b1a83a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EYLEAAfliberceptInjectionMember_df28e9a6-25dc-4da4-a507-5057b3081bd2" xlink:href="regn-20230331.xsd#regn_EYLEAAfliberceptInjectionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f9d0fb77-fa03-408e-982e-4aef96b1a83a" xlink:to="loc_regn_EYLEAAfliberceptInjectionMember_df28e9a6-25dc-4da4-a507-5057b3081bd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_33fced3e-e0fa-4c90-a00d-4a0843caeca6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_bb5cd0fb-e4dc-4599-8767-2876075120d4" xlink:to="loc_srt_CounterpartyNameAxis_33fced3e-e0fa-4c90-a00d-4a0843caeca6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_33fced3e-e0fa-4c90-a00d-4a0843caeca6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_33fced3e-e0fa-4c90-a00d-4a0843caeca6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_33fced3e-e0fa-4c90-a00d-4a0843caeca6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_178ee13d-16f6-4c06-ada7-5f9ec6b4aa23" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_33fced3e-e0fa-4c90-a00d-4a0843caeca6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_178ee13d-16f6-4c06-ada7-5f9ec6b4aa23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CelltrionIncMember_794572cd-e102-4362-ab53-03e403adc599" xlink:href="regn-20230331.xsd#regn_CelltrionIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_178ee13d-16f6-4c06-ada7-5f9ec6b4aa23" xlink:to="loc_regn_CelltrionIncMember_794572cd-e102-4362-ab53-03e403adc599" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ApotexIncMember_7c87b0a5-12c5-42a8-b44f-eada8e5435df" xlink:href="regn-20230331.xsd#regn_ApotexIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_178ee13d-16f6-4c06-ada7-5f9ec6b4aa23" xlink:to="loc_regn_ApotexIncMember_7c87b0a5-12c5-42a8-b44f-eada8e5435df" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>regn-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:22cd9e9c-8c6e-43d9-ac99-edd9ddfa2dcd,g:8ddcabf6-ffb8-41b1-9a90-14e4490a05f1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_4e9fa63d-4227-4656-bff5-5ca8c0278070_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued contingent consideration for Libtayo intangible asset</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_3d65a301-b1c1-4d73-b899-efe4f32cf5e0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_4b265fbf-3fbf-4bf5-b723-1d2dd6c45cd5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of Common Stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f90e706c-07a5-41f5-a97e-626206e6fcc4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6fb8af0a-ef93-4da2-ae7a-6f878e7a5ff7_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_44f53269-851f-49b2-a54d-7224418f6b56_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_UnrestrictedMember_baaee874-c87b-4bee-abba-b0182efa4614_terseLabel_en-US" xlink:label="lab_regn_UnrestrictedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrestricted</link:label>
    <link:label id="lab_regn_UnrestrictedMember_label_en-US" xlink:label="lab_regn_UnrestrictedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrestricted [Member]</link:label>
    <link:label id="lab_regn_UnrestrictedMember_documentation_en-US" xlink:label="lab_regn_UnrestrictedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments whose use is not restricted in whole or in part, by contractual agreements or regulatory requirements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UnrestrictedMember" xlink:href="regn-20230331.xsd#regn_UnrestrictedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_UnrestrictedMember" xlink:to="lab_regn_UnrestrictedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_f5397a87-d6dc-4d25-91b3-f6f082fb1583_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_MilestoneTypeDomain_e511ff10-4509-49b6-9b5f-719c356b2885_terseLabel_en-US" xlink:label="lab_regn_MilestoneTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Type [Domain]</link:label>
    <link:label id="lab_regn_MilestoneTypeDomain_label_en-US" xlink:label="lab_regn_MilestoneTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Type [Domain]</link:label>
    <link:label id="lab_regn_MilestoneTypeDomain_documentation_en-US" xlink:label="lab_regn_MilestoneTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MilestoneTypeDomain" xlink:href="regn-20230331.xsd#regn_MilestoneTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_MilestoneTypeDomain" xlink:to="lab_regn_MilestoneTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_e00b985a-11a7-415e-b382-3091db6a55f4_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_86158a47-d96e-472f-8885-0e221b92e20c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_b428cfe8-6260-4b12-9d9a-8ed86d4f6bf8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value and Unrealized Losses of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_8c7d4e90-8c80-4b66-bc59-e11e8502dc27_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_941c259e-7bf3-493e-bc24-480bc205917f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statements of Operations</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8da7344d-d85c-4620-8cc1-ed1983bbec09_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7c557181-a3c8-446f-8ccb-9cc19f76358c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_94d004ba-1f07-4ea1-bca6-6f70e660666e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ShareRepurchaseProgramNovember2021Member_e682ce7b-672f-44cb-b919-e9d336914485_terseLabel_en-US" xlink:label="lab_regn_ShareRepurchaseProgramNovember2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November 2021 Share Repurchase Program</link:label>
    <link:label id="lab_regn_ShareRepurchaseProgramNovember2021Member_label_en-US" xlink:label="lab_regn_ShareRepurchaseProgramNovember2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program, November 2021 [Member]</link:label>
    <link:label id="lab_regn_ShareRepurchaseProgramNovember2021Member_documentation_en-US" xlink:label="lab_regn_ShareRepurchaseProgramNovember2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program, November 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgramNovember2021Member" xlink:href="regn-20230331.xsd#regn_ShareRepurchaseProgramNovember2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ShareRepurchaseProgramNovember2021Member" xlink:to="lab_regn_ShareRepurchaseProgramNovember2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_427003b9-559f-45e7-b158-f74b939096b4_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods, collaboration and contract manufacturing</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e49dec8f-fc7d-4f0d-9c88-6f431f22adbe_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fbe6e469-1084-4f1d-af42-4c73873991df_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_f70b2281-e6e2-4b48-8b35-f35bf8b1b2bc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_NumberOfInterPartiesReviewIPRPetitionsFiled_5a153dcd-d6d4-4d5d-ad0c-a5e0907a3861_terseLabel_en-US" xlink:label="lab_regn_NumberOfInterPartiesReviewIPRPetitionsFiled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of IPR filed</link:label>
    <link:label id="lab_regn_NumberOfInterPartiesReviewIPRPetitionsFiled_label_en-US" xlink:label="lab_regn_NumberOfInterPartiesReviewIPRPetitionsFiled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Inter Parties Review (IPR) Petitions Filed</link:label>
    <link:label id="lab_regn_NumberOfInterPartiesReviewIPRPetitionsFiled_documentation_en-US" xlink:label="lab_regn_NumberOfInterPartiesReviewIPRPetitionsFiled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Inter Parties Review (IPR) Petitions Filed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_NumberOfInterPartiesReviewIPRPetitionsFiled" xlink:href="regn-20230331.xsd#regn_NumberOfInterPartiesReviewIPRPetitionsFiled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_NumberOfInterPartiesReviewIPRPetitionsFiled" xlink:to="lab_regn_NumberOfInterPartiesReviewIPRPetitionsFiled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_2daf8807-382a-4f7f-af71-99aeca2e9cce_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3783f24b-f790-4a48-b6d2-ba80b7bba84b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_870b0844-260e-45dd-acdf-21efb66fa00a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_200943a0-4709-4e0c-875d-155668e0e3ec_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_06567e84-08b2-42d0-aa0d-9f3e78875d32_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8291c031-d6a5-4019-a58f-06441b205de3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_A226PatentAnd992PatentMember_3f74b483-d4cc-410f-a5a0-c1e0980462ee_terseLabel_en-US" xlink:label="lab_regn_A226PatentAnd992PatentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'226 and '992 Patents</link:label>
    <link:label id="lab_regn_A226PatentAnd992PatentMember_label_en-US" xlink:label="lab_regn_A226PatentAnd992PatentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'226 Patent And '992 Patent [Member]</link:label>
    <link:label id="lab_regn_A226PatentAnd992PatentMember_documentation_en-US" xlink:label="lab_regn_A226PatentAnd992PatentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'226 Patent And '992 Patent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A226PatentAnd992PatentMember" xlink:href="regn-20230331.xsd#regn_A226PatentAnd992PatentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_A226PatentAnd992PatentMember" xlink:to="lab_regn_A226PatentAnd992PatentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ShareOfProfitLossesInConnectionWithCommercializationMember_deffaaad-b3c1-45ed-8749-a28fffbd7021_terseLabel_en-US" xlink:label="lab_regn_ShareOfProfitLossesInConnectionWithCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's share of profits in connection with commercialization</link:label>
    <link:label id="lab_regn_ShareOfProfitLossesInConnectionWithCommercializationMember_label_en-US" xlink:label="lab_regn_ShareOfProfitLossesInConnectionWithCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Of Profit (Losses) In Connection With Commercialization [Member]</link:label>
    <link:label id="lab_regn_ShareOfProfitLossesInConnectionWithCommercializationMember_documentation_en-US" xlink:label="lab_regn_ShareOfProfitLossesInConnectionWithCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Of Profit (Losses) In Connection With Commercialization [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareOfProfitLossesInConnectionWithCommercializationMember" xlink:href="regn-20230331.xsd#regn_ShareOfProfitLossesInConnectionWithCommercializationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ShareOfProfitLossesInConnectionWithCommercializationMember" xlink:to="lab_regn_ShareOfProfitLossesInConnectionWithCommercializationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_90297b4c-1cf4-41b5-890a-66ca246fd086_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_2f5d54d6-6a5a-48e4-8837-13d43cfbab46_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ShareRepurchaseProgramJanuary2023Member_b1d6857e-a317-4858-9ab6-62e3df4c1dbe_terseLabel_en-US" xlink:label="lab_regn_ShareRepurchaseProgramJanuary2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program, January 2023</link:label>
    <link:label id="lab_regn_ShareRepurchaseProgramJanuary2023Member_label_en-US" xlink:label="lab_regn_ShareRepurchaseProgramJanuary2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program, January 2023 [Member]</link:label>
    <link:label id="lab_regn_ShareRepurchaseProgramJanuary2023Member_documentation_en-US" xlink:label="lab_regn_ShareRepurchaseProgramJanuary2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program, January 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgramJanuary2023Member" xlink:href="regn-20230331.xsd#regn_ShareRepurchaseProgramJanuary2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ShareRepurchaseProgramJanuary2023Member" xlink:to="lab_regn_ShareRepurchaseProgramJanuary2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RestrictedMember_e236c7c1-d292-4a0d-88d9-ba029883a3d7_terseLabel_en-US" xlink:label="lab_regn_RestrictedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted</link:label>
    <link:label id="lab_regn_RestrictedMember_label_en-US" xlink:label="lab_regn_RestrictedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted [Member]</link:label>
    <link:label id="lab_regn_RestrictedMember_documentation_en-US" xlink:label="lab_regn_RestrictedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RestrictedMember" xlink:href="regn-20230331.xsd#regn_RestrictedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RestrictedMember" xlink:to="lab_regn_RestrictedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_68caa872-9cb7-4b9d-87ae-6dd86ad95fef_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_InmazebMember_63ed193d-956d-4d26-96a9-a66368660957_terseLabel_en-US" xlink:label="lab_regn_InmazebMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inmazeb</link:label>
    <link:label id="lab_regn_InmazebMember_label_en-US" xlink:label="lab_regn_InmazebMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inmazeb [Member]</link:label>
    <link:label id="lab_regn_InmazebMember_documentation_en-US" xlink:label="lab_regn_InmazebMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inmazeb</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_InmazebMember" xlink:href="regn-20230331.xsd#regn_InmazebMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_InmazebMember" xlink:to="lab_regn_InmazebMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SonomaBiotherapeuticsIncMember_c25c596e-683d-4984-a9d9-a14da014d8c1_terseLabel_en-US" xlink:label="lab_regn_SonomaBiotherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sonoma Biotherapeutics, Inc.</link:label>
    <link:label id="lab_regn_SonomaBiotherapeuticsIncMember_label_en-US" xlink:label="lab_regn_SonomaBiotherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sonoma Biotherapeutics, Inc. [Member]</link:label>
    <link:label id="lab_regn_SonomaBiotherapeuticsIncMember_documentation_en-US" xlink:label="lab_regn_SonomaBiotherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sonoma Biotherapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SonomaBiotherapeuticsIncMember" xlink:href="regn-20230331.xsd#regn_SonomaBiotherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SonomaBiotherapeuticsIncMember" xlink:to="lab_regn_SonomaBiotherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_74605602-757b-40dd-8f1d-216785ea5594_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_9ac513ac-cbe0-4445-b2bb-f78c970d8a94_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1240a320-40a5-44a7-b70f-11b48123176d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d840c29b-6174-4881-a6a4-4a19a786dd61_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assets measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_fc55b2ab-336d-44f8-8b67-332b42e8a16d_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales or maturities of marketable and other securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_2f7a336c-d7ae-4b3d-8748-9b7590fe0f0c_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_b54ec914-43d2-4929-9946-0e87a04ca3bd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_DevelopmentMilestoneMember_4a43d761-2c38-436a-a3eb-5624df3b3b5e_terseLabel_en-US" xlink:label="lab_regn_DevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestone</link:label>
    <link:label id="lab_regn_DevelopmentMilestoneMember_label_en-US" xlink:label="lab_regn_DevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestone [Member]</link:label>
    <link:label id="lab_regn_DevelopmentMilestoneMember_documentation_en-US" xlink:label="lab_regn_DevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DevelopmentMilestoneMember" xlink:href="regn-20230331.xsd#regn_DevelopmentMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_DevelopmentMilestoneMember" xlink:to="lab_regn_DevelopmentMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a28b4a38-5395-4954-9e6a-ae7d97cf20bc_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3d771ddb-202c-4eb4-8049-06c86c6838dd_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_743e9286-4014-4a0d-bded-103a11b9d87a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_01d1d443-0a8e-4dd0-8cc8-03f6e747bf76_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash items, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_70affe31-a308-44b1-b50a-61362561be2f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant, and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_51403f35-a90a-4b62-9b4b-2e4d3bc6f5b2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_86eefd72-f63a-4e49-87fc-5ecad215fb30_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_a79fb4cb-f4c9-4a2d-a76d-83ef8c27cdff_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost of shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_16c5d5df-3427-4e93-8c47-542f32b8bb60_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_8686a71f-9865-4bf7-bc4b-22d938293ed2_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c799c8d0-5753-4784-893e-c175d1d94ff4_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_78b410da-586c-4f13-b33b-33b6ab2b359e_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income - basic and diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_054c04b6-1cbe-4a11-a050-bd8b78055c27_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_29b398dc-afae-4d04-8a61-c274201f40a9_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_b376dc49-d92a-4c90-ab83-eaad87bd0b9d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_944a2606-0057-480d-b532-fea069de7a53_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_655e6bde-4759-4da5-a69a-376cffbe6524_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued capital expenditures</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_6c73ef96-5441-482d-b03f-a2a73056b82d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_e1929770-8b1f-4587-b998-2fc62d73d4f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_22e85dfc-da94-4fee-8791-bc01c46b56e4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6aed5bfd-16f6-4b49-b7fc-b385de49a54c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_cca8136b-2d3e-490c-818d-eb3c653481a1_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value - Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_MilestoneTypeAxis_0ac67aac-b984-4430-990e-39f4cfaee4ac_terseLabel_en-US" xlink:label="lab_regn_MilestoneTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Type [Axis]</link:label>
    <link:label id="lab_regn_MilestoneTypeAxis_label_en-US" xlink:label="lab_regn_MilestoneTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Type [Axis]</link:label>
    <link:label id="lab_regn_MilestoneTypeAxis_documentation_en-US" xlink:label="lab_regn_MilestoneTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MilestoneTypeAxis" xlink:href="regn-20230331.xsd#regn_MilestoneTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_MilestoneTypeAxis" xlink:to="lab_regn_MilestoneTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_fa1d55be-186c-49af-9781-3550b9d1cd43_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_32ff9d15-586a-436c-9e64-ad823cba62af_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_26e2d438-1a0e-43a2-b6b6-c1af94642c95_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_06e7e646-405d-433c-8c43-8b9e6986a079_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_6ac3c236-17b0-4696-a43c-62e8ef93a121_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure, Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SalesBasedMilestoneEarnedMember_b9d07345-fc5a-42f4-8751-5f95822a7cb0_terseLabel_en-US" xlink:label="lab_regn_SalesBasedMilestoneEarnedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based milestones earned</link:label>
    <link:label id="lab_regn_SalesBasedMilestoneEarnedMember_label_en-US" xlink:label="lab_regn_SalesBasedMilestoneEarnedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestone Earned [Member]</link:label>
    <link:label id="lab_regn_SalesBasedMilestoneEarnedMember_documentation_en-US" xlink:label="lab_regn_SalesBasedMilestoneEarnedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestone Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestoneEarnedMember" xlink:href="regn-20230331.xsd#regn_SalesBasedMilestoneEarnedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SalesBasedMilestoneEarnedMember" xlink:to="lab_regn_SalesBasedMilestoneEarnedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bf799fae-b151-44a5-893e-fcb7b369a04a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_ceb8a448-50fd-4ce4-9112-63f1b5c522c6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_00ba6cdf-f961-45f8-84b1-52fb8d1bf1e6_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount_2043090d-0b8f-41e7-b3eb-477fedb36658_terseLabel_en-US" xlink:label="lab_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, variable consideration amount</link:label>
    <link:label id="lab_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount_label_en-US" xlink:label="lab_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:label id="lab_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount_documentation_en-US" xlink:label="lab_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:href="regn-20230331.xsd#regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:to="lab_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_CollaborationandContractManufacturingMember_bcbf2e80-da02-458e-b895-e22db877faa6_terseLabel_en-US" xlink:label="lab_regn_CollaborationandContractManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of collaboration and contract manufacturing</link:label>
    <link:label id="lab_regn_CollaborationandContractManufacturingMember_label_en-US" xlink:label="lab_regn_CollaborationandContractManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Contract Manufacturing [Member]</link:label>
    <link:label id="lab_regn_CollaborationandContractManufacturingMember_documentation_en-US" xlink:label="lab_regn_CollaborationandContractManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Contract Manufacturing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationandContractManufacturingMember" xlink:href="regn-20230331.xsd#regn_CollaborationandContractManufacturingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_CollaborationandContractManufacturingMember" xlink:to="lab_regn_CollaborationandContractManufacturingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_McKessonCorporationMember_675aac54-9e51-48cd-8fd5-e5098aab00d2_terseLabel_en-US" xlink:label="lab_regn_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation</link:label>
    <link:label id="lab_regn_McKessonCorporationMember_label_en-US" xlink:label="lab_regn_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation [Member]</link:label>
    <link:label id="lab_regn_McKessonCorporationMember_documentation_en-US" xlink:label="lab_regn_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_McKessonCorporationMember" xlink:href="regn-20230331.xsd#regn_McKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_McKessonCorporationMember" xlink:to="lab_regn_McKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_EvkeezaMember_3d36a34a-00bc-4cc9-8f48-fdf1f42b01ae_terseLabel_en-US" xlink:label="lab_regn_EvkeezaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evkeeza</link:label>
    <link:label id="lab_regn_EvkeezaMember_label_en-US" xlink:label="lab_regn_EvkeezaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evkeeza [Member]</link:label>
    <link:label id="lab_regn_EvkeezaMember_documentation_en-US" xlink:label="lab_regn_EvkeezaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evkeeza</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EvkeezaMember" xlink:href="regn-20230331.xsd#regn_EvkeezaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_EvkeezaMember" xlink:to="lab_regn_EvkeezaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_9bc72e7b-e724-4d7b-a63a-757238a9c530_terseLabel_en-US" xlink:label="lab_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities after five years</link:label>
    <link:label id="lab_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_label_en-US" xlink:label="lab_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5</link:label>
    <link:label id="lab_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_documentation_en-US" xlink:label="lab_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:href="regn-20230331.xsd#regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:to="lab_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_c99dcac8-a53f-4a7f-a1b0-204915723ba0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, at cost; 23.5 shares in 2023 and 22.6 shares in 2022</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f5d39648-583b-46a6-bcaf-15cd973a94f2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f05c8401-a3d7-417b-9c23-ae01bcf96ac1_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_2173a221-ad8f-47f4-a730-7b8303dc7ae8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a2ff289c-c805-43d1-9627-7db846994b47_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_da4850f1-b1e5-44af-a30f-d941fb72823a_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8aefe06e-25f7-4a79-b211-6776c45e21f9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PaymentsToAcquireIntangibleAssets1_ed6d312c-90a2-44f3-8c26-1a34025c2b89_negatedTerseLabel_en-US" xlink:label="lab_regn_PaymentsToAcquireIntangibleAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Libtayo intangible asset</link:label>
    <link:label id="lab_regn_PaymentsToAcquireIntangibleAssets1_label_en-US" xlink:label="lab_regn_PaymentsToAcquireIntangibleAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Intangible Assets1</link:label>
    <link:label id="lab_regn_PaymentsToAcquireIntangibleAssets1_documentation_en-US" xlink:label="lab_regn_PaymentsToAcquireIntangibleAssets1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Intangible Assets1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PaymentsToAcquireIntangibleAssets1" xlink:href="regn-20230331.xsd#regn_PaymentsToAcquireIntangibleAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PaymentsToAcquireIntangibleAssets1" xlink:to="lab_regn_PaymentsToAcquireIntangibleAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_8fa60ec3-e6c4-49b4-90aa-f39535557f9b_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_765e19cb-b00d-43fe-af35-0da72f7e2b09_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_LIBTAYONetProductSalesMember_f1df69c8-f4a5-4a7b-9b8d-12df2237012a_terseLabel_en-US" xlink:label="lab_regn_LIBTAYONetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Libtayo</link:label>
    <link:label id="lab_regn_LIBTAYONetProductSalesMember_label_en-US" xlink:label="lab_regn_LIBTAYONetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBTAYO Net Product Sales [Member]</link:label>
    <link:label id="lab_regn_LIBTAYONetProductSalesMember_documentation_en-US" xlink:label="lab_regn_LIBTAYONetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBTAYO Net Product Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LIBTAYONetProductSalesMember" xlink:href="regn-20230331.xsd#regn_LIBTAYONetProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_LIBTAYONetProductSalesMember" xlink:to="lab_regn_LIBTAYONetProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_e87d4b74-caa8-4872-8c6c-46fb9f1a9722_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_9c1131c6-46f5-40ac-a523-6d628c90fe37_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_4b1e5683-1542-4ed2-a271-b037f3452715_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_67fb793e-5418-4610-b661-1ca7ed7de397_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_1facee9f-1fc1-4bfc-a8c1-6fcfb8b35b86_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember_ef0c14f5-ae17-4bdb-b33b-2e83cc459e21_terseLabel_en-US" xlink:label="lab_regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time payment in connection with change in Japan arrangement</link:label>
    <link:label id="lab_regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember_label_en-US" xlink:label="lab_regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time Payment in Connection With Change in Japan Arrangement [Member]</link:label>
    <link:label id="lab_regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember_documentation_en-US" xlink:label="lab_regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time Payment in Connection With Change in Japan Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember" xlink:href="regn-20230331.xsd#regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember" xlink:to="lab_regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ReimbursementForManufacturingOfExCommercialSuppliesMember_6258da5e-31df-4f36-8ddd-80acc104d27d_terseLabel_en-US" xlink:label="lab_regn_ReimbursementForManufacturingOfExCommercialSuppliesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement for manufacturing of ex-U.S. commercial supplies</link:label>
    <link:label id="lab_regn_ReimbursementForManufacturingOfExCommercialSuppliesMember_label_en-US" xlink:label="lab_regn_ReimbursementForManufacturingOfExCommercialSuppliesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement For Manufacturing Of ex-Commercial Supplies [Member]</link:label>
    <link:label id="lab_regn_ReimbursementForManufacturingOfExCommercialSuppliesMember_documentation_en-US" xlink:label="lab_regn_ReimbursementForManufacturingOfExCommercialSuppliesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement For Manufacturing Of ex-Commercial Supplies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementForManufacturingOfExCommercialSuppliesMember" xlink:href="regn-20230331.xsd#regn_ReimbursementForManufacturingOfExCommercialSuppliesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ReimbursementForManufacturingOfExCommercialSuppliesMember" xlink:to="lab_regn_ReimbursementForManufacturingOfExCommercialSuppliesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_GrossProductRevenueMember_3557b470-66a8-4603-b3db-1f66e16afee5_terseLabel_en-US" xlink:label="lab_regn_GrossProductRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross product revenue</link:label>
    <link:label id="lab_regn_GrossProductRevenueMember_label_en-US" xlink:label="lab_regn_GrossProductRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Product Revenue [Member]</link:label>
    <link:label id="lab_regn_GrossProductRevenueMember_documentation_en-US" xlink:label="lab_regn_GrossProductRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Sales Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_GrossProductRevenueMember" xlink:href="regn-20230331.xsd#regn_GrossProductRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_GrossProductRevenueMember" xlink:to="lab_regn_GrossProductRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_d73e517f-9f55-42d5-9221-c2d94c2d1512_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_4df0976f-9711-422a-b715-660f2c661904_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_EyleaNetProductSalesMember_3e7ac270-99fa-407b-87d9-8aaf66186334_terseLabel_en-US" xlink:label="lab_regn_EyleaNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EYLEA</link:label>
    <link:label id="lab_regn_EyleaNetProductSalesMember_label_en-US" xlink:label="lab_regn_EyleaNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EYLEA Net Product Sales [Member]</link:label>
    <link:label id="lab_regn_EyleaNetProductSalesMember_documentation_en-US" xlink:label="lab_regn_EyleaNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue during the period derived from a specified product line (EYLEA), after deducting applicable provisions for discounts, returns, rebates, chargebacks, distribution fees, and other sales-related deductions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EyleaNetProductSalesMember" xlink:href="regn-20230331.xsd#regn_EyleaNetProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_EyleaNetProductSalesMember" xlink:to="lab_regn_EyleaNetProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1b5f479b-84d8-4df7-b70e-80e088c8efec_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_1625bb16-8e7d-4cd1-bbfc-a67970ca88e6_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_NetProfitInConnectionWithCommercializationMember_e86b4e53-538c-452d-b826-d1e8b5ac8901_terseLabel_en-US" xlink:label="lab_regn_NetProfitInConnectionWithCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's share of profits in connection with commercialization of EYLEA outside the United States</link:label>
    <link:label id="lab_regn_NetProfitInConnectionWithCommercializationMember_label_en-US" xlink:label="lab_regn_NetProfitInConnectionWithCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Profit In Connection With Commercialization [Member]</link:label>
    <link:label id="lab_regn_NetProfitInConnectionWithCommercializationMember_documentation_en-US" xlink:label="lab_regn_NetProfitInConnectionWithCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Profit In Connection With Commercialization [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_NetProfitInConnectionWithCommercializationMember" xlink:href="regn-20230331.xsd#regn_NetProfitInConnectionWithCommercializationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_NetProfitInConnectionWithCommercializationMember" xlink:to="lab_regn_NetProfitInConnectionWithCommercializationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_b9a7f456-5b9b-4792-8c52-e17d90aba8a1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_bddcbcd2-32ef-42e2-8ff0-d082f5b1101f_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_f15a2439-fc67-40b3-906e-83de8a1bd2a1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_7b157ff4-0b8a-4f6a-a281-2050231ff7ac_verboseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_67893123-2dba-4f8e-a1bf-1c5adeb356a0_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_a58beed3-01bd-4bf4-9d9e-1482ea6a8bfd_terseLabel_en-US" xlink:label="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance/distribution of Common Stock for 401(k) Savings Plan</link:label>
    <link:label id="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_label_en-US" xlink:label="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued/Distributed During Period, Value, Employee Benefit Plan</link:label>
    <link:label id="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_documentation_en-US" xlink:label="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued/Distributed During Period, Value, Employee Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" xlink:href="regn-20230331.xsd#regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" xlink:to="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5af1af39-f762-4370-9e9f-8bf656282622_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_3477006b-54bf-4b16-8510-711c620a8157_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_80160437-e5fd-4bcf-b8e5-b5d332621b52_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_d5feddf3-bfa2-41cc-ac0e-8bd91c623d49_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_e73ae408-040a-4be1-9908-0c5e2f7651e3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_87c008a6-5bd9-4d3e-a400-2b24f03df89d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3ee80b6e-1071-4b27-ac7b-1add898cf2a7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_735567ce-2cec-4132-91e2-2f2f9e46a10c_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_fd86ebfb-6e75-44d5-ab25-9fbbef6ff490_verboseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_06170a82-9720-4748-8edc-8f309f7c1792_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts_dd1b142b-6b1f-4f42-8f2b-f3259930e149_terseLabel_en-US" xlink:label="lab_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage share of profits to reimburse collaborating party</link:label>
    <link:label id="lab_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts_label_en-US" xlink:label="lab_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Quarterly Profits Required To Be Paid For Reimbursement Of Development Costs</link:label>
    <link:label id="lab_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts_documentation_en-US" xlink:label="lab_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Quarterly Profits Required To Be Paid For Reimbursement Of Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts" xlink:href="regn-20230331.xsd#regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts" xlink:to="lab_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c3ccdbac-6dd9-44b3-a374-fbb364e12a31_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_e3f7b280-a0e4-41e0-93ed-3d76e61cb3d5_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_dd15b47f-5af5-4503-8e3e-c3718ed551d1_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_885da369-a1c8-48e3-ab5e-7c78bb168654_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f5fabc53-0703-43cb-ba31-1a349d206eaf_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_11b0f115-4a31-4810-b64c-d35a42c85d20_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_f4c02978-7a08-468c-adaf-2aa4100feddc_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f31c708-6386-484e-b4b1-d20872437918_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RonapreveMember_7319c4b7-c628-447d-b5bd-2148b9406f81_terseLabel_en-US" xlink:label="lab_regn_RonapreveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ronapreve</link:label>
    <link:label id="lab_regn_RonapreveMember_label_en-US" xlink:label="lab_regn_RonapreveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ronapreve [Member]</link:label>
    <link:label id="lab_regn_RonapreveMember_documentation_en-US" xlink:label="lab_regn_RonapreveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ronapreve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RonapreveMember" xlink:href="regn-20230331.xsd#regn_RonapreveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RonapreveMember" xlink:to="lab_regn_RonapreveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_155f966b-943a-45f0-b379-0f4cf5d3429c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_42d3e572-ff23-4dcd-a3ee-9dbd41a8ac21_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8fd89fed-bc07-4ee2-b5bb-4c01d698f230_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) increase in deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c2f2b4ed-81a5-445e-8ff3-3c64de5f57e8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_5cb0fc22-cfda-417b-8611-35eb71e5bbdd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_73b96f95-f4df-4a99-a4a6-7222048b90cb_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_101edd79-3421-467c-acaa-575f84989014_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_b35cff87-a8c5-463c-9ccc-60aef0bf3383_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_882fb878-82f4-4683-b500-203631648d53_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0328da1b-9467-40da-9196-5a92533e2c29_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_dd4ab2f7-f8ff-4ebe-a82f-4bd522c5e1d4_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty_16cdf3fb-01aa-4592-a098-0ec30a247f86_terseLabel_en-US" xlink:label="lab_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of trial costs required to be funded by collaborating party</link:label>
    <link:label id="lab_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty_label_en-US" xlink:label="lab_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Trial Costs Required To Be Funded By Collaborating Party</link:label>
    <link:label id="lab_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty_documentation_en-US" xlink:label="lab_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Trial Costs Required To Be Funded By Collaborating Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" xlink:href="regn-20230331.xsd#regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" xlink:to="lab_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_05031db3-4a24-4d78-9e7b-43f9874e96e5_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SalesBasedMilestonesMember_313f22fe-c1e3-42d3-b900-7f3bf971f24d_terseLabel_en-US" xlink:label="lab_regn_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestones</link:label>
    <link:label id="lab_regn_SalesBasedMilestonesMember_label_en-US" xlink:label="lab_regn_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestones [Member]</link:label>
    <link:label id="lab_regn_SalesBasedMilestonesMember_documentation_en-US" xlink:label="lab_regn_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestonesMember" xlink:href="regn-20230331.xsd#regn_SalesBasedMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SalesBasedMilestonesMember" xlink:to="lab_regn_SalesBasedMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales_b918d734-5fc0-4218-867d-6a3c443a736f_terseLabel_en-US" xlink:label="lab_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment to collaborating party, percentage of net product sales</link:label>
    <link:label id="lab_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales_label_en-US" xlink:label="lab_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Payment to Collaborating Party, Percentage of Net Product Sales</link:label>
    <link:label id="lab_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales_documentation_en-US" xlink:label="lab_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Payment to Collaborating Party, Percentage of Net Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales" xlink:href="regn-20230331.xsd#regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales" xlink:to="lab_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_bb1fae84-7e69-4eb3-b1e9-6ce56ed760f1_terseLabel_en-US" xlink:label="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for achieving sales target for milestone payment, rolling basis</link:label>
    <link:label id="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_label_en-US" xlink:label="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for Achieving Sales Target for Milestone Payment, Rolling Basis</link:label>
    <link:label id="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_documentation_en-US" xlink:label="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for Achieving Sales Target for Milestone Payment, Rolling Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" xlink:href="regn-20230331.xsd#regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" xlink:to="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_0948de5e-6e6b-43f1-9b1f-a419bdd698b8_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_93108f60-20d7-463e-92ff-386efb237db4_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_cae39948-7e99-435b-b86f-90b076ad2f97_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of sales to customers as percentage of total gross product revenue</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_60fd8273-7f2a-4fd5-851d-c126b5abb860_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Non-Cash Investing and Financing Activities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ClassificationOfInvestmentAxis_1e865e8a-cb47-4897-b22b-daa422781ed4_terseLabel_en-US" xlink:label="lab_regn_ClassificationOfInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classification of Investment [Axis]</link:label>
    <link:label id="lab_regn_ClassificationOfInvestmentAxis_label_en-US" xlink:label="lab_regn_ClassificationOfInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classification of Investment [Axis]</link:label>
    <link:label id="lab_regn_ClassificationOfInvestmentAxis_documentation_en-US" xlink:label="lab_regn_ClassificationOfInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents the general categories of investments, which may be classified as Unrestricted or Restricted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentAxis" xlink:href="regn-20230331.xsd#regn_ClassificationOfInvestmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ClassificationOfInvestmentAxis" xlink:to="lab_regn_ClassificationOfInvestmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_5b4c0445-f65c-4fa1-847e-21b097ac3021_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_d70e932d-f839-4758-9a1d-955095d4f5f7_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_8e05e464-6d30-4c35-aeec-536173185cb2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e637afaa-623a-4bf4-9e75-0baf08c3473e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_c632002c-7497-46fb-9aaf-c9ece11e6732_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interim Financial Statements</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_BesseMedicalMember_3ae2f980-f5a6-4f7b-ab2f-ccfa5f259365_terseLabel_en-US" xlink:label="lab_regn_BesseMedicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Besse Medical, a subsidiary of AmerisourceBergen Corporation</link:label>
    <link:label id="lab_regn_BesseMedicalMember_label_en-US" xlink:label="lab_regn_BesseMedicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Besse Medical [Member]</link:label>
    <link:label id="lab_regn_BesseMedicalMember_documentation_en-US" xlink:label="lab_regn_BesseMedicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Besse Medical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BesseMedicalMember" xlink:href="regn-20230331.xsd#regn_BesseMedicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_BesseMedicalMember" xlink:to="lab_regn_BesseMedicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_abc38b11-12fd-496f-abe9-f1ee6766c437_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SalesMilestoneThreeMember_2e0d0bf4-41a1-4b1a-9656-a7f1f8cdb360_terseLabel_en-US" xlink:label="lab_regn_SalesMilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Three</link:label>
    <link:label id="lab_regn_SalesMilestoneThreeMember_label_en-US" xlink:label="lab_regn_SalesMilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Three [Member]</link:label>
    <link:label id="lab_regn_SalesMilestoneThreeMember_documentation_en-US" xlink:label="lab_regn_SalesMilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestoneThreeMember" xlink:href="regn-20230331.xsd#regn_SalesMilestoneThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SalesMilestoneThreeMember" xlink:to="lab_regn_SalesMilestoneThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_e2e73961-1813-484c-bb9f-4a47e2668036_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accounts receivable and deferred revenue information</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ad2ef0e1-a767-4987-85fd-af397d095fde_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SalesBasedMilestoneTwoMember_4dffef31-33ca-4eca-8762-efaccdd3fb3d_terseLabel_en-US" xlink:label="lab_regn_SalesBasedMilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestone Two</link:label>
    <link:label id="lab_regn_SalesBasedMilestoneTwoMember_label_en-US" xlink:label="lab_regn_SalesBasedMilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestone Two [Member]</link:label>
    <link:label id="lab_regn_SalesBasedMilestoneTwoMember_documentation_en-US" xlink:label="lab_regn_SalesBasedMilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestone Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestoneTwoMember" xlink:href="regn-20230331.xsd#regn_SalesBasedMilestoneTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SalesBasedMilestoneTwoMember" xlink:to="lab_regn_SalesBasedMilestoneTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_9aeae7f2-aff1-4062-8fc7-40cda4d1a337_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_6aae67aa-5d81-4ad1-986f-b3bcfe50e13e_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_650e796d-3e1e-42b6-a528-d3423cc4919f_terseLabel_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sovereign bonds</link:label>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_482e447a-02b4-443e-a35c-f12e00744b43_verboseLabel_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sovereign bonds</link:label>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sovereign Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SovereignDebtSecuritiesMember" xlink:to="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_51da5868-50c1-42b7-ba21-e6518a1b8b30_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_1230d717-fd81-4a18-817a-eeebb299485f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_b837a254-eb76-4ce0-85a0-83e81608306e_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss - Less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_cedf3038-4013-4857-a639-609789bceb8a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_e5789884-5d70-47ed-8dd5-b76fb7990335_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_A631PatentMember_0fde6e63-3dab-4e98-8e17-f42e0452711f_terseLabel_en-US" xlink:label="lab_regn_A631PatentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'631 Patent</link:label>
    <link:label id="lab_regn_A631PatentMember_label_en-US" xlink:label="lab_regn_A631PatentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'631 Patent [Member]</link:label>
    <link:label id="lab_regn_A631PatentMember_documentation_en-US" xlink:label="lab_regn_A631PatentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'631 Patent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A631PatentMember" xlink:href="regn-20230331.xsd#regn_A631PatentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_A631PatentMember" xlink:to="lab_regn_A631PatentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7d3d1ade-8dea-4f2a-856b-eac02861a3ee_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SG&amp;A expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_7621f0b7-ca1c-40cf-afd8-e6473419bb8e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9cd242dd-a335-4d5e-86c2-c45bfe2ce000_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_349fdf7c-09cc-4ee8-846b-21603d31d836_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived_2ac5c49d-54fa-42f1-98b0-59d30137e59e_terseLabel_en-US" xlink:label="lab_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Levels of twelve-month sales at which sales milestone payments would be received</link:label>
    <link:label id="lab_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived_label_en-US" xlink:label="lab_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Levels Of Twelve Month Sales At Which Sales Milestone Payments Would Be Received</link:label>
    <link:label id="lab_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived_documentation_en-US" xlink:label="lab_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Levels Of Twelve Month Sales At Which Sales Milestone Payments Would Be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived" xlink:href="regn-20230331.xsd#regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived" xlink:to="lab_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_12353208-5cf3-49ff-a166-b77fecce5447_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss - 12 Months or Greater</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_7f2f49ff-6a89-4195-a511-b658feaa46f4_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d3dbc1d8-8ef6-41b0-95ef-4d2fa9e79723_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_02ed464c-b55e-4232-b3f8-c46a8fd80d60_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable</link:label>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAccountsReceivableMember" xlink:to="lab_us-gaap_TradeAccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7497d406-35f2-459d-af91-d888fbaa3196_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_91905341-72ae-4e23-bdc3-a9d47ddeae32_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_90d6f4a8-4fe1-496d-8346-d4f7995b7232_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f30df8e4-f0e1-4681-9409-28bb0ebf0ba6_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_cde968c6-7bff-4fc6-88a6-0652fe321520_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SalesMilestoneFiveMember_74917d91-6601-4042-a079-046decc9e590_terseLabel_en-US" xlink:label="lab_regn_SalesMilestoneFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Five</link:label>
    <link:label id="lab_regn_SalesMilestoneFiveMember_label_en-US" xlink:label="lab_regn_SalesMilestoneFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Five [Member]</link:label>
    <link:label id="lab_regn_SalesMilestoneFiveMember_documentation_en-US" xlink:label="lab_regn_SalesMilestoneFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestoneFiveMember" xlink:href="regn-20230331.xsd#regn_SalesMilestoneFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SalesMilestoneFiveMember" xlink:to="lab_regn_SalesMilestoneFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_724a6993-851e-4010-a562-7846e313ba71_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_71ea2490-d44b-4e8a-b4b8-136a393394e4_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_72d9f2e2-03ee-40b8-9ac3-4b00b74b60d9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_43fe1f71-5d75-486a-82cc-30488de14bf1_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_8c50c157-c013-4e6c-9434-df447cba70bf_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_6c80b3b8-d136-48c5-bf04-d560af3b2ee5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_4f579cec-bc62-4113-8f9e-3138418c9d8a_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statements of Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d364af2d-2ce4-437a-a23d-1497f9ef09f7_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_1c2bb5e1-9a3e-4834-9809-8a8ace5bb280_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_bba5c74e-10fb-4b67-81ce-6e6daf387efc_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3e04917e-9655-4069-a631-8492323c5569_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_a39a23ab-1387-45e7-a816-47c9649692e3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_aaf5880d-897e-440a-8679-b9057661ff16_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_a215fc61-1413-471e-8de6-90ba1fa2ea34_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Based on Contractual Maturity Dates</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_37b73524-5159-46b5-8a00-118d7fb64bad_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SanofiMember_5dc2668e-6d00-4dce-b03d-229de206ccbe_terseLabel_en-US" xlink:label="lab_regn_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi</link:label>
    <link:label id="lab_regn_SanofiMember_label_en-US" xlink:label="lab_regn_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi [Member]</link:label>
    <link:label id="lab_regn_SanofiMember_documentation_en-US" xlink:label="lab_regn_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiMember" xlink:href="regn-20230331.xsd#regn_SanofiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SanofiMember" xlink:to="lab_regn_SanofiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_cf79405c-dea0-49b0-b633-6d8c92c3fead_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_4ba267f0-ac5a-4f01-8e34-2c31cb88f871_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of Common Stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f2f2ff5d-9785-483a-a985-8d5429cb0e6b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ff967751-4e9f-4481-9bb6-267b90a893e3_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0fc72531-bee0-4757-a70b-0375be46cb71_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RegeneronsObligationOfResearchAndDevelopmentExpensesNetOfReimbursementOfResearchAndDevelopmentExpensesMember_bada81b9-d0b6-4f08-9fa3-cde935aa7906_terseLabel_en-US" xlink:label="lab_regn_RegeneronsObligationOfResearchAndDevelopmentExpensesNetOfReimbursementOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's obligation for its share of Bayer R&amp;D expenses, net of reimbursement of R&amp;D expenses</link:label>
    <link:label id="lab_regn_RegeneronsObligationOfResearchAndDevelopmentExpensesNetOfReimbursementOfResearchAndDevelopmentExpensesMember_label_en-US" xlink:label="lab_regn_RegeneronsObligationOfResearchAndDevelopmentExpensesNetOfReimbursementOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's Obligation Of Research And Development Expenses, Net of Reimbursement Of Research And Development Expenses [Member]</link:label>
    <link:label id="lab_regn_RegeneronsObligationOfResearchAndDevelopmentExpensesNetOfReimbursementOfResearchAndDevelopmentExpensesMember_documentation_en-US" xlink:label="lab_regn_RegeneronsObligationOfResearchAndDevelopmentExpensesNetOfReimbursementOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's Obligation Of Research And Development Expenses, Net of Reimbursement Of Research And Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegeneronsObligationOfResearchAndDevelopmentExpensesNetOfReimbursementOfResearchAndDevelopmentExpensesMember" xlink:href="regn-20230331.xsd#regn_RegeneronsObligationOfResearchAndDevelopmentExpensesNetOfReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RegeneronsObligationOfResearchAndDevelopmentExpensesNetOfReimbursementOfResearchAndDevelopmentExpensesMember" xlink:to="lab_regn_RegeneronsObligationOfResearchAndDevelopmentExpensesNetOfReimbursementOfResearchAndDevelopmentExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_13e79250-6ce2-4da7-9189-c861e7ec0dc6_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss - Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_UpFrontPaymentToCollaboratingParty_f289c0e5-b61a-42e0-9961-931aab0e9aaa_terseLabel_en-US" xlink:label="lab_regn_UpFrontPaymentToCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-front payment to collaborating party</link:label>
    <link:label id="lab_regn_UpFrontPaymentToCollaboratingParty_label_en-US" xlink:label="lab_regn_UpFrontPaymentToCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-Front Payment to Collaborating Party</link:label>
    <link:label id="lab_regn_UpFrontPaymentToCollaboratingParty_documentation_en-US" xlink:label="lab_regn_UpFrontPaymentToCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-Front Payment to Collaborating Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UpFrontPaymentToCollaboratingParty" xlink:href="regn-20230331.xsd#regn_UpFrontPaymentToCollaboratingParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_UpFrontPaymentToCollaboratingParty" xlink:to="lab_regn_UpFrontPaymentToCollaboratingParty" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_7714012e-145a-4483-8ceb-9fe523b91225_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RocheCollaborationAgreementMember_f71613c0-f2e7-4fa3-9714-8cc975213c8d_terseLabel_en-US" xlink:label="lab_regn_RocheCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche Collaboration Agreement</link:label>
    <link:label id="lab_regn_RocheCollaborationAgreementMember_label_en-US" xlink:label="lab_regn_RocheCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche Collaboration Agreement [Member]</link:label>
    <link:label id="lab_regn_RocheCollaborationAgreementMember_documentation_en-US" xlink:label="lab_regn_RocheCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RocheCollaborationAgreementMember" xlink:href="regn-20230331.xsd#regn_RocheCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RocheCollaborationAgreementMember" xlink:to="lab_regn_RocheCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_846c94e5-7da6-43cd-97a6-68a788e9223f_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_5a10936d-4369-48f2-8934-ab8adc91fac0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_dcda4ba8-e301-4ea0-bc53-2e04295b5fae_totalLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total adjustments</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_4b6252ab-bec0-4267-a8c2-0eaa5b6fce50_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, par value $.01 per share; 30.0 shares authorized; issued and outstanding - none</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_07ba1840-a1cf-445d-8549-67a697d383c9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards and restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_7b89c90f-a722-4bdd-b530-ea7e9e50809f_terseLabel_en-US" xlink:label="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement for manufacturing of commercial supplies</link:label>
    <link:label id="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_8b0f1325-a62f-4e0e-a07d-16e8380d4da5_verboseLabel_en-US" xlink:label="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement for manufacturing of ex-U.S. commercial supplies</link:label>
    <link:label id="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_label_en-US" xlink:label="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement For Manufacturing Of Commercial Supplies [Member]</link:label>
    <link:label id="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_documentation_en-US" xlink:label="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement For Manufacturing Of Commercial Supplies [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember" xlink:href="regn-20230331.xsd#regn_ReimbursementForManufacturingOfCommercialSuppliesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember" xlink:to="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_33922461-c1fb-4a69-9ca5-a3c93fd8343f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_25b8818e-84a8-4891-8ef1-20c6dd2f3d18_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-front payment to be made to collaborator</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_69c38008-726f-4dbe-8d37-9f5c685f3b14_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_451fe322-50e9-40c4-ab43-f5cf1eaeb949_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_0c03f92c-047c-4d6a-a086-77b77922697c_netLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_9889600d-8ae1-40dd-9d6a-a66418e48e89_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_a89b2740-64a8-4f8f-aa5d-9e82f5c51fb9_terseLabel_en-US" xlink:label="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts recognized in connection with up-front payments received</link:label>
    <link:label id="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_label_en-US" xlink:label="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Recognized In Connection With Up-Front Payments [Member]</link:label>
    <link:label id="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_documentation_en-US" xlink:label="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Recognized In Connection With Up-Front Payments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" xlink:href="regn-20230331.xsd#regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" xlink:to="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts_e63c3d69-1325-481f-bee7-0e23bbd6cb14_terseLabel_en-US" xlink:label="lab_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of share of profits used to reimburse collaborating party for trial costs</link:label>
    <link:label id="lab_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts_label_en-US" xlink:label="lab_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Share of Profits Used to Reimburse Collaborating Party for Trial Costs</link:label>
    <link:label id="lab_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts_documentation_en-US" xlink:label="lab_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Share of Profits Used to Reimburse Collaborating Party for Trial Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts" xlink:href="regn-20230331.xsd#regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts" xlink:to="lab_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_bc8eb8e0-c9d9-49bc-9afa-470e53ba1e5d_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SalesBasedMilestoneOneMember_b0c9999f-bde3-4618-9aaf-2e9878d51781_terseLabel_en-US" xlink:label="lab_regn_SalesBasedMilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestone One</link:label>
    <link:label id="lab_regn_SalesBasedMilestoneOneMember_label_en-US" xlink:label="lab_regn_SalesBasedMilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestone One [Member]</link:label>
    <link:label id="lab_regn_SalesBasedMilestoneOneMember_documentation_en-US" xlink:label="lab_regn_SalesBasedMilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestone One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestoneOneMember" xlink:href="regn-20230331.xsd#regn_SalesBasedMilestoneOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SalesBasedMilestoneOneMember" xlink:to="lab_regn_SalesBasedMilestoneOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_16b08f73-318d-4108-8f91-b0c888ff56f8_terseLabel_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters</link:label>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:to="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_18940579-f6d0-4acd-8685-1a42ed84814a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_9b525a4c-8c4b-4dd0-b8d1-55a192ca85f7_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_63d7e044-d60b-4ace-8d7b-186b815e5b61_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_MarketableAndOtherSecuritiesGainLoss_47dc834f-e1cc-4d8e-aa9e-646326b4714e_negatedTerseLabel_en-US" xlink:label="lab_regn_MarketableAndOtherSecuritiesGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses on marketable and other securities, net</link:label>
    <link:label id="lab_regn_MarketableAndOtherSecuritiesGainLoss_label_en-US" xlink:label="lab_regn_MarketableAndOtherSecuritiesGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable and Other Securities, Gain (Loss)</link:label>
    <link:label id="lab_regn_MarketableAndOtherSecuritiesGainLoss_documentation_en-US" xlink:label="lab_regn_MarketableAndOtherSecuritiesGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable and Other Securities, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MarketableAndOtherSecuritiesGainLoss" xlink:href="regn-20230331.xsd#regn_MarketableAndOtherSecuritiesGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_MarketableAndOtherSecuritiesGainLoss" xlink:to="lab_regn_MarketableAndOtherSecuritiesGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_a3638bc5-8a4c-49e8-ac99-e434a28a52a4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_078f08cc-69b7-4972-937d-ccac1d2dd555_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_ba4e9900-f9b1-4a30-8eef-75c609a65076_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_89e6b8dc-f27e-4cb9-bce4-584f323a55e1_terseLabel_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of R&amp;D expenses</link:label>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_label_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Research And Development Expenses [Member]</link:label>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_documentation_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Research And Development Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember" xlink:href="regn-20230331.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember" xlink:to="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_18ccf9b2-a43a-4c61-a65f-7424a18c7033_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_0cdf9eab-2194-475f-9243-b44a80ae1ee6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6e1ec2ee-24c4-4298-bcba-208d63b02905_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_CollaborationRevenueMember_2e8b2aa5-583f-41dd-a5c7-676b71457efd_terseLabel_en-US" xlink:label="lab_regn_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_regn_CollaborationRevenueMember_label_en-US" xlink:label="lab_regn_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue [Member]</link:label>
    <link:label id="lab_regn_CollaborationRevenueMember_documentation_en-US" xlink:label="lab_regn_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationRevenueMember" xlink:href="regn-20230331.xsd#regn_CollaborationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_CollaborationRevenueMember" xlink:to="lab_regn_CollaborationRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_4db5eb96-504a-4e1a-a524-33d5a6700548_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_c9c52c1b-329e-45e2-a1c5-445131a6597c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ClassificationOfInvestmentDomain_8634473c-3d01-488e-826f-a92639e17500_terseLabel_en-US" xlink:label="lab_regn_ClassificationOfInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classification of Investment [Domain]</link:label>
    <link:label id="lab_regn_ClassificationOfInvestmentDomain_label_en-US" xlink:label="lab_regn_ClassificationOfInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classification of Investment [Domain]</link:label>
    <link:label id="lab_regn_ClassificationOfInvestmentDomain_documentation_en-US" xlink:label="lab_regn_ClassificationOfInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provides general categories of investments for which information is required or determined to be disclosed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentDomain" xlink:href="regn-20230331.xsd#regn_ClassificationOfInvestmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ClassificationOfInvestmentDomain" xlink:to="lab_regn_ClassificationOfInvestmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b1a38502-3f0f-42bd-85a7-3f082e89d4a9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments in connection with Common Stock tendered for employee tax obligations</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_dc85e0dd-6dd0-4ccd-84f1-58c967b72d17_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_0a5322c9-987f-4940-a18a-2dc926ddc0b3_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_f336b636-3827-48bf-b1ff-92525009be0b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PraluentNetProductSalesMember_df2d47f1-14bd-4049-a7d5-8306a817579c_terseLabel_en-US" xlink:label="lab_regn_PraluentNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Praluent</link:label>
    <link:label id="lab_regn_PraluentNetProductSalesMember_label_en-US" xlink:label="lab_regn_PraluentNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Praluent Net Product Sales [Member]</link:label>
    <link:label id="lab_regn_PraluentNetProductSalesMember_documentation_en-US" xlink:label="lab_regn_PraluentNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Praluent Net Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PraluentNetProductSalesMember" xlink:href="regn-20230331.xsd#regn_PraluentNetProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PraluentNetProductSalesMember" xlink:to="lab_regn_PraluentNetProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_4781c3ea-e1be-44ca-aae0-4f2b2541d460_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_68a5e0b8-985f-4a26-a3d7-fa435172b7f6_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, treasury (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_ab591580-417a-4913-ad33-1011472baf12_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, treasury (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember_7b6a45ce-2180-4a9b-b857-83d378a272fb_terseLabel_en-US" xlink:label="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of commercialization-related expenses</link:label>
    <link:label id="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember_label_en-US" xlink:label="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Commercialization-Related Expenses [Member]</link:label>
    <link:label id="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember_documentation_en-US" xlink:label="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Commercialization-Related Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfCommercializationRelatedExpensesMember" xlink:href="regn-20230331.xsd#regn_ReimbursementOfCommercializationRelatedExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ReimbursementOfCommercializationRelatedExpensesMember" xlink:to="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_c2112fab-ad8c-45f9-a52b-02b224721332_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_d6b6bbad-86da-429c-8de4-c8985f859de8_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining authorized repurchase amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_6850abff-6923-4ee3-b5a9-769e58651626_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_d45ad8f0-c669-4dfa-893b-81e737c7babc_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_d316df54-e836-47a8-80ae-4e956b1ccdf3_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside United States</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6e70e21d-2418-41e1-956e-c6c0a82a6f6c_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_d087af84-e7c3-4eff-8997-98f3b2bfc373_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_a3a4f891-b6d9-4b8f-b8d7-bcecee2e6d6b_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ef13b2df-f7e7-4c0c-98d3-9ca659c93c8a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3c8a99d5-1631-4679-8fe2-c2131cc5685c_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_479f1cdb-193a-42d4-8a40-ad0d59317552_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_44ce96bf-a348-4aad-9768-a0f77500e5a8_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_34296b00-9729-40e5-84d8-2d2600a40237_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:to="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_64cca5ee-0e69-4151-b370-98033fc632a4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_471549bd-9e7d-4141-a349-ce3120bec8e8_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_00497d63-a752-4ab6-8f30-f584b417d949_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8d25faa3-deac-424f-b125-39373f63f37f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_BayerCollaborationAgreementMember_ac58536b-3e82-4a8f-b2fa-26c677314686_terseLabel_en-US" xlink:label="lab_regn_BayerCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer</link:label>
    <link:label id="lab_regn_BayerCollaborationAgreementMember_label_en-US" xlink:label="lab_regn_BayerCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer Collaboration Agreement [Member]</link:label>
    <link:label id="lab_regn_BayerCollaborationAgreementMember_documentation_en-US" xlink:label="lab_regn_BayerCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer Collaboration Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember" xlink:href="regn-20230331.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_BayerCollaborationAgreementMember" xlink:to="lab_regn_BayerCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f5227507-43c5-4d00-9dc9-712a371c3b64_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation charges</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_bdcd6260-6a28-4b79-a093-f2be129d883b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_762263b7-dc57-41ab-b634-1c22920ffcca_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_08ed236a-2bf3-4cf1-bd73-a2c3f949213a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_bda58b18-a086-49d0-b4db-a0b12d5dde4d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventoryNetOfReserves_9daa7c7a-5c25-49ab-9daf-9ec6501797ef_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventoryNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred costs</link:label>
    <link:label id="lab_us-gaap_OtherInventoryNetOfReserves_label_en-US" xlink:label="lab_us-gaap_OtherInventoryNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventoryNetOfReserves" xlink:to="lab_us-gaap_OtherInventoryNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SonomaBiotherapeuticsIncCollaborationAgreementMember_e3fe187c-6aab-47ca-bc40-4b6a2dd03c05_terseLabel_en-US" xlink:label="lab_regn_SonomaBiotherapeuticsIncCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sonoma Biotherapeutics, Inc. Collaboration Agreement</link:label>
    <link:label id="lab_regn_SonomaBiotherapeuticsIncCollaborationAgreementMember_label_en-US" xlink:label="lab_regn_SonomaBiotherapeuticsIncCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sonoma Biotherapeutics, Inc. Collaboration Agreement [Member]</link:label>
    <link:label id="lab_regn_SonomaBiotherapeuticsIncCollaborationAgreementMember_documentation_en-US" xlink:label="lab_regn_SonomaBiotherapeuticsIncCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sonoma Biotherapeutics, Inc. Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SonomaBiotherapeuticsIncCollaborationAgreementMember" xlink:href="regn-20230331.xsd#regn_SonomaBiotherapeuticsIncCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SonomaBiotherapeuticsIncCollaborationAgreementMember" xlink:to="lab_regn_SonomaBiotherapeuticsIncCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_CelltrionIncMember_c573dbc7-b574-43a5-9f00-63a691c9886b_terseLabel_en-US" xlink:label="lab_regn_CelltrionIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Celltrion, Inc.</link:label>
    <link:label id="lab_regn_CelltrionIncMember_label_en-US" xlink:label="lab_regn_CelltrionIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Celltrion, Inc. [Member]</link:label>
    <link:label id="lab_regn_CelltrionIncMember_documentation_en-US" xlink:label="lab_regn_CelltrionIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Celltrion, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CelltrionIncMember" xlink:href="regn-20230331.xsd#regn_CelltrionIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_CelltrionIncMember" xlink:to="lab_regn_CelltrionIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_e5cd8076-ada3-4dd2-8795-f0562113dc57_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9c9dbbe9-12b8-4ba7-9ef4-ae89d70290e8_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in accounts payable, accrued expenses, and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_bd595631-2d50-4944-965f-e5744a40cb1e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_569bab9c-a5cb-48b2-9c78-423c849ff526_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer concentration risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_ae672484-3a1a-460a-87fd-da6a17f60be5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_47d65981-78f6-446d-948c-6f282a4b833d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value - 12 Months or Greater</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RegulatoryMilestoneMember_422a5b0b-5578-4c6b-8db8-c54696e22d43_terseLabel_en-US" xlink:label="lab_regn_RegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestone</link:label>
    <link:label id="lab_regn_RegulatoryMilestoneMember_label_en-US" xlink:label="lab_regn_RegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestone [Member]</link:label>
    <link:label id="lab_regn_RegulatoryMilestoneMember_documentation_en-US" xlink:label="lab_regn_RegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegulatoryMilestoneMember" xlink:href="regn-20230331.xsd#regn_RegulatoryMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RegulatoryMilestoneMember" xlink:to="lab_regn_RegulatoryMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ResearchAndDevelopmentExpensesAndReductionOfResearchAndDevelopmentExpenseMember_9691d0f1-4f07-4f30-9d7e-4cf546b7dec9_terseLabel_en-US" xlink:label="lab_regn_ResearchAndDevelopmentExpensesAndReductionOfResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(R&amp;D expense)/Reduction of R&amp;D expense</link:label>
    <link:label id="lab_regn_ResearchAndDevelopmentExpensesAndReductionOfResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_regn_ResearchAndDevelopmentExpensesAndReductionOfResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expenses And Reduction of Research And Development Expense [Member]</link:label>
    <link:label id="lab_regn_ResearchAndDevelopmentExpensesAndReductionOfResearchAndDevelopmentExpenseMember_documentation_en-US" xlink:label="lab_regn_ResearchAndDevelopmentExpensesAndReductionOfResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expenses And Reduction of Research And Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchAndDevelopmentExpensesAndReductionOfResearchAndDevelopmentExpenseMember" xlink:href="regn-20230331.xsd#regn_ResearchAndDevelopmentExpensesAndReductionOfResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ResearchAndDevelopmentExpensesAndReductionOfResearchAndDevelopmentExpenseMember" xlink:to="lab_regn_ResearchAndDevelopmentExpensesAndReductionOfResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_381d3604-006a-4faf-86bc-d4c35d714c80_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_6360fa5b-5898-48f3-aa48-7dd3bf856497_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_a61726d7-5a23-4501-ae3c-6171ec24d632_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_59273617-d895-4451-b8db-06333b45aa02_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses on marketable and other securities, net</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RestOfWorldMember_773f378f-394d-458f-8bf1-416e7f79ccbe_terseLabel_en-US" xlink:label="lab_regn_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROW</link:label>
    <link:label id="lab_regn_RestOfWorldMember_label_en-US" xlink:label="lab_regn_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest Of World [Member]</link:label>
    <link:label id="lab_regn_RestOfWorldMember_documentation_en-US" xlink:label="lab_regn_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest Of World</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RestOfWorldMember" xlink:href="regn-20230331.xsd#regn_RestOfWorldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RestOfWorldMember" xlink:to="lab_regn_RestOfWorldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_10768f8d-8ea7-4bcf-aff2-840916a0d7a0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_d50e2ab6-83d2-4eed-845c-f1e8578c6f2d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_8b13aeab-0014-41a1-a5e7-54236ae3736d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_01c9138c-e099-4095-8100-c0f381dcb5dd_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b7dc682c-a2a6-4a87-b27d-a553e78fbeac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_432baef1-ead2-4fc9-8095-ee21a8c489ab_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_d37c6471-624d-4de8-8d6e-9223c6cd21c6_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_25e05e50-88ea-49aa-8175-1effcecfcbd6_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_8b61c591-b129-4b5a-9017-96a93a658e1e_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_7f94941d-0bf3-4aa4-83f2-2d06da814095_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_c5ea0c93-ce07-43f2-8d04-eddac8e2f633_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_d60d0189-42ed-448d-839c-719af482e61d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ApotexIncMember_c3e93a1a-a009-49a8-832e-e4262e246355_terseLabel_en-US" xlink:label="lab_regn_ApotexIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apotex Inc.</link:label>
    <link:label id="lab_regn_ApotexIncMember_label_en-US" xlink:label="lab_regn_ApotexIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apotex Inc. [Member]</link:label>
    <link:label id="lab_regn_ApotexIncMember_documentation_en-US" xlink:label="lab_regn_ApotexIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apotex Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ApotexIncMember" xlink:href="regn-20230331.xsd#regn_ApotexIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ApotexIncMember" xlink:to="lab_regn_ApotexIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_6c8c5bdc-7d51-4171-851d-a5efebf74df9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_5605232d-6f51-4c7e-999a-5e9c07e6e6ee_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e1ed39f8-0b17-4eb6-9673-eb6d27ab89b0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on debt securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_51d6797a-5d72-4d1f-b525-914676b6d36e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_57004ca3-101c-48e0-be93-40b0b6766e21_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory valuation reserves</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_64afcbc9-bc4d-493b-8b7a-5c0e712b7baa_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_bcfacab4-e07d-4ec3-9b1d-a940c0bb4e28_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_e01363c0-8fcb-42cf-bf20-ce0a31386d98_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_71f82db8-9983-4b49-bb75-7b93d4838238_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_602712c5-cde1-42d6-9a12-22e035d279d4_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_a8dfe98c-4978-446f-92be-4461e2a39db3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_5388c7e0-b964-418d-8777-82886698dd69_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_6786b7d3-d44f-4de1-baf5-ca952e5890e6_netLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_d9b43521-6327-4373-8ff9-c7451cd51e14_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_9f71d978-6f40-4d00-ae01-52f25d57ffef_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8c2aa35a-5e98-4a70-958f-10341c2ec3dd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Common Stock for equity awards granted under long-term incentive plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProjectMember_4561b272-5417-40b7-a649-0def7e33c6d4_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:label id="lab_us-gaap_ProjectMember_label_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember" xlink:to="lab_us-gaap_ProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_CostOfGoodsSoldMember_4a112898-d455-4f31-a86e-4060673fe469_terseLabel_en-US" xlink:label="lab_regn_CostOfGoodsSoldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_regn_CostOfGoodsSoldMember_label_en-US" xlink:label="lab_regn_CostOfGoodsSoldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Goods Sold [Member]</link:label>
    <link:label id="lab_regn_CostOfGoodsSoldMember_documentation_en-US" xlink:label="lab_regn_CostOfGoodsSoldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CostOfGoodsSoldMember" xlink:href="regn-20230331.xsd#regn_CostOfGoodsSoldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_CostOfGoodsSoldMember" xlink:to="lab_regn_CostOfGoodsSoldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_736982c4-45ea-454b-9fcb-b0e050559777_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of Common Stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_c1090f26-c777-495e-bcb2-318286ebe738_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_71589a82-8657-4750-bf2e-0bf57c1b3031_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RegeneronsShareOfCommercialExpensesMember_c8a1a741-9c24-4f20-a206-e92f2d54441a_terseLabel_en-US" xlink:label="lab_regn_RegeneronsShareOfCommercialExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's obligation for its share of Sanofi commercial expenses</link:label>
    <link:label id="lab_regn_RegeneronsShareOfCommercialExpensesMember_label_en-US" xlink:label="lab_regn_RegeneronsShareOfCommercialExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's Share Of Commercial Expenses [Member]</link:label>
    <link:label id="lab_regn_RegeneronsShareOfCommercialExpensesMember_documentation_en-US" xlink:label="lab_regn_RegeneronsShareOfCommercialExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's Share Of Commercial Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegeneronsShareOfCommercialExpensesMember" xlink:href="regn-20230331.xsd#regn_RegeneronsShareOfCommercialExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RegeneronsShareOfCommercialExpensesMember" xlink:to="lab_regn_RegeneronsShareOfCommercialExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_82509bf8-3107-4cc8-9348-d1d32273525d_verboseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of product sales</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_fd1c31bc-e11e-4988-b6bf-8dfc990d9e86_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of collaborative revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SanofiCollaborationAgreementAntibodyMember_89f9eb21-ba50-4d5b-9012-7f4db6253959_terseLabel_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementAntibodyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Antibody</link:label>
    <link:label id="lab_regn_SanofiCollaborationAgreementAntibodyMember_label_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementAntibodyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Antibody [Member]</link:label>
    <link:label id="lab_regn_SanofiCollaborationAgreementAntibodyMember_documentation_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementAntibodyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Antibody [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember" xlink:href="regn-20230331.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SanofiCollaborationAgreementAntibodyMember" xlink:to="lab_regn_SanofiCollaborationAgreementAntibodyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_4df0d266-6f4a-49de-80df-c9c022b3a91f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_6fb56982-8df0-464f-a1b0-06a990ded54b_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_936b7080-7e3b-4c35-b83a-4fd16e2f320e_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_A338PatentAnd069PatentMember_48462ff4-dfd6-4396-8802-6b8b13b83244_terseLabel_en-US" xlink:label="lab_regn_A338PatentAnd069PatentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'338 Patent And '069 Patent</link:label>
    <link:label id="lab_regn_A338PatentAnd069PatentMember_label_en-US" xlink:label="lab_regn_A338PatentAnd069PatentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'338 Patent And '069 Patent [Member]</link:label>
    <link:label id="lab_regn_A338PatentAnd069PatentMember_documentation_en-US" xlink:label="lab_regn_A338PatentAnd069PatentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'338 Patent And '069 Patent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A338PatentAnd069PatentMember" xlink:href="regn-20230331.xsd#regn_A338PatentAnd069PatentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_A338PatentAnd069PatentMember" xlink:to="lab_regn_A338PatentAnd069PatentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_8981ed83-a5aa-4227-9d6a-f94e28248624_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_dd757757-38ef-49d2-a7e6-a866daa4620c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_1f8a8464-c0aa-4b20-bc5e-e3baeac379bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shares Repurchased</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_5ce9255c-50e2-4adf-bec0-a72f50efc54e_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_33af1038-2c2a-4f18-beee-19d9acc07146_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d80df6d1-3026-4d48-a2bf-8d374b729f46_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_21d3599c-20bb-4f57-a0d1-d068123bd15d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_442c9b32-b53b-4687-a74a-0d003a2f1e3b_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_cf997c0e-ec6d-43f1-85b6-afb9e06724d3_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_2540fb94-48ee-4399-a76c-4cacc53c3d6a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_f94494f7-88d2-4f4a-8eee-7a47c975af1d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable and other securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_90f6f582-25e3-479a-bf41-927dd96c76ca_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_f42a99f8-d9a2-4078-9bd5-c8becd649de6_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and government agency obligations</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_5455075b-d6e4-4fa7-9fdf-80a69d5b03d8_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and government agency obligations</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_fb947260-7bf3-4702-8f12-a06ce74d3c48_netLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and government agency obligations</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_edfec75b-e3e5-4b81-b67b-04b35f05bc59_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_f2099e2c-2fe8-437b-b8d8-c3974cdb9562_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_6f5154bd-6866-4376-98c4-3e44cf27d04a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_552111f4-c34d-42b1-9d43-f88e74c6b192_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measured on a recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_e2609cf1-c3c9-404a-b61c-dccfbf14a99a_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_892fb1ac-bd25-4cfd-9384-99b38a769915_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration, License, and Other Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_cfed57a3-b327-4aaa-97e3-4d87e0345b49_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value - Less than 12 Months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_ebac4c44-b782-476f-aef5-caa7fbc6be48_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_5207384b-0c6f-4229-babf-27c4cb2073b5_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_87f11b44-2c6f-4603-b618-c41973aed96b_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1c01bf0-2982-4d84-b5c3-41975ba1abce_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_72703432-4c71-4b99-8b6b-a8bb1449a9d6_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_e1445cf1-e5c3-480a-b943-490e30d6f4cb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_95fb92fd-878e-4ec0-b735-47d8dd357edc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_867b9edd-917c-4956-9fc2-ab8cafbd40bc_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_3b5d8e86-b3bd-4b9e-9310-2680e731790a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_EYLEAAfliberceptInjectionMember_54f5b550-f05e-4e4e-954c-ca442b1403e1_terseLabel_en-US" xlink:label="lab_regn_EYLEAAfliberceptInjectionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EYLEA</link:label>
    <link:label id="lab_regn_EYLEAAfliberceptInjectionMember_label_en-US" xlink:label="lab_regn_EYLEAAfliberceptInjectionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EYLEA Aflibercept Injection [Member]</link:label>
    <link:label id="lab_regn_EYLEAAfliberceptInjectionMember_documentation_en-US" xlink:label="lab_regn_EYLEAAfliberceptInjectionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EYLEA Aflibercept Injection</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EYLEAAfliberceptInjectionMember" xlink:href="regn-20230331.xsd#regn_EYLEAAfliberceptInjectionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_EYLEAAfliberceptInjectionMember" xlink:to="lab_regn_EYLEAAfliberceptInjectionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_cf98c1e6-11d2-45b7-95f1-2703484863c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_dfcd0c4c-4ce6-460a-9e05-7a44a1fb84b3_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_38a4794d-07b2-4626-a43e-a8c1d0b70c6d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SanofiCollaborationAgreementImmunooncologyMember_79c922e7-b720-4f70-8481-0ec350e5015c_terseLabel_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Immuno-oncology</link:label>
    <link:label id="lab_regn_SanofiCollaborationAgreementImmunooncologyMember_b84a212f-92d1-4c64-a0c1-749fcdbd2355_verboseLabel_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Immuno-oncology</link:label>
    <link:label id="lab_regn_SanofiCollaborationAgreementImmunooncologyMember_label_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Immuno-oncology [Member]</link:label>
    <link:label id="lab_regn_SanofiCollaborationAgreementImmunooncologyMember_documentation_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Immuno-oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:href="regn-20230331.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:to="lab_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SanofisShareofLibtayoU.S.GrossProfitsMember_7c6c789a-4556-46a8-98ed-0ed3c669654a_terseLabel_en-US" xlink:label="lab_regn_SanofisShareofLibtayoU.S.GrossProfitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits</link:label>
    <link:label id="lab_regn_SanofisShareofLibtayoU.S.GrossProfitsMember_label_en-US" xlink:label="lab_regn_SanofisShareofLibtayoU.S.GrossProfitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi's Share of Libtayo U.S. Gross Profits [Member]</link:label>
    <link:label id="lab_regn_SanofisShareofLibtayoU.S.GrossProfitsMember_documentation_en-US" xlink:label="lab_regn_SanofisShareofLibtayoU.S.GrossProfitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi's Share of Libtayo U.S. Gross Profits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofisShareofLibtayoU.S.GrossProfitsMember" xlink:href="regn-20230331.xsd#regn_SanofisShareofLibtayoU.S.GrossProfitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SanofisShareofLibtayoU.S.GrossProfitsMember" xlink:to="lab_regn_SanofisShareofLibtayoU.S.GrossProfitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5ee027ed-a13a-43c3-9a83-43256e22b5d9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_51f9472a-0a61-4df6-b0d9-4e04e5daf3f1_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_53a88552-6b8e-488f-814a-658e5186b83e_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_e7481592-dea0-40f0-89e5-16bd632d8020_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of Common Stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dbb77829-2c7f-4a8d-bf66-b249084e0d9f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_421391ca-88ac-4b2e-acb0-e88649d972a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_0bfbe400-3e32-4bbe-930f-ef389dcac4a9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_482ec0aa-3da9-4afe-883d-b0c29b7065df_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_cbd9dd0b-c31f-48c2-b737-95dcd44066c2_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5accd975-0157-47e9-b14e-85c65ecc409b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_AcquiredInProcessResearchAndDevelopment_3ed544ab-3ccc-46a5-89c9-cdebc297bd39_terseLabel_en-US" xlink:label="lab_regn_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_regn_AcquiredInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_regn_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired In-Process Research and Development</link:label>
    <link:label id="lab_regn_AcquiredInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_regn_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired In-Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AcquiredInProcessResearchAndDevelopment" xlink:href="regn-20230331.xsd#regn_AcquiredInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_AcquiredInProcessResearchAndDevelopment" xlink:to="lab_regn_AcquiredInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_9d484f3c-cea8-430b-96e9-ed4c196d7a2e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_2fedf138-1ef1-4c8f-aae3-13da8f3137a5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(R&amp;D expense)/Reduction of R&amp;D expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_85c034a2-d34f-4325-bf0b-7adb6d31c770_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_40aa2958-2eb3-449f-9854-43c5452f9e24_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_25da91ce-ec45-48e9-8580-d51d988d5151_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_LossContingencyExParteReexaminationFiledNumber_ea216138-505c-4d08-bf96-fb984e6ea129_terseLabel_en-US" xlink:label="lab_regn_LossContingencyExParteReexaminationFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of ex parte reexamination requests</link:label>
    <link:label id="lab_regn_LossContingencyExParteReexaminationFiledNumber_label_en-US" xlink:label="lab_regn_LossContingencyExParteReexaminationFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Ex Parte Reexamination, Filed, Number</link:label>
    <link:label id="lab_regn_LossContingencyExParteReexaminationFiledNumber_documentation_en-US" xlink:label="lab_regn_LossContingencyExParteReexaminationFiledNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Ex Parte Reexamination, Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LossContingencyExParteReexaminationFiledNumber" xlink:href="regn-20230331.xsd#regn_LossContingencyExParteReexaminationFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_LossContingencyExParteReexaminationFiledNumber" xlink:to="lab_regn_LossContingencyExParteReexaminationFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_783c6dae-0271-4e7d-86cb-fb66779d5e5d_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities owned not readily marketable</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_260ccbb9-a956-462c-9742-aee23bedeb81_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_43351eb1-ba49-431b-b890-82603640abfa_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b5eed78e-1cc1-464f-ae8c-5c568f08fa2b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9b66d276-1a19-4ed7-9712-dcfe556d6ec0_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_751bcc6e-b8e3-4712-9723-9a214e48bb65_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_0d2e93d6-af6f-4d28-b919-580d9eeaa050_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of preferred stock</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember_eeece69b-d12e-4671-adb0-bf358c0791b4_terseLabel_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's obligation for its share of Sanofi R&amp;D expenses, net of reimbursement of R&amp;D expenses</link:label>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember_label_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Research And Development Expenses, Net Of Obligation For Share Of R&amp;D Expenses [Member]</link:label>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember_documentation_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Research And Development Expenses, Net Of Obligation For Share Of R&amp;D Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember" xlink:href="regn-20230331.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember" xlink:to="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_17ad91ef-a216-4bd2-a637-85fccef487e6_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>regn-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:22cd9e9c-8c6e-43d9-ac99-edd9ddfa2dcd,g:8ddcabf6-ffb8-41b1-9a90-14e4490a05f1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.regeneron.com/role/Cover" xlink:type="simple" xlink:href="regn-20230331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d25f2a42-a7d0-4367-b3c1-80b3c7311a12" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_96833a31-d7a4-429e-a178-443587ae80a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d25f2a42-a7d0-4367-b3c1-80b3c7311a12" xlink:to="loc_dei_EntitiesTable_96833a31-d7a4-429e-a178-443587ae80a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b9aad427-58bd-4cd0-98e5-f1b3d37d4175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_96833a31-d7a4-429e-a178-443587ae80a9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b9aad427-58bd-4cd0-98e5-f1b3d37d4175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_12f7bd10-b54a-46b9-aee9-732b1257e2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b9aad427-58bd-4cd0-98e5-f1b3d37d4175" xlink:to="loc_us-gaap_ClassOfStockDomain_12f7bd10-b54a-46b9-aee9-732b1257e2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_d9c3ce79-fb27-4c78-9978-393d9d050cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_12f7bd10-b54a-46b9-aee9-732b1257e2bb" xlink:to="loc_us-gaap_CommonClassAMember_d9c3ce79-fb27-4c78-9978-393d9d050cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e1e73ad2-d318-4203-acf6-a2eae40da926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_12f7bd10-b54a-46b9-aee9-732b1257e2bb" xlink:to="loc_us-gaap_CommonStockMember_e1e73ad2-d318-4203-acf6-a2eae40da926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_96833a31-d7a4-429e-a178-443587ae80a9" xlink:to="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f3af2d66-8c27-412a-aed6-9600025a5558" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_DocumentType_f3af2d66-8c27-412a-aed6-9600025a5558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_07e25a5a-6212-42d1-a4e0-3e726c5d0ef2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_DocumentQuarterlyReport_07e25a5a-6212-42d1-a4e0-3e726c5d0ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3ee56e72-c21c-4768-ad59-2547f4bb08bf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_DocumentPeriodEndDate_3ee56e72-c21c-4768-ad59-2547f4bb08bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_057a6116-bf2a-4937-b5e8-45384e0d6944" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_DocumentTransitionReport_057a6116-bf2a-4937-b5e8-45384e0d6944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4790cb6d-7c76-4561-9150-f8fdaa683256" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityFileNumber_4790cb6d-7c76-4561-9150-f8fdaa683256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_733f20c4-0c77-44ef-9a47-0b5d796cd4b5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityRegistrantName_733f20c4-0c77-44ef-9a47-0b5d796cd4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_dc9d3916-19d8-4c07-9801-4311cb5afdc5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_dc9d3916-19d8-4c07-9801-4311cb5afdc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_16200ddb-9b41-40fd-97c4-5b964b433f10" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityTaxIdentificationNumber_16200ddb-9b41-40fd-97c4-5b964b433f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ee0e7500-6234-47e6-a4c9-c3055b21a2e8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityAddressAddressLine1_ee0e7500-6234-47e6-a4c9-c3055b21a2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b7bd8688-6b13-4cd4-abee-e670ccde7c2d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityAddressCityOrTown_b7bd8688-6b13-4cd4-abee-e670ccde7c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_dc8c03a7-ddf5-474f-83f8-a4441e76f075" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityAddressStateOrProvince_dc8c03a7-ddf5-474f-83f8-a4441e76f075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bcec20ae-3d6e-41fd-b6dc-0fe128f47425" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityAddressPostalZipCode_bcec20ae-3d6e-41fd-b6dc-0fe128f47425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_62549b0c-60a7-4dfa-9e40-d41ee0d083e4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_CityAreaCode_62549b0c-60a7-4dfa-9e40-d41ee0d083e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_18d10d1d-8946-4290-92fd-642ccd3e6b41" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_LocalPhoneNumber_18d10d1d-8946-4290-92fd-642ccd3e6b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_449c6be3-f411-4a79-a0d0-43b8630b5797" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_Security12bTitle_449c6be3-f411-4a79-a0d0-43b8630b5797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_925bbec9-6d68-46ae-882c-365b06cad1fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_TradingSymbol_925bbec9-6d68-46ae-882c-365b06cad1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d87a5f05-a909-4ea7-abe7-eeb0d05e539f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_SecurityExchangeName_d87a5f05-a909-4ea7-abe7-eeb0d05e539f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_be5f9dcb-cf21-4f8d-ad33-2c1fcc69275a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityCurrentReportingStatus_be5f9dcb-cf21-4f8d-ad33-2c1fcc69275a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_3f1e2acb-5e27-48fa-86bd-d7e84bb58ce9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityInteractiveDataCurrent_3f1e2acb-5e27-48fa-86bd-d7e84bb58ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_13d00516-6ec1-4bf7-a4ae-7a3d93031d1d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityFilerCategory_13d00516-6ec1-4bf7-a4ae-7a3d93031d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_a3bab69e-9954-42bb-9518-b1bb42823b9b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntitySmallBusiness_a3bab69e-9954-42bb-9518-b1bb42823b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_02f093bd-a170-4522-af38-e408870f98ae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityEmergingGrowthCompany_02f093bd-a170-4522-af38-e408870f98ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_fec84fc8-6843-4407-b02c-d2ee01000890" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityShellCompany_fec84fc8-6843-4407-b02c-d2ee01000890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ef1a1c68-380a-47ea-968d-c63984fcb24f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ef1a1c68-380a-47ea-968d-c63984fcb24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3d228664-9784-4c85-afe2-d73a77c265b3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_EntityCentralIndexKey_3d228664-9784-4c85-afe2-d73a77c265b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_031cd6be-e76d-42a0-8c78-2a377a30e265" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_CurrentFiscalYearEndDate_031cd6be-e76d-42a0-8c78-2a377a30e265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_65c4ea65-af7f-4d8c-bad6-c40996013398" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_DocumentFiscalYearFocus_65c4ea65-af7f-4d8c-bad6-c40996013398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_856e3ba9-0805-4395-a395-3fa9b0054b9b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_DocumentFiscalPeriodFocus_856e3ba9-0805-4395-a395-3fa9b0054b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e5bf54a1-ae3e-4f8e-9e09-0f7f58ea9fec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_496e7a68-5453-455b-b95c-55071e5b792b" xlink:to="loc_dei_AmendmentFlag_e5bf54a1-ae3e-4f8e-9e09-0f7f58ea9fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="simple" xlink:href="regn-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2eae98a8-5bba-4949-8e1d-4ad1d5e6e8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ffea5c4c-c5fa-4065-ac78-fef41de0ceb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2eae98a8-5bba-4949-8e1d-4ad1d5e6e8c1" xlink:to="loc_us-gaap_StatementTable_ffea5c4c-c5fa-4065-ac78-fef41de0ceb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a36c06c8-15fa-4d4e-9d87-5953a7c38488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ffea5c4c-c5fa-4065-ac78-fef41de0ceb0" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a36c06c8-15fa-4d4e-9d87-5953a7c38488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_15ae93b7-099b-4d7f-bfd7-f7821ec7f90c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a36c06c8-15fa-4d4e-9d87-5953a7c38488" xlink:to="loc_us-gaap_ClassOfStockDomain_15ae93b7-099b-4d7f-bfd7-f7821ec7f90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_d977c095-f604-49af-9b22-d5119d634496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_15ae93b7-099b-4d7f-bfd7-f7821ec7f90c" xlink:to="loc_us-gaap_CommonClassAMember_d977c095-f604-49af-9b22-d5119d634496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_11435938-98ce-497a-bc2b-50592685f900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_15ae93b7-099b-4d7f-bfd7-f7821ec7f90c" xlink:to="loc_us-gaap_CommonStockMember_11435938-98ce-497a-bc2b-50592685f900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3259dab4-a88a-4e96-9cd8-0fe57c76722e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ffea5c4c-c5fa-4065-ac78-fef41de0ceb0" xlink:to="loc_us-gaap_StatementLineItems_3259dab4-a88a-4e96-9cd8-0fe57c76722e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ba0f6de1-5796-40c7-8a03-42a2950e0c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3259dab4-a88a-4e96-9cd8-0fe57c76722e" xlink:to="loc_us-gaap_AssetsAbstract_ba0f6de1-5796-40c7-8a03-42a2950e0c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_a444c82b-0a00-43b0-bdc3-ca93333f430a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ba0f6de1-5796-40c7-8a03-42a2950e0c1e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_a444c82b-0a00-43b0-bdc3-ca93333f430a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_05f0f9ed-e269-4d08-9e06-624341b352b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a444c82b-0a00-43b0-bdc3-ca93333f430a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_05f0f9ed-e269-4d08-9e06-624341b352b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_e870d5fa-3212-418d-a1d6-22bb760553f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a444c82b-0a00-43b0-bdc3-ca93333f430a" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_e870d5fa-3212-418d-a1d6-22bb760553f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e8a224d1-e7b6-435a-9533-0e752fbd5763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a444c82b-0a00-43b0-bdc3-ca93333f430a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e8a224d1-e7b6-435a-9533-0e752fbd5763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7f692899-a027-4ae6-ac3b-5430c99264ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a444c82b-0a00-43b0-bdc3-ca93333f430a" xlink:to="loc_us-gaap_InventoryNet_7f692899-a027-4ae6-ac3b-5430c99264ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_668328fd-4dd1-4ef8-90ad-6c4fbc0a13d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a444c82b-0a00-43b0-bdc3-ca93333f430a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_668328fd-4dd1-4ef8-90ad-6c4fbc0a13d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_27d6090b-2b95-480e-a95b-7473a931a53a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a444c82b-0a00-43b0-bdc3-ca93333f430a" xlink:to="loc_us-gaap_AssetsCurrent_27d6090b-2b95-480e-a95b-7473a931a53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_9636bc15-ac64-4f5e-89f5-5fd12abaf39c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ba0f6de1-5796-40c7-8a03-42a2950e0c1e" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_9636bc15-ac64-4f5e-89f5-5fd12abaf39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_8904a0bc-1647-4298-b234-91b785fc2127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ba0f6de1-5796-40c7-8a03-42a2950e0c1e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_8904a0bc-1647-4298-b234-91b785fc2127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_39b4a721-0101-408d-aefe-1a35310fbdd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ba0f6de1-5796-40c7-8a03-42a2950e0c1e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_39b4a721-0101-408d-aefe-1a35310fbdd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_2a3d20c9-2af8-41e0-bd4d-439482c37300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ba0f6de1-5796-40c7-8a03-42a2950e0c1e" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_2a3d20c9-2af8-41e0-bd4d-439482c37300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_cb44d157-8306-4ece-8702-c6f038613e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ba0f6de1-5796-40c7-8a03-42a2950e0c1e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_cb44d157-8306-4ece-8702-c6f038613e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0c9ac63a-d8bb-4ae5-86d0-18f5d0bdfbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ba0f6de1-5796-40c7-8a03-42a2950e0c1e" xlink:to="loc_us-gaap_Assets_0c9ac63a-d8bb-4ae5-86d0-18f5d0bdfbc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a89dc8e5-4168-4425-9526-381eca8cd2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3259dab4-a88a-4e96-9cd8-0fe57c76722e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a89dc8e5-4168-4425-9526-381eca8cd2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5e8fa7e8-8ea4-48e1-ab9f-b88b0227df1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a89dc8e5-4168-4425-9526-381eca8cd2b8" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_5e8fa7e8-8ea4-48e1-ab9f-b88b0227df1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2166f841-1683-470b-a36d-5c4a1cbe6d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5e8fa7e8-8ea4-48e1-ab9f-b88b0227df1c" xlink:to="loc_us-gaap_AccountsPayableCurrent_2166f841-1683-470b-a36d-5c4a1cbe6d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_2866c967-6145-4f89-bf79-3cb68eb27f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5e8fa7e8-8ea4-48e1-ab9f-b88b0227df1c" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_2866c967-6145-4f89-bf79-3cb68eb27f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8d3e31e3-5ef6-4e53-ae14-4d200970b272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5e8fa7e8-8ea4-48e1-ab9f-b88b0227df1c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8d3e31e3-5ef6-4e53-ae14-4d200970b272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_26365d64-32e3-46b1-ab6a-51e09a9c481f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5e8fa7e8-8ea4-48e1-ab9f-b88b0227df1c" xlink:to="loc_us-gaap_LiabilitiesCurrent_26365d64-32e3-46b1-ab6a-51e09a9c481f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_09e44681-c6b1-4019-ba50-860adfb770dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a89dc8e5-4168-4425-9526-381eca8cd2b8" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_09e44681-c6b1-4019-ba50-860adfb770dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_64bb5498-70d4-44c0-ba1c-052e0ebf094f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a89dc8e5-4168-4425-9526-381eca8cd2b8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_64bb5498-70d4-44c0-ba1c-052e0ebf094f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ccb2b7a7-7f1b-477a-87a4-e7fd8d164e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a89dc8e5-4168-4425-9526-381eca8cd2b8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ccb2b7a7-7f1b-477a-87a4-e7fd8d164e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e6811cf4-77f0-4939-9a7d-c595812a0e61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a89dc8e5-4168-4425-9526-381eca8cd2b8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e6811cf4-77f0-4939-9a7d-c595812a0e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_658bc223-27cc-4caf-82d7-885a7a419cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a89dc8e5-4168-4425-9526-381eca8cd2b8" xlink:to="loc_us-gaap_Liabilities_658bc223-27cc-4caf-82d7-885a7a419cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_69b25dc7-5b5c-4c7d-a4be-640e98f1f870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a89dc8e5-4168-4425-9526-381eca8cd2b8" xlink:to="loc_us-gaap_StockholdersEquityAbstract_69b25dc7-5b5c-4c7d-a4be-640e98f1f870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_df5759ab-416a-4518-bce6-280958828db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_69b25dc7-5b5c-4c7d-a4be-640e98f1f870" xlink:to="loc_us-gaap_PreferredStockValue_df5759ab-416a-4518-bce6-280958828db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_54cf2c96-2343-4713-bfe1-1c9fa113fe6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_69b25dc7-5b5c-4c7d-a4be-640e98f1f870" xlink:to="loc_us-gaap_CommonStockValue_54cf2c96-2343-4713-bfe1-1c9fa113fe6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_951dcc3b-ed21-46e3-8665-f33021926718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_69b25dc7-5b5c-4c7d-a4be-640e98f1f870" xlink:to="loc_us-gaap_AdditionalPaidInCapital_951dcc3b-ed21-46e3-8665-f33021926718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_da81c001-0ec2-4040-8510-5ae2ea9762cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_69b25dc7-5b5c-4c7d-a4be-640e98f1f870" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_da81c001-0ec2-4040-8510-5ae2ea9762cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_47b002b4-ee01-4707-b406-67266e0f985e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_69b25dc7-5b5c-4c7d-a4be-640e98f1f870" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_47b002b4-ee01-4707-b406-67266e0f985e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_9b7a1dc6-64cf-478a-aadc-82bd46ccfbd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_69b25dc7-5b5c-4c7d-a4be-640e98f1f870" xlink:to="loc_us-gaap_TreasuryStockCommonValue_9b7a1dc6-64cf-478a-aadc-82bd46ccfbd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c4f7618b-d09a-4881-94a8-53122d025e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_69b25dc7-5b5c-4c7d-a4be-640e98f1f870" xlink:to="loc_us-gaap_StockholdersEquity_c4f7618b-d09a-4881-94a8-53122d025e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_eaac56f7-6377-4524-99a6-3098d6b14488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a89dc8e5-4168-4425-9526-381eca8cd2b8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_eaac56f7-6377-4524-99a6-3098d6b14488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="simple" xlink:href="regn-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3bac5c9f-0fb1-415f-9921-558d1902ce46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ab7c624c-eadd-4ecb-8407-00efe6082cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3bac5c9f-0fb1-415f-9921-558d1902ce46" xlink:to="loc_us-gaap_StatementTable_ab7c624c-eadd-4ecb-8407-00efe6082cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ba7130ce-b549-4990-a573-f70f5fdd6721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ab7c624c-eadd-4ecb-8407-00efe6082cbd" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ba7130ce-b549-4990-a573-f70f5fdd6721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3cd1080e-5e7f-45d1-adb2-7dcf4fec88c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ba7130ce-b549-4990-a573-f70f5fdd6721" xlink:to="loc_us-gaap_ClassOfStockDomain_3cd1080e-5e7f-45d1-adb2-7dcf4fec88c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_bf7e74a0-dd8b-439a-af33-71b38ac21655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3cd1080e-5e7f-45d1-adb2-7dcf4fec88c9" xlink:to="loc_us-gaap_CommonClassAMember_bf7e74a0-dd8b-439a-af33-71b38ac21655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_603a180d-2220-4cf8-83db-f27a625fda96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3cd1080e-5e7f-45d1-adb2-7dcf4fec88c9" xlink:to="loc_us-gaap_CommonStockMember_603a180d-2220-4cf8-83db-f27a625fda96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6f4c0940-d036-4dc0-ada2-f3ebfb918d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ab7c624c-eadd-4ecb-8407-00efe6082cbd" xlink:to="loc_us-gaap_StatementLineItems_6f4c0940-d036-4dc0-ada2-f3ebfb918d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a3d6adc-e47a-463a-b22d-30ad0e8e3396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f4c0940-d036-4dc0-ada2-f3ebfb918d79" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a3d6adc-e47a-463a-b22d-30ad0e8e3396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1313698e-d0b2-40be-b9ac-432226cf549d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a3d6adc-e47a-463a-b22d-30ad0e8e3396" xlink:to="loc_us-gaap_StockholdersEquityAbstract_1313698e-d0b2-40be-b9ac-432226cf549d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_69de9250-97fd-4910-92c2-b3a424f57230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1313698e-d0b2-40be-b9ac-432226cf549d" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_69de9250-97fd-4910-92c2-b3a424f57230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ffd5c891-d4ca-416f-a89d-d3af0afa7691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1313698e-d0b2-40be-b9ac-432226cf549d" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ffd5c891-d4ca-416f-a89d-d3af0afa7691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b9d7fdbe-d4e5-492c-9d5d-3b1ba178da9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1313698e-d0b2-40be-b9ac-432226cf549d" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b9d7fdbe-d4e5-492c-9d5d-3b1ba178da9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f39b92e3-c31b-439e-9253-df03acf7326b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1313698e-d0b2-40be-b9ac-432226cf549d" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f39b92e3-c31b-439e-9253-df03acf7326b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_137b0a39-d208-4415-9c69-bd21f0dd2710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1313698e-d0b2-40be-b9ac-432226cf549d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_137b0a39-d208-4415-9c69-bd21f0dd2710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b3a50189-c7a6-4783-b872-51c97e931535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1313698e-d0b2-40be-b9ac-432226cf549d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b3a50189-c7a6-4783-b872-51c97e931535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_509442f8-52cd-471f-b86b-e522d388d81f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1313698e-d0b2-40be-b9ac-432226cf549d" xlink:to="loc_us-gaap_CommonStockSharesIssued_509442f8-52cd-471f-b86b-e522d388d81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b445c5d9-c201-4df2-97eb-e1247e908000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1313698e-d0b2-40be-b9ac-432226cf549d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b445c5d9-c201-4df2-97eb-e1247e908000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_4cfec303-93ef-45cd-9d51-373b0543a00d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1313698e-d0b2-40be-b9ac-432226cf549d" xlink:to="loc_us-gaap_TreasuryStockCommonShares_4cfec303-93ef-45cd-9d51-373b0543a00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited" xlink:type="simple" xlink:href="regn-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_144e4754-e786-4378-8e69-93eed9a6f133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_af299f61-5d01-4ba5-bbc2-34ce60b48fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_144e4754-e786-4378-8e69-93eed9a6f133" xlink:to="loc_us-gaap_StatementTable_af299f61-5d01-4ba5-bbc2-34ce60b48fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a01d2b97-b648-46b6-9a52-2bb0caed040a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_af299f61-5d01-4ba5-bbc2-34ce60b48fbe" xlink:to="loc_srt_ProductOrServiceAxis_a01d2b97-b648-46b6-9a52-2bb0caed040a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3014acf5-9448-4b27-863b-c581729f5f75" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a01d2b97-b648-46b6-9a52-2bb0caed040a" xlink:to="loc_srt_ProductsAndServicesDomain_3014acf5-9448-4b27-863b-c581729f5f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_ad01a960-2e12-427d-bd42-4fc3ab80432b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3014acf5-9448-4b27-863b-c581729f5f75" xlink:to="loc_us-gaap_ProductMember_ad01a960-2e12-427d-bd42-4fc3ab80432b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationRevenueMember_7e1c250d-3777-49a4-966e-64b579c1f98d" xlink:href="regn-20230331.xsd#regn_CollaborationRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3014acf5-9448-4b27-863b-c581729f5f75" xlink:to="loc_regn_CollaborationRevenueMember_7e1c250d-3777-49a4-966e-64b579c1f98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_76cf8b66-bbd4-41d8-8ec1-ae64f5d4b508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3014acf5-9448-4b27-863b-c581729f5f75" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_76cf8b66-bbd4-41d8-8ec1-ae64f5d4b508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationandContractManufacturingMember_7902e244-0f78-4fe8-bcc3-3934e2bd1652" xlink:href="regn-20230331.xsd#regn_CollaborationandContractManufacturingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3014acf5-9448-4b27-863b-c581729f5f75" xlink:to="loc_regn_CollaborationandContractManufacturingMember_7902e244-0f78-4fe8-bcc3-3934e2bd1652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dce0f452-6617-4acf-bdfb-39c5f5abe1db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_af299f61-5d01-4ba5-bbc2-34ce60b48fbe" xlink:to="loc_us-gaap_StatementLineItems_dce0f452-6617-4acf-bdfb-39c5f5abe1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_160b1531-671d-4ff5-81ee-8cb3f8dae7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dce0f452-6617-4acf-bdfb-39c5f5abe1db" xlink:to="loc_us-gaap_IncomeStatementAbstract_160b1531-671d-4ff5-81ee-8cb3f8dae7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_1bdf288f-e8a1-4ec8-98df-e1677baf29f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_160b1531-671d-4ff5-81ee-8cb3f8dae7f4" xlink:to="loc_us-gaap_RevenuesAbstract_1bdf288f-e8a1-4ec8-98df-e1677baf29f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_213a8f7f-81bf-443e-9015-fafd86d4ed3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1bdf288f-e8a1-4ec8-98df-e1677baf29f3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_213a8f7f-81bf-443e-9015-fafd86d4ed3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_aa73266e-8c0b-4897-bb97-e3ddfd12cfaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_160b1531-671d-4ff5-81ee-8cb3f8dae7f4" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_aa73266e-8c0b-4897-bb97-e3ddfd12cfaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4e78fc33-2e3c-44b1-9888-44aa97f0e7be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_aa73266e-8c0b-4897-bb97-e3ddfd12cfaf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4e78fc33-2e3c-44b1-9888-44aa97f0e7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AcquiredInProcessResearchAndDevelopment_c1218fff-0b63-4b5f-8aee-696c4d3e2058" xlink:href="regn-20230331.xsd#regn_AcquiredInProcessResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_aa73266e-8c0b-4897-bb97-e3ddfd12cfaf" xlink:to="loc_regn_AcquiredInProcessResearchAndDevelopment_c1218fff-0b63-4b5f-8aee-696c4d3e2058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fdd0f44d-82e6-4bed-a6fa-07dc5122c3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_aa73266e-8c0b-4897-bb97-e3ddfd12cfaf" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fdd0f44d-82e6-4bed-a6fa-07dc5122c3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6345c00b-fbcc-4518-b3ab-a48777350130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_aa73266e-8c0b-4897-bb97-e3ddfd12cfaf" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6345c00b-fbcc-4518-b3ab-a48777350130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_2aeb0e8f-e93d-46ac-a4c2-f1682dddb0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_aa73266e-8c0b-4897-bb97-e3ddfd12cfaf" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_2aeb0e8f-e93d-46ac-a4c2-f1682dddb0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ae75f08b-4278-4f7e-9e67-c2103e8971a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_aa73266e-8c0b-4897-bb97-e3ddfd12cfaf" xlink:to="loc_us-gaap_CostsAndExpenses_ae75f08b-4278-4f7e-9e67-c2103e8971a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8a18ea6a-c4c7-4de3-ac5b-970e10ab0e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_160b1531-671d-4ff5-81ee-8cb3f8dae7f4" xlink:to="loc_us-gaap_OperatingIncomeLoss_8a18ea6a-c4c7-4de3-ac5b-970e10ab0e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d165deb9-806c-4f95-a839-14aef6d28548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_160b1531-671d-4ff5-81ee-8cb3f8dae7f4" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d165deb9-806c-4f95-a839-14aef6d28548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_18e193d5-fe0e-46e4-a1e0-e8c5238f5ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d165deb9-806c-4f95-a839-14aef6d28548" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_18e193d5-fe0e-46e4-a1e0-e8c5238f5ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_c96d3a8b-1450-4250-81fb-b76767f898ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d165deb9-806c-4f95-a839-14aef6d28548" xlink:to="loc_us-gaap_InterestExpense_c96d3a8b-1450-4250-81fb-b76767f898ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_cd220ec6-129a-4387-827c-1d9031e030df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d165deb9-806c-4f95-a839-14aef6d28548" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_cd220ec6-129a-4387-827c-1d9031e030df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_97125950-a568-47f7-bc5e-d6b9730d8160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_160b1531-671d-4ff5-81ee-8cb3f8dae7f4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_97125950-a568-47f7-bc5e-d6b9730d8160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b6214a3d-5377-42b9-8d1e-40e47764aadc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_160b1531-671d-4ff5-81ee-8cb3f8dae7f4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b6214a3d-5377-42b9-8d1e-40e47764aadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ff527fcf-d34d-44de-98e1-728f179a3cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_160b1531-671d-4ff5-81ee-8cb3f8dae7f4" xlink:to="loc_us-gaap_NetIncomeLoss_ff527fcf-d34d-44de-98e1-728f179a3cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6412e64d-2149-4e2b-a411-fbf2ad62a44c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_160b1531-671d-4ff5-81ee-8cb3f8dae7f4" xlink:to="loc_us-gaap_EarningsPerShareBasic_6412e64d-2149-4e2b-a411-fbf2ad62a44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2b966a66-ddd5-49ca-949f-f5ebf9ce10c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_160b1531-671d-4ff5-81ee-8cb3f8dae7f4" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2b966a66-ddd5-49ca-949f-f5ebf9ce10c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fb50d5ee-8b38-4e3c-8eae-17f006847d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_160b1531-671d-4ff5-81ee-8cb3f8dae7f4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fb50d5ee-8b38-4e3c-8eae-17f006847d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_eaecbc47-6dd9-473e-b0d2-868c35a1446f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_160b1531-671d-4ff5-81ee-8cb3f8dae7f4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_eaecbc47-6dd9-473e-b0d2-868c35a1446f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_b563009c-4080-442f-9d8e-d7c276d01d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dce0f452-6617-4acf-bdfb-39c5f5abe1db" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_b563009c-4080-442f-9d8e-d7c276d01d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_74bd62f4-7eb6-4f1c-9c0e-39642525863d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_b563009c-4080-442f-9d8e-d7c276d01d7b" xlink:to="loc_us-gaap_NetIncomeLoss_74bd62f4-7eb6-4f1c-9c0e-39642525863d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_fbc02748-bb71-4560-bbea-fa225c9823b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_b563009c-4080-442f-9d8e-d7c276d01d7b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_fbc02748-bb71-4560-bbea-fa225c9823b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2cb6600f-d416-4f92-b49f-00d7c528c463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_fbc02748-bb71-4560-bbea-fa225c9823b3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2cb6600f-d416-4f92-b49f-00d7c528c463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_ffcdb886-2276-4190-b39b-e465634524cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_fbc02748-bb71-4560-bbea-fa225c9823b3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_ffcdb886-2276-4190-b39b-e465634524cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_be3bf7ea-a9e1-446c-8c9d-e21b7ab05e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_b563009c-4080-442f-9d8e-d7c276d01d7b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_be3bf7ea-a9e1-446c-8c9d-e21b7ab05e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="simple" xlink:href="regn-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_bbe60f28-e2dd-487a-8781-b8c9aa9dee3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_74140cc1-b547-4d61-80cf-1adb4da44cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_bbe60f28-e2dd-487a-8781-b8c9aa9dee3d" xlink:to="loc_us-gaap_StatementTable_74140cc1-b547-4d61-80cf-1adb4da44cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bb677f32-6280-4005-af91-455b65500b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_74140cc1-b547-4d61-80cf-1adb4da44cda" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bb677f32-6280-4005-af91-455b65500b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e0bac490-3e08-4784-81aa-07abc47a3646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bb677f32-6280-4005-af91-455b65500b34" xlink:to="loc_us-gaap_ClassOfStockDomain_e0bac490-3e08-4784-81aa-07abc47a3646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_43d3d76c-257c-41b8-ab6b-440ed496fb95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e0bac490-3e08-4784-81aa-07abc47a3646" xlink:to="loc_us-gaap_CommonClassAMember_43d3d76c-257c-41b8-ab6b-440ed496fb95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_576a0a97-867a-4396-b0f9-14ccc5576a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_74140cc1-b547-4d61-80cf-1adb4da44cda" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_576a0a97-867a-4396-b0f9-14ccc5576a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c7e94e2e-d9d6-4f78-a13b-203d878f847c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_576a0a97-867a-4396-b0f9-14ccc5576a3e" xlink:to="loc_us-gaap_EquityComponentDomain_c7e94e2e-d9d6-4f78-a13b-203d878f847c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c9d66002-382c-4b78-9f6c-b207d89e938a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c7e94e2e-d9d6-4f78-a13b-203d878f847c" xlink:to="loc_us-gaap_CommonStockMember_c9d66002-382c-4b78-9f6c-b207d89e938a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_cbbfc990-baa5-461a-ae1d-05de85a3a2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c7e94e2e-d9d6-4f78-a13b-203d878f847c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_cbbfc990-baa5-461a-ae1d-05de85a3a2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9930c60b-fe09-4dff-85c9-f4f16216b008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c7e94e2e-d9d6-4f78-a13b-203d878f847c" xlink:to="loc_us-gaap_RetainedEarningsMember_9930c60b-fe09-4dff-85c9-f4f16216b008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_27183498-feef-41e0-a7e4-6e2c023b20b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c7e94e2e-d9d6-4f78-a13b-203d878f847c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_27183498-feef-41e0-a7e4-6e2c023b20b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_58516a29-368e-47a3-a563-53bbd470bce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c7e94e2e-d9d6-4f78-a13b-203d878f847c" xlink:to="loc_us-gaap_TreasuryStockCommonMember_58516a29-368e-47a3-a563-53bbd470bce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_56eed85a-ab81-48d0-a00e-cc862228406a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_74140cc1-b547-4d61-80cf-1adb4da44cda" xlink:to="loc_us-gaap_StatementLineItems_56eed85a-ab81-48d0-a00e-cc862228406a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_56eed85a-ab81-48d0-a00e-cc862228406a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1c8cd69d-1382-4d81-97c9-c98881fcee52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1c8cd69d-1382-4d81-97c9-c98881fcee52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_e8dd59cc-a066-485f-91c5-00c4f395598b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_us-gaap_TreasuryStockCommonShares_e8dd59cc-a066-485f-91c5-00c4f395598b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5cbbb9f3-fdd8-4c11-8ecc-3647d7e5054a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_us-gaap_StockholdersEquity_5cbbb9f3-fdd8-4c11-8ecc-3647d7e5054a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_cdcd8300-8f22-4a7c-9579-378a17dcba20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_cdcd8300-8f22-4a7c-9579-378a17dcba20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_765b78f9-1251-413d-b84b-a4e192807794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_765b78f9-1251-413d-b84b-a4e192807794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_f72da5d1-e4fd-4c6d-ad39-3b135951f563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_f72da5d1-e4fd-4c6d-ad39-3b135951f563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_97f1c7d1-f5ee-45a7-ad08-dc4f81eb8b84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_97f1c7d1-f5ee-45a7-ad08-dc4f81eb8b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_82004cbb-59e7-4538-8fab-9b60901d7d8b" xlink:href="regn-20230331.xsd#regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_82004cbb-59e7-4538-8fab-9b60901d7d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_ddcda904-d229-48bc-ba31-0f845af75833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_ddcda904-d229-48bc-ba31-0f845af75833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_b88c2bf7-33e2-43fe-a4dd-eb5922d9d02a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_b88c2bf7-33e2-43fe-a4dd-eb5922d9d02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_10b7f029-cbcd-4569-89d7-2a197149341f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_10b7f029-cbcd-4569-89d7-2a197149341f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5aa85eb9-9eb4-4e7f-ab10-43a59a8251ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_us-gaap_NetIncomeLoss_5aa85eb9-9eb4-4e7f-ab10-43a59a8251ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4041ac40-fc9e-4863-a47c-7a7d3b3b9c87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4041ac40-fc9e-4863-a47c-7a7d3b3b9c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_93c58235-1bca-4678-86da-6df62479290d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_93c58235-1bca-4678-86da-6df62479290d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_d7da822b-82a9-43a3-a7d6-25e1aa6fb555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_us-gaap_TreasuryStockCommonShares_d7da822b-82a9-43a3-a7d6-25e1aa6fb555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fc42af2f-87e7-40aa-8be6-169de863901e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61f3912e-f34c-49f1-894a-7cc12c9a4264" xlink:to="loc_us-gaap_StockholdersEquity_fc42af2f-87e7-40aa-8be6-169de863901e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="simple" xlink:href="regn-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6d510a43-7004-47dc-ae05-8f7f22120aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9427f644-46d6-4e3b-96a6-4109ec94a704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6d510a43-7004-47dc-ae05-8f7f22120aa6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9427f644-46d6-4e3b-96a6-4109ec94a704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5abb1423-6859-4b12-8027-cb038dcc486e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9427f644-46d6-4e3b-96a6-4109ec94a704" xlink:to="loc_us-gaap_NetIncomeLoss_5abb1423-6859-4b12-8027-cb038dcc486e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_61aab19a-5c46-4c60-9cdd-35dcd6baf9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9427f644-46d6-4e3b-96a6-4109ec94a704" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_61aab19a-5c46-4c60-9cdd-35dcd6baf9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b15e9921-3b93-418a-987b-0c8e8035d5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_61aab19a-5c46-4c60-9cdd-35dcd6baf9e4" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b15e9921-3b93-418a-987b-0c8e8035d5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4a7f721f-be36-494c-bacd-7054df17e362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_61aab19a-5c46-4c60-9cdd-35dcd6baf9e4" xlink:to="loc_us-gaap_ShareBasedCompensation_4a7f721f-be36-494c-bacd-7054df17e362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MarketableAndOtherSecuritiesGainLoss_0fa18f3a-af9d-40d8-acc7-0c4c87b61b09" xlink:href="regn-20230331.xsd#regn_MarketableAndOtherSecuritiesGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_61aab19a-5c46-4c60-9cdd-35dcd6baf9e4" xlink:to="loc_regn_MarketableAndOtherSecuritiesGainLoss_0fa18f3a-af9d-40d8-acc7-0c4c87b61b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_5f2ab347-ae5f-447c-a985-9c4df156334a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_61aab19a-5c46-4c60-9cdd-35dcd6baf9e4" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_5f2ab347-ae5f-447c-a985-9c4df156334a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_7f284ae6-d44c-4690-9d86-3bc47959ccf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_61aab19a-5c46-4c60-9cdd-35dcd6baf9e4" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_7f284ae6-d44c-4690-9d86-3bc47959ccf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8bb37019-4353-40c7-b5a4-4db00622e4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_61aab19a-5c46-4c60-9cdd-35dcd6baf9e4" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8bb37019-4353-40c7-b5a4-4db00622e4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ed26ffeb-e0da-4238-8915-fc289e59154f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8bb37019-4353-40c7-b5a4-4db00622e4a5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ed26ffeb-e0da-4238-8915-fc289e59154f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_ffc70c54-6dee-4d3e-bffd-d1cbfdc592ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8bb37019-4353-40c7-b5a4-4db00622e4a5" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_ffc70c54-6dee-4d3e-bffd-d1cbfdc592ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_193aa478-adef-4ba6-b8e7-33ab940e2c19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8bb37019-4353-40c7-b5a4-4db00622e4a5" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_193aa478-adef-4ba6-b8e7-33ab940e2c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d321ebce-50f7-48df-9a22-fa621eaebbdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8bb37019-4353-40c7-b5a4-4db00622e4a5" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d321ebce-50f7-48df-9a22-fa621eaebbdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_42851452-fdd5-4fb2-ae78-b65f66990f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8bb37019-4353-40c7-b5a4-4db00622e4a5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_42851452-fdd5-4fb2-ae78-b65f66990f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_60ecf270-4dfe-447d-a01f-e58709ad750e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_61aab19a-5c46-4c60-9cdd-35dcd6baf9e4" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_60ecf270-4dfe-447d-a01f-e58709ad750e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fe28bbf2-b579-4427-82d7-02ed11721d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9427f644-46d6-4e3b-96a6-4109ec94a704" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fe28bbf2-b579-4427-82d7-02ed11721d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d16bb4ad-66fc-4e76-8562-56324acd3c62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6d510a43-7004-47dc-ae05-8f7f22120aa6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d16bb4ad-66fc-4e76-8562-56324acd3c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2cf41861-382e-4788-be9e-59d1476c2a83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d16bb4ad-66fc-4e76-8562-56324acd3c62" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2cf41861-382e-4788-be9e-59d1476c2a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_91685a1b-7b45-49c0-8b9a-75f7f2123651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d16bb4ad-66fc-4e76-8562-56324acd3c62" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_91685a1b-7b45-49c0-8b9a-75f7f2123651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_5a03ad8c-52f3-488d-bf04-77cc725b219e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d16bb4ad-66fc-4e76-8562-56324acd3c62" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_5a03ad8c-52f3-488d-bf04-77cc725b219e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PaymentsToAcquireIntangibleAssets1_147c3260-72e2-4aac-a4a6-cc059e57597d" xlink:href="regn-20230331.xsd#regn_PaymentsToAcquireIntangibleAssets1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d16bb4ad-66fc-4e76-8562-56324acd3c62" xlink:to="loc_regn_PaymentsToAcquireIntangibleAssets1_147c3260-72e2-4aac-a4a6-cc059e57597d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8a74b011-6a48-408a-8f75-b82f86a21ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d16bb4ad-66fc-4e76-8562-56324acd3c62" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8a74b011-6a48-408a-8f75-b82f86a21ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99d3674e-f907-4dbd-8720-4d6b5b2b9e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6d510a43-7004-47dc-ae05-8f7f22120aa6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99d3674e-f907-4dbd-8720-4d6b5b2b9e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_cb4d6735-e37b-4442-9f2f-b4037ab6a3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99d3674e-f907-4dbd-8720-4d6b5b2b9e58" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_cb4d6735-e37b-4442-9f2f-b4037ab6a3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a0bc5e37-ef8f-4e7b-9106-39188cead888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99d3674e-f907-4dbd-8720-4d6b5b2b9e58" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a0bc5e37-ef8f-4e7b-9106-39188cead888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5b818511-20fa-4c86-b31f-49bec04c335c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99d3674e-f907-4dbd-8720-4d6b5b2b9e58" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5b818511-20fa-4c86-b31f-49bec04c335c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fe1df57d-7e5c-4d7b-a150-a6aa1a56c13e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99d3674e-f907-4dbd-8720-4d6b5b2b9e58" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fe1df57d-7e5c-4d7b-a150-a6aa1a56c13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_19ccdfb0-e496-4e6f-af54-eb37e7b97389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6d510a43-7004-47dc-ae05-8f7f22120aa6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_19ccdfb0-e496-4e6f-af54-eb37e7b97389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_691539e2-cf7f-4bce-8604-216a33d5aaa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6d510a43-7004-47dc-ae05-8f7f22120aa6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_691539e2-cf7f-4bce-8604-216a33d5aaa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_298face3-d158-49e9-898f-bb2646dce008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6d510a43-7004-47dc-ae05-8f7f22120aa6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_298face3-d158-49e9-898f-bb2646dce008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/InterimFinancialStatements" xlink:type="simple" xlink:href="regn-20230331.xsd#InterimFinancialStatements"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/InterimFinancialStatements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b064060e-8ce5-4071-8122-5f1c29e7ed15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_fc2e775a-330b-4cf4-8c1d-5cd2f74dba6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b064060e-8ce5-4071-8122-5f1c29e7ed15" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_fc2e775a-330b-4cf4-8c1d-5cd2f74dba6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSales" xlink:type="simple" xlink:href="regn-20230331.xsd#ProductSales"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/ProductSales" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_05ffe388-beeb-4dcb-a622-c5e61a3ed337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_4135a34a-443f-49c2-9d22-b83b5c943f15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_05ffe388-beeb-4dcb-a622-c5e61a3ed337" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_4135a34a-443f-49c2-9d22-b83b5c943f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements" xlink:type="simple" xlink:href="regn-20230331.xsd#CollaborationLicenseandOtherAgreements"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_aa15edf8-a251-44be-9174-44cc11715d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_d947378e-f951-4a31-83f1-e0ef2996c7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_aa15edf8-a251-44be-9174-44cc11715d8d" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_d947378e-f951-4a31-83f1-e0ef2996c7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="regn-20230331.xsd#NetIncomePerShare"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/NetIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0bab109d-a0c9-42c5-bd52-9c4f092a696f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_b752d971-eb74-42a4-8a3d-93e59b826c53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0bab109d-a0c9-42c5-bd52-9c4f092a696f" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_b752d971-eb74-42a4-8a3d-93e59b826c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecurities" xlink:type="simple" xlink:href="regn-20230331.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_cab7eeb9-2428-4bce-b0c0-0096581c7f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_2144d635-24cd-4160-91f1-a603794b7025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_cab7eeb9-2428-4bce-b0c0-0096581c7f1c" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_2144d635-24cd-4160-91f1-a603794b7025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="regn-20230331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0c4195f0-4d33-46da-910a-0dfd6699a74e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_7cd6e046-c9db-409b-be5d-af9f4b7e72b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0c4195f0-4d33-46da-910a-0dfd6699a74e" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_7cd6e046-c9db-409b-be5d-af9f4b7e72b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/Inventories" xlink:type="simple" xlink:href="regn-20230331.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_29b4b4fa-867c-49b4-ae87-fa426147b18a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_8ae06af7-842c-4d04-b8cc-ba3a13e6a055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_29b4b4fa-867c-49b4-ae87-fa426147b18a" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_8ae06af7-842c-4d04-b8cc-ba3a13e6a055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/IncomeTaxes" xlink:type="simple" xlink:href="regn-20230331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_85f0c40d-ddac-47b0-985c-64200fdb69a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_71376fdd-7905-495a-8cf4-43f86173e3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_85f0c40d-ddac-47b0-985c-64200fdb69a5" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_71376fdd-7905-495a-8cf4-43f86173e3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquity" xlink:type="simple" xlink:href="regn-20230331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_54166036-3a4f-4eeb-aaac-3be83982ee3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_e7c160b8-411d-4e51-9334-6606d9d86861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_54166036-3a4f-4eeb-aaac-3be83982ee3c" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_e7c160b8-411d-4e51-9334-6606d9d86861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CashFlows" xlink:type="simple" xlink:href="regn-20230331.xsd#CashFlows"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_d30b14f9-0e5b-4362-8c26-9fc69d9ec16c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_3fbf83af-7b7b-48a1-acf3-34920399f0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_d30b14f9-0e5b-4362-8c26-9fc69d9ec16c" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_3fbf83af-7b7b-48a1-acf3-34920399f0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/LegalMatters" xlink:type="simple" xlink:href="regn-20230331.xsd#LegalMatters"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/LegalMatters" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8e6db79f-bc56-4eca-b6ab-c81ce7bd8d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_222d4c35-245d-4244-9c97-45ffbddce551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8e6db79f-bc56-4eca-b6ab-c81ce7bd8d6b" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_222d4c35-245d-4244-9c97-45ffbddce551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/InterimFinancialStatementsPolicies" xlink:type="simple" xlink:href="regn-20230331.xsd#InterimFinancialStatementsPolicies"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/InterimFinancialStatementsPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ed24b6b2-65fb-40ba-8fee-b90334214dba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2a897e8f-ed94-4f96-b49a-fc23961d2b61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ed24b6b2-65fb-40ba-8fee-b90334214dba" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2a897e8f-ed94-4f96-b49a-fc23961d2b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock_36b40461-d118-4e45-bb65-fb506d04216a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ed24b6b2-65fb-40ba-8fee-b90334214dba" xlink:to="loc_us-gaap_LegalCostsPolicyTextBlock_36b40461-d118-4e45-bb65-fb506d04216a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesTables" xlink:type="simple" xlink:href="regn-20230331.xsd#ProductSalesTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/ProductSalesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ef682602-aca7-4a9e-8c56-3d3798343536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_24b575d3-1081-4f79-b83c-2d6ce35154df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ef682602-aca7-4a9e-8c56-3d3798343536" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_24b575d3-1081-4f79-b83c-2d6ce35154df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_d8ddcb47-4176-4979-98b6-fe75fabdf9af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ef682602-aca7-4a9e-8c56-3d3798343536" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_d8ddcb47-4176-4979-98b6-fe75fabdf9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables" xlink:type="simple" xlink:href="regn-20230331.xsd#CollaborationLicenseandOtherAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_174f1af4-372b-4f3a-8e6e-0f4a9eb40084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_92343f00-a9c8-40ab-80cc-5861cddd3f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_174f1af4-372b-4f3a-8e6e-0f4a9eb40084" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_92343f00-a9c8-40ab-80cc-5861cddd3f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_dec5ef11-bc23-49a0-8b8e-d38162ec0dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_174f1af4-372b-4f3a-8e6e-0f4a9eb40084" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_dec5ef11-bc23-49a0-8b8e-d38162ec0dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="regn-20230331.xsd#NetIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/NetIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2c1ec5c4-e1ba-4bd0-be5a-57f7bcfe74f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_007fe49f-3f63-497d-8d5e-22ce1a4426a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2c1ec5c4-e1ba-4bd0-be5a-57f7bcfe74f7" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_007fe49f-3f63-497d-8d5e-22ce1a4426a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_e8bcecc9-cacd-475d-9971-17150ddc2836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2c1ec5c4-e1ba-4bd0-be5a-57f7bcfe74f7" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_e8bcecc9-cacd-475d-9971-17150ddc2836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="regn-20230331.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_35e1fa5b-6bd2-4d14-8d33-4750c51558a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_0094e772-2e09-4639-b226-aaa3e2ae2b66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_35e1fa5b-6bd2-4d14-8d33-4750c51558a3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_0094e772-2e09-4639-b226-aaa3e2ae2b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_70f77637-787b-4540-9b28-bd5c4303f2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_35e1fa5b-6bd2-4d14-8d33-4750c51558a3" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_70f77637-787b-4540-9b28-bd5c4303f2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_8d162cb8-e3e6-46b3-bc08-0e68088acd98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_35e1fa5b-6bd2-4d14-8d33-4750c51558a3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_8d162cb8-e3e6-46b3-bc08-0e68088acd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="regn-20230331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4576b683-fcfc-4c95-a96f-a3eea69c4857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_31c168f0-ab76-4f0a-b601-afdcdd075965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4576b683-fcfc-4c95-a96f-a3eea69c4857" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_31c168f0-ab76-4f0a-b601-afdcdd075965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/InventoriesTables" xlink:type="simple" xlink:href="regn-20230331.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_91ff139e-6d2f-4df3-ac3d-b9a0aec2bd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_d857627e-a996-4f24-b53c-a3d8b5eb7857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_91ff139e-6d2f-4df3-ac3d-b9a0aec2bd0e" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_d857627e-a996-4f24-b53c-a3d8b5eb7857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="regn-20230331.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_1b38eb36-ef74-42c6-b845-e4448ba2bc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_02c8d4d1-72fa-4a65-8d80-206c830f3e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1b38eb36-ef74-42c6-b845-e4448ba2bc4d" xlink:to="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_02c8d4d1-72fa-4a65-8d80-206c830f3e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CashFlowsTables" xlink:type="simple" xlink:href="regn-20230331.xsd#CashFlowsTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CashFlowsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_3df2a11f-36ee-42a7-971b-f18e9390b9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_78fb5b61-3c72-4754-8940-010852ef9379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_3df2a11f-36ee-42a7-971b-f18e9390b9e7" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_78fb5b61-3c72-4754-8940-010852ef9379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9ee2949b-fc1e-4b85-82b4-3bfe0843bd47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_3df2a11f-36ee-42a7-971b-f18e9390b9e7" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9ee2949b-fc1e-4b85-82b4-3bfe0843bd47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_1af99036-fc04-42b2-bcbb-e37861caa299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_3df2a11f-36ee-42a7-971b-f18e9390b9e7" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_1af99036-fc04-42b2-bcbb-e37861caa299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#ProductSalesScheduleofNetProductSalesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cbc93904-bc2b-4ce6-ab3d-9cbc37e62c73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_27b92d0a-4ba4-46ab-acad-e2b4b7fb70c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cbc93904-bc2b-4ce6-ab3d-9cbc37e62c73" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_27b92d0a-4ba4-46ab-acad-e2b4b7fb70c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4d6fc976-e1e9-427f-9cfd-e872a9f669d4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_27b92d0a-4ba4-46ab-acad-e2b4b7fb70c5" xlink:to="loc_srt_StatementGeographicalAxis_4d6fc976-e1e9-427f-9cfd-e872a9f669d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cfc0b1a0-e14f-4abe-a3fe-9ce0dc0c6283" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4d6fc976-e1e9-427f-9cfd-e872a9f669d4" xlink:to="loc_srt_SegmentGeographicalDomain_cfc0b1a0-e14f-4abe-a3fe-9ce0dc0c6283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_145fe1e3-83d8-4ba8-b2c4-4a9ed4c3bd66" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cfc0b1a0-e14f-4abe-a3fe-9ce0dc0c6283" xlink:to="loc_country_US_145fe1e3-83d8-4ba8-b2c4-4a9ed4c3bd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RestOfWorldMember_e2b9fd72-fdfa-4ed8-95f4-57fe7fddc0ed" xlink:href="regn-20230331.xsd#regn_RestOfWorldMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cfc0b1a0-e14f-4abe-a3fe-9ce0dc0c6283" xlink:to="loc_regn_RestOfWorldMember_e2b9fd72-fdfa-4ed8-95f4-57fe7fddc0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_223324f2-cd81-438a-8d0d-89deab6d351b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_27b92d0a-4ba4-46ab-acad-e2b4b7fb70c5" xlink:to="loc_srt_ProductOrServiceAxis_223324f2-cd81-438a-8d0d-89deab6d351b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0d3177cb-efb4-403a-99bb-f41b5d44a531" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_223324f2-cd81-438a-8d0d-89deab6d351b" xlink:to="loc_srt_ProductsAndServicesDomain_0d3177cb-efb4-403a-99bb-f41b5d44a531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_d41f2f9d-e4d5-4fef-b79e-7246469bd300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0d3177cb-efb4-403a-99bb-f41b5d44a531" xlink:to="loc_us-gaap_ProductMember_d41f2f9d-e4d5-4fef-b79e-7246469bd300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EyleaNetProductSalesMember_b55ed30c-867e-4ca2-81d0-48cce122ffd6" xlink:href="regn-20230331.xsd#regn_EyleaNetProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_d41f2f9d-e4d5-4fef-b79e-7246469bd300" xlink:to="loc_regn_EyleaNetProductSalesMember_b55ed30c-867e-4ca2-81d0-48cce122ffd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LIBTAYONetProductSalesMember_5773b224-8189-40af-bd09-3e29a2fb8475" xlink:href="regn-20230331.xsd#regn_LIBTAYONetProductSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_d41f2f9d-e4d5-4fef-b79e-7246469bd300" xlink:to="loc_regn_LIBTAYONetProductSalesMember_5773b224-8189-40af-bd09-3e29a2fb8475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PraluentNetProductSalesMember_95190dc3-351e-4fc4-b5e3-483511810001" xlink:href="regn-20230331.xsd#regn_PraluentNetProductSalesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_d41f2f9d-e4d5-4fef-b79e-7246469bd300" xlink:to="loc_regn_PraluentNetProductSalesMember_95190dc3-351e-4fc4-b5e3-483511810001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EvkeezaMember_4c1ecdc8-7030-46bd-b823-84e606d10687" xlink:href="regn-20230331.xsd#regn_EvkeezaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_d41f2f9d-e4d5-4fef-b79e-7246469bd300" xlink:to="loc_regn_EvkeezaMember_4c1ecdc8-7030-46bd-b823-84e606d10687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_InmazebMember_5408412f-9064-43b4-b1d7-d71e37f50f07" xlink:href="regn-20230331.xsd#regn_InmazebMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_d41f2f9d-e4d5-4fef-b79e-7246469bd300" xlink:to="loc_regn_InmazebMember_5408412f-9064-43b4-b1d7-d71e37f50f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_849009af-40a2-4c89-9fc8-4448f92e3d30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_27b92d0a-4ba4-46ab-acad-e2b4b7fb70c5" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_849009af-40a2-4c89-9fc8-4448f92e3d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c8a1574c-003d-401c-97f8-1fbf2f3ddea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_849009af-40a2-4c89-9fc8-4448f92e3d30" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c8a1574c-003d-401c-97f8-1fbf2f3ddea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesNarrativeDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#ProductSalesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/ProductSalesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7a89f36c-1722-4886-9c4a-cec9bbbab6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_dba7a20a-3db1-45fa-aff3-7fd850ad45aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7a89f36c-1722-4886-9c4a-cec9bbbab6a2" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_dba7a20a-3db1-45fa-aff3-7fd850ad45aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_e77cae1e-104d-45bc-a43a-a9a0231fe608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_dba7a20a-3db1-45fa-aff3-7fd850ad45aa" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_e77cae1e-104d-45bc-a43a-a9a0231fe608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_c69f0aba-9f61-481c-9abd-7977d888ee3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_e77cae1e-104d-45bc-a43a-a9a0231fe608" xlink:to="loc_us-gaap_ReceivableTypeDomain_c69f0aba-9f61-481c-9abd-7977d888ee3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_48a7c0eb-ceff-4987-a5c3-33dcc465fbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_c69f0aba-9f61-481c-9abd-7977d888ee3f" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_48a7c0eb-ceff-4987-a5c3-33dcc465fbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_26886fbd-7dee-423c-b61f-76923fd52e04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_dba7a20a-3db1-45fa-aff3-7fd850ad45aa" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_26886fbd-7dee-423c-b61f-76923fd52e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7a69596e-530c-42b6-b6f8-521e29ad15ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_26886fbd-7dee-423c-b61f-76923fd52e04" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7a69596e-530c-42b6-b6f8-521e29ad15ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f7b43b39-5df9-46d5-87cd-40f6cf7982a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_cd86a27d-3cfa-405a-a874-0cb0a9e58f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f7b43b39-5df9-46d5-87cd-40f6cf7982a8" xlink:to="loc_us-gaap_ConcentrationRiskTable_cd86a27d-3cfa-405a-a874-0cb0a9e58f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e72171df-12ce-4492-8c81-83198d3c9ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_cd86a27d-3cfa-405a-a874-0cb0a9e58f0e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e72171df-12ce-4492-8c81-83198d3c9ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7034b8e5-f7f2-434e-8e75-e054a4d65b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_e72171df-12ce-4492-8c81-83198d3c9ffa" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7034b8e5-f7f2-434e-8e75-e054a4d65b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_GrossProductRevenueMember_c4db9256-b164-4c55-971c-03876b1dc537" xlink:href="regn-20230331.xsd#regn_GrossProductRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7034b8e5-f7f2-434e-8e75-e054a4d65b30" xlink:to="loc_regn_GrossProductRevenueMember_c4db9256-b164-4c55-971c-03876b1dc537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_3fb78fdd-45b4-4542-a4f4-7e9945edc35b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_cd86a27d-3cfa-405a-a874-0cb0a9e58f0e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_3fb78fdd-45b4-4542-a4f4-7e9945edc35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_82074d7c-44fe-4d6a-bc66-8f8d616bd452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3fb78fdd-45b4-4542-a4f4-7e9945edc35b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_82074d7c-44fe-4d6a-bc66-8f8d616bd452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_0a4f8acd-634c-4b68-86ee-7ab4950da66e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_82074d7c-44fe-4d6a-bc66-8f8d616bd452" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_0a4f8acd-634c-4b68-86ee-7ab4950da66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_cf528978-7b6b-4801-a222-0c2b7467fe8a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_cd86a27d-3cfa-405a-a874-0cb0a9e58f0e" xlink:to="loc_srt_MajorCustomersAxis_cf528978-7b6b-4801-a222-0c2b7467fe8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e8eacb6e-4e7e-4645-9499-7fa90e1118f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_cf528978-7b6b-4801-a222-0c2b7467fe8a" xlink:to="loc_srt_NameOfMajorCustomerDomain_e8eacb6e-4e7e-4645-9499-7fa90e1118f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BesseMedicalMember_66a25973-1f2c-458c-9f37-856da4a8ec28" xlink:href="regn-20230331.xsd#regn_BesseMedicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e8eacb6e-4e7e-4645-9499-7fa90e1118f2" xlink:to="loc_regn_BesseMedicalMember_66a25973-1f2c-458c-9f37-856da4a8ec28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_McKessonCorporationMember_e11c7e88-7006-45db-9365-2a10cd54a690" xlink:href="regn-20230331.xsd#regn_McKessonCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e8eacb6e-4e7e-4645-9499-7fa90e1118f2" xlink:to="loc_regn_McKessonCorporationMember_e11c7e88-7006-45db-9365-2a10cd54a690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_51f7730f-a261-4b7c-90ff-42fa9bb23123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_cd86a27d-3cfa-405a-a874-0cb0a9e58f0e" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_51f7730f-a261-4b7c-90ff-42fa9bb23123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_7511195d-391f-4c58-a845-0488d06a2f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_51f7730f-a261-4b7c-90ff-42fa9bb23123" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_7511195d-391f-4c58-a845-0488d06a2f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_efa5c71d-4946-4593-975e-1906f7363109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_cef21ad3-5518-46a8-b516-05615eb69602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_efa5c71d-4946-4593-975e-1906f7363109" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_cef21ad3-5518-46a8-b516-05615eb69602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_55ab6572-8fda-4360-9da0-1106f50b3e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cef21ad3-5518-46a8-b516-05615eb69602" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_55ab6572-8fda-4360-9da0-1106f50b3e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_d7632b8a-30b0-4cbf-bd40-c8366507b7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_55ab6572-8fda-4360-9da0-1106f50b3e1f" xlink:to="loc_us-gaap_ProjectMember_d7632b8a-30b0-4cbf-bd40-c8366507b7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember_3ed29f98-d4cd-4412-994f-a6fbd9a88121" xlink:href="regn-20230331.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_d7632b8a-30b0-4cbf-bd40-c8366507b7ef" xlink:to="loc_regn_SanofiCollaborationAgreementAntibodyMember_3ed29f98-d4cd-4412-994f-a6fbd9a88121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_f2a50643-85e9-4a35-b662-efa09aafb46e" xlink:href="regn-20230331.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_d7632b8a-30b0-4cbf-bd40-c8366507b7ef" xlink:to="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_f2a50643-85e9-4a35-b662-efa09aafb46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_eb4825aa-c1be-466c-9fad-63252abadf62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cef21ad3-5518-46a8-b516-05615eb69602" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_eb4825aa-c1be-466c-9fad-63252abadf62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_876b0799-42c8-424c-a5b7-e7796bfdc477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_eb4825aa-c1be-466c-9fad-63252abadf62" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_876b0799-42c8-424c-a5b7-e7796bfdc477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationRevenueMember_14968896-342b-4e64-a23c-ae6e2a3c534c" xlink:href="regn-20230331.xsd#regn_CollaborationRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_876b0799-42c8-424c-a5b7-e7796bfdc477" xlink:to="loc_regn_CollaborationRevenueMember_14968896-342b-4e64-a23c-ae6e2a3c534c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_22ff9367-3ba7-4f79-a5c6-16b3a7792f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_876b0799-42c8-424c-a5b7-e7796bfdc477" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_22ff9367-3ba7-4f79-a5c6-16b3a7792f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6b693d86-462a-4805-9c22-873b3e5c4782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_876b0799-42c8-424c-a5b7-e7796bfdc477" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6b693d86-462a-4805-9c22-873b3e5c4782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CostOfGoodsSoldMember_def0e25b-c579-4934-8ec8-7e5dd5bd9600" xlink:href="regn-20230331.xsd#regn_CostOfGoodsSoldMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_876b0799-42c8-424c-a5b7-e7796bfdc477" xlink:to="loc_regn_CostOfGoodsSoldMember_def0e25b-c579-4934-8ec8-7e5dd5bd9600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_fbc85b9e-351a-4c87-b6dc-67b5dd565181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_876b0799-42c8-424c-a5b7-e7796bfdc477" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_fbc85b9e-351a-4c87-b6dc-67b5dd565181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b819f0e0-da6c-41d2-9d6f-6d011024d6ab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cef21ad3-5518-46a8-b516-05615eb69602" xlink:to="loc_srt_ProductOrServiceAxis_b819f0e0-da6c-41d2-9d6f-6d011024d6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d2080893-b3b1-4364-92ed-92038cc407d6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b819f0e0-da6c-41d2-9d6f-6d011024d6ab" xlink:to="loc_srt_ProductsAndServicesDomain_d2080893-b3b1-4364-92ed-92038cc407d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareOfProfitLossesInConnectionWithCommercializationMember_c5848b29-647c-4b29-8a1f-9efcd1e289b8" xlink:href="regn-20230331.xsd#regn_ShareOfProfitLossesInConnectionWithCommercializationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d2080893-b3b1-4364-92ed-92038cc407d6" xlink:to="loc_regn_ShareOfProfitLossesInConnectionWithCommercializationMember_c5848b29-647c-4b29-8a1f-9efcd1e289b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestoneEarnedMember_73379881-8a51-4b80-9d08-cf24b47d84b1" xlink:href="regn-20230331.xsd#regn_SalesBasedMilestoneEarnedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d2080893-b3b1-4364-92ed-92038cc407d6" xlink:to="loc_regn_SalesBasedMilestoneEarnedMember_73379881-8a51-4b80-9d08-cf24b47d84b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_e552143c-668b-4f4b-b4b9-cb141b2ff67c" xlink:href="regn-20230331.xsd#regn_ReimbursementForManufacturingOfCommercialSuppliesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d2080893-b3b1-4364-92ed-92038cc407d6" xlink:to="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_e552143c-668b-4f4b-b4b9-cb141b2ff67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember_e5412dfb-67c5-4864-aa83-b82c83d2c043" xlink:href="regn-20230331.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d2080893-b3b1-4364-92ed-92038cc407d6" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember_e5412dfb-67c5-4864-aa83-b82c83d2c043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementForManufacturingOfExCommercialSuppliesMember_a1039828-be16-4fc9-a8f4-99516e7fbd3d" xlink:href="regn-20230331.xsd#regn_ReimbursementForManufacturingOfExCommercialSuppliesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d2080893-b3b1-4364-92ed-92038cc407d6" xlink:to="loc_regn_ReimbursementForManufacturingOfExCommercialSuppliesMember_a1039828-be16-4fc9-a8f4-99516e7fbd3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_35a2a64a-c81d-4a2f-97be-cfb1bba12afd" xlink:href="regn-20230331.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d2080893-b3b1-4364-92ed-92038cc407d6" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_35a2a64a-c81d-4a2f-97be-cfb1bba12afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfCommercializationRelatedExpensesMember_ac7da540-d451-422c-8879-5233ce8f7a3f" xlink:href="regn-20230331.xsd#regn_ReimbursementOfCommercializationRelatedExpensesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d2080893-b3b1-4364-92ed-92038cc407d6" xlink:to="loc_regn_ReimbursementOfCommercializationRelatedExpensesMember_ac7da540-d451-422c-8879-5233ce8f7a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegeneronsShareOfCommercialExpensesMember_36094e31-0a97-4bef-9391-b7f61813cd69" xlink:href="regn-20230331.xsd#regn_RegeneronsShareOfCommercialExpensesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d2080893-b3b1-4364-92ed-92038cc407d6" xlink:to="loc_regn_RegeneronsShareOfCommercialExpensesMember_36094e31-0a97-4bef-9391-b7f61813cd69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofisShareofLibtayoU.S.GrossProfitsMember_981e118a-159d-4468-90c8-58e9ca1d49b4" xlink:href="regn-20230331.xsd#regn_SanofisShareofLibtayoU.S.GrossProfitsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d2080893-b3b1-4364-92ed-92038cc407d6" xlink:to="loc_regn_SanofisShareofLibtayoU.S.GrossProfitsMember_981e118a-159d-4468-90c8-58e9ca1d49b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_10dbc159-a0d1-4a63-9c64-1ac5c4329c7e" xlink:href="regn-20230331.xsd#regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d2080893-b3b1-4364-92ed-92038cc407d6" xlink:to="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_10dbc159-a0d1-4a63-9c64-1ac5c4329c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_61821607-dff8-4137-a624-d923883b7098" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cef21ad3-5518-46a8-b516-05615eb69602" xlink:to="loc_srt_StatementGeographicalAxis_61821607-dff8-4137-a624-d923883b7098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_888bdfc0-0272-4cda-9822-d9beaa9cff41" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_61821607-dff8-4137-a624-d923883b7098" xlink:to="loc_srt_SegmentGeographicalDomain_888bdfc0-0272-4cda-9822-d9beaa9cff41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_feb1044f-af33-4214-82f2-685e04c4cf40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_888bdfc0-0272-4cda-9822-d9beaa9cff41" xlink:to="loc_us-gaap_NonUsMember_feb1044f-af33-4214-82f2-685e04c4cf40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d55af94f-5528-4040-8535-5569fe9c4965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cef21ad3-5518-46a8-b516-05615eb69602" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_d55af94f-5528-4040-8535-5569fe9c4965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a0452ad1-7596-47a8-a57d-c97037fbe073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d55af94f-5528-4040-8535-5569fe9c4965" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a0452ad1-7596-47a8-a57d-c97037fbe073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3f63eecd-c941-4346-8845-413c96479f60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4f2d1e6e-2926-4586-b749-7b9e5abed953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3f63eecd-c941-4346-8845-413c96479f60" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4f2d1e6e-2926-4586-b749-7b9e5abed953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_0d363c0b-ede5-4a17-b73d-3540708b0cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4f2d1e6e-2926-4586-b749-7b9e5abed953" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_0d363c0b-ede5-4a17-b73d-3540708b0cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_4aaa9814-1482-41ff-a996-3bfe305f105d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_0d363c0b-ede5-4a17-b73d-3540708b0cf0" xlink:to="loc_us-gaap_ProjectMember_4aaa9814-1482-41ff-a996-3bfe305f105d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember_9f406ea2-651d-4a69-bfe7-22629dfe0069" xlink:href="regn-20230331.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_4aaa9814-1482-41ff-a996-3bfe305f105d" xlink:to="loc_regn_SanofiCollaborationAgreementAntibodyMember_9f406ea2-651d-4a69-bfe7-22629dfe0069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3a758c49-a2ff-442a-a5df-890a43d43c48" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4f2d1e6e-2926-4586-b749-7b9e5abed953" xlink:to="loc_srt_RangeAxis_3a758c49-a2ff-442a-a5df-890a43d43c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a87cf70a-6bd1-49e5-b58d-7cb1b1998a1c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3a758c49-a2ff-442a-a5df-890a43d43c48" xlink:to="loc_srt_RangeMember_a87cf70a-6bd1-49e5-b58d-7cb1b1998a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a3a6f95a-5552-4708-a537-16a890f69bc0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a87cf70a-6bd1-49e5-b58d-7cb1b1998a1c" xlink:to="loc_srt_MinimumMember_a3a6f95a-5552-4708-a537-16a890f69bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_65ecf91c-d356-477c-86e1-2fc8dfa7c60d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a87cf70a-6bd1-49e5-b58d-7cb1b1998a1c" xlink:to="loc_srt_MaximumMember_65ecf91c-d356-477c-86e1-2fc8dfa7c60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MilestoneTypeAxis_90d6c14c-22ea-4d6b-ae35-5550ee4d2723" xlink:href="regn-20230331.xsd#regn_MilestoneTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4f2d1e6e-2926-4586-b749-7b9e5abed953" xlink:to="loc_regn_MilestoneTypeAxis_90d6c14c-22ea-4d6b-ae35-5550ee4d2723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MilestoneTypeDomain_95e0caa1-cb35-477b-836f-c1b46fe30522" xlink:href="regn-20230331.xsd#regn_MilestoneTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_MilestoneTypeAxis_90d6c14c-22ea-4d6b-ae35-5550ee4d2723" xlink:to="loc_regn_MilestoneTypeDomain_95e0caa1-cb35-477b-836f-c1b46fe30522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestoneThreeMember_8b51460d-d69e-4e28-ba6a-b9af90436bf9" xlink:href="regn-20230331.xsd#regn_SalesMilestoneThreeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_MilestoneTypeDomain_95e0caa1-cb35-477b-836f-c1b46fe30522" xlink:to="loc_regn_SalesMilestoneThreeMember_8b51460d-d69e-4e28-ba6a-b9af90436bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestoneFiveMember_cefe6212-45dd-4a87-ab94-8312d3916e06" xlink:href="regn-20230331.xsd#regn_SalesMilestoneFiveMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_MilestoneTypeDomain_95e0caa1-cb35-477b-836f-c1b46fe30522" xlink:to="loc_regn_SalesMilestoneFiveMember_cefe6212-45dd-4a87-ab94-8312d3916e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_dc3b3348-37af-463c-93c4-3004585c730a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4f2d1e6e-2926-4586-b749-7b9e5abed953" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_dc3b3348-37af-463c-93c4-3004585c730a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty_9874afe6-8bc6-47b1-b3f7-484abee03ab4" xlink:href="regn-20230331.xsd#regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_dc3b3348-37af-463c-93c4-3004585c730a" xlink:to="loc_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty_9874afe6-8bc6-47b1-b3f7-484abee03ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts_388a6fe6-f471-4297-86ef-7d5a425b4ec6" xlink:href="regn-20230331.xsd#regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_dc3b3348-37af-463c-93c4-3004585c730a" xlink:to="loc_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts_388a6fe6-f471-4297-86ef-7d5a425b4ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts_2d5e91e5-2747-462e-ba39-997e3165b460" xlink:href="regn-20230331.xsd#regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_dc3b3348-37af-463c-93c4-3004585c730a" xlink:to="loc_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts_2d5e91e5-2747-462e-ba39-997e3165b460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93214353-7814-4771-9540-d60b39718126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_dc3b3348-37af-463c-93c4-3004585c730a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93214353-7814-4771-9540-d60b39718126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived_761b4bf4-e809-49d2-b173-b2cb5c2386ed" xlink:href="regn-20230331.xsd#regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_dc3b3348-37af-463c-93c4-3004585c730a" xlink:to="loc_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived_761b4bf4-e809-49d2-b173-b2cb5c2386ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_9a12dc82-5d77-4d0d-b87e-8eafbef5b624" xlink:href="regn-20230331.xsd#regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_dc3b3348-37af-463c-93c4-3004585c730a" xlink:to="loc_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_9a12dc82-5d77-4d0d-b87e-8eafbef5b624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount_116a51fe-0cc7-4aa9-83ed-498004f0680d" xlink:href="regn-20230331.xsd#regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_dc3b3348-37af-463c-93c4-3004585c730a" xlink:to="loc_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount_116a51fe-0cc7-4aa9-83ed-498004f0680d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d19309dd-06cb-4b6b-98a2-80a4affdfbc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_adf9e0e0-167a-407a-8367-97e73dc6cf9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d19309dd-06cb-4b6b-98a2-80a4affdfbc2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_adf9e0e0-167a-407a-8367-97e73dc6cf9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ac55740a-1e64-4c46-924a-9773d2a3fa10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_adf9e0e0-167a-407a-8367-97e73dc6cf9e" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ac55740a-1e64-4c46-924a-9773d2a3fa10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_66a93705-bc3a-431e-bc23-e19ed1861f86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ac55740a-1e64-4c46-924a-9773d2a3fa10" xlink:to="loc_us-gaap_ProjectMember_66a93705-bc3a-431e-bc23-e19ed1861f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember_1da42d39-53db-459f-b0a9-2b4573f3a5ea" xlink:href="regn-20230331.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_66a93705-bc3a-431e-bc23-e19ed1861f86" xlink:to="loc_regn_SanofiCollaborationAgreementAntibodyMember_1da42d39-53db-459f-b0a9-2b4573f3a5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_229832ec-f097-4a61-9b74-f354fa03896d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_adf9e0e0-167a-407a-8367-97e73dc6cf9e" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_229832ec-f097-4a61-9b74-f354fa03896d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8ab5a4eb-d688-47ea-8eb2-5561ae124987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_229832ec-f097-4a61-9b74-f354fa03896d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8ab5a4eb-d688-47ea-8eb2-5561ae124987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f4bd8682-5b03-484c-99bb-e803f23baccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_229832ec-f097-4a61-9b74-f354fa03896d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_f4bd8682-5b03-484c-99bb-e803f23baccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_da086c00-6464-4dea-b196-ba24ea395515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ab766e4e-ad3f-495c-a9af-16a7f62a5981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_da086c00-6464-4dea-b196-ba24ea395515" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ab766e4e-ad3f-495c-a9af-16a7f62a5981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ca4856bd-f52a-4067-ba97-febea009507c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ab766e4e-ad3f-495c-a9af-16a7f62a5981" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ca4856bd-f52a-4067-ba97-febea009507c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_9cbb8f44-4fd7-4632-b6ac-b5f9169aa0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ca4856bd-f52a-4067-ba97-febea009507c" xlink:to="loc_us-gaap_ProjectMember_9cbb8f44-4fd7-4632-b6ac-b5f9169aa0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_3d7b4701-9595-43e7-90ac-fa8813229250" xlink:href="regn-20230331.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_9cbb8f44-4fd7-4632-b6ac-b5f9169aa0e8" xlink:to="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_3d7b4701-9595-43e7-90ac-fa8813229250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MilestoneTypeAxis_27aa1db7-343c-4350-a73b-b9ab0759b6bd" xlink:href="regn-20230331.xsd#regn_MilestoneTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ab766e4e-ad3f-495c-a9af-16a7f62a5981" xlink:to="loc_regn_MilestoneTypeAxis_27aa1db7-343c-4350-a73b-b9ab0759b6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MilestoneTypeDomain_783b5ad7-78b0-4269-9c36-cb9f0d858bbe" xlink:href="regn-20230331.xsd#regn_MilestoneTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_MilestoneTypeAxis_27aa1db7-343c-4350-a73b-b9ab0759b6bd" xlink:to="loc_regn_MilestoneTypeDomain_783b5ad7-78b0-4269-9c36-cb9f0d858bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegulatoryMilestoneMember_4ea85cda-86fc-4078-9f69-a8eb847d02eb" xlink:href="regn-20230331.xsd#regn_RegulatoryMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_MilestoneTypeDomain_783b5ad7-78b0-4269-9c36-cb9f0d858bbe" xlink:to="loc_regn_RegulatoryMilestoneMember_4ea85cda-86fc-4078-9f69-a8eb847d02eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestoneOneMember_dceddb0e-896c-43b7-afc5-671e777aeb45" xlink:href="regn-20230331.xsd#regn_SalesBasedMilestoneOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_MilestoneTypeDomain_783b5ad7-78b0-4269-9c36-cb9f0d858bbe" xlink:to="loc_regn_SalesBasedMilestoneOneMember_dceddb0e-896c-43b7-afc5-671e777aeb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestoneTwoMember_df502265-22cf-4bf6-a12d-6babc0843040" xlink:href="regn-20230331.xsd#regn_SalesBasedMilestoneTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_MilestoneTypeDomain_783b5ad7-78b0-4269-9c36-cb9f0d858bbe" xlink:to="loc_regn_SalesBasedMilestoneTwoMember_df502265-22cf-4bf6-a12d-6babc0843040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestonesMember_34a5d5d6-56fb-4db3-9340-bb79ed7d3b13" xlink:href="regn-20230331.xsd#regn_SalesBasedMilestonesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_MilestoneTypeDomain_783b5ad7-78b0-4269-9c36-cb9f0d858bbe" xlink:to="loc_regn_SalesBasedMilestonesMember_34a5d5d6-56fb-4db3-9340-bb79ed7d3b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_b6e563de-24eb-4b84-a2bc-1cabd002c11a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ab766e4e-ad3f-495c-a9af-16a7f62a5981" xlink:to="loc_dei_LegalEntityAxis_b6e563de-24eb-4b84-a2bc-1cabd002c11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_be601c87-2278-42f6-a5a5-db32b3ac4d2c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_b6e563de-24eb-4b84-a2bc-1cabd002c11a" xlink:to="loc_dei_EntityDomain_be601c87-2278-42f6-a5a5-db32b3ac4d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiMember_65e391a4-b06a-4305-b76c-6477495e29df" xlink:href="regn-20230331.xsd#regn_SanofiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_be601c87-2278-42f6-a5a5-db32b3ac4d2c" xlink:to="loc_regn_SanofiMember_65e391a4-b06a-4305-b76c-6477495e29df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2fd42750-0a3d-429c-ae9d-e38fdd537f79" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ab766e4e-ad3f-495c-a9af-16a7f62a5981" xlink:to="loc_srt_CounterpartyNameAxis_2fd42750-0a3d-429c-ae9d-e38fdd537f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93e30dc6-807a-4173-aed2-89dad1b8a463" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2fd42750-0a3d-429c-ae9d-e38fdd537f79" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93e30dc6-807a-4173-aed2-89dad1b8a463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiMember_079c8ed8-05cd-4c5c-8c14-b9944b32c721" xlink:href="regn-20230331.xsd#regn_SanofiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93e30dc6-807a-4173-aed2-89dad1b8a463" xlink:to="loc_regn_SanofiMember_079c8ed8-05cd-4c5c-8c14-b9944b32c721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ad6b1ccf-aa00-4812-b8bc-cb4e0fccea39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ab766e4e-ad3f-495c-a9af-16a7f62a5981" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_ad6b1ccf-aa00-4812-b8bc-cb4e0fccea39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UpFrontPaymentToCollaboratingParty_7a6343c0-9dbf-4856-ae86-c22c844d3db4" xlink:href="regn-20230331.xsd#regn_UpFrontPaymentToCollaboratingParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ad6b1ccf-aa00-4812-b8bc-cb4e0fccea39" xlink:to="loc_regn_UpFrontPaymentToCollaboratingParty_7a6343c0-9dbf-4856-ae86-c22c844d3db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_39ac9540-6332-4dc0-b90a-76d890aff4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ad6b1ccf-aa00-4812-b8bc-cb4e0fccea39" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_39ac9540-6332-4dc0-b90a-76d890aff4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales_755bfcb4-f459-43c2-a63f-0666b45e19f0" xlink:href="regn-20230331.xsd#regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ad6b1ccf-aa00-4812-b8bc-cb4e0fccea39" xlink:to="loc_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales_755bfcb4-f459-43c2-a63f-0666b45e19f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_515ee8af-a8ea-4995-9bd7-dd1c101bbcae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a691b55d-246f-4237-a5a4-f37e56194ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_515ee8af-a8ea-4995-9bd7-dd1c101bbcae" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a691b55d-246f-4237-a5a4-f37e56194ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_52579fae-62a7-4512-a9ff-c3a472957955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a691b55d-246f-4237-a5a4-f37e56194ebe" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_52579fae-62a7-4512-a9ff-c3a472957955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_6a87be91-5a27-475d-9bf1-178971c75dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_52579fae-62a7-4512-a9ff-c3a472957955" xlink:to="loc_us-gaap_ProjectMember_6a87be91-5a27-475d-9bf1-178971c75dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_f960d4b9-5ce1-4d5a-baff-1ec0062b10f6" xlink:href="regn-20230331.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_6a87be91-5a27-475d-9bf1-178971c75dfb" xlink:to="loc_regn_BayerCollaborationAgreementMember_f960d4b9-5ce1-4d5a-baff-1ec0062b10f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_be0fa605-62de-4571-ad19-331d54e4573e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a691b55d-246f-4237-a5a4-f37e56194ebe" xlink:to="loc_srt_StatementGeographicalAxis_be0fa605-62de-4571-ad19-331d54e4573e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0ff34008-36e8-4b26-a0c3-4be77e0dd7c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_be0fa605-62de-4571-ad19-331d54e4573e" xlink:to="loc_srt_SegmentGeographicalDomain_0ff34008-36e8-4b26-a0c3-4be77e0dd7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_067201ea-4ab0-43fe-801d-e4d48a3d5d40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0ff34008-36e8-4b26-a0c3-4be77e0dd7c1" xlink:to="loc_us-gaap_NonUsMember_067201ea-4ab0-43fe-801d-e4d48a3d5d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1e3d1dd7-92e8-425d-95d5-397090b8fad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a691b55d-246f-4237-a5a4-f37e56194ebe" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1e3d1dd7-92e8-425d-95d5-397090b8fad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fe332a3e-3ee2-4a0b-b4a3-3c3d4f2b6be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1e3d1dd7-92e8-425d-95d5-397090b8fad9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fe332a3e-3ee2-4a0b-b4a3-3c3d4f2b6be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationRevenueMember_53e0e164-f6f4-4ca8-bbe8-5c479448897f" xlink:href="regn-20230331.xsd#regn_CollaborationRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fe332a3e-3ee2-4a0b-b4a3-3c3d4f2b6be3" xlink:to="loc_regn_CollaborationRevenueMember_53e0e164-f6f4-4ca8-bbe8-5c479448897f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchAndDevelopmentExpensesAndReductionOfResearchAndDevelopmentExpenseMember_8cf1484a-707e-4cb0-9bb5-a3fef3fb8ebb" xlink:href="regn-20230331.xsd#regn_ResearchAndDevelopmentExpensesAndReductionOfResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fe332a3e-3ee2-4a0b-b4a3-3c3d4f2b6be3" xlink:to="loc_regn_ResearchAndDevelopmentExpensesAndReductionOfResearchAndDevelopmentExpenseMember_8cf1484a-707e-4cb0-9bb5-a3fef3fb8ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_85e1900d-0ce8-49de-8e46-0c7bfab93285" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a691b55d-246f-4237-a5a4-f37e56194ebe" xlink:to="loc_srt_ProductOrServiceAxis_85e1900d-0ce8-49de-8e46-0c7bfab93285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_235c6842-d09d-4e83-901f-bda9af31d176" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_85e1900d-0ce8-49de-8e46-0c7bfab93285" xlink:to="loc_srt_ProductsAndServicesDomain_235c6842-d09d-4e83-901f-bda9af31d176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_NetProfitInConnectionWithCommercializationMember_5b9ca3eb-1c03-419e-adfd-7434151bdf38" xlink:href="regn-20230331.xsd#regn_NetProfitInConnectionWithCommercializationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_235c6842-d09d-4e83-901f-bda9af31d176" xlink:to="loc_regn_NetProfitInConnectionWithCommercializationMember_5b9ca3eb-1c03-419e-adfd-7434151bdf38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_fc26cba5-6ec4-4a95-836b-13663e4ddf85" xlink:href="regn-20230331.xsd#regn_ReimbursementForManufacturingOfCommercialSuppliesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_235c6842-d09d-4e83-901f-bda9af31d176" xlink:to="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_fc26cba5-6ec4-4a95-836b-13663e4ddf85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember_efb8a243-cee5-4f65-8910-a10a7534135a" xlink:href="regn-20230331.xsd#regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_235c6842-d09d-4e83-901f-bda9af31d176" xlink:to="loc_regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember_efb8a243-cee5-4f65-8910-a10a7534135a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegeneronsObligationOfResearchAndDevelopmentExpensesNetOfReimbursementOfResearchAndDevelopmentExpensesMember_18c65e67-9d0a-4272-a457-8319ea90bb12" xlink:href="regn-20230331.xsd#regn_RegeneronsObligationOfResearchAndDevelopmentExpensesNetOfReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_235c6842-d09d-4e83-901f-bda9af31d176" xlink:to="loc_regn_RegeneronsObligationOfResearchAndDevelopmentExpensesNetOfReimbursementOfResearchAndDevelopmentExpensesMember_18c65e67-9d0a-4272-a457-8319ea90bb12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4dbc01aa-f839-4cbd-abf1-73ff13ef91fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a691b55d-246f-4237-a5a4-f37e56194ebe" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_4dbc01aa-f839-4cbd-abf1-73ff13ef91fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_908a5820-d2c6-4c9e-abae-eedfa03f01c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4dbc01aa-f839-4cbd-abf1-73ff13ef91fd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_908a5820-d2c6-4c9e-abae-eedfa03f01c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3238c8ba-4931-4fff-add4-548cafdad1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_aaec540f-ebf8-49ad-a960-d933a09f0102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3238c8ba-4931-4fff-add4-548cafdad1b9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_aaec540f-ebf8-49ad-a960-d933a09f0102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_96795e93-a1d2-4813-9d31-233f107c8504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_aaec540f-ebf8-49ad-a960-d933a09f0102" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_96795e93-a1d2-4813-9d31-233f107c8504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_8d17a6db-6329-4fa2-b828-17603833ea5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_96795e93-a1d2-4813-9d31-233f107c8504" xlink:to="loc_us-gaap_ProjectMember_8d17a6db-6329-4fa2-b828-17603833ea5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_106583d0-233d-4592-b1d3-7bf6e35bcbbf" xlink:href="regn-20230331.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_8d17a6db-6329-4fa2-b828-17603833ea5c" xlink:to="loc_regn_BayerCollaborationAgreementMember_106583d0-233d-4592-b1d3-7bf6e35bcbbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_bad81ce4-3d5f-469f-a4b7-050e04c9929f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_aaec540f-ebf8-49ad-a960-d933a09f0102" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_bad81ce4-3d5f-469f-a4b7-050e04c9929f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5604f21e-2e7c-4e11-bf33-1afe2a2b05ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bad81ce4-3d5f-469f-a4b7-050e04c9929f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5604f21e-2e7c-4e11-bf33-1afe2a2b05ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_d8381753-9748-468c-a606-6f080125e1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bad81ce4-3d5f-469f-a4b7-050e04c9929f" xlink:to="loc_us-gaap_ContractWithCustomerLiability_d8381753-9748-468c-a606-6f080125e1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2bfdea9b-1bab-48be-a79b-64deabc4644d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_c12c175a-96e4-4ce5-9994-a2b2dd7a34be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2bfdea9b-1bab-48be-a79b-64deabc4644d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_c12c175a-96e4-4ce5-9994-a2b2dd7a34be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ec50b96c-5374-4609-b0b0-b36fc99b57b9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c12c175a-96e4-4ce5-9994-a2b2dd7a34be" xlink:to="loc_srt_ProductOrServiceAxis_ec50b96c-5374-4609-b0b0-b36fc99b57b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_357c5e8f-b093-4b29-a37e-1e6897dae5cb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ec50b96c-5374-4609-b0b0-b36fc99b57b9" xlink:to="loc_srt_ProductsAndServicesDomain_357c5e8f-b093-4b29-a37e-1e6897dae5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RonapreveMember_efb0674f-b7d6-48b0-b437-f372a8527849" xlink:href="regn-20230331.xsd#regn_RonapreveMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_357c5e8f-b093-4b29-a37e-1e6897dae5cb" xlink:to="loc_regn_RonapreveMember_efb0674f-b7d6-48b0-b437-f372a8527849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cf138e1c-698c-495f-bb13-933cc6f0d6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c12c175a-96e4-4ce5-9994-a2b2dd7a34be" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cf138e1c-698c-495f-bb13-933cc6f0d6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_e180a0c2-78e0-496e-a8b4-5ecc5ef88438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_cf138e1c-698c-495f-bb13-933cc6f0d6c4" xlink:to="loc_us-gaap_ProjectMember_e180a0c2-78e0-496e-a8b4-5ecc5ef88438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RocheCollaborationAgreementMember_255da977-2ffa-4014-9528-70edafd9fb93" xlink:href="regn-20230331.xsd#regn_RocheCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_e180a0c2-78e0-496e-a8b4-5ecc5ef88438" xlink:to="loc_regn_RocheCollaborationAgreementMember_255da977-2ffa-4014-9528-70edafd9fb93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1d668305-3585-486b-9f99-a9ae03e68d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c12c175a-96e4-4ce5-9994-a2b2dd7a34be" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1d668305-3585-486b-9f99-a9ae03e68d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1b079972-3655-4331-9ece-ba4432c1bdc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1d668305-3585-486b-9f99-a9ae03e68d9f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1b079972-3655-4331-9ece-ba4432c1bdc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationRevenueMember_2976b3af-e3d7-469a-9ae0-43ca2ebd8c1e" xlink:href="regn-20230331.xsd#regn_CollaborationRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1b079972-3655-4331-9ece-ba4432c1bdc0" xlink:to="loc_regn_CollaborationRevenueMember_2976b3af-e3d7-469a-9ae0-43ca2ebd8c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_56a2a69a-d15c-4d4a-a805-78ff7461d7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c12c175a-96e4-4ce5-9994-a2b2dd7a34be" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_56a2a69a-d15c-4d4a-a805-78ff7461d7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ae2172d4-923f-4d5e-be0b-4717c1d36e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_56a2a69a-d15c-4d4a-a805-78ff7461d7c2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ae2172d4-923f-4d5e-be0b-4717c1d36e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9a14a059-d192-4733-80f0-33afc921bccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a6654264-78d4-41d5-ac4d-d562ec8dcaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9a14a059-d192-4733-80f0-33afc921bccd" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a6654264-78d4-41d5-ac4d-d562ec8dcaa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1db80afa-8846-4234-82ed-842e89071954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a6654264-78d4-41d5-ac4d-d562ec8dcaa0" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1db80afa-8846-4234-82ed-842e89071954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_35039296-ad3f-49cc-9a97-86fe58ffcf3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1db80afa-8846-4234-82ed-842e89071954" xlink:to="loc_us-gaap_ProjectMember_35039296-ad3f-49cc-9a97-86fe58ffcf3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RocheCollaborationAgreementMember_83180a73-df2a-4045-b56e-4f7bcd0767b2" xlink:href="regn-20230331.xsd#regn_RocheCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_35039296-ad3f-49cc-9a97-86fe58ffcf3f" xlink:to="loc_regn_RocheCollaborationAgreementMember_83180a73-df2a-4045-b56e-4f7bcd0767b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_70c3a879-36cb-443d-83a9-62da24a0211d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a6654264-78d4-41d5-ac4d-d562ec8dcaa0" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_70c3a879-36cb-443d-83a9-62da24a0211d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_34e56eaf-f6d5-4ab0-ab1d-be77a503b417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_70c3a879-36cb-443d-83a9-62da24a0211d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_34e56eaf-f6d5-4ab0-ab1d-be77a503b417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_19a21bfa-7243-4766-848c-90c9aba5e8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_68032f0c-bd5a-4cf5-83d8-fd5741a24c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_19a21bfa-7243-4766-848c-90c9aba5e8d2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_68032f0c-bd5a-4cf5-83d8-fd5741a24c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_90d70b21-3579-4db6-afb2-14e277a4cf82" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_68032f0c-bd5a-4cf5-83d8-fd5741a24c01" xlink:to="loc_srt_CounterpartyNameAxis_90d70b21-3579-4db6-afb2-14e277a4cf82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88c252a7-e961-4b06-8c51-3c4aba345b30" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_90d70b21-3579-4db6-afb2-14e277a4cf82" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88c252a7-e961-4b06-8c51-3c4aba345b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SonomaBiotherapeuticsIncMember_17ec5dc4-0741-426a-a38b-d4b9dbdc857f" xlink:href="regn-20230331.xsd#regn_SonomaBiotherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88c252a7-e961-4b06-8c51-3c4aba345b30" xlink:to="loc_regn_SonomaBiotherapeuticsIncMember_17ec5dc4-0741-426a-a38b-d4b9dbdc857f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_c23b8adb-1368-4187-80b0-86762d762cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_68032f0c-bd5a-4cf5-83d8-fd5741a24c01" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_c23b8adb-1368-4187-80b0-86762d762cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_0523c1b3-d094-4cd9-8551-687b62949df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_c23b8adb-1368-4187-80b0-86762d762cbe" xlink:to="loc_us-gaap_ProjectMember_0523c1b3-d094-4cd9-8551-687b62949df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SonomaBiotherapeuticsIncCollaborationAgreementMember_e3070733-c9bc-4a99-bd83-4ace8bf0a6bc" xlink:href="regn-20230331.xsd#regn_SonomaBiotherapeuticsIncCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_0523c1b3-d094-4cd9-8551-687b62949df7" xlink:to="loc_regn_SonomaBiotherapeuticsIncCollaborationAgreementMember_e3070733-c9bc-4a99-bd83-4ace8bf0a6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MilestoneTypeAxis_f142b492-bfb4-4a1b-879e-3c1dc119516a" xlink:href="regn-20230331.xsd#regn_MilestoneTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_68032f0c-bd5a-4cf5-83d8-fd5741a24c01" xlink:to="loc_regn_MilestoneTypeAxis_f142b492-bfb4-4a1b-879e-3c1dc119516a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MilestoneTypeDomain_8e700fa2-7637-4847-b66b-99880d8cc79e" xlink:href="regn-20230331.xsd#regn_MilestoneTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_MilestoneTypeAxis_f142b492-bfb4-4a1b-879e-3c1dc119516a" xlink:to="loc_regn_MilestoneTypeDomain_8e700fa2-7637-4847-b66b-99880d8cc79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DevelopmentMilestoneMember_34b8255c-888d-4fab-8ec1-a453de637556" xlink:href="regn-20230331.xsd#regn_DevelopmentMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_MilestoneTypeDomain_8e700fa2-7637-4847-b66b-99880d8cc79e" xlink:to="loc_regn_DevelopmentMilestoneMember_34b8255c-888d-4fab-8ec1-a453de637556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f24dc9d7-8754-42fc-9210-5b3e52e98759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_68032f0c-bd5a-4cf5-83d8-fd5741a24c01" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f24dc9d7-8754-42fc-9210-5b3e52e98759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1cfc0721-fba8-4a63-89e9-b6644f683d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f24dc9d7-8754-42fc-9210-5b3e52e98759" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1cfc0721-fba8-4a63-89e9-b6644f683d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_017acdbe-60b3-4c6f-b7c1-40da58fdba72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1cfc0721-fba8-4a63-89e9-b6644f683d2d" xlink:to="loc_us-gaap_SubsequentEventMember_017acdbe-60b3-4c6f-b7c1-40da58fdba72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f6f6f69e-3808-44f8-be13-60416aed3e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_68032f0c-bd5a-4cf5-83d8-fd5741a24c01" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_f6f6f69e-3808-44f8-be13-60416aed3e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UpFrontPaymentToCollaboratingParty_e3b03028-8b43-45a5-9572-d68edd6df8a7" xlink:href="regn-20230331.xsd#regn_UpFrontPaymentToCollaboratingParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f6f6f69e-3808-44f8-be13-60416aed3e2f" xlink:to="loc_regn_UpFrontPaymentToCollaboratingParty_e3b03028-8b43-45a5-9572-d68edd6df8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_4af97b0a-c7cb-4c0d-89df-db1627a8d8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f6f6f69e-3808-44f8-be13-60416aed3e2f" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_4af97b0a-c7cb-4c0d-89df-db1627a8d8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97fb21d2-b2bf-40a0-9cb4-150ae46364eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f6f6f69e-3808-44f8-be13-60416aed3e2f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97fb21d2-b2bf-40a0-9cb4-150ae46364eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d2efef7e-3890-4515-a750-4c779850b816" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_405a770c-ab29-4cf5-a52a-16a355357829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d2efef7e-3890-4515-a750-4c779850b816" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_405a770c-ab29-4cf5-a52a-16a355357829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7f7f5e4e-b178-4a70-9356-c80cba52153e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_405a770c-ab29-4cf5-a52a-16a355357829" xlink:to="loc_us-gaap_AwardTypeAxis_7f7f5e4e-b178-4a70-9356-c80cba52153e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d7295a8-d944-41fd-b588-dd7b781db06c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7f7f5e4e-b178-4a70-9356-c80cba52153e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d7295a8-d944-41fd-b588-dd7b781db06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1409c73e-5b40-41c8-85fa-adbd231cd677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d7295a8-d944-41fd-b588-dd7b781db06c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1409c73e-5b40-41c8-85fa-adbd231cd677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e2a59c35-9e1d-4757-89d7-543ca378db62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d7295a8-d944-41fd-b588-dd7b781db06c" xlink:to="loc_us-gaap_RestrictedStockMember_e2a59c35-9e1d-4757-89d7-543ca378db62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_5b33c64a-6864-42bc-915f-f113fd1af11e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_405a770c-ab29-4cf5-a52a-16a355357829" xlink:to="loc_us-gaap_EarningsPerShareDilutedLineItems_5b33c64a-6864-42bc-915f-f113fd1af11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_62b1c140-2a34-4b73-ac40-d207c0737e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_5b33c64a-6864-42bc-915f-f113fd1af11e" xlink:to="loc_us-gaap_NetIncomeLoss_62b1c140-2a34-4b73-ac40-d207c0737e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9db6cab9-2c33-46da-b17a-9579598ae822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_5b33c64a-6864-42bc-915f-f113fd1af11e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9db6cab9-2c33-46da-b17a-9579598ae822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ef29ef8f-9a24-44a5-b02e-ed1b96b06653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_5b33c64a-6864-42bc-915f-f113fd1af11e" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ef29ef8f-9a24-44a5-b02e-ed1b96b06653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_16a26f97-6913-4e5c-b779-b70260621c94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_5b33c64a-6864-42bc-915f-f113fd1af11e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_16a26f97-6913-4e5c-b779-b70260621c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_237e6702-6383-4891-93c6-b02e47c51849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_5b33c64a-6864-42bc-915f-f113fd1af11e" xlink:to="loc_us-gaap_EarningsPerShareBasic_237e6702-6383-4891-93c6-b02e47c51849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c60bf1b7-31a9-4153-bbfe-0bef3824ad60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_5b33c64a-6864-42bc-915f-f113fd1af11e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c60bf1b7-31a9-4153-bbfe-0bef3824ad60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8b273a12-54e2-4bb0-8ca4-af467ca030ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_257c3e15-7467-4901-a084-1d1529ce9e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8b273a12-54e2-4bb0-8ca4-af467ca030ab" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_257c3e15-7467-4901-a084-1d1529ce9e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_049f48f5-cf30-4c9f-ba27-8aad94dcaf13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_257c3e15-7467-4901-a084-1d1529ce9e0a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_049f48f5-cf30-4c9f-ba27-8aad94dcaf13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5a181cef-733b-47d0-983d-65401ddc824e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_049f48f5-cf30-4c9f-ba27-8aad94dcaf13" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5a181cef-733b-47d0-983d-65401ddc824e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3a3797bd-c75a-4939-8ee9-186659305229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5a181cef-733b-47d0-983d-65401ddc824e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3a3797bd-c75a-4939-8ee9-186659305229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_dd5a6645-afce-4a94-82ea-25bf106d7e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_257c3e15-7467-4901-a084-1d1529ce9e0a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_dd5a6645-afce-4a94-82ea-25bf106d7e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7608ce0d-608f-4503-8883-944a0c56f3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_dd5a6645-afce-4a94-82ea-25bf106d7e0f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7608ce0d-608f-4503-8883-944a0c56f3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_343fee80-c524-41c4-891e-cc6ffecdef95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d8aeadad-7651-4631-ae5a-d7dae67eb1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_343fee80-c524-41c4-891e-cc6ffecdef95" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d8aeadad-7651-4631-ae5a-d7dae67eb1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_599e0781-30b3-416e-ae67-90d89f6da31f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d8aeadad-7651-4631-ae5a-d7dae67eb1cf" xlink:to="loc_us-gaap_FinancialInstrumentAxis_599e0781-30b3-416e-ae67-90d89f6da31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_40090e1b-3d53-4c88-821d-6f3d2e243054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_599e0781-30b3-416e-ae67-90d89f6da31f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_40090e1b-3d53-4c88-821d-6f3d2e243054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_0869baca-7554-44dc-a14d-98f57dff387a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_40090e1b-3d53-4c88-821d-6f3d2e243054" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_0869baca-7554-44dc-a14d-98f57dff387a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_b428071e-7bc2-4a92-a5e7-2248d163ff29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_40090e1b-3d53-4c88-821d-6f3d2e243054" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_b428071e-7bc2-4a92-a5e7-2248d163ff29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_476c8c66-e7ce-4f69-85ba-e5d848170c10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_40090e1b-3d53-4c88-821d-6f3d2e243054" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_476c8c66-e7ce-4f69-85ba-e5d848170c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_53b6e601-8edb-4e8c-a859-bf511a7f1922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_40090e1b-3d53-4c88-821d-6f3d2e243054" xlink:to="loc_us-gaap_CommercialPaperMember_53b6e601-8edb-4e8c-a859-bf511a7f1922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_a80f9651-8063-4ed1-a9d9-0e0d1699098b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_40090e1b-3d53-4c88-821d-6f3d2e243054" xlink:to="loc_us-gaap_CertificatesOfDepositMember_a80f9651-8063-4ed1-a9d9-0e0d1699098b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_bc004e59-8cfc-4752-bfc4-71ca383960f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_40090e1b-3d53-4c88-821d-6f3d2e243054" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_bc004e59-8cfc-4752-bfc4-71ca383960f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_86c67bde-9398-4695-ae5a-404085ad52eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d8aeadad-7651-4631-ae5a-d7dae67eb1cf" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_86c67bde-9398-4695-ae5a-404085ad52eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c9e0831e-c4e3-4de7-9b32-71411341c326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_86c67bde-9398-4695-ae5a-404085ad52eb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c9e0831e-c4e3-4de7-9b32-71411341c326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4d7c63e9-6655-4bae-b345-5f118325f53c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_86c67bde-9398-4695-ae5a-404085ad52eb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4d7c63e9-6655-4bae-b345-5f118325f53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_16c97e34-60c1-443e-8da9-151c1b5e1308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_86c67bde-9398-4695-ae5a-404085ad52eb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_16c97e34-60c1-443e-8da9-151c1b5e1308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_286b4d87-b45d-44c3-a4ba-f550a2d9c0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_86c67bde-9398-4695-ae5a-404085ad52eb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_286b4d87-b45d-44c3-a4ba-f550a2d9c0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_08762389-42bc-419d-8928-03e5aa8ba174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_87729632-3289-4017-9a88-3de68a45b666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_08762389-42bc-419d-8928-03e5aa8ba174" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_87729632-3289-4017-9a88-3de68a45b666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_36ca87b2-5dcc-460a-ad14-611848d65f54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_08762389-42bc-419d-8928-03e5aa8ba174" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_36ca87b2-5dcc-460a-ad14-611848d65f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_2b8c1c80-2629-4f21-8dd7-160002ff156d" xlink:href="regn-20230331.xsd#regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_08762389-42bc-419d-8928-03e5aa8ba174" xlink:to="loc_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5_2b8c1c80-2629-4f21-8dd7-160002ff156d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7b330266-faa4-4a7e-9c28-afea6c2afa47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_08762389-42bc-419d-8928-03e5aa8ba174" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7b330266-faa4-4a7e-9c28-afea6c2afa47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_afc627f1-e676-4b6f-b8b5-e8c4cd037c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f92646c6-d525-4b83-ba8b-6f4b637ed90f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_afc627f1-e676-4b6f-b8b5-e8c4cd037c82" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f92646c6-d525-4b83-ba8b-6f4b637ed90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c292354f-91b3-4ffc-a36c-9c8d4deee405" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f92646c6-d525-4b83-ba8b-6f4b637ed90f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c292354f-91b3-4ffc-a36c-9c8d4deee405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_62c19203-51bf-48fa-aeee-2e3a03f7b2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c292354f-91b3-4ffc-a36c-9c8d4deee405" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_62c19203-51bf-48fa-aeee-2e3a03f7b2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_d9112525-6aac-4980-b479-47136e167dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_62c19203-51bf-48fa-aeee-2e3a03f7b2fe" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_d9112525-6aac-4980-b479-47136e167dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_64525ecf-bf12-45fa-be5e-9fef1bdd507f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_62c19203-51bf-48fa-aeee-2e3a03f7b2fe" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_64525ecf-bf12-45fa-be5e-9fef1bdd507f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_7681cb99-8343-4e73-a792-e8e86ef1417c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_62c19203-51bf-48fa-aeee-2e3a03f7b2fe" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_7681cb99-8343-4e73-a792-e8e86ef1417c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_0b0865dc-92ac-4e39-ab4b-53f925268479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_62c19203-51bf-48fa-aeee-2e3a03f7b2fe" xlink:to="loc_us-gaap_CommercialPaperMember_0b0865dc-92ac-4e39-ab4b-53f925268479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_b42d25aa-2532-4883-8707-b4ab3780028b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_62c19203-51bf-48fa-aeee-2e3a03f7b2fe" xlink:to="loc_us-gaap_CertificatesOfDepositMember_b42d25aa-2532-4883-8707-b4ab3780028b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_a127f877-c354-476e-b108-9dd9e1291f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_62c19203-51bf-48fa-aeee-2e3a03f7b2fe" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_a127f877-c354-476e-b108-9dd9e1291f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_681316fc-1ba3-4d8b-95c9-ecfeeae80deb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f92646c6-d525-4b83-ba8b-6f4b637ed90f" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_681316fc-1ba3-4d8b-95c9-ecfeeae80deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_33767d06-ebb7-4a99-9e4a-74da2b8e6aef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_681316fc-1ba3-4d8b-95c9-ecfeeae80deb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_33767d06-ebb7-4a99-9e4a-74da2b8e6aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_5e85ad07-b47d-4d91-af4c-9ed1e2602060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_681316fc-1ba3-4d8b-95c9-ecfeeae80deb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_5e85ad07-b47d-4d91-af4c-9ed1e2602060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_7cdb3492-ad55-449a-abe5-7ed5e1f91151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_681316fc-1ba3-4d8b-95c9-ecfeeae80deb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_7cdb3492-ad55-449a-abe5-7ed5e1f91151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3b335e40-e60b-42d8-a22d-884aaefc4c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_681316fc-1ba3-4d8b-95c9-ecfeeae80deb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3b335e40-e60b-42d8-a22d-884aaefc4c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_ddebf0bf-e92d-4776-94dd-0a096ea77887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_681316fc-1ba3-4d8b-95c9-ecfeeae80deb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_ddebf0bf-e92d-4776-94dd-0a096ea77887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_b55567e6-1b98-47bf-a79e-fb18702816e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_681316fc-1ba3-4d8b-95c9-ecfeeae80deb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_b55567e6-1b98-47bf-a79e-fb18702816e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f558ed0f-fe0d-4ad6-bd2d-e1cfe0c0e936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29aafef5-7e48-4fcf-a027-84e69925c126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f558ed0f-fe0d-4ad6-bd2d-e1cfe0c0e936" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29aafef5-7e48-4fcf-a027-84e69925c126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5637f780-bf38-49ef-b2dc-f382c4f4aed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29aafef5-7e48-4fcf-a027-84e69925c126" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5637f780-bf38-49ef-b2dc-f382c4f4aed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9aa7de7d-2108-419e-9344-0c71678ca62c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5637f780-bf38-49ef-b2dc-f382c4f4aed0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9aa7de7d-2108-419e-9344-0c71678ca62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_01d6981c-d302-4677-a3c5-1e89c65b2039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9aa7de7d-2108-419e-9344-0c71678ca62c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_01d6981c-d302-4677-a3c5-1e89c65b2039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_df9a1066-17d4-484f-a4a4-c8dff252b247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29aafef5-7e48-4fcf-a027-84e69925c126" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_df9a1066-17d4-484f-a4a4-c8dff252b247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f33fda03-ea80-430f-9b62-dfcfb2545881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_df9a1066-17d4-484f-a4a4-c8dff252b247" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f33fda03-ea80-430f-9b62-dfcfb2545881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_76da1bd0-9961-48a3-9866-d6b6ee329812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f33fda03-ea80-430f-9b62-dfcfb2545881" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_76da1bd0-9961-48a3-9866-d6b6ee329812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4cc31212-0ce8-40b3-a201-90b8c933de77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f33fda03-ea80-430f-9b62-dfcfb2545881" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4cc31212-0ce8-40b3-a201-90b8c933de77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4f5c2751-d0e8-4a26-9eba-7fbdc7cced2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29aafef5-7e48-4fcf-a027-84e69925c126" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4f5c2751-d0e8-4a26-9eba-7fbdc7cced2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4acdd16-61b3-4a28-8954-d58fb9921e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4f5c2751-d0e8-4a26-9eba-7fbdc7cced2e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4acdd16-61b3-4a28-8954-d58fb9921e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_4216533c-4bed-40b1-9285-c6b05a82c546" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4acdd16-61b3-4a28-8954-d58fb9921e30" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_4216533c-4bed-40b1-9285-c6b05a82c546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_c594c65a-8e8d-457b-95b7-7d94f970fa2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4acdd16-61b3-4a28-8954-d58fb9921e30" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_c594c65a-8e8d-457b-95b7-7d94f970fa2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_169cc162-31cc-4107-a710-4be65f0ad580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4acdd16-61b3-4a28-8954-d58fb9921e30" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_169cc162-31cc-4107-a710-4be65f0ad580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_3608dd25-e5e7-4826-9df2-3a6151789411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4acdd16-61b3-4a28-8954-d58fb9921e30" xlink:to="loc_us-gaap_CommercialPaperMember_3608dd25-e5e7-4826-9df2-3a6151789411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_dd10178f-d75c-4aa2-8212-bbd20a89e271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4acdd16-61b3-4a28-8954-d58fb9921e30" xlink:to="loc_us-gaap_CertificatesOfDepositMember_dd10178f-d75c-4aa2-8212-bbd20a89e271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_8ce92c22-cc59-4b06-9ab6-17d098d42338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a4acdd16-61b3-4a28-8954-d58fb9921e30" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_8ce92c22-cc59-4b06-9ab6-17d098d42338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentAxis_818f4851-09c8-4d0c-8dca-310021bfdbbe" xlink:href="regn-20230331.xsd#regn_ClassificationOfInvestmentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29aafef5-7e48-4fcf-a027-84e69925c126" xlink:to="loc_regn_ClassificationOfInvestmentAxis_818f4851-09c8-4d0c-8dca-310021bfdbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentDomain_7a1aa4ac-3a0b-470e-a462-328ce7c9e9b4" xlink:href="regn-20230331.xsd#regn_ClassificationOfInvestmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ClassificationOfInvestmentAxis_818f4851-09c8-4d0c-8dca-310021bfdbbe" xlink:to="loc_regn_ClassificationOfInvestmentDomain_7a1aa4ac-3a0b-470e-a462-328ce7c9e9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UnrestrictedMember_93c698b5-f0b7-4029-bbd4-14298609fef9" xlink:href="regn-20230331.xsd#regn_UnrestrictedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ClassificationOfInvestmentDomain_7a1aa4ac-3a0b-470e-a462-328ce7c9e9b4" xlink:to="loc_regn_UnrestrictedMember_93c698b5-f0b7-4029-bbd4-14298609fef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RestrictedMember_ca1afcc6-ae06-4714-a3f4-cb2d2039675c" xlink:href="regn-20230331.xsd#regn_RestrictedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ClassificationOfInvestmentDomain_7a1aa4ac-3a0b-470e-a462-328ce7c9e9b4" xlink:to="loc_regn_RestrictedMember_ca1afcc6-ae06-4714-a3f4-cb2d2039675c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d663a8d1-bdfa-4f42-b678-6b3e3f59b862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29aafef5-7e48-4fcf-a027-84e69925c126" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d663a8d1-bdfa-4f42-b678-6b3e3f59b862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9ee0dde1-9f30-415b-9751-59a44f9e0aec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d663a8d1-bdfa-4f42-b678-6b3e3f59b862" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9ee0dde1-9f30-415b-9751-59a44f9e0aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_84aef472-6b4b-437c-bac2-292af42efa61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d663a8d1-bdfa-4f42-b678-6b3e3f59b862" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_84aef472-6b4b-437c-bac2-292af42efa61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_d36abc49-3415-42c1-a228-37a11d196c35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d663a8d1-bdfa-4f42-b678-6b3e3f59b862" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_d36abc49-3415-42c1-a228-37a11d196c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_72fb9d0c-26ec-4d37-8f95-20eb4d1d1ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d663a8d1-bdfa-4f42-b678-6b3e3f59b862" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_72fb9d0c-26ec-4d37-8f95-20eb4d1d1ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_85848348-1d63-4147-99da-964bbbc43b36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_ef905b52-27a9-4516-afb6-69d34f63c8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_85848348-1d63-4147-99da-964bbbc43b36" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_ef905b52-27a9-4516-afb6-69d34f63c8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_a044002e-8854-47da-bf2b-9c72a4d92a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_85848348-1d63-4147-99da-964bbbc43b36" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_a044002e-8854-47da-bf2b-9c72a4d92a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_6de391e6-00c3-4b1e-8b14-82910c5c9ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_85848348-1d63-4147-99da-964bbbc43b36" xlink:to="loc_us-gaap_LongTermDebtFairValue_6de391e6-00c3-4b1e-8b14-82910c5c9ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_90446516-24f9-4319-af9d-e2d4f103890f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_e25f35c1-e298-4299-8d67-ec1ac4c610dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_90446516-24f9-4319-af9d-e2d4f103890f" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_e25f35c1-e298-4299-8d67-ec1ac4c610dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_9a4e785d-5ea3-459b-b270-19c1aa8c0f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_90446516-24f9-4319-af9d-e2d4f103890f" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_9a4e785d-5ea3-459b-b270-19c1aa8c0f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_68348bc2-6605-464f-bb6b-a20d939be77c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_90446516-24f9-4319-af9d-e2d4f103890f" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_68348bc2-6605-464f-bb6b-a20d939be77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryNetOfReserves_3e7f00e3-49fd-456b-b049-647ac65f5cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryNetOfReserves"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_90446516-24f9-4319-af9d-e2d4f103890f" xlink:to="loc_us-gaap_OtherInventoryNetOfReserves_3e7f00e3-49fd-456b-b049-647ac65f5cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d250e282-e672-4146-afe4-fc461a5ef4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_90446516-24f9-4319-af9d-e2d4f103890f" xlink:to="loc_us-gaap_InventoryNet_d250e282-e672-4146-afe4-fc461a5ef4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#InventoriesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/InventoriesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_44c4b991-7f3b-4dff-a5da-55d072b65464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_5f9d9008-9381-4c61-a34c-1cad33b58375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_44c4b991-7f3b-4dff-a5da-55d072b65464" xlink:to="loc_us-gaap_InventoryValuationReserves_5f9d9008-9381-4c61-a34c-1cad33b58375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_234bb747-72d5-4bc3-8c4e-3d145d02559d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4de75131-faf6-48ae-9451-23c2f6999e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_234bb747-72d5-4bc3-8c4e-3d145d02559d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4de75131-faf6-48ae-9451-23c2f6999e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_23133ac7-e182-4f98-907b-f838ca2e5edb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_30bb35ae-f8ed-4fdf-8d98-eba154fdbc06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_23133ac7-e182-4f98-907b-f838ca2e5edb" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_30bb35ae-f8ed-4fdf-8d98-eba154fdbc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_4fafad40-4b6a-49c7-adb8-21c4e1054f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_30bb35ae-f8ed-4fdf-8d98-eba154fdbc06" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_4fafad40-4b6a-49c7-adb8-21c4e1054f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_dd8f1aba-511b-4ed1-8a4c-f2f91441fa0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_4fafad40-4b6a-49c7-adb8-21c4e1054f10" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_dd8f1aba-511b-4ed1-8a4c-f2f91441fa0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgramNovember2021Member_86dd76d1-d20a-486d-bc4a-c9ea5953cb01" xlink:href="regn-20230331.xsd#regn_ShareRepurchaseProgramNovember2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_dd8f1aba-511b-4ed1-8a4c-f2f91441fa0a" xlink:to="loc_regn_ShareRepurchaseProgramNovember2021Member_86dd76d1-d20a-486d-bc4a-c9ea5953cb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgramJanuary2023Member_b9160e71-0421-4e57-baae-08241642f030" xlink:href="regn-20230331.xsd#regn_ShareRepurchaseProgramJanuary2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_dd8f1aba-511b-4ed1-8a4c-f2f91441fa0a" xlink:to="loc_regn_ShareRepurchaseProgramJanuary2023Member_b9160e71-0421-4e57-baae-08241642f030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_35bd0f55-1b38-4cc9-8b5d-84f470f7e4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_30bb35ae-f8ed-4fdf-8d98-eba154fdbc06" xlink:to="loc_us-gaap_ClassOfStockLineItems_35bd0f55-1b38-4cc9-8b5d-84f470f7e4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d3d53f84-a377-45e5-b829-f90692775dad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_35bd0f55-1b38-4cc9-8b5d-84f470f7e4e4" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d3d53f84-a377-45e5-b829-f90692775dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_837011bf-6740-48df-ab34-2aba02be5802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_35bd0f55-1b38-4cc9-8b5d-84f470f7e4e4" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_837011bf-6740-48df-ab34-2aba02be5802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquityScheduleofShareRepurchasesDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#StockholdersEquityScheduleofShareRepurchasesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StockholdersEquityScheduleofShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_42ab0c1f-7084-40b2-94d4-651ba7b0f113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_e1b58821-268a-41a3-98ff-280c2c6d369b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_42ab0c1f-7084-40b2-94d4-651ba7b0f113" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_e1b58821-268a-41a3-98ff-280c2c6d369b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_bf957a41-6ca1-458b-afcb-7008f3ee4599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_42ab0c1f-7084-40b2-94d4-651ba7b0f113" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_bf957a41-6ca1-458b-afcb-7008f3ee4599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#CashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_c8337d5a-a8d9-43e1-86aa-7a50721ddf2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c898289b-63f1-4555-97b5-35ea8c063c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_c8337d5a-a8d9-43e1-86aa-7a50721ddf2d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c898289b-63f1-4555-97b5-35ea8c063c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_8102ee01-53cd-4177-8efd-b957afc92921" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_c8337d5a-a8d9-43e1-86aa-7a50721ddf2d" xlink:to="loc_us-gaap_RestrictedCash_8102ee01-53cd-4177-8efd-b957afc92921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ab5ccd21-1bd5-42b3-98e8-340d914a9bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_c8337d5a-a8d9-43e1-86aa-7a50721ddf2d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ab5ccd21-1bd5-42b3-98e8-340d914a9bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#CashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_65c0805a-3ec1-4423-86c5-df303bb1d994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_4841aeed-b268-4793-ac7f-04a3e26c0acb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_65c0805a-3ec1-4423-86c5-df303bb1d994" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_4841aeed-b268-4793-ac7f-04a3e26c0acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_9e1dbba2-4c1f-4bb7-a01d-e74dd24aad11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_65c0805a-3ec1-4423-86c5-df303bb1d994" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_9e1dbba2-4c1f-4bb7-a01d-e74dd24aad11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/LegalMattersDetails" xlink:type="simple" xlink:href="regn-20230331.xsd#LegalMattersDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/LegalMattersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_78ff73ad-28e0-46b1-8a03-7afcdc85ef15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_bb5cd0fb-e4dc-4599-8767-2876075120d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_78ff73ad-28e0-46b1-8a03-7afcdc85ef15" xlink:to="loc_us-gaap_LossContingenciesTable_bb5cd0fb-e4dc-4599-8767-2876075120d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_df6e9843-689f-4345-976c-2f3ed8fca970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bb5cd0fb-e4dc-4599-8767-2876075120d4" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_df6e9843-689f-4345-976c-2f3ed8fca970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_366a787a-1952-4fa3-acfb-8e1a9094bd53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_df6e9843-689f-4345-976c-2f3ed8fca970" xlink:to="loc_us-gaap_LossContingencyNatureDomain_366a787a-1952-4fa3-acfb-8e1a9094bd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A226PatentAnd992PatentMember_c88489bf-0173-48db-934d-b949b42ea62e" xlink:href="regn-20230331.xsd#regn_A226PatentAnd992PatentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_366a787a-1952-4fa3-acfb-8e1a9094bd53" xlink:to="loc_regn_A226PatentAnd992PatentMember_c88489bf-0173-48db-934d-b949b42ea62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A338PatentAnd069PatentMember_5c5e21f6-b729-4b34-8f52-6b53de2d3a37" xlink:href="regn-20230331.xsd#regn_A338PatentAnd069PatentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_366a787a-1952-4fa3-acfb-8e1a9094bd53" xlink:to="loc_regn_A338PatentAnd069PatentMember_5c5e21f6-b729-4b34-8f52-6b53de2d3a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A631PatentMember_3e6f396f-6ed7-43b5-b721-216331a1a0b7" xlink:href="regn-20230331.xsd#regn_A631PatentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_366a787a-1952-4fa3-acfb-8e1a9094bd53" xlink:to="loc_regn_A631PatentMember_3e6f396f-6ed7-43b5-b721-216331a1a0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0de13f45-0634-49fd-953e-55592dfb8d4f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bb5cd0fb-e4dc-4599-8767-2876075120d4" xlink:to="loc_srt_ProductOrServiceAxis_0de13f45-0634-49fd-953e-55592dfb8d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f9d0fb77-fa03-408e-982e-4aef96b1a83a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0de13f45-0634-49fd-953e-55592dfb8d4f" xlink:to="loc_srt_ProductsAndServicesDomain_f9d0fb77-fa03-408e-982e-4aef96b1a83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EYLEAAfliberceptInjectionMember_df28e9a6-25dc-4da4-a507-5057b3081bd2" xlink:href="regn-20230331.xsd#regn_EYLEAAfliberceptInjectionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f9d0fb77-fa03-408e-982e-4aef96b1a83a" xlink:to="loc_regn_EYLEAAfliberceptInjectionMember_df28e9a6-25dc-4da4-a507-5057b3081bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_33fced3e-e0fa-4c90-a00d-4a0843caeca6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bb5cd0fb-e4dc-4599-8767-2876075120d4" xlink:to="loc_srt_CounterpartyNameAxis_33fced3e-e0fa-4c90-a00d-4a0843caeca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_178ee13d-16f6-4c06-ada7-5f9ec6b4aa23" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_33fced3e-e0fa-4c90-a00d-4a0843caeca6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_178ee13d-16f6-4c06-ada7-5f9ec6b4aa23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CelltrionIncMember_794572cd-e102-4362-ab53-03e403adc599" xlink:href="regn-20230331.xsd#regn_CelltrionIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_178ee13d-16f6-4c06-ada7-5f9ec6b4aa23" xlink:to="loc_regn_CelltrionIncMember_794572cd-e102-4362-ab53-03e403adc599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ApotexIncMember_7c87b0a5-12c5-42a8-b44f-eada8e5435df" xlink:href="regn-20230331.xsd#regn_ApotexIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_178ee13d-16f6-4c06-ada7-5f9ec6b4aa23" xlink:to="loc_regn_ApotexIncMember_7c87b0a5-12c5-42a8-b44f-eada8e5435df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_732502bd-63d2-44e3-8287-b1d08eebeb98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bb5cd0fb-e4dc-4599-8767-2876075120d4" xlink:to="loc_us-gaap_LossContingenciesLineItems_732502bd-63d2-44e3-8287-b1d08eebeb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LossContingencyExParteReexaminationFiledNumber_0fcfddea-07c3-4b1e-9cce-f4f8d1adba4e" xlink:href="regn-20230331.xsd#regn_LossContingencyExParteReexaminationFiledNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_732502bd-63d2-44e3-8287-b1d08eebeb98" xlink:to="loc_regn_LossContingencyExParteReexaminationFiledNumber_0fcfddea-07c3-4b1e-9cce-f4f8d1adba4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_NumberOfInterPartiesReviewIPRPetitionsFiled_93f091db-8411-489c-ba95-17a9616e06dc" xlink:href="regn-20230331.xsd#regn_NumberOfInterPartiesReviewIPRPetitionsFiled"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_732502bd-63d2-44e3-8287-b1d08eebeb98" xlink:to="loc_regn_NumberOfInterPartiesReviewIPRPetitionsFiled_93f091db-8411-489c-ba95-17a9616e06dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373853571424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 11, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-19034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">REGENERON PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3444607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">777 Old Saw Mill River Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tarrytown<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10591-6707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">847-7000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock - par value $.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">REGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000872589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,892,108<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373853642976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,916.3<span></span>
</td>
<td class="nump">$ 3,105.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">5,043.4<span></span>
</td>
<td class="nump">4,636.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">5,118.6<span></span>
</td>
<td class="nump">5,328.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">2,424.7<span></span>
</td>
<td class="nump">2,401.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">406.2<span></span>
</td>
<td class="nump">411.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">16,909.2<span></span>
</td>
<td class="nump">15,884.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">6,066.6<span></span>
</td>
<td class="nump">6,591.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment, net</a></td>
<td class="nump">3,880.9<span></span>
</td>
<td class="nump">3,763.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">928.7<span></span>
</td>
<td class="nump">915.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">1,924.9<span></span>
</td>
<td class="nump">1,723.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">349.6<span></span>
</td>
<td class="nump">336.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">30,059.9<span></span>
</td>
<td class="nump">29,214.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">599.5<span></span>
</td>
<td class="nump">589.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">2,074.3<span></span>
</td>
<td class="nump">2,074.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">426.3<span></span>
</td>
<td class="nump">477.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,100.1<span></span>
</td>
<td class="nump">3,141.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">1,981.8<span></span>
</td>
<td class="nump">1,981.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities</a></td>
<td class="nump">720.0<span></span>
</td>
<td class="nump">720.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">85.5<span></span>
</td>
<td class="nump">69.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">677.3<span></span>
</td>
<td class="nump">638.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">6,564.7<span></span>
</td>
<td class="nump">6,550.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, par value $.01 per share; 30.0 shares authorized; issued and outstanding - none</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">10,597.7<span></span>
</td>
<td class="nump">9,949.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">24,124.5<span></span>
</td>
<td class="nump">23,306.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(181.6)<span></span>
</td>
<td class="num">(238.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury Stock, at cost; 23.5 shares in 2023 and 22.6 shares in 2022</a></td>
<td class="num">(11,045.5)<span></span>
</td>
<td class="num">(10,353.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">23,495.2<span></span>
</td>
<td class="nump">22,664.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">30,059.9<span></span>
</td>
<td class="nump">29,214.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373853279296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, shares authorized (in shares)</a></td>
<td class="nump">30.0<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">23.5<span></span>
</td>
<td class="nump">22.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized (in shares)</a></td>
<td class="nump">40.0<span></span>
</td>
<td class="nump">40.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued (in shares)</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding (in shares)</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized (in shares)</a></td>
<td class="nump">320.0<span></span>
</td>
<td class="nump">320.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued (in shares)</a></td>
<td class="nump">131.4<span></span>
</td>
<td class="nump">130.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373854567888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 3,162.1<span></span>
</td>
<td class="nump">$ 2,965.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,101.2<span></span>
</td>
<td class="nump">843.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">56.1<span></span>
</td>
<td class="nump">28.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="nump">601.1<span></span>
</td>
<td class="nump">450.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating (income) expense, net</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(20.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total Expenses</a></td>
<td class="nump">2,215.4<span></span>
</td>
<td class="nump">1,706.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">946.7<span></span>
</td>
<td class="nump">1,258.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(70.7)<span></span>
</td>
<td class="num">(183.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(18.0)<span></span>
</td>
<td class="num">(13.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="num">(88.7)<span></span>
</td>
<td class="num">(197.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">858.0<span></span>
</td>
<td class="nump">1,061.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">40.2<span></span>
</td>
<td class="nump">87.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 817.8<span></span>
</td>
<td class="nump">$ 973.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - basic (in dollars per share)</a></td>
<td class="nump">$ 7.64<span></span>
</td>
<td class="nump">$ 9.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - diluted (in dollars per share)</a></td>
<td class="nump">$ 7.17<span></span>
</td>
<td class="nump">$ 8.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic (in shares)</a></td>
<td class="nump">107.1<span></span>
</td>
<td class="nump">106.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding - diluted (in shares)</a></td>
<td class="nump">114.0<span></span>
</td>
<td class="nump">113.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Statements of Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 817.8<span></span>
</td>
<td class="nump">$ 973.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on debt securities</a></td>
<td class="nump">57.2<span></span>
</td>
<td class="num">(144.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Unrealized gain on cash flow hedges</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">875.0<span></span>
</td>
<td class="nump">829.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,668.0<span></span>
</td>
<td class="nump">1,638.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods, collaboration and contract manufacturing</a></td>
<td class="nump">208.4<span></span>
</td>
<td class="nump">207.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=regn_CollaborationRevenueMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,378.1<span></span>
</td>
<td class="nump">1,232.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">116.0<span></span>
</td>
<td class="nump">94.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=regn_CollaborationandContractManufacturingMember', window );">Cost of collaboration and contract manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods, collaboration and contract manufacturing</a></td>
<td class="nump">$ 249.1<span></span>
</td>
<td class="nump">$ 197.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired In-Process Research and Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_CollaborationandContractManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_CollaborationandContractManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373849790496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Class A Stock</div></th>
<th class="th">
<div>Class A Stock </div>
<div>Common Stock</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning Balance, treasury (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 18,768.8<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 8,087.5<span></span>
</td>
<td class="nump">$ 18,968.3<span></span>
</td>
<td class="num">$ (26.2)<span></span>
</td>
<td class="num">$ (8,260.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans</a></td>
<td class="nump">593.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">593.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</a></td>
<td class="num">(105.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(105.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock for 401(k) Savings Plan</a></td>
<td class="nump">14.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of Common Stock</a></td>
<td class="num">(352.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (352.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation charges</a></td>
<td class="nump">165.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">973.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">973.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(143.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(143.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending Balance, treasury (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 19,914.7<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">8,754.1<span></span>
</td>
<td class="nump">19,941.8<span></span>
</td>
<td class="num">(170.1)<span></span>
</td>
<td class="num">$ (8,611.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning Balance, treasury (in shares) at Dec. 31, 2022</a></td>
<td class="num">(22.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 22,664.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">9,949.3<span></span>
</td>
<td class="nump">23,306.7<span></span>
</td>
<td class="num">(238.8)<span></span>
</td>
<td class="num">$ (10,353.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans</a></td>
<td class="nump">491.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">491.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</a></td>
<td class="num">(99.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(99.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock for 401(k) Savings Plan</a></td>
<td class="nump">20.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of Common Stock</a></td>
<td class="num">(693.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (693.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation charges</a></td>
<td class="nump">237.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">817.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">817.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">$ 57.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending Balance, treasury (in shares) at Mar. 31, 2023</a></td>
<td class="num">(23.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 23,495.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 10,597.7<span></span>
</td>
<td class="nump">$ 24,124.5<span></span>
</td>
<td class="num">$ (181.6)<span></span>
</td>
<td class="num">$ (11,045.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued/Distributed During Period, Value, Employee Benefit Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373849745808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 817.8<span></span>
</td>
<td class="nump">$ 973.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">99.5<span></span>
</td>
<td class="nump">74.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">238.7<span></span>
</td>
<td class="nump">166.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_MarketableAndOtherSecuritiesGainLoss', window );">Losses on marketable and other securities, net</a></td>
<td class="nump">166.6<span></span>
</td>
<td class="nump">204.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items, net</a></td>
<td class="nump">20.6<span></span>
</td>
<td class="nump">84.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income taxes</a></td>
<td class="num">(216.5)<span></span>
</td>
<td class="num">(225.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease in accounts receivable</a></td>
<td class="nump">210.1<span></span>
</td>
<td class="nump">1,197.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(46.8)<span></span>
</td>
<td class="num">(88.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Increase in prepaid expenses and other assets</a></td>
<td class="num">(5.5)<span></span>
</td>
<td class="num">(44.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">(Decrease) increase in deferred revenue</a></td>
<td class="num">(35.9)<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable, accrued expenses, and other liabilities</a></td>
<td class="nump">119.0<span></span>
</td>
<td class="num">(250.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Total adjustments</a></td>
<td class="nump">549.8<span></span>
</td>
<td class="nump">1,128.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">1,367.6<span></span>
</td>
<td class="nump">2,101.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable and other securities</a></td>
<td class="num">(1,749.4)<span></span>
</td>
<td class="num">(2,309.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales or maturities of marketable and other securities</a></td>
<td class="nump">1,792.8<span></span>
</td>
<td class="nump">746.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="num">(178.2)<span></span>
</td>
<td class="num">(141.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_PaymentsToAcquireIntangibleAssets1', window );">Payments for Libtayo intangible asset</a></td>
<td class="num">(100.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(235.7)<span></span>
</td>
<td class="num">(1,705.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of Common Stock</a></td>
<td class="nump">485.2<span></span>
</td>
<td class="nump">521.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments in connection with Common Stock tendered for employee tax obligations</a></td>
<td class="num">(97.0)<span></span>
</td>
<td class="num">(98.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of Common Stock</a></td>
<td class="num">(710.7)<span></span>
</td>
<td class="num">(358.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(322.5)<span></span>
</td>
<td class="nump">64.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">809.4<span></span>
</td>
<td class="nump">461.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">3,119.4<span></span>
</td>
<td class="nump">2,898.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">$ 3,928.8<span></span>
</td>
<td class="nump">$ 3,359.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_MarketableAndOtherSecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable and Other Securities, Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_MarketableAndOtherSecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_PaymentsToAcquireIntangibleAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Intangible Assets1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_PaymentsToAcquireIntangibleAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373853188800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Financial Statements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Interim Financial Statements</a></td>
<td class="text">Interim Financial Statements<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Condensed Consolidated Financial Statements of Regeneron Pharmaceuticals, Inc. and its subsidiaries ("Regeneron," "Company," "we," "us," and "our") have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and disclosures necessary for a presentation of the Company's financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, these financial statements reflect all normal recurring adjustments and accruals necessary for a fair statement of the Company's condensed consolidated financial statements for such periods. The results of operations for any interim period are not necessarily indicative of the results for the full year. The December&#160;31, 2022 Condensed Consolidated Balance Sheet data were derived from audited financial statements, but do not include all disclosures required by accounting principles generally accepted in the United States of America. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior period amounts to conform with the current period's presentation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373855590144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Sales<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Product Sales</a></td>
<td class="text">Product Sales<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.140%"><tr><td style="width:1.0%"/><td style="width:42.910%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.347%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.102%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.868%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.102%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,433.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(a) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evkeeza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inmazeb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,638.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Prior to July 1, 2022, Regeneron recorded net product sales of Libtayo in the United States and Sanofi recorded net product sales of Libtayo outside the United States. Effective July 1, 2022, the Company records global net product sales of Libtayo. See Note 3 for further details.</span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of world ("ROW")</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, the Company had $3.578 billion and $3.586&#160;billion, respectively, of trade accounts receivable that were recorded within Accounts receivable, net.</span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had product sales to certain customers that accounted for more than 10% of total gross product revenue for the three months ended March&#160;31, 2023 and 2022. Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.210%"><tr><td style="width:1.0%"/><td style="width:62.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.939%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Besse Medical, a subsidiary of AmerisourceBergen Corporation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373962163088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration, License, and Other Agreements</a></td>
<td class="text">Collaboration, License, and Other Agreements<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">a. Sanofi</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in our Statements of Operations in connection with our collaborations with Sanofi are detailed below:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.888%"><tr><td style="width:1.0%"/><td style="width:44.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.265%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antibody:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of antibodies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-based milestones earned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Sanofi R&amp;D expenses, net of reimbursement of R&amp;D expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(R&amp;D expense)/Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of SG&amp;A expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immuno-oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of Libtayo outside the United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of ex-U.S. commercial supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of R&amp;D expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of SG&amp;A expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Sanofi commercial expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&amp;A expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in connection with up-front payments received</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As described within the "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Immuno-Oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">" section below, effective July 1, 2022, the Company obtained the exclusive right to develop, commercialize, and manufacture Libtayo worldwide.</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antibody</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a global, strategic collaboration with Sanofi to research, develop, and commercialize fully human monoclonal antibodies (the "Antibody Collaboration"), which currently consists of Dupixent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (dupilumab), Kevzara</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sarilumab), and itepekimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Antibody License and Collaboration Agreement (the "LCA"), Sanofi is generally responsible for funding 80% to 100% of agreed-upon development costs. The Company is obligated to reimburse Sanofi for 30% to 50% of worldwide development expenses that were funded by Sanofi based on the Company's share of collaboration profits from commercialization of collaboration products. Under the terms of the LCA, the Company was required to apply 10% of its share of the profits from the Antibody Collaboration in any calendar quarter to reimburse Sanofi for these development costs. On July 1, 2022, an amendment to the LCA became effective, pursuant to which the percentage of the Company's share of profits used to reimburse Sanofi for such development costs increased from 10% to 20%. A portion of the value associated with the increase in reimbursement percentage was deemed to be contingent consideration attributable to the Company's acquisition of the Libtayo (cemiplimab) rights described within the "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immuno-Oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" section below; this portion will be recorded as an increase to the Libtayo intangible asset over time as the Company repays such development costs to Sanofi. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanofi leads commercialization activities for products under the Antibody Collaboration, subject to the Company's right to co-commercialize such products. In addition to profit and loss sharing, the Company is entitled to receive sales milestone payments from Sanofi. During the three months ended March 31, 2022, the Company earned a $50.0&#160;million sales-based milestone from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $2.0&#160;billion on a rolling twelve-month basis. The Company is entitled to receive the final sales milestone payment of $50.0&#160;million when such sales outside the United States exceed $3.0&#160;billion on a rolling twelve-month basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Company's Antibody Collaboration with Sanofi:</span></div><div style="margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.502%"><tr><td style="width:1.0%"/><td style="width:49.268%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.489%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immuno-Oncology</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was previously a party to a collaboration with Sanofi for antibody-based cancer treatments in the field of immuno-oncology (the "IO Collaboration"). Under the terms of the Immuno-oncology License and Collaboration Agreement, the parties were co-developing and co-commercializing Libtayo. The parties shared equally, on an ongoing basis, development and commercialization expenses for Libtayo. The Company had principal control over the development of Libtayo and led commercialization activities in the United States, while Sanofi led commercialization activities outside of the United States. The parties shared equally in profits and losses in connection with the commercialization of Libtayo.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective July 1, 2022, the Company obtained the exclusive right to develop, commercialize, and manufacture Libtayo worldwide under an Amended and Restated Immuno-oncology License and Collaboration Agreement with Sanofi (the "A&amp;R IO LCA"). In connection with the A&amp;R IO LCA, in 2022, the Company made a $900.0&#160;million up-front payment to Sanofi, as well as a $100.0&#160;million regulatory milestone payment. In addition, Sanofi earned a $65.0&#160;million sales-based milestone upon the achievement of a specified amount of worldwide net product sales of Libtayo in 2022 and is eligible to receive an additional $35.0&#160;million sales-based milestone upon the achievement of a specified amount of worldwide net product sales of Libtayo in 2023 (aggregate of $100.0&#160;million in sales-based milestones eligible to be earned under the terms of the A&amp;R IO LCA). The Company also pays Sanofi an 11% royalty on net product sales of Libtayo through March 31, 2034. The transaction was accounted for as an asset acquisition and amounts paid to Sanofi in connection with obtaining the worldwide rights to Libtayo, including the up-front payment and any contingent consideration, are recorded as an intangible asset.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">b. Bayer </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a license and collaboration agreement with Bayer for the global development and commercialization of EYLEA (aflibercept) and aflibercept 8 mg outside the United States. Agreed-upon development expenses incurred by the Company and Bayer are generally shared equally. Bayer markets EYLEA outside the United States, and the companies share equally in profits and losses from such sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Statements of Operations in connection with its Bayer collaboration are as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"/><td style="width:49.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.931%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.934%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of EYLEA outside the United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of ex-U.S. commercial supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One-time payment in connection with change in Japan arrangement</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Bayer R&amp;D expenses, net of reimbursement of R&amp;D expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(R&amp;D expense)/Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 16.75pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Company's Bayer collaboration:</span></div><div style="margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.795%"><tr><td style="width:1.0%"/><td style="width:49.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">c. Roche</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to a collaboration agreement (the "Roche Collaboration Agreement") with Roche to develop, manufacture, and distribute the casirivimab and imdevimab antibody cocktail (known as REGEN-COV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States and Ronapreve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in other countries). Under the terms of the collaboration agreement, the parties jointly fund certain studies, and the Company has the right to distribute the product in the United States while Roche has the right to distribute the product outside of the United States. The parties share gross profits from worldwide sales based on a pre-specified formula, depending on the amount of manufactured product supplied by each party to the market. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Statements of Operations in connection with the Roche Collaboration Agreement are as follows:</span></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.818%"><tr><td style="width:1.0%"/><td style="width:48.814%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global gross profit payment from Roche in connection with sales of Ronapreve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement of research and development expenses from Roche was not material for the three months ended March&#160;31, 2023 and 2022.</span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Roche Collaboration Agreement:</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.368%"><tr><td style="width:1.0%"/><td style="width:58.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.810%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.810%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.296%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>d. Sonoma Biotherapeutics, Inc.<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company and Sonoma Biotherapeutics, Inc. entered into a license and collaboration agreement to bring together the Company's </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VelociSuite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technologies with Sonoma's technology platform for the discovery, development, and commercialization of novel regulatory T cell (T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">reg</span>) therapies for autoimmune diseases. In connection with the agreement, the Company made a $45.0&#160;million up-front payment (which was recorded to Acquired in-process research and development expense in the first quarter of 2023) and, in April 2023, the Company purchased an aggregate of $30.0&#160;million of Sonoma preferred stock. Sonoma is also eligible to receive a $45.0&#160;million development milestone payment. The Company and Sonoma will co-fund research and development activities and share equally any future commercial expenses and profits. The Company will have the option to lead late-stage development and commercialization on all products globally, with Sonoma retaining rights to co-promote all such products in the United States.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373853558880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income Per Share</a></td>
<td class="text">Net Income Per Share <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share is computed by dividing net income by the weighted average number of shares of Common Stock and Class A Stock outstanding. Net income per share is presented on a combined basis, inclusive of Common Stock and Class A Stock outstanding, as each class of stock has equivalent economic rights. Diluted net income per share includes the potential dilutive effect of other securities as if such securities were converted or exercised during the period, when the effect is dilutive. The calculations of basic and diluted net income per share are as follows:</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.304%"><tr><td style="width:1.0%"/><td style="width:64.719%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.838%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">973.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards and restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from diluted per share amounts because their effect would have been antidilutive include the following:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.298%"><tr><td style="width:1.0%"/><td style="width:54.015%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.692%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Shares in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373945873552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities as of March&#160;31, 2023 and December&#160;31, 2022 consist of both available-for-sale debt securities of investment grade issuers (see below and Note 6) as well as equity securities of publicly traded companies (see Note 6).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's investments in available-for-sale debt securities:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"/><td style="width:46.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of March&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,819.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,592.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,902.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,903.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,280.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,051.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,975.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,684.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,945.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,939.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,320.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,018.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its investments in available-for-sale debt securities based on their contractual maturity dates. The available-for-sale debt securities as of March&#160;31, 2023 mature at various dates through August 2028. The fair values of available-for-sale debt securities by contractual maturity consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.473%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.933%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.933%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,043.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,636.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,996.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,381.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities after five years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,051.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,018.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the fair value of the Company's available-for-sale debt securities&#160;that have unrealized losses, aggregated by investment category and length of time that the individual securities have been in a continuous loss position.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.590%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of March&#160;31, 2023</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,293.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,464.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,687.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,445.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,200.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,645.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,300.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76.9)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,332.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225.9)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,633.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302.8)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrealized losses on corporate bonds as of March 31, 2023 were primarily driven by increases in interest rates. The Company has reviewed its portfolio of available-for-sale debt securities and determined that the decline in fair value below cost did not result from credit-related factors. In addition, the Company does not intend to sell, and it is not more likely than not that the Company will be required to sell, such securities before recovery of their amortized cost bases.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to marketable securities, for the three months ended March&#160;31, 2023 and 2022, amounts reclassified from Accumulated other comprehensive loss into Other (expense) income, net were related to realized gains and losses on sales of available-for-sale debt securities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023 and 2022, realized gains and losses on sales of marketable securities were not material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373855819616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company's assets which are measured at fair value on a recurring basis. The following fair value hierarchy is used to classify assets, based on inputs to valuation techniques utilized to measure fair value:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Quoted prices in active markets for identical assets</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Significant other observable inputs, such as quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuations in which significant inputs used are observable</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Significant other unobservable inputs</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:49.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.781%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of March&#160;31, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,268.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,592.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,592.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,903.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,903.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (unrestricted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (restricted)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,532.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,329.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,662.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,574.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,684.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,684.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,939.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,939.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (unrestricted)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (restricted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,185.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,185.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,891.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,298.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,592.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held certain restricted equity securities as of March&#160;31, 2023 which are subject to transfer restrictions that expire at various dates through 2024. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, we recorded $164.7 million and $211.2&#160;million of net unrealized losses, respectively, on equity securities in Other (expense) income, net.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the investments summarized in the table above, as of both March&#160;31, 2023 and December&#160;31, 2022, the Company had $48.3&#160;million in equity investments that do not have a readily determinable fair value. These investments are recorded within Other noncurrent assets.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term debt, which was determined based on Level 2 inputs, was estimated to be $1.516&#160;billion and $1.443&#160;billion as of March&#160;31, 2023 and December&#160;31, 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373853558880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.555%"><tr><td style="width:1.0%"/><td style="width:47.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.165%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,424.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,401.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory balances in the table above are net of reserves of $752.3 million and $720.7 million as of March&#160;31, 2023 and December&#160;31, 2022, respectively. Deferred costs represent the costs of product manufactured and shipped to the Company's collaborators for which recognition of revenue has been deferred.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373938237664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal, state, and foreign income taxes. The Company's effective tax rate was 4.7% and 8.3% for the three months ended March&#160;31, 2023 and 2022, respectively. The Company's effective tax rate for the three months ended March&#160;31, 2023 was positively impacted, compared to the U.S. federal statutory rate, primarily by stock-based compensation and income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Inflation Reduction Act of 2022 ("IRA") was signed into law in the United States. The IRA created a new corporate alternative minimum tax of 15% on adjusted financial statement income and an excise tax of 1% of the value of certain stock repurchases. The provisions of the IRA became effective for periods beginning after December&#160;31, 2022.&#160;The IRA had no impact on the Company's financial statements for the three months ended March 31, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's effective tax rate for the three months ended March&#160;31, 2022 was positively impacted, compared to the U.S. federal statutory rate, primarily by income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate and stock-based compensation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373856722240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Programs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, our board of directors authorized a share repurchase program to repurchase up to $3.0 billion of our Common Stock. The share repurchase program permits the Company to make repurchases through a variety of methods, including open-market transactions (including pursuant to a trading plan adopted in accordance with Rule 10b5-1 of the Exchange Act), privately negotiated transactions, accelerated share repurchases, block trades, and other transactions in compliance with Rule 10b-18 of the Exchange Act. Repurchases may be made from time to time at management&#8217;s discretion, and the timing and amount of any such repurchases will be determined based on share price, market conditions, legal requirements, and other relevant factors. The program has no time limit and can be discontinued at any time. There can be no assurance as to the timing or number of shares of any repurchases in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, our board of directors authorized an additional share repurchase program to repurchase up to $3.0&#160;billion of our Common Stock. The share repurchase program was approved under terms substantially similar to the share repurchase program described above. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, an aggregate of $3.051 billion remained available for share repurchases under the Company's share repurchase programs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the shares of our Common Stock we repurchased and the cost of the shares, which were recorded as Treasury Stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.432%"><tr><td style="width:1.0%"/><td style="width:61.076%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of shares </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373853558880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Flows<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Statement of Cash Flows</a></td>
<td class="text">Statement of Cash Flows<div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheet to the total of the same such amounts shown in the Condensed Consolidated Statement of Cash Flows:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.210%"><tr><td style="width:1.0%"/><td style="width:58.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.172%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,916.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,345.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in Other noncurrent assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,928.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,359.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists of amounts held by financial institutions pursuant to contractual arrangements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental disclosure of non-cash investing and financing activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:31.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued capital expenditures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued contingent consideration for Libtayo intangible asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI https://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373938237664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Matters<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Matters</a></td>
<td class="text">Legal Matters<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is a party to legal proceedings in the course of the Company's business. The outcome of any such proceedings, regardless of the merits, is inherently uncertain. If the Company were unable to prevail in any such proceedings, its consolidated financial position, results of operations, and future cash flows may be materially impacted. Costs associated with the Company's involvement in legal proceedings are expensed as incurred. The Company recognizes accruals for loss contingencies associated with such proceedings when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. As of March&#160;31, 2023 and December&#160;31, 2022, the Company's accruals for loss contingencies were not material. There are certain loss contingencies that the Company deems reasonably possible for which the possible loss or range of possible loss is not estimable at this time. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to Praluent (alirocumab) Injection</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described below, the Company is currently a party to patent infringement actions initiated by Amgen Inc. (and/or its affiliated entities) against the Company and/or Sanofi (and/or the Company's and Sanofi's respective affiliated entities) in a number of jurisdictions relating to Praluent. In addition, as described below, the Company filed a lawsuit against Amgen alleging that Amgen engaged in an anticompetitive bundling scheme which was designed to exclude Praluent from the market in violation of federal and state laws.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United States</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, Amgen has asserted claims of U.S. Patent Nos. 8,829,165 (the "'165 Patent") and 8,859,741 (the "'741 Patent"), and sought a permanent injunction to prevent the Company and the Sanofi defendants from commercial manufacturing, using, offering to sell, or selling within the United States (as well as importing into the United States) (collectively, "Commercializing") Praluent. Amgen also seeks a judgment of patent infringement of the asserted patents, monetary damages (together with interest), costs and expenses of the lawsuits, and attorneys' fees. As previously reported, on February 11, 2021, the United States Court of Appeals for the Federal Circuit (the "Federal Circuit") affirmed the lower court's decision that certain of Amgen's asserted patent claims are invalid based on lack of enablement. On April 14, 2021, Amgen filed a petition for a rehearing en banc with the Federal Circuit, which was denied on June 21, 2021. On November 4, 2022, the United States Supreme Court granted Amgen's petition for writ of certiorari. An oral hearing was held on March 27, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2022, the Company filed a lawsuit against Amgen in the United States District Court for the District of Delaware, alleging that, beginning in 2020, Amgen engaged in an anticompetitive bundling scheme which was designed to exclude Praluent from the market in violation of federal and state laws. The lawsuit seeks damages for harm caused by the alleged scheme, as well as injunctive relief restraining Amgen from continuing its alleged anticompetitive conduct. On August 1, 2022, Amgen filed a motion to dismiss the complaint. On August 11, 2022, Amgen filed a motion to stay these proceedings pending resolution of the patent litigation described in the preceding paragraph. An oral hearing on Amgen's motion to dismiss and motion to stay was held on January 6, 2023. On February 10, 2023, the court denied Amgen's motion to stay; and on March 21, 2023, the court denied Amgen's motion to dismiss. A trial has been scheduled to begin in November 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Europe</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen has asserted European Patent No. 2,215,124 (the "'124 Patent"), which pertains to PCSK9 monoclonal antibodies, in certain countries in Europe. In October 2020, the '124 Patent claims directed to compositions of matter and medical use relevant to Praluent were ruled invalid based on a lack of inventive step by the Technical Board of Appeal (the "TBA") of the European Patent Office (the "EPO"). Following the EPO's decision, each of the '124 Patent infringement proceedings initiated by Amgen against the Company and certain of Sanofi's affiliated entities in these countries was dismissed, including in Germany. The dismissal in Germany followed an earlier finding of infringement and granting of an injunction, both of which were subsequently overturned. As a result of the overturned injunction in Germany, the Company and/or certain of Sanofi's affiliated entities are seeking damages caused by Amgen's enforcement of the injunction. As part of its opposition to these damages claims, on March 23, 2022, Amgen filed a counterclaim that asserted the German designation of European Patent No. 2,641,917 (the "'917 Patent") and seeks, among other things, a judgment of patent infringement, injunctive relief, and monetary damages. The '917 Patent is a divisional patent of the '124 Patent discussed above (i.e., a patent that shares the same priority date, disclosure, and patent term of the parent '124 Patent but contains claims to a different invention). The '917 Patent is also subject to opposition proceedings in the EPO, which were initiated by Sanofi on May 5, 2021. An oral hearing before the EPO was held on February 21, 2023, at which the '917 Patent was revoked. Amgen filed a notice to appeal to the TBA of the EPO on February 27, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to EYLEA (aflibercept) Injection</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company's patents pertaining to EYLEA are subject to post-grant proceedings before the United States Patent and Trademark Office ("USPTO"), EPO, or other comparable foreign authorities, including those described in greater detail below. In addition, the Company has filed patent infringement lawsuits in several jurisdictions alleging infringement of certain Company patents pertaining to EYLEA, including those described in greater detail below. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United States</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 11, 2020, anonymous parties filed two requests for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex parte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reexamination of the Company's U.S. Patent Nos. 10,406,226 (the "'226 Patent") and 10,464,992 (the "'992 Patent"), and the USPTO has granted both requests.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2021, Mylan Pharmaceuticals Inc. filed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review ("IPR") petitions in the USPTO against the Company's U.S. Patent Nos. 9,254,338 (the "'338 Patent") and 9,669,069 (the "'069 Patent") seeking declarations of invalidity of the '338 Patent and the '069 Patent. On November 10, 2021, the USPTO issued a decision instituting both IPR proceedings. On December 9, 2021, Apotex Inc. and Celltrion, Inc. each filed two separate IPR petitions against the Company's '338 and '069 Patents requesting that their IPRs be instituted and joined with the IPR proceedings initiated by Mylan concerning the '338 and '069 Patents, which petitions were granted on February 9, 2022. An oral hearing was held on August 10, 2022. On November 9, 2022, the USPTO issued final written decisions finding that the claims of the '338 and '069 Patents are unpatentable and, therefore, invalid. On January 10, 2023, the Company filed notices of appeal of the USPTO written decisions concerning the '338 and '069 Patents with the Federal Circuit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, Mylan filed IPR petitions against the Company's U.S. Patent Nos. 10,130,681 (the "'681 Patent") and 10,888,601 (the "'601 Patent") (each filed July 1, 2022) and 10,857,205 (the "'205 Patent") (filed October 28, 2022) seeking declarations of invalidity of each of these patents. On January 11, 2023, the USPTO instituted IPR proceedings concerning the '681 Patent and the '601 Patent. On February 21, 2023, the Company filed a Notice of Disclaimer with the USPTO, disclaiming all claims of the '205 Patent; and, as a result, on March 1, 2023, the USPTO denied institution of Mylan's IPR petition against the '205 Patent. On January 6, 2023 and March 26, 2023, Samsung Bioepis Co., Ltd. filed separate IPR petitions against the Company's '681 Patent and '601 Patent, respectively, seeking declarations of invalidity of such patents.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 9, 2022, Apotex filed an IPR petition against the Company's U.S. Patent No. 11,253,572 (the "'572 Patent") seeking a declaration of invalidity of the '572 Patent. On March 10, 2023, the USPTO declined to institute an IPR proceeding concerning the '572 Patent. On April 27, 2023, Samsung Bioepis Co., Ltd. filed a separate IPR petition against the '572 Patent seeking a declaration of invalidity of the '572 Patent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 17, 2023 and February 28, 2023, Celltrion filed IPR petitions against the '992 Patent and the '226 Patent, respectively, seeking declarations of invalidity of such patents.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2022, the Company filed a patent infringement lawsuit against Mylan in the United States District Court for the Northern District of West Virginia alleging that Mylan's filing for a U.S. Food and Drug Administration approval of an aflibercept biosimilar infringes certain Company patents. On April 20, 2023, Mylan filed a motion for summary judgment or partial summary judgment concerning four of the asserted patents. On April 26, 2023, the Company filed a stipulation accepting summary judgment of noninfringement of all asserted claims of the Company's U.S. Patent No. 11,104,715. A trial has been scheduled to begin on June 12, 2023 concerning certain claims of the '601 Patent, the '572 Patent, and the Company's U.S. Patent No. 11,084,865.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Europe</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 26 and October 27, 2021, anonymous parties initiated opposition proceedings in the EPO against the Company's European Patent No. 2,944,306 (the "'306 Patent") seeking revocation of the '306 Patent in its entirety.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Canada</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, July 15, August 30, and October 4, 2022, the Company and Bayer Inc. filed patent infringement lawsuits against BGP Pharma ULC d.b.a Viatris Canada ("Viatris Canada") in the Federal Court of Canada seeking a declaration that the making, constructing, using, or selling of an aflibercept biosimilar would directly or indirectly infringe one or more claims of the Company's Canadian Patent Nos. 2,654,510 (the "'510 Patent) and 3,007,276 (the "'276 Patent") (in the lawsuit filed on June 15, 2022); the Company's Canadian Patent No. 2,965,495 (the "'495 Patent") (in the lawsuit filed on July 15, 2022); the Company's Canadian Patent No. 2,906,768 (the "'768 Patent") (in the lawsuit filed on August 30, 2022, which has been joined with the lawsuit filed on July 15, 2022); and the Company's Canadian Patent No. 3,129,193 (the "'193 Patent") (in the lawsuit filed on October 4, 2022). A trial for the lawsuit concerning the '510 Patent and the '276 Patent has been scheduled for March 2024; a trial for the lawsuit concerning the '193 Patent has been scheduled for May 2024; and a trial for the lawsuit concerning the '495 Patent and the '768 Patent has been scheduled for November/December 2024. The filing of the lawsuit concerning the '510 Patent and the '276 Patent resulted in a statutory 24-month stay of regulatory approval of Viatris Canada's aflibercept biosimilar in Canada unless the lawsuit is resolved earlier. On March 27, 2023, in light of the transfer of the New Drug Submission ("NDS") discussed below, the Company filed a motion in the Federal Court of Canada seeking termination of the Viatris Canada action relating to the '510 Patent and the '276 Patent in the Federal Court of Canada.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2023, following the transfer of Viatris Canada's NDS of its aflibercept biosimilar to Biosimilar Collaborations Ireland Limited ("BCIL"), the Company and Bayer Inc. filed a patent infringement lawsuit against BCIL in the Federal Court of Canada seeking a declaration that the making, constructing, using, or selling of an aflibercept biosimilar would directly or indirectly infringe one or more claims of the Company's '510 and '276 Patents. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">South Korea</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2022 and December 13, 2022, Samsung Bioepis Co., Ltd. initiated invalidation proceedings before the Intellectual Property Trial</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Appeal Board of the Korean Intellectual Property Office against the Company's Korean Patent Nos. 1131429 and 1406811, respectively, seeking revocation of each of such patents in its entirety.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 16, 2023, the Company filed patent infringement lawsuits against Samsung Bioepis Co., Ltd. and its parent Samsung Biologics Co., Ltd. before the Seoul Central District Court seeking a declaration that the making, constructing, using, or selling of an aflibercept biosimilar would infringe one or more claims of Company's Korean Patent No. 659477 (the "'477 Patent").</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 2, 2023, the Company filed an affirmative scope confirmation action against Samsung Bioepis Co., Ltd. before the Intellectual Property Tribunal and Appeal Board of the Korean Intellectual Property Office seeking a ruling that Samsung Bioepis's aflibercept biosimilar is covered by the claims of the '477 Patent. On March 7, 2023, the action was designated for expedited proceedings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Proceedings Relating to EYLEA (aflibercept) Injection Pre-filled Syringe</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2020, Novartis Pharma AG, Novartis Pharmaceuticals Corporation, and Novartis Technology LLC (collectively, "Novartis") filed a patent infringement lawsuit (as amended on August 2, 2021) in the U.S. District Court for the Northern District of New York asserting claims of Novartis's U.S. Patent No. 9,220,631 (the "'631 Patent") and seeking preliminary and permanent injunctions to prevent the Company from continuing to infringe the '631 Patent. Novartis also seeks a judgment of patent infringement of the '631 Patent, monetary damages (together with interest), an order of willful infringement of the '631 Patent (which would allow the court in its discretion to award damages up to three times the amount assessed), costs and </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses of the lawsuits, and attorneys' fees. On November 7, 2022, the Company and Novartis entered into a stipulation staying the lawsuit in light of the decision in the IPR proceeding discussed below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 16, 2020, the Company initiated two IPR petitions in the USPTO seeking a declaration of invalidity of the '631 Patent on two separate grounds. On October 26, 2021, the USPTO issued a decision instituting the IPR proceeding. An oral hearing was held on July 21, 2022. On October 25, 2022, the Patent Trial and Appeal Board ("PTAB") of the USPTO issued a final written decision invalidating all claims of the '631 Patent. On December 23, 2022, Novartis filed a notice of appeal of the PTAB's decision to the Federal Circuit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 17, 2020, the Company filed an antitrust lawsuit against Novartis and Vetter Pharma International Gmbh ("Vetter") in the United States District Court for the Southern District of New York seeking a declaration that the '631 Patent is unenforceable and a judgment that the defendants' conduct violates Sections 1 and 2 of the Sherman Antitrust Act of 1890, as amended (the "Sherman Antitrust Act"). The Company is also seeking injunctive relief and treble damages. On September 4, 2020, Novartis filed, and Vetter moved to join, a motion to dismiss the complaint, to transfer the lawsuit to the Northern District of New York, or to stay the suit; and on October 19, 2020, Novartis filed, and Vetter moved to join, a second motion to dismiss the complaint on different grounds. On January 25, 2021, the Company filed an amended complaint seeking a judgment that Novartis's conduct violates Section 2 of the Sherman Antitrust Act based on additional grounds, as well as a judgment of tortious interference with contract. On February 22, 2021, Novartis filed, and Vetter moved to join, a motion to dismiss the amended complaint. On September 21, 2021, the court granted Novartis and Vetter's motion to transfer this lawsuit to the Northern District of New York. As a result, this lawsuit was transferred to the same judge that had been assigned to the patent infringement lawsuit discussed above. On November 5, 2021, the Company filed a motion to stay these proceedings in light of the pending IPR proceeding discussed above. On January 31, 2022, the court denied the Company's motion to stay these proceedings and granted Novartis and Vetter's motion to dismiss the amended complaint. On June 10, 2022, the Company filed an appeal of the District Court's decision to dismiss the amended complaint with the U.S. Court of Appeals for the Second Circuit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to REGEN-COV (casirivimab and imdevimab)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 5, 2020, Allele Biotechnology and Pharmaceuticals, Inc. ("Allele") filed a lawsuit (as amended on April 8, 2021 and December 12, 2022) against the Company in the United States District Court for the Southern District of New York, asserting infringement of U.S. Patent No. 10,221,221 (the "'221 Patent").</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allele seeks a judgment of patent infringement of the '221 Patent, an award of monetary damages (together with interest), an order of willful infringement of the '221 Patent (which would allow the court in its discretion to award damages up to three times the amount assessed), costs and expenses of the lawsuit, and attorneys' fees. On July 16, 2021, the Company filed a motion to dismiss the complaint, which motion was denied on March 2, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting documents relating to its support of 501(c)(3) organizations that provide financial assistance to patients; documents concerning its provision of financial assistance to patients with respect to products sold or developed by Regeneron (including EYLEA, Praluent, ARCALYST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and ZALTRAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); and certain other related documents and communications. On June 24, 2020, the U.S. Attorney's Office for the District of Massachusetts filed a civil complaint in the U.S. District Court for the District of Massachusetts alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law. On August 24, 2020, the Company filed a motion to dismiss the complaint in its entirety. On December 4, 2020, the court denied the motion to dismiss. On December 28, 2022, the U.S. Attorney&#8217;s Office for the District of Massachusetts filed a motion for partial summary judgment. On January 31, 2023, the Company filed a motion for summary judgment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company and Regeneron Healthcare Solutions, Inc., a wholly-owned subsidiary of the Company, each received a civil investigative demand ("CID") from the U.S. Department of Justice pursuant to the federal False Claims Act relating to remuneration paid to physicians in the form of consulting fees, advisory boards, speaker fees, and payment or reimbursement for travel and entertainment allegedly in violation of the federal Anti-Kickback Statute. The CIDs relate to EYLEA, Praluent, Dupixent, ZALTRAP, ARCALYST, and Kevzara and cover the period from January 2015 to the present. On June 3, 2021, the United States District Court for the Central District of California unsealed a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaint filed against the Company, Regeneron Healthcare Solutions, Inc., and Sanofi-Aventis U.S. LLC by two </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plaintiffs (known as relators) purportedly on behalf of the United States and various states (the "State Plaintiffs"), asserting causes of action under the federal False Claims Act and state law. Also on June 3, 2021, the United States and the State Plaintiffs notified the court of their decision to decline to intervene in the case. On October 29, 2021, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plaintiffs filed an amended complaint in this matter. On January 14, 2022, the Company filed a motion to dismiss the amended complaint in its entirety.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company received a CID from the U.S. Department of Justice pursuant to the federal False Claims Act. The CID states that the investigation concerns allegations that the Company (i) violated the False Claims Act by paying kickbacks to distributors and ophthalmology practices to induce purchase of EYLEA, including through discounts, rebates, credit card fees, free units of EYLEA, and inventory management systems; and (ii) inflated reimbursement rates for EYLEA by excluding applicable discounts, rebates, and benefits from the average sales price reported to the Centers for Medicare &amp; Medicaid Services. The CID covers the period from January 2011 through June 2021. The Company is cooperating with this investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Department of Insurance Subpoena</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Company received a subpoena from the Insurance Commissioner for the State of California pursuant to the California Insurance Code. The subpoena seeks information relating to the marketing, sale, and distribution of EYLEA, including (i) discounts, rebates, credit card fees, and inventory management systems; (ii) Regeneron's relationships with distributors; (iii) price reporting; (iv) speaker programs; and (v) patient support programs. The subpoena covers the period from January 1, 2014 through August 1, 2021. The Company is cooperating with this investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Initiated by Other Payors Relating to Patient Assistance Organization Support</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to several lawsuits relating to the conduct alleged in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. These lawsuits were filed by UnitedHealthcare Insurance Company and United Healthcare Services, Inc. (collectively, "UHC") and Humana Inc. ("Humana") in the United States District Court for the Southern District of New York on December 17, 2020 and July 22, 2021, respectively; and by Blue Cross and Blue Shield of Massachusetts, Inc. and Blue Cross and Blue Shield of Massachusetts HMO Blue, Inc. (collectively, "BCBS"), Medical Mutual of Ohio ("MMO"), Horizon Healthcare Services, Inc. d/b/a Horizon Blue Cross Blue Shield of New Jersey ("Horizon"), and Local 464A United Food and Commercial Workers Union Welfare Service Benefit Fund ("Local 464A") in the U.S. District Court for the District of Massachusetts on December 20, 2021, February 23, 2022, April 4, 2022, and June 17, 2022, respectively. These lawsuits allege causes of action under state law and the federal Racketeer Influenced and Corrupt Organizations Act and seek monetary damages and equitable relief. The MMO and Local 464A lawsuits are putative class action lawsuits. On December 29, 2021, the lawsuits filed by UHC and Humana were stayed by the United States District Court for the Southern District of New York pending resolution of the proceedings before the U.S. District Court for the District of Massachusetts discussed under "Department of Justice Matters" above. On September 27, 2022, the lawsuits filed by BCBS, MMO, and Horizon were stayed by the U.S. District Court for the District of Massachusetts pending resolution of the proceedings before the same court discussed under "Department of Justice Matters" above; and, in light of these stays, the parties to the Local 464A action have also agreed to stay that matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Proceedings Relating to Shareholder Derivative Complaint</span></div>On June 29, 2021, an alleged shareholder filed a shareholder derivative complaint in the New York Supreme Court, naming the current and certain former members of the Company's board of directors and certain current and former executive officers of the Company as defendants and Regeneron as a nominal defendant. The complaint asserts that the individual defendants breached their fiduciary duties in relation to the allegations in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. The complaint seeks an award of damages allegedly sustained by the Company; an order requiring Regeneron to take all necessary actions to reform and improve its corporate governance and internal procedures; disgorgement from the individual defendants of all profits and benefits obtained by them resulting from their sales of Regeneron stock; and costs and disbursements of the action, including attorneys' fees. On July 28, 2021, the defendants filed a notice of removal, removing the case from the New York Supreme Court to the U.S. District Court for the Southern District of New York. On September 23, 2021, the plaintiff moved to remand the case to the New York Supreme Court. Also on September 23, 2021, the individual defendants moved to dismiss the complaint in its entirety. On December 19, 2022, the U.S. District Court for the Southern District of New York denied the plaintiff's motion to remand the case and granted a motion to stay the case pending resolution of the proceedings before the U.S. District Court for the District of Massachusetts discussed under "Department of Justice Matters" above. As a result of the stay, the court also terminated the Company's motion to dismiss the complaint without prejudice. The Company can therefore renew the motion to dismiss upon conclusion of the stay.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373856695424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Financial Statements (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Condensed Consolidated Financial Statements of Regeneron Pharmaceuticals, Inc. and its subsidiaries ("Regeneron," "Company," "we," "us," and "our") have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and disclosures necessary for a presentation of the Company's financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, these financial statements reflect all normal recurring adjustments and accruals necessary for a fair statement of the Company's condensed consolidated financial statements for such periods. The results of operations for any interim period are not necessarily indicative of the results for the full year. The December&#160;31, 2022 Condensed Consolidated Balance Sheet data were derived from audited financial statements, but do not include all disclosures required by accounting principles generally accepted in the United States of America. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Legal Matters</a></td>
<td class="text">Costs associated with the Company's involvement in legal proceedings are expensed as incurred.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149975-122751<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373853129664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Sales (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of product sales</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.140%"><tr><td style="width:1.0%"/><td style="width:42.910%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.347%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.102%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.868%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.102%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,433.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(a) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evkeeza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inmazeb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,638.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Prior to July 1, 2022, Regeneron recorded net product sales of Libtayo in the United States and Sanofi recorded net product sales of Libtayo outside the United States. Effective July 1, 2022, the Company records global net product sales of Libtayo. See Note 3 for further details.</span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of world ("ROW")</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in our Statements of Operations in connection with our collaborations with Sanofi are detailed below:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.888%"><tr><td style="width:1.0%"/><td style="width:44.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.265%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antibody:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of antibodies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-based milestones earned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Sanofi R&amp;D expenses, net of reimbursement of R&amp;D expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(R&amp;D expense)/Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of SG&amp;A expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immuno-oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of Libtayo outside the United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of ex-U.S. commercial supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of R&amp;D expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of SG&amp;A expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Sanofi commercial expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&amp;A expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in connection with up-front payments received</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As described within the "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Immuno-Oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">" section below, effective July 1, 2022, the Company obtained the exclusive right to develop, commercialize, and manufacture Libtayo worldwide.</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Statements of Operations in connection with its Bayer collaboration are as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"/><td style="width:49.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.931%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.934%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of EYLEA outside the United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of ex-U.S. commercial supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One-time payment in connection with change in Japan arrangement</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Bayer R&amp;D expenses, net of reimbursement of R&amp;D expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(R&amp;D expense)/Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 16.75pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Statements of Operations in connection with the Roche Collaboration Agreement are as follows:</span></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.818%"><tr><td style="width:1.0%"/><td style="width:48.814%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global gross profit payment from Roche in connection with sales of Ronapreve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules of sales to customers as percentage of total gross product revenue</a></td>
<td class="text">Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.210%"><tr><td style="width:1.0%"/><td style="width:62.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.939%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Besse Medical, a subsidiary of AmerisourceBergen Corporation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373856697024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of collaborative revenue</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.140%"><tr><td style="width:1.0%"/><td style="width:42.910%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.347%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.102%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.868%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.102%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,433.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(a) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROW</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evkeeza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inmazeb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,638.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Prior to July 1, 2022, Regeneron recorded net product sales of Libtayo in the United States and Sanofi recorded net product sales of Libtayo outside the United States. Effective July 1, 2022, the Company records global net product sales of Libtayo. See Note 3 for further details.</span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rest of world ("ROW")</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in our Statements of Operations in connection with our collaborations with Sanofi are detailed below:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.888%"><tr><td style="width:1.0%"/><td style="width:44.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.265%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antibody:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of antibodies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-based milestones earned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Sanofi R&amp;D expenses, net of reimbursement of R&amp;D expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(R&amp;D expense)/Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of SG&amp;A expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immuno-oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of Libtayo outside the United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of ex-U.S. commercial supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of R&amp;D expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of SG&amp;A expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Sanofi commercial expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&amp;A expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in connection with up-front payments received</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As described within the "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Immuno-Oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">" section below, effective July 1, 2022, the Company obtained the exclusive right to develop, commercialize, and manufacture Libtayo worldwide.</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Statements of Operations in connection with its Bayer collaboration are as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"/><td style="width:49.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.931%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.934%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of EYLEA outside the United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of ex-U.S. commercial supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One-time payment in connection with change in Japan arrangement</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Bayer R&amp;D expenses, net of reimbursement of R&amp;D expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(R&amp;D expense)/Reduction of R&amp;D expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 16.75pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the Company's Statements of Operations in connection with the Roche Collaboration Agreement are as follows:</span></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.818%"><tr><td style="width:1.0%"/><td style="width:48.814%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.651%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global gross profit payment from Roche in connection with sales of Ronapreve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of accounts receivable and deferred revenue information</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Company's Antibody Collaboration with Sanofi:</span></div><div style="margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.502%"><tr><td style="width:1.0%"/><td style="width:49.268%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.489%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Company's Bayer collaboration:</span></div><div style="margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.795%"><tr><td style="width:1.0%"/><td style="width:49.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Roche Collaboration Agreement:</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.368%"><tr><td style="width:1.0%"/><td style="width:58.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.810%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.810%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.296%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373853569024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Net Income (Loss) Per Share</a></td>
<td class="text">The calculations of basic and diluted net income per share are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.304%"><tr><td style="width:1.0%"/><td style="width:64.719%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.838%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">973.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards and restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive Securities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from diluted per share amounts because their effect would have been antidilutive include the following:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.298%"><tr><td style="width:1.0%"/><td style="width:54.015%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.692%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Shares in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373853271456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Available-for-sale Debt Securities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's investments in available-for-sale debt securities:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"/><td style="width:46.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of March&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,819.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,592.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,902.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,903.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,280.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,051.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,975.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,684.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,945.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,939.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,320.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,018.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Marketable Securities, Based on Contractual Maturity Dates</a></td>
<td class="text">The fair values of available-for-sale debt securities by contractual maturity consist of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.473%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.933%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.933%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,043.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,636.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,996.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,381.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities after five years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,051.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,018.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Fair Value and Unrealized Losses of Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the fair value of the Company's available-for-sale debt securities&#160;that have unrealized losses, aggregated by investment category and length of time that the individual securities have been in a continuous loss position.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.590%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of March&#160;31, 2023</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,293.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,464.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,687.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,445.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,200.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,645.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,300.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76.9)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,332.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225.9)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,633.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302.8)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373853182288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of assets measured at fair value on a recurring basis</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company's assets which are measured at fair value on a recurring basis. The following fair value hierarchy is used to classify assets, based on inputs to valuation techniques utilized to measure fair value:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Quoted prices in active markets for identical assets</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Significant other observable inputs, such as quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuations in which significant inputs used are observable</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Significant other unobservable inputs</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:49.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.781%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of March&#160;31, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,268.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,592.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,592.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,903.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,903.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (unrestricted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (restricted)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,532.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,329.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,662.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,574.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,684.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,684.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,939.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,939.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (unrestricted)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (restricted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,185.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,185.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,891.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,298.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,592.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373853178704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.555%"><tr><td style="width:1.0%"/><td style="width:47.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.165%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,424.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,401.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373855984368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock', window );">Schedule of Shares Repurchased</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the shares of our Common Stock we repurchased and the cost of the shares, which were recorded as Treasury Stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.432%"><tr><td style="width:1.0%"/><td style="width:61.076%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of shares </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23309-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTreasuryStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373856861184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Flows (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheet to the total of the same such amounts shown in the Condensed Consolidated Statement of Cash Flows:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.210%"><tr><td style="width:1.0%"/><td style="width:58.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.172%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,916.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,345.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in Other noncurrent assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,928.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,359.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Restrictions on Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheet to the total of the same such amounts shown in the Condensed Consolidated Statement of Cash Flows:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.210%"><tr><td style="width:1.0%"/><td style="width:58.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.172%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,916.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,345.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in Other noncurrent assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,928.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,359.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Summary of Non-Cash Investing and Financing Activities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:31.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued capital expenditures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued contingent consideration for Libtayo intangible asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373851637056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Sales - Schedule of Net Product Sales (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 3,162.1<span></span>
</td>
<td class="nump">$ 2,965.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,668.0<span></span>
</td>
<td class="nump">1,638.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | EYLEA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,433.8<span></span>
</td>
<td class="nump">1,517.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Libtayo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">109.7<span></span>
</td>
<td class="nump">78.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Praluent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">40.2<span></span>
</td>
<td class="nump">33.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Evkeeza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">14.9<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Inmazeb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=regn_RestOfWorldMember', window );">ROW | Libtayo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 67.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_EyleaNetProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_EyleaNetProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_LIBTAYONetProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_LIBTAYONetProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_PraluentNetProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_PraluentNetProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_EvkeezaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_EvkeezaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_InmazebMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_InmazebMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=regn_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=regn_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373849596048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Product Sales - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 5,118.6<span></span>
</td>
<td class="nump">$ 5,328.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember', window );">Trade accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 3,578.0<span></span>
</td>
<td class="nump">$ 3,586.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373853643216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Sales - Schedule of Concentration of Risk, by Risk Factor (Details) - Gross product revenue - Customer concentration risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=regn_GrossProductRevenueMember', window );">Besse Medical, a subsidiary of AmerisourceBergen Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=regn_GrossProductRevenueMember', window );">McKesson Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=regn_GrossProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=regn_GrossProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=regn_BesseMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=regn_BesseMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=regn_McKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=regn_McKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373853718912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Amounts Recognized In Statement of Operations with Sanofi (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 3,162.1<span></span>
</td>
<td class="nump">$ 2,965.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Collaboration revenue | Regeneron's share of profits in connection with commercialization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">636.5<span></span>
</td>
<td class="nump">415.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Collaboration revenue | Sales-based milestones earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Collaboration revenue | Reimbursement for manufacturing of commercial supplies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">161.9<span></span>
</td>
<td class="nump">160.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | (R&amp;D expense)/Reduction of R&amp;D expense | Regeneron's obligation for its share of Sanofi R&amp;D expenses, net of reimbursement of R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="num">(26.4)<span></span>
</td>
<td class="nump">26.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | SG&amp;A expense | Reimbursement of commercialization-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">117.6<span></span>
</td>
<td class="nump">91.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | Collaboration revenue | Regeneron's share of profits in connection with commercialization | Outside United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | Collaboration revenue | Reimbursement for manufacturing of ex-U.S. commercial supplies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | (R&amp;D expense)/Reduction of R&amp;D expense | Reimbursement of R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">21.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | SG&amp;A expense | Reimbursement of commercialization-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">19.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | SG&amp;A expense | Regeneron's obligation for its share of Sanofi commercial expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(9.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | Cost of goods sold | Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(32.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | Other operating income | Amounts recognized in connection with up-front payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 18.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=regn_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=regn_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ShareOfProfitLossesInConnectionWithCommercializationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ShareOfProfitLossesInConnectionWithCommercializationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_SalesBasedMilestoneEarnedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_SalesBasedMilestoneEarnedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ReimbursementForManufacturingOfCommercialSuppliesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ReimbursementForManufacturingOfCommercialSuppliesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ReimbursementOfCommercializationRelatedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ReimbursementOfCommercializationRelatedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ReimbursementForManufacturingOfExCommercialSuppliesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ReimbursementForManufacturingOfExCommercialSuppliesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_RegeneronsShareOfCommercialExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_RegeneronsShareOfCommercialExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=regn_CostOfGoodsSoldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=regn_CostOfGoodsSoldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_SanofisShareofLibtayoU.S.GrossProfitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_SanofisShareofLibtayoU.S.GrossProfitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373853604016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,162.1<span></span>
</td>
<td class="nump">$ 2,965.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts', window );">Percentage share of profits to reimburse collaborating party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts', window );">Percentage of share of profits used to reimburse collaborating party for trial costs</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Sales Milestone Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived', window );">Levels of twelve-month sales at which sales milestone payments would be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis', window );">Period for achieving sales target for milestone payment, rolling basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Sales Milestone Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived', window );">Levels of twelve-month sales at which sales milestone payments would be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis', window );">Period for achieving sales target for milestone payment, rolling basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Revenue, remaining performance obligation, variable consideration amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty', window );">Percentage of trial costs required to be funded by collaborating party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts', window );">Percentage share of profits to reimburse collaborating party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty', window );">Percentage of trial costs required to be funded by collaborating party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts', window );">Percentage share of profits to reimburse collaborating party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Levels Of Twelve Month Sales At Which Sales Milestone Payments Would Be Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Quarterly Profits Required To Be Paid For Reimbursement Of Development Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Share of Profits Used to Reimburse Collaborating Party for Trial Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Trial Costs Required To Be Funded By Collaborating Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period for Achieving Sales Target for Milestone Payment, Rolling Basis</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_MilestoneTypeAxis=regn_SalesMilestoneThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_MilestoneTypeAxis=regn_SalesMilestoneThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_MilestoneTypeAxis=regn_SalesMilestoneFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_MilestoneTypeAxis=regn_SalesMilestoneFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373853547344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Schedule of Contract Balances, Antibody Collaboration (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 5,118.6<span></span>
</td>
<td class="nump">$ 5,328.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">731.5<span></span>
</td>
<td class="nump">692.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 377.5<span></span>
</td>
<td class="nump">$ 415.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373849823872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Up-front payment to be made to collaborator</a></td>
<td class="nump">$ 3,162.1<span></span>
</td>
<td class="nump">$ 2,965.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=regn_SanofiMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_UpFrontPaymentToCollaboratingParty', window );">Up-front payment to collaborating party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales', window );">Royalty payment to collaborating party, percentage of net product sales</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | Regulatory Milestone | Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_UpFrontPaymentToCollaboratingParty', window );">Up-front payment to collaborating party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | Sales-Based Milestone One | Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Up-front payment to be made to collaborator</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | Sales-Based Milestone Two | Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Up-front payment to be made to collaborator</a></td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | Sales-Based Milestones | Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Up-front payment to be made to collaborator</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Payment to Collaborating Party, Percentage of Net Product Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_UpFrontPaymentToCollaboratingParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Up-Front Payment to Collaborating Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_UpFrontPaymentToCollaboratingParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=regn_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=regn_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_MilestoneTypeAxis=regn_RegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_MilestoneTypeAxis=regn_RegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=regn_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=regn_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_MilestoneTypeAxis=regn_SalesBasedMilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_MilestoneTypeAxis=regn_SalesBasedMilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_MilestoneTypeAxis=regn_SalesBasedMilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_MilestoneTypeAxis=regn_SalesBasedMilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_MilestoneTypeAxis=regn_SalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_MilestoneTypeAxis=regn_SalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373849783376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Bayer (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 3,162.1<span></span>
</td>
<td class="nump">$ 2,965.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember', window );">Bayer | Outside United States | Collaboration revenue | Regeneron's share of profits in connection with commercialization of EYLEA outside the United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">331.6<span></span>
</td>
<td class="nump">338.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember', window );">Bayer | Outside United States | Collaboration revenue | Reimbursement for manufacturing of ex-U.S. commercial supplies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">25.3<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember', window );">Bayer | Outside United States | Collaboration revenue | One-time payment in connection with change in Japan arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">21.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember', window );">Bayer | Outside United States | (R&amp;D expense)/Reduction of R&amp;D expense | Regeneron's obligation for its share of Bayer R&amp;D expenses, net of reimbursement of R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="num">$ (13.4)<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=regn_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=regn_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_NetProfitInConnectionWithCommercializationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_NetProfitInConnectionWithCommercializationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ReimbursementForManufacturingOfCommercialSuppliesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ReimbursementForManufacturingOfCommercialSuppliesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=regn_ResearchAndDevelopmentExpensesAndReductionOfResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=regn_ResearchAndDevelopmentExpensesAndReductionOfResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_RegeneronsObligationOfResearchAndDevelopmentExpensesNetOfReimbursementOfResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_RegeneronsObligationOfResearchAndDevelopmentExpensesNetOfReimbursementOfResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373849653440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Schedule of Contract Balances, Bayer Collaboration (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 5,118.6<span></span>
</td>
<td class="nump">$ 5,328.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember', window );">Bayer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">356.8<span></span>
</td>
<td class="nump">348.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 134.3<span></span>
</td>
<td class="nump">$ 131.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373852553152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Roche (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 3,162.1<span></span>
</td>
<td class="nump">$ 2,965.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=regn_RonapreveMember', window );">Ronapreve | Roche Collaboration Agreement | Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 222.2<span></span>
</td>
<td class="nump">$ 216.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_RonapreveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_RonapreveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_RocheCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_RocheCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=regn_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=regn_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373853577120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Schedule of Contract Balances - Roche (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 5,118.6<span></span>
</td>
<td class="nump">$ 5,328.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_RocheCollaborationAgreementMember', window );">Roche Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 220.6<span></span>
</td>
<td class="nump">$ 396.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_RocheCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_RocheCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373857103056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Sonoma Biotherapeutics, Inc. Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,162.1<span></span>
</td>
<td class="nump">$ 2,965.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SonomaBiotherapeuticsIncCollaborationAgreementMember', window );">Sonoma Biotherapeutics, Inc. Collaboration Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Purchase of preferred stock</a></td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=regn_SonomaBiotherapeuticsIncMember', window );">Sonoma Biotherapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_UpFrontPaymentToCollaboratingParty', window );">Up-front payment to collaborating party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=regn_SonomaBiotherapeuticsIncMember', window );">Sonoma Biotherapeutics, Inc. | Sonoma Biotherapeutics, Inc. Collaboration Agreement | Development Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_UpFrontPaymentToCollaboratingParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Up-Front Payment to Collaborating Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_UpFrontPaymentToCollaboratingParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SonomaBiotherapeuticsIncCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SonomaBiotherapeuticsIncCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=regn_SonomaBiotherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=regn_SonomaBiotherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_MilestoneTypeAxis=regn_DevelopmentMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_MilestoneTypeAxis=regn_DevelopmentMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373853633632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income - basic and diluted</a></td>
<td class="nump">$ 817.8<span></span>
</td>
<td class="nump">$ 973.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares - basic (in shares)</a></td>
<td class="nump">107.1<span></span>
</td>
<td class="nump">106.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares - diluted (in shares)</a></td>
<td class="nump">114.0<span></span>
</td>
<td class="nump">113.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - basic (in dollars per share)</a></td>
<td class="nump">$ 7.64<span></span>
</td>
<td class="nump">$ 9.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - diluted (in dollars per share)</a></td>
<td class="nump">$ 7.17<span></span>
</td>
<td class="nump">$ 8.61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards and restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373852393584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Schedule of Antidilutive Securities Excluded From Computation (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Stock options (in shares)</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373854825488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Investments in Available For Sale Debt Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">$ 10,280.8<span></span>
</td>
<td class="nump">$ 10,320.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">10.6<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(240.1)<span></span>
</td>
<td class="num">(302.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">10,051.3<span></span>
</td>
<td class="nump">10,018.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">6,819.1<span></span>
</td>
<td class="nump">6,975.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(231.7)<span></span>
</td>
<td class="num">(291.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">6,592.2<span></span>
</td>
<td class="nump">6,684.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. government and government agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">2,902.2<span></span>
</td>
<td class="nump">2,945.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(4.3)<span></span>
</td>
<td class="num">(6.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">2,903.4<span></span>
</td>
<td class="nump">2,939.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember', window );">Sovereign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">72.6<span></span>
</td>
<td class="nump">67.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">70.4<span></span>
</td>
<td class="nump">64.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">279.1<span></span>
</td>
<td class="nump">121.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">279.1<span></span>
</td>
<td class="nump">121.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">153.9<span></span>
</td>
<td class="nump">182.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">153.7<span></span>
</td>
<td class="nump">182.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">53.9<span></span>
</td>
<td class="nump">28.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1.5)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 52.5<span></span>
</td>
<td class="nump">$ 27.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373855946544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Debt Securities Based on Contractual Maturity Dates (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturities within one year</a></td>
<td class="nump">$ 5,043.4<span></span>
</td>
<td class="nump">$ 4,636.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturities after one year through five years</a></td>
<td class="nump">4,996.6<span></span>
</td>
<td class="nump">5,381.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5', window );">Maturities after five years</a></td>
<td class="nump">11.3<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 10,051.3<span></span>
</td>
<td class="nump">$ 10,018.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373851228640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Fair Value and Unrealized Losses of Debt Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value - Less than 12 Months</a></td>
<td class="nump">$ 1,222.7<span></span>
</td>
<td class="nump">$ 3,300.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss - Less than 12 months</a></td>
<td class="num">(8.4)<span></span>
</td>
<td class="num">(76.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value - 12 Months or Greater</a></td>
<td class="nump">5,464.5<span></span>
</td>
<td class="nump">4,332.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Loss - 12 Months or Greater</a></td>
<td class="num">(231.7)<span></span>
</td>
<td class="num">(225.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value - Total</a></td>
<td class="nump">6,687.2<span></span>
</td>
<td class="nump">7,633.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Loss - Total</a></td>
<td class="num">(240.1)<span></span>
</td>
<td class="num">(302.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value - Less than 12 Months</a></td>
<td class="nump">707.1<span></span>
</td>
<td class="nump">2,445.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss - Less than 12 months</a></td>
<td class="num">(8.1)<span></span>
</td>
<td class="num">(73.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value - 12 Months or Greater</a></td>
<td class="nump">5,293.7<span></span>
</td>
<td class="nump">4,200.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Loss - 12 Months or Greater</a></td>
<td class="num">(223.6)<span></span>
</td>
<td class="num">(218.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value - Total</a></td>
<td class="nump">6,000.8<span></span>
</td>
<td class="nump">6,645.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Loss - Total</a></td>
<td class="num">(231.7)<span></span>
</td>
<td class="num">(291.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. government and government agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value - Less than 12 Months</a></td>
<td class="nump">228.1<span></span>
</td>
<td class="nump">785.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss - Less than 12 months</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value - 12 Months or Greater</a></td>
<td class="nump">79.2<span></span>
</td>
<td class="nump">71.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Loss - 12 Months or Greater</a></td>
<td class="num">(4.2)<span></span>
</td>
<td class="num">(4.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value - Total</a></td>
<td class="nump">307.3<span></span>
</td>
<td class="nump">856.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Loss - Total</a></td>
<td class="num">(4.3)<span></span>
</td>
<td class="num">(6.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember', window );">Sovereign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value - Less than 12 Months</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">18.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss - Less than 12 months</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value - 12 Months or Greater</a></td>
<td class="nump">64.0<span></span>
</td>
<td class="nump">45.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Loss - 12 Months or Greater</a></td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(1.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value - Total</a></td>
<td class="nump">64.0<span></span>
</td>
<td class="nump">64.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Loss - Total</a></td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value - Less than 12 Months</a></td>
<td class="nump">212.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss - Less than 12 months</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value - 12 Months or Greater</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Loss - 12 Months or Greater</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value - Total</a></td>
<td class="nump">212.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Loss - Total</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value - Less than 12 Months</a></td>
<td class="nump">74.9<span></span>
</td>
<td class="nump">40.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss - Less than 12 months</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value - 12 Months or Greater</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Loss - 12 Months or Greater</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value - Total</a></td>
<td class="nump">77.8<span></span>
</td>
<td class="nump">40.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Loss - Total</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value - Less than 12 Months</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss - Less than 12 months</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value - 12 Months or Greater</a></td>
<td class="nump">24.7<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Loss - 12 Months or Greater</a></td>
<td class="num">(1.5)<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value - Total</a></td>
<td class="nump">24.7<span></span>
</td>
<td class="nump">26.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Loss - Total</a></td>
<td class="num">$ (1.5)<span></span>
</td>
<td class="num">$ (1.7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373850600560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Assets Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">$ 10,051.3<span></span>
</td>
<td class="nump">$ 10,018.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">6,592.2<span></span>
</td>
<td class="nump">6,684.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. government and government agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">2,903.4<span></span>
</td>
<td class="nump">2,939.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember', window );">Sovereign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">70.4<span></span>
</td>
<td class="nump">64.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">279.1<span></span>
</td>
<td class="nump">121.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">153.7<span></span>
</td>
<td class="nump">182.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">52.5<span></span>
</td>
<td class="nump">27.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,422.7<span></span>
</td>
<td class="nump">1,662.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure, Total</a></td>
<td class="nump">12,532.7<span></span>
</td>
<td class="nump">12,891.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Unrestricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">20.7<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Restricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">1,038.0<span></span>
</td>
<td class="nump">1,185.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">6,592.2<span></span>
</td>
<td class="nump">6,684.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | U.S. government and government agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">2,903.4<span></span>
</td>
<td class="nump">2,939.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Sovereign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">70.4<span></span>
</td>
<td class="nump">64.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">279.1<span></span>
</td>
<td class="nump">121.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">153.7<span></span>
</td>
<td class="nump">182.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">52.5<span></span>
</td>
<td class="nump">27.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">154.1<span></span>
</td>
<td class="nump">88.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure, Total</a></td>
<td class="nump">1,203.1<span></span>
</td>
<td class="nump">1,298.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1 | Unrestricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">20.7<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1 | Restricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">1,028.3<span></span>
</td>
<td class="nump">1,185.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1 | U.S. government and government agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1 | Sovereign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,268.6<span></span>
</td>
<td class="nump">1,574.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure, Total</a></td>
<td class="nump">11,329.6<span></span>
</td>
<td class="nump">11,592.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2 | Unrestricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2 | Restricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">9.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">6,592.2<span></span>
</td>
<td class="nump">6,684.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2 | U.S. government and government agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">2,903.4<span></span>
</td>
<td class="nump">2,939.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2 | Sovereign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">70.4<span></span>
</td>
<td class="nump">64.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">279.1<span></span>
</td>
<td class="nump">121.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">153.7<span></span>
</td>
<td class="nump">182.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">$ 52.5<span></span>
</td>
<td class="nump">$ 27.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ClassificationOfInvestmentAxis=regn_UnrestrictedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ClassificationOfInvestmentAxis=regn_UnrestrictedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ClassificationOfInvestmentAxis=regn_RestrictedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ClassificationOfInvestmentAxis=regn_RestrictedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373854629920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Losses on marketable and other securities, net</a></td>
<td class="nump">$ 164.7<span></span>
</td>
<td class="nump">$ 211.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Securities owned not readily marketable</a></td>
<td class="nump">48.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt fair value</a></td>
<td class="nump">$ 1,516.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,443.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373849628160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Schedule of Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 844.6<span></span>
</td>
<td class="nump">$ 818.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">855.7<span></span>
</td>
<td class="nump">963.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">169.3<span></span>
</td>
<td class="nump">98.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInventoryNetOfReserves', window );">Deferred costs</a></td>
<td class="nump">555.1<span></span>
</td>
<td class="nump">521.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total Inventories</a></td>
<td class="nump">$ 2,424.7<span></span>
</td>
<td class="nump">$ 2,401.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after of valuation reserves and allowances, of inventory, classified as other, expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373857097248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory valuation reserves</a></td>
<td class="nump">$ 752.3<span></span>
</td>
<td class="nump">$ 720.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373855643648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">4.70%<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373854901856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remaining authorized repurchase amount</a></td>
<td class="nump">$ 3,051,000,000.000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgramNovember2021Member', window );">November 2021 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgramJanuary2023Member', window );">Share Repurchase Program, January 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgramNovember2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgramNovember2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgramJanuary2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgramJanuary2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373849673216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Share Repurchases (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Number of shares (in shares)</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Total cost of shares</a></td>
<td class="nump">$ 693.9<span></span>
</td>
<td class="nump">$ 352.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373851601152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Flows - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,916.3<span></span>
</td>
<td class="nump">$ 3,105.9<span></span>
</td>
<td class="nump">$ 3,345.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash included in Other noncurrent assets</a></td>
<td class="nump">12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows</a></td>
<td class="nump">$ 3,928.8<span></span>
</td>
<td class="nump">$ 3,119.4<span></span>
</td>
<td class="nump">$ 3,359.2<span></span>
</td>
<td class="nump">$ 2,898.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373854775024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Flows - Summary of Non-cash Investing and Financing Activities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accrued capital expenditures</a></td>
<td class="nump">$ 90.3<span></span>
</td>
<td class="nump">$ 80.7<span></span>
</td>
<td class="nump">$ 70.8<span></span>
</td>
<td class="nump">$ 74.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1', window );">Accrued contingent consideration for Libtayo intangible asset</a></td>
<td class="nump">$ 55.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 135.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140373849753952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Legal Matters (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 09, 2021 </div>
<div>claim</div>
</th>
<th class="th">
<div>Jul. 16, 2020 </div>
<div>claim</div>
</th>
<th class="th">
<div>Feb. 11, 2020 </div>
<div>request</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A226PatentAnd992PatentMember', window );">'226 and '992 Patents | EYLEA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_LossContingencyExParteReexaminationFiledNumber', window );">Number of ex parte reexamination requests | request</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A338PatentAnd069PatentMember', window );">'338 Patent And '069 Patent | Celltrion, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_NumberOfInterPartiesReviewIPRPetitionsFiled', window );">Number of IPR filed</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A338PatentAnd069PatentMember', window );">'338 Patent And '069 Patent | Apotex Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_NumberOfInterPartiesReviewIPRPetitionsFiled', window );">Number of IPR filed</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A631PatentMember', window );">'631 Patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_regn_NumberOfInterPartiesReviewIPRPetitionsFiled', window );">Number of IPR filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_LossContingencyExParteReexaminationFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Ex Parte Reexamination, Filed, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_LossContingencyExParteReexaminationFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_NumberOfInterPartiesReviewIPRPetitionsFiled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Inter Parties Review (IPR) Petitions Filed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_NumberOfInterPartiesReviewIPRPetitionsFiled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A226PatentAnd992PatentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A226PatentAnd992PatentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_EYLEAAfliberceptInjectionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_EYLEAAfliberceptInjectionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A338PatentAnd069PatentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A338PatentAnd069PatentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=regn_CelltrionIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=regn_CelltrionIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=regn_ApotexIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=regn_ApotexIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A631PatentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A631PatentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>regn-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:regn="http://www.regeneron.com/20230331"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="regn-20230331.xsd" xlink:type="simple"/>
    <context id="ibb12656df12e495a99ae9761ff452049_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i52501e7fdeda4b63b53fa2c38deee3ba_I20230411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-11</instant>
        </period>
    </context>
    <context id="i95399a66c34747c7ae8a30809bebb551_I20230411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-11</instant>
        </period>
    </context>
    <context id="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia687c58bde834c42ab9a8d978528b6c1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6b8134b6a41640a59debc09f522f7159_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic62e60ebc7424784abaf7166a92b5115_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iad84cd28f95b42f29a3715741068591b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7b7c4d8560fb43119f17d189a9cc1ec6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i89d2806ddfda4899b23a4e2a27b639ee_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9cd61146d31845f7aa0a400c1de8c9af_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5e96d85f6116487bb808133461cb06a1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i322b8ce5df5b4c60ad8cc95df009f249_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i375b286d61df4bd4851e798baea9fbed_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia7d1404e1f794d79bf92b04d446901cf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3e0ca86da19f48e88d9bf110de7b69c2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5bf386a54cb94d3693610866086baa33_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if30714371f9e46528af3d8f6681b15c7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iee31f7d64fe049c7a439d288ec9486d5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3f33b378dd044be2997a03a26a5d3b48_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i464958bff30b4da893895a523da36762_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1fa0f967adc9439caf372e79f15e9e65_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ica431963a44548bd8c3c65e67df71293_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib5c88fce876d4566b4cbbac88f11de2b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i015fc10968404f9596294e54195211db_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i185b612165b347b2b4aa073de182131b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5afdea61952c4451a233ed8c133cf438_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibfb86f8ed7f34a63aa1ea7aa30866925_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2ccec8fe40c04d699a63e2967214f0b4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibcec73dff80346e1895f9d7262e1ea33_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1e41e273a91b4f7080ff818a13fe99be_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icef282f2e36944018a2590dcf58321d6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i46042c6680c54f40880fde0d8f818288_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib287cdc989b242ed899986d4cbe3af11_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic23d397894814b2486b54d92fc4b1a6d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i97aac951375a4b61997b83f703090509_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1a88badb1d6e4841ab079e4f443a7e4c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i38ccce571fef4b90bc060bfc54280e73_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifcb31e106e34471ea566f05963a75c5e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i80bf6dc29204481a9c4efae367ed366e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if6c18de361b24fb9a6ed97dcb156b4ac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if6b622c0a75c4abf85767c76eeb3eb23_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i12fb29cdd4ea4b8b919c34781498d6c1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6bfc42c5e2314ceda9b705bf6f75c36e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i64fe108807dd4be4af7e9ea5f30001e4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib5bc7a6419f1432ca3b84fea5414f7a3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i936952c9103a4c52811822936c6feffb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i763f240b37e34f9e97c13b9647d2763e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id7292cbbd4824b5b8b48cd9b81256747_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i39ca18ca3a794b3c9cc3567ecaf855ed_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ide8d66252aa645be98653f0b578cbb44_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia23f7613df634004b007e3599b0e97f9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7298587e584844a686de7edf412eb7a2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4c137cb80c2348b6b72faccb7cba8e93_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EyleaNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idb40dc2b4e6d4ddc9267422ed2896f2b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EyleaNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9d3ca332ac7b44e7afd08a842efc7831_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1493138d25f94132897d582fa5633635_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i539fd4a3ebc04eee85f11898f58b8e50_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">regn:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1d4c5cb7b7d440c39db96ce2e6fcdf63_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">regn:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i97633ca31aaf4a5494aff1cd47af72b6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:PraluentNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6180931ab3794a16a3d092c67267848f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:PraluentNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i170bf04d3efb4e2ba2dbc70f34869ad4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EvkeezaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie7a13e46bf874e5d863afd595bc4af6a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EvkeezaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4ee16d3d639e46f8a41fb5fef9f9301a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:InmazebMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0510a432e77041dca5a54640cff8ad6f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:InmazebMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib8a607a3e56c41779c0e4d7f40f3276c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iddde8724f2d94806b024d0d0b38bb09c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i66be2d5d13e14c65a79a0cd9a1fdba09_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:BesseMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iffa15815bae94096ae1f51c8a0ecfdf8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:BesseMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id1c2ae76df8543b98e4b8e032206851d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id5edea8b3603449e90ce4d1565b6ee02_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib2f2c59d2425478cb9a759cbb016a8e3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic3e3b5297b2d4da18d1e8bf81c32ed78_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3a2817fbcc324c0dace63bfa58aa3472_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SalesBasedMilestoneEarnedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i496ebaf3b22440b2b2d69aab06cd1a36_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SalesBasedMilestoneEarnedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2cadf695465b4d2c823616dee5674384_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iea1238f837994a0a8d152d9ed98974c4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ied6deae52c5a4fddbad0b5bb2c2d457d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic09e4f946d7f4b20bff8285f40f649f9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id88f78210881451481543b0e7df5322b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i83fd3849cf8b49c990d30ebab1b52082_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia9bce6102ed54468900a9f32c759ef8c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ied033f1452834cc0b77499b012220842_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6d4d7003a52c48d286f50a758bf9d9fb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfExCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id312ecfecca44b6cad64d0a4dead7154_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfExCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3b748b8781634cf7bad7b7c57fea08bc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifeba37fd20ba4aa5aa90737cd4da0556_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie398e6bd3f1649b1b129db816c08a863_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iba78c9e3c2b14c9f8c6d4c4c6903cefe_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4b3cda38a64e4813ba22059700b5a833_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfCommercialExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i13a2eb4e3a324853b0f3388887ed2b2c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfCommercialExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icf4bf1050794419cbf96df94e7e5a822_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofisShareofLibtayoU.S.GrossProfitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CostOfGoodsSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2fd3f28a70a64843aab800c66e3727dd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofisShareofLibtayoU.S.GrossProfitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CostOfGoodsSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1cfd4128aea7458a926f5ef7dc7d8228_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1807e85b9a734966b305aebfce1a2b3e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i93a73ef5b43a4b719c774ecb420922ef_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iaa0640ad68f44c88a2dbc0ebca2b3b73_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i76483ad7f52e40cab4a22bb58eb53286_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i38436edb47124f8fb19121d45a1874e7_D20220630-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia4de45f3331e49d0bc3791fd059ee5a4_D20220701-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="icd392818c90b43539fc9c9768bb1ca18_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:MilestoneTypeAxis">regn:SalesMilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idd80951ec63945c1a0f004821f556950_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:MilestoneTypeAxis">regn:SalesMilestoneFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i78bee0b457e64f8ca4716924e360fafb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:MilestoneTypeAxis">regn:SalesMilestoneFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i50cbbeeb8ba0490fb582afb27330f7db_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iaea9b652c53d4a4c82b1a7b4ea756d8c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia67b58013e1b4eb9829600ae26b049f1_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib05c9a4e748542a39f0ded000f62b58a_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:MilestoneTypeAxis">regn:RegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i157885e3534940e6bbf0c1712c537758_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:MilestoneTypeAxis">regn:SalesBasedMilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i51a33fff830d49e2836b1dcc69fd8e6d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:MilestoneTypeAxis">regn:SalesBasedMilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idfc4183c9b684d69800dbe32f7df3f9c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:MilestoneTypeAxis">regn:SalesBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i28142adb16bf44cd9637c180668c9386_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibb424b76bb944bb487058cb7b71b5478_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:NetProfitInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iba893ed59b6f4ef9b1de82284a9c172b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:NetProfitInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0252272660b2483c9bdc58226cbd09da_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idde62877d41141df8937d3435f4c3667_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibf1d66b82008486885a981ea123058f2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:OneTimePaymentInConnectionWithChangeInJapanArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia020696b0d3c4162aea4b7989e504a75_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:OneTimePaymentInConnectionWithChangeInJapanArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9a5fff795cfe4c74b86bc4bd5174db81_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsObligationOfResearchAndDevelopmentExpensesNetOfReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:ResearchAndDevelopmentExpensesAndReductionOfResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie08517bc56f64a56855dedc1fd282413_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsObligationOfResearchAndDevelopmentExpensesNetOfReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:ResearchAndDevelopmentExpensesAndReductionOfResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic9e294aebc65480da80f32f7028adbb2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i102f804ba9484132ae7196bde6f74767_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i64841568e706401985fc84aa04b36f1e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RonapreveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i29f6f63a87914141b95f4f2c48ff1364_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RonapreveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i38fd75f0c02644a59d387c1d665dac3e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7e796f5592204aff856a0effed5d30f5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9c9892adbc9444b2ba40d227075a443b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:SonomaBiotherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib6c0a3e1eb3f4fa4b60c33bacffd2f52_D20230401-20230430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SonomaBiotherapeuticsIncCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="id3456908093f4728b4a4f17cb0d3cd19_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:SonomaBiotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SonomaBiotherapeuticsIncCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:MilestoneTypeAxis">regn:DevelopmentMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3b0f6d873f2441d7890447099c7468ad_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i899f0e7929c744418d1f315d17e1594a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i084af335d0d14bb79b9fc2db8159a242_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2be78b3922ff4f9196bd6708075600e8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7aef696237bd4fa2bb67d81627a03291_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic57e069f15ea4d1eb588c09adef593ba_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8903a1b5844542cfbc9e394aa701aed8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifdb936c554134642a68368b066e9f82a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifdb70d5f062d4e928b605b2f2599a47d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie9bf0ce9cab24153b67d76ba77f2f319_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i418c3363911e44aba24f1ae219890db8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iab279394f6cf43de9deae81fa065d878_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idf94038a80c74b0d9edbcbeccb24dde9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if8a4bb9880684a74adbfbf4815ad715c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5a32793eceeb4ea687e38aa30fc6de37_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i31e5c62bbe8047b78e6c3041593ef2fe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1d7998c008a645b497664f16dfdf9c3e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i076e28d6501548bba1781c8d95c229c1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i42bb7405dae2448892d28fe5254d753b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i69a16600ec214325aa04a3be1bcacc1a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iccd0b582761d43a79ac5b665419222c1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0ed1181d127f48eeae6cc93827001b60_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4d138ebcdd8d4f6f9da1861a1980e8fe_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6a4637e5ee1a4615bd9757cfde09d5ed_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib78b4e7f93bf4cb2b480289b8085219d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2861028cb0f04545abad3da8e9947ae3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3d31ef08646d47068b930b62221f25c5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9bb4ac30d7174141bd68e0e5165503a4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i27a37895006f481b99b894294d32f453_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i45e1a224580a4ab4a851ce1cd380e58b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic48dc13ed46549c38aa86d1646750b7e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifc9d4a9ec68c46a2a1444ba0c21c58d1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia2532a7ae6c44f0183a1a72036a1dbd2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie2c1cf62b52f4290802d97ca8e3f7314_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i07b68bd2a55e4e4e98087d12385f43b6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i924a1104d72e45899f48ce68164557a6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if6c8f015a8c6464c939619f06315efe8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i319e916558384549ac07e82dc579d15f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i407aae8d570145af8c0266b54d98beec_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i50f8bc3a2ad94180966f9ebe0be125f0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idb363b73e6244abcb656ed2ab62f8f78_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i923780b5c4714bd0b32f8a52e41383bd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0b2c64ec3f6040309efed4a34a2e340c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6e1656e9d1074b078faaced1a79a540d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i96714fa1a4ef4fbea15e01d83966c0d7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icd6e5891198641dc82ba047fab579cec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i906a5a8877744181bffbf220eeea0a73_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaba3655e9756414b9e6fd04ad3ee2f24_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i25b7eaabac2f458b96618bac777bd2ca_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic0fce717fc9443019cee095389f2baf5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5c5fb90e07b84a9a87b35eaaf73fad05_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icc7e444572ae46a385283f8406b98c84_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0392b26a3fbc4c43a64deca654005f83_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1a3f2f6efec84786af7fd186d6c5c4c9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if32b8d821f0642acafbc9612834c9293_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2b5bb5d7a78a4a57b46ccf314f728939_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1b9fc3319f5841518dd67e46c582c888_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icdc9ce269439490ab1af63a29b885fa0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia11171f0e5db4eed91923c0534566b26_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5d989b03e30442ce8a9b3481c7124765_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2536f989b03944a4b9a0d7e8f56ea080_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i85985f6f1c3c4f01b858acc29e09e5ca_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1da2e40825b44fd59ead3dde06e37600_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i442be721ac15405da1349485e18c28ac_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia2bcc6312921492999cec875c39d9b73_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2c67c7b931244e59af10a080716aafec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7f2bd6363aa141e7a2a47119609b54b9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4849fbe85bf94052b4be3ec967ec493f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib961b996c000420b839a622c158db724_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8a829313946c4d029d2545a0b99636f6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i57cc71aadf054c0aa6efa5f790dfbd1e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i551685f126c4400481a7132a780426b0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1c8af3a2f8cb4400af2f7e31cff2cfb3_I20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramNovember2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="i5e3a527460f44b9181602c95f95e6612_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramJanuary2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="iffc0c76d2e7c4dffaaaad5977285af04_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i64798e076fa64db2b5de1538f7e77d5f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9d8a843a06e446c69b2ab4242c134351_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EYLEAAfliberceptInjectionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A226PatentAnd992PatentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="i1194a9d0d6454fd98015eb8688e54523_I20211209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:CelltrionIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A338PatentAnd069PatentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-09</instant>
        </period>
    </context>
    <context id="ice77d20fb98c4a08910e2616a45f1fbd_I20211209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:ApotexIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A338PatentAnd069PatentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-09</instant>
        </period>
    </context>
    <context id="i6b0615f9b30640a6aff828894aee0920_I20200716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A631PatentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-16</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="request">
        <measure>regn:request</measure>
    </unit>
    <unit id="claim">
        <measure>regn:claim</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80L2ZyYWc6MWU4NTg5MjY0MTA5NGIxMTljM2JhZDg3YTdmYmI3OGMvdGFibGU6MTU4YmMzM2U2MzBhNDBmZjhjZTNjZjI3NGEzMzEwMzEvdGFibGVyYW5nZToxNThiYzMzZTYzMGE0MGZmOGNlM2NmMjc0YTMzMTAzMV80LTEtMS0xLTIyMTU2OA_006f4281-06c6-4fb7-a611-8728e5f3faac">0000872589</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80L2ZyYWc6MWU4NTg5MjY0MTA5NGIxMTljM2JhZDg3YTdmYmI3OGMvdGFibGU6MTU4YmMzM2U2MzBhNDBmZjhjZTNjZjI3NGEzMzEwMzEvdGFibGVyYW5nZToxNThiYzMzZTYzMGE0MGZmOGNlM2NmMjc0YTMzMTAzMV81LTEtMS0xLTIyMTU2OA_8fb17fa8-eeb0-4dd4-a404-7d1b00b33ffa">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80L2ZyYWc6MWU4NTg5MjY0MTA5NGIxMTljM2JhZDg3YTdmYmI3OGMvdGFibGU6MTU4YmMzM2U2MzBhNDBmZjhjZTNjZjI3NGEzMzEwMzEvdGFibGVyYW5nZToxNThiYzMzZTYzMGE0MGZmOGNlM2NmMjc0YTMzMTAzMV85LTEtMS0xLTIyMTU2OA_4c71bfbb-1aab-4a68-99c1-502d204630b2">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80L2ZyYWc6MWU4NTg5MjY0MTA5NGIxMTljM2JhZDg3YTdmYmI3OGMvdGFibGU6MTU4YmMzM2U2MzBhNDBmZjhjZTNjZjI3NGEzMzEwMzEvdGFibGVyYW5nZToxNThiYzMzZTYzMGE0MGZmOGNlM2NmMjc0YTMzMTAzMV8xMC0xLTEtMS0yMjE1Njg_b8e4e60c-6af9-4042-9fbc-606ee3d2b561">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80L2ZyYWc6MWU4NTg5MjY0MTA5NGIxMTljM2JhZDg3YTdmYmI3OGMvdGFibGU6MTU4YmMzM2U2MzBhNDBmZjhjZTNjZjI3NGEzMzEwMzEvdGFibGVyYW5nZToxNThiYzMzZTYzMGE0MGZmOGNlM2NmMjc0YTMzMTAzMV8xMS0xLTEtMS0yMjE1Njg_5904549f-ec4f-432b-9e5f-cb1eb00ca8f9">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGV4dHJlZ2lvbjoyNzI0ZjBiZmVhYTM0ZDQzODQ4NDU3MTlmNjY3ZDY3Ml80MjE_3e4f8a7f-8242-4f52-9014-0e1651241925">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6NzdiZTk2NDU4MjJmNGY1YTg5MGEzZWY1YWU0OTUyY2MvdGFibGVyYW5nZTo3N2JlOTY0NTgyMmY0ZjVhODkwYTNlZjVhZTQ5NTJjY18xLTAtMS0xLTIyMTU2OA_d0c3f146-20a9-4edd-adc9-0f1289a28c19">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6NzdiZTk2NDU4MjJmNGY1YTg5MGEzZWY1YWU0OTUyY2MvdGFibGVyYW5nZTo3N2JlOTY0NTgyMmY0ZjVhODkwYTNlZjVhZTQ5NTJjY18yLTEtMS0xLTIyMTU2OC90ZXh0cmVnaW9uOmZiYzM5MWM3ZDdmZTQwODA4MjliMjA3NjYwNTBiMzRhXzM1_9ee2ebe6-3874-4354-b1ba-350c61adcdeb">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6NzdiZTk2NDU4MjJmNGY1YTg5MGEzZWY1YWU0OTUyY2MvdGFibGVyYW5nZTo3N2JlOTY0NTgyMmY0ZjVhODkwYTNlZjVhZTQ5NTJjY180LTAtMS0xLTIyMTU2OA_fa7851fd-8659-4522-84bd-013fba9e9bde">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6MGY3YzVkN2RkYjZlNDMyYmEyYTQ1NTBjMmNkMDE5YWUvdGFibGVyYW5nZTowZjdjNWQ3ZGRiNmU0MzJiYTJhNDU1MGMyY2QwMTlhZV8wLTEtMS0xLTIyMTU2OC90ZXh0cmVnaW9uOjk2ZDUzZWFhY2MwMTQzYzQ5Zjc0NjY4MTYzYjc3NDAzXzI5_3e6a7380-1daa-40ec-b998-7fffbe691ccf">000-19034</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGV4dHJlZ2lvbjoyNzI0ZjBiZmVhYTM0ZDQzODQ4NDU3MTlmNjY3ZDY3Ml80MjI_453202d6-28b2-4915-8827-4bdbfdd75daf">REGENERON PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6OGI0Y2M4OGEyMzNmNDM1Nzk4ZTIyNzI1NGJlNWYyMDUvdGFibGVyYW5nZTo4YjRjYzg4YTIzM2Y0MzU3OThlMjI3MjU0YmU1ZjIwNV8wLTAtMS0xLTIyMTU2OA_ff236772-933e-4c88-88fa-3adc5b8b047d">NY</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6OGI0Y2M4OGEyMzNmNDM1Nzk4ZTIyNzI1NGJlNWYyMDUvdGFibGVyYW5nZTo4YjRjYzg4YTIzM2Y0MzU3OThlMjI3MjU0YmU1ZjIwNV8wLTItMS0xLTIyMTU2OA_5df7b15d-da11-4d8d-ad16-4a62580eeb27">13-3444607</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6ZjU4MmVkYzkzZjFkNDAwNmFmMzk2MzdhMmE1M2Q4ZWYvdGFibGVyYW5nZTpmNTgyZWRjOTNmMWQ0MDA2YWYzOTYzN2EyYTUzZDhlZl8wLTAtMS0xLTIyMTU2OC90ZXh0cmVnaW9uOjc3NGViZjAzYjczZDRlMzRhM2Q2NDlhNjczM2IwMTBkXzQ_2cd2660f-cdeb-438a-89f7-9f3c259c6dc2">777 Old Saw Mill River Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6ZjU4MmVkYzkzZjFkNDAwNmFmMzk2MzdhMmE1M2Q4ZWYvdGFibGVyYW5nZTpmNTgyZWRjOTNmMWQ0MDA2YWYzOTYzN2EyYTUzZDhlZl8wLTAtMS0xLTIyMTU2OC90ZXh0cmVnaW9uOjc3NGViZjAzYjczZDRlMzRhM2Q2NDlhNjczM2IwMTBkXzg_2f013d3e-a063-4d76-8eb2-f7fcebe1041a">Tarrytown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6ZjU4MmVkYzkzZjFkNDAwNmFmMzk2MzdhMmE1M2Q4ZWYvdGFibGVyYW5nZTpmNTgyZWRjOTNmMWQ0MDA2YWYzOTYzN2EyYTUzZDhlZl8wLTAtMS0xLTIyMTU2OC90ZXh0cmVnaW9uOjc3NGViZjAzYjczZDRlMzRhM2Q2NDlhNjczM2IwMTBkXzEy_78345745-bd6c-47c0-9d99-8db4da2ac9a1">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6ZjU4MmVkYzkzZjFkNDAwNmFmMzk2MzdhMmE1M2Q4ZWYvdGFibGVyYW5nZTpmNTgyZWRjOTNmMWQ0MDA2YWYzOTYzN2EyYTUzZDhlZl8wLTAtMS0xLTIyMTU2OC90ZXh0cmVnaW9uOjc3NGViZjAzYjczZDRlMzRhM2Q2NDlhNjczM2IwMTBkXzE1_e3ac042a-ab0d-4e40-ac67-d72facdef692">10591-6707</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGV4dHJlZ2lvbjoyNzI0ZjBiZmVhYTM0ZDQzODQ4NDU3MTlmNjY3ZDY3Ml80MjM_9ba0c02b-58db-49e6-91ec-f0fd274f075c">914</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGV4dHJlZ2lvbjoyNzI0ZjBiZmVhYTM0ZDQzODQ4NDU3MTlmNjY3ZDY3Ml80MjQ_ac4f15a6-aee4-4ea6-a211-4a55f22ab0a2">847-7000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6YjgzNTRiNzBjNTAxNDc0ZThmMmIyODIwYmFkYWYwNGUvdGFibGVyYW5nZTpiODM1NGI3MGM1MDE0NzRlOGYyYjI4MjBiYWRhZjA0ZV8xLTAtMS0xLTIyMTU2OA_4d4538b7-f514-49dd-855a-9cbf81e3b7e8">Common Stock - par value $.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6YjgzNTRiNzBjNTAxNDc0ZThmMmIyODIwYmFkYWYwNGUvdGFibGVyYW5nZTpiODM1NGI3MGM1MDE0NzRlOGYyYjI4MjBiYWRhZjA0ZV8xLTEtMS0xLTIyMTU2OA_cea02312-3c88-4610-bb81-53fa39d261bf">REGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6YjgzNTRiNzBjNTAxNDc0ZThmMmIyODIwYmFkYWYwNGUvdGFibGVyYW5nZTpiODM1NGI3MGM1MDE0NzRlOGYyYjI4MjBiYWRhZjA0ZV8xLTItMS0xLTIyMTU2OA_9e514baa-2c25-4fc1-bd34-7bc10bc3826c">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6MjlkODJlYzdlODNiNDAxZDg5NThkYmE1ZWJhNzg1ZTEvdGFibGVyYW5nZToyOWQ4MmVjN2U4M2I0MDFkODk1OGRiYTVlYmE3ODVlMV8wLTEtMS0xLTIyMTU2OA_758940c9-be8a-42de-bfd8-b182694cbd5b">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6MjlkODJlYzdlODNiNDAxZDg5NThkYmE1ZWJhNzg1ZTEvdGFibGVyYW5nZToyOWQ4MmVjN2U4M2I0MDFkODk1OGRiYTVlYmE3ODVlMV8yLTEtMS0xLTIyMTU2OA_6d3f36c1-1e2a-4f2c-92e8-054f896f100d">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6ZTU0ZjAwYmZhZWU0NGIwMzkzMTJkY2ViOTEzZjBiMGIvdGFibGVyYW5nZTplNTRmMDBiZmFlZTQ0YjAzOTMxMmRjZWI5MTNmMGIwYl8wLTAtMS0xLTIyMTU2OA_cf0819cc-38bd-4c43-a21f-ea76c274cf3f">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6ZTU0ZjAwYmZhZWU0NGIwMzkzMTJkY2ViOTEzZjBiMGIvdGFibGVyYW5nZTplNTRmMDBiZmFlZTQ0YjAzOTMxMmRjZWI5MTNmMGIwYl8wLTEwLTEtMS0yMjE1Njg_136b47ea-4b60-44c2-baca-8ce1df8da497">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6ZTU0ZjAwYmZhZWU0NGIwMzkzMTJkY2ViOTEzZjBiMGIvdGFibGVyYW5nZTplNTRmMDBiZmFlZTQ0YjAzOTMxMmRjZWI5MTNmMGIwYl8wLTEzLTEtMS0yMjE1Njg_21e6de52-33a3-4f78-8ba8-d8ec468775c2">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6YTFmNGVkYWQzZmNkNDY3M2E3YmMxYjIyNmI2YWY2NWEvdGFibGVyYW5nZTphMWY0ZWRhZDNmY2Q0NjczYTdiYzFiMjI2YjZhZjY1YV8yLTQtMS0xLTIyMTU2OA_118c78f3-d3a6-4228-abbd-037f22499493">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i52501e7fdeda4b63b53fa2c38deee3ba_I20230411"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6ZWRlYzUwYjMzZDY2NGYxYWEyNTlhYjFlNzY1NzhkMmYvdGFibGVyYW5nZTplZGVjNTBiMzNkNjY0ZjFhYTI1OWFiMWU3NjU3OGQyZl8xLTItMS0xLTIyMTU2OA_e6b41b46-5a33-4551-a1de-53fb4e651bd0"
      unitRef="shares">1818146</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i95399a66c34747c7ae8a30809bebb551_I20230411"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xL2ZyYWc6MjcyNGYwYmZlYWEzNGQ0Mzg0ODQ1NzE5ZjY2N2Q2NzIvdGFibGU6ZWRlYzUwYjMzZDY2NGYxYWEyNTlhYjFlNzY1NzhkMmYvdGFibGVyYW5nZTplZGVjNTBiMzNkNjY0ZjFhYTI1OWFiMWU3NjU3OGQyZl8yLTItMS0xLTIyMTU2OA_941415e6-e901-4079-bcc6-3c08b5735b17"
      unitRef="shares">107892108</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfNC0xLTEtMS0yMjE1Njg_f176381c-39db-406a-9db1-d0521f8c4a9b"
      unitRef="usd">3916300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfNC0zLTEtMS0yMjE1Njg_12d91e70-c31c-40ad-a49b-6c3430644e2d"
      unitRef="usd">3105900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfNS0xLTEtMS0yMjE1Njg_cef106e5-9350-4f44-a18a-44c8a5da12a6"
      unitRef="usd">5043400000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfNS0zLTEtMS0yMjE1Njg_7730cdd0-e960-4340-af60-5b4addc804c8"
      unitRef="usd">4636400000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfNi0xLTEtMS0yMjE1Njg_8b570119-2942-498a-8efa-704adf3d4c74"
      unitRef="usd">5118600000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfNi0zLTEtMS0yMjE1Njg_00c993eb-9100-427f-91de-2794cd9d0af3"
      unitRef="usd">5328700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfNy0xLTEtMS0yMjE1Njg_2fa9af6a-702a-49d5-ad5e-563bc1632469"
      unitRef="usd">2424700000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfNy0zLTEtMS0yMjE1Njg_506e644d-e7db-4b35-9340-806044046a6a"
      unitRef="usd">2401900000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfOC0xLTEtMS0yMjE1Njg_84d9b22e-3140-4d79-bec8-a804f9e02928"
      unitRef="usd">406200000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfOC0zLTEtMS0yMjE1Njg_a6d528b3-357f-41c6-b721-b7dcf5c341db"
      unitRef="usd">411200000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfOS0xLTEtMS0yMjE1Njg_8cd67c76-0527-4c01-a323-afd48c1b04f5"
      unitRef="usd">16909200000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfOS0zLTEtMS0yMjE1Njg_8573151a-646c-4201-ab5f-a1cfe1ba8819"
      unitRef="usd">15884100000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMTEtMS0xLTEtMjIxNTY4_5c53d441-2631-4fbb-b81d-8cd1e18044da"
      unitRef="usd">6066600000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMTEtMy0xLTEtMjIxNTY4_00bece50-b741-4267-a866-8c750a83c51f"
      unitRef="usd">6591800000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMTItMS0xLTEtMjIxNTY4_75abcb14-7fbd-4085-a085-eb7126a86906"
      unitRef="usd">3880900000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMTItMy0xLTEtMjIxNTY4_5c640a00-0aff-4b89-9c0b-e97a0d99f659"
      unitRef="usd">3763000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMTMtMS0xLTEtMjIxNTY4_eb767ba0-41c7-4aac-814d-9ccfa93547ec"
      unitRef="usd">928700000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMTMtMy0xLTEtMjIxNTY4_ebfc990f-e1a8-478f-9b36-58f9105769e6"
      unitRef="usd">915500000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMTQtMS0xLTEtMjIxNTY4_cfb391a9-a2d6-44b1-b5a2-992b17df5055"
      unitRef="usd">1924900000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMTQtMy0xLTEtMjIxNTY4_2ccb98ea-c91f-4fb6-9ddd-d9980af6133c"
      unitRef="usd">1723700000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMTUtMS0xLTEtMjIxNTY4_04b92b05-be39-4678-863b-a6700018b31b"
      unitRef="usd">349600000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMTUtMy0xLTEtMjIxNTY4_74fc2af6-d89e-4eb7-8a33-92f36f031433"
      unitRef="usd">336400000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMTYtMS0xLTEtMjIxNTY4_0093e000-9222-4d13-8b59-dc34f0658bae"
      unitRef="usd">30059900000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMTYtMy0xLTEtMjIxNTY4_9a7646b9-d083-46dd-8656-325646525316"
      unitRef="usd">29214500000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjAtMS0xLTEtMjIxNTY4_0bfc9715-328b-41ff-af0f-c92dd754424a"
      unitRef="usd">599500000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjAtMy0xLTEtMjIxNTY4_150200b4-f64e-42bf-a285-741b8f886458"
      unitRef="usd">589200000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjEtMS0xLTEtMjIxNTY4_ae66def1-a622-4ad1-bcbc-024572200d25"
      unitRef="usd">2074300000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjEtMy0xLTEtMjIxNTY4_24f720a6-8a5c-4407-a475-6944f9bf66d5"
      unitRef="usd">2074200000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjMtMS0xLTEtMjIxNTY4_51d9c472-7ecb-41c6-84ce-eb76d869032a"
      unitRef="usd">426300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjMtMy0xLTEtMjIxNTY4_94762ce9-d3c0-416c-9a10-f8bd1cc5264b"
      unitRef="usd">477900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjQtMS0xLTEtMjIxNTY4_97a7c68e-2e59-4080-8cf1-bde85205dfb6"
      unitRef="usd">3100100000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjQtMy0xLTEtMjIxNTY4_1f94b7df-b320-4cff-8721-08efff1030e5"
      unitRef="usd">3141300000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjYtMS0xLTEtMjIxNTY4_c18dcfd4-6799-4d86-8dfa-1013974e82b5"
      unitRef="usd">1981800000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjYtMy0xLTEtMjIxNTY4_9be9d421-cb48-400d-b95d-a4b2c87ca403"
      unitRef="usd">1981400000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjctMS0xLTEtMjIxNTY4_9c3c41d8-fd5d-4e95-a9fe-541fcb324b82"
      unitRef="usd">720000000.0</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjctMy0xLTEtMjIxNTY4_040ea0de-1b66-49f9-b5dc-c25142c65f42"
      unitRef="usd">720000000.0</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjgtMS0xLTEtMjIxNTY4_ae78f857-059a-4ba7-81eb-145a4b086ef0"
      unitRef="usd">85500000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjgtMy0xLTEtMjIxNTY4_cd4e3222-c5a5-4be4-a2ef-78bfd0496c29"
      unitRef="usd">69800000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjktMS0xLTEtMjIxNTY4_20232dc2-a833-4c19-a99d-c7d8956febd3"
      unitRef="usd">677300000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMjktMy0xLTEtMjIxNTY4_3d33a747-2b97-47ff-af5c-f70a7c794dc8"
      unitRef="usd">638000000.0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzAtMS0xLTEtMjIxNTY4_c4f527e8-dae4-41a6-980d-33ce8999fe1a"
      unitRef="usd">6564700000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzAtMy0xLTEtMjIxNTY4_2471eb97-a4cd-43ad-a201-36ac94e63f7f"
      unitRef="usd">6550500000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzMtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246OWY2ZmE3NTdlM2M1NDBlMTkxZTRlMTM4NmNlYmFhOTlfMzE_1478c81f-0c4f-4122-a651-ee68fc688945"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzMtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246OWY2ZmE3NTdlM2M1NDBlMTkxZTRlMTM4NmNlYmFhOTlfMzE_6ae6dd97-5aae-476b-9596-2d23e306c553"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzMtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246OWY2ZmE3NTdlM2M1NDBlMTkxZTRlMTM4NmNlYmFhOTlfNDU_716cfe69-54ff-4245-be0a-a8207f12dc3c"
      unitRef="shares">30000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzMtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246OWY2ZmE3NTdlM2M1NDBlMTkxZTRlMTM4NmNlYmFhOTlfNDU_804bc133-afb5-4602-862c-57ab92fdb97d"
      unitRef="shares">30000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzMtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246OWY2ZmE3NTdlM2M1NDBlMTkxZTRlMTM4NmNlYmFhOTlfOTI_073eb672-b4a4-40f9-936c-f44825088f40"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzMtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246OWY2ZmE3NTdlM2M1NDBlMTkxZTRlMTM4NmNlYmFhOTlfOTI_65c772be-eb7e-4364-a4a6-f35ba83d77a5"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzMtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246OWY2ZmE3NTdlM2M1NDBlMTkxZTRlMTM4NmNlYmFhOTlfOTI_7144f1e0-bf56-41e9-81c5-b5d2fc31e288"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzMtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246OWY2ZmE3NTdlM2M1NDBlMTkxZTRlMTM4NmNlYmFhOTlfOTI_a134cdbd-d8d0-4087-8e06-8b9a88dcad43"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzMtMS0xLTEtMjIxNTY4_bdb0b4e9-8c44-465f-a3fb-5f2333fbd836"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzMtMy0xLTEtMjIxNTY4_9b9e5294-6900-40cf-8659-a867723c5e71"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6b8134b6a41640a59debc09f522f7159_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzQtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MGVkZTY5NWQ1M2FjNGQ2MTliYTI5Mjk0MjZlODJlN2FfNDI_42479e7b-a05e-4058-b76f-d03e0702b270"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic62e60ebc7424784abaf7166a92b5115_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzQtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MGVkZTY5NWQ1M2FjNGQ2MTliYTI5Mjk0MjZlODJlN2FfNDI_b6329031-d39a-4235-8ce7-f234ac9568f3"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic62e60ebc7424784abaf7166a92b5115_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzQtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MGVkZTY5NWQ1M2FjNGQ2MTliYTI5Mjk0MjZlODJlN2FfNTY_1fcea8c6-286c-4328-8207-a5b5c85a7826"
      unitRef="shares">40000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6b8134b6a41640a59debc09f522f7159_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzQtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MGVkZTY5NWQ1M2FjNGQ2MTliYTI5Mjk0MjZlODJlN2FfNTY_c75c8ed6-627d-4892-b586-fd1a57475c49"
      unitRef="shares">40000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6b8134b6a41640a59debc09f522f7159_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzQtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MGVkZTY5NWQ1M2FjNGQ2MTliYTI5Mjk0MjZlODJlN2FfMTEw_1850ab07-d381-4193-b17b-4ca54df71ba2"
      unitRef="shares">1800000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic62e60ebc7424784abaf7166a92b5115_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzQtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MGVkZTY5NWQ1M2FjNGQ2MTliYTI5Mjk0MjZlODJlN2FfMTEw_bcc44fae-1bee-4f1f-96c3-ab35ce752cef"
      unitRef="shares">1800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6b8134b6a41640a59debc09f522f7159_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzQtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MGVkZTY5NWQ1M2FjNGQ2MTliYTI5Mjk0MjZlODJlN2FfMTEw_ce341e73-6a9d-4876-9adb-f5a2c8549047"
      unitRef="shares">1800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic62e60ebc7424784abaf7166a92b5115_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzQtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MGVkZTY5NWQ1M2FjNGQ2MTliYTI5Mjk0MjZlODJlN2FfMTEw_f3a8befd-2481-4251-a1c9-554b575205f4"
      unitRef="shares">1800000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ic62e60ebc7424784abaf7166a92b5115_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzQtMS0xLTEtMjIxNTY4_cbc61bce-fb9b-43f0-a0b6-f11af4684fb7"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i6b8134b6a41640a59debc09f522f7159_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzQtMy0xLTEtMjIxNTY4_44c7af5b-f070-448d-b5b8-113c6c195982"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iad84cd28f95b42f29a3715741068591b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzUtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MzNhZmQyMzViNmE5NDhhMzgxNTExYTM2MGNhMzBiOGFfMjg_072f5a26-e0ed-4895-a326-bed3e4167bab"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7b7c4d8560fb43119f17d189a9cc1ec6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzUtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MzNhZmQyMzViNmE5NDhhMzgxNTExYTM2MGNhMzBiOGFfMjg_b870d173-12fa-49a6-90c7-ff23895699fe"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7b7c4d8560fb43119f17d189a9cc1ec6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzUtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MzNhZmQyMzViNmE5NDhhMzgxNTExYTM2MGNhMzBiOGFfNDI_686a77f4-4c5e-4255-a21d-688fe9a4e20d"
      unitRef="shares">320000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iad84cd28f95b42f29a3715741068591b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzUtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MzNhZmQyMzViNmE5NDhhMzgxNTExYTM2MGNhMzBiOGFfNDI_cb09a7df-ceff-40f8-8553-ae17f2c5609d"
      unitRef="shares">320000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7b7c4d8560fb43119f17d189a9cc1ec6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzUtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MzNhZmQyMzViNmE5NDhhMzgxNTExYTM2MGNhMzBiOGFfODA_559a8622-7891-4838-ab9e-2c695fb4ac2a"
      unitRef="shares">131400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="iad84cd28f95b42f29a3715741068591b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzUtMC0xLTEtMjIxNTY4L3RleHRyZWdpb246MzNhZmQyMzViNmE5NDhhMzgxNTExYTM2MGNhMzBiOGFfOTU_0241bd9c-01d0-418e-9187-6c663472fb51"
      unitRef="shares">130400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i7b7c4d8560fb43119f17d189a9cc1ec6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzUtMS0xLTEtMjIxNTY4_17c1f7ca-c1c9-4470-adef-ec9dd0d8ceee"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="iad84cd28f95b42f29a3715741068591b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzUtMy0xLTEtMjIxNTY4_9dd3d959-c73c-4236-8782-24255707092d"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzYtMS0xLTEtMjIxNTY4_4783ffae-ba69-4b7e-bd09-28d70ab35747"
      unitRef="usd">10597700000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzYtMy0xLTEtMjIxNTY4_53ac3299-5c92-4ba8-ad5e-4cba6653a34a"
      unitRef="usd">9949300000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzctMS0xLTEtMjIxNTY4_1dd96bd2-a3af-4737-bbdc-5a0acb209399"
      unitRef="usd">24124500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzctMy0xLTEtMjIxNTY4_7a7b7821-7dff-4e31-9511-8604b6d0a333"
      unitRef="usd">23306700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzgtMS0xLTEtMjIxNTY4_6d6ebba8-bb36-4775-967d-89fff00a0303"
      unitRef="usd">-181600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzgtMy0xLTEtMjIxNTY4_9fab1c75-e80c-4e67-9480-59a2dbd1d6bb"
      unitRef="usd">-238800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzktMC0xLTEtMjIxNTY4L3RleHRyZWdpb246ZWI2ZjhhZWRjNjJiNDY4Nzg1YjA3OGFkM2FiNTE0NTdfMjk_94a08668-2290-4808-9293-db322264afb4"
      unitRef="shares">23500000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzktMC0xLTEtMjIxNTY4L3RleHRyZWdpb246ZWI2ZjhhZWRjNjJiNDY4Nzg1YjA3OGFkM2FiNTE0NTdfNTE_bac98e47-41a2-4798-96fd-407c598002fc"
      unitRef="shares">22600000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzktMS0xLTEtMjIxNTY4_806de7eb-7816-4d4e-879b-d204cd2a0a05"
      unitRef="usd">11045500000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfMzktMy0xLTEtMjIxNTY4_4b65e88a-ceda-4410-b800-93d38d42725f"
      unitRef="usd">10353300000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:StockholdersEquity
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfNDAtMS0xLTEtMjIxNTY4_819cdb89-f625-4fdb-bd59-ddc3e6173868"
      unitRef="usd">23495200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfNDAtMy0xLTEtMjIxNTY4_fd0e9625-1992-474b-b8fa-6864ed8ae83f"
      unitRef="usd">22664000000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfNDEtMS0xLTEtMjIxNTY4_562a1166-0a7f-48c3-a86c-74165b5eabe1"
      unitRef="usd">30059900000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xNi9mcmFnOjFiZTUwMWM1YzJlMDQ0ODRiNjUwOGZkOTI3ODYzNGM4L3RhYmxlOmM2MWNjYzE0MjBjMjRkYTJhNGRlZDgzMzE4ODhiOGM5L3RhYmxlcmFuZ2U6YzYxY2NjMTQyMGMyNGRhMmE0ZGVkODMzMTg4OGI4YzlfNDEtMy0xLTEtMjIxNTY4_f76ac8ff-3590-48aa-9626-d051ecef94d0"
      unitRef="usd">29214500000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89d2806ddfda4899b23a4e2a27b639ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNC02LTEtMS0yMjE1Njg_3fcad1af-c965-42a8-b8a8-d7e432006069"
      unitRef="usd">1668000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9cd61146d31845f7aa0a400c1de8c9af_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNC04LTEtMS0yMjE1Njg_34a56638-08f8-44fb-89ea-deeda3db1c4b"
      unitRef="usd">1638600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e96d85f6116487bb808133461cb06a1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNS02LTEtMS0yMjE1Njg_4f417908-8883-4dc5-ba6a-bb591529de7d"
      unitRef="usd">1378100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i322b8ce5df5b4c60ad8cc95df009f249_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNS04LTEtMS0yMjE1Njg_40de85d7-1570-4cd8-8dbf-0c18f6e3d7e5"
      unitRef="usd">1232500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i375b286d61df4bd4851e798baea9fbed_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNi02LTEtMS0yMjE1Njg_91302d3c-6928-4f9f-843c-269c75ddf84b"
      unitRef="usd">116000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7d1404e1f794d79bf92b04d446901cf_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNi04LTEtMS0yMjE1Njg_1d275220-7bd9-4136-9fcb-8406b144a762"
      unitRef="usd">94000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNy02LTEtMS0yMjE1Njg_263b8a92-6351-428c-841d-59656365bea7"
      unitRef="usd">3162100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNy04LTEtMS0yMjE1Njg_a0482dc8-0c3e-4811-a588-b4e0c7cc9418"
      unitRef="usd">2965100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTAtNi0xLTEtMjIxNTY4_50854ab9-66ca-4c4c-8404-ac9503abe377"
      unitRef="usd">1101200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTAtOC0xLTEtMjIxNTY4_8fa50eca-acd8-4e90-b9f1-f3aa836e8d8d"
      unitRef="usd">843800000</us-gaap:ResearchAndDevelopmentExpense>
    <regn:AcquiredInProcessResearchAndDevelopment
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTEtNi0xLTEtMjIxNTY4_90287ee7-0f49-4d5b-a9fa-e7e03a829ae2"
      unitRef="usd">56100000</regn:AcquiredInProcessResearchAndDevelopment>
    <regn:AcquiredInProcessResearchAndDevelopment
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTEtOC0xLTEtMjIxNTY4_c4dc90c9-68d5-4208-9360-8865f0cdf258"
      unitRef="usd">28100000</regn:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTItNi0xLTEtMjIxNTY4_934ceaaa-fdaf-421c-86e7-c1c3ef0a20df"
      unitRef="usd">601100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTItOC0xLTEtMjIxNTY4_23ebe79b-b564-43bf-a4d2-4e20011af565"
      unitRef="usd">450000000.0</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i89d2806ddfda4899b23a4e2a27b639ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTMtNi0xLTEtMjIxNTY4_5b7476f4-09ac-4efd-b040-9c27ed465d6f"
      unitRef="usd">208400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9cd61146d31845f7aa0a400c1de8c9af_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTMtOC0xLTEtMjIxNTY4_385d2a22-8efc-4d2d-ab0c-c187ebfecaa0"
      unitRef="usd">207300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3e0ca86da19f48e88d9bf110de7b69c2_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTQtNi0xLTEtMjIxNTY4_6f0df168-0fac-4256-9874-8574d73b79a8"
      unitRef="usd">249100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5bf386a54cb94d3693610866086baa33_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTQtOC0xLTEtMjIxNTY4_c2883fff-2edb-4b32-8b6a-122e3888918b"
      unitRef="usd">197600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTUtNi0xLTEtMjIxNTY4_ea0130a6-0af0-4df2-88de-17dac7312324"
      unitRef="usd">500000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTUtOC0xLTEtMjIxNTY4_0f237ce9-8111-4a05-bc38-21bd314033f9"
      unitRef="usd">20200000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostsAndExpenses
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTYtNi0xLTEtMjIxNTY4_af830f8b-1f14-4652-8e2d-6507952f6278"
      unitRef="usd">2215400000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTYtOC0xLTEtMjIxNTY4_0fb60a82-fb47-4411-97b6-3946bf7a7421"
      unitRef="usd">1706600000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTgtNi0xLTEtMjIxNTY4_69a85f62-b8d6-46e5-ae4f-b6fefbe1f6b2"
      unitRef="usd">946700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMTgtOC0xLTEtMjIxNTY4_50b5688d-2a6f-447b-a5b8-d43c814d0bfd"
      unitRef="usd">1258500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMjEtNi0xLTEtMjIxNTY4_f6b117bf-3684-4b81-85a1-5a753cc61e82"
      unitRef="usd">-70700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMjEtOC0xLTEtMjIxNTY4_e6989d07-02f4-43a3-a411-df32bc2f2ce4"
      unitRef="usd">-183800000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMjItNi0xLTEtMjIxNTY4_8fe19550-1a2d-49e7-bdae-9a1aa6d02dc6"
      unitRef="usd">18000000.0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMjItOC0xLTEtMjIxNTY4_d8087f8a-e932-4b21-9af3-c4770090d05b"
      unitRef="usd">13600000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMjMtNi0xLTEtMjIxNTY4_aaeeb356-c1b0-4978-91d8-f6ddf36e48e8"
      unitRef="usd">-88700000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMjMtOC0xLTEtMjIxNTY4_a55502cb-3bf7-40bc-8873-c543a8e691c2"
      unitRef="usd">-197400000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMjUtNi0xLTEtMjIxNTY4_090923c6-23f9-4287-b7be-c564d4f02b53"
      unitRef="usd">858000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMjUtOC0xLTEtMjIxNTY4_f4ec7491-815c-44bd-a996-84096b3b0701"
      unitRef="usd">1061100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMjctNi0xLTEtMjIxNTY4_98fd03d2-c7d5-4e00-bb86-7a09395f58ed"
      unitRef="usd">40200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMjctOC0xLTEtMjIxNTY4_5faf3f5b-cc9e-4e87-92bb-57f76aaa70e4"
      unitRef="usd">87600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMjktNi0xLTEtMjIxNTY4_37fb1fac-2f92-48b2-ba24-a07ce40f3a85"
      unitRef="usd">817800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMjktOC0xLTEtMjIxNTY4_6583963b-4705-4b82-9c69-3259c57f2c4a"
      unitRef="usd">973500000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMzEtNi0xLTEtMjIxNTY4_b567779a-a8bc-441f-bd6d-392c26f51085"
      unitRef="usdPerShare">7.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMzEtOC0xLTEtMjIxNTY4_1501ba35-80a0-4995-a08c-1918aac9a3e9"
      unitRef="usdPerShare">9.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMzItNi0xLTEtMjIxNTY4_a6117a81-11fb-48b1-9865-c236e3dd9c02"
      unitRef="usdPerShare">7.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMzItOC0xLTEtMjIxNTY4_15f5ef34-69dd-497d-b932-b3b766ade013"
      unitRef="usdPerShare">8.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMzQtNi0xLTEtMjIxNTY4_68ef17e2-6e01-472c-9def-c4fce0d1c77d"
      unitRef="shares">107100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMzQtOC0xLTEtMjIxNTY4_3e9f1b2b-8c4e-4996-a070-2ae1167fc6d8"
      unitRef="shares">106800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMzUtNi0xLTEtMjIxNTY4_c9e4eefb-1ca5-44cc-ba01-4ba52a9780a1"
      unitRef="shares">114000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMzUtOC0xLTEtMjIxNTY4_57d765b8-5c29-425e-af2f-d0bf17dec38c"
      unitRef="shares">113100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMzgtNi0xLTEtMjIxNTY4_a4f55dff-0f4c-4e39-9490-4e5f5b2be00b"
      unitRef="usd">817800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfMzgtOC0xLTEtMjIxNTY4_834433c9-6ddc-4529-9f9e-4313d5a8090f"
      unitRef="usd">973500000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNDAtNi0xLTEtMjIxNTY4_b151c779-eb0d-431e-96da-79b4a7372c1d"
      unitRef="usd">57200000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNDAtOC0xLTEtMjIxNTY4_b5424e6a-6e10-4a8b-bad3-5b030ff24b89"
      unitRef="usd">-144900000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNDEtNi0xLTEtMjIxNTY4_e97f35e1-e9a7-4d51-b18b-3aceff41e319"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNDEtOC0xLTEtMjIxNTY4_60f2093b-8039-477a-aae7-6bea30e1ee85"
      unitRef="usd">1000000.0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNDItNi0xLTEtMjIxNTY4_4532eb3b-a958-4c60-a5ce-abab9ade0051"
      unitRef="usd">875000000.0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8xOS9mcmFnOjI1Y2UyMjliOWQ1MDQ3MjI5ODQzYmJiMDVjODkxZWI5L3RhYmxlOmUxMzdlZjM4YWRhMDRlMjI4NDEyYmQ0OGExMGMyMzVlL3RhYmxlcmFuZ2U6ZTEzN2VmMzhhZGEwNGUyMjg0MTJiZDQ4YTEwYzIzNWVfNDItOC0xLTEtMjIxNTY4_627bdd75-4118-4f4a-ad3f-c4533d760b4e"
      unitRef="usd">829600000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if30714371f9e46528af3d8f6681b15c7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMi0yLTEtMS0yMjE1Njg_4e6653cb-9122-4f75-8f26-3763a35cc7a2"
      unitRef="shares">1800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if30714371f9e46528af3d8f6681b15c7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMi00LTEtMS0yMjE1Njg_c04a01f8-3578-4e67-a7fe-f7588ac2424f"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iee31f7d64fe049c7a439d288ec9486d5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMi02LTEtMS0yMjE1Njg_d1d44564-4125-4d90-8a73-72f8d27662a3"
      unitRef="shares">130400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iee31f7d64fe049c7a439d288ec9486d5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMi04LTEtMS0yMjE1Njg_5a3db6f5-4138-484d-ac68-572e2f7f8e3d"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3f33b378dd044be2997a03a26a5d3b48_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMi0xMC0xLTEtMjIxNTY4_4798fa36-065e-4f51-b4cb-8625bce4ea40"
      unitRef="usd">9949300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i464958bff30b4da893895a523da36762_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMi0xMi0xLTEtMjIxNTY4_b07b2325-88f8-4ca3-af9d-267a75141f6f"
      unitRef="usd">23306700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1fa0f967adc9439caf372e79f15e9e65_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMi0xNC0xLTEtMjIxNTY4_8655af7f-b597-4011-9a3a-86f9f8314c64"
      unitRef="usd">-238800000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ica431963a44548bd8c3c65e67df71293_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMi0xNi0xLTEtMjIxNTY4_899c14ac-c486-49ad-aa2e-d3f1b29521aa"
      unitRef="shares">22600000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="ica431963a44548bd8c3c65e67df71293_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMi0xOC0xLTEtMjIxNTY4_7bab9f58-0680-4dc2-ab75-93b92e27d271"
      unitRef="usd">-10353300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMi0yMC0xLTEtMjIxNTY4_3c9b729c-f0b5-430b-9c4b-c7a5c85ecbc0"
      unitRef="usd">22664000000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ib5c88fce876d4566b4cbbac88f11de2b_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMy02LTEtMS0yMjE1Njg_bee991ac-6535-407b-808d-67f6006eeeec"
      unitRef="shares">1100000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i015fc10968404f9596294e54195211db_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMy0xMC0xLTEtMjIxNTY4_bbf4d0f8-d3a6-474e-b245-20a7524568d2"
      unitRef="usd">491300000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMy0yMC0xLTEtMjIxNTY4_a773d6d6-fa8b-4c2a-87bd-c4bcafb45ef7"
      unitRef="usd">491300000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="ib5c88fce876d4566b4cbbac88f11de2b_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfNC02LTEtMS0yMjE1Njg_944285e0-4464-464f-b62a-14439d10a523"
      unitRef="shares">100000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i015fc10968404f9596294e54195211db_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfNC0xMC0xLTEtMjIxNTY4_27caf7ba-1613-45ff-886a-33d8ca2cf4eb"
      unitRef="usd">99200000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfNC0yMC0xLTEtMjIxNTY4_c0ae7685-0f55-4086-b0eb-881c412a9c91"
      unitRef="usd">99200000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i015fc10968404f9596294e54195211db_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfNS0xMC0xLTEtMjIxNTY4_ecc4673b-ecfe-4fde-9fcd-dfe752d3f621"
      unitRef="usd">18900000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i185b612165b347b2b4aa073de182131b_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfNS0xOC0xLTEtMjIxNTY4_d03d09d9-7fb2-4cf2-862a-313ef58ec774"
      unitRef="usd">1700000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfNS0yMC0xLTEtMjIxNTY4_261417f5-0f3f-493e-a091-bd5ff9b37fd1"
      unitRef="usd">20600000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i185b612165b347b2b4aa073de182131b_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfNi0xNi0xLTEtMjIxNTY4_42f698f3-3665-4c07-8564-20c9867c9c04"
      unitRef="shares">900000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i185b612165b347b2b4aa073de182131b_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfNi0xOC0xLTEtMjIxNTY4_65438d08-7519-4e97-bcc3-55259403234f"
      unitRef="usd">693900000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfNi0yMC0xLTEtMjIxNTY4_f57f53ff-76fc-4cf3-9f31-8d99a1a33f8e"
      unitRef="usd">693900000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i015fc10968404f9596294e54195211db_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfNy0xMC0xLTEtMjIxNTY4_ccad5ecd-a541-4980-8c75-64a2ad4ae0fd"
      unitRef="usd">237400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfNy0yMC0xLTEtMjIxNTY4_1ff22945-8f32-44b6-933a-5be5ebe6426e"
      unitRef="usd">237400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i5afdea61952c4451a233ed8c133cf438_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfOC0xMi0xLTEtMjIxNTY4_d60cce47-1263-4ed1-bb99-a84aad7ccd80"
      unitRef="usd">817800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfOC0yMC0xLTEtMjIxNTY4_97025a76-0b13-4bb4-b6db-98e414a69831"
      unitRef="usd">817800000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibfb86f8ed7f34a63aa1ea7aa30866925_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfOS0xNC0xLTEtMjIxNTY4_2e02fa4f-be81-49f3-9faa-c3b8ea12df6a"
      unitRef="usd">57200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfOS0yMC0xLTEtMjIxNTY4_4cc0695d-b42d-4dfe-8b7c-6b38d9411d47"
      unitRef="usd">57200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2ccec8fe40c04d699a63e2967214f0b4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMTAtMi0xLTEtMjIxNTY4_9fafc18f-315e-4abf-a8d4-3e0f20644f53"
      unitRef="shares">1800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2ccec8fe40c04d699a63e2967214f0b4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMTAtNC0xLTEtMjIxNTY4_4667be44-ab8a-47e0-a0cb-f53b2da377b7"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibcec73dff80346e1895f9d7262e1ea33_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMTAtNi0xLTEtMjIxNTY4_1fd52ef1-7f0a-4551-bd57-90b43ec5e655"
      unitRef="shares">131400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ibcec73dff80346e1895f9d7262e1ea33_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMTAtOC0xLTEtMjIxNTY4_711001e9-3bdd-4dc2-a599-9020b51a76b3"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1e41e273a91b4f7080ff818a13fe99be_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMTAtMTAtMS0xLTIyMTU2OA_f843a63e-c399-4f3a-ba8a-fb13f034d333"
      unitRef="usd">10597700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icef282f2e36944018a2590dcf58321d6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMTAtMTItMS0xLTIyMTU2OA_3765b211-7596-4fbb-8d01-2b3cc964e413"
      unitRef="usd">24124500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i46042c6680c54f40880fde0d8f818288_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMTAtMTQtMS0xLTIyMTU2OA_015bd7c0-5ea6-4154-aa27-adde610caabd"
      unitRef="usd">-181600000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ib287cdc989b242ed899986d4cbe3af11_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMTAtMTYtMS0xLTIyMTU2OA_10b2ce3f-0625-42e9-b066-c444d1e3ac50"
      unitRef="shares">23500000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="ib287cdc989b242ed899986d4cbe3af11_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMTAtMTgtMS0xLTIyMTU2OA_b1e2b5b9-2498-4def-a1a1-9ad8d48723c8"
      unitRef="usd">-11045500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMTAtMjAtMS0xLTIyMTU2OA_06a6992c-b9e5-4b30-982c-ff8c5bc0badf"
      unitRef="usd">23495200000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic23d397894814b2486b54d92fc4b1a6d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzEtMi0xLTEtMjIxNTY4_1badbc87-b12d-4d8c-94f2-4d61e6abadc6"
      unitRef="shares">1800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic23d397894814b2486b54d92fc4b1a6d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzEtNC0xLTEtMjIxNTY4_cac7688d-40c6-4dae-b6d5-2e8e8cae62c5"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i97aac951375a4b61997b83f703090509_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzEtNi0xLTEtMjIxNTY4_6f01066f-3798-4619-bceb-c44dfe2ec842"
      unitRef="shares">126200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i97aac951375a4b61997b83f703090509_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzEtOC0xLTEtMjIxNTY4_c0b2554e-ccea-4afb-b3e7-a0fa5c1a7c74"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1a88badb1d6e4841ab079e4f443a7e4c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzEtMTAtMS0xLTIyMTU2OA_a44b8f9c-0087-4ddb-b525-d54f1708d8a0"
      unitRef="usd">8087500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i38ccce571fef4b90bc060bfc54280e73_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzEtMTItMS0xLTIyMTU2OA_1dfe3ab5-79bc-4a42-99be-0c1e3c9f56b0"
      unitRef="usd">18968300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifcb31e106e34471ea566f05963a75c5e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzEtMTQtMS0xLTIyMTU2OA_bd9166d8-2e1e-444d-91b7-6c4640e41deb"
      unitRef="usd">-26200000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i80bf6dc29204481a9c4efae367ed366e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzEtMTYtMS0xLTIyMTU2OA_833ad5bc-f5d1-45fc-8c97-84eb32f317be"
      unitRef="shares">19400000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i80bf6dc29204481a9c4efae367ed366e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzEtMTgtMS0xLTIyMTU2OA_09d90b14-8c30-485c-88d5-e4ccedc34f8c"
      unitRef="usd">-8260900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if6c18de361b24fb9a6ed97dcb156b4ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzEtMjAtMS0xLTIyMTU2OA_b9ebd7b9-022a-460b-b7cb-9ec7e4bad935"
      unitRef="usd">18768800000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="if6b622c0a75c4abf85767c76eeb3eb23_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzItNi0xLTEtMjIxNTY4_8e0efcd6-1adc-4a91-9bea-b472fd2c206f"
      unitRef="shares">1600000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i12fb29cdd4ea4b8b919c34781498d6c1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzItMTAtMS0xLTIyMTU2OA_3b9f3df7-3c5a-4675-9e02-72a154de6714"
      unitRef="usd">593700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzItMjAtMS0xLTIyMTU2OA_43252183-3cc9-4165-a4e0-cc35e9194f2e"
      unitRef="usd">593700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="if6b622c0a75c4abf85767c76eeb3eb23_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzMtNi0xLTEtMjIxNTY4_4a5e0317-19c8-4a71-889f-980adaa5c298"
      unitRef="shares">200000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i12fb29cdd4ea4b8b919c34781498d6c1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzMtMTAtMS0xLTIyMTU2OA_d80b1950-8fe4-45ac-94c8-6b1d6c3dc817"
      unitRef="usd">105800000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzMtMjAtMS0xLTIyMTU2OA_c3981e66-bb37-4f3f-bce7-3a489344ca72"
      unitRef="usd">105800000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i12fb29cdd4ea4b8b919c34781498d6c1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzQtMTAtMS0xLTIyMTU2OA_19b7a026-d3b9-4c67-ab44-68b266fac813"
      unitRef="usd">12800000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i6bfc42c5e2314ceda9b705bf6f75c36e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzQtMTgtMS0xLTIyMTU2OA_a6c56bae-46ad-4f96-b8da-43ded4915364"
      unitRef="usd">1700000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzQtMjAtMS0xLTIyMTU2OA_95df147c-71ab-4474-8313-7ca7c5d1f179"
      unitRef="usd">14500000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i6bfc42c5e2314ceda9b705bf6f75c36e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzUtMTYtMS0xLTIyMTU2OA_05a15310-b773-4bba-9a93-2d6a80f2fc0f"
      unitRef="shares">500000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i6bfc42c5e2314ceda9b705bf6f75c36e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzUtMTgtMS0xLTIyMTU2OA_5b66e771-5e64-40df-b2e5-9f80533f5661"
      unitRef="usd">352000000.0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzUtMjAtMS0xLTIyMTU2OA_7d9c0bba-5a01-4d38-974c-4980c69bea09"
      unitRef="usd">352000000.0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i12fb29cdd4ea4b8b919c34781498d6c1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzYtMTAtMS0xLTIyMTU2OA_68d4e5f4-a2c6-4c4a-9ecb-c2703e7b40af"
      unitRef="usd">165900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzYtMjAtMS0xLTIyMTU2OA_c7319959-4b77-4113-930d-8caf5f09057d"
      unitRef="usd">165900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i64fe108807dd4be4af7e9ea5f30001e4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzctMTItMS0xLTIyMTU2OA_37fc974e-a271-4985-a4fe-ac8110b4511c"
      unitRef="usd">973500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzctMjAtMS0xLTIyMTU2OA_2c270ae6-cb1d-483e-921b-789e0a502918"
      unitRef="usd">973500000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib5bc7a6419f1432ca3b84fea5414f7a3_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzgtMTQtMS0xLTIyMTU2OA_e1325fd9-c4e4-4029-9a3e-8aa70fa2ad5d"
      unitRef="usd">-143900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzgtMjAtMS0xLTIyMTU2OA_d1ed6080-99b6-4928-9f81-d175a5c1733d"
      unitRef="usd">-143900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i936952c9103a4c52811822936c6feffb_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzktMi0xLTEtMjIxNTY4_48565f52-3b33-45c3-be63-2c27fbf20792"
      unitRef="shares">1800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i936952c9103a4c52811822936c6feffb_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzktNC0xLTEtMjIxNTY4_ead0ea3f-0884-4243-bcd2-2b106f26ba2d"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i763f240b37e34f9e97c13b9647d2763e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzktNi0xLTEtMjIxNTY4_10c4676f-94f3-40ad-add1-89807b505b8b"
      unitRef="shares">127600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i763f240b37e34f9e97c13b9647d2763e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzktOC0xLTEtMjIxNTY4_635c7d9d-72dd-4b6f-a587-b860a0476ba7"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id7292cbbd4824b5b8b48cd9b81256747_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzktMTAtMS0xLTIyMTU2OA_eab5df00-7ad4-4f81-b1b0-7049ba1edd5a"
      unitRef="usd">8754100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i39ca18ca3a794b3c9cc3567ecaf855ed_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzktMTItMS0xLTIyMTU2OA_fdc4e9e1-da52-4bde-979e-5db5deb11775"
      unitRef="usd">19941800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ide8d66252aa645be98653f0b578cbb44_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzktMTQtMS0xLTIyMTU2OA_e6ca388b-6eef-4aa8-9b39-b37eb3531342"
      unitRef="usd">-170100000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ia23f7613df634004b007e3599b0e97f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzktMTYtMS0xLTIyMTU2OA_426829ca-436e-4179-a5b8-f8dcc744e498"
      unitRef="shares">19900000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="ia23f7613df634004b007e3599b0e97f9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzktMTgtMS0xLTIyMTU2OA_06720d2b-c10c-4435-a8ac-bb33a9b23374"
      unitRef="usd">-8611200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7298587e584844a686de7edf412eb7a2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yMi9mcmFnOmQ5NmEzNjFmZTY1MjRmOGU5MmQ0MWI1ODcyNmIyZGE2L3RhYmxlOjI3NGUwYjhjZDQwNTQxZDE4M2ZjZjU0MTBiMGY2OGViL3RhYmxlcmFuZ2U6Mjc0ZTBiOGNkNDA1NDFkMTgzZmNmNTQxMGIwZjY4ZWJfMzktMjAtMS0xLTIyMTU2OA_36069bf5-ddc6-4e44-b195-1b13d1bfb574"
      unitRef="usd">19914700000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMy0yLTEtMS0yMjE1Njg_fa7cf586-c2f9-4aec-a591-9c373d2be169"
      unitRef="usd">817800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMy00LTEtMS0yMjE1Njg_9a8e43e4-8a9b-4938-aa27-d82913a089a6"
      unitRef="usd">973500000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfNS0yLTEtMS0yMjE1Njg_1e7b5780-ddd8-4679-b139-db4ea228b604"
      unitRef="usd">99500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfNS00LTEtMS0yMjE1Njg_b958c1fd-19ff-4d01-841d-5731c7ec0792"
      unitRef="usd">74300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfNi0yLTEtMS0yMjE1Njg_076ed5c7-a811-40f8-9b55-920e46e896f5"
      unitRef="usd">238700000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfNi00LTEtMS0yMjE1Njg_ae153679-096b-48d4-b67a-c092f29bb217"
      unitRef="usd">166900000</us-gaap:ShareBasedCompensation>
    <regn:MarketableAndOtherSecuritiesGainLoss
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfNy0yLTEtMS0yMjE1Njg_70670848-1dba-48c6-b365-5427166c8ffa"
      unitRef="usd">-166600000</regn:MarketableAndOtherSecuritiesGainLoss>
    <regn:MarketableAndOtherSecuritiesGainLoss
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfNy00LTEtMS0yMjE1Njg_f7df926c-9ca3-4c8e-88b1-481f55ad3ab9"
      unitRef="usd">-204500000</regn:MarketableAndOtherSecuritiesGainLoss>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfOC0yLTEtMS0yMjE1Njg_c6b3ad47-12c5-4309-a87e-792cabe01874"
      unitRef="usd">-20600000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfOC00LTEtMS0yMjE1Njg_2ce555dd-94c1-43fc-8ea4-c6f45adb9072"
      unitRef="usd">-84300000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfOS0yLTEtMS0yMjE1Njg_bbb24f30-bd6a-48b9-aa47-0ea01171f716"
      unitRef="usd">216500000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfOS00LTEtMS0yMjE1Njg_08a4e4b0-9c5b-4cd8-b739-61a5187ea8be"
      unitRef="usd">225000000.0</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTItMi0xLTEtMjIxNTY4_84147ecf-4f4c-45d0-a500-245270905fd4"
      unitRef="usd">-210100000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTItNC0xLTEtMjIxNTY4_855d72d4-e8ca-4852-973a-974878c103f9"
      unitRef="usd">-1197500000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTMtMi0xLTEtMjIxNTY4_7e71bb44-f58f-47ca-9f35-8d9696e7827e"
      unitRef="usd">46800000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTMtNC0xLTEtMjIxNTY4_46cb6aa8-433c-4ab2-a971-e1da1df6f2ac"
      unitRef="usd">88600000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTQtMi0xLTEtMjIxNTY4_fa9aca57-ede3-497c-b6e6-0a582a22e772"
      unitRef="usd">5500000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTQtNC0xLTEtMjIxNTY4_860feb04-4c37-4f05-8bb4-803d0dc6d165"
      unitRef="usd">44800000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTUtMi0xLTEtMjIxNTY4_d08e0afd-e401-4576-90fd-427335f3a7d9"
      unitRef="usd">-35900000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTUtNC0xLTEtMjIxNTY4_bdd54621-fca8-4482-b8b3-59f6534b8141"
      unitRef="usd">9500000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTYtMi0xLTEtMjIxNTY4_508dc007-d17f-4662-a657-710b2e8e0dfa"
      unitRef="usd">119000000.0</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTYtNC0xLTEtMjIxNTY4_073eca43-03da-49fe-a3b2-5857bb8cb44f"
      unitRef="usd">-250400000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTctMi0xLTEtMjIxNTY4_21154cb1-d9d2-4687-9ea4-7f4defe51c19"
      unitRef="usd">549800000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTctNC0xLTEtMjIxNTY4_d639ac58-e678-45e7-9907-cfaaccbc42fa"
      unitRef="usd">1128200000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTgtMi0xLTEtMjIxNTY4_1f2bfa1a-8189-4740-acfc-f0b7d1bfee86"
      unitRef="usd">1367600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMTgtNC0xLTEtMjIxNTY4_b77d4301-3f53-4cb6-ac81-49cc79344677"
      unitRef="usd">2101700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMjEtMi0xLTEtMjIxNTY4_07fa5934-a212-412e-ba90-ef3b8c44ce1b"
      unitRef="usd">1749400000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMjEtNC0xLTEtMjIxNTY4_412b9e79-c5b9-45c0-a8d5-c46be4953232"
      unitRef="usd">2309800000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMjItMi0xLTEtMjIxNTY4_ece95c41-25eb-4998-933c-7d9a3ffd9600"
      unitRef="usd">1792800000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMjItNC0xLTEtMjIxNTY4_e165257c-2c86-4b13-aaa2-3bf59e1bab31"
      unitRef="usd">746300000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMjMtMi0xLTEtMjIxNTY4_bd7acd66-0321-4b20-879a-94218f242604"
      unitRef="usd">178200000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMjMtNC0xLTEtMjIxNTY4_9fc3e378-5063-4bf8-8447-6897bf0cb1ea"
      unitRef="usd">141800000</us-gaap:PaymentsToAcquireProductiveAssets>
    <regn:PaymentsToAcquireIntangibleAssets1
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMjQtMi0xLTEtMjIxNTY4_a3ea2b2b-dd69-4704-8d67-31bf9e306379"
      unitRef="usd">100900000</regn:PaymentsToAcquireIntangibleAssets1>
    <regn:PaymentsToAcquireIntangibleAssets1
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMjQtNC0xLTEtMjIxNTY4_95a3cc53-2cb1-401e-bf11-f19eb755c574"
      unitRef="usd">0</regn:PaymentsToAcquireIntangibleAssets1>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMjYtMi0xLTEtMjIxNTY4_148a8080-6f86-406e-8e04-fdaaabce1ada"
      unitRef="usd">-235700000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMjYtNC0xLTEtMjIxNTY4_b785eb7b-a4d0-4ac6-8473-4fab0bb4528c"
      unitRef="usd">-1705300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMjktMi0xLTEtMjIxNTY4_38252a7f-f57a-42f3-a08e-4550c80f3d83"
      unitRef="usd">485200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMjktNC0xLTEtMjIxNTY4_a05df068-1d5c-4160-a05e-29027685bb7c"
      unitRef="usd">521600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMzAtMi0xLTEtMjIxNTY4_ac7911d5-6a54-44a0-af43-8f66b4f39c30"
      unitRef="usd">97000000.0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMzAtNC0xLTEtMjIxNTY4_71065a1b-38ab-4bc2-a613-05a98649560f"
      unitRef="usd">98800000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMzEtMi0xLTEtMjIxNTY4_569da2a9-367a-4b1a-83b5-dae2bf88a3a1"
      unitRef="usd">710700000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMzEtNC0xLTEtMjIxNTY4_cc71736b-4c32-4ecd-bccf-139877b1c521"
      unitRef="usd">358100000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMzItMi0xLTEtMjIxNTY4_be084511-1ad2-40d5-be31-537893691a93"
      unitRef="usd">-322500000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMzItNC0xLTEtMjIxNTY4_cf7b2c7c-d631-4187-a2eb-f0c7357c59ed"
      unitRef="usd">64700000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMzQtMi0xLTEtMjIxNTY4_32854c38-01d9-479d-b8b1-c928a6bf18e4"
      unitRef="usd">809400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMzQtNC0xLTEtMjIxNTY4_8906683b-0b98-4c33-97ea-73ab4d912d37"
      unitRef="usd">461100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMzYtMi0xLTEtMjIxNTY4_bb41c3f3-38b5-47a3-84eb-8d383c38dd0c"
      unitRef="usd">3119400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if6c18de361b24fb9a6ed97dcb156b4ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMzYtNC0xLTEtMjIxNTY4_86f904a3-401d-40c2-81fd-0b2fdc75ee00"
      unitRef="usd">2898100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMzgtMi0xLTEtMjIxNTY4_8e1df0a7-8069-4134-b33e-75a0a09ac0bb"
      unitRef="usd">3928800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7298587e584844a686de7edf412eb7a2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8yNS9mcmFnOjkwNTY5ZWNjNjk3NzRlZDdiZGUzYzg2NmM0ZGNlMTI4L3RhYmxlOmMwYmEwMjVjYzE4NTRlYWJiZDE4NWQxZDcyN2QxNzZlL3RhYmxlcmFuZ2U6YzBiYTAyNWNjMTg1NGVhYmJkMTg1ZDFkNzI3ZDE3NmVfMzgtNC0xLTEtMjIxNTY4_0737db13-256d-426f-8448-df84f1728177"
      unitRef="usd">3359200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zMS9mcmFnOmJjNDM5ZDMzMmI1MzQ4NTU4NWZmZGY1NGQ1NWFlZWM1L3RleHRyZWdpb246YmM0MzlkMzMyYjUzNDg1NTg1ZmZkZjU0ZDU1YWVlYzVfMjA3OQ_04595932-8fb7-47e1-9549-935c23c34869">Interim Financial Statements&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim Condensed Consolidated Financial Statements of Regeneron Pharmaceuticals, Inc. and its subsidiaries ("Regeneron," "Company," "we," "us," and "our") have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and disclosures necessary for a presentation of the Company's financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, these financial statements reflect all normal recurring adjustments and accruals necessary for a fair statement of the Company's condensed consolidated financial statements for such periods. The results of operations for any interim period are not necessarily indicative of the results for the full year. The December&#160;31, 2022 Condensed Consolidated Balance Sheet data were derived from audited financial statements, but do not include all disclosures required by accounting principles generally accepted in the United States of America. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior period amounts to conform with the current period's presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zMS9mcmFnOmJjNDM5ZDMzMmI1MzQ4NTU4NWZmZGY1NGQ1NWFlZWM1L3RleHRyZWdpb246YmM0MzlkMzMyYjUzNDg1NTg1ZmZkZjU0ZDU1YWVlYzVfMjA3MA_9bce019f-c803-49c8-ae5b-bfeeb26856ca">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim Condensed Consolidated Financial Statements of Regeneron Pharmaceuticals, Inc. and its subsidiaries ("Regeneron," "Company," "we," "us," and "our") have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and disclosures necessary for a presentation of the Company's financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, these financial statements reflect all normal recurring adjustments and accruals necessary for a fair statement of the Company's condensed consolidated financial statements for such periods. The results of operations for any interim period are not necessarily indicative of the results for the full year. The December&#160;31, 2022 Condensed Consolidated Balance Sheet data were derived from audited financial statements, but do not include all disclosures required by accounting principles generally accepted in the United States of America. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RleHRyZWdpb246N2E2NWI1ZDA3NjU4NDc0NGE4MjdlNTNiYzBlMTk2NzdfNTI5_a85d46c4-b85c-4b48-a766-d36c10e189e3">Product Sales&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product sales consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.140%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.868%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EYLEA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,433.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,517.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Libtayo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;(a) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROW&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Praluent&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Evkeeza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inmazeb&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,668.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,638.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; Prior to July 1, 2022, Regeneron recorded net product sales of Libtayo in the United States and Sanofi recorded net product sales of Libtayo outside the United States. Effective July 1, 2022, the Company records global net product sales of Libtayo. See Note 3 for further details.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rest of world ("ROW")&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023 and December&#160;31, 2022, the Company had $3.578 billion and $3.586&#160;billion, respectively, of trade accounts receivable that were recorded within Accounts receivable, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had product sales to certain customers that accounted for more than 10% of total gross product revenue for the three months ended March&#160;31, 2023 and 2022. Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.210%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Besse Medical, a subsidiary of AmerisourceBergen Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RleHRyZWdpb246N2E2NWI1ZDA3NjU4NDc0NGE4MjdlNTNiYzBlMTk2NzdfNTE2_991a8a6e-363f-4334-b882-ea0cdb8d1fad">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product sales consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.140%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.868%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EYLEA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,433.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,517.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Libtayo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;(a) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROW&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Praluent&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Evkeeza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inmazeb&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,668.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,638.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; Prior to July 1, 2022, Regeneron recorded net product sales of Libtayo in the United States and Sanofi recorded net product sales of Libtayo outside the United States. Effective July 1, 2022, the Company records global net product sales of Libtayo. See Note 3 for further details.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rest of world ("ROW")&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in our Statements of Operations in connection with our collaborations with Sanofi are detailed below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.888%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Antibody:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's share of profits in connection with commercialization of antibodies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales-based milestones earned&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of commercial supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of Sanofi R&amp;amp;D expenses, net of reimbursement of R&amp;amp;D expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(R&amp;amp;D expense)/Reduction of R&amp;amp;D expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of commercialization-related expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of SG&amp;amp;A expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immuno-oncology&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's share of profits in connection with commercialization of Libtayo outside the United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of ex-U.S. commercial supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of R&amp;amp;D expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of R&amp;amp;D expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of commercialization-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of SG&amp;amp;A expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of Sanofi commercial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;SG&amp;amp;A expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts recognized in connection with up-front payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;As described within the "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Immuno-Oncology&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;" section below, effective July 1, 2022, the Company obtained the exclusive right to develop, commercialize, and manufacture Libtayo worldwide.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in the Company's Statements of Operations in connection with its Bayer collaboration are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.931%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.934%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's share of profits in connection with commercialization of EYLEA outside the United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of ex-U.S. commercial supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One-time payment in connection with change in Japan arrangement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of Bayer R&amp;amp;D expenses, net of reimbursement of R&amp;amp;D expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(R&amp;amp;D expense)/Reduction of R&amp;amp;D expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 16.75pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in the Company's Statements of Operations in connection with the Roche Collaboration Agreement are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:13pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.818%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Global gross profit payment from Roche in connection with sales of Ronapreve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c137cb80c2348b6b72faccb7cba8e93_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfMi03LTEtMS0yMjE1Njg_58eb9abc-b2a4-4071-b2ae-8b8fdfd4dbd6"
      unitRef="usd">1433800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb40dc2b4e6d4ddc9267422ed2896f2b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfMi05LTEtMS0yMjE1Njg_14a56ded-65e0-47e7-b2de-c86759322ffa"
      unitRef="usd">1517600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d3ca332ac7b44e7afd08a842efc7831_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfMy03LTEtMS0yMjE1Njg_0c13c6bb-123c-4b52-b13b-92270f79d64d"
      unitRef="usd">109700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1493138d25f94132897d582fa5633635_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfMy05LTEtMS0yMjE1Njg_017cc011-54fc-46b7-b080-94307dcbff7d"
      unitRef="usd">78900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i539fd4a3ebc04eee85f11898f58b8e50_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfNC03LTEtMS0yMjE1Njg_a27b931a-5f03-4a75-a020-e14bb9f771b9"
      unitRef="usd">67200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d4c5cb7b7d440c39db96ce2e6fcdf63_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfNC05LTEtMS0yMjE1Njg_f8a7aab3-d388-490b-a1b4-f3a05baf2bf3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97633ca31aaf4a5494aff1cd47af72b6_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfNS03LTEtMS0yMjE1Njg_165addcc-861c-4611-b95a-fe37ed236714"
      unitRef="usd">40200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6180931ab3794a16a3d092c67267848f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfNS05LTEtMS0yMjE1Njg_0dbbd23f-c13f-4a09-9b08-81c2e4e16171"
      unitRef="usd">33600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i170bf04d3efb4e2ba2dbc70f34869ad4_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfNy03LTEtMS0yMjE1Njg_a92b7b9f-8c87-4647-9188-4026e6cd6776"
      unitRef="usd">14900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7a13e46bf874e5d863afd595bc4af6a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfNy05LTEtMS0yMjE1Njg_87b07a80-7d81-4d23-935b-d79924fc3846"
      unitRef="usd">8500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ee16d3d639e46f8a41fb5fef9f9301a_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfOC03LTEtMS0yMjE1Njg_8c55f97b-af4a-4d7f-82c1-db62036f2dac"
      unitRef="usd">2200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0510a432e77041dca5a54640cff8ad6f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfOC05LTEtMS0yMjE1Njg_fc0508d1-7ca3-451a-afa7-69000bbb40ed"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89d2806ddfda4899b23a4e2a27b639ee_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfMTAtNy0xLTEtMjIxNTY4_6c4dd142-e616-4e77-b88b-069864e7bcdc"
      unitRef="usd">1668000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9cd61146d31845f7aa0a400c1de8c9af_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOmI4ZmZjODA4M2NmODRiNjVhNjRiMTBhYmVlMWJiN2I3L3RhYmxlcmFuZ2U6YjhmZmM4MDgzY2Y4NGI2NWE2NGIxMGFiZWUxYmI3YjdfMTAtOS0xLTEtMjIxNTY4_1cb3ab6b-2ec1-4177-87a0-4f71b6b3d1e0"
      unitRef="usd">1638600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib8a607a3e56c41779c0e4d7f40f3276c_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RleHRyZWdpb246N2E2NWI1ZDA3NjU4NDc0NGE4MjdlNTNiYzBlMTk2NzdfMjE5OTAyMzI1NjE4NQ_f673a450-a306-480c-b863-b7322d3c6303"
      unitRef="usd">3578000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iddde8724f2d94806b024d0d0b38bb09c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RleHRyZWdpb246N2E2NWI1ZDA3NjU4NDc0NGE4MjdlNTNiYzBlMTk2NzdfMTA4_35d2db18-6074-4a0f-8dce-9e2dc4a18419"
      unitRef="usd">3586000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RleHRyZWdpb246N2E2NWI1ZDA3NjU4NDc0NGE4MjdlNTNiYzBlMTk2NzdfNDg1_970527fe-2ca9-41c4-ac2d-21bda264f738">Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.210%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Besse Medical, a subsidiary of AmerisourceBergen Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i66be2d5d13e14c65a79a0cd9a1fdba09_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOjQxOTY4MGUwNWY0MjRiNGQ5NDU0NjU1NTUzYTcyNTZmL3RhYmxlcmFuZ2U6NDE5NjgwZTA1ZjQyNGI0ZDk0NTQ2NTU1NTNhNzI1NmZfMi02LTEtMS0yMjE1Njg_33cec460-8c4f-4462-8670-c665ae915de6"
      unitRef="number">0.52</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iffa15815bae94096ae1f51c8a0ecfdf8_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOjQxOTY4MGUwNWY0MjRiNGQ5NDU0NjU1NTUzYTcyNTZmL3RhYmxlcmFuZ2U6NDE5NjgwZTA1ZjQyNGI0ZDk0NTQ2NTU1NTNhNzI1NmZfMi04LTEtMS0yMjE1Njg_b4345235-bdc5-41eb-ac2e-022188770201"
      unitRef="number">0.55</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id1c2ae76df8543b98e4b8e032206851d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOjQxOTY4MGUwNWY0MjRiNGQ5NDU0NjU1NTUzYTcyNTZmL3RhYmxlcmFuZ2U6NDE5NjgwZTA1ZjQyNGI0ZDk0NTQ2NTU1NTNhNzI1NmZfMy02LTEtMS0yMjE1Njg_de9fa14a-7cfd-4acb-80d2-6735e765107b"
      unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id5edea8b3603449e90ce4d1565b6ee02_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNC9mcmFnOjdhNjViNWQwNzY1ODQ3NDRhODI3ZTUzYmMwZTE5Njc3L3RhYmxlOjQxOTY4MGUwNWY0MjRiNGQ5NDU0NjU1NTUzYTcyNTZmL3RhYmxlcmFuZ2U6NDE5NjgwZTA1ZjQyNGI0ZDk0NTQ2NTU1NTNhNzI1NmZfMy04LTEtMS0yMjE1Njg_88c2ad48-8f35-4b27-b303-478220a1b6dc"
      unitRef="number">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfMTM0MjM_e7794623-d4f5-4690-96f3-ab0ddae71c47">Collaboration, License, and Other Agreements&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;a. Sanofi&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in our Statements of Operations in connection with our collaborations with Sanofi are detailed below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.888%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Antibody:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's share of profits in connection with commercialization of antibodies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales-based milestones earned&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of commercial supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of Sanofi R&amp;amp;D expenses, net of reimbursement of R&amp;amp;D expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(R&amp;amp;D expense)/Reduction of R&amp;amp;D expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of commercialization-related expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of SG&amp;amp;A expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immuno-oncology&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's share of profits in connection with commercialization of Libtayo outside the United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of ex-U.S. commercial supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of R&amp;amp;D expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of R&amp;amp;D expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of commercialization-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of SG&amp;amp;A expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of Sanofi commercial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;SG&amp;amp;A expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts recognized in connection with up-front payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;As described within the "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Immuno-Oncology&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;" section below, effective July 1, 2022, the Company obtained the exclusive right to develop, commercialize, and manufacture Libtayo worldwide.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Antibody&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to a global, strategic collaboration with Sanofi to research, develop, and commercialize fully human monoclonal antibodies (the "Antibody Collaboration"), which currently consists of Dupixent&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (dupilumab), Kevzara&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (sarilumab), and itepekimab&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Antibody License and Collaboration Agreement (the "LCA"), Sanofi is generally responsible for funding 80% to 100% of agreed-upon development costs. The Company is obligated to reimburse Sanofi for 30% to 50% of worldwide development expenses that were funded by Sanofi based on the Company's share of collaboration profits from commercialization of collaboration products. Under the terms of the LCA, the Company was required to apply 10% of its share of the profits from the Antibody Collaboration in any calendar quarter to reimburse Sanofi for these development costs. On July 1, 2022, an amendment to the LCA became effective, pursuant to which the percentage of the Company's share of profits used to reimburse Sanofi for such development costs increased from 10% to 20%. A portion of the value associated with the increase in reimbursement percentage was deemed to be contingent consideration attributable to the Company's acquisition of the Libtayo (cemiplimab) rights described within the "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Immuno-Oncology&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;" section below; this portion will be recorded as an increase to the Libtayo intangible asset over time as the Company repays such development costs to Sanofi. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sanofi leads commercialization activities for products under the Antibody Collaboration, subject to the Company's right to co-commercialize such products. In addition to profit and loss sharing, the Company is entitled to receive sales milestone payments from Sanofi. During the three months ended March 31, 2022, the Company earned a $50.0&#160;million sales-based milestone from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $2.0&#160;billion on a rolling twelve-month basis. The Company is entitled to receive the final sales milestone payment of $50.0&#160;million when such sales outside the United States exceed $3.0&#160;billion on a rolling twelve-month basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Company's Antibody Collaboration with Sanofi:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.502%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;731.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Immuno-Oncology&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was previously a party to a collaboration with Sanofi for antibody-based cancer treatments in the field of immuno-oncology (the "IO Collaboration"). Under the terms of the Immuno-oncology License and Collaboration Agreement, the parties were co-developing and co-commercializing Libtayo. The parties shared equally, on an ongoing basis, development and commercialization expenses for Libtayo. The Company had principal control over the development of Libtayo and led commercialization activities in the United States, while Sanofi led commercialization activities outside of the United States. The parties shared equally in profits and losses in connection with the commercialization of Libtayo.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective July 1, 2022, the Company obtained the exclusive right to develop, commercialize, and manufacture Libtayo worldwide under an Amended and Restated Immuno-oncology License and Collaboration Agreement with Sanofi (the "A&amp;amp;R IO LCA"). In connection with the A&amp;amp;R IO LCA, in 2022, the Company made a $900.0&#160;million up-front payment to Sanofi, as well as a $100.0&#160;million regulatory milestone payment. In addition, Sanofi earned a $65.0&#160;million sales-based milestone upon the achievement of a specified amount of worldwide net product sales of Libtayo in 2022 and is eligible to receive an additional $35.0&#160;million sales-based milestone upon the achievement of a specified amount of worldwide net product sales of Libtayo in 2023 (aggregate of $100.0&#160;million in sales-based milestones eligible to be earned under the terms of the A&amp;amp;R IO LCA). The Company also pays Sanofi an 11% royalty on net product sales of Libtayo through March 31, 2034. The transaction was accounted for as an asset acquisition and amounts paid to Sanofi in connection with obtaining the worldwide rights to Libtayo, including the up-front payment and any contingent consideration, are recorded as an intangible asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;b. Bayer &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to a license and collaboration agreement with Bayer for the global development and commercialization of EYLEA (aflibercept) and aflibercept 8 mg outside the United States. Agreed-upon development expenses incurred by the Company and Bayer are generally shared equally. Bayer markets EYLEA outside the United States, and the companies share equally in profits and losses from such sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in the Company's Statements of Operations in connection with its Bayer collaboration are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.931%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.934%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's share of profits in connection with commercialization of EYLEA outside the United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of ex-U.S. commercial supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One-time payment in connection with change in Japan arrangement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of Bayer R&amp;amp;D expenses, net of reimbursement of R&amp;amp;D expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(R&amp;amp;D expense)/Reduction of R&amp;amp;D expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 16.75pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Company's Bayer collaboration:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.795%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;c. Roche&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a party to a collaboration agreement (the "Roche Collaboration Agreement") with Roche to develop, manufacture, and distribute the casirivimab and imdevimab antibody cocktail (known as REGEN-COV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States and Ronapreve&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in other countries). Under the terms of the collaboration agreement, the parties jointly fund certain studies, and the Company has the right to distribute the product in the United States while Roche has the right to distribute the product outside of the United States. The parties share gross profits from worldwide sales based on a pre-specified formula, depending on the amount of manufactured product supplied by each party to the market. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in the Company's Statements of Operations in connection with the Roche Collaboration Agreement are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:13pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.818%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Global gross profit payment from Roche in connection with sales of Ronapreve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reimbursement of research and development expenses from Roche was not material for the three months ended March&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Roche Collaboration Agreement:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;d. Sonoma Biotherapeutics, Inc.&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, the Company and Sonoma Biotherapeutics, Inc. entered into a license and collaboration agreement to bring together the Company's &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;VelociSuite&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; technologies with Sonoma's technology platform for the discovery, development, and commercialization of novel regulatory T cell (T&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"&gt;reg&lt;/span&gt;) therapies for autoimmune diseases. In connection with the agreement, the Company made a $45.0&#160;million up-front payment (which was recorded to Acquired in-process research and development expense in the first quarter of 2023) and, in April 2023, the Company purchased an aggregate of $30.0&#160;million of Sonoma preferred stock. Sonoma is also eligible to receive a $45.0&#160;million development milestone payment. The Company and Sonoma will co-fund research and development activities and share equally any future commercial expenses and profits. The Company will have the option to lead late-stage development and commercialization on all products globally, with Sonoma retaining rights to co-promote all such products in the United States.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2f2c59d2425478cb9a759cbb016a8e3_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMy04LTEtMS0yMjE1Njg_a6b27af3-f11c-4e98-b54b-6999d126d5a9"
      unitRef="usd">636500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3e3b5297b2d4da18d1e8bf81c32ed78_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMy0xMC0xLTEtMjIxNTY4_38a94c32-ea6f-4f0e-9f23-a628aa413540"
      unitRef="usd">415300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a2817fbcc324c0dace63bfa58aa3472_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfNC04LTEtMS0yMjE1Njg_7b1a98cd-bef9-4382-b706-d785f884badf"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i496ebaf3b22440b2b2d69aab06cd1a36_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfNC0xMC0xLTEtMjIxNTY4_911e654c-c8ff-4865-8b17-2638402b086b"
      unitRef="usd">50000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2cadf695465b4d2c823616dee5674384_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfNS04LTEtMS0yMjE1Njg_c5c37a27-f934-4a5d-b44f-6f4881a54e4e"
      unitRef="usd">161900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea1238f837994a0a8d152d9ed98974c4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfNS0xMC0xLTEtMjIxNTY4_82bc67c5-0dec-4a48-b87c-b4fbec26841d"
      unitRef="usd">160800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied6deae52c5a4fddbad0b5bb2c2d457d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfNy04LTEtMS0yMjE1Njg_962e7a11-1f73-43ac-8927-db4d816167b5"
      unitRef="usd">-26400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic09e4f946d7f4b20bff8285f40f649f9_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfNy0xMC0xLTEtMjIxNTY4_fe77eab0-6e0f-4463-9f86-013e537e1837"
      unitRef="usd">26800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id88f78210881451481543b0e7df5322b_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfOC04LTEtMS0yMjE1Njg_bcdf27e7-5157-4fc4-84a3-9939748ecb9c"
      unitRef="usd">117600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83fd3849cf8b49c990d30ebab1b52082_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfOC0xMC0xLTEtMjIxNTY4_ced57a6a-e326-46a4-bf25-986496d66ec8"
      unitRef="usd">91700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia9bce6102ed54468900a9f32c759ef8c_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTEtOC0xLTEtMjIxNTY4_3e2ffba4-3930-4c41-b382-4d1ea612377a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied033f1452834cc0b77499b012220842_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTEtMTAtMS0xLTIyMTU2OA_f0adabba-2ebe-4b7b-b411-9e7967571623"
      unitRef="usd">2800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d4d7003a52c48d286f50a758bf9d9fb_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTItOC0xLTEtMjIxNTY4_c4706a8c-fada-41e4-b7fc-b0b86fd3122d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id312ecfecca44b6cad64d0a4dead7154_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTItMTAtMS0xLTIyMTU2OA_fe4c3114-3f3c-4a61-96c8-27a7af6e86f7"
      unitRef="usd">2000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b748b8781634cf7bad7b7c57fea08bc_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTMtOC0xLTEtMjIxNTY4_a14beb3b-bcff-497c-9dc7-cad364687baf"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifeba37fd20ba4aa5aa90737cd4da0556_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTMtMTAtMS0xLTIyMTU2OA_cfbb2cc9-79c2-4171-9c2c-e47a5ee3a4ae"
      unitRef="usd">21500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie398e6bd3f1649b1b129db816c08a863_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTQtOC0xLTEtMjIxNTY4_33a75d67-1c57-4e6e-9480-3a1e5aa6e3f1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba78c9e3c2b14c9f8c6d4c4c6903cefe_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTQtMTAtMS0xLTIyMTU2OA_9d33f2ee-4d64-4b8a-b556-37f407652151"
      unitRef="usd">19000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b3cda38a64e4813ba22059700b5a833_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTUtOC0xLTEtMjIxNTY4_35af6322-b784-46a3-b37a-9e87af6eb082"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i13a2eb4e3a324853b0f3388887ed2b2c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTUtMTAtMS0xLTIyMTU2OA_5b5695bf-55a8-46ba-9dc6-853038b193da"
      unitRef="usd">-9200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf4bf1050794419cbf96df94e7e5a822_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTYtOC0xLTEtMjIxNTY4_e50036cd-86e4-426f-97a6-0deb3f788295"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2fd3f28a70a64843aab800c66e3727dd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTYtMTAtMS0xLTIyMTU2OA_3080010b-c104-4c09-8d1f-f899b68f5a95"
      unitRef="usd">-32300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1cfd4128aea7458a926f5ef7dc7d8228_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTctOC0xLTEtMjIxNTY4_3d9ff175-c1f5-4fbe-a0b8-49d24ecda86d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1807e85b9a734966b305aebfce1a2b3e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjU1ZjQxZjFhNjI5ZDRmNTg5MzJmODkzYjBhNzUwMmMzL3RhYmxlcmFuZ2U6NTVmNDFmMWE2MjlkNGY1ODkzMmY4OTNiMGE3NTAyYzNfMTctMTAtMS0xLTIyMTU2OA_53d55dc7-0a2f-48f0-a379-98876a316be1"
      unitRef="usd">18100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <regn:PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty
      contextRef="i93a73ef5b43a4b719c774ecb420922ef_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfNTc0_e2cfb571-0cfb-43de-8514-af97e4e76cbd"
      unitRef="number">0.80</regn:PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty>
    <regn:PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty
      contextRef="iaa0640ad68f44c88a2dbc0ebca2b3b73_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfNTgw_c05e1c59-0f9b-42e9-a1d7-7b432a1430c3"
      unitRef="number">1</regn:PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty>
    <regn:PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts
      contextRef="i93a73ef5b43a4b719c774ecb420922ef_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfNjU4_e8a8c446-b532-444c-ad4a-9c44d9fc63ee"
      unitRef="number">0.30</regn:PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts>
    <regn:PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts
      contextRef="iaa0640ad68f44c88a2dbc0ebca2b3b73_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfNjY0_00ae7ff2-ab7c-4130-be67-db8ee84dcc7d"
      unitRef="number">0.50</regn:PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts>
    <regn:PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts
      contextRef="i76483ad7f52e40cab4a22bb58eb53286_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfOTE3_cb1a95f7-7b3a-4fe4-9843-a36af4d43dba"
      unitRef="number">0.10</regn:PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts>
    <regn:PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts
      contextRef="i38436edb47124f8fb19121d45a1874e7_D20220630-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfMTI4NQ_d78291f1-1111-4557-bfe6-f143abcc2e10"
      unitRef="number">0.10</regn:PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts>
    <regn:PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts
      contextRef="ia4de45f3331e49d0bc3791fd059ee5a4_D20220701-20220701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfMTI5MQ_cfb68af1-906f-49b2-90c1-64882d7b0783"
      unitRef="number">0.20</regn:PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd392818c90b43539fc9c9768bb1ca18_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfMjAxNA_a6671463-dfa5-4501-b415-c28923dee220"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <regn:LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived
      contextRef="icd392818c90b43539fc9c9768bb1ca18_D20220101-20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfMjE1MQ_e1cfd003-6f79-492e-8b80-47acbc78691a"
      unitRef="usd">2000000000</regn:LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived>
    <regn:PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis
      contextRef="icd392818c90b43539fc9c9768bb1ca18_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfMTMzNTM_e6c36bb8-96cd-4687-8538-e56d960f7c0e">P12M</regn:PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis>
    <regn:RevenueRemainingPerformanceObligationVariableConsiderationAmount
      contextRef="idd80951ec63945c1a0f004821f556950_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfMjQ3Mg_f9fba110-cac5-4d62-b96a-c3088b801497"
      unitRef="usd">50000000</regn:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <regn:LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived
      contextRef="i78bee0b457e64f8ca4716924e360fafb_D20230101-20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfMjY1MQ_b88032ed-9ee8-4548-9cff-564c0267246f"
      unitRef="usd">3000000000</regn:LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived>
    <regn:PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis
      contextRef="i78bee0b457e64f8ca4716924e360fafb_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfMTMzNjc_d4c7d913-5e2c-48aa-938d-f2b025479670">P12M</regn:PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfMTM0MDI_2f716675-ead5-40f7-b7ab-3c6f9665c33f">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Company's Antibody Collaboration with Sanofi:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.502%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;731.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Company's Bayer collaboration:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.795%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Roche Collaboration Agreement:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i50cbbeeb8ba0490fb582afb27330f7db_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjA1ZjczYWUzYTZiYjRiZmM4YmU3ZjdlMTk4MDllMTg3L3RhYmxlcmFuZ2U6MDVmNzNhZTNhNmJiNGJmYzhiZTdmN2UxOTgwOWUxODdfMi0yLTEtMS0yMjE1Njg_33cc13e5-348f-4fdf-b349-282f5bbb73bc"
      unitRef="usd">731500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iaea9b652c53d4a4c82b1a7b4ea756d8c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjA1ZjczYWUzYTZiYjRiZmM4YmU3ZjdlMTk4MDllMTg3L3RhYmxlcmFuZ2U6MDVmNzNhZTNhNmJiNGJmYzhiZTdmN2UxOTgwOWUxODdfMi00LTEtMS0yMjE1Njg_bfec8a9d-2b14-4eb8-aa5d-53e823e97c6f"
      unitRef="usd">692300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i50cbbeeb8ba0490fb582afb27330f7db_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjA1ZjczYWUzYTZiYjRiZmM4YmU3ZjdlMTk4MDllMTg3L3RhYmxlcmFuZ2U6MDVmNzNhZTNhNmJiNGJmYzhiZTdmN2UxOTgwOWUxODdfMy0yLTEtMS0yMjE1Njg_9b2c17a8-e3a8-4813-a342-5f7ee32dd064"
      unitRef="usd">377500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="iaea9b652c53d4a4c82b1a7b4ea756d8c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjA1ZjczYWUzYTZiYjRiZmM4YmU3ZjdlMTk4MDllMTg3L3RhYmxlcmFuZ2U6MDVmNzNhZTNhNmJiNGJmYzhiZTdmN2UxOTgwOWUxODdfMy00LTEtMS0yMjE1Njg_5c5e7459-a964-45df-a1a8-dc3540af4c7f"
      unitRef="usd">415800000</us-gaap:ContractWithCustomerLiability>
    <regn:UpFrontPaymentToCollaboratingParty
      contextRef="ia67b58013e1b4eb9829600ae26b049f1_D20220701-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfNjA0NzMxMzk3ODU4OQ_268b540f-4d63-44e1-bf9d-d023f6b7d2d8"
      unitRef="usd">900000000</regn:UpFrontPaymentToCollaboratingParty>
    <regn:UpFrontPaymentToCollaboratingParty
      contextRef="ib05c9a4e748542a39f0ded000f62b58a_D20220701-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfMzg4MQ_54b856f0-93a0-4be3-95d5-78c3790ad5fd"
      unitRef="usd">100000000</regn:UpFrontPaymentToCollaboratingParty>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i157885e3534940e6bbf0c1712c537758_D20220701-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfNjA0NzMxMzk3ODU0NA_ed88d6b7-4fa2-42ec-8274-f3236c94eaf4"
      unitRef="usd">65000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51a33fff830d49e2836b1dcc69fd8e6d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfNjA0NzMxMzk3ODU1OQ_a94084a8-a9b4-4873-9509-848f591f801d"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idfc4183c9b684d69800dbe32f7df3f9c_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfMzkzMQ_28e11216-732e-4b54-8243-d42486d0146d"
      unitRef="usd">100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <regn:RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales
      contextRef="i28142adb16bf44cd9637c180668c9386_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfNDA4Mw_1d0d9c20-8555-48de-982b-b764d58c96e1"
      unitRef="number">0.11</regn:RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb424b76bb944bb487058cb7b71b5478_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjM5M2FiMzQ4ZTNlOTRiNDM5NGE1YmI4ZDRjZmUxMTNiL3RhYmxlcmFuZ2U6MzkzYWIzNDhlM2U5NGI0Mzk0YTViYjhkNGNmZTExM2JfMi04LTEtMS0yMjE1Njg_9bb2ce4b-34d7-443b-b651-56598d7a20e8"
      unitRef="usd">331600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba893ed59b6f4ef9b1de82284a9c172b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjM5M2FiMzQ4ZTNlOTRiNDM5NGE1YmI4ZDRjZmUxMTNiL3RhYmxlcmFuZ2U6MzkzYWIzNDhlM2U5NGI0Mzk0YTViYjhkNGNmZTExM2JfMi0xMC0xLTEtMjIxNTY4_dcb56e6f-de6d-42a5-8b7d-b21ebf656117"
      unitRef="usd">338400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0252272660b2483c9bdc58226cbd09da_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjM5M2FiMzQ4ZTNlOTRiNDM5NGE1YmI4ZDRjZmUxMTNiL3RhYmxlcmFuZ2U6MzkzYWIzNDhlM2U5NGI0Mzk0YTViYjhkNGNmZTExM2JfMy04LTEtMS0yMjE1Njg_401a3c42-684b-4ed7-b904-4fe45a32a6e5"
      unitRef="usd">25300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idde62877d41141df8937d3435f4c3667_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjM5M2FiMzQ4ZTNlOTRiNDM5NGE1YmI4ZDRjZmUxMTNiL3RhYmxlcmFuZ2U6MzkzYWIzNDhlM2U5NGI0Mzk0YTViYjhkNGNmZTExM2JfMy0xMC0xLTEtMjIxNTY4_4b50ce66-2c0a-4311-bd07-43ff4744ccd7"
      unitRef="usd">25000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf1d66b82008486885a981ea123058f2_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjM5M2FiMzQ4ZTNlOTRiNDM5NGE1YmI4ZDRjZmUxMTNiL3RhYmxlcmFuZ2U6MzkzYWIzNDhlM2U5NGI0Mzk0YTViYjhkNGNmZTExM2JfNC04LTEtMS0yMjE1Njg_1d336e48-11af-4833-b805-4462644723cf"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia020696b0d3c4162aea4b7989e504a75_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjM5M2FiMzQ4ZTNlOTRiNDM5NGE1YmI4ZDRjZmUxMTNiL3RhYmxlcmFuZ2U6MzkzYWIzNDhlM2U5NGI0Mzk0YTViYjhkNGNmZTExM2JfNC0xMC0xLTEtMjIxNTY4_f5fed62b-2755-4863-937f-450e7c2166c6"
      unitRef="usd">21900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a5fff795cfe4c74b86bc4bd5174db81_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjM5M2FiMzQ4ZTNlOTRiNDM5NGE1YmI4ZDRjZmUxMTNiL3RhYmxlcmFuZ2U6MzkzYWIzNDhlM2U5NGI0Mzk0YTViYjhkNGNmZTExM2JfNS00LTEtMS0yNDg0Mjc_09d88d9e-e7c5-48cd-a39d-3856eaf6900c"
      unitRef="usd">-13400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie08517bc56f64a56855dedc1fd282413_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjM5M2FiMzQ4ZTNlOTRiNDM5NGE1YmI4ZDRjZmUxMTNiL3RhYmxlcmFuZ2U6MzkzYWIzNDhlM2U5NGI0Mzk0YTViYjhkNGNmZTExM2JfNS02LTEtMS0yNDg0Mjc_1796e1ff-913d-4030-b8e5-f98c94c412e8"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic9e294aebc65480da80f32f7028adbb2_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjM3MTZlNGM5ZDA3NjQwYTc4YzIwZjUxNmE1ZDJkZmI0L3RhYmxlcmFuZ2U6MzcxNmU0YzlkMDc2NDBhNzhjMjBmNTE2YTVkMmRmYjRfMi0yLTEtMS0yMjE1Njg_8fde4bc4-d7a0-4854-ad44-5a0da62f4095"
      unitRef="usd">356800000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i102f804ba9484132ae7196bde6f74767_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjM3MTZlNGM5ZDA3NjQwYTc4YzIwZjUxNmE1ZDJkZmI0L3RhYmxlcmFuZ2U6MzcxNmU0YzlkMDc2NDBhNzhjMjBmNTE2YTVkMmRmYjRfMi00LTEtMS0yMjE1Njg_55365a9b-1266-448f-b46a-04775c0d5e3b"
      unitRef="usd">348200000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ic9e294aebc65480da80f32f7028adbb2_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjM3MTZlNGM5ZDA3NjQwYTc4YzIwZjUxNmE1ZDJkZmI0L3RhYmxlcmFuZ2U6MzcxNmU0YzlkMDc2NDBhNzhjMjBmNTE2YTVkMmRmYjRfMy0yLTEtMS0yMjE1Njg_df10e486-ce15-4214-bdb8-67f73b131e1b"
      unitRef="usd">134300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i102f804ba9484132ae7196bde6f74767_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjM3MTZlNGM5ZDA3NjQwYTc4YzIwZjUxNmE1ZDJkZmI0L3RhYmxlcmFuZ2U6MzcxNmU0YzlkMDc2NDBhNzhjMjBmNTE2YTVkMmRmYjRfMy00LTEtMS0yMjE1Njg_f6eb2663-106d-49d0-8cdd-03999a8de43a"
      unitRef="usd">131900000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64841568e706401985fc84aa04b36f1e_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOmRmMTc3ZTg0ZmMxZDRkYTJiZTgxYmNjN2I5YjdiMjJlL3RhYmxlcmFuZ2U6ZGYxNzdlODRmYzFkNGRhMmJlODFiY2M3YjliN2IyMmVfMi04LTEtMS0yMjE1Njg_5d7445d1-a256-473f-a19a-c5bc68d2f474"
      unitRef="usd">222200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29f6f63a87914141b95f4f2c48ff1364_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOmRmMTc3ZTg0ZmMxZDRkYTJiZTgxYmNjN2I5YjdiMjJlL3RhYmxlcmFuZ2U6ZGYxNzdlODRmYzFkNGRhMmJlODFiY2M3YjliN2IyMmVfMi0xMC0xLTEtMjIxNTY4_fd234a02-d748-43ea-848b-2b6661e9638b"
      unitRef="usd">216300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i38fd75f0c02644a59d387c1d665dac3e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjQ3ZWI4N2VjNmYwYzQwYTk5ZjA1ODM3YTAyMDhjNjBlL3RhYmxlcmFuZ2U6NDdlYjg3ZWM2ZjBjNDBhOTlmMDU4MzdhMDIwOGM2MGVfMi0yLTEtMS0yMjE1Njg_ade58d72-a45f-4cda-9686-e323a96c51ea"
      unitRef="usd">220600000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i7e796f5592204aff856a0effed5d30f5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RhYmxlOjQ3ZWI4N2VjNmYwYzQwYTk5ZjA1ODM3YTAyMDhjNjBlL3RhYmxlcmFuZ2U6NDdlYjg3ZWM2ZjBjNDBhOTlmMDU4MzdhMDIwOGM2MGVfMi00LTEtMS0yMjE1Njg_fd332cd6-e279-41bb-ac19-95bdddbe187b"
      unitRef="usd">396600000</us-gaap:AccountsReceivableNetCurrent>
    <regn:UpFrontPaymentToCollaboratingParty
      contextRef="i9c9892adbc9444b2ba40d227075a443b_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfOTg5NTYwNDY4Mzc5OA_38e1373c-afb4-4400-9d49-a3f5862e232e"
      unitRef="usd">45000000</regn:UpFrontPaymentToCollaboratingParty>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="ib6c0a3e1eb3f4fa4b60c33bacffd2f52_D20230401-20230430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfOTg5NTYwNDY4MzkyOA_cb39d3e8-3b8a-4914-8387-46be2a7c58ce"
      unitRef="usd">30000000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3456908093f4728b4a4f17cb0d3cd19_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl8zNy9mcmFnOjc0NjhlN2VkYWNlZDRhNjE4MjE4OGEwNjhiNTg5MWMyL3RleHRyZWdpb246NzQ2OGU3ZWRhY2VkNGE2MTgyMTg4YTA2OGI1ODkxYzJfOTg5NTYwNDY4Mzk0Mw_97c4dc4d-898e-4df7-a40c-3d91e576e8d7"
      unitRef="usd">45000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RleHRyZWdpb246Y2UyODgyY2NmMTIyNGY0OWFlYzZmNWU0MmJkYjFkYjJfNzU1_6a6cb5e2-ac58-4d98-b560-81560a1992e6">Net Income Per Share &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income per share is computed by dividing net income by the weighted average number of shares of Common Stock and Class A Stock outstanding. Net income per share is presented on a combined basis, inclusive of Common Stock and Class A Stock outstanding, as each class of stock has equivalent economic rights. Diluted net income per share includes the potential dilutive effect of other securities as if such securities were converted or exercised during the period, when the effect is dilutive. The calculations of basic and diluted net income per share are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.304%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;817.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;973.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards and restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares which have been excluded from diluted per share amounts because their effect would have been antidilutive include the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.298%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.450%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.450%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.693%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RleHRyZWdpb246Y2UyODgyY2NmMTIyNGY0OWFlYzZmNWU0MmJkYjFkYjJfNzYz_8b918097-4edf-430e-b337-c2b44c4a5ecc">The calculations of basic and diluted net income per share are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.304%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;817.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;973.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards and restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfMi02LTEtMS0yMjE1Njg_fa7cf586-c2f9-4aec-a591-9c373d2be169"
      unitRef="usd">817800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfMi04LTEtMS0yMjE1Njg_9a8e43e4-8a9b-4938-aa27-d82913a089a6"
      unitRef="usd">973500000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfNC02LTEtMS0yMjE1Njg_68ef17e2-6e01-472c-9def-c4fce0d1c77d"
      unitRef="shares">107100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfNC04LTEtMS0yMjE1Njg_3e9f1b2b-8c4e-4996-a070-2ae1167fc6d8"
      unitRef="shares">106800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i3b0f6d873f2441d7890447099c7468ad_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfNi02LTEtMS0yMjE1Njg_f04ddb55-c0d3-480c-ab17-f1f1d3e35ab4"
      unitRef="shares">5000000.0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i899f0e7929c744418d1f315d17e1594a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfNi04LTEtMS0yMjE1Njg_34ebd9b0-a2a3-4241-8f10-bab2bcdf5dc9"
      unitRef="shares">5000000.0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i084af335d0d14bb79b9fc2db8159a242_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfNy02LTEtMS0yMjE1Njg_44b875f0-536e-4460-98a4-f4b296c56bb9"
      unitRef="shares">1900000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i2be78b3922ff4f9196bd6708075600e8_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfNy04LTEtMS0yMjE1Njg_8d13b272-993a-4e09-b449-181bf32f6034"
      unitRef="shares">1300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfOC02LTEtMS0yMjE1Njg_7270f1a6-b17c-46b8-a4c8-480d71c7f234"
      unitRef="shares">114000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfOC04LTEtMS0yMjE1Njg_ba6b35b1-2a2a-4504-866d-c467e69297af"
      unitRef="shares">113100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfMTAtNi0xLTEtMjIxNTY4_b567779a-a8bc-441f-bd6d-392c26f51085"
      unitRef="usdPerShare">7.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfMTAtOC0xLTEtMjIxNTY4_1501ba35-80a0-4995-a08c-1918aac9a3e9"
      unitRef="usdPerShare">9.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfMTEtNi0xLTEtMjIxNTY4_a6117a81-11fb-48b1-9865-c236e3dd9c02"
      unitRef="usdPerShare">7.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjI0MDQzNjNkMjk3MTRlY2E5OTMwMzNhNGY5OTYyOWJlL3RhYmxlcmFuZ2U6MjQwNDM2M2QyOTcxNGVjYTk5MzAzM2E0Zjk5NjI5YmVfMTEtOC0xLTEtMjIxNTY4_15f5ef34-69dd-497d-b932-b3b766ade013"
      unitRef="usdPerShare">8.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RleHRyZWdpb246Y2UyODgyY2NmMTIyNGY0OWFlYzZmNWU0MmJkYjFkYjJfNzYx_04545c16-bbca-4885-837e-6de7ba5905ff">&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares which have been excluded from diluted per share amounts because their effect would have been antidilutive include the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.298%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.450%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.450%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.693%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7aef696237bd4fa2bb67d81627a03291_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjQwMDhjYjJlMmVhMDQzMjg4MjBkYzcwMjM1MmY4NjY1L3RhYmxlcmFuZ2U6NDAwOGNiMmUyZWEwNDMyODgyMGRjNzAyMzUyZjg2NjVfMi02LTEtMS0yMjE1Njg_291fa9d4-3d64-48f0-a82b-e2104e503f6f"
      unitRef="shares">1700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic57e069f15ea4d1eb588c09adef593ba_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80MC9mcmFnOmNlMjg4MmNjZjEyMjRmNDlhZWM2ZjVlNDJiZGIxZGIyL3RhYmxlOjQwMDhjYjJlMmVhMDQzMjg4MjBkYzcwMjM1MmY4NjY1L3RhYmxlcmFuZ2U6NDAwOGNiMmUyZWEwNDMyODgyMGRjNzAyMzUyZjg2NjVfMi04LTEtMS0yMjE1Njg_8324bb97-d01f-4e62-8a1e-c5c75fff177a"
      unitRef="shares">2200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RleHRyZWdpb246YzE3YjdmZGZkNjEwNDJiNjhiM2Q1OGVjZDdmYjhkMzZfMTI1Nw_b00369ad-46a3-4189-ad45-c5ce9d8c0089">Marketable Securities&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities as of March&#160;31, 2023 and December&#160;31, 2022 consist of both available-for-sale debt securities of investment grade issuers (see below and Note 6) as well as equity securities of publicly traded companies (see Note 6).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company's investments in available-for-sale debt securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,819.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,592.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,902.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,903.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,280.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,051.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,975.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(291.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,684.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,945.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,939.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,320.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(302.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,018.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies its investments in available-for-sale debt securities based on their contractual maturity dates. The available-for-sale debt securities as of March&#160;31, 2023 mature at various dates through August 2028. The fair values of available-for-sale debt securities by contractual maturity consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.473%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturities within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,043.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,636.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturities after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,996.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,381.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturities after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,051.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,018.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the fair value of the Company's available-for-sale debt securities&#160;that have unrealized losses, aggregated by investment category and length of time that the individual securities have been in a continuous loss position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;707.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,293.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,000.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,222.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,464.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,687.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,445.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,200.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,645.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(291.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,300.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,332.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,633.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(302.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unrealized losses on corporate bonds as of March 31, 2023 were primarily driven by increases in interest rates. The Company has reviewed its portfolio of available-for-sale debt securities and determined that the decline in fair value below cost did not result from credit-related factors. In addition, the Company does not intend to sell, and it is not more likely than not that the Company will be required to sell, such securities before recovery of their amortized cost bases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to marketable securities, for the three months ended March&#160;31, 2023 and 2022, amounts reclassified from Accumulated other comprehensive loss into Other (expense) income, net were related to realized gains and losses on sales of available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2023 and 2022, realized gains and losses on sales of marketable securities were not material.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RleHRyZWdpb246YzE3YjdmZGZkNjEwNDJiNjhiM2Q1OGVjZDdmYjhkMzZfMTI4NA_4942d177-dd00-458a-b89f-fa6d7a4f21a4">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company's investments in available-for-sale debt securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,819.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,592.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,902.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,903.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,280.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,051.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,975.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(291.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,684.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,945.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,939.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,320.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(302.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,018.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8903a1b5844542cfbc9e394aa701aed8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMi0yLTEtMS0yMjE1Njg_b998f3f9-8729-455c-b3ce-8a279cdbc31e"
      unitRef="usd">6819100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8903a1b5844542cfbc9e394aa701aed8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMi00LTEtMS0yMjE1Njg_74990bc7-5883-41f5-9bdd-66e82167008f"
      unitRef="usd">4800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8903a1b5844542cfbc9e394aa701aed8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMi02LTEtMS0yMjE1Njg_2ca19163-ba05-4733-b29e-075d872773b0"
      unitRef="usd">231700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8903a1b5844542cfbc9e394aa701aed8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMi04LTEtMS0yMjE1Njg_9aa2e0d0-71c6-481e-8314-96860cbbbd35"
      unitRef="usd">6592200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifdb936c554134642a68368b066e9f82a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMy0yLTEtMS0yMjE1Njg_14ba1c64-18ae-4376-a562-a3dceede6c78"
      unitRef="usd">2902200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifdb936c554134642a68368b066e9f82a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMy00LTEtMS0yMjE1Njg_a846bbc2-8bc2-407b-bbfd-0a7c19628e61"
      unitRef="usd">5500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifdb936c554134642a68368b066e9f82a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMy02LTEtMS0yMjE1Njg_db2ec1be-43ce-47b2-9a19-9d89d1b6838f"
      unitRef="usd">4300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifdb936c554134642a68368b066e9f82a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMy04LTEtMS0yMjE1Njg_55b2cc14-5645-4402-bdce-2c21c3557854"
      unitRef="usd">2903400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifdb70d5f062d4e928b605b2f2599a47d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNC0yLTEtMS0yMjE1Njg_5f3da1df-2928-4934-b709-0554ee8a2d0d"
      unitRef="usd">72600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifdb70d5f062d4e928b605b2f2599a47d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNC00LTEtMS0yMjE1Njg_78bded6c-e12c-427b-a3c6-34903822b4ea"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifdb70d5f062d4e928b605b2f2599a47d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNC02LTEtMS0yMjE1Njg_5cfe9b65-2145-4480-81f9-5a165f32c016"
      unitRef="usd">2300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifdb70d5f062d4e928b605b2f2599a47d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNC04LTEtMS0yMjE1Njg_731976b3-0841-46a9-8e73-8525f78fcf85"
      unitRef="usd">70400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie9bf0ce9cab24153b67d76ba77f2f319_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNS0yLTEtMS0yMjE1Njg_e584501d-e995-4a72-9090-e127028ce819"
      unitRef="usd">279100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie9bf0ce9cab24153b67d76ba77f2f319_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNS00LTEtMS0yMjE1Njg_ba8c364b-5009-42db-851f-9fcbcdab4b59"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie9bf0ce9cab24153b67d76ba77f2f319_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNS02LTEtMS0yMjE1Njg_44ddf870-5a9f-4219-ae4b-e96b063a2c17"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie9bf0ce9cab24153b67d76ba77f2f319_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNS04LTEtMS0yMjE1Njg_04162509-121f-4dcb-8202-3bb5ddb498d9"
      unitRef="usd">279100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i418c3363911e44aba24f1ae219890db8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNi0yLTEtMS0yMjE1Njg_d579b79d-50d8-4371-9a26-9027061a787b"
      unitRef="usd">153900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i418c3363911e44aba24f1ae219890db8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNi00LTEtMS0yMjE1Njg_4387965d-9216-43cf-b04b-34b8f1cf767d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i418c3363911e44aba24f1ae219890db8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNi02LTEtMS0yMjE1Njg_9600e0e1-e09f-428a-b211-6090271b2bf3"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i418c3363911e44aba24f1ae219890db8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNi04LTEtMS0yMjE1Njg_6e2bab55-633a-48f7-8222-13967e05879e"
      unitRef="usd">153700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iab279394f6cf43de9deae81fa065d878_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNy0yLTEtMS0yMjE1Njg_1636660b-8ee2-4d0e-ae5e-00bc2ea2f5fb"
      unitRef="usd">53900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iab279394f6cf43de9deae81fa065d878_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNy00LTEtMS0yMjE1Njg_70bc3b7c-a91b-4dfd-9946-f7d92214cafa"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iab279394f6cf43de9deae81fa065d878_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNy02LTEtMS0yMjE1Njg_04ae6f45-190d-42df-9c1d-82ff1eb5d5d1"
      unitRef="usd">1500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iab279394f6cf43de9deae81fa065d878_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfNy04LTEtMS0yMjE1Njg_5a70aaba-6bc2-4b2d-9373-ec516b53e16b"
      unitRef="usd">52500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfOC0yLTEtMS0yMjE1Njg_7e818f4c-69c1-4dda-bf98-223ed0d290ad"
      unitRef="usd">10280800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfOC00LTEtMS0yMjE1Njg_1751fb13-df6f-43ce-a86a-9da874eaa7f6"
      unitRef="usd">10600000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfOC02LTEtMS0yMjE1Njg_ed0bc025-2ae6-46ad-97f7-280ca5f48492"
      unitRef="usd">240100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfOC04LTEtMS0yMjE1Njg_6b1ba3c3-ceff-4ae1-9de6-b72cd5fbda96"
      unitRef="usd">10051300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idf94038a80c74b0d9edbcbeccb24dde9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTEtMi0xLTEtMjIxNTY4_8882fbb2-0cfc-4f07-9e11-724bd3c06de5"
      unitRef="usd">6975500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idf94038a80c74b0d9edbcbeccb24dde9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTEtNC0xLTEtMjIxNTY4_7598b910-e5ba-416d-ad0c-656d240960ff"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idf94038a80c74b0d9edbcbeccb24dde9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTEtNi0xLTEtMjIxNTY4_b824d8ee-a585-4583-8975-d67a034225fe"
      unitRef="usd">291100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idf94038a80c74b0d9edbcbeccb24dde9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTEtOC0xLTEtMjIxNTY4_7d2b4526-f541-450f-af1a-86030f2f77d7"
      unitRef="usd">6684400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if8a4bb9880684a74adbfbf4815ad715c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTItMi0xLTEtMjIxNTY4_7811fd27-0580-43ef-aaea-382747e77894"
      unitRef="usd">2945400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if8a4bb9880684a74adbfbf4815ad715c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTItNC0xLTEtMjIxNTY4_0de1ba83-24d0-457a-adc3-016d25cfd3c0"
      unitRef="usd">900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if8a4bb9880684a74adbfbf4815ad715c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTItNi0xLTEtMjIxNTY4_1cde2c36-c5f9-44e7-8a77-86a091e7b467"
      unitRef="usd">6900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if8a4bb9880684a74adbfbf4815ad715c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTItOC0xLTEtMjIxNTY4_3b6ca285-9a54-4557-9180-30f59943c87f"
      unitRef="usd">2939400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5a32793eceeb4ea687e38aa30fc6de37_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTMtMi0xLTEtMjIxNTY4_53ae7634-291c-4ff8-ab5f-a78915f4a845"
      unitRef="usd">67100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5a32793eceeb4ea687e38aa30fc6de37_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTMtNC0xLTEtMjIxNTY4_3cce665c-bc7e-4b05-a430-097a2bb913df"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5a32793eceeb4ea687e38aa30fc6de37_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTMtNi0xLTEtMjIxNTY4_17a8ec7f-aea2-4071-97f3-3eb797a21002"
      unitRef="usd">3000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5a32793eceeb4ea687e38aa30fc6de37_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTMtOC0xLTEtMjIxNTY4_df1976f8-698f-4fe0-966d-7987db735d31"
      unitRef="usd">64100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i31e5c62bbe8047b78e6c3041593ef2fe_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTQtMi0xLTEtMjIxNTY4_d1b0d336-bc35-47c9-9705-872ac58cd3c8"
      unitRef="usd">121100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i31e5c62bbe8047b78e6c3041593ef2fe_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTQtNC0xLTEtMjIxNTY4_d2ba7a50-224c-4b80-ba8c-5886e55c64db"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i31e5c62bbe8047b78e6c3041593ef2fe_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTQtNi0xLTEtMjIxNTY4_6cde1173-89a4-4ef6-839d-073728ec7a2d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i31e5c62bbe8047b78e6c3041593ef2fe_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTQtOC0xLTEtMjIxNTY4_ec9a2dd7-9e76-4a73-b81d-6e62fa1bb219"
      unitRef="usd">121100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1d7998c008a645b497664f16dfdf9c3e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTUtMi0xLTEtMjIxNTY4_3b9dc8b2-2a2d-476c-ac61-04005321dd08"
      unitRef="usd">182100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1d7998c008a645b497664f16dfdf9c3e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTUtNC0xLTEtMjIxNTY4_511ee6e7-2a08-40ad-910b-9362f6449766"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1d7998c008a645b497664f16dfdf9c3e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTUtNi0xLTEtMjIxNTY4_361b0c42-1778-4fb4-af40-90c814119f01"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1d7998c008a645b497664f16dfdf9c3e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTUtOC0xLTEtMjIxNTY4_5643898e-f966-424d-83e7-2113506a6167"
      unitRef="usd">182000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i076e28d6501548bba1781c8d95c229c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTYtMi0xLTEtMjIxNTY4_38594c31-d232-4549-839b-55956d6d2752"
      unitRef="usd">28900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i076e28d6501548bba1781c8d95c229c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTYtNC0xLTEtMjIxNTY4_4210fcbd-8af2-4a58-84d7-26b03dbce2a1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i076e28d6501548bba1781c8d95c229c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTYtNi0xLTEtMjIxNTY4_e672f188-bae1-4dfc-a9a4-559a52b24861"
      unitRef="usd">1700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i076e28d6501548bba1781c8d95c229c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTYtOC0xLTEtMjIxNTY4_db93bc6a-e075-4fe9-b054-0da07ba76b4b"
      unitRef="usd">27200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTctMi0xLTEtMjIxNTY4_c4a0fd19-5d7a-43f8-9bd3-29b730443547"
      unitRef="usd">10320100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTctNC0xLTEtMjIxNTY4_2fdad84c-8518-4cd9-8384-28dcb84c3175"
      unitRef="usd">900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTctNi0xLTEtMjIxNTY4_1847e3f1-183e-4786-8b0a-e17d734cb070"
      unitRef="usd">302800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjFiNzQzOWQ2ZWMxZDQ2NWZiYTQ0OGQ0Y2JjNjFiMzZiL3RhYmxlcmFuZ2U6MWI3NDM5ZDZlYzFkNDY1ZmJhNDQ4ZDRjYmM2MWIzNmJfMTctOC0xLTEtMjIxNTY4_16200ac0-ad13-4e96-8a1d-5dd062fd4ff5"
      unitRef="usd">10018200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RleHRyZWdpb246YzE3YjdmZGZkNjEwNDJiNjhiM2Q1OGVjZDdmYjhkMzZfMTI3MQ_54d498e8-3891-4f25-ba09-265f87994ec0">The fair values of available-for-sale debt securities by contractual maturity consist of the following:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.473%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturities within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,043.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,636.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturities after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,996.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,381.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturities after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,051.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,018.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjU2YTVjNmVhNjBkNzRhNGJiOGQ0ZWY5Mjk5NmQ4YjhjL3RhYmxlcmFuZ2U6NTZhNWM2ZWE2MGQ3NGE0YmI4ZDRlZjkyOTk2ZDhiOGNfMi0yLTEtMS0yMjE1Njg_e7a37f73-3b3a-4fa6-9427-629fd647deed"
      unitRef="usd">5043400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjU2YTVjNmVhNjBkNzRhNGJiOGQ0ZWY5Mjk5NmQ4YjhjL3RhYmxlcmFuZ2U6NTZhNWM2ZWE2MGQ3NGE0YmI4ZDRlZjkyOTk2ZDhiOGNfMi00LTEtMS0yMjE1Njg_0dc21fbe-6092-49d0-9af2-f2b65440619d"
      unitRef="usd">4636400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjU2YTVjNmVhNjBkNzRhNGJiOGQ0ZWY5Mjk5NmQ4YjhjL3RhYmxlcmFuZ2U6NTZhNWM2ZWE2MGQ3NGE0YmI4ZDRlZjkyOTk2ZDhiOGNfMy0yLTEtMS0yMjE1Njg_28326190-b643-419b-88b0-fb3630c8d917"
      unitRef="usd">4996600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjU2YTVjNmVhNjBkNzRhNGJiOGQ0ZWY5Mjk5NmQ4YjhjL3RhYmxlcmFuZ2U6NTZhNWM2ZWE2MGQ3NGE0YmI4ZDRlZjkyOTk2ZDhiOGNfMy00LTEtMS0yMjE1Njg_a55437fb-7fe9-4a32-9f38-6b83eb21b0e9"
      unitRef="usd">5381400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <regn:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjU2YTVjNmVhNjBkNzRhNGJiOGQ0ZWY5Mjk5NmQ4YjhjL3RhYmxlcmFuZ2U6NTZhNWM2ZWE2MGQ3NGE0YmI4ZDRlZjkyOTk2ZDhiOGNfNC0yLTEtMS0yMjU2MDY_d68e720d-d795-4166-ab6c-ced4ace238fe"
      unitRef="usd">11300000</regn:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5>
    <regn:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjU2YTVjNmVhNjBkNzRhNGJiOGQ0ZWY5Mjk5NmQ4YjhjL3RhYmxlcmFuZ2U6NTZhNWM2ZWE2MGQ3NGE0YmI4ZDRlZjkyOTk2ZDhiOGNfNC00LTEtMS0yMjU2MDY_39234e90-bf05-44f4-9267-8c1a36c0942c"
      unitRef="usd">400000</regn:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjU2YTVjNmVhNjBkNzRhNGJiOGQ0ZWY5Mjk5NmQ4YjhjL3RhYmxlcmFuZ2U6NTZhNWM2ZWE2MGQ3NGE0YmI4ZDRlZjkyOTk2ZDhiOGNfNC0yLTEtMS0yMjE1Njg_3d14aaa3-09f9-42a7-9adf-b8cb0d37b080"
      unitRef="usd">10051300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjU2YTVjNmVhNjBkNzRhNGJiOGQ0ZWY5Mjk5NmQ4YjhjL3RhYmxlcmFuZ2U6NTZhNWM2ZWE2MGQ3NGE0YmI4ZDRlZjkyOTk2ZDhiOGNfNC00LTEtMS0yMjE1Njg_cbf63a22-075c-4063-a5fb-5a6dd89e6a11"
      unitRef="usd">10018200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RleHRyZWdpb246YzE3YjdmZGZkNjEwNDJiNjhiM2Q1OGVjZDdmYjhkMzZfMTI2MQ_e0f3e3ff-43d1-447e-80a7-3e8b1f01b1ec">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the fair value of the Company's available-for-sale debt securities&#160;that have unrealized losses, aggregated by investment category and length of time that the individual securities have been in a continuous loss position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;707.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,293.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,000.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,222.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,464.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,687.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,445.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,200.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,645.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(291.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,300.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,332.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,633.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(302.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i8903a1b5844542cfbc9e394aa701aed8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMi0xLTEtMS0yMjE1Njg_4f09dd90-25ce-424b-b91d-2474afeaf582"
      unitRef="usd">707100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i8903a1b5844542cfbc9e394aa701aed8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMi0zLTEtMS0yMjE1Njg_198c9dc0-24de-45d3-9c61-1bac85fa71ec"
      unitRef="usd">8100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i8903a1b5844542cfbc9e394aa701aed8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMi01LTEtMS0yMjE1Njg_f6d167cb-498f-445d-91e2-57012cf073fa"
      unitRef="usd">5293700000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i8903a1b5844542cfbc9e394aa701aed8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMi03LTEtMS0yMjE1Njg_36b72479-d5ea-45d8-9f2d-802123a01a5f"
      unitRef="usd">223600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i8903a1b5844542cfbc9e394aa701aed8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMi05LTEtMS0yMjE1Njg_ad44f3c7-a2d3-4b63-8eac-753a6e5e2686"
      unitRef="usd">6000800000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i8903a1b5844542cfbc9e394aa701aed8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMi0xMS0xLTEtMjIxNTY4_976b7dec-d32c-45e9-b1e1-66b99704decf"
      unitRef="usd">231700000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ifdb936c554134642a68368b066e9f82a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMy0xLTEtMS0yMjE1Njg_46fec0d5-626f-432c-b1a1-09b8bbfccc98"
      unitRef="usd">228100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ifdb936c554134642a68368b066e9f82a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMy0zLTEtMS0yMjE1Njg_20488778-efed-47b9-8ddc-850f29d39649"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ifdb936c554134642a68368b066e9f82a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMy01LTEtMS0yMjE1Njg_25bdee4e-0bf0-4403-993e-57fe04f60b81"
      unitRef="usd">79200000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ifdb936c554134642a68368b066e9f82a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMy03LTEtMS0yMjE1Njg_21b86220-14da-417b-be09-88c99e8546b1"
      unitRef="usd">4200000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ifdb936c554134642a68368b066e9f82a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMy05LTEtMS0yMjE1Njg_191808e4-2ecc-4837-8bb5-7bcca80a9574"
      unitRef="usd">307300000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ifdb936c554134642a68368b066e9f82a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMy0xMS0xLTEtMjIxNTY4_5981b94c-1f61-4f51-a5d1-52ab246f9e47"
      unitRef="usd">4300000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ifdb70d5f062d4e928b605b2f2599a47d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNC0xLTEtMS0yMjE1Njg_10fc6ec1-28e4-48f6-9137-e449c1f2a1f3"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ifdb70d5f062d4e928b605b2f2599a47d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNC0zLTEtMS0yMjE1Njg_3d74254d-4604-46a0-a605-442bc1d509bc"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ifdb70d5f062d4e928b605b2f2599a47d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNC01LTEtMS0yMjE1Njg_94e9291e-19b2-4db7-8d7a-13bfb1347703"
      unitRef="usd">64000000.0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ifdb70d5f062d4e928b605b2f2599a47d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNC03LTEtMS0yMjE1Njg_76abb273-6ae9-4c11-8b52-b88b0b00bb81"
      unitRef="usd">2300000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ifdb70d5f062d4e928b605b2f2599a47d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNC05LTEtMS0yMjE1Njg_2d4101b3-1e89-4314-8622-4892661e856d"
      unitRef="usd">64000000.0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ifdb70d5f062d4e928b605b2f2599a47d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNC0xMS0xLTEtMjIxNTY4_47717a9b-1976-42f6-9fc6-7e580aab0bcf"
      unitRef="usd">2300000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ie9bf0ce9cab24153b67d76ba77f2f319_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNS0xLTEtMS0yMjE1Njg_767e3a28-bd0c-4343-b85a-482c483a8e24"
      unitRef="usd">212600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ie9bf0ce9cab24153b67d76ba77f2f319_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNS0zLTEtMS0yMjE1Njg_7704be7b-b231-4193-b128-e911e68b9e13"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ie9bf0ce9cab24153b67d76ba77f2f319_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNS01LTEtMS0yMjE1Njg_8d93d9ff-5e15-4b45-a043-8a02742275a4"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ie9bf0ce9cab24153b67d76ba77f2f319_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNS03LTEtMS0yMjE1Njg_350bd0cb-4808-438e-aefc-1184ac606a71"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ie9bf0ce9cab24153b67d76ba77f2f319_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNS05LTEtMS0yMjE1Njg_e4206c7a-9c53-471b-abf6-b791bc37069b"
      unitRef="usd">212600000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ie9bf0ce9cab24153b67d76ba77f2f319_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNS0xMS0xLTEtMjIxNTY4_563ff237-595e-4c3c-9d81-1794b0552cd5"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i418c3363911e44aba24f1ae219890db8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNi0xLTEtMS0yMjE1Njg_d8036948-a1e1-4187-b8e1-ba3eb8b84ef3"
      unitRef="usd">74900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i418c3363911e44aba24f1ae219890db8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNi0zLTEtMS0yMjE1Njg_a63f242a-44fe-4a39-87d9-df489f09f843"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i418c3363911e44aba24f1ae219890db8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNi01LTEtMS0yMjE1Njg_5e8ff423-cc88-44b8-9972-911e1be08579"
      unitRef="usd">2900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i418c3363911e44aba24f1ae219890db8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNi03LTEtMS0yMjE1Njg_c3cdb74f-b6b8-44a9-a9f6-5ebcb85555ac"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i418c3363911e44aba24f1ae219890db8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNi05LTEtMS0yMjE1Njg_e45f0586-974a-4360-a6e1-d1c2be7dc631"
      unitRef="usd">77800000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i418c3363911e44aba24f1ae219890db8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNi0xMS0xLTEtMjIxNTY4_c940a884-b9b2-4d94-8b5b-575f01a9e349"
      unitRef="usd">200000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="iab279394f6cf43de9deae81fa065d878_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNy0xLTEtMS0yMjE1Njg_0fe0859c-7381-4313-a3ad-91cfa651cd6b"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="iab279394f6cf43de9deae81fa065d878_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNy0zLTEtMS0yMjE1Njg_6beec839-f9fe-4697-8c82-e71d3bd78184"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="iab279394f6cf43de9deae81fa065d878_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNy01LTEtMS0yMjE1Njg_43c351fd-cb0e-4676-84be-9fe0d9966cb4"
      unitRef="usd">24700000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="iab279394f6cf43de9deae81fa065d878_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNy03LTEtMS0yMjE1Njg_016b935a-873a-4853-8562-8795ecddfed9"
      unitRef="usd">1500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="iab279394f6cf43de9deae81fa065d878_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNy05LTEtMS0yMjE1Njg_c9a84038-ac4e-4e51-b6f0-18c7b6c3303c"
      unitRef="usd">24700000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="iab279394f6cf43de9deae81fa065d878_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfNy0xMS0xLTEtMjIxNTY4_81dd018d-856f-45e1-99c7-9a32a3ec2b44"
      unitRef="usd">1500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfOC0xLTEtMS0yMjE1Njg_c8370dce-df5b-4206-9182-58051c41d7c0"
      unitRef="usd">1222700000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfOC0zLTEtMS0yMjE1Njg_63b69e9d-2fb8-4139-9a8e-b771aeb8ea6f"
      unitRef="usd">8400000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfOC01LTEtMS0yMjE1Njg_0d4880d8-cea7-450e-aa75-0ee6b9d4c71b"
      unitRef="usd">5464500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfOC03LTEtMS0yMjE1Njg_07d493dd-fee6-45c8-9f02-02b2eeb8ed1a"
      unitRef="usd">231700000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfOC05LTEtMS0yMjE1Njg_675932f6-6615-4659-8760-3b2c9deea901"
      unitRef="usd">6687200000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfOC0xMS0xLTEtMjIxNTY4_8dd9de3e-8526-472a-a5c3-8301bd6c6d96"
      unitRef="usd">240100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="idf94038a80c74b0d9edbcbeccb24dde9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTEtMS0xLTEtMjIxNTY4_0cafb543-0241-46ec-be80-76f95c6b3aea"
      unitRef="usd">2445400000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="idf94038a80c74b0d9edbcbeccb24dde9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTEtMy0xLTEtMjIxNTY4_94933aef-da5a-48d7-83e9-d241dffd49a0"
      unitRef="usd">73100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="idf94038a80c74b0d9edbcbeccb24dde9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTEtNS0xLTEtMjIxNTY4_38b81f4d-ab4a-4683-b47d-f14106ae5f32"
      unitRef="usd">4200400000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="idf94038a80c74b0d9edbcbeccb24dde9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTEtNy0xLTEtMjIxNTY4_29816d6d-32d6-49d2-a8b6-d72ab41c9d82"
      unitRef="usd">218000000.0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="idf94038a80c74b0d9edbcbeccb24dde9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTEtOS0xLTEtMjIxNTY4_f0638f8e-5149-4b79-b21d-194528959707"
      unitRef="usd">6645800000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="idf94038a80c74b0d9edbcbeccb24dde9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTEtMTEtMS0xLTIyMTU2OA_f932d441-e410-4f08-9257-0d31950033d3"
      unitRef="usd">291100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="if8a4bb9880684a74adbfbf4815ad715c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTItMS0xLTEtMjIxNTY4_2d4a6d2b-c082-49fb-8699-9c4eda3c249b"
      unitRef="usd">785200000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="if8a4bb9880684a74adbfbf4815ad715c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTItMy0xLTEtMjIxNTY4_3b2c9607-066f-4280-8451-43d3c920055f"
      unitRef="usd">2000000.0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="if8a4bb9880684a74adbfbf4815ad715c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTItNS0xLTEtMjIxNTY4_2e7ee07b-8f27-4b63-a050-c4dcbb7a9597"
      unitRef="usd">71000000.0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="if8a4bb9880684a74adbfbf4815ad715c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTItNy0xLTEtMjIxNTY4_3bddf6a1-a754-491c-a561-0ddb2b691930"
      unitRef="usd">4900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="if8a4bb9880684a74adbfbf4815ad715c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTItOS0xLTEtMjIxNTY4_6dfc32fb-6527-4d81-b14c-7cdcca84fd55"
      unitRef="usd">856200000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="if8a4bb9880684a74adbfbf4815ad715c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTItMTEtMS0xLTIyMTU2OA_6836ede5-3527-4ab7-840b-4aa5ccee9671"
      unitRef="usd">6900000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i5a32793eceeb4ea687e38aa30fc6de37_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTMtMS0xLTEtMjIxNTY4_de2d2cff-7679-4244-abc8-28de93d0245f"
      unitRef="usd">18600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i5a32793eceeb4ea687e38aa30fc6de37_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTMtMy0xLTEtMjIxNTY4_dcef1af4-b5ee-42ca-9dfe-083092cc1503"
      unitRef="usd">1100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i5a32793eceeb4ea687e38aa30fc6de37_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTMtNS0xLTEtMjIxNTY4_3cea1529-5150-438c-819c-f7364e9d1d07"
      unitRef="usd">45600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i5a32793eceeb4ea687e38aa30fc6de37_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTMtNy0xLTEtMjIxNTY4_c8379f4e-ebe4-4b47-9c9d-670657a5ba08"
      unitRef="usd">1900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i5a32793eceeb4ea687e38aa30fc6de37_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTMtOS0xLTEtMjIxNTY4_cb5c5973-0aff-4895-ac2a-fc056f9043a0"
      unitRef="usd">64200000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i5a32793eceeb4ea687e38aa30fc6de37_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTMtMTEtMS0xLTIyMTU2OA_f2e953d7-0d33-4aed-a055-1f84d2762b7f"
      unitRef="usd">3000000.0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i1d7998c008a645b497664f16dfdf9c3e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTUtMS0xLTEtMjIxNTY4_299ab533-1706-4cbd-b36c-19f48c1731a1"
      unitRef="usd">40200000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i1d7998c008a645b497664f16dfdf9c3e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTUtMy0xLTEtMjIxNTY4_dad73754-1d98-443d-baba-4badd41f7896"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i1d7998c008a645b497664f16dfdf9c3e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTUtNS0xLTEtMjIxNTY4_578ba941-6ae5-4daf-9f28-779d4e048e78"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i1d7998c008a645b497664f16dfdf9c3e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTUtNy0xLTEtMjIxNTY4_bfa1faa7-cf01-46af-86d0-b93b55b84b74"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i1d7998c008a645b497664f16dfdf9c3e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTUtOS0xLTEtMjIxNTY4_d412b30f-b422-4859-8f21-fb055ff5a075"
      unitRef="usd">40200000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i1d7998c008a645b497664f16dfdf9c3e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTUtMTEtMS0xLTIyMTU2OA_6b54bf62-d01f-42ac-9660-291cc0157efe"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i076e28d6501548bba1781c8d95c229c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTYtMS0xLTEtMjIxNTY4_368560c6-87d3-4cbc-b388-c1c2353ef1f2"
      unitRef="usd">11500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i076e28d6501548bba1781c8d95c229c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTYtMy0xLTEtMjIxNTY4_2de5578f-4446-4899-8fb8-c4d06bd39423"
      unitRef="usd">600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i076e28d6501548bba1781c8d95c229c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTYtNS0xLTEtMjIxNTY4_5a8f30d4-30cd-4399-8bbd-70d26c9195b8"
      unitRef="usd">15200000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i076e28d6501548bba1781c8d95c229c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTYtNy0xLTEtMjIxNTY4_c3f5f2e5-9874-4391-9b69-720102e6b945"
      unitRef="usd">1100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i076e28d6501548bba1781c8d95c229c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTYtOS0xLTEtMjIxNTY4_1937588c-b71a-49a0-874a-fae20faf1c98"
      unitRef="usd">26700000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i076e28d6501548bba1781c8d95c229c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTYtMTEtMS0xLTIyMTU2OA_0926143e-5e64-4861-af13-d5ee28d24c20"
      unitRef="usd">1700000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTctMS0xLTEtMjIxNTY4_1fc4e3c4-31d3-46cb-b585-5ab26456b90e"
      unitRef="usd">3300900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTctMy0xLTEtMjIxNTY4_62111bf0-8b6d-457c-a97b-d702af61cb68"
      unitRef="usd">76900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTctNS0xLTEtMjIxNTY4_4e2c0767-9427-4463-b031-97e3e7516418"
      unitRef="usd">4332200000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTctNy0xLTEtMjIxNTY4_c34d2470-48ca-4b11-9b16-5e5f40bb3bc3"
      unitRef="usd">225900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTctOS0xLTEtMjIxNTY4_8cae2399-fdb3-4469-83fa-ef16f0106e1e"
      unitRef="usd">7633100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80My9mcmFnOmMxN2I3ZmRmZDYxMDQyYjY4YjNkNThlY2Q3ZmI4ZDM2L3RhYmxlOjBhMGFhZWEwNWExZTQ2NmU5MmRjYWE1Yjk0ZGFkYThlL3RhYmxlcmFuZ2U6MGEwYWFlYTA1YTFlNDY2ZTkyZGNhYTViOTRkYWRhOGVfMTctMTEtMS0xLTIyMTU2OA_154a3667-59f4-4ad3-ba1e-9718da4baab2"
      unitRef="usd">302800000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RleHRyZWdpb246OGI4M2VkYjU5NDVhNDJlOTgxNjY5YmQ3MDkzOWRiN2ZfMTU1Mw_5317ee1c-ffbd-4ca8-b8ba-096542acc374">Fair Value Measurements&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the Company's assets which are measured at fair value on a recurring basis. The following fair value hierarchy is used to classify assets, based on inputs to valuation techniques utilized to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Quoted prices in active markets for identical assets&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Significant other observable inputs, such as quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuations in which significant inputs used are observable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Significant other unobservable inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,422.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,268.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,592.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,592.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,903.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,903.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (unrestricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (restricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,038.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,028.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,532.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,329.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,662.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,574.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,684.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,684.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,939.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,939.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (unrestricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (restricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,185.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,185.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,891.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,298.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,592.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company held certain restricted equity securities as of March&#160;31, 2023 which are subject to transfer restrictions that expire at various dates through 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023 and 2022, we recorded $164.7 million and $211.2&#160;million of net unrealized losses, respectively, on equity securities in Other (expense) income, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the investments summarized in the table above, as of both March&#160;31, 2023 and December&#160;31, 2022, the Company had $48.3&#160;million in equity investments that do not have a readily determinable fair value. These investments are recorded within Other noncurrent assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our long-term debt, which was determined based on Level 2 inputs, was estimated to be $1.516&#160;billion and $1.443&#160;billion as of March&#160;31, 2023 and December&#160;31, 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RleHRyZWdpb246OGI4M2VkYjU5NDVhNDJlOTgxNjY5YmQ3MDkzOWRiN2ZfMTU2Mg_744e7f8f-22b8-4975-b739-f2092b768ff5">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the Company's assets which are measured at fair value on a recurring basis. The following fair value hierarchy is used to classify assets, based on inputs to valuation techniques utilized to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Quoted prices in active markets for identical assets&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Significant other observable inputs, such as quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuations in which significant inputs used are observable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Significant other unobservable inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,422.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,268.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,592.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,592.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,903.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,903.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (unrestricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (restricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,038.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,028.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,532.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,329.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,662.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,574.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,684.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,684.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,939.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,939.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (unrestricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (restricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,185.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,185.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,891.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,298.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,592.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i42bb7405dae2448892d28fe5254d753b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMy0xLTEtMS0yNDI2ODM_6300a0ae-ae4a-4ec2-9a82-e1cbf05df41d"
      unitRef="usd">1422700000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i69a16600ec214325aa04a3be1bcacc1a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMy0zLTEtMS0yNDI2ODM_a9434102-093a-4f73-9b90-7a200c577985"
      unitRef="usd">154100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iccd0b582761d43a79ac5b665419222c1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMy01LTEtMS0yNDI2ODM_70ee2acd-7cdd-44e9-8fa1-cd050c0e62a9"
      unitRef="usd">1268600000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0ed1181d127f48eeae6cc93827001b60_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMy0xLTEtMS0yMjE1Njg_2afa656f-96c1-4499-be52-e0395920653d"
      unitRef="usd">6592200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4d138ebcdd8d4f6f9da1861a1980e8fe_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMy0zLTEtMS0yMjE1Njg_907a29d0-7b28-4b74-aab8-cf24b64a9e93"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6a4637e5ee1a4615bd9757cfde09d5ed_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMy01LTEtMS0yMjE1Njg_dc016eca-adbd-441e-8cff-9a21acc5ee09"
      unitRef="usd">6592200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib78b4e7f93bf4cb2b480289b8085219d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfNC0xLTEtMS0yMjE1Njg_d9d7cfee-54be-4e54-829a-ec0365c60667"
      unitRef="usd">2903400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2861028cb0f04545abad3da8e9947ae3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfNC0zLTEtMS0yMjE1Njg_dfd14a29-ae3e-4ab7-83de-7de4cf933339"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3d31ef08646d47068b930b62221f25c5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfNC01LTEtMS0yMjE1Njg_d1d61ead-6711-4952-b123-7feea5a3679b"
      unitRef="usd">2903400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9bb4ac30d7174141bd68e0e5165503a4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfNS0xLTEtMS0yMjE1Njg_c1ec6deb-0474-4c10-9412-25f4f6753c94"
      unitRef="usd">70400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i27a37895006f481b99b894294d32f453_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfNS0zLTEtMS0yMjE1Njg_fe041058-83f1-429a-a9ca-0610055ce560"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i45e1a224580a4ab4a851ce1cd380e58b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfNS01LTEtMS0yMjE1Njg_54e93644-9090-413b-b053-1c140635d9d2"
      unitRef="usd">70400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic48dc13ed46549c38aa86d1646750b7e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfNi0xLTEtMS0yMjE1Njg_bae6c4b6-191e-45b3-a88b-f1ec3573e76b"
      unitRef="usd">279100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifc9d4a9ec68c46a2a1444ba0c21c58d1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfNi0zLTEtMS0yMjE1Njg_0caadf70-dcea-4070-841e-ce5677b7050b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia2532a7ae6c44f0183a1a72036a1dbd2_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfNi01LTEtMS0yMjE1Njg_450cf43f-a6ef-4662-803c-3c4e268ec7be"
      unitRef="usd">279100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie2c1cf62b52f4290802d97ca8e3f7314_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfNy0xLTEtMS0yMjE1Njg_f4e42a63-ea9e-4e5c-8a39-9229a1cf5d4b"
      unitRef="usd">153700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i07b68bd2a55e4e4e98087d12385f43b6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfNy0zLTEtMS0yMjE1Njg_68ce4da5-2232-452c-87b8-4369cf5a561e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i924a1104d72e45899f48ce68164557a6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfNy01LTEtMS0yMjE1Njg_8e6cc02c-840a-45be-b573-2c7795500080"
      unitRef="usd">153700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if6c8f015a8c6464c939619f06315efe8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfOC0xLTEtMS0yMjE1Njg_a20d7746-70f1-42e1-ac39-8e837669a572"
      unitRef="usd">52500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i319e916558384549ac07e82dc579d15f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfOC0zLTEtMS0yMjE1Njg_42cf0347-049e-41d9-8ce6-90fbb70595db"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i407aae8d570145af8c0266b54d98beec_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfOC01LTEtMS0yMjE1Njg_2003fa35-cbd1-4e46-ad26-4a8ac59f9020"
      unitRef="usd">52500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i50f8bc3a2ad94180966f9ebe0be125f0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfOS0xLTEtMS0yMjE1Njg_73483734-08d5-4aa1-9d00-0f789eee06a1"
      unitRef="usd">20700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="idb363b73e6244abcb656ed2ab62f8f78_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfOS0zLTEtMS0yMjE1Njg_3e574906-0726-4254-a1bd-245f1e16de92"
      unitRef="usd">20700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i923780b5c4714bd0b32f8a52e41383bd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfOS01LTEtMS0yMjE1Njg_84ed7f6f-fafa-4666-9f2f-88c3275dc03a"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0b2c64ec3f6040309efed4a34a2e340c_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTAtMS0xLTEtMjIxNTY4_bde2c5d2-73a1-43ca-9693-f2e7133a7189"
      unitRef="usd">1038000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6e1656e9d1074b078faaced1a79a540d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTAtMy0xLTEtMjIxNTY4_ee606183-ed26-42d7-ba2e-707785c92abd"
      unitRef="usd">1028300000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i96714fa1a4ef4fbea15e01d83966c0d7_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTAtNS0xLTEtMjIxNTY4_e6ecb1c6-c869-4660-97fe-1dc2785302bc"
      unitRef="usd">9700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i42bb7405dae2448892d28fe5254d753b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTMtMS0xLTEtMjQxNzkz_3a58a5ec-2b23-4c1b-a1f5-002c3e515e1e"
      unitRef="usd">12532700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i69a16600ec214325aa04a3be1bcacc1a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTMtMy0xLTEtMjQxNzkz_ccf9ea07-e8f5-4b88-9a0a-d7ff0149e6ad"
      unitRef="usd">1203100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iccd0b582761d43a79ac5b665419222c1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTMtNS0xLTEtMjQxNzkz_6afabb6c-25ab-43bd-81f2-7f508f34598d"
      unitRef="usd">11329600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icd6e5891198641dc82ba047fab579cec_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjAtMS0xLTEtMjQyNjg1_95382e7a-f66d-47db-873d-1b3d554a05b5"
      unitRef="usd">1662800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i906a5a8877744181bffbf220eeea0a73_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjAtMy0xLTEtMjQyNjg1_a2057f0e-a0f6-46d8-8d61-5285d16d3db8"
      unitRef="usd">88300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iaba3655e9756414b9e6fd04ad3ee2f24_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjAtNS0xLTEtMjQyNjg1_00638480-83ab-4d7d-9550-16e57c69f0c5"
      unitRef="usd">1574500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i25b7eaabac2f458b96618bac777bd2ca_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTUtMS0xLTEtMjIxNTY4_8f412dfa-8ab4-420c-9584-eab2aa41fd11"
      unitRef="usd">6684400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic0fce717fc9443019cee095389f2baf5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTUtMy0xLTEtMjIxNTY4_ab72dffb-5d7d-49ee-b4df-17ceb30e33f2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5c5fb90e07b84a9a87b35eaaf73fad05_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTUtNS0xLTEtMjIxNTY4_d0f44e14-0e61-4ffd-986a-e8815a3d2827"
      unitRef="usd">6684400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icc7e444572ae46a385283f8406b98c84_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTYtMS0xLTEtMjIxNTY4_9d94e348-aee9-439c-b7f9-9b618c14ce5e"
      unitRef="usd">2939400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0392b26a3fbc4c43a64deca654005f83_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTYtMy0xLTEtMjIxNTY4_1812874a-9f93-4b89-9b61-8f63d816f5a6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1a3f2f6efec84786af7fd186d6c5c4c9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTYtNS0xLTEtMjIxNTY4_45932b31-e240-46fa-9c81-3693437830ba"
      unitRef="usd">2939400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if32b8d821f0642acafbc9612834c9293_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTctMS0xLTEtMjIxNTY4_2a6c8634-2148-4211-895f-5806d14069db"
      unitRef="usd">64100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2b5bb5d7a78a4a57b46ccf314f728939_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTctMy0xLTEtMjIxNTY4_7afe3665-1d7a-4031-a524-ed5c47093c64"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1b9fc3319f5841518dd67e46c582c888_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTctNS0xLTEtMjIxNTY4_1ffbf06c-ab22-4b9a-88a9-98f1d321ac1d"
      unitRef="usd">64100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icdc9ce269439490ab1af63a29b885fa0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTgtMS0xLTEtMjIxNTY4_9eb51f9a-66bc-4a5a-87d3-e2c2191cc041"
      unitRef="usd">121100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia11171f0e5db4eed91923c0534566b26_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTgtMy0xLTEtMjIxNTY4_a129b632-8ff6-4341-be5a-d0379c247b4b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5d989b03e30442ce8a9b3481c7124765_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTgtNS0xLTEtMjIxNTY4_76cc9ad5-03aa-4289-99f0-e8caf039465b"
      unitRef="usd">121100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2536f989b03944a4b9a0d7e8f56ea080_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTktMS0xLTEtMjIxNTY4_bfce9630-545f-4910-b2d5-e964667e8cf8"
      unitRef="usd">182000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i85985f6f1c3c4f01b858acc29e09e5ca_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTktMy0xLTEtMjIxNTY4_919a5acc-9b3d-4bcc-9fa5-4581cd79031e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1da2e40825b44fd59ead3dde06e37600_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMTktNS0xLTEtMjIxNTY4_c76c200c-c54a-4d7c-8b26-3b04f871af91"
      unitRef="usd">182000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i442be721ac15405da1349485e18c28ac_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjAtMS0xLTEtMjIxNTY4_5e6a4cb4-f3b7-49ca-992e-a85baf1daecc"
      unitRef="usd">27200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia2bcc6312921492999cec875c39d9b73_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjAtMy0xLTEtMjIxNTY4_55164cae-2be4-4304-98cc-9ee6d8acb06f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2c67c7b931244e59af10a080716aafec_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjAtNS0xLTEtMjIxNTY4_099b385e-def5-4970-9f46-6d23360b25c5"
      unitRef="usd">27200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7f2bd6363aa141e7a2a47119609b54b9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjEtMS0xLTEtMjIxNTY4_47321a5f-ed9a-4864-a790-a1b1e3ee49de"
      unitRef="usd">24600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4849fbe85bf94052b4be3ec967ec493f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjEtMy0xLTEtMjIxNTY4_9141bc03-3b40-4b7b-a689-53f118c524a6"
      unitRef="usd">24600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib961b996c000420b839a622c158db724_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjEtNS0xLTEtMjIxNTY4_0751b667-0358-4ace-88da-ce97627991ba"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8a829313946c4d029d2545a0b99636f6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjItMS0xLTEtMjIxNTY4_b284411f-e7e9-43a0-aaec-f0eb1dff9b21"
      unitRef="usd">1185400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i57cc71aadf054c0aa6efa5f790dfbd1e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjItMy0xLTEtMjIxNTY4_c0f0a0ec-b9ba-46ff-a2ae-71b5772c475a"
      unitRef="usd">1185400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i551685f126c4400481a7132a780426b0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjItNS0xLTEtMjIxNTY4_95643b76-300d-4234-8b3f-5a17b13fcb13"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icd6e5891198641dc82ba047fab579cec_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjMtMS0xLTEtMjIxNTY4_eabf07bf-3c4a-4b46-b874-e3a1ed9301fb"
      unitRef="usd">12891000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i906a5a8877744181bffbf220eeea0a73_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjMtMy0xLTEtMjIxNTY4_922ab22e-a67c-4851-97a7-f4fc9d8c6f48"
      unitRef="usd">1298300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaba3655e9756414b9e6fd04ad3ee2f24_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RhYmxlOjdhN2ZmZWQ1ZjQ1NTQ4ODZhMjczZWUyMDg0MDU1ZGY2L3RhYmxlcmFuZ2U6N2E3ZmZlZDVmNDU1NDg4NmEyNzNlZTIwODQwNTVkZjZfMjMtNS0xLTEtMjIxNTY4_c0564e1d-8f43-431f-bd79-c362695c2236"
      unitRef="usd">11592700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RleHRyZWdpb246OGI4M2VkYjU5NDVhNDJlOTgxNjY5YmQ3MDkzOWRiN2ZfODY1_b8a74b7f-bec5-438d-86a1-0a4c2f8520e8"
      unitRef="usd">-164700000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RleHRyZWdpb246OGI4M2VkYjU5NDVhNDJlOTgxNjY5YmQ3MDkzOWRiN2ZfNDM5ODA0NjUxMjg5OQ_17aa9871-7966-4ec1-bbbe-f053da74356a"
      unitRef="usd">-211200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RleHRyZWdpb246OGI4M2VkYjU5NDVhNDJlOTgxNjY5YmQ3MDkzOWRiN2ZfMTIyNg_49373a58-b1e2-4f63-b322-42b2b9ce015c"
      unitRef="usd">48300000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RleHRyZWdpb246OGI4M2VkYjU5NDVhNDJlOTgxNjY5YmQ3MDkzOWRiN2ZfMTIyNg_9906d7c6-413c-41dd-ac87-ed3e4ab7327c"
      unitRef="usd">48300000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:LongTermDebtFairValue
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RleHRyZWdpb246OGI4M2VkYjU5NDVhNDJlOTgxNjY5YmQ3MDkzOWRiN2ZfNDM5ODA0NjUxNDg2Ng_386c0eb6-787f-4773-9ede-a79a4377b564"
      unitRef="usd">1516000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80Ni9mcmFnOjhiODNlZGI1OTQ1YTQyZTk4MTY2OWJkNzA5MzlkYjdmL3RleHRyZWdpb246OGI4M2VkYjU5NDVhNDJlOTgxNjY5YmQ3MDkzOWRiN2ZfNDM5ODA0NjUxNDkxOA_74c3cdf0-7a48-4749-80aa-85d604dd9196"
      unitRef="usd">1443000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RleHRyZWdpb246MmU5MTlmZjFiMDFmNDhkY2IzMzk2ZjA3OGU3NzFlOGFfNTEx_95edc051-5188-4106-8fa2-5a4344bda172">Inventories&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.555%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;844.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;818.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;963.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,424.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,401.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory balances in the table above are net of reserves of $752.3 million and $720.7 million as of March&#160;31, 2023 and December&#160;31, 2022, respectively. Deferred costs represent the costs of product manufactured and shipped to the Company's collaborators for which recognition of revenue has been deferred.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RleHRyZWdpb246MmU5MTlmZjFiMDFmNDhkY2IzMzk2ZjA3OGU3NzFlOGFfNTE0_69b81c5b-ff57-4ad1-8e70-fcc85ca17ed8">&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.555%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;844.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;818.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;963.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,424.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,401.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RhYmxlOmU4ODI0OTIxNzhhNDQ1NjhiZDY0MDQ1OGNjZWY2ZDAxL3RhYmxlcmFuZ2U6ZTg4MjQ5MjE3OGE0NDU2OGJkNjQwNDU4Y2NlZjZkMDFfMi0xLTEtMS0yMjE1Njg_db13622d-c8ca-44d9-9b2b-e646b280b6e3"
      unitRef="usd">844600000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RhYmxlOmU4ODI0OTIxNzhhNDQ1NjhiZDY0MDQ1OGNjZWY2ZDAxL3RhYmxlcmFuZ2U6ZTg4MjQ5MjE3OGE0NDU2OGJkNjQwNDU4Y2NlZjZkMDFfMi0zLTEtMS0yMjE1Njg_9354569a-f3e7-4656-8208-d4ccbb4ff520"
      unitRef="usd">818400000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RhYmxlOmU4ODI0OTIxNzhhNDQ1NjhiZDY0MDQ1OGNjZWY2ZDAxL3RhYmxlcmFuZ2U6ZTg4MjQ5MjE3OGE0NDU2OGJkNjQwNDU4Y2NlZjZkMDFfMy0xLTEtMS0yMjE1Njg_11b5b113-5ecd-43c6-915a-82ac656990df"
      unitRef="usd">855700000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RhYmxlOmU4ODI0OTIxNzhhNDQ1NjhiZDY0MDQ1OGNjZWY2ZDAxL3RhYmxlcmFuZ2U6ZTg4MjQ5MjE3OGE0NDU2OGJkNjQwNDU4Y2NlZjZkMDFfMy0zLTEtMS0yMjE1Njg_d520b9ca-6119-4159-8b9b-2a176944ee50"
      unitRef="usd">963100000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RhYmxlOmU4ODI0OTIxNzhhNDQ1NjhiZDY0MDQ1OGNjZWY2ZDAxL3RhYmxlcmFuZ2U6ZTg4MjQ5MjE3OGE0NDU2OGJkNjQwNDU4Y2NlZjZkMDFfNC0xLTEtMS0yMjE1Njg_de4efdd2-e301-4241-b1f9-765709cecd2e"
      unitRef="usd">169300000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RhYmxlOmU4ODI0OTIxNzhhNDQ1NjhiZDY0MDQ1OGNjZWY2ZDAxL3RhYmxlcmFuZ2U6ZTg4MjQ5MjE3OGE0NDU2OGJkNjQwNDU4Y2NlZjZkMDFfNC0zLTEtMS0yMjE1Njg_de92b731-0d6b-4f1e-b647-bebbfdcadb55"
      unitRef="usd">98600000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:OtherInventoryNetOfReserves
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RhYmxlOmU4ODI0OTIxNzhhNDQ1NjhiZDY0MDQ1OGNjZWY2ZDAxL3RhYmxlcmFuZ2U6ZTg4MjQ5MjE3OGE0NDU2OGJkNjQwNDU4Y2NlZjZkMDFfNS0xLTEtMS0yMjE1Njg_f9b42ebd-9114-43e9-be3d-f65553b428c9"
      unitRef="usd">555100000</us-gaap:OtherInventoryNetOfReserves>
    <us-gaap:OtherInventoryNetOfReserves
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RhYmxlOmU4ODI0OTIxNzhhNDQ1NjhiZDY0MDQ1OGNjZWY2ZDAxL3RhYmxlcmFuZ2U6ZTg4MjQ5MjE3OGE0NDU2OGJkNjQwNDU4Y2NlZjZkMDFfNS0zLTEtMS0yMjE1Njg_bddf06d4-83c9-4580-976c-b2de1b79e9db"
      unitRef="usd">521800000</us-gaap:OtherInventoryNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RhYmxlOmU4ODI0OTIxNzhhNDQ1NjhiZDY0MDQ1OGNjZWY2ZDAxL3RhYmxlcmFuZ2U6ZTg4MjQ5MjE3OGE0NDU2OGJkNjQwNDU4Y2NlZjZkMDFfNi0xLTEtMS0yMjE1Njg_99c0832b-f26b-4602-bee1-70cf5b78ce61"
      unitRef="usd">2424700000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RhYmxlOmU4ODI0OTIxNzhhNDQ1NjhiZDY0MDQ1OGNjZWY2ZDAxL3RhYmxlcmFuZ2U6ZTg4MjQ5MjE3OGE0NDU2OGJkNjQwNDU4Y2NlZjZkMDFfNi0zLTEtMS0yMjE1Njg_2e9b16d9-f63d-4e90-80b5-362a307305eb"
      unitRef="usd">2401900000</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RleHRyZWdpb246MmU5MTlmZjFiMDFmNDhkY2IzMzk2ZjA3OGU3NzFlOGFfMjE5OTAyMzI1Njk5NQ_c26b9809-92bb-40f5-80b2-05c354c34e78"
      unitRef="usd">752300000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="ia687c58bde834c42ab9a8d978528b6c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl80OS9mcmFnOjJlOTE5ZmYxYjAxZjQ4ZGNiMzM5NmYwNzhlNzcxZThhL3RleHRyZWdpb246MmU5MTlmZjFiMDFmNDhkY2IzMzk2ZjA3OGU3NzFlOGFfMjE5OTAyMzI1NzAwNg_5a5c478e-e8b8-4d24-a9ea-65f3622dd4a6"
      unitRef="usd">720700000</us-gaap:InventoryValuationReserves>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82MS9mcmFnOmI4ZWRmNGZlN2ZhNTQxZWZiMGFlNTFjMDk1N2Y0NmRmL3RleHRyZWdpb246YjhlZGY0ZmU3ZmE1NDFlZmIwYWU1MWMwOTU3ZjQ2ZGZfMTIxMA_57a4af48-57a8-4d99-88de-031fe0c2bca0">Income Taxes&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to U.S. federal, state, and foreign income taxes. The Company's effective tax rate was 4.7% and 8.3% for the three months ended March&#160;31, 2023 and 2022, respectively. The Company's effective tax rate for the three months ended March&#160;31, 2023 was positively impacted, compared to the U.S. federal statutory rate, primarily by stock-based compensation and income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, the Inflation Reduction Act of 2022 ("IRA") was signed into law in the United States. The IRA created a new corporate alternative minimum tax of 15% on adjusted financial statement income and an excise tax of 1% of the value of certain stock repurchases. The provisions of the IRA became effective for periods beginning after December&#160;31, 2022.&#160;The IRA had no impact on the Company's financial statements for the three months ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's effective tax rate for the three months ended March&#160;31, 2022 was positively impacted, compared to the U.S. federal statutory rate, primarily by income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate and stock-based compensation.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82MS9mcmFnOmI4ZWRmNGZlN2ZhNTQxZWZiMGFlNTFjMDk1N2Y0NmRmL3RleHRyZWdpb246YjhlZGY0ZmU3ZmE1NDFlZmIwYWU1MWMwOTU3ZjQ2ZGZfMTk3_6b1f7e5b-93cc-4a33-abcf-e92ad468baee"
      unitRef="number">0.047</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82MS9mcmFnOmI4ZWRmNGZlN2ZhNTQxZWZiMGFlNTFjMDk1N2Y0NmRmL3RleHRyZWdpb246YjhlZGY0ZmU3ZmE1NDFlZmIwYWU1MWMwOTU3ZjQ2ZGZfMjA0_a4332ddf-28b7-407d-bc89-8f4c0e52ced7"
      unitRef="number">0.083</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82NC9mcmFnOjYzYjNmYWU2MmE2NjQzMDRiOGI0OTRkMzRmOTc0MTViL3RleHRyZWdpb246NjNiM2ZhZTYyYTY2NDMwNGI4YjQ5NGQzNGY5NzQxNWJfMTU5Ng_429d2079-16bd-45da-b607-9c9a88b3b60f">Stockholders' Equity&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Repurchase Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, our board of directors authorized a share repurchase program to repurchase up to $3.0 billion of our Common Stock. The share repurchase program permits the Company to make repurchases through a variety of methods, including open-market transactions (including pursuant to a trading plan adopted in accordance with Rule 10b5-1 of the Exchange Act), privately negotiated transactions, accelerated share repurchases, block trades, and other transactions in compliance with Rule 10b-18 of the Exchange Act. Repurchases may be made from time to time at management&#x2019;s discretion, and the timing and amount of any such repurchases will be determined based on share price, market conditions, legal requirements, and other relevant factors. The program has no time limit and can be discontinued at any time. There can be no assurance as to the timing or number of shares of any repurchases in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, our board of directors authorized an additional share repurchase program to repurchase up to $3.0&#160;billion of our Common Stock. The share repurchase program was approved under terms substantially similar to the share repurchase program described above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, an aggregate of $3.051 billion remained available for share repurchases under the Company's share repurchase programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the shares of our Common Stock we repurchased and the cost of the shares, which were recorded as Treasury Stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.432%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.076%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cost of shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i1c8af3a2f8cb4400af2f7e31cff2cfb3_I20211130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82NC9mcmFnOjYzYjNmYWU2MmE2NjQzMDRiOGI0OTRkMzRmOTc0MTViL3RleHRyZWdpb246NjNiM2ZhZTYyYTY2NDMwNGI4YjQ5NGQzNGY5NzQxNWJfMjE5OTAyMzI1ODUwNg_c7920216-af8a-49a2-99c0-6ab248484ae8"
      unitRef="usd">3000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i5e3a527460f44b9181602c95f95e6612_I20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82NC9mcmFnOjYzYjNmYWU2MmE2NjQzMDRiOGI0OTRkMzRmOTc0MTViL3RleHRyZWdpb246NjNiM2ZhZTYyYTY2NDMwNGI4YjQ5NGQzNGY5NzQxNWJfNTQ5NzU1ODE2MjA2_4a919bfc-200a-40c1-8717-87d653f0d497"
      unitRef="usd">3000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82NC9mcmFnOjYzYjNmYWU2MmE2NjQzMDRiOGI0OTRkMzRmOTc0MTViL3RleHRyZWdpb246NjNiM2ZhZTYyYTY2NDMwNGI4YjQ5NGQzNGY5NzQxNWJfNTQ5NzU1ODE2NzA2_0dc8448b-a325-426f-9481-86feab0db059"
      unitRef="usd">3051000000.000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:ScheduleOfTreasuryStockByClassTextBlock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82NC9mcmFnOjYzYjNmYWU2MmE2NjQzMDRiOGI0OTRkMzRmOTc0MTViL3RleHRyZWdpb246NjNiM2ZhZTYyYTY2NDMwNGI4YjQ5NGQzNGY5NzQxNWJfMTYwMg_bf8d50f4-acca-41e5-8b33-3351ef188762">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the shares of our Common Stock we repurchased and the cost of the shares, which were recorded as Treasury Stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.432%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.076%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cost of shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfTreasuryStockByClassTextBlock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82NC9mcmFnOjYzYjNmYWU2MmE2NjQzMDRiOGI0OTRkMzRmOTc0MTViL3RhYmxlOjhhZTUyNTA0MTVmYzRjM2I4ZTM1ZDFmMzdlOWQyM2EzL3RhYmxlcmFuZ2U6OGFlNTI1MDQxNWZjNGMzYjhlMzVkMWYzN2U5ZDIzYTNfMi01LTEtMS0yMjE1Njg_9d0110ee-c6be-475c-b6a3-8577f60b3bec"
      unitRef="shares">900000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82NC9mcmFnOjYzYjNmYWU2MmE2NjQzMDRiOGI0OTRkMzRmOTc0MTViL3RhYmxlOjhhZTUyNTA0MTVmYzRjM2I4ZTM1ZDFmMzdlOWQyM2EzL3RhYmxlcmFuZ2U6OGFlNTI1MDQxNWZjNGMzYjhlMzVkMWYzN2U5ZDIzYTNfMi03LTEtMS0yMjE1Njg_796ea0c9-864f-4e10-b4ab-88a45ba7491b"
      unitRef="shares">600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82NC9mcmFnOjYzYjNmYWU2MmE2NjQzMDRiOGI0OTRkMzRmOTc0MTViL3RhYmxlOjhhZTUyNTA0MTVmYzRjM2I4ZTM1ZDFmMzdlOWQyM2EzL3RhYmxlcmFuZ2U6OGFlNTI1MDQxNWZjNGMzYjhlMzVkMWYzN2U5ZDIzYTNfMy01LTEtMS0yMjE1Njg_fa1e076f-d0c6-4b33-aa0f-9e5b6fe74b2c"
      unitRef="usd">693900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82NC9mcmFnOjYzYjNmYWU2MmE2NjQzMDRiOGI0OTRkMzRmOTc0MTViL3RhYmxlOjhhZTUyNTA0MTVmYzRjM2I4ZTM1ZDFmMzdlOWQyM2EzL3RhYmxlcmFuZ2U6OGFlNTI1MDQxNWZjNGMzYjhlMzVkMWYzN2U5ZDIzYTNfMy03LTEtMS0yMjE1Njg_443a6232-b39e-40d0-9a59-a9f33090ad7f"
      unitRef="usd">352000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RleHRyZWdpb246MzE2OGU5ZjMxMDgxNDc4N2I2ZmYzZDc3MjNiZTUwYzdfNDYy_594dc7f5-1eef-406f-89b0-6401657c862b">Statement of Cash Flows&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheet to the total of the same such amounts shown in the Condensed Consolidated Statement of Cash Flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.210%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,916.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,345.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash included in Other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,928.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,359.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash consists of amounts held by financial institutions pursuant to contractual arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Supplemental disclosure of non-cash investing and financing activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.276%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued contingent consideration for Libtayo intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RleHRyZWdpb246MzE2OGU5ZjMxMDgxNDc4N2I2ZmYzZDc3MjNiZTUwYzdfNDU4_35569009-7b97-49e1-bb67-8ff56bace723">&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheet to the total of the same such amounts shown in the Condensed Consolidated Statement of Cash Flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.210%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,916.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,345.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash included in Other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,928.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,359.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RleHRyZWdpb246MzE2OGU5ZjMxMDgxNDc4N2I2ZmYzZDc3MjNiZTUwYzdfNDY3_de40c4fe-9717-409b-a989-527e0b3e04fa">&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheet to the total of the same such amounts shown in the Condensed Consolidated Statement of Cash Flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.210%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,916.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,345.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash included in Other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,928.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,359.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjc4OTQ4ZDEwNDQwNTRkYzdhMjQ4ZjlmYjYxNDhlYjZhL3RhYmxlcmFuZ2U6Nzg5NDhkMTA0NDA1NGRjN2EyNDhmOWZiNjE0OGViNmFfMi0yLTEtMS0yMjE1Njg_f176381c-39db-406a-9db1-d0521f8c4a9b"
      unitRef="usd">3916300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7298587e584844a686de7edf412eb7a2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjc4OTQ4ZDEwNDQwNTRkYzdhMjQ4ZjlmYjYxNDhlYjZhL3RhYmxlcmFuZ2U6Nzg5NDhkMTA0NDA1NGRjN2EyNDhmOWZiNjE0OGViNmFfMi00LTEtMS0yMjE1Njg_806c0754-ad35-4b17-9695-b65cf8bd0c36"
      unitRef="usd">3345700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjc4OTQ4ZDEwNDQwNTRkYzdhMjQ4ZjlmYjYxNDhlYjZhL3RhYmxlcmFuZ2U6Nzg5NDhkMTA0NDA1NGRjN2EyNDhmOWZiNjE0OGViNmFfMy0yLTEtMS0yMjE1Njg_7847a7bb-4e61-4176-b806-627e786a6320"
      unitRef="usd">12500000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i7298587e584844a686de7edf412eb7a2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjc4OTQ4ZDEwNDQwNTRkYzdhMjQ4ZjlmYjYxNDhlYjZhL3RhYmxlcmFuZ2U6Nzg5NDhkMTA0NDA1NGRjN2EyNDhmOWZiNjE0OGViNmFfMy00LTEtMS0yMjE1Njg_99256a3d-6d03-4871-8927-635b58cf9aa8"
      unitRef="usd">13500000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib18b866589c84ae4b4eb07c3c0320ecd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjc4OTQ4ZDEwNDQwNTRkYzdhMjQ4ZjlmYjYxNDhlYjZhL3RhYmxlcmFuZ2U6Nzg5NDhkMTA0NDA1NGRjN2EyNDhmOWZiNjE0OGViNmFfNC0yLTEtMS0yMjE1Njg_a2a204c1-f613-4c1f-96bd-c589c5c6d95c"
      unitRef="usd">3928800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7298587e584844a686de7edf412eb7a2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjc4OTQ4ZDEwNDQwNTRkYzdhMjQ4ZjlmYjYxNDhlYjZhL3RhYmxlcmFuZ2U6Nzg5NDhkMTA0NDA1NGRjN2EyNDhmOWZiNjE0OGViNmFfNC00LTEtMS0yMjE1Njg_e5fdd641-a6d7-44dc-a16a-a4ebc085a426"
      unitRef="usd">3359200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RleHRyZWdpb246MzE2OGU5ZjMxMDgxNDc4N2I2ZmYzZDc3MjNiZTUwYzdfNDU2_8a5c6acf-6305-4d4c-8c82-be83bef29664">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.276%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued contingent consideration for Libtayo intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjI1NTBjMDhmYjdlMjRmZDRhMGVlYjBlNWNjYTA2ZmNjL3RhYmxlcmFuZ2U6MjU1MGMwOGZiN2UyNGZkNGEwZWViMGU1Y2NhMDZmY2NfMi0xLTEtMS0yMjE1Njg_27694601-0e68-4320-9adc-3cf250f3888a"
      unitRef="usd">90300000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="iffc0c76d2e7c4dffaaaad5977285af04_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjI1NTBjMDhmYjdlMjRmZDRhMGVlYjBlNWNjYTA2ZmNjL3RhYmxlcmFuZ2U6MjU1MGMwOGZiN2UyNGZkNGEwZWViMGU1Y2NhMDZmY2NfMi0zLTEtMS0yMjE1Njg_c5ef1358-35c9-49b1-a642-89ec2ba45160"
      unitRef="usd">70800000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjI1NTBjMDhmYjdlMjRmZDRhMGVlYjBlNWNjYTA2ZmNjL3RhYmxlcmFuZ2U6MjU1MGMwOGZiN2UyNGZkNGEwZWViMGU1Y2NhMDZmY2NfMi01LTEtMS0yMjE1Njg_8603272a-d937-4909-b20d-6c04bf988361"
      unitRef="usd">80700000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i64798e076fa64db2b5de1538f7e77d5f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjI1NTBjMDhmYjdlMjRmZDRhMGVlYjBlNWNjYTA2ZmNjL3RhYmxlcmFuZ2U6MjU1MGMwOGZiN2UyNGZkNGEwZWViMGU1Y2NhMDZmY2NfMi03LTEtMS0yMjE1Njg_8c22ffdd-81df-4a94-a235-c2f2ab597c64"
      unitRef="usd">74800000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjI1NTBjMDhmYjdlMjRmZDRhMGVlYjBlNWNjYTA2ZmNjL3RhYmxlcmFuZ2U6MjU1MGMwOGZiN2UyNGZkNGEwZWViMGU1Y2NhMDZmY2NfMy0xLTEtMS0yMjE1Njg_2630ac4a-f598-445f-8999-4b1bbb42422b"
      unitRef="usd">55200000</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="iffc0c76d2e7c4dffaaaad5977285af04_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjI1NTBjMDhmYjdlMjRmZDRhMGVlYjBlNWNjYTA2ZmNjL3RhYmxlcmFuZ2U6MjU1MGMwOGZiN2UyNGZkNGEwZWViMGU1Y2NhMDZmY2NfMy0zLTEtMS0yMjE1Njg_78c1c7d4-6ca6-4533-acf1-c866b72caf0d"
      unitRef="usd">135500000</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="ic4c0422d40c54f0e92ba6370d8a1f70c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjI1NTBjMDhmYjdlMjRmZDRhMGVlYjBlNWNjYTA2ZmNjL3RhYmxlcmFuZ2U6MjU1MGMwOGZiN2UyNGZkNGEwZWViMGU1Y2NhMDZmY2NfMy01LTEtMS0yMjE1Njg_46da2239-a3b5-4a3e-a0a8-a7f8bf26c825"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="i64798e076fa64db2b5de1538f7e77d5f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl82Ny9mcmFnOjMxNjhlOWYzMTA4MTQ3ODdiNmZmM2Q3NzIzYmU1MGM3L3RhYmxlOjI1NTBjMDhmYjdlMjRmZDRhMGVlYjBlNWNjYTA2ZmNjL3RhYmxlcmFuZ2U6MjU1MGMwOGZiN2UyNGZkNGEwZWViMGU1Y2NhMDZmY2NfMy03LTEtMS0yMjE1Njg_f0037bd2-f238-4dcb-be85-2990fc2bd12b"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl83MC9mcmFnOmExYjBmZTBkM2E1NDQxNTk5MzY1ZDVhOGMwZTllYjhiL3RleHRyZWdpb246YTFiMGZlMGQzYTU0NDE1OTkzNjVkNWE4YzBlOWViOGJfMjU2Njg_37f440bd-d741-4442-b6eb-4edb8176c7bb">Legal Matters&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is a party to legal proceedings in the course of the Company's business. The outcome of any such proceedings, regardless of the merits, is inherently uncertain. If the Company were unable to prevail in any such proceedings, its consolidated financial position, results of operations, and future cash flows may be materially impacted. Costs associated with the Company's involvement in legal proceedings are expensed as incurred. The Company recognizes accruals for loss contingencies associated with such proceedings when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. As of March&#160;31, 2023 and December&#160;31, 2022, the Company's accruals for loss contingencies were not material. There are certain loss contingencies that the Company deems reasonably possible for which the possible loss or range of possible loss is not estimable at this time. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proceedings Relating to Praluent (alirocumab) Injection&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As described below, the Company is currently a party to patent infringement actions initiated by Amgen Inc. (and/or its affiliated entities) against the Company and/or Sanofi (and/or the Company's and Sanofi's respective affiliated entities) in a number of jurisdictions relating to Praluent. In addition, as described below, the Company filed a lawsuit against Amgen alleging that Amgen engaged in an anticompetitive bundling scheme which was designed to exclude Praluent from the market in violation of federal and state laws.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the United States, Amgen has asserted claims of U.S. Patent Nos. 8,829,165 (the "'165 Patent") and 8,859,741 (the "'741 Patent"), and sought a permanent injunction to prevent the Company and the Sanofi defendants from commercial manufacturing, using, offering to sell, or selling within the United States (as well as importing into the United States) (collectively, "Commercializing") Praluent. Amgen also seeks a judgment of patent infringement of the asserted patents, monetary damages (together with interest), costs and expenses of the lawsuits, and attorneys' fees. As previously reported, on February 11, 2021, the United States Court of Appeals for the Federal Circuit (the "Federal Circuit") affirmed the lower court's decision that certain of Amgen's asserted patent claims are invalid based on lack of enablement. On April 14, 2021, Amgen filed a petition for a rehearing en banc with the Federal Circuit, which was denied on June 21, 2021. On November 4, 2022, the United States Supreme Court granted Amgen's petition for writ of certiorari. An oral hearing was held on March 27, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 27, 2022, the Company filed a lawsuit against Amgen in the United States District Court for the District of Delaware, alleging that, beginning in 2020, Amgen engaged in an anticompetitive bundling scheme which was designed to exclude Praluent from the market in violation of federal and state laws. The lawsuit seeks damages for harm caused by the alleged scheme, as well as injunctive relief restraining Amgen from continuing its alleged anticompetitive conduct. On August 1, 2022, Amgen filed a motion to dismiss the complaint. On August 11, 2022, Amgen filed a motion to stay these proceedings pending resolution of the patent litigation described in the preceding paragraph. An oral hearing on Amgen's motion to dismiss and motion to stay was held on January 6, 2023. On February 10, 2023, the court denied Amgen's motion to stay; and on March 21, 2023, the court denied Amgen's motion to dismiss. A trial has been scheduled to begin in November 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amgen has asserted European Patent No. 2,215,124 (the "'124 Patent"), which pertains to PCSK9 monoclonal antibodies, in certain countries in Europe. In October 2020, the '124 Patent claims directed to compositions of matter and medical use relevant to Praluent were ruled invalid based on a lack of inventive step by the Technical Board of Appeal (the "TBA") of the European Patent Office (the "EPO"). Following the EPO's decision, each of the '124 Patent infringement proceedings initiated by Amgen against the Company and certain of Sanofi's affiliated entities in these countries was dismissed, including in Germany. The dismissal in Germany followed an earlier finding of infringement and granting of an injunction, both of which were subsequently overturned. As a result of the overturned injunction in Germany, the Company and/or certain of Sanofi's affiliated entities are seeking damages caused by Amgen's enforcement of the injunction. As part of its opposition to these damages claims, on March 23, 2022, Amgen filed a counterclaim that asserted the German designation of European Patent No. 2,641,917 (the "'917 Patent") and seeks, among other things, a judgment of patent infringement, injunctive relief, and monetary damages. The '917 Patent is a divisional patent of the '124 Patent discussed above (i.e., a patent that shares the same priority date, disclosure, and patent term of the parent '124 Patent but contains claims to a different invention). The '917 Patent is also subject to opposition proceedings in the EPO, which were initiated by Sanofi on May 5, 2021. An oral hearing before the EPO was held on February 21, 2023, at which the '917 Patent was revoked. Amgen filed a notice to appeal to the TBA of the EPO on February 27, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proceedings Relating to EYLEA (aflibercept) Injection&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company's patents pertaining to EYLEA are subject to post-grant proceedings before the United States Patent and Trademark Office ("USPTO"), EPO, or other comparable foreign authorities, including those described in greater detail below. In addition, the Company has filed patent infringement lawsuits in several jurisdictions alleging infringement of certain Company patents pertaining to EYLEA, including those described in greater detail below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 11, 2020, anonymous parties filed two requests for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ex parte&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; reexamination of the Company's U.S. Patent Nos. 10,406,226 (the "'226 Patent") and 10,464,992 (the "'992 Patent"), and the USPTO has granted both requests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 5, 2021, Mylan Pharmaceuticals Inc. filed &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;inter partes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; review ("IPR") petitions in the USPTO against the Company's U.S. Patent Nos. 9,254,338 (the "'338 Patent") and 9,669,069 (the "'069 Patent") seeking declarations of invalidity of the '338 Patent and the '069 Patent. On November 10, 2021, the USPTO issued a decision instituting both IPR proceedings. On December 9, 2021, Apotex Inc. and Celltrion, Inc. each filed two separate IPR petitions against the Company's '338 and '069 Patents requesting that their IPRs be instituted and joined with the IPR proceedings initiated by Mylan concerning the '338 and '069 Patents, which petitions were granted on February 9, 2022. An oral hearing was held on August 10, 2022. On November 9, 2022, the USPTO issued final written decisions finding that the claims of the '338 and '069 Patents are unpatentable and, therefore, invalid. On January 10, 2023, the Company filed notices of appeal of the USPTO written decisions concerning the '338 and '069 Patents with the Federal Circuit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, Mylan filed IPR petitions against the Company's U.S. Patent Nos. 10,130,681 (the "'681 Patent") and 10,888,601 (the "'601 Patent") (each filed July 1, 2022) and 10,857,205 (the "'205 Patent") (filed October 28, 2022) seeking declarations of invalidity of each of these patents. On January 11, 2023, the USPTO instituted IPR proceedings concerning the '681 Patent and the '601 Patent. On February 21, 2023, the Company filed a Notice of Disclaimer with the USPTO, disclaiming all claims of the '205 Patent; and, as a result, on March 1, 2023, the USPTO denied institution of Mylan's IPR petition against the '205 Patent. On January 6, 2023 and March 26, 2023, Samsung Bioepis Co., Ltd. filed separate IPR petitions against the Company's '681 Patent and '601 Patent, respectively, seeking declarations of invalidity of such patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 9, 2022, Apotex filed an IPR petition against the Company's U.S. Patent No. 11,253,572 (the "'572 Patent") seeking a declaration of invalidity of the '572 Patent. On March 10, 2023, the USPTO declined to institute an IPR proceeding concerning the '572 Patent. On April 27, 2023, Samsung Bioepis Co., Ltd. filed a separate IPR petition against the '572 Patent seeking a declaration of invalidity of the '572 Patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 17, 2023 and February 28, 2023, Celltrion filed IPR petitions against the '992 Patent and the '226 Patent, respectively, seeking declarations of invalidity of such patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 2, 2022, the Company filed a patent infringement lawsuit against Mylan in the United States District Court for the Northern District of West Virginia alleging that Mylan's filing for a U.S. Food and Drug Administration approval of an aflibercept biosimilar infringes certain Company patents. On April 20, 2023, Mylan filed a motion for summary judgment or partial summary judgment concerning four of the asserted patents. On April 26, 2023, the Company filed a stipulation accepting summary judgment of noninfringement of all asserted claims of the Company's U.S. Patent No. 11,104,715. A trial has been scheduled to begin on June 12, 2023 concerning certain claims of the '601 Patent, the '572 Patent, and the Company's U.S. Patent No. 11,084,865.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 26 and October 27, 2021, anonymous parties initiated opposition proceedings in the EPO against the Company's European Patent No. 2,944,306 (the "'306 Patent") seeking revocation of the '306 Patent in its entirety.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Canada&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 15, July 15, August 30, and October 4, 2022, the Company and Bayer Inc. filed patent infringement lawsuits against BGP Pharma ULC d.b.a Viatris Canada ("Viatris Canada") in the Federal Court of Canada seeking a declaration that the making, constructing, using, or selling of an aflibercept biosimilar would directly or indirectly infringe one or more claims of the Company's Canadian Patent Nos. 2,654,510 (the "'510 Patent) and 3,007,276 (the "'276 Patent") (in the lawsuit filed on June 15, 2022); the Company's Canadian Patent No. 2,965,495 (the "'495 Patent") (in the lawsuit filed on July 15, 2022); the Company's Canadian Patent No. 2,906,768 (the "'768 Patent") (in the lawsuit filed on August 30, 2022, which has been joined with the lawsuit filed on July 15, 2022); and the Company's Canadian Patent No. 3,129,193 (the "'193 Patent") (in the lawsuit filed on October 4, 2022). A trial for the lawsuit concerning the '510 Patent and the '276 Patent has been scheduled for March 2024; a trial for the lawsuit concerning the '193 Patent has been scheduled for May 2024; and a trial for the lawsuit concerning the '495 Patent and the '768 Patent has been scheduled for November/December 2024. The filing of the lawsuit concerning the '510 Patent and the '276 Patent resulted in a statutory 24-month stay of regulatory approval of Viatris Canada's aflibercept biosimilar in Canada unless the lawsuit is resolved earlier. On March 27, 2023, in light of the transfer of the New Drug Submission ("NDS") discussed below, the Company filed a motion in the Federal Court of Canada seeking termination of the Viatris Canada action relating to the '510 Patent and the '276 Patent in the Federal Court of Canada.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 23, 2023, following the transfer of Viatris Canada's NDS of its aflibercept biosimilar to Biosimilar Collaborations Ireland Limited ("BCIL"), the Company and Bayer Inc. filed a patent infringement lawsuit against BCIL in the Federal Court of Canada seeking a declaration that the making, constructing, using, or selling of an aflibercept biosimilar would directly or indirectly infringe one or more claims of the Company's '510 and '276 Patents. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;South Korea&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 31, 2022 and December 13, 2022, Samsung Bioepis Co., Ltd. initiated invalidation proceedings before the Intellectual Property Trial&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and Appeal Board of the Korean Intellectual Property Office against the Company's Korean Patent Nos. 1131429 and 1406811, respectively, seeking revocation of each of such patents in its entirety.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 16, 2023, the Company filed patent infringement lawsuits against Samsung Bioepis Co., Ltd. and its parent Samsung Biologics Co., Ltd. before the Seoul Central District Court seeking a declaration that the making, constructing, using, or selling of an aflibercept biosimilar would infringe one or more claims of Company's Korean Patent No. 659477 (the "'477 Patent").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 2, 2023, the Company filed an affirmative scope confirmation action against Samsung Bioepis Co., Ltd. before the Intellectual Property Tribunal and Appeal Board of the Korean Intellectual Property Office seeking a ruling that Samsung Bioepis's aflibercept biosimilar is covered by the claims of the '477 Patent. On March 7, 2023, the action was designated for expedited proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Proceedings Relating to EYLEA (aflibercept) Injection Pre-filled Syringe&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 19, 2020, Novartis Pharma AG, Novartis Pharmaceuticals Corporation, and Novartis Technology LLC (collectively, "Novartis") filed a patent infringement lawsuit (as amended on August 2, 2021) in the U.S. District Court for the Northern District of New York asserting claims of Novartis's U.S. Patent No. 9,220,631 (the "'631 Patent") and seeking preliminary and permanent injunctions to prevent the Company from continuing to infringe the '631 Patent. Novartis also seeks a judgment of patent infringement of the '631 Patent, monetary damages (together with interest), an order of willful infringement of the '631 Patent (which would allow the court in its discretion to award damages up to three times the amount assessed), costs and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;expenses of the lawsuits, and attorneys' fees. On November 7, 2022, the Company and Novartis entered into a stipulation staying the lawsuit in light of the decision in the IPR proceeding discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 16, 2020, the Company initiated two IPR petitions in the USPTO seeking a declaration of invalidity of the '631 Patent on two separate grounds. On October 26, 2021, the USPTO issued a decision instituting the IPR proceeding. An oral hearing was held on July 21, 2022. On October 25, 2022, the Patent Trial and Appeal Board ("PTAB") of the USPTO issued a final written decision invalidating all claims of the '631 Patent. On December 23, 2022, Novartis filed a notice of appeal of the PTAB's decision to the Federal Circuit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 17, 2020, the Company filed an antitrust lawsuit against Novartis and Vetter Pharma International Gmbh ("Vetter") in the United States District Court for the Southern District of New York seeking a declaration that the '631 Patent is unenforceable and a judgment that the defendants' conduct violates Sections 1 and 2 of the Sherman Antitrust Act of 1890, as amended (the "Sherman Antitrust Act"). The Company is also seeking injunctive relief and treble damages. On September 4, 2020, Novartis filed, and Vetter moved to join, a motion to dismiss the complaint, to transfer the lawsuit to the Northern District of New York, or to stay the suit; and on October 19, 2020, Novartis filed, and Vetter moved to join, a second motion to dismiss the complaint on different grounds. On January 25, 2021, the Company filed an amended complaint seeking a judgment that Novartis's conduct violates Section 2 of the Sherman Antitrust Act based on additional grounds, as well as a judgment of tortious interference with contract. On February 22, 2021, Novartis filed, and Vetter moved to join, a motion to dismiss the amended complaint. On September 21, 2021, the court granted Novartis and Vetter's motion to transfer this lawsuit to the Northern District of New York. As a result, this lawsuit was transferred to the same judge that had been assigned to the patent infringement lawsuit discussed above. On November 5, 2021, the Company filed a motion to stay these proceedings in light of the pending IPR proceeding discussed above. On January 31, 2022, the court denied the Company's motion to stay these proceedings and granted Novartis and Vetter's motion to dismiss the amended complaint. On June 10, 2022, the Company filed an appeal of the District Court's decision to dismiss the amended complaint with the U.S. Court of Appeals for the Second Circuit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proceedings Relating to REGEN-COV (casirivimab and imdevimab)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 5, 2020, Allele Biotechnology and Pharmaceuticals, Inc. ("Allele") filed a lawsuit (as amended on April 8, 2021 and December 12, 2022) against the Company in the United States District Court for the Southern District of New York, asserting infringement of U.S. Patent No. 10,221,221 (the "'221 Patent").&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allele seeks a judgment of patent infringement of the '221 Patent, an award of monetary damages (together with interest), an order of willful infringement of the '221 Patent (which would allow the court in its discretion to award damages up to three times the amount assessed), costs and expenses of the lawsuit, and attorneys' fees. On July 16, 2021, the Company filed a motion to dismiss the complaint, which motion was denied on March 2, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Department of Justice Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting documents relating to its support of 501(c)(3) organizations that provide financial assistance to patients; documents concerning its provision of financial assistance to patients with respect to products sold or developed by Regeneron (including EYLEA, Praluent, ARCALYST&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and ZALTRAP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;); and certain other related documents and communications. On June 24, 2020, the U.S. Attorney's Office for the District of Massachusetts filed a civil complaint in the U.S. District Court for the District of Massachusetts alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law. On August 24, 2020, the Company filed a motion to dismiss the complaint in its entirety. On December 4, 2020, the court denied the motion to dismiss. On December 28, 2022, the U.S. Attorney&#x2019;s Office for the District of Massachusetts filed a motion for partial summary judgment. On January 31, 2023, the Company filed a motion for summary judgment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company and Regeneron Healthcare Solutions, Inc., a wholly-owned subsidiary of the Company, each received a civil investigative demand ("CID") from the U.S. Department of Justice pursuant to the federal False Claims Act relating to remuneration paid to physicians in the form of consulting fees, advisory boards, speaker fees, and payment or reimbursement for travel and entertainment allegedly in violation of the federal Anti-Kickback Statute. The CIDs relate to EYLEA, Praluent, Dupixent, ZALTRAP, ARCALYST, and Kevzara and cover the period from January 2015 to the present. On June 3, 2021, the United States District Court for the Central District of California unsealed a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; complaint filed against the Company, Regeneron Healthcare Solutions, Inc., and Sanofi-Aventis U.S. LLC by two &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; plaintiffs (known as relators) purportedly on behalf of the United States and various states (the "State Plaintiffs"), asserting causes of action under the federal False Claims Act and state law. Also on June 3, 2021, the United States and the State Plaintiffs notified the court of their decision to decline to intervene in the case. On October 29, 2021, the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; plaintiffs filed an amended complaint in this matter. On January 14, 2022, the Company filed a motion to dismiss the amended complaint in its entirety.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Company received a CID from the U.S. Department of Justice pursuant to the federal False Claims Act. The CID states that the investigation concerns allegations that the Company (i) violated the False Claims Act by paying kickbacks to distributors and ophthalmology practices to induce purchase of EYLEA, including through discounts, rebates, credit card fees, free units of EYLEA, and inventory management systems; and (ii) inflated reimbursement rates for EYLEA by excluding applicable discounts, rebates, and benefits from the average sales price reported to the Centers for Medicare &amp;amp; Medicaid Services. The CID covers the period from January 2011 through June 2021. The Company is cooperating with this investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;California Department of Insurance Subpoena&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, the Company received a subpoena from the Insurance Commissioner for the State of California pursuant to the California Insurance Code. The subpoena seeks information relating to the marketing, sale, and distribution of EYLEA, including (i) discounts, rebates, credit card fees, and inventory management systems; (ii) Regeneron's relationships with distributors; (iii) price reporting; (iv) speaker programs; and (v) patient support programs. The subpoena covers the period from January 1, 2014 through August 1, 2021. The Company is cooperating with this investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proceedings Initiated by Other Payors Relating to Patient Assistance Organization Support&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to several lawsuits relating to the conduct alleged in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. These lawsuits were filed by UnitedHealthcare Insurance Company and United Healthcare Services, Inc. (collectively, "UHC") and Humana Inc. ("Humana") in the United States District Court for the Southern District of New York on December 17, 2020 and July 22, 2021, respectively; and by Blue Cross and Blue Shield of Massachusetts, Inc. and Blue Cross and Blue Shield of Massachusetts HMO Blue, Inc. (collectively, "BCBS"), Medical Mutual of Ohio ("MMO"), Horizon Healthcare Services, Inc. d/b/a Horizon Blue Cross Blue Shield of New Jersey ("Horizon"), and Local 464A United Food and Commercial Workers Union Welfare Service Benefit Fund ("Local 464A") in the U.S. District Court for the District of Massachusetts on December 20, 2021, February 23, 2022, April 4, 2022, and June 17, 2022, respectively. These lawsuits allege causes of action under state law and the federal Racketeer Influenced and Corrupt Organizations Act and seek monetary damages and equitable relief. The MMO and Local 464A lawsuits are putative class action lawsuits. On December 29, 2021, the lawsuits filed by UHC and Humana were stayed by the United States District Court for the Southern District of New York pending resolution of the proceedings before the U.S. District Court for the District of Massachusetts discussed under "Department of Justice Matters" above. On September 27, 2022, the lawsuits filed by BCBS, MMO, and Horizon were stayed by the U.S. District Court for the District of Massachusetts pending resolution of the proceedings before the same court discussed under "Department of Justice Matters" above; and, in light of these stays, the parties to the Local 464A action have also agreed to stay that matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Proceedings Relating to Shareholder Derivative Complaint&lt;/span&gt;&lt;/div&gt;On June 29, 2021, an alleged shareholder filed a shareholder derivative complaint in the New York Supreme Court, naming the current and certain former members of the Company's board of directors and certain current and former executive officers of the Company as defendants and Regeneron as a nominal defendant. The complaint asserts that the individual defendants breached their fiduciary duties in relation to the allegations in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. The complaint seeks an award of damages allegedly sustained by the Company; an order requiring Regeneron to take all necessary actions to reform and improve its corporate governance and internal procedures; disgorgement from the individual defendants of all profits and benefits obtained by them resulting from their sales of Regeneron stock; and costs and disbursements of the action, including attorneys' fees. On July 28, 2021, the defendants filed a notice of removal, removing the case from the New York Supreme Court to the U.S. District Court for the Southern District of New York. On September 23, 2021, the plaintiff moved to remand the case to the New York Supreme Court. Also on September 23, 2021, the individual defendants moved to dismiss the complaint in its entirety. On December 19, 2022, the U.S. District Court for the Southern District of New York denied the plaintiff's motion to remand the case and granted a motion to stay the case pending resolution of the proceedings before the U.S. District Court for the District of Massachusetts discussed under "Department of Justice Matters" above. As a result of the stay, the court also terminated the Company's motion to dismiss the complaint without prejudice. The Company can therefore renew the motion to dismiss upon conclusion of the stay.</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LegalCostsPolicyTextBlock
      contextRef="ibb12656df12e495a99ae9761ff452049_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl83MC9mcmFnOmExYjBmZTBkM2E1NDQxNTk5MzY1ZDVhOGMwZTllYjhiL3RleHRyZWdpb246YTFiMGZlMGQzYTU0NDE1OTkzNjVkNWE4YzBlOWViOGJfNjA0NzMxNDAzMjk4MA_2b72728b-d483-4464-9531-f51ebcd22481">Costs associated with the Company's involvement in legal proceedings are expensed as incurred.</us-gaap:LegalCostsPolicyTextBlock>
    <regn:LossContingencyExParteReexaminationFiledNumber
      contextRef="i9d8a843a06e446c69b2ab4242c134351_I20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl83MC9mcmFnOmExYjBmZTBkM2E1NDQxNTk5MzY1ZDVhOGMwZTllYjhiL3RleHRyZWdpb246YTFiMGZlMGQzYTU0NDE1OTkzNjVkNWE4YzBlOWViOGJfNzU5Nw_3d0c9bfb-22b2-46f2-b020-d246ac9bb05e"
      unitRef="request">2</regn:LossContingencyExParteReexaminationFiledNumber>
    <regn:NumberOfInterPartiesReviewIPRPetitionsFiled
      contextRef="i1194a9d0d6454fd98015eb8688e54523_I20211209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl83MC9mcmFnOmExYjBmZTBkM2E1NDQxNTk5MzY1ZDVhOGMwZTllYjhiL3RleHRyZWdpb246YTFiMGZlMGQzYTU0NDE1OTkzNjVkNWE4YzBlOWViOGJfODIwMg_03d14199-b4f1-4bb3-bc8d-ed89acf5f9e4"
      unitRef="claim">2</regn:NumberOfInterPartiesReviewIPRPetitionsFiled>
    <regn:NumberOfInterPartiesReviewIPRPetitionsFiled
      contextRef="ice77d20fb98c4a08910e2616a45f1fbd_I20211209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl83MC9mcmFnOmExYjBmZTBkM2E1NDQxNTk5MzY1ZDVhOGMwZTllYjhiL3RleHRyZWdpb246YTFiMGZlMGQzYTU0NDE1OTkzNjVkNWE4YzBlOWViOGJfODIwMg_136cabe1-e7ab-4707-bd76-88559a3cc990"
      unitRef="claim">2</regn:NumberOfInterPartiesReviewIPRPetitionsFiled>
    <regn:NumberOfInterPartiesReviewIPRPetitionsFiled
      contextRef="i6b0615f9b30640a6aff828894aee0920_I20200716"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ0YzFlZjM3NzBmYjRjZmNhZGY4OGMzNjg1ZTYxMGViL3NlYzpkNGMxZWYzNzcwZmI0Y2ZjYWRmODhjMzY4NWU2MTBlYl83MC9mcmFnOmExYjBmZTBkM2E1NDQxNTk5MzY1ZDVhOGMwZTllYjhiL3RleHRyZWdpb246YTFiMGZlMGQzYTU0NDE1OTkzNjVkNWE4YzBlOWViOGJfMTM4OTA_7734b002-47b7-41f6-999c-4eac6f9e35a2"
      unitRef="claim">2</regn:NumberOfInterPartiesReviewIPRPetitionsFiled>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>65
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MX?=%]G1(]D;R3?J Q3.7DH?IRS6C'A-J _A^R;G<O5$_4#RC,_P?4$L#!!0
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M&LE3R-M-]?KV'G;\O-!+5YEXB $X+RMQG1VA_M1^2GMV4C,[KP00J11/SZN
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M!T,,L=:)4]N!;G]][20;$L@Z2Q?U"_'+S/B923P>,]@Q?B\"C"7X$=)(#*U
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M=?WIF-(!,P[_:'OHH<9*13LG1XG6A@G5.R:=$G75XXN\VSZGLI-!3:.=X[>
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M7ZYYL.)I44!\?Y\D^?<WQ1.E#\]9O_X_4$L#!!0    ( -DYI%;_!!T;Q 8
M +$;   8    >&PO=V]R:W-H965T<R]S:&5E=#8N>&ULK5E;;Z,X%/XK5G:T
MZDA-@@T$Z+:1VK2C&:DW33H[SPXXC;> ,^#TLK]^CX$ B0WMK-*'!LCQR7>N
MWS$^?1'94[YB3*+7)$[SL\%*RO7)>)R'*Y;0?"36+(5OEB)+J(3;['&<KS-&
MHV)1$H^)94W&">7I8'I:/+O/IJ=B(V.>LOL,Y9LDH=G;!8O%R]D #[8/OO/'
ME50/QM/3-7UD<R9_K.\SN!O76B*>L#3G(D496YX-SO')S"9J02'Q-V<O>>L:
M*5,60CRIFV_1V<!2B%C,0JE44/AX9C,6QTH3X/A5*1W4OZD6MJ^WVK\4QH,Q
M"YJSF8A_\DBNS@;^ $5L23>Q_"Y>OK+*(%?I"T6<%__12R5K#5"XR:5(JL6
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M_!'I -G0+N[GW=N/SG5&\ ;.M2>>QF8&.>A,N#59[*)O>!<'O[6O4&TG_\A
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M&]#[TE(/N@4GZ*^?B[\ 4$L#!!0    ( -DYI%8_SY<L)P0  %0)   8
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&ULE59_C^(V$/TJH_2VW950@(1?MPM(
ML$?5;6^O"+H]557_<,) K'7LG.TLM_?I.W8""UV6MA(*CCWSYLWSC)WA5NE'
MDR%:^)H+:49!9FUQW6R:-,.<F5 5*&EEK73.++WJ3=,4&MG*.^6B&;5:O6;.
MN S&0S\WU^.A*JW@$N<:3)GG3#]/4:CM*&@'NXD%WV36333'PX)M<(GVH9AK
M>FON458\1VFXDJ!Q/0HF[>MIQ]E[@]\Y;LW!&%PFB5*/[N5N-0I:CA *3*U#
M8/3WA+<HA ,B&E]JS& ?TCD>CG?H/_K<*9>$&;Q5XC-?V6P4# )8X9J5PB[4
M]B>L\^DZO%0)XY^PK6P[_0#2TEB5U\[$(.>R^F=?:QT.' :M-QRBVB'RO*M
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M#R,R&T3MZ ;FFHD2I3W"[[3(@O![,'MZ1/S&CE;;'0(;A%VXDSG[ALG18G2
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MQU7(<F46&34%33O0E&Z.SLH6KSVE8[C@AB?Q#8]B]/J!*E351V]4V[*[D.*
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M<G+,+36EI*DX$0W=R@M>UZQ[FX4A'Y=O\?(N_P[$+!"OY!I^Z#\+B5M@T2W
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M70!]KY2RCPNWP? W6OT%4$L#!!0    ( -DYI%:JG."PHP,  %H)   9
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M=)''ET/XI%<JLKDCRZ6+6@G2/HFA@**)^73R?4QPG!E$+#&2E;+($NSX^YZ
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M/"#?#5C=(KHF#369BQB1TFN%F92]".!\Z5S<+,3 =LI=_ =02P,$%     @
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M<5JA_[,-&_!]98S?&^& PS^*V=]02P,$%     @ V3FD5@HT[KFM&P  V%X
M !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&ULW5Q[;]O&EO\JA"[0V !C
M2[(LVS=M -M)&K=Q;,1IB[N+_6-$CJ1I^% YI!WWT]_SF!G.4)1DI]W%Q0)-
M39'S.'/F/'[GS./[A[+ZHI=2UM'7/"OT#X-E7:_^>7BHDZ7,A3XH5[* +_.R
MRD4-/ZO%H5Y54J14*<\.Q\/A]# 7JAB\_I[>W5:OOR^;.E.%O*TBW>2YJ!XO
M9%8^_# 8#>R+3VJQK/'%X>OO5V(A[V3]R^JV@E^'KI54Y;+0JBRB2LY_&)R/
M_GDQP?)4X%<E'[3W'.%(9F7Y!7]<I3\,ADB0S&128PL"_MS+2YEEV!"0\8=I
M<^"ZQ(K^LVW]'8T=QC(36EZ6V6\JK9<_#$X'42KGHLGJ3^7#>VG&<XSM)66F
MZ?_1 Y<]'@^BI-%UF9O*0$&N"OXKOAH^>!5.AQLJC$V%,='-'1&5;T0M7G]?
ME0]1A:6A-7R@H5)M($X5."EW=05?%=2K7W^0"Y%%UZ*N9:6_/ZRA2?QPF)CJ
M%UQ]O*'Z471=%O521V^+5*9A_4,@Q=$SMO1<C+<V>"VJ@^AH%$?CX?AH2WM'
M;GQ'U-[1AO8NRSQ7-4A1K2-1I-$ED*N*A2P2)77T1NDD*W53R>B_SV>ZKD!(
M_J>/"]S)I+\35)Q_ZI5(Y \#T PMJWLY>/W=/T;3X:LM0YBX(4RVM;Y[BIY1
M/7I7E7E4@UI%=4E_XZA>2F!+OA+%8Z2 2]%*5/4C?L^HZJHJ$RE3X)J.5$'%
MD[*IM(S*N5_YA8YFC8;>M3Z(/L-[L %)F5,Q;%LWR=)O+ :E7H@JS:"";2J7
ME:KAB\*NEK*"><L>HZ9(9%6#A3F(KH(NHP<H I_%+*,! ??OA<J0S/X>H7$@
MOM!EIE)1RS2:JT* +. P2ZW04"!9&G2:: +C5PE\"W51?.9-C<*2"+V,YF#0
M-.CB8S0#PJ&U"IH!:A60ED#;!T"E1K'3NH0>L+<'52\[+%/%?9G=2Y10)'N=
MY0+ZDU_!"&MH0&"%I*DJ;/ZSQXA*)N6B4'^"4(LDJ1J1Z0A,=@3232/VA+Y+
M3Y=+T<-2%L IG 1X/6/F+D4-HI$I,5.9 O%X4%F& [?D$'MP:"(O&Q@+,(_[
M%@46 X>A2YRGQTAJD#M!##HG)H/. P56Z:FA-S*1^4Q6]NTX[K!MUR!),(JR
M=A-#[()WR$XC37WU:)R^A*52YMHG'^1$*V0)]ORP5 G/J'M-C<*G2D"C.+SP
M"S 5R6(FX%OJ#]ZB,AY$M]X\?)*90-)0LF\KD34H(WLB4U"F@<K[T57QN_%N
MP,E4ZJ12,YB*&?K:-<6F>2)]\E1\!>PAR9M7R 020T%-HJ2!0I"<S!ZC\QQ8
M!!TF!T!"D1[""%&9Q'P.\D"%H"J4EWH_$@O@K@[Y:.K<B:*<*]=$9U)AYKG
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MPM$/@.^%Z4D)UJ<XFDPD7["N)$21TV3=@'%=50 J1A,[0IX_:R!8PZ$VCDH
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M&+;8[!.@(5E+VN,YQ_ JD99U5=6LZL#V># <G,]Z#I9"08"\?*Z7USO9;()
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M]W$=IT#^AS#P*4?0C7*(.45-BNJ(0UJ<I(OBW.$&+7H*LL@%M97$*FHI3.C
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M@"8@C0#VSP2>H,H?8Z"Z>AO^!U!+ P04    " #9.:16SN*S69\&  !4%0
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M\RP"T]P4&\/I*MS.UMK172^\%G2Y1N,=Z/M&TQG>&CY!?UU?_0-02P,$%
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M1= XO!@$H#OO=XE5:^^WI;+D7A_6]%RB=@6T7BEE=XG;H'^ YW\ 4$L#!!0
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MH*P#_E](W-C&L%V^?=2SWU!+ P04    " #9.:16^8C_HNL"  "M"0  &0
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M6P+^^:1-P8TF7?Y;QUN&.ZS'-4^&4YG@)3GOZ-:71#R0SNS]+\%X\+%NT)[
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MC('^?L6Y>KDQ/U <&IW]#U!+ P04    " #9.:16)+3&2^H%  "'*P  &0
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M&CRMRN$2OR= V0)\GDMI7B;VR&J^4)+?4$L#!!0    ( -DYI%8 "UR<KP0
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M!?[^0)H W,^%T"\3TV&['VKR%U!+ P04    " #9.:16>VSS"OP&  "O+@
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M#,3_MXSQGV^*9Y;K9]3G_P-02P,$%     @ V3FD5G[X#3Y<"@  ]6H  !D
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M>2_BC<AK@>KGMUE6/K^H/_CH]$E7R_\#4$L#!!0    ( -DYI%:$N$%I\ (
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M#TU"-&D6&C)K0!S5$$?_,Y [S4^%.GI6[)7,#'5<,K,/3M'JRB,/K1N2<93
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M*8/!"0J3KL.Y0(O*-HFET-AR[##'GP)(DX#K*R'T+C ;M+^9Y ]02P,$%
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M>]*%GM,4^AXV'0UJ"=[@XX?PK/6YR?!#BHT.*38^D-A&:N(Z-?$N]=?4I'8
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M<X_D,*=K;N[D]CM4\3@',\FU^Y)M91MX)%MK(XL*C!X43)1_^E3IL - GF9
M5 &B?4#W#4!< >)]0.\-0+<"=-^[0E(!7.A^&;L3;DP-3?M*;HFRULAF&TY]
MAT:]F+!Y,C4*9QGB3#JB>DFN,%LT.273,EF(G).?4IQF=NY:;$ ;)A:$BIQ<
M,4%%9GM#N\/,,-#D> R&,JY/D.)^.B;'1R?DB#!!;ACGF VZ[QMTU2[H9Y5;
MEZ5;T1MNQ>1&"K/49")RR!OPXW9\&+40^*A1+53T(M1EU,IX0U6'Q.$7$@51
MW.#0Z/WPJ"F>=O@8LE;XY/WPL$6,N,Z:V/'%;5EC\\$U)H]KMJ$<A-'DSW"F
MC<+C_[=ITTO6;C.KO1(O](IF,/#PSM.@-N"EGS^%O>!;D^ ?23;^2++)!Y&]
MVIINO37=-O9TF&5J#3G)Z(H9R@D\84G)F5GC4DU;4K+U')LM*IOT:]#!!-_L
M2GUH=!YTSEX;C0^-SH+.^6NC28-1=\?H5<A)'7+ROI#QQ./5A'EHFYKEH*BK
M1EA.R0\V,_19XK5DJ%BP&0="M0;3I$ERX&22=*(]34JC,-BQ"O84.>0)XZ23
M[$G22E0*XN]<\ 6HA:NL&J-<"U.>VGJT+MY#5[/VQB_#BU'8,#[&8E_6YO_T
MY4L!+ZX%$YIPF.-2N.OHKBJK;]DQ<N7*RTP:+%:NN<0'"RAK@/-S*<U+QRY0
M/X'2?U!+ P04    " #9.:16'7$>M%8#  "/$@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970U,RYX;6RMF.UNFS 40%_%8M*Z257X2DC2)9'2TFJ9VBEJM4W3
MM!\.W"16 5/;^9C4AY]M* T308WF/P&#[[%]X@O8HQUECWP-(- ^33(^MM9"
MY!>VS:,UI)AW: Z9O+.D+,5"%MG*YCD#'.N@-+$]QPGL%)/,FHSTM3F;C.A&
M)"2#.4-\DZ:8_;F$A.[&EFN]7+@GJ[50%^S)*,<K> #Q+9\S6;(K2DQ2R#BA
M&6*P'%M3]R)T?16@:WPGL.,'YT@-94'IHRK,XK'EJ!Y! I%0""P/6[B")%$D
MV8^G$FI5;:K P_,7^HT>O!S, G.XHLD/$HOUV!I8*(8EWB3BGNX^0SF@GN)%
M-.'Z%^V*NCW/0M&&"YJ6P;('*<F*(]Z7(@X"/.=(@%<&>&\-\,L _]^ 8UWJ
ME@%=;:88BO808H$G(T9WB*G:DJ9.M$P=+8=/,O6_/P@F[Q(9)R:WL,()NL-"
M ./H0P@"DX1_'-E"PE45.RI!EP7(.P(*(>H@9WB./,=S491@DC9 KMHA7S9)
M![F!ACA'(6$[Y 86$N*6$ 9/&^"BCK&EI4J55ZGR-+=[A'OF>0'"68S.AD,/
MS;& 3'#TC*Y_WEY/FX2UXE1"7_ <1S"V9,9R8%NP)N_?N8'SJ4F<25AH"%;3
MZ%<:?4WWC\TXRCFZHID@V0JRB !'OVYE'303D/+?32)]DR)-PD)#L)K(;B6R
MVSH?OV[2!3!$EPCV*,=,@)SLL,?R*8%%\5C64U_-T<8L*.2V-G*J7).PL(#U
M-$R]O[83;V1O&XSU*F.]]@SV_4&9N&BJ$MD)AB_E9Z1>/H))<>=HED6=)E>M
M^%-=F82%AF UK4&E-3"=T8%)D29AH2%8362_$ME_8T;/YO=H21*(F^3U6_*B
M,-+:S*E&#,%J1@:5D<%_9.PTIT(^^XYE:ROZU$EF$A8:@M64#BNE0]/9.C0I
MTB0L- 2KB72=UV]GQT2^EI2VA&UOZ%0KIFAU+0=+"K<]:0/?+9.T44=K]*G3
MR2@M-$6KFWM=8;B>Z=QTC:XRC-)"4[2ZS=>%AMOZ^?WF]#2ZO"AI+<D>FFJP
MT&(?+/[55LT=9BN2<93 4N*=3E]VA16['T5!T%SO!RRH$#35IVO ,3!50=Y?
M4OE6+0MJBZ':@YK\!5!+ P04    " #9.:16[(2FECX#   F%   #0   'AL
M+W-T>6QE<RYX;6S=6&U/VS 0_BN1&1-($VF;D3:CK;150IJT34CP8=^0VSBM
M)<?.')>U_'I\<9J^X.LZ/@RZ5!#?/;[G'I\OC:%?FJ5@MS/&3+#(A2P'9&9,
M\2D,R\F,Y;2\4 63%LF4SJFQIIZ&9:$934L(RD78:;7B,*=<DF%?SO/KW)3!
M1,VE&9!NXPK<[6LZ(.WX(PD<W4BE;$#NS][_FBMS]2YP]Y,/)R>MB];]^=4N
M<E9#YR3T$E]N$Z^)_A08'Z1HGR24NGL8]5YNE+QW #E*C)$FGBJ>-D4\1<*Z
M+6_Q-R+!J(+#NDV&_4S)=;=$Q#DL.\U9\$#%@(RHX&/-(2JC.1=+Y^Z 8Z*$
MTH&Q;6K3M<%3/CJX[2SHX)HGYU+I*K?+X'Z/Z^D[P,H"@5R(1F"'.,>P7U!C
MF);7UJ@F5\YG4%"/[Y:%53C5=-GN7))U0'6S2<9*ITPW:=IDY1KV!<M CN;3
M&=R-*D( C5&Y':2<3I6DE8951#VPM!,FQ"T\WC^S+>Y%MK%OU:[)9F@%U4-'
MXPS@WV1SW)NTT8MX@X(_*/-E;I<C*QNZD]UHEO%%92^R1@#&WL;9:5&(Y6?!
MIS)G;O$')QSVZ2HNF"G-'VTV:)6)=3!-@@>F#9]L>GYK6MRQA5FUTR+#-7>.
M4/._K?.42::IV!1M>_\M5_G%BJ/N:TFNOE5V!7LUUN_LMR[R\AA$QL<@\BAZ
MLG<,(I,C$-E]M6_-O2+#^I2Q<939.L@TW@ .C /R XZ?8ITT&,^Y,%S6UHRG
M*9//SC.6WM"Q_2-HB]_.3UE&Y\+<->" K,??6<KG>=+,NH%"U+/6XV^PO';<
MG%9M+BY3MF#IJ#;U=%P- SNP6>L+ G:1Z^KR(UB,P_P(8%@>3 $6XZ*P//_3
M>GKH>AR&:>MYD1X:TT-C7)0/&54?+(\_)K&7?Z5)$D5QC%5T-/(J&&%UBV/X
M\;-AVB "RP.9_J[6^&[C';*_#[ ]W=<AV$KQ3L16BM<:$'_=("))_+N-Y8$(
M;!>PWH'\_CS04_Z8*()=Q;1A3S".) F&0"_Z>S2.D>K$\/'O#_:41%&2^!'
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
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MT_7QE^7WR=&K<L$YP&_[QR]02P,$%     @ V3FD5BIDTJ;* 0  FQ\  !,
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M;%!+ 0(4 Q0    ( -DYI%9*:3V![P   "L"   1              "  :\
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M2P$"% ,4    " #9.:16&'M5'=4#  !%$0  &               @(%U%0
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ V3FD5C&Z!^D6
M!P  BR,  !@              ("!@!D  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( -DYI%:RHI1Q^@D  '-=   8              "
M@<P@  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #9.:16
M_P0=&\0&  "Q&P  &               @('\*@  >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ V3FD5N;9%;MA!   B@H  !@
M     ("!]C$  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M -DYI%8_SY<L)P0  %0)   8              " @8TV  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    " #9.:16^38J7S\,  "#*   &
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M970Q,RYX;6Q02P$"% ,4    " #9.:16JIS@L*,#  !:"0  &0
M    @(&R7   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M -DYI%:I0=1 H 0  /$*   9              " @8Q@  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ V3FD5L'4.C:8 P  70@  !D
M             ("!8V4  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    " #9.:16"C3NN:T;  #87@  &0              @($R:0  >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( -DYI%9&4X39>@0
M -T*   9              " @1:%  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ V3FD5HVW:A5F!@  AA,  !D              ("!
MQXD  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #9.:16
MSN*S69\&  !4%0  &0              @(%DD   >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( -DYI%;<\&D\50,  !D(   9
M      " @3J7  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ V3FD5IR?NPW\!0  ^0\  !D              ("!QIH  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #9.:16ZFT_4+D$  "Z"P
M&0              @('YH   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( -DYI%:;:Y[?F@(  (P%   9              " @>FE  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ V3FD5KD0)LF4
M @  I 4  !D              ("!NJ@  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    " #9.:160&SO$IL#   B"P  &0
M@(&%JP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( -DY
MI%:3(& "-@0  * 7   9              " @5>O  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ V3FD5O$BNQ>+ @  X <  !D
M         ("!Q+,  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    " #9.:16^8C_HNL"  "M"0  &0              @(&&M@  >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( -DYI%8^,E93?P8  $ J
M   9              " @:BY  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ V3FD5B2TQDOJ!0  ARL  !D              ("!7L
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #9.:16$%G7
M2M0"  "M"   &0              @(%_Q@  >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( -DYI%8 "UR<KP0   <?   9
M  " @8K)  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
MV3FD5M#LDX=2!   )A(  !D              ("!<,X  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    " #9.:16Q[K00<8"  "'"   &0
M            @('YT@  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( -DYI%963E4=WP(  *X(   9              " @?;5  !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ V3FD5C/*Q;ZC @
M\P<  !D              ("!#-D  'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    " #9.:16JO%0)LH#  #+$@  &0              @('F
MVP  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( -DYI%;?
M?IU1YP,  "H/   9              " @>??  !X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ V3FD5OC7>QR8 @  "@<  !D
M     ("!!>0  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -DYI%:$N$%I\ (  -$(   9              "
M@9T! 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ V3FD
M5C0&0N*X @  D@<  !D              ("!Q 0! 'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q02P$"% ,4    " #9.:16-^FV)2<"   -!0  &0
M        @(&S!P$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0
M   ( -DYI%;D),EP0 (  (X%   9              " @1$* 0!X;"]W;W)K
M<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ V3FD5OD_$,8! P  UPT
M !D              ("!B P! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q0
M2P$"% ,4    " #9.:165X4#RI0"  !R!@  &0              @(' #P$
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( -DYI%8K(B8R
M% ,  .0)   9              " @8L2 0!X;"]W;W)K<VAE971S+W-H965T
M-3$N>&UL4$L! A0#%     @ V3FD5D7 ?+(* P  #@D  !D
M ("!UA4! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " #9
M.:16'7$>M%8#  "/$@  &0              @($7&0$ >&PO=V]R:W-H965T
M<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( -DYI%;LA*:6/@,  "84   -
M          "  :0< 0!X;"]S='EL97,N>&UL4$L! A0#%     @ V3FD5I>*
MNQS     $P(   L              ( !#2 ! %]R96QS+RYR96QS4$L! A0#
M%     @ V3FD5NPY/-,R!   /2,   \              ( !]B ! 'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( -DYI%9\?ND;U $  ,8?   :
M      "  54E 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( -DYI%8J9-*FR@$  )L?   3              "  6$G 0!;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     ] #T HA   %PI 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>209</ContextCount>
  <ElementCount>194</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>84</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Interim Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/InterimFinancialStatements</Role>
      <ShortName>Interim Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Product Sales</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/ProductSales</Role>
      <ShortName>Product Sales</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Collaboration, License, and Other Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements</Role>
      <ShortName>Collaboration, License, and Other Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Net Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/NetIncomePerShare</Role>
      <ShortName>Net Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CashFlows</Role>
      <ShortName>Cash Flows</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Legal Matters</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/LegalMatters</Role>
      <ShortName>Legal Matters</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Interim Financial Statements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/InterimFinancialStatementsPolicies</Role>
      <ShortName>Interim Financial Statements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Product Sales (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/ProductSalesTables</Role>
      <ShortName>Product Sales (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/ProductSales</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Collaboration, License, and Other Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables</Role>
      <ShortName>Collaboration, License, and Other Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Net Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/NetIncomePerShareTables</Role>
      <ShortName>Net Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/NetIncomePerShare</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/MarketableSecurities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/Inventories</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/StockholdersEquity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Cash Flows (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CashFlowsTables</Role>
      <ShortName>Cash Flows (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/CashFlows</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Product Sales - Schedule of Net Product Sales (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails</Role>
      <ShortName>Product Sales - Schedule of Net Product Sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Product Sales - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/ProductSalesNarrativeDetails</Role>
      <ShortName>Product Sales - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Product Sales - Schedule of Concentration of Risk, by Risk Factor (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails</Role>
      <ShortName>Product Sales - Schedule of Concentration of Risk, by Risk Factor (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized In Statement of Operations with Sanofi (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Amounts Recognized In Statement of Operations with Sanofi (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Antibody Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Schedule of Contract Balances, Antibody Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Bayer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Bayer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Bayer Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Schedule of Contract Balances, Bayer Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Roche (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Roche (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances - Roche (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Schedule of Contract Balances - Roche (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Collaboration, License, and Other Agreements - Sonoma Biotherapeutics, Inc. Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Sonoma Biotherapeutics, Inc. Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails</Role>
      <ShortName>Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Net Income Per Share - Schedule of Antidilutive Securities Excluded From Computation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails</Role>
      <ShortName>Net Income Per Share - Schedule of Antidilutive Securities Excluded From Computation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Marketable Securities - Schedule of Investments in Available For Sale Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Schedule of Investments in Available For Sale Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Marketable Securities - Schedule of Debt Securities Based on Contractual Maturity Dates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails</Role>
      <ShortName>Marketable Securities - Schedule of Debt Securities Based on Contractual Maturity Dates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Marketable Securities - Schedule of Fair Value and Unrealized Losses of Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Schedule of Fair Value and Unrealized Losses of Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Fair Value Measurements - Schedule of Assets Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Assets Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Inventories - Schedule of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails</Role>
      <ShortName>Inventories - Schedule of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Inventories - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/InventoriesNarrativeDetails</Role>
      <ShortName>Inventories - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/IncomeTaxes</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Stockholders' Equity - Schedule of Share Repurchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StockholdersEquityScheduleofShareRepurchasesDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Share Repurchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Cash Flows - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Cash Flows - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Cash Flows - Summary of Non-cash Investing and Financing Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails</Role>
      <ShortName>Cash Flows - Summary of Non-cash Investing and Financing Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="regn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Legal Matters (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/LegalMattersDetails</Role>
      <ShortName>Legal Matters (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/LegalMatters</ParentRole>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="regn-20230331.htm">regn-20230331.htm</File>
    <File>regn-20230331.xsd</File>
    <File>regn-20230331_cal.xml</File>
    <File>regn-20230331_def.xml</File>
    <File>regn-20230331_lab.xml</File>
    <File>regn-20230331_pre.xml</File>
    <File>regn-ex_101x3312023x10q.htm</File>
    <File>regn-ex_311x3312022x10q.htm</File>
    <File>regn-ex_312x3312022x10q.htm</File>
    <File>regn-ex_32x3312022x10q.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="604">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>70
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "regn-20230331.htm": {
   "axisCustom": 2,
   "axisStandard": 21,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 604,
    "http://xbrl.sec.gov/dei/2022": 30
   },
   "contextCount": 209,
   "dts": {
    "calculationLink": {
     "local": [
      "regn-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "regn-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "regn-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "regn-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "regn-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "regn-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 374,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 15,
   "keyStandard": 179,
   "memberCustom": 51,
   "memberStandard": 29,
   "nsprefix": "regn",
   "nsuri": "http://www.regeneron.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.regeneron.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Net Income Per Share",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.regeneron.com/role/NetIncomePerShare",
     "shortName": "Net Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Marketable Securities",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.regeneron.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.regeneron.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Inventories",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.regeneron.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.regeneron.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.regeneron.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Cash Flows",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.regeneron.com/role/CashFlows",
     "shortName": "Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Legal Matters",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.regeneron.com/role/LegalMatters",
     "shortName": "Legal Matters",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Interim Financial Statements (Policies)",
     "menuCat": "Policies",
     "order": "18",
     "role": "http://www.regeneron.com/role/InterimFinancialStatementsPolicies",
     "shortName": "Interim Financial Statements (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Product Sales (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.regeneron.com/role/ProductSalesTables",
     "shortName": "Product Sales (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ib18b866589c84ae4b4eb07c3c0320ecd_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ib18b866589c84ae4b4eb07c3c0320ecd_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Collaboration, License, and Other Agreements (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables",
     "shortName": "Collaboration, License, and Other Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Net Income Per Share (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.regeneron.com/role/NetIncomePerShareTables",
     "shortName": "Net Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Marketable Securities (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.regeneron.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.regeneron.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Inventories (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.regeneron.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.regeneron.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Cash Flows (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.regeneron.com/role/CashFlowsTables",
     "shortName": "Cash Flows (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Product Sales - Schedule of Net Product Sales (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails",
     "shortName": "Product Sales - Schedule of Net Product Sales (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "i4c137cb80c2348b6b72faccb7cba8e93_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ib18b866589c84ae4b4eb07c3c0320ecd_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Product Sales - Narrative (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.regeneron.com/role/ProductSalesNarrativeDetails",
     "shortName": "Product Sales - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ib8a607a3e56c41779c0e4d7f40f3276c_I20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "i66be2d5d13e14c65a79a0cd9a1fdba09_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Product Sales - Schedule of Concentration of Risk, by Risk Factor (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails",
     "shortName": "Product Sales - Schedule of Concentration of Risk, by Risk Factor (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "i66be2d5d13e14c65a79a0cd9a1fdba09_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ib18b866589c84ae4b4eb07c3c0320ecd_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ib18b866589c84ae4b4eb07c3c0320ecd_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized In Statement of Operations with Sanofi (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
     "shortName": "Collaboration, License, and Other Agreements - Amounts Recognized In Statement of Operations with Sanofi (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ib2f2c59d2425478cb9a759cbb016a8e3_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
     "shortName": "Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "i76483ad7f52e40cab4a22bb58eb53286_D20230101-20230331",
      "decimals": "2",
      "lang": "en-US",
      "name": "regn:PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ib18b866589c84ae4b4eb07c3c0320ecd_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Antibody Collaboration (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails",
     "shortName": "Collaboration, License, and Other Agreements - Schedule of Contract Balances, Antibody Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "i50cbbeeb8ba0490fb582afb27330f7db_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
     "shortName": "Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ia67b58013e1b4eb9829600ae26b049f1_D20220701-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "regn:UpFrontPaymentToCollaboratingParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Bayer (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
     "shortName": "Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Bayer (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb424b76bb944bb487058cb7b71b5478_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ib18b866589c84ae4b4eb07c3c0320ecd_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Bayer Collaboration (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails",
     "shortName": "Collaboration, License, and Other Agreements - Schedule of Contract Balances, Bayer Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ic9e294aebc65480da80f32f7028adbb2_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Roche (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
     "shortName": "Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Roche (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "i64841568e706401985fc84aa04b36f1e_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ib18b866589c84ae4b4eb07c3c0320ecd_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances - Roche (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheDetails",
     "shortName": "Collaboration, License, and Other Agreements - Schedule of Contract Balances - Roche (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "i38fd75f0c02644a59d387c1d665dac3e_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Collaboration, License, and Other Agreements - Sonoma Biotherapeutics, Inc. Narrative (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails",
     "shortName": "Collaboration, License, and Other Agreements - Sonoma Biotherapeutics, Inc. Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ib6c0a3e1eb3f4fa4b60c33bacffd2f52_D20230401-20230430",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails",
     "shortName": "Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "i3b0f6d873f2441d7890447099c7468ad_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "i7aef696237bd4fa2bb67d81627a03291_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Net Income Per Share - Schedule of Antidilutive Securities Excluded From Computation (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails",
     "shortName": "Net Income Per Share - Schedule of Antidilutive Securities Excluded From Computation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "i7aef696237bd4fa2bb67d81627a03291_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ib18b866589c84ae4b4eb07c3c0320ecd_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Marketable Securities - Schedule of Investments in Available For Sale Debt Securities (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails",
     "shortName": "Marketable Securities - Schedule of Investments in Available For Sale Debt Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ib18b866589c84ae4b4eb07c3c0320ecd_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ib18b866589c84ae4b4eb07c3c0320ecd_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Marketable Securities - Schedule of Debt Securities Based on Contractual Maturity Dates (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails",
     "shortName": "Marketable Securities - Schedule of Debt Securities Based on Contractual Maturity Dates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ib18b866589c84ae4b4eb07c3c0320ecd_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ib18b866589c84ae4b4eb07c3c0320ecd_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Marketable Securities - Schedule of Fair Value and Unrealized Losses of Debt Securities (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
     "shortName": "Marketable Securities - Schedule of Fair Value and Unrealized Losses of Debt Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ib18b866589c84ae4b4eb07c3c0320ecd_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ib18b866589c84ae4b4eb07c3c0320ecd_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Fair Value Measurements - Schedule of Assets Measured at Fair Value on a Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Schedule of Assets Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "i42bb7405dae2448892d28fe5254d753b_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ib18b866589c84ae4b4eb07c3c0320ecd_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Inventories - Schedule of Inventories (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails",
     "shortName": "Inventories - Schedule of Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ib18b866589c84ae4b4eb07c3c0320ecd_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ib18b866589c84ae4b4eb07c3c0320ecd_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Inventories - Narrative (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.regeneron.com/role/InventoriesNarrativeDetails",
     "shortName": "Inventories - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ib18b866589c84ae4b4eb07c3c0320ecd_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.regeneron.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ib18b866589c84ae4b4eb07c3c0320ecd_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ib18b866589c84ae4b4eb07c3c0320ecd_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "i97aac951375a4b61997b83f703090509_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "i97aac951375a4b61997b83f703090509_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Stockholders' Equity - Schedule of Share Repurchases (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.regeneron.com/role/StockholdersEquityScheduleofShareRepurchasesDetails",
     "shortName": "Stockholders' Equity - Schedule of Share Repurchases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ib18b866589c84ae4b4eb07c3c0320ecd_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Cash Flows - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.regeneron.com/role/CashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Cash Flows - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "i7298587e584844a686de7edf412eb7a2_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Cash Flows - Summary of Non-cash Investing and Financing Activities (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.regeneron.com/role/CashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails",
     "shortName": "Cash Flows - Summary of Non-cash Investing and Financing Activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "i9d8a843a06e446c69b2ab4242c134351_I20200211",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "regn:LossContingencyExParteReexaminationFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "request",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Legal Matters (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.regeneron.com/role/LegalMattersDetails",
     "shortName": "Legal Matters (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "i9d8a843a06e446c69b2ab4242c134351_I20200211",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "regn:LossContingencyExParteReexaminationFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "request",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Interim Financial Statements",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.regeneron.com/role/InterimFinancialStatements",
     "shortName": "Interim Financial Statements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Product Sales",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.regeneron.com/role/ProductSales",
     "shortName": "Product Sales",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Collaboration, License, and Other Agreements",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements",
     "shortName": "Collaboration, License, and Other Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20230331.htm",
      "contextRef": "ibb12656df12e495a99ae9761ff452049_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 84,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "regn_A226PatentAnd992PatentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "'226 Patent And '992 Patent",
        "label": "'226 Patent And '992 Patent [Member]",
        "terseLabel": "'226 and '992 Patents"
       }
      }
     },
     "localname": "A226PatentAnd992PatentMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_A338PatentAnd069PatentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "'338 Patent And '069 Patent",
        "label": "'338 Patent And '069 Patent [Member]",
        "terseLabel": "'338 Patent And '069 Patent"
       }
      }
     },
     "localname": "A338PatentAnd069PatentMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_A631PatentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "'631 Patent",
        "label": "'631 Patent [Member]",
        "terseLabel": "'631 Patent"
       }
      }
     },
     "localname": "A631PatentMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_AcquiredInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired In-Process Research and Development",
        "label": "Acquired In-Process Research and Development",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "AcquiredInProcessResearchAndDevelopment",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Recognized In Connection With Up-Front Payments [Member]",
        "label": "Amounts Recognized In Connection With Up-Front Payments [Member]",
        "terseLabel": "Amounts recognized in connection with up-front payments received"
       }
      }
     },
     "localname": "AmountsRecognizedInConnectionWithUpFrontPaymentsMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ApotexIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Apotex Inc.",
        "label": "Apotex Inc. [Member]",
        "terseLabel": "Apotex Inc."
       }
      }
     },
     "localname": "ApotexIncMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_BayerCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer Collaboration Agreement [Member]",
        "label": "Bayer Collaboration Agreement [Member]",
        "terseLabel": "Bayer"
       }
      }
     },
     "localname": "BayerCollaborationAgreementMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_BesseMedicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Besse Medical [Member]",
        "label": "Besse Medical [Member]",
        "terseLabel": "Besse Medical, a subsidiary of AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "BesseMedicalMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_CelltrionIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Celltrion, Inc.",
        "label": "Celltrion, Inc. [Member]",
        "terseLabel": "Celltrion, Inc."
       }
      }
     },
     "localname": "CelltrionIncMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ClassificationOfInvestmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the general categories of investments, which may be classified as Unrestricted or Restricted.",
        "label": "Classification of Investment [Axis]",
        "terseLabel": "Classification of Investment [Axis]"
       }
      }
     },
     "localname": "ClassificationOfInvestmentAxis",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "regn_ClassificationOfInvestmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provides general categories of investments for which information is required or determined to be disclosed.",
        "label": "Classification of Investment [Domain]",
        "terseLabel": "Classification of Investment [Domain]"
       }
      }
     },
     "localname": "ClassificationOfInvestmentDomain",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_CollaborationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Revenue",
        "label": "Collaboration Revenue [Member]",
        "terseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "CollaborationRevenueMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_CollaborationandContractManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and Contract Manufacturing [Member]",
        "label": "Collaboration and Contract Manufacturing [Member]",
        "terseLabel": "Cost of collaboration and contract manufacturing"
       }
      }
     },
     "localname": "CollaborationandContractManufacturingMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_CostOfGoodsSoldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Of Goods Sold",
        "label": "Cost Of Goods Sold [Member]",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsSoldMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5",
        "terseLabel": "Maturities after five years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_DevelopmentMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Milestone",
        "label": "Development Milestone [Member]",
        "terseLabel": "Development Milestone"
       }
      }
     },
     "localname": "DevelopmentMilestoneMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_EYLEAAfliberceptInjectionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EYLEA Aflibercept Injection",
        "label": "EYLEA Aflibercept Injection [Member]",
        "terseLabel": "EYLEA"
       }
      }
     },
     "localname": "EYLEAAfliberceptInjectionMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_EvkeezaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evkeeza",
        "label": "Evkeeza [Member]",
        "terseLabel": "Evkeeza"
       }
      }
     },
     "localname": "EvkeezaMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_EyleaNetProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue during the period derived from a specified product line (EYLEA), after deducting applicable provisions for discounts, returns, rebates, chargebacks, distribution fees, and other sales-related deductions.",
        "label": "EYLEA Net Product Sales [Member]",
        "terseLabel": "EYLEA"
       }
      }
     },
     "localname": "EyleaNetProductSalesMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_GrossProductRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross Sales Revenue [Member]",
        "label": "Gross Product Revenue [Member]",
        "terseLabel": "Gross product revenue"
       }
      }
     },
     "localname": "GrossProductRevenueMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_InmazebMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inmazeb",
        "label": "Inmazeb [Member]",
        "terseLabel": "Inmazeb"
       }
      }
     },
     "localname": "InmazebMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_LIBTAYONetProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "LIBTAYO Net Product Sales [Member]",
        "label": "LIBTAYO Net Product Sales [Member]",
        "terseLabel": "Libtayo"
       }
      }
     },
     "localname": "LIBTAYONetProductSalesMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Levels Of Twelve Month Sales At Which Sales Milestone Payments Would Be Received",
        "label": "Levels Of Twelve Month Sales At Which Sales Milestone Payments Would Be Received",
        "terseLabel": "Levels of twelve-month sales at which sales milestone payments would be received"
       }
      }
     },
     "localname": "LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_LossContingencyExParteReexaminationFiledNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Ex Parte Reexamination, Filed, Number",
        "label": "Loss Contingency, Ex Parte Reexamination, Filed, Number",
        "terseLabel": "Number of ex parte reexamination requests"
       }
      }
     },
     "localname": "LossContingencyExParteReexaminationFiledNumber",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "regn_MarketableAndOtherSecuritiesGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable and Other Securities, Gain (Loss)",
        "label": "Marketable and Other Securities, Gain (Loss)",
        "negatedTerseLabel": "Losses on marketable and other securities, net"
       }
      }
     },
     "localname": "MarketableAndOtherSecuritiesGainLoss",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_McKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "McKesson Corporation [Member]",
        "label": "McKesson Corporation [Member]",
        "terseLabel": "McKesson Corporation"
       }
      }
     },
     "localname": "McKessonCorporationMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_MilestoneTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Type",
        "label": "Milestone Type [Axis]",
        "terseLabel": "Milestone Type [Axis]"
       }
      }
     },
     "localname": "MilestoneTypeAxis",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "regn_MilestoneTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Type [Domain]",
        "label": "Milestone Type [Domain]",
        "terseLabel": "Milestone Type [Domain]"
       }
      }
     },
     "localname": "MilestoneTypeDomain",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_NetProfitInConnectionWithCommercializationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Profit In Connection With Commercialization [Member]",
        "label": "Net Profit In Connection With Commercialization [Member]",
        "terseLabel": "Regeneron's share of profits in connection with commercialization of EYLEA outside the United States"
       }
      }
     },
     "localname": "NetProfitInConnectionWithCommercializationMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_NumberOfInterPartiesReviewIPRPetitionsFiled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Inter Parties Review (IPR) Petitions Filed",
        "label": "Number of Inter Parties Review (IPR) Petitions Filed",
        "terseLabel": "Number of IPR filed"
       }
      }
     },
     "localname": "NumberOfInterPartiesReviewIPRPetitionsFiled",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "regn_OneTimePaymentInConnectionWithChangeInJapanArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One-time Payment in Connection With Change in Japan Arrangement",
        "label": "One-time Payment in Connection With Change in Japan Arrangement [Member]",
        "terseLabel": "One-time payment in connection with change in Japan arrangement"
       }
      }
     },
     "localname": "OneTimePaymentInConnectionWithChangeInJapanArrangementMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_PaymentsToAcquireIntangibleAssets1": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Intangible Assets1",
        "label": "Payments To Acquire Intangible Assets1",
        "negatedTerseLabel": "Payments for Libtayo intangible asset"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets1",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Quarterly Profits Required To Be Paid For Reimbursement Of Development Costs",
        "label": "Percentage Of Quarterly Profits Required To Be Paid For Reimbursement Of Development Costs",
        "terseLabel": "Percentage share of profits to reimburse collaborating party"
       }
      }
     },
     "localname": "PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Share of Profits Used to Reimburse Collaborating Party for Trial Costs",
        "label": "Percentage of Share of Profits Used to Reimburse Collaborating Party for Trial Costs",
        "terseLabel": "Percentage of share of profits used to reimburse collaborating party for trial costs"
       }
      }
     },
     "localname": "PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Trial Costs Required To Be Funded By Collaborating Party",
        "label": "Percentage of Trial Costs Required To Be Funded By Collaborating Party",
        "terseLabel": "Percentage of trial costs required to be funded by collaborating party"
       }
      }
     },
     "localname": "PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period for Achieving Sales Target for Milestone Payment, Rolling Basis",
        "label": "Period for Achieving Sales Target for Milestone Payment, Rolling Basis",
        "terseLabel": "Period for achieving sales target for milestone payment, rolling basis"
       }
      }
     },
     "localname": "PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "regn_PraluentNetProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Praluent Net Product Sales",
        "label": "Praluent Net Product Sales [Member]",
        "terseLabel": "Praluent"
       }
      }
     },
     "localname": "PraluentNetProductSalesMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_RegeneronsObligationOfResearchAndDevelopmentExpensesNetOfReimbursementOfResearchAndDevelopmentExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regeneron's Obligation Of Research And Development Expenses, Net of Reimbursement Of Research And Development Expenses",
        "label": "Regeneron's Obligation Of Research And Development Expenses, Net of Reimbursement Of Research And Development Expenses [Member]",
        "terseLabel": "Regeneron's obligation for its share of Bayer R&amp;D expenses, net of reimbursement of R&amp;D expenses"
       }
      }
     },
     "localname": "RegeneronsObligationOfResearchAndDevelopmentExpensesNetOfReimbursementOfResearchAndDevelopmentExpensesMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_RegeneronsShareOfCommercialExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regeneron's Share Of Commercial Expenses",
        "label": "Regeneron's Share Of Commercial Expenses [Member]",
        "terseLabel": "Regeneron's obligation for its share of Sanofi commercial expenses"
       }
      }
     },
     "localname": "RegeneronsShareOfCommercialExpensesMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_RegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory Milestone",
        "label": "Regulatory Milestone [Member]",
        "terseLabel": "Regulatory Milestone"
       }
      }
     },
     "localname": "RegulatoryMilestoneMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ReimbursementForManufacturingOfCommercialSuppliesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement For Manufacturing Of Commercial Supplies [Member]",
        "label": "Reimbursement For Manufacturing Of Commercial Supplies [Member]",
        "terseLabel": "Reimbursement for manufacturing of commercial supplies",
        "verboseLabel": "Reimbursement for manufacturing of ex-U.S. commercial supplies"
       }
      }
     },
     "localname": "ReimbursementForManufacturingOfCommercialSuppliesMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ReimbursementForManufacturingOfExCommercialSuppliesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement For Manufacturing Of ex-Commercial Supplies",
        "label": "Reimbursement For Manufacturing Of ex-Commercial Supplies [Member]",
        "terseLabel": "Reimbursement for manufacturing of ex-U.S. commercial supplies"
       }
      }
     },
     "localname": "ReimbursementForManufacturingOfExCommercialSuppliesMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ReimbursementOfCommercializationRelatedExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement Of Commercialization-Related Expenses",
        "label": "Reimbursement Of Commercialization-Related Expenses [Member]",
        "terseLabel": "Reimbursement of commercialization-related expenses"
       }
      }
     },
     "localname": "ReimbursementOfCommercializationRelatedExpensesMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ReimbursementOfResearchAndDevelopmentExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement Of Research And Development Expenses [Member]",
        "label": "Reimbursement Of Research And Development Expenses [Member]",
        "terseLabel": "Reimbursement of R&amp;D expenses"
       }
      }
     },
     "localname": "ReimbursementOfResearchAndDevelopmentExpensesMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement Of Research And Development Expenses, Net Of Obligation For Share Of R&amp;D Expenses",
        "label": "Reimbursement Of Research And Development Expenses, Net Of Obligation For Share Of R&amp;D Expenses [Member]",
        "terseLabel": "Regeneron's obligation for its share of Sanofi R&amp;D expenses, net of reimbursement of R&amp;D expenses"
       }
      }
     },
     "localname": "ReimbursementOfResearchAndDevelopmentExpensesNetOfObligationForShareOfRDExpensesMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ResearchAndDevelopmentExpensesAndReductionOfResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Expenses And Reduction of Research And Development Expense",
        "label": "Research And Development Expenses And Reduction of Research And Development Expense [Member]",
        "terseLabel": "(R&amp;D expense)/Reduction of R&amp;D expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensesAndReductionOfResearchAndDevelopmentExpenseMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_RestOfWorldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rest Of World",
        "label": "Rest Of World [Member]",
        "terseLabel": "ROW"
       }
      }
     },
     "localname": "RestOfWorldMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_RestrictedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted [Member]",
        "label": "Restricted [Member]",
        "terseLabel": "Restricted"
       }
      }
     },
     "localname": "RestrictedMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "terseLabel": "Revenue, remaining performance obligation, variable consideration amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_RocheCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche Collaboration Agreement",
        "label": "Roche Collaboration Agreement [Member]",
        "terseLabel": "Roche Collaboration Agreement"
       }
      }
     },
     "localname": "RocheCollaborationAgreementMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_RonapreveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ronapreve",
        "label": "Ronapreve [Member]",
        "terseLabel": "Ronapreve"
       }
      }
     },
     "localname": "RonapreveMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Payment to Collaborating Party, Percentage of Net Product Sales",
        "label": "Royalty Payment to Collaborating Party, Percentage of Net Product Sales",
        "terseLabel": "Royalty payment to collaborating party, percentage of net product sales"
       }
      }
     },
     "localname": "RoyaltyPaymentToCollaboratingPartyPercentageOfNetProductSales",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_SalesBasedMilestoneEarnedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-Based Milestone Earned",
        "label": "Sales-Based Milestone Earned [Member]",
        "terseLabel": "Sales-based milestones earned"
       }
      }
     },
     "localname": "SalesBasedMilestoneEarnedMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SalesBasedMilestoneOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-Based Milestone One",
        "label": "Sales-Based Milestone One [Member]",
        "terseLabel": "Sales-Based Milestone One"
       }
      }
     },
     "localname": "SalesBasedMilestoneOneMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SalesBasedMilestoneTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-Based Milestone Two",
        "label": "Sales-Based Milestone Two [Member]",
        "terseLabel": "Sales-Based Milestone Two"
       }
      }
     },
     "localname": "SalesBasedMilestoneTwoMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SalesBasedMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-Based Milestones",
        "label": "Sales-Based Milestones [Member]",
        "terseLabel": "Sales-Based Milestones"
       }
      }
     },
     "localname": "SalesBasedMilestonesMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SalesMilestoneFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Milestone Five",
        "label": "Sales Milestone Five [Member]",
        "terseLabel": "Sales Milestone Five"
       }
      }
     },
     "localname": "SalesMilestoneFiveMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SalesMilestoneThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Milestone Three",
        "label": "Sales Milestone Three [Member]",
        "terseLabel": "Sales Milestone Three"
       }
      }
     },
     "localname": "SalesMilestoneThreeMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SanofiCollaborationAgreementAntibodyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi Collaboration Agreement, Antibody [Member]",
        "label": "Sanofi Collaboration Agreement, Antibody [Member]",
        "terseLabel": "Sanofi Collaboration Agreement, Antibody"
       }
      }
     },
     "localname": "SanofiCollaborationAgreementAntibodyMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SanofiCollaborationAgreementImmunooncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi Collaboration Agreement, Immuno-oncology [Member]",
        "label": "Sanofi Collaboration Agreement, Immuno-oncology [Member]",
        "terseLabel": "Sanofi Collaboration Agreement, Immuno-oncology",
        "verboseLabel": "Sanofi Collaboration Agreement, Immuno-oncology"
       }
      }
     },
     "localname": "SanofiCollaborationAgreementImmunooncologyMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SanofiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi",
        "label": "Sanofi [Member]",
        "terseLabel": "Sanofi"
       }
      }
     },
     "localname": "SanofiMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SanofisShareofLibtayoU.S.GrossProfitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi's Share of Libtayo U.S. Gross Profits [Member]",
        "label": "Sanofi's Share of Libtayo U.S. Gross Profits [Member]",
        "terseLabel": "Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits"
       }
      }
     },
     "localname": "SanofisShareofLibtayoU.S.GrossProfitsMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ShareOfProfitLossesInConnectionWithCommercializationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Of Profit (Losses) In Connection With Commercialization [Member]",
        "label": "Share Of Profit (Losses) In Connection With Commercialization [Member]",
        "terseLabel": "Regeneron's share of profits in connection with commercialization"
       }
      }
     },
     "localname": "ShareOfProfitLossesInConnectionWithCommercializationMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ShareRepurchaseProgramJanuary2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase Program, January 2023",
        "label": "Share Repurchase Program, January 2023 [Member]",
        "terseLabel": "Share Repurchase Program, January 2023"
       }
      }
     },
     "localname": "ShareRepurchaseProgramJanuary2023Member",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ShareRepurchaseProgramNovember2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase Program, November 2021",
        "label": "Share Repurchase Program, November 2021 [Member]",
        "terseLabel": "November 2021 Share Repurchase Program"
       }
      }
     },
     "localname": "ShareRepurchaseProgramNovember2021Member",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SonomaBiotherapeuticsIncCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sonoma Biotherapeutics, Inc. Collaboration Agreement",
        "label": "Sonoma Biotherapeutics, Inc. Collaboration Agreement [Member]",
        "terseLabel": "Sonoma Biotherapeutics, Inc. Collaboration Agreement"
       }
      }
     },
     "localname": "SonomaBiotherapeuticsIncCollaborationAgreementMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SonomaBiotherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sonoma Biotherapeutics, Inc.",
        "label": "Sonoma Biotherapeutics, Inc. [Member]",
        "terseLabel": "Sonoma Biotherapeutics, Inc."
       }
      }
     },
     "localname": "SonomaBiotherapeuticsIncMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued/Distributed During Period, Value, Employee Benefit Plan",
        "label": "Stock Issued/Distributed During Period, Value, Employee Benefit Plan",
        "terseLabel": "Issuance/distribution of Common Stock for 401(k) Savings Plan"
       }
      }
     },
     "localname": "StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_UnrestrictedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments whose use is not restricted in whole or in part, by contractual agreements or regulatory requirements.",
        "label": "Unrestricted [Member]",
        "terseLabel": "Unrestricted"
       }
      }
     },
     "localname": "UnrestrictedMember",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_UpFrontPaymentToCollaboratingParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Up-Front Payment to Collaborating Party",
        "label": "Up-Front Payment to Collaborating Party",
        "terseLabel": "Up-front payment to collaborating party"
       }
      }
     },
     "localname": "UpFrontPaymentToCollaboratingParty",
     "nsuri": "http://www.regeneron.com/20230331",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r156",
      "r157",
      "r254",
      "r259",
      "r453",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails",
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r207",
      "r465",
      "r519",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r296",
      "r407",
      "r424",
      "r443",
      "r444",
      "r462",
      "r473",
      "r477",
      "r517",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r296",
      "r407",
      "r424",
      "r443",
      "r444",
      "r462",
      "r473",
      "r477",
      "r517",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r207",
      "r465",
      "r519",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r204",
      "r409",
      "r463",
      "r475",
      "r513",
      "r514",
      "r519",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/LegalMattersDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r204",
      "r409",
      "r463",
      "r475",
      "r513",
      "r514",
      "r519",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/LegalMattersDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r289",
      "r296",
      "r321",
      "r322",
      "r323",
      "r383",
      "r407",
      "r424",
      "r443",
      "r444",
      "r462",
      "r473",
      "r477",
      "r510",
      "r517",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r289",
      "r296",
      "r321",
      "r322",
      "r323",
      "r383",
      "r407",
      "r424",
      "r443",
      "r444",
      "r462",
      "r473",
      "r477",
      "r510",
      "r517",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r156",
      "r157",
      "r254",
      "r259",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails",
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r205",
      "r206",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r464",
      "r476",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r205",
      "r206",
      "r432",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r464",
      "r476",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r12",
      "r474"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r208",
      "r209"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheDetails",
      "http://www.regeneron.com/role/ProductSalesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r131",
      "r418",
      "r429",
      "r430"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r19",
      "r22",
      "r89",
      "r375",
      "r425",
      "r426",
      "r489",
      "r490",
      "r491",
      "r496",
      "r497",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r4",
      "r474"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r496",
      "r497",
      "r498",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedLabel": "Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r86",
      "r87",
      "r297"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation charges"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Total adjustments"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Stock options (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r470",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-Backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r104",
      "r111",
      "r125",
      "r153",
      "r195",
      "r198",
      "r202",
      "r222",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r347",
      "r349",
      "r364",
      "r474",
      "r515",
      "r516",
      "r527"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r121",
      "r133",
      "r153",
      "r222",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r347",
      "r349",
      "r364",
      "r474",
      "r515",
      "r516",
      "r527"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Assets, Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r211",
      "r229"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost Basis"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r59",
      "r213",
      "r417"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Maturities after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r59",
      "r212",
      "r416"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Maturities within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r56",
      "r210",
      "r229",
      "r410"
     ],
     "calculation": {
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Available-for-sale debt securities",
        "totalLabel": "Total",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/InterimFinancialStatementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r41",
      "r42",
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Accrued capital expenditures"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "auth_ref": [
      "r97",
      "r98",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by project.",
        "label": "Project [Axis]",
        "terseLabel": "Project [Axis]"
       }
      }
     },
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r40",
      "r123",
      "r447"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.regeneron.com/role/CashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r35",
      "r40",
      "r44"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
      "http://www.regeneron.com/role/CashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r35",
      "r95"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "verboseLabel": "Statement of Cash Flows"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CashFlows"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit",
        "verboseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r153",
      "r173",
      "r177",
      "r179",
      "r181",
      "r188",
      "r189",
      "r222",
      "r245",
      "r247",
      "r248",
      "r249",
      "r252",
      "r253",
      "r257",
      "r258",
      "r261",
      "r265",
      "r272",
      "r364",
      "r445",
      "r484",
      "r494",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r344",
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration, License, and Other Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Class A Stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r496",
      "r497",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "netLabel": "Common Stock",
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common Stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common Stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common Stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r3",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "terseLabel": "Common Stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r3",
      "r474"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r23",
      "r139",
      "r141",
      "r147",
      "r412",
      "r420"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Statements of Comprehensive Income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r51",
      "r52",
      "r92",
      "r93",
      "r207",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r51",
      "r52",
      "r92",
      "r93",
      "r207",
      "r431",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r51",
      "r52",
      "r92",
      "r93",
      "r207",
      "r433",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r51",
      "r52",
      "r92",
      "r93",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r49",
      "r51",
      "r52",
      "r53",
      "r92",
      "r94",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r51",
      "r52",
      "r92",
      "r93",
      "r207",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of accounts receivable and deferred revenue information"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r274",
      "r275",
      "r286"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r274",
      "r275",
      "r286"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r274",
      "r275",
      "r286"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "netLabel": "Corporate bonds",
        "terseLabel": "Corporate bonds",
        "verboseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r28",
      "r409"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods, collaboration and contract manufacturing"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total Expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r50",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer concentration risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r219",
      "r233",
      "r459"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Fair Value - 12 Months or Greater"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r219",
      "r233"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedLabel": "Unrealized Loss - 12 Months or Greater"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r219",
      "r233",
      "r459"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Fair Value - Less than 12 Months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r219",
      "r233"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Unrealized Loss - Less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Available-for-sale Debt Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r217",
      "r230",
      "r459"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "totalLabel": "Fair Value - Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r218",
      "r231"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Unrealized Loss - Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r216",
      "r459",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Fair Value and Unrealized Losses of Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r328",
      "r329"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r38",
      "r193"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r285",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of collaborative revenue",
        "verboseLabel": "Schedule of product sales"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables",
      "http://www.regeneron.com/role/ProductSalesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r148",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r171",
      "r173",
      "r179",
      "r180",
      "r181",
      "r185",
      "r354",
      "r355",
      "r413",
      "r421",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income per share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r148",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r173",
      "r179",
      "r180",
      "r181",
      "r185",
      "r354",
      "r355",
      "r413",
      "r421",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net income per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareDilutedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r72",
      "r119",
      "r142",
      "r143",
      "r144",
      "r158",
      "r159",
      "r160",
      "r162",
      "r168",
      "r170",
      "r187",
      "r223",
      "r273",
      "r325",
      "r326",
      "r327",
      "r335",
      "r336",
      "r353",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r375",
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r126",
      "r363",
      "r449"
     ],
     "calculation": {
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r422",
      "r506"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedTerseLabel": "Losses on marketable and other securities, net"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r221"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Securities owned not readily marketable"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r356",
      "r357",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r255",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r357",
      "r380",
      "r381",
      "r382",
      "r460",
      "r461",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r356",
      "r357",
      "r358",
      "r359",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r255",
      "r290",
      "r295",
      "r357",
      "r380",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r255",
      "r290",
      "r295",
      "r357",
      "r381",
      "r460",
      "r461",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r255",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r380",
      "r381",
      "r382",
      "r460",
      "r461",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r360",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Measured on a recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r214",
      "r215",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r232",
      "r234",
      "r235",
      "r256",
      "r270",
      "r351",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r459",
      "r503",
      "r504",
      "r505",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r25",
      "r101",
      "r106",
      "r116",
      "r195",
      "r197",
      "r201",
      "r203",
      "r414",
      "r458"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r237",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r154",
      "r332",
      "r333",
      "r334",
      "r337",
      "r339",
      "r341",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r155",
      "r169",
      "r170",
      "r194",
      "r330",
      "r338",
      "r340",
      "r423"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Increase (decrease) in accounts payable, accrued expenses, and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Decrease in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r408",
      "r492"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "(Decrease) increase in deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Increase in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Increase in prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "verboseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r181",
      "r298"
     ],
     "calculation": {
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Effect of dilutive securities (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r63",
      "r64"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r96",
      "r108",
      "r145",
      "r192",
      "r373"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r62",
      "r450"
     ],
     "calculation": {
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r132",
      "r448",
      "r474"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r62",
      "r452"
     ],
     "calculation": {
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r61",
      "r487"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Inventory valuation reserves"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r62",
      "r451"
     ],
     "calculation": {
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Marketable Securities, Based on Contractual Maturity Dates"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r60",
      "r102",
      "r109",
      "r117",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LegalCostsPolicyTextBlock": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.",
        "label": "Legal Costs, Policy [Policy Text Block]",
        "terseLabel": "Legal Matters"
       }
      }
     },
     "localname": "LegalCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/InterimFinancialStatementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "Legal Matters"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LegalMatters"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r13",
      "r153",
      "r222",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r348",
      "r349",
      "r350",
      "r364",
      "r457",
      "r515",
      "r527",
      "r528"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r8",
      "r105",
      "r114",
      "r474",
      "r495",
      "r507",
      "r525"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r14",
      "r122",
      "r153",
      "r222",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r348",
      "r349",
      "r350",
      "r364",
      "r474",
      "r515",
      "r527",
      "r528"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Long-term debt fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r66",
      "r67",
      "r239",
      "r240",
      "r241",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r66",
      "r67",
      "r239",
      "r240",
      "r241",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r66",
      "r67",
      "r239",
      "r240",
      "r241",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r35",
      "r36",
      "r39"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r26",
      "r39",
      "r107",
      "r115",
      "r120",
      "r137",
      "r140",
      "r144",
      "r153",
      "r161",
      "r163",
      "r164",
      "r165",
      "r166",
      "r169",
      "r170",
      "r178",
      "r195",
      "r197",
      "r201",
      "r203",
      "r222",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r355",
      "r364",
      "r458",
      "r515"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income - basic and diluted"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Outside United States"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r41",
      "r42",
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired",
        "terseLabel": "Accrued contingent consideration for Libtayo intangible asset"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r195",
      "r197",
      "r201",
      "r203",
      "r458"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Interim Financial Statements"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/InterimFinancialStatements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r134",
      "r136"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Unrealized gain on cash flow hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r24",
      "r72",
      "r138",
      "r141",
      "r146",
      "r365",
      "r370",
      "r371",
      "r411",
      "r419",
      "r489",
      "r490"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r135",
      "r136"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherInventoryNetOfReserves": {
     "auth_ref": [
      "r61",
      "r486"
     ],
     "calculation": {
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after of valuation reserves and allowances, of inventory, classified as other, expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Other Inventory, Net of Reserves",
        "terseLabel": "Deferred costs"
       }
      }
     },
     "localname": "OtherInventoryNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other non-cash items, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other (expense) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other operating income (expense).",
        "label": "Other Operating Income (Expense) [Member]",
        "terseLabel": "Other operating income"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedTerseLabel": "Other operating (income) expense, net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchases of Common Stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Payments in connection with Common Stock tendered for employee tax obligations"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).",
        "label": "Payments to Acquire Interest in Subsidiaries and Affiliates",
        "terseLabel": "Purchase of preferred stock"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable and other securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r149",
      "r521",
      "r522",
      "r523"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred Stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred Stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r2",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred Stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred Stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r2",
      "r474"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred Stock, par value $.01 per share; 30.0 shares authorized; issued and outstanding - none"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r488"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of Common Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "verboseLabel": "Sales or maturities of marketable and other securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProjectMember": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Planned program of work.",
        "label": "Project [Domain]",
        "terseLabel": "Project [Domain]"
       }
      }
     },
     "localname": "ProjectMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r509",
      "r526"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Property, plant, and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r88",
      "r118",
      "r535"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "(R&amp;D expense)/Reduction of R&amp;D expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r485",
      "r493",
      "r536",
      "r537"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash included in Other noncurrent assets"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock awards and restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r5",
      "r79",
      "r113",
      "r428",
      "r430",
      "r474"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r119",
      "r158",
      "r159",
      "r160",
      "r162",
      "r168",
      "r170",
      "r223",
      "r325",
      "r326",
      "r327",
      "r335",
      "r336",
      "r353",
      "r425",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r190",
      "r191",
      "r196",
      "r199",
      "r200",
      "r204",
      "r205",
      "r207",
      "r284",
      "r285",
      "r409"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Up-front payment to be made to collaborator"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r287",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Product Sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSales"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CashFlowsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Summary of Non-Cash Investing and Financing Activities"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CashFlowsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and Diluted Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": {
     "auth_ref": [
      "r46",
      "r48",
      "r173",
      "r177",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Complete disclosure pertaining to an entity's diluted earnings per share.",
        "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r356",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of assets measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r9",
      "r10",
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory, Current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r44",
      "r103",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CashFlowsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r69",
      "r70",
      "r71",
      "r73",
      "r74",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r128",
      "r129",
      "r130",
      "r188",
      "r257",
      "r258",
      "r259",
      "r261",
      "r265",
      "r270",
      "r272",
      "r462",
      "r484",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": {
     "auth_ref": [
      "r80",
      "r81",
      "r82",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table Text Block]",
        "terseLabel": "Schedule of Shares Repurchased"
       }
      }
     },
     "localname": "ScheduleOfTreasuryStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r49",
      "r51",
      "r52",
      "r53",
      "r92",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedules of sales to customers as percentage of total gross product revenue"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general, and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "SG&amp;A expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedTerseLabel": "Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SovereignDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by foreign government (not within the country of domicile of the entity).",
        "label": "Sovereign Debt Securities [Member]",
        "terseLabel": "Sovereign bonds",
        "verboseLabel": "Sovereign bonds"
       }
      }
     },
     "localname": "SovereignDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r153",
      "r173",
      "r177",
      "r179",
      "r181",
      "r188",
      "r189",
      "r222",
      "r245",
      "r247",
      "r248",
      "r249",
      "r252",
      "r253",
      "r257",
      "r258",
      "r261",
      "r265",
      "r272",
      "r364",
      "r445",
      "r484",
      "r494",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r16",
      "r72",
      "r119",
      "r142",
      "r143",
      "r144",
      "r158",
      "r159",
      "r160",
      "r162",
      "r168",
      "r170",
      "r187",
      "r223",
      "r273",
      "r325",
      "r326",
      "r327",
      "r335",
      "r336",
      "r353",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r375",
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r187",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r2",
      "r3",
      "r72",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r2",
      "r3",
      "r79",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of Common Stock for equity awards granted under long-term incentive plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Share repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Remaining authorized repurchase amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r2",
      "r3",
      "r72",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedTerseLabel": "Repurchases of Common Stock (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r2",
      "r3",
      "r72",
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedTerseLabel": "Repurchases of Common Stock"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r3",
      "r6",
      "r7",
      "r54",
      "r474",
      "r495",
      "r507",
      "r525"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:",
        "verboseLabel": "Stockholders' Equity Attributable to Parent [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r84",
      "r152",
      "r258",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r273",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r372",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r372",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r372",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSonomaBiotherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business.",
        "label": "Trade Accounts Receivable [Member]",
        "terseLabel": "Trade accounts receivable"
       }
      }
     },
     "localname": "TradeAccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r214",
      "r215",
      "r256",
      "r270",
      "r351",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r503",
      "r504",
      "r505",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "negatedPeriodEndLabel": "Ending Balance, treasury (in shares)",
        "negatedPeriodStartLabel": "Beginning Balance, treasury (in shares)",
        "terseLabel": "Treasury stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r18",
      "r80",
      "r83"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Value",
        "negatedTerseLabel": "Treasury Stock, at cost; 23.5 shares in 2023 and 22.6 shares in 2022"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r3",
      "r72",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Number of shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityScheduleofShareRepurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r72",
      "r79",
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "terseLabel": "Total cost of shares"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityScheduleofShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r415",
      "r470",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "netLabel": "U.S. government and government agency obligations",
        "terseLabel": "U.S. government and government agency obligations",
        "verboseLabel": "U.S. government and government agency obligations"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r172",
      "r181"
     ],
     "calculation": {
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding - diluted (in shares)",
        "totalLabel": "Weighted average shares - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r171",
      "r181"
     ],
     "calculation": {
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding - basic (in shares)",
        "verboseLabel": "Weighted average shares - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6806780-109447",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "https://asc.fasb.org/topic&trid=2134446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r478": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r479": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r481": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r482": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r483": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>71
<FILENAME>0001804220-23-000016-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001804220-23-000016-xbrl.zip
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M0/!3$. ;0*"BQ3(:E85@4<:\9YEAB&728XN0I31&L_("D^?)-#R:_*<LY#,
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M&7R<%G#KTV5C-)@KS*T)FB$M3,"18Z<,"B[ZJ$K 8"JM6"RMF O3\M@1$Z0
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M.90%AH,5? .+9#UQI@+0PRR\*W,*4(>B"Q++F,Z(I @#NPA(<ZIT!,Y1AA-
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MGO' K396&"JR'6J4DR)8EKQP%-4Y/:.4U;33^^)B'[>G2V9HIEK.&PV.3FH
MC0<K$LO?*1H5YG>]:K)D9HF,R2=@,CY.P[ IY*E%+@O#H:DB%X]>*V,R!!&O
M,OI@+$TE);!HHO$8%?.RZ2*7%F%190Y7]-=J1&\EY5JB<(I:JYWA21-.+)'$
M5N;P$!I[G3FH1"A1*@'7Q4&=Q03.1U=B<"%%%KT1+#,'IAISX+1(7RMW>*3<
MH2GLJ6D]=T:<J1(33QR34D3(.Q!!8'+@>-2 )*'T%+77HLD2DXHW%6\67A2"
MQA03G 85A1$4'=$VBB0$1QV%;\I6J4&L.SI.IHM"4 AGDO5 B-'99 D9CB23
M$*1(5!,3#)89/:OYW<8RIBLD54A:-"1QX_/S24U33,)9XCQ1Q"4O!3,D:EXA
MJ2V0-%7%0;/EQ=%)T-;YS) $@U)9",33R+U-4CE2TIY7K3)KO&)2Q:1E26E,
MWG$:*5&1"Z%I1*E4(M*J3).DE_'KH%3K+A8'0%-U%RY8JE0P4#HR0,G&!DN=
M!N6%$B0*&J);69_I$YH[8[%%N//(W;=SEE"8S!94\,PR(H2A:+V("2-7.@:N
MU#_H:BVA6)2F3I50&,XQR,P2D@P4A$P>C+<:C(B.L\2I=C%3!3NCW= R:VIE
M"(^5(=P>=6K1PP.!TE31 [$AVYM49"CB!(21&91,D!!%WKO!<Y&,+RX5ILB:
MK;A4<:G]WI2D/#4APQ!U3"1G4<5@=?".9F-<8'7PM@6-IJL4G(TN:&>!,(8@
M%''@M'=@H]=1. R6RXDW12O3J@2YAF:=GL,,F8$SDY^[_1#[XV=0AI.V: KJ
MSFAT6G)^R[C3<Z.A,]&=HBV=.-&<#OZ-PS#JO!EBUM20U3=K5:<WZ+^!<1P>
MEZ&I^<G*^-237KZ1.C&USGBI8JIB:A_=F.E^2<HIQCPICM$R \%(K;37*F;#
M/CK&)]-XV.4T'G;# LD"JS%LG0[SVCW/CS$(Y[Z8R=>?<!1#F=<3^R,LMUCI
MQUST8V<ZO<Y$$I,/"BB&$LJQ%*R+"$YHE@+SC*A4$O.G^]=4;6ZW-E?070HQ
MS9/$PY)CUH<@(@IGG*76<Z$-%=:$;/\UA;A_8.\T5L!M!'!G)/1P9Q,/20/W
MLMA[6F93CS#0#*D4(2I-Q<JZM/SN+5ZK-E?0K6*J8JIBJF*J8GKB8IJGM%5X
M(A@+8M)^ED3+'"JN23!(DR:^,LT6,LWIR(+@3#)J.)3FVB"HDH B$O">RYBM
M!Y%8;!_3;*AAR'*&%;X()8QCB1B4R,%)?BU^B$/?'4TB#J/)^X.3(JI1!_NA
M\SZ.QOGIRYO#_.VPZTO(8?0Y)'%\TAN<Q=@9XX?.P.4'G:C9[:(.3SM/[7;G
M7?N2 :J8JI@>7DQS9GTV'W:8?,IS[(:?!\-#_/!G=WQ4$B#R,N87*CEI@)SL
M3L<=!,I(.-5 K3<@4%,PQB:PAF! E)Y94XIL:P+W$JER1=RE$-,\Z:Z-QQPV
MPMO3T?@X<^_1B]C#3%(/!Q5U%X.Z,X(/P1!'K210IK.#D%@:L64$5J4TW//@
M#=5EQ)R<D6E6D;>U*EV1MXJIBJF*J8JIBJEM8IJ';C8>>*AT\Q[IYG0$PG-K
M:%0*G..Z3#1.I7N?!H["6"Z$1\U:13=K34/?QQ]"MT00W.E$76<5. A"OWOW
M?>< W^>''G6>][!?RQ=JX+R*J8JIBJF*J8IIZ<7T$#[B8<Q/?355Z)*&S,@:
MVK[(9_@I]F/JC@L#J81]+L+^^RS_,+5.(V$* G<6A%<:T D!RCBF5$)O*"_M
MMN]>B%PUN@)O%5,54Q53%5,K:(QRR0OF962<"A\#YJ.02)=4TM)S%2N-:2V-
MF>KPA,I+Y3""4!A )*O F8 @>(A!6"JY$J6LN4UYSU6AVUK%4!7ZGA5Z.I!@
M94A4: ^:H@,AM ##*0?M47L9:*+:9H46=V^!W[Y*AH?IOW:SD,&+>'(Z]$<X
MRE>\%BBHE04UHEW%5,54Q53%5,54Q53%5,54Q53%M$QBFK,XL3$7XA=]$S[;
M6#,:(U;GPES.A9>SAE00B51R2L!IS4$XAV#1<F!!H2&))4]2*4:<]BW4DI@E
M5-T%NOYOHK<3-V%5V[G5=LK)+YU246L*,BH!@H0$CD4)-ADB.4]2*;JRSB5;
M(U5Q'Z?B+J91457<)A5WVIFO@_6DG+(2LV!$X :L%AZ$-<2KTG^8V%8I;D-5
M 6UVY$\V/KBRY_,C?JZ"Z60]&+Z)=3I!31&I8JIBJF*J8JIB6GXQM:0%S.%@
M(R]=N0/LE19<._U-/.F.L3=Q;KGK);DORF"E47<<#^+P?=?'<U[^(OK!F_[D
M*I6BST_17\VJ U FBULF <B\ N$%EGED#CS3A$?M!,$R%T3)&0,2J^ZW6_<K
M1%<Q53%5,54Q53&U34PMZ153>6DK>.F,AC*:4VNE!>&T!D$I!\M) .,QR40L
MD3JTCY<^@43PO3@N VT'Q['F?==LH"JF*J8JIBJF*J8JIBJFEAE.2J1(B3%$
MAR!<%)ATM!%EXOD6:11S&TZ9^^U,J-]O@U%-2)W/RO'CW<.=J1&Q.GFK101D
MFI:TF#*X*^4?O:&4."$I]2OK5O.[E[M61:UX6L54Q53%5,74"G;2N%NWLI,[
ML9-I'RPK20 8%7A' PC#(UA&'6AC(T%)F*6F?>SD">3P[H^/XG"2O3N,1[$_
MZKZ/G5[>]*N=?AR7]AQC_%#S>&OHL(JIBJF*J8JIBJF*J8JIBJF*Z1:EITXZ
MKU$):A,5G'GDSH@440HJDL:;#*(>Y0?.WUTW6"<T?O,JB_]LOV9C=C\=XH=J
MQ\YEQ[X9[Q[^?MV.C90SF8(%+\HLU&RW@L5LS!I$31(R#++D$@D^(Y?HYF6H
M58DKUE8Q53$MJ9CNN1M#/1+O\4B<=NT&&H,BAH"U3H&PS)1N*A0"U1*EIYKS
M=AV)2YU9.Z6">J8*_H2],I5QM;.+0W_4X72U4]1GH7FV-[B&&PQ#',)X</*L
M2&\TZ'5#IZS&/RUN^P!NO@YOEBLKF;>4<!1>,D.I82R_ZE7*B^)>[]PL*'7>
M*'O2=..\C]O^Z7@TQGY9MPID<P'9N_%NMX#8=@:TG0][AZ_$:V&DDDDRX(YS
M$-)S<%%Q*)&KY!(CVI:QLS.&6"U"J9I1I)E\X0&Q:K8V_<^\H;T;/OR28L@T
M1VH*0";04498Q^%H^[^GW?'92IG,>XSC_"$?QL]2]T,,\#$.!Q5.YH23O<UK
M<!(QD(@\ 3%&@& BPXD/#)BC1"6F'++PR:!I*.1]X]-U6;)6[H!R2Z3P,TF#
M5CPQ01S7D8MDH]6><F>5T('E]V(E#0^AY==) R5>**T26)$R:2 8(&],"L8:
MHITDTAE71E_J-?64=+RRE\I>&D>R6>REXM=<^+5_G:4H+KT.-H!F(8!P&<E0
M&@W.*()$Z$Q3=.EB32MZ5?1ZDN@5-+/,.Q>$8<*5\UP8'ZPSE$FEA6[*]NJ?
M'D,8C.'B&A7:YO7G3/<CB^AD2(2 QI!-L.*3=M3E'XFP#FD,0>+*NEG54E2
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M ,;@--KN\(V;<'/+Q>Y0;<3(FTI6(%ZWT_ZPS6)-?SZ,L5^!SVSE)$(S0+Z
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MM@CT^9O0T1GK/'+4<L2Q(OFWB+33*:3 @PLR%WOEC#U:@,BJ9,LL ;$$Q E
M#([CX*GC4<+>"-Y0J3BE,5!M9*)N[@1+)2 ^+R"*24 DW H)\CB2(N+LBZ<
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M>&D-VEZN"!>[>9;L09RN;';3 BSJ>/=&10!Z;V\NBO'@D@ SJVK<.B!/7DK
M5"FY5RD!2:M,R 6DT<>,/WX:?5$U;!$%"A;66+-L.?_+1/Y/H:E[ 0G:R]3V
M*YO:_CIET_ 9C5QIL_\6+4#[=$=CTA_93%.IQ5PZM/D&J,!Y0=S3\PJ:O<X
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M&Z:>3O.W$ V<@=PB!0<>XM8[I'&@2"HF8!(%P<J!W/E@3'V<W&C/#YLE8BP
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MTAETAX$<Q2+-1MR=XSA<T+W\/8Q-.PX%S>R565SO+R_[WO#S43!)=O$:QFG
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MZTAI%R/@D5!1\J2]Y8I(0WEDL 7L[04[RT/KJ1;57CZTG-:8T1B0B5$#O>(
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MS.#P\7"]@%VX]9R)6T=!0]#KC=8PI";?\BGV^D4 WSUVVA5\&&5S*^J%?ZK
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MR*X^+(Q:C,!UA537?AW:N8<772[R>JFBZS I>6CT^MV&&_2'.0&][36ZC1^
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MF$#[?];/0G-G\U,+^@=M_G18:WV O_]L[-$:VSMJ-N#^TUKKGYF%"410G(M
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MT+T5E7W2%64?:3G9P&RP6BOKHI4EODY"H":*2 6G$.^PP$&MW[(8KMR:4_W
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M1#OXZ?A0 )3>Z$A"S_")8%2^5:+J2B;>!D38#S":LI-@JQT42?R4I9IQWTF
M<+W&X[K&4PA$?3$<'10DP2TJ7_^"]VY])MZZ2;NZE3#O$1^-+9"RDU18CY:Q
MD8$F!RG$ #$&+E.":34!SG@]YVJK3;!9[($>_=;8!7NOOW6W/\A/UEJ>0^"$
MQAR)S-00!XP1PV5(:.CI!$W_1&<>93NA2E>5KFKR\=+05_?%!?HRRMG@&"6@
M@B>2Z41\HI%HI1.7U&F:\\*RCRM]5?JZKW.FA^:O>LYT*YZZJ&8%B\MF 8A7
M5A&IK" 652J2M/%42,Y5AI5U[M@CJ\96"6J9"*H%_%2/ANZ#G[9F]*C$@U1<
MDZQ*47I%,_&9>6(U%33S;$PRQ0S45C[&?G53YJ%SJ*?Y=V^08#!Y1MS!S' F
MPX,' NO[M7=KG9W2RVZPCZ/K^$$Z]\\=&,2CSC#@,!O?>6UT=[=].*R7(3AK
M*6+$&^E3R"%+RY1/AJE8_6/M)\;7L_XQ8QG+B1M"E:5$"D!B].")L-Q( \98
M-VWD*56K&G94?"\GOFNH\YW@>L9Q1!.PX-$,0W45<:V,)SY%02C3B:N8B^^[
M9*37"I7+ANEKM<)[8%!7+\NM0'U16+.8@$>A2539$2G!$.L-_M&>.@8F2%VL
MF#F@KC7K6HOG%L"Y.B7N \XS3@D1=/3<*N*\DBBCE2&.H18N:%;.21&MR8WN
M+5RK=.^G$$KTKG@:\(W!W84278G7GD2I#>5%J;4!N$5+BV9M#0CK/>(@Z@3"
MW)UOH5+8-2AL<]9]H(0'HX4DW+$27I,M\4%EXHUU3&7IK2SA-:96OJKXK<$H
MRP7V&9^"0!U":Q5)B :(#%01+P4EU!G/42]E(CWF8)1'CO?K^!4>&O#5KW K
M8,_X%8RW$ V*;?"<2%H:VI@LB(!@"K9Q@_"5=;%&'U7LQB/'<PO@7$O=+0BQ
M,ZZ#E)DS&K5M[6Q&O1LH<5HG8IPU*1BA$J[5NI:MTKN?1">]X?X^C&+/]SL'
M_@!&-2CA+HE+,%!1H^X)EDH3C 4=!95,(9EEGJ$Z#EI!8&]F'0>)!9J$T&A+
M"$6DB0Y5#C0HK.$^*AN3B'9EG?%Y :/UA+("N'H.6HSV&<]!XL$;KRCA7$8B
M@Z4D>!N)LE:#PAT@4ZA-]"K>[QSO%QP'%>^+P?M%Z:YC L9,20+QDDC(FECA
M$J%&&%Y<#9[7IID5[S?'>_4L+ BZ,YX%B [!F4J:O-%$>@1QL"P1#9IGST+@
MS+5/,7\*(0DORE@RCF8"36F@! ?#<6]20Q/NDL!8,L[92*GU6JH@G=%:9J93
M3ME%43T,[2"R][,>!A%<BC9PPI'/B#0Z$A\U(Q3WA!*<I42+A\'R5OE(*X"7
M$\#5PW"O:)_Q,"C& #081#NU1-)2Z9C10)Q M47+9MEK;,*RXOTZL0D/#?@:
MFW K8,^(<<T"C9(39@P".P=)?):4.!HMDXRY3-G\UIHU-J&U>&X!G*L'84&(
MG?$@*"V%=19(=EH3R64B5A3)S)A05'O-2I924;QGXXEJ<,)=PN[Y> P34AX%
M<%)/MWR-4;A+ J-& [=)*\J4M"%X9BR+-CD5.7>150]"*XCLPQP/@E5.1L%(
MXH(3J:0KIQB!*.643CIQHTKW%%N3J"M^JP-AN< ^XT"0G-$< ^HJ/B/8O;+$
MRH1:BPY4I!"!>U:/+)<5[]=Q(#PTX*L#X5; OBC%01N>F;6H]T)I=9LC\24J
M :6X5SQP:34"FZV96C1A>?#< CA7!\*"$#N;W!"<"%%[ M2HDMS@2*!*$IH\
M-<$;'61 O=NL\1;)X=M&(-Q%DZ9?_>ZX,=/T0>;U9GJ:W1 7/#N/ADE+8EA4
M-B2P0D;)?7 >>=18Q6W0=^G)J&5H%D6W<=;-$:6G.3%'5#*>2)$M<2$)PETP
M@DHIE#1-WT3!YQVSW,QENR!PM;S\=R782K#M(]A:@_-.B'7&I<1S\LG*2*QB
MELB8BO_82H+62 RV>):-6D@-SLJIE5.?%*=>QYWWT*1:W7FW(M696B56&A"9
M$68%$&FL)C903X"99'"! S5T95U0OF9O'Q%4&;4RZM-@U!80:JU">Q^$.N-M
M99I3ZB,E/C%!)#@D5,\242E1C2JLS%DUYC]E]O8>UW80:^.L_6U2-M]I$_7I
M<W4/]Q% L>D(?_(4^WZTTQN<#-8BGH[?*:.SY_EN[W \Z>6C^T<Q+RC>WH7.
MB^$^WOFH$_M^/.YE!%"G-\'_'WR!\:2TSBFO._X$? 3!1<8((<1JF)R)"NL$
M/X;402Z8X#U&#0>413_T_0ZBL7SKJ)-*,MI:I]SW"E?T3=[:IA_%W7/][,7T
M@GB-2>>+'_6&A^/IE?'6N'MV=CO/#W=P8LMW[5KGCW-+=9Z<0F"\-,?,C(-T
MRCOGP1G-<I:*4^D^;93[4489:5Z(PE+G>>GUCYEZ<3*'Z9]'+WX\_^;QXV_@
M&+?+(V_C_?_9'\;/RTE"??B?MT<?_TX'@4O]X?M+\6$O[7]\]?%S=^_EU^[&
MOWK=O=W>)G_#ME[]M?=Q(^&X=S\C&96RUF+SS2<EDW06+!'6,2(S5R1XZ@BN
M1+;&.0F13H5(;W (Z7FA\FB8 BD@)E\JF$?O%+4,2F 59\8@G0,R^P&NRV1T
M"-.MG3WNPR^^?SA-@+S*'CZ:OV_QS7$/-Q1>95(N/.SWAU\+J\SPP FQ-21Q
M55)@XCPK1-Q,,#K7;(N)-=5H:7B_XYEIVEA--] O9P=9MCSY*=%.Z1)YIN\/
MQO#LY,7OJ3<^Z/NC9[U!PQ;-CWX_/W8UI^M7&>CTX]^_]M)D]YF6:]*(HB@<
MGW$=WWCZ*5MK=(@+[#_]3.$OE;KT8[K&;OB9$^)&O_S98)E;<]8NT6#=U0;T
MB]/):QQ"WN"K<\R"8T \C 9LYFK C5CJH$2Z0CCTHYV$#8BP'V T,P]7W$ M
ML0";*S[K3?!N\2KNI->##MZH7[H(SO@(GM+R%Y7HB3\_O\ZV?Q19(<?:;%&7
MOO8FNV@<# ?0.0)_)\4K?_6[2PV_Q^YNNO;S/QJ'4F V6*V5==%*#S)("-1$
M$:G@%%7@QJ%T;*K=W*'T8YO_W>SRK0%\P#W^)]H4?Q63XBFXF=[S#]M_[77W
M_]KM[OWS<_?[V]WNJW_UBHL)[Z\V]SZK[OX;O,;NWD4W4W?[XV[W[TW^\>^7
M?//5&]%]]9)^:*[_%I_U\]'6]F?^<6,7K]7-FSUZU+B8WM&CS;V7#)_Y$Q@O
M3#:"B" \FHA>$R>Y(9J[G+0T"2"MK*M5*L7">AU=&4H/'*M;*;%2XH/XV"LE
MWB,ETHN42%/D+ <@FCI.I$N4N))[E'G02DJJF4-*E*M:Z.6AQ*=0B.V,PNPS
MFC"G^O*INSKWODS?J8WC'I7F^+PL-[+D]G2=_\1E+H0YKHRY>,8\FE4BN14<
M69&2H*4@DKE K V4Y""TH"6GAYG"F,[I-=VBVA(5]TNN'E7<WR?N9S0EKY1$
MZS$04W+!I!><N"PLT<$*")P%"JX8C\*RVVM*M:;,[92A6^H^-:_UGG2?$>##
M7@ABO4"'I_1V$O#PO-\?EOK#Z?D@O<.I[</94(B&)0LOJLIXUV"\[HNSF@Z.
M?>/#IZ0M&$X32<8IU'2T)AX%&XF0I(_ A<VPLL[8FFA1"FR%>,O4G KQ]D"<
M7H2X<%Q(*,9,I@AQF25Q7!MB(_-"1^HDCR4[:%&NGS9X=UJ7Y%Y#VV\]-8^&
M;>_'F?2TXMH?0H.:VHPB,>F]%X2ZC#8C]X8XGS()-I;.@R902Z=A[6H!6M0"
M ;7,R4*53BN=UC2A1T"G,RZX&+(6GG-"C8I$4BV(5SD0Y75*UH'VC-UOEM"]
MI@A="-(_FS1T_OVK9@A<2! XGS:T_D<8_79YZL$Q(F4)W&]:0.&=GXV@CT/X
M L?Q^L=P/?.KXW'0'S_Q >?L<'+Y3V:"-1\HK8GQ2^?BLB'.F\*S?W='/R)4
M=X"$$?C/I'%@/O/]K_YHO/+;^<7$=3L[[]>=LDN6]-+YS/DF\^FN,)W3;8>\
M.!PU>_89X@Y&Y5LX5-^6H71V1T6*_$<OR<@@"V-H#C+FB#J<M5%HJT S"N&3
M65EO<K Z?_SFE_4!AGF)![_,$U^2^DJB7_,(<\AB;G(6I2+;1!.+ :U$:X/0
M $(%D148%>RIFG17&8H_=^F=+SWQO\=L?^KH>^H)BWSSS2>@68#(F4@T$XF4
M!HBE:"$*L(%ER@*#>#$!<7DS@D^S&SO'.8.[PZ_C:=[C:4+E22;D<?;P?XVO
MD%TY5>HFNW[2V?5? (V!DXW7Z>/.@_%JQ^_LC&"GN)-+*N:/'.1.<3'O#$='
M'3_ ;\-@9[+;# &?O=-<L0RF-\ Y[Z62N7DFI[.Y5P 8-'G,)VFE)6>XW+5S
MHMZL_2IULZR5FI>2<N_)E<ZM676CY$K!UAB[_..;9A:Z-74G69!*\#K6.M:G
M/E9W-<3>-FG7+6D6WK]A7,03WICQSB9^??<JH22/=CI.)Z$S''5>H8C% 3[E
M^=@>3GS_/I*3?V:?MR)#^9=>A#M<AY^Y$9Y?5N?E@HGUDV.+:^0IM'R[%L.K
MTUA>5XF'N\IS7^44_?',WP]SME/LV<6FIS^B>:K[K.ZSNL_:/W\_VV=/(6#\
MQ7!T4'0&Z(3A(,W@[,89C(\ZPN!Z#_]H8@BLH\*SH*R42O*80W0@G/3>4.8A
MV:N&9/W<8?[BU(,XWW5>[-%M-$<9G]IACR28X)^[FZ_^W/WX]\NOW;]??ONX
M_89W]]^KS?VW>+^7[,/>9_KQU9^?/^#O9VJ.OGKY]</??_8_;#]G'[;_['<W
M<)3;GX\^ONKN?MC^J[>U_?8SCGEWZ]5?^;3=R)E@ IFI2\E1PE6$TB$ZD.!8
M(EP:Z3/XK"Q?63?4W+[=R+6 LZQU("KU+0GU7:=N?3NY[TR=^_*U2H77H\+O
M%ZF0.1M=BDB%,B$5JB2(BYH1AD"P*GM33B+7[1PBO'9WRLJ!E0-;\-1+1X$G
MU+<U^O=PL .CIQ!H>F^$R"X28M:):1,#D<YF@@N?B&/ B<(UQRU C<B^Y'IS
M)^:T[*W:867&I67&Y=,.+U)CU0YO189B)HE)!X-&L2-)@2_:H24N\T0L+8D3
M'I=:Y95USL6<<C=5/ZPLN(PLV#H2G$]]50M<(/&IF8H_2<HLHB&>HT4L@Q;$
M@H_$*.$U*.#:ZI5UO8I;<4Z?MZH%5OY;6OYKGQ8XGP"KKG>[0Q&DN_.-V)Q!
M;0]7B23!(RI[X$A@P(C6P3E#)7Y4E#W!YMB]+5/V%E0%=LI2= Y-G>VD1-R<
M&/OAP0/!]_W:N[7.SA#',V@2'4I^P]E_[L @'G6& 8?9Q,U='FCRY*L\YA2<
MT%$IR834DGMMA;:!:@TN6^[KZ6_[B>YHSNFOSA!I4D1S73*PD.P"\XQ0%VP(
M.<;H;#%JYQUZU!JN[4;W=927=L*[JC6W0OO, 2>GTEIC+($,B4@3'+$I16(5
MS=PEX;1TI<S9;0XX*\RK$+_N&5Z%]75@/7-,QU5( !((#9D2*:D@S@D@RF2@
M,FL:+%M9-VYAM6 JN*L,K\=0]P+VF6,HSH+5G%/"9/)$,A-( (J"W$;GP"JI
M X)=SL%ZE>&MA7GK4'[9.4L%[W7 .W.4PARSU((D'&(DT@I#T,Q6Q(08O:7>
M*2-7U@4U"ZN"63'\=$5U/2NX"Q?:S%F!<I8%)R-A63,BLV+$J\2(XKZ41,H.
M9.F$- ?2#R*1GT)>V[OBY,<W!O/SVJ[$1$^BJP$2D:%)9:IYDN!*-5BJ L]<
M.>>EN7*=[46[]<_&<^3>-TCD.XR&E:NNP57=%[/N?D9SU! 9X44)D39KXA@J
M(2"EBRQSS[)804W#<L9_;U&O@]K-Y$G@?D8UJ32P"!J8.0<0R4BN9")24Z0!
M[2GQNFE\PD-D25$78J6!2@/W1 /U0.!V^)XY$'!E+1T#PES@1.(B$YN,)TR$
M'-#B-(:BF-=RC59P+QFXK^EE:"&ZJ__A5F"?.1 PVH? C2#:EX:LD3%B@^*D
M%,.F@=+0G/[Q6[D?*LR?N@RO!P*+ ._,@0 N&:,L",+ (G@%DZ2<[J%I[KC6
M^*;2J4KJI81P^R1U/0^X"Q_;S'D JM?,>!=0^S::2%Z<;#EJ8D!9ZCT*Y29W
MH"T">4'Y :T^#W@QW-^'4>SY?N? '_RD9//C/)J\!A.!"YE&<+&<73$E@C;)
MZ."-R3P+YFJ<?_M)Z=VLX]]H \)S2T*B$?4,*= ^4![U#!ZE%=X"E\A)C,])
M7J^!!^U&]W44C7;"NZH@MT+[C'_?&"H#E,A +AB1S"':&8(?'&.@;7# 1(WS
M7S*8+QW*?UZKJQ[GW13N,^Y^FYQ(+F>B@"DB@U3$4Y3PUE-N).=&>;FPX[R*
M^XK[6SK\*PTL@@9F"U0I6K3[@$H]M:CC6R ><B2,6>FCIMH;5FF@TL"":*">
M""P"Q3,G B YU=%XXJ(21!H6B ]9DV <"U$8JEVHEOIR8KA]EGH]$K@+[]ML
MBH 6.7-AB'(*B(PB$I<L(\PX&:A2/";5(H/\*:0(O"ACR;W2^[CID)>@:59<
M4P4N(R3);!1"B^)#DM('SV5F'CASUM$4:O^7)>"F.?U?DJ5".VF)+_7-<)$-
M"19?!2\@V& EE)0 (]=<C4!8,G!?1]UH)[JK(G(KL,\<#'C40[CDGDB940_Q
MPA%KDB,I2^LR==G*6Q\,5)A7&5[C_>\2UC,'  ILSI(+$J.UB.U@B7.&D[+,
M+ "URK@2<51%^+)A>_E$> WW7RC69[S\4<04C,PDZ%"P[AWQ+FNB(,1@%?[/
MQRK"EPSFK4-Y=>XO KQSG/LJ4V4U<4:B$BYT2;Q%8SNQR .8%+4HE?K,POHH
M5 @_74E=??MWX3^;\>U')ZFW5I(P3;9ULN3?!:(,8IUY!V):5/<V!?EJN/^U
ML/A\/(8)*8\".*FG *E1_Y<1D@_<..%DUC%+D< E\&!9]E2K9,V#^?9KI-#M
M.6M.U7^:BT_ 16*$927K4! O?&GN&;/7BL6D0XT4JKAOB]>_TL B:&#F-$ '
M@&B%(]F5TP#M#+'1<@*&)1&2L<S6N.%* _=% _58X';XGCD6D"(*Q3+NY4 +
MOHTF5@8@B'::G-,ZAI+T)V_?N[N"N\7>AG:BN_HA;@7VF7,!RG1P0GEBC2AY
MO4H0JS3'?SH%,:4,R:VLLS75CA##"O.EE.'U7& 1X)TY%XC.6TF%)3Y*E-2@
M& DZ4\)L-$%'@>L6JZ1>2@BW3U+7<X&[\+'-G M8EA)E-A4QG$L+84:<BX8X
M+[@7$'F0LD4"^;8Q_[4Y^E-KCGX-8@O,!JNULBY:Z4$&"8&:*"(5G*)VVH;S
MA<'A/DG#"3F^?R7 :Q#@UIQ> ]$*0U,$DK(*I&0U$L<L)\I2Q:)DR42*_+?*
M.;^]6G,OG=0K,U9F7+C.UTYJK-K@K<AP]JA%!.U0GR<\EZA-)ASJ@19(,(9Y
M"!:\SBOK=DW>/DBD<F#EP!8\]=)1X,_+557M\%:$.',V19.TEB9+(GB#UC$%
MXKU1A +HX)*,AH65=;4JM9QC(5?ML#+CTC+C\FF']>QNH60X>W9GDG0B)9*1
M_9 ,HR4N4TXH#QR*=IB87UGG@LTQE*M^6%EP&5FP=21XV=%FU0(71GPSYY[:
M*"=*@P2M2^52K4H] DV)"#RZ!. =92OK>E5;,R=_HFJ!E?^6EO_:IP76<^&[
M.!:9/1=.":E- +&*H[)GN"=>14&LH"PD'75RNL1Z+"2%^V[)[OC,^&04Q_O;
M-4RVZ.B0*USCS,,*?*(T/,3-W3F!\B+N4$=91UE'.;F _WNK$YEZ7^Y:6)LY
MPGHZ/A2LPY$O-/P,GPA&Y5LEU;04C]R "/L!1E.-5+#5#@ID?DK6S;CO))>^
M7J->HZW7> J9YB^&HX/""M )PT&:R3"_=3QKZQ[XZL;:O$=LMTEV#8LL95?B
MM;VET<A DX,48H 8 Y<IP;0Z-V>\!K0MI^6V.754G;?<:/0Y*"D(Y9(1J2&2
M )82H[-340?AH;CI5Z54<P(YECY0OY+9,I'9=?Q+[62SZGFZ)7\=7> O)YU
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M4O$:HA4^-?+&C0.@5Z:Q./*.U[@NS9TO#<>E>8>SUK2=&$R.'27#@#?ZTC#
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MC8\9UC(Q82&@IF23S#J[Y)G5S#-G*=@,=POK%G9/7A)$?[^(:$?1MG<)3?S
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MG"J3*1!/LR92)TMLTHPH;E5B.HD4[,JZ?93!#Y6''BD/^>"%5@J<4:@OR>!
MYT2E3P* 9RZKOM1JDNI>U)<HU<)*2XD5Q8^63"*EF@MAJ!:;J%VFL=&7E)$U
MD?.^B[F<I#(3A  9XT9'2(7)F4#P9Y<&?R^[TZ$MUWAJ!81>#$<'Q0T'M^@R
M]B2"&KD*!CR*PUBZ$]G@M&86_X4*>D@\^JL*PMH$\?[/D][/)AS8+!E/V1/K
M@R22TXART$H"/G#O)<N)L=)O75O9JBZ(-5AYT0Y!FB,89G)T4@K*' H'6KQ*
M+O/@L[I;7->,QIM#^F+^@0\&$9T#446KE0Z !)DR829"$!2$R+R6%GH"D%91
MY> H4!.L],Y;$X1"V9V-R#[1.X9T%=6WP_5,PD*B64I@DE#0C,B<T62UVA.P
MEBDO$K?<M%%4/[7N!._7WJUU=DK7XL$^#"8=/TCG_KD#@WC4&08<:7/L7UL:
M_R1:S8"44AGN06HOK.)69"NI#LY&>V6O6V6P^V>P#[/&ADM.@I"6> !'I'"1
M!),=<0%MR,AD! 5-RW7A6M5JL99*672% N%XX CH'**,4G@M$61>*[RRRO;*
MIWK5V+AO2%\T-IAEW!KIB<M.E/#[*9J)S5HDRW167K>Q?DJ%]((AS1#,/&O(
M@'+9H%Z:34[,ZJ2C0HR[*JK;C.L98T,J)W@0C "7E$B=$>'1,B*T$U(8*VCP
M;1353^W<XETQ+/"-03VW^$7# ]S.-J$8RE1+[J-'U<-I%%X"R8F[.U Y*@5=
M@X+BK+7 O8Y6"TDX0Y-!<H9:A5.9*$MU*HW972F1KF6K6C%6)^:BSQN#"D$E
MXXWUTBL3I(XQ"R:SX1:E3S45VHKGBZ:"\1F$UHHP7$TB*2H77G%)()62F=2)
MJ&4]EW@"D&;!Y2@$<UE9R12S*6D#B&ME>;365E'\P-"=L098B;JF.A(?.$<K
MWWEBK4=3WV:6!&<^LM0Z4?S4SAU>#/?W811[OM\Y\ <PJL<*ER<_11>!:R>%
MDX[ZP'S6PG,7K%79TTI #TI .W-.#B HEI%VM Z1H!Z(!&22(, C9X[%2"4K
M58W8PFI\5"=C"X'K&6,&+7A0*4B Y)CC(E(EI,*-P74U!MH*Z)D@)89LJP4G
M-I<D(2$9"8"H3E08%[E$.V]Q_<\JI-L+:96<=8$*$%1*'@'5RB"D9=$PW 7Z
M#H*4*G2O!=T98\#H&)U/BE#AT8[GY<C/94K 1I\I:E1:A?;)XJ=V,/"BC"7C
M:";0E!))<# <]R;U@.#RQ :A\Y2+G)2^&+DTF5)53H.GMAH%#TM$G^<T2\@1
MG!:4**DRD8Y1$CCR$KXIM<:EB]DB$5E>6R4\9N!:Y=!JUYE%$66F+%AE?8S<
M 76@[CHCJ1H%-P?T1:, S3FT[&,DJ (F(D-YE;TB4J$^F(RCHM0NKB<$CQ[2
M+'D.DEJN@I0Y*0<^B92 :A!&TRJ+'QJZ,T9!1*N 4QI)5-*7?/I(;.":B$!E
MMH;Y[%C[9/%3.R)HJK:2\EB0SJ33UY."2[LA2![ - =<JFF*P(1TTBI@-G+4
M,BH1/73UH8M$I$![&8,D602#1D'IH.8X$&]5\!D%"\2XLL[-&F^1<Z)Z%1=]
M4,!1>=2"<<>9=-RY4M/0&A6%2RY<O6Q8M0D>K)K8"9X5TS)Z($C$DDA!)7&V
M& 8 .B$#!ZIS/2AX I#F49MH@D-02PG*(9G3XI<S3'N?KUZQM(KB.Z^Q=0Q=
MZM".1UV))"BM.9RA:,Y+373B0F@:N"HUMEHFBI]"U><YC94/![6U\A5(R&0>
MDA9:>,\D ^.YEX8QIZD+2H8K1R/7EHZW)IR7L[J_-"46464"R7DBK9;$&T>)
M9X&! ) NE?QB>?O&&-5YV%Z,2BM=#H#V7G9HL_,@ RY^=-I E$[DBM'[Q.BL
MCU^R$*D@(I3$PF "\=HZHD1FS$;%94D8KAA]W!@-3K/@G(XX(LEIL,)Y7?I/
M*9N"N7HYW5^W-Z^V^(VQ.ZO0&\6"UH90H2R1/@*Q-GD2P1G-C7.L) 6W[WSN
M*13-G:/3WU:C?Q)N!>LM=X*5L+4H$^4N<265IX6=A,Y7#BG^-1/5&@6WH:/7
M<^)_N)62,53W35-.R*.F[R&23"&PE+,+O)PYKC*K6E6CH+H&%QU#;&(TS/N4
MJ9*1>J\AHQF(IE_*(3&H&&X-AB^: Y%FZBF"-KC@2YV13#SW0 P+RA@>I5&^
M8O@I8%@Q;55F',4P7DQ:Y@T3W!N+!H(.5P[YJ1;!'<)WQB)P2DL1C":"TD0D
M%Y+8(#)1GIG 1([XIXVG<[?U\E^W[\]Q$]3I("[V0;V\O^Y3Z!>TD*EY-#2X
MJ+Z,M3_W/1#BYJQ- CYD:D(F(I8XR" U"=9( L(S2$Y0EIODJ%5<XX6%0BX"
M0BUOG%8)M!+HO3:,K 1Z/P0Z<S[$>2DR \1K$XFTBA%GO"%9YNB2C3K+DM2U
MRMWB&DA6_JS\6?ESL8TN*W_>"W_.)N)07#=@B=@L!9&"91*2<20*S;53D7.A
MD3_9JG)\S3P" FU,^=\F):(3_YMZ7]9/'JI[N(]PB>M_X)LGC[#O1SN]P<E(
M+:+G^)TR.GN>VO8.QY->/KI_S/*"V>U=Z+P8[N.=CSJ[T$<Q@;/@>X/.CV.]
M#LP<^ODFV7_3C^+N="D%6^T@8D7GZVXO[G;\"#KCP[ '<=*9##N3$8XPP^CT
MHJ4?26>RZR<=^';0PR_CJR]^U!L>CCNIJ24PV<4=L+-;+BK7.J<[I9GXI9SH
M#9R[P0X^%Y1G ^CLXT]VQQT8))SB>5-9.KH4%ESM? 6<N5CV=^K\?]>)?PB,
M:Z539ARD4]XY7\[06<Y2<2K=IXUR(\HH(\T+,4NW8YPY?'45_^?[P0APIK]#
M>H4;Z-_#\>.NGMZ'_WE[]/'O=!"XU%NO7LM-_A=^]EYU-_[:[6[\J[^UO?.M
MN_=!?=A_(S8W/G_?^OMM#PD[;VU\8)^"]48&@[0)42&!6J12[1FA7D:>+2X/
M% 54RSGLV<'MV2]+7W;(=?9#E)%*SI.D4<E,P?'@M3 T6<^RH;'9#_QD/_"Z
M'^YE/W0W-M76QG/:W7O_;7-O1VV]^<2,]\X:1HS3FDB(C(00@&2J1,*-(Y0N
M=?$9NS2H_62+($T/8-(Y/%V+#NI'8QBO%BX^0'[N?8'^T6H'OSI+\R@&MI"P
M1IU_($W#8 S_C6_%X3ZLEHNN/0)6?HT@0N6@ 4X15,C.O<$7E%*EB=889=@^
MCKR9-IR+AKN+!M#Q8?@%)V$J!O$Q=R\E\ V(L!]@=.XCI/3)6;GKKTGKS :K
MM;(N6NE!!@F!FB@B%4@;,37*\UPV_SEH_^Y-=H>'>!.?<*8W8 *C_=Z@26(Y
M4;"?[Z->-JDXGH?CS>W71]V=3]()([RR)##@1&8M2!"EGBT//+@(E*EX/5M)
M6Q.5#0E*%P')?7#>)F=*F[*@([OIF65=[D4LMW-4)Q.1I9F(^"<EXJ,U!-"4
ME3X8P0TNMYSG1OH%=?=.*?DL)35:<QIV!L,)$L<7Y")D\F8%<?%_+&$GXQJB
M3HV+N-9!)7]\GMB*@GZJ4G[%C7!*]3@>W""CIH=@8UQ?3O.M8?%BQ/QXWL+)
MP\,1"KK!#BDS@A,3)JO'ILE7).V3B<)G#WZ,?W&V_PTH"#L<9^G@<(+BL7P/
MIPNW>#&!4#8$N ^2UA=1^V]\BFT<;4D;/,7EU1#IGA@BSRI2W8T=CN@45D<*
M01-C4=>6Q@CB($%)V/%2&!-4Z0; UA2[+!$@W%#7OB%KU_5?U/I__K;U_).1
MB+B4*3&^='<QTA%+O2=6)4UE*J5]BY]J3<K+O/RGZW^IR^-G:MY9)?L"D9;;
ME1W3&QSZJ3@X0ZW']"9+J9>FHB)^X=D(^KY<ZO>OO339/7&ZGOG5L<)-?_S$
MA_&P?SBY_"=G.#PBY\/H@2B<R:N(F7-#7/\CC'Y;OS"I9_Z62TSWOXP,,J*=
MYB!CCCYE:Z/05H%FR ZHLJV<_&AW='+; [\#)*!L_4Q\QKL^\_VO_FB\\MMY
M4P>MFK.+==UYGO<0S9]+%B'GFRR"N\(:3(VR5)2"9C\^.QPD&)5OX5!]6X;2
MV1T5>OV/7R^J0;V@T83^^,TOZP,,\Q(/?IDG_D41Y:@H-X\PAV%:[NPP<SG6
MG$J@AV#XSOW<?/ZC_W'NK&8!7O+S2MIK-*T&D^'HZ,<!Y#9>_Y_]8?S\P$K8
MUKL3):PH3B_5Q_T/WS[L/?_V<>^-_/BJV]O\OJFZ^Q^^=K_O]O%ZWSYN[^Y>
M5,(V]]^KS>W^_L>]/WN;&W_N=S=V/W_@K[]O?O^,=WXNMEZ]Q['_V=]Z]6?N
M;K_\]LDI2)$J1A2SJ'8QJHG-GA.%2K>4(7EF^%1?1NT'TO.BR/K2(E$8107-
MTDOM04/(-A@:N!,)YQQ0KSTHLG2$&O#ZR9PWE>4N',6=0^P%/6NZ'+^\VUUO
MF7=Q%])A'[;RZ>9Y,;6[&ZGUA+</_:1=L"RJ0')6ADB?&+%@*,DQ6A5Q\T"R
M%[?#Y92L6T')E_F?3S=QV6'CWGA2S(SB'<[#?G_XM9Q;7]'/+G[ZG*=:Y]2#
M?6HQ-(?F^+A]?S"&9R<O?D^]\4'?'SWK#9I!-S_Z_?S]BKI[X<R\N=_TXV--
M6*DUI51AX.,X^.,;'^O):PTY7P@ F'XFS1I5YM*/Z1J[]+.?79;+-:;%C2[[
M\ULRINYFL%>[["]R#7Z9&C3[U3EA6---]$!!1S.2O3&R&HN\@Q;WI<G'3V 2
M3MP/,_-PQ5W1DHB[YHK/>A.\6[Q"O-D_7@].CL+'E^>>+^N:%L7A*>_IXD"[
MSEY^%/45WOJOG7+B,.KY_DS!Y%\]Z*41<(\]Q/;:S_]HXF@7%0IP:H/@!MP\
MV7]=F&SEMX!/\:5%A2IO:)%,8V;WW\NMC==T:_OU-_Q\M[OQAG7W=GL?-S[0
M37R]]:J[A^/@'S>>?[L8,_MQ>T=N[KU1FWLOT6)Y2;L;[_G6JW]][NZ]^8JO
MY0?>Q6?^^!DMG+S9.XZ7?4>/\/MXCYU/*3"A.<=-:Z,G4B9'7."!@)8Z<$N#
M!K&R;N4":E)=%P\/G)Y>>:WRVAW%O%1>6S2O?;_(:TXHJ;3S) LP1&JEB>74
MDB1C#$'FK#A%7F-V894U[IS7GD)UWK^'H\^D-R 'HV&$\<V:<SR-(H*+5K'*
MS+\>_.]TWBL7W9B+CF9U+,:""HP)HG!AB!11$\=*%V_N(Q*3*Z6:D(N46EA.
M4HN2,RMD[TQ[J)!=%&1GU(>$ZD$H_7,T8XY(IARQP07"/3/:20F@4'UP6MR^
MSV^M]7DMP/W9&_3&NY Z.\-AJMV[[D]!.)GX5V7>*]O<E&VZ+^8X84!"3HD3
M$)01R24C@65'C%:&ELI'B4-)NW.WK_I0RP"V%[(+5Q J9!<%V5D%H:2I&L$(
M33H0F1F0H*4A 4+(*?H4E$(%P2[,;5H]"%?#VP9D&(V@/.!X4AT(=ZX?-/E9
MIXQ32>;&)/-N5B_(+D@.(1''6.G_!P[Y1222M5)*X&<VNI5U?-TJ*Z0Z#EJJ
M%U2H+@RJ,_I 2"E3G22Q(CHBE:7$&1U)X E8, Y<"@A5SM9LBZ!Z6X?!#<],
MY]=*HC\KE_2T#E47,4&/AOX6[LE YEN.X@%+089S@DJ<B]0*'DCFQ3C2E*/>
M HP8&K,*QD;0;&6=KTH^KY#0K8Y?%X"<Y8@[J1Q:.?0!74N50Q?+H3,*)0<7
MF$X.C3VT^"0X2BP-B@C-O:!&4 6AX5#*UMRCX=#'6M#R%#>=X/M^$*=ES"Z4
M[FKJWY2Z:,-<2C0TAEEY_1!5N$X'7"I[-!F*/TS%1PS[&V<((FS5UO;SH\WO
MKQ&^GU7WS:>(RH^SU!'' VI!-*N"8$ZHBD+)*"08N[)N%)]SJG/C8HH+)_JZ
M_M=?_^_/OW9W/BFOHC06"" DB4Q<$N_ $ZUR$W*=FFZ_AM.?%M.\?8&7SGF7
M.'YX4-AE,&GX9_H>WN-@-$R'<=)!KCO,.(S#\HMRD_%N[^!@6FWJ3'W _RJI
MH?T^$M?(XSX9EUUQ7,RJE/#:&4S+%S94AEOI$#J[^"QH!@QPWTW'<Z72,U>K
ME5+LB64N@F#7.G=>#*"4R-SVWUI7#(!OGF!U_[7\B-_IOOK8[_*/N]WM-WB-
MC[W-5W_VN]M_[FUN?&9=_H%V]]_.5&3ZL+?;Q_'0C_OOQ<=]5*$V<+S[K[]^
M^/L]V_Q[\^O6-KZ_]X9_?-74R/NV^?R3,E[Z+"W!%P6?SI6.OD"H8!EHY"%Z
M>K$< %*H$]XE%KU#;#-K7<;O@<!+X/MQMAQ F?4.3ON-Z@'\\G:MW^Z_KN_=
M&Y\MROU^[=U:)P-JF;Z_BL/RDU+1%%D(Z06O,#@N]8IJ$\YH4T/P#"&A#CME
MO?)Q!WD)FH)YEXI/%%Y(GHLM3RUF"ER>#.H4@6]Q8"^F:XWZ\M8!3*O"_'#"
M$_[D$/E9?-*!90,J$"=B)-(+07R(F8#C/DEM@P=$U#R/T7\V.^1ZRWS+JM-U
MF6^RS'O/Z2<OA4#E)Q-42 VJQ2:1$*TK/1LB!<4C)%,$XJQ2_)^-CG&C6O7G
M%:)?LL8U[U-(9EK<KER_T\,KEQ8%J[CC\.7HA^YTEMT:<CML;,)1PW('HUXI
MZXP7"$?X(<IE,JT#6JX"@_%4+I1G.N9 \*/!M ;T"3GN'8YZXW32RJ!44#U]
MIG&G/_P*Y;'\X%=C>12M#5X/.L\/=W (9VI;OQ[D_G0:WT)1=LNKY[$QN,N7
M.O]8>?WV^<I_-PM::LHWLXMKU_=?3^SU]\@J^/:[(IF.!1#^IA-'T)1D]6C
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MW7E;GB]T2-P+$D4T"+'286)!-)W2].1I7R0-"L=GW^$FC?^^^W!_H0'F8^/
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M*LQ<F'"QW:NL_'E+[LRSO[Z<'2M'Q'9!7 4",HD.RYEYDE'9HH-0V-43\:,
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MO)D;Z5E%-PG&+%M<+<22XW;L/C6^<B02Z1E[(ZAD<DK%CDL(.6@= "%'U&K
M6E-6NIIXPO7V@%)6BYO;+D1=<SQ(M"H4"H+*"*P5$5A]&8$E([!D!%8Y%U]E
MP&\4@?5D1-5,!%:[T]%I>Z!IF@IK:A-C0(!PM,QNJ]VC\$95([">6<,ZGPZT
ML YD039CQ),9C5C1G'QP"KH7$IMOZ@Z8,?/GDCX7Y$S-6O8/1-?DCKEN(B7G
M89M9X9Z5P]@U6EVU8P^,=JNKMT@7--6^UN\/=$)I:Z"U1#6'GMJ5.8P[['%V
M=Z%?W1W_M]=KZT:KI37TGM%KZ*K=;0P& [.A4V)V[0%M=XBVI)9#,>2QD/K]
MG)2!G(B,8N^CGZ4G\+Z#_)YG(3C/S<N>OZNKDPX9RHOL)JTX=R=/8\2BF2%Y
MWOIQ5+N^._Z0%?:;6>GB%,6</7MQ2E1>\\EGEF=UVU)J-U,>:R[;$)=7*+7O
M+TP?K+YS)4?'>HOH6&8SPS)\ 6K8LYZT3,F$8_Z#LKJ1PD[ "!#WO@+4/HV-
M$0;+L$>R()FUPE"9HV>IJOZ$Z35_C6"=L2>*!"89JWF=.'TIZ[GQSZ0 KZ@D
MC,T'J-#25?:^EN#-[8@7^SM.H77,EZKV!RV>HR<L%MQ(L/#YFBA/E^_/E^CO
MO-C4;'EAYJ .*&XGK>%7R ;3YRPY[&#K^3,;^P\\^!,#4NI/%Q.NLUN1^(#S
MPH&X+2O-*\SFG2LRK.";:;G=A*@L,$&ML7!@8WZA2O#"]>,\66W /#E-_ ]:
M)T].YZ^$.,ILQ P/B_B4,QLM0Z6G<"BKJ"HJF<&%$FLNU)XNFG<B[.&"D9?,
M/L.V"N2.66Q0[D!V-9.XJB5;_GE,F8//#%)JA08J9J&/QP*B4BBNG,,[>.@Y
MB%<H7%HOOH^<+ADYX%MDJ(E%*A&LHJG>B%@\$(B$625R?'"5N7*F,F91/E^%
M:$]7Y)X5QI,*W4N%\&P%":H76_45*EL779I/+B:M,+O&*3Z-+=P0W5JDOF3W
ML,"ZBPQDAHFOG#"7@HVVW:4]?&XY>:E6#8$ME<F\.?MT=MDXN?I#.3))Z 3.
M W9"Y.[4L4797V^J 9%U0S$Z"0LZ=ET*'/:#XT>9(P-W/N,!$76*CFK\A9P[
M8YGK@F6+\/0I=2;B0TLK*"PH.[TU":J>\W;,VNKG<C1:=0U(%?Q_5E9-G7<C
M;_?4M/*'CPCT>*Z7)0,><YUPOP968-^!QR6;:P\>ER7FJ^76J[QYY4G6N$1$
MY;L4CQ7;CN4C!;3#I.*G:"R($A3X#5<'XE_:4+T*.WZJ]DTJJ[=0@<WC"'8:
M<1YXJEUL3'SJD:P[#"-JQP+I0$@0L1:+&MM< #83<Q2'(+\4*DE9V/16E)?*
M."1>G#">8,= ?+O34H_,-T?M-W!%A\1S?H@ 5R9(8HRV8]%<0W*4*$&P\GC-
M;J ;#D[P/C=7+GB<!3#A$&'2W.:)<3CE$-%FW,/LHS8"*_;1OH-EAA^HZT]X
ML,@-'5*/!ABAG=4H%D6+D^X/P!9O3HZ__'5[MQ/:VVUVUG%/S+ME$5<;;?8V
M-B5 QBQ0%C4I[G[[QR]J3W^_3Y[!B=_?QU_N;HZO)0"?#T"1#I/VD&#\D>T!
M4#B[-.P9?SR.L=<(NX"9=J'I></7QH0A[08!(K&;4RK6B$-9/FB:6IWVL$K9
M9]+("LT$C=\=\][ 1BNW+#M$-$[(1;!@GPQ>52WQ0EC":).,\Q$D5R">W*2*
M%H="AZQ\YZ@BP)[)DN="5@NFVL+(<UKH@MY*!3MOOU#T+G^0__BEKZF]]QL<
M9RY;?%EF^")%>DG.]XK<\XI(($_QXYQYIX76NUF'8\93/H-2'8U,+"%X*QJ)
M"=4)34J/(]]UIPW_$<TKV(/&L1P$5S'M073TR;%Z?OVPTT?(NY ]H"EWC%,?
MU4[.3U$;*P@!BV6D21R$L6ATM/*6Y%E_0(' 4&%]GA"'V84FHVGH $_.W$#H
M<6-- F##L<M>1ID7=FT!*\?L+0.])/ %\&ERC]U\^,^L%\HT*5004&=LP#*Y
MB,\P.B# O;FPC=H!DD3>]8<WEF,9)<5V>$]2$F&*/C\54@[--2[(9(#3>.)\
M9Y\$+\O$ K[NW^G##Q(008@?!.V9 )KY%C^0G"#72>UI(*K0O"6HO;SE\A+:
M.A>LS=)[7 =^Q]H5,6@DA-_-<M6S_E_L*!$9[[64=4:T!?V:-T'4U[W0<.Z\
M*4[CF#7A$0&4& >*8<F/OH3_'/PY\!W;!N7_W@-2J!!Q"_T@?(,TBO<EQ[PQ
M3S'HB+AVZE(M7 X$_P,)F"L@%,W>N0.*,?CK=")6]'Z;8L,Q>J[\IZ]OVO%^
M9D',16LG$H"9V&0C5L"W8-KE!0-Y0"P0/\ RFE!<$R36HK-ZD%^)Q+P5F+?"
MW<6@"S>9-PLLUEI=6(=AM8RX<((5Z4TR:+<0M#N00;LR:%<&[99S\54&_$9!
MNT\&X<X$[:J#WF#0ANDUVM$MFPP,4!^[O;ZJJC ,'50U:/<\L3+-^3!R2BNH
M5UO52E.E+1'VTJBFG&+LIVT+A)TI;YG.+_3(>9.$JW I;$[F,[#^'HL1OA?J
M8RB8>X09D"BN\LB>R0A&=\?<=3IAT9)8[9_);%;,=VB.0%IC+5+GV^,%?CP<
M,;\4^IE"S)PV<(-UQ0PP$1$DO< 2ZK*-KBF,M@US@S%'-6L#BGHVG"X1+K)P
M&D9T'')SXI'C8'B:S;=<5+0#!E!4+WEJ(.R=-Z%G@3^3"0AYC-(N6B2.;8!<
M:N.BT@,GV%IPB&$F+D6#/IYT0+EHGYST">.3?-X+UI 9M*Q_D/'DO?C3 4D:
MA%X$9W;Z3-,.5ZG::@K4%$OG@L],'Q-2N95#A$@X81&3*F*\>J8DGK,3%._C
MN1?& 7.NW K/4C7V_QSCW:SLOM*=E@$$'A=E?=!NE<0>,*6N:'F9I66YG_*C
M6<("E<[)_>N.Q^/6%Y7NP3:CE*?7XY7BURZE1<+P-4=<D,JM1UB>IB&,?J2&
MD7\F#D*@KB-G(KQP>>+(WH!7\G<?UH1?/[Q)K8"3P!\&)*51\(OPZZ7^QN2)
M&9 ]00:8Q5K54TJ0-):I2W*P-";J/-\#Z(IYG:[)%/E</EKJ6IS/<>:-O<IY
M@8%ZL'.K!K16PF8&1Y!83EF0H.B;FY;FF+VL23RL,%&G%IL9+QJW'(@"!AO[
MZ+((2&[(JJT,D*@E<9)W+,@QW0)KVY0NB)NQ<K;/ BU,_1["VI6WD0IVG82+
MS63#?_U\(O+&/\=(8Y*@,O[75L/G_9P3+4D#8#/S;(\T)#A?IH83(=C_!S>&
MG09^R$4\]N?MR&'Y(C/PKV=-_9[QEO+YXHH]L 10'TX^W*+9DLM!KG(1LS(:
M,,S5R/$!8A<7K,WT9S]P?LR8J8M'8+TUWI+TN=P29Y:'@/L-$(1.\3SXXTFW
MT"\^KD'OZL?)R:1EKY$UTH"%9_P)8$>2#(_ 3']2U\XM1_G 143E8\R\5MF0
MM;7*&BS'__Q!:VD/QRSX.TV4X1&)J0V/XP)&XJ:)A'E<F+LA_#(O,Q^GUN'4
MZ)OH,3>@.="(LGIN-KJ63)J +@CB252@GCES,X@$\_%RS WV/U@/$\=YI@1G
M9H 0LV>5+3U )23BCD/3)8B@?/')(S-.YX(E.1TF(P^?3_*7F-$.C)S.4;.?
MO\!)P#>KT!CG?7O+^K1OA#X;DL]BT'\A%74>7GB;ZWA"'.N2R[@(;AOMX=F@
M8L'_(A1AD_V+]EPS,?HAWTU8%WD#O"ZVX(DYO!2X-P(=D2<!D2&HM58N_AZ4
M=6%_KX88L:6Z/+<CN*DCW\5S.(7)'OB-/4DDAF>X"DH%GI52UF)3V].FLS34
M*256Z,\1$E>8@V3:FR#WG95!=RZJ*:5 (,D&H 3Q:UC'9.0DN]2,@R IHIJ$
M::'NAGE$C"0L*&5I)#6R>"7,Q'R4]AS(#2F&HM^I&;,U^DP8G!M58;&_24K?
M3"@*RYOR_#'+.TV?XLPBVS/WBQ:,:8!%CA7G7X+%!QB3PDUE#H(4Y%L6NF+%
MHOA]J@XF%SYO?BNI #R3Y1868M53EIO&F80P$F%UK<62Q3&\SX+5,9+680G&
MV4$@/$#79=F]'K!86#L62<I*(K&^HF.1;X*QKY1Y"$U1<XHJ0]1U/29^<SV=
M9:"ZG+I;,9#]]PB%H1\(I3VU82P^3=%K UYG1KN"!<\W"GL<BZ0R%M C1@4$
MX&8]&"?;9ACYYKV(7$SCXV%5J94QQ5Z^];R=8FFDO A_$Y)(;@OSR<YP5;$X
M=)U_2&\JVEU3<"R^V@G&KF*^*V6567&@$!*0NIVS%,. QVZEZTM2_!:N+@LW
M6#;#XD-.9]L@9%$=S$4=;B3#Y>(<4S 4DN5F(9%/M%N4),B?*K=HF$O%3):%
MR\_'?S*I)RGCO2(=<?'1H8$*P(Z19-_@_IBT:,XR":.VO%LQ+,2CCXLC395X
M(OPE;ASF@(BK;<Z+%\L+ [RZN 2MM?6X!!R"%R1YTGO9KLE@AH,-9F"U;I?Y
MIE-8+\>FY^@ $\R[]X8-E]H"(>:U OX5L!A8T;L&/K3S.]=;[,H!WJ=H.TK%
M7._:_^,7M=MZ/__ORZQI,5@N4E?-/YFA!3D6J_2+]6E 2)R&#A.\/J9I5(!>
MEF@ S!0&9%3LD:N)B/->D$:W)FGJU@Y'51<^  #??V)@^W"E,7N,Y\!YRD<4
MV=56XS\LY@-CB%&B0.6AX?H^JYC!;()<\F7JE>,]8*\1)7#">RX>QYY0_Y@2
ME7<CV'$$<KW":J5F@:3B6S@GYBGTN.2;R>!+DK8?41K(^?&QRDDA[9:E]XET
M! =-Q[5TS'I-J25QT?#QD>*_<0C_XJ)J(,XD5F+"2SV+);-@?HY:8Y#=>%$2
MM.I0+)_D3E.A/*0K -?D%^Q/+-[%J\2#6EO#NCVF@PG(N!C,P34C_(2*D6?A
M)Y"4V,H-M) ^L,=0PV./ X*-^:L8/9PE(+'A69DPOI^DV#2,#SL)>9_/@"I\
M%M'%&\DBX"M_>?D^8$07A;;A"#46IGVMP!:!40(ZR1S,-XG+$T"Y2RQNN=<P
M\B7M21@N1S6N>J$;>>QC?7;$!6&W XD4<*R."=#,W<PR-'S8/W(GV"8JL,D,
M 9DP7$MP*X5EFH/)_=:4Y6&R61Z=D,FRPFL EW,F+1.&?HL=0]B&DOXI:"V!
M+V$.3+?&2.\9ATG>,7TM)A>N)K$6E(LMK+1%437@'5<7YH5N;0'8<D7,*):"
MJ1\L0YMIR4!MF',G\7 #:CQR5>.1L*XIB,4>M?*:<B+[8['EB-M;F-=_UWF6
MSR*;9<Z\?";]YU=M2:GT+$=(IKEN$=@6 -6-L>A*'M1?' /T4E]">G\7M&1)
M)4<F'3O =V8Q)4GADZBR30KH.@&FGL_ 6N1 2E!O$=0AB*7S]._LX9[2'SN'
M]&ME],H1?0 5F6-XO=!XIJ^,00Z>^#\HHS5UQ;= S@.=E;"_G(A.Z#W_Q7:(
M)QX:@JX0^2'[[*+J![L7;]R<?;KL]-1V _[1\9].O1!9R2L^@#2?Q)0+^3!7
ML81+IZC*)-TQ#0>#5QP;I''446W?=?PWQ7&3!E$%L?:?2>M+@!A&;">S9:W-
M8QZZ/L)H#P5'B["9%.@GQ6A0(=IF$9TL&,*Y!ZB-DG AKE3PZ)F10YF;!FW6
M\ 6VG\\4.RN1SIFU'3  U#: .<XC*CY:::H>CRU]KX3$IM&4E]P-%_BM%&+!
M[&CN3U/%%ZD-13_J0G$>IT[JS^2E<\1&3$=EMOI,'PI E[1 F0<5V.0-SD!5
M\T2-S+1 GP#S3RPIU2A8:]BY$RCJ=+Q)%.IJB7*WJ-5J4F1$Q'BY!/3(47)<
MF$J08<VLDH6OHN\!W5,)*-#ILFB#3Z@X\ 6&8L'1)84>^=[@#E(>;<UK8N%W
MB=4A/?6"TI7'JO1>B7A-K@C&8:(!XA:+&B!:,@P6S,Q.E^,@OZUA!*NGZ;LN
M)<Q 0*P'--.D1=/FP00/S9Q;?:EJ7>=FE;EC>@_$8NASEUCZHV^X3N* 9XDJ
M&##-PG6<\82P7FU+SF*UFBI2/K#+&PW#8BX+'E/>C)4$<T\PW,*<O@?XY[K7
MA@CO_';0BI2[HP^)ZQO!A\@8PPR!PRP8H@@:FI9@OJFP-PE/'I(2PW$='J^;
M)&7QC&IV_OAXP0BQZ;5[S^XZY;6S@EC4"EUTS#RHB>%/&+.0=:P57,]ZW0$U
M%R0"-P[/>_7-5Y69>]+R(H!-K@@SK N[#%!AY'"(H?79JYZ8>GZ")"4,A.,;
ML[&)6X(F279M"E<OL\$DUB(^1O(P^HJ),"8]^&[L86SD&W[T;.6>E</W80Q$
M%QF]H 5+48E=#C8!L)/ 2B/7?"]QO&X/)N]GD1/V%-MH.@VX]YNG7K#L!W>J
MF*/$LJR,D9M-7)K9UA9C&J>,R0R"4A?(6)V/[C"37P+IF;VS:IZIP?@-N\O<
MZIQ;,>,EV"I.?(![.V(?X;COR9!]A&DI_SV?K5+/ 1V(^B0IQ,)HYL:@Y8EG
MQ'&3W?,2C9$@OL6<MV5G*/@& */!(_XG+ <B3^<8-8LH_P5;"B2QUSPZ)PF5
MSP@F?P0@QVS'W&Z?C_H%B''+_30)Q,FGX)C,_.XD:3H9'F<<+#&-IVET^&"2
M1/>>)\L@6G$C9!X,\P19-&.=)A%JR,,G($V:R5W)PHZ 6OL3<7ESKR'YR8MR
M297,]^(^A=S?)&@QQQ@&_DPX$8U#$UR?OS84J5<F.695 N&5;TDE>S@=I *<
MOJV4,$PR056!+]5R\#H*<,,5](99'"L!Z7(\X<-S1^\T8WU+YN;[GOB(B+A$
MO,ZX=F%-YLPHURJ<!\2.6>VA;-4, LD/(N&*EY_AZ0:L9_@1CVIQ@EPP.^L-
MZO+,GCPN%6XXJWQO8( -+)@U?\21TA"5]S.$?!*#=&$FB W 9+$',"J= -4=
M@X+ 2 O,Q?]2CA(49;$N5W^<GS;40?K[&R2VN,%$K."!9,)]$8:^R9>?5HE-
M.XM.DLZBB B,GB0DC*&JB!2"I0C?&2!0DBF<"2KH'X/M'STAA*;%T'.#9'0L
MH6#Y&"2+AB;0/.PL&K/Z[2@P7@(B*)BEZK,MHS\6T0 S KS09]U ,,4BQ>C;
MS,4C_#:SN@^<'E_#PH7-53+/"$@APVT^D2F7[).X1/S42?PDN/!&9 #8U<:9
M:.-RGQXB(F X;W[B)31I9OO%/==GI11!5")>U(QRL1H%-Q:O/H.FC'"Q>X;X
MGJ80"AV$CYV1)C/QO"_SX"'E'A-0%=/."..\>S^)$69>39OO)BFUE^T#+B)&
MJV%6(V',%D9"IR,+M^-EE5+8S'E:SSV%@D(1\WW,/%//QU"+"Y82-0Y69!KA
MB!5@3LP1S-N+=>&<I,Y24K4)I0A\07@XG332#OL[*>?G=84%?:C'3:5V Z1
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M;C(E+C.51HI+"<Z)W4[]V(N"Z4H\K2MG<>!/*( &O@<$/ZJ=?<44%;@1OQ&
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M)K/Z*##/"*W:4K+Q-B*&2Y/O<S=>@$_'FS5_[1X=*QH)V.;?XK3C72M[A1B
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M"6*08[R2,0XJWX6SEEZ_HE3Z^O;B^/E$^H"CZZ\#'R/JZ4XT"/FHC'%_EHZ
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MP4A!*Q)_F<YD<"_/P;H"^:!(&^# ##(_-AJY(G>E$ Q8.CP(B.1E3M_1FRF
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M<;.)=JMWU6:O(?(@T$_E=(Q)!2H)F3I-8XD0YT+CI3F]:E^<.8.+RW/ ;NO
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M&\%5C69(MJJ#7#:![<(B":%=POXF- (=1R/Z,=#7TM+0G/"'((3@=<@="P\
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MKDL6@P8B:<+23 8!_J_>.ZTP\E7YW11,*W%'_\3# LI1%U&;>V3K0&Q1K@,
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MSOQT; /Q.DS]8>3-G<+92T1_D,1]NPI9!QF2;I)&[M?S(5$XDBU\S42E'D5
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M%_C11+@R(P5![Q[X>Y0"  !.3C2=1G&:A7ZJZBU_A/NR% VC+,UP;W!XE[9
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ML[.&NCYTCM#3_P2)Y4=H!X/5PAT TC%L,"8FT71^UHD[]&D.D<938>U( ?
M@*FRN70LTHHM$M1XCXU5H4T1<X,JA+$,$ZTYBK242TZ91J0&J"PA6)T!D9E,
M'H9&PC^?4:V61$0EV1#3C'(L%5!#8.2X?8/WER3XSYS7-U3A'*[.8!:4E 0J
MS%" 9L_?PSJ@R623C-/>*:DIPD(34)25!A.5KHB5*?O4*Z%39^ A3 7!_)P
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MMKQ8.XJW\'II[?P^N9/U;*XB+$U$RZY&=<4T=Z<^/"OH@P],>QXUK EKNKM
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MQV8\G$7D(/&O24#J(']H-3,/9TW\1NH.\K4"0X3W3\M/?K 6^-5= *]A?6>
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MG &2TB*F 44>K#]74'?>;GU%97C:9^2)6_C5O$*!<$WGA\N-:OJ2K+Z1M8M
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MTCR?:EE^R[W95(NVJ8\P47+N]",$U^U8DX:'LU;Y-X7Z4.<U/M <C,)$K!+
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M%%J$]H[< 5%NCW#\*/[E\>PH,0Y7$.:NV7'&'ESF\:O >?07TP8SF-AC6 "
M8(#&NV75(<Z"DGD=]1NTG(AH_2W5;4S:R&13J <BI".QLYNRJ/Z;*X3FBN3"
MM2_W*2ZW/]2YO"6(X6PRLD)OFZN & $-EG$DXNGH[I>LY9L: ?K=!N#R_A8E
MK"^TTJS7TSM*>3$AJF!Z<,.=KUBM]2X*9Z&Q(,W/A5@]*B+'Q<F0&HSC;LP!
M4J1CM#ZD;1XSO)FH0H/R?(2BZ2>#+T &EUWH417K-J\:QD2AP I6()=^0=L(
MK6T$:PNJ(< ;D1R0L6R=Z^?EX@,UWZ;); CE6>0"FHRIY5B*"Q<EI"9='1J&
MD)+9W]6NU7S'JYC?6OD/T6H2X%NRHLM<Q3XS5=K^)<5=L&&PHS;-$A))H]6"
M\( 7# KOKJVE,279%*)I$2O#V]].R":U"5UMMY2A8?%\6-P@?;AC*ML _"9_
M^])@(R#XR>6@FA%$32\<B[;HA=6;MSY6_<B@R+<,MR,UUY?KYAS0$-?T?E/*
MTVU,QTPB6TA:IX:XQ4=9,M/>[P!E69+7,/FLO+ A0>3'M)A<J-_#VSEF"-J;
M%4[X<U2Q2M+U*5X"DB1;O^&0#:$GVG:@&J7*18MI]0/]"O3#'"A!CE]55VUQ
M.Z<-&(TH9GK#LY)BS4HSY<+U&Q7BL=G&.BK$?4GC3B 57*_"FMJRA7V1M*IB
M_5Z#Z_@WI'@:C&S)$\6&2#_.IMEB<.>1 Y4T@-!9D.*Q^$S!:F/2A\:+P7EF
MP*VX'P!.==*[R!RL0:L I$]7_?CEBNP+A'X=ZBX/MLGTA8Z^Q!Z2J?!HJ2!;
MZ117Z#Y<Y:\-R=8H0Q)%'$$3!8QBAW*<_HNO:I)" #OR H[$ZU [1** OG=(
M,_#JQ>O3#E(X[^6>U.^%!\X;A5HB:]RPA=\ G%\+9PZKA] !=Q%IGN!"2DJ=
MB5Y&1M?T36NE*\[-4^L0G&L14/A ?:[>,ZF7O"O8+A+!*C[[4:?L>W0Z_#VF
MA"9%LJU"\S4ZX]4&5+SGZPI;;N&G::/RBDR\C*) JTZ"-V)3W5#K+B$(Z&!A
M*2=^!9Q9%&(*R'!<G3 X@L@&,=Q.*VG5A@TJWR1CB(?I>H\&B+$L'"7IP@]U
M4KPC5J4_5L.FG!NQF#(9?$@RIH./>![P6$?G/]?T[J"$C,V(W!X%4>)S*7\R
MW[M] RFZ3N6O]0VH3J1#1Y' L 401DG9\6BOB(YMLO@P$!^U -!_!':'O4NO
M/R4F9V SF?AE=(%C*2B-^1[J/Y,\4]AHN,?AQ$L7%+9L%[?%((_==@X;M!YB
MK#$HSTG60S# !/Q4<,%Z2 J/?E"@Y!2>![X9X!^XHF2$*U$A7!E,L#C4L6 I
M1B$E"I]W@,&LA,QB*B(2.[^GSII62D/\I<8X]O[E5=#7V"+K5#B<=G=CC1-K
M<JUMZ;;SKO W!' 4JJ"S+FN>S#D4]J@LEW":5UC[NH@OS8-MM764YRR5KMR<
M1^- A$P!'2I%I\+R:2&1@[\[<EANFU91F:N-H>)*,-N4%T"@MA9#T?_M\M76
M#+[LEITETYR%M)X$ETU:UD.*@+Q.8M59*H")_PA,'U9<-UPM:OUO8J%OQ[48
M:XUJ[>J!.#]LQ1?$@\)03P*6CI =17!6F._.B#V2MT2L0=;1K-;KFI5KJAI*
MN<++@TN_P01KP4#OJN6F]64#4'.5%ZJ4]L:B^ .>.E$1PA1,C-7AWC8&&' 7
MA%P%(4+]D9OB;S)H%CB"Y!'-!EP&PB[A5_@(\^U,,#-JS+Q5C\[DSO8A*4Y-
M(KR-)0T$)*'H1#05V:/CUV\-_#5MP?11[/PW>-]*@U$:-"KDDVT1S2>QH%!'
M5D>/@+N_\RZQ/_Q4)]A1/N$RFV4L;C;]^*I875":ZE'NKHCI251VB*!4U9(J
MZ*#92-HAWN1 B-<3K!,E3,F/#VDK%G'0)8><"I\*=EI0];*(C3A<JYC?HX<3
MQ!!SDCG$/WT>%I!&@6MSU/FI]]?Q%,JA:1&_A%?^HL3)HU_ ^=9H,KC^**_
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MZR7*:5 J.%HSDR /T5-R"<K^\UOHYP%D/F!Y0+6X;2^03GY3TM0L'2L;XMO
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M%/G'H.S$F@.&[*!V _8MTV6_IC]<N"VM38$>P:*%:2R].8>9KMWV@J>,P(I
M@<YR5V;EC!'T<S7 F3L2=*WYV,)_9N"?[=RV@_^70?FE@F0H]+\BETB8=.#*
MZ:MS>!>8<<GUE2U0@]_ \G\J>Y^U9<DIO0^)%?9:H1<][[IVPWPQ]&6-3I(>
M9V\#0MLJ7MW$QTOWMB.)P*;3L@W(;,V;Y>Z((I%KF@(/K6Y[WH!8&\1'$HH#
MBPM2&8(-RM)#PGG= _*@A0]:I7&[7\9J]Y,./3GSKL8@+/96<A-C&R+_@ZF8
M.FQV,FKPQ_WYVNY:]Q$.FCE&N\X?P/+P-SQ&MW_AV=![J_YO*D'Y&V7C^HMF
M26!#.\]WY/#=L@[\>G_R'#@G[,RWC*J!!EGF!?&N%E\:MD1;RE6C2*C"-+0*
M_A&!2,P2XE<;\.:8KA_\G/.:\&(B*NV\!/PS.6I^4Y1;Q&_+*.[( MU:@@B3
MR(4A9DLT!"A:5L_O8FB7H*;J/\%L:]FE+28"G^SRLK@(D@-1(22WOF!TL "U
M?Z5OL:(D=A4^#_$_)F.\[ROD52W^;=_TF)#2O4.0EE''OP"A725")$9)'=BR
MP-8T';)XDSDU7;?1&.G1:,)MW:L/(]Y1OJ)MNNX(3:?!8E-*Q\<1$'S(/"='
MQ'_YH!SZYHAF^F#6>W]9\$&!%=W,CWCJ"\H1$7LB<L,SR8AW%Z&;6<K%-B%G
M@?*4G#-*L50@IP(B0^B\7^(@^EA@,$*_PD4LV J3IUCK75SIA *>@/VPR2TJ
M)$8M%-4EK/*H^AB*X22N>V][H7[*-,J!;A <?1<+WKG]@+AR-Q-%'\"2*<--
MM!N"[,@ QSN"8 F(1BAD\C@P0:[&&(,_X[E33'\V:HU^OL/BLP72))#&AZHE
M7Q_:%Q VB&TOY;4):RX;1':1N&-9Y41JA!#DGTUMC[MNICR*M,,J[ZM%7\BU
MAS)15>U@7!#5!;8I*>Z/NW[V[=],N7Z":VAV)AHYM@^#A@;<HGYG]Z3ZY /_
M9CB_R/#M-6V<T2S,.YF^H'\-,#W"WA#![1IUB9.UFW3EXG.>GNV09PZ3?$UR
MF9AM[BP;TW_N*!-4!NI2!#$/@HK8PPVH714:G%@4V=C=!/4,%&F.0+;^TK4[
M25W;-B'36V3(973%,CG^PH1A&&?>D?6Z<1M-M#JR'+>B"#*KDBQCEAXHNTI1
MPPN8F:.5/V!0/J2*! (:_2)NA\VVF)&;AZD'P/V88@4_E#)O8R'$?J3])&E"
M(*BA(D+5!<%<_LJSS7EF3)S+Y0[(6TP6M1)15ZD%M2!^3R6;J&R[84U3\@QT
M2\OZ1!UP=8/TQ90O:%';T7_D :"B )4O'P J#P"5SQ6@0M'>1VJHJ0D%^PW$
M^@Q_@"@8:5_I<\R10)TN6&\3Z3B$74QI@3&-0D5Q;@<>7<\50C!V]?G:Q5 .
MR6NJ)1[1OB7,;ID^[D?25\1/ZE!!+UP\\H4E52$AT>-]P:M)/P.O0<(<HM7-
MN15&; 5(!ACA([A4= 0!<,JTK;F0S;*9RH4CTJ?OC4:OF7K$CHC*M%(CQOKP
MW.:,-2 C1!U'A%A1B'H\E.\AE0I,U?3XY@D0\LFI8=I;3*O1TA]1BWA!_OP1
M^/,[^5@[10KXBFIJ'!IWSL8XIBNW9FK)CNDA%HU2V 1FR<G?C2..$%]09VW(
M$W#D Z_Y/*645>D5 F]M*?_+O#;-8D"69!Q/)"43A?%KR1*Q/D^>>D!H9I\+
M8-6&K4H3,?%=H_AJV/@C,:7LB!I,7O6(IN9F"H)4)SN$02N,/B%&Y[4[YZRA
M]#F,=TU5K]"O E</AZ1^'00-_A%^!6A; H3-._-@W'*D[1$].ZTU(>BI.D2_
MHH@0Q=@L"#O'F@8LBXR^(?J%.:>TM+(O?N*^;WHW>_I4** !T.!J,";^3]Y)
M0O.R-(@'=$(W9(N-RE<$'9# M5'":;,'"W-X&0MOA$QD0R8<[$6.@5V"[/1P
M%,ES(Z*7J>=,';00)J/]&PO)3NR\E7UG-F$AE@MW5\34!3+5$_.S-UQGG?N
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M N RQ"<O'PV:/,0;['=>M1R8PA=9MJL^<B:N:N6[A.>#!$7P<D=K#FXKZ*6
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M9G+C:&?T_CQ(GCV2@F&606*?<AZW?FSQ2"+LAY<[U68>320L!VV;D+27=U,
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M- ?58@8!HR330H$5S:O2C&&T3G*^HJ0A+X8Y1231#,QFM#O+;05D.'# G7:
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M.H#]>Y#LG@-N6:R!U^I(-XKP@1G'' \KOHG$-@2#U;%M'#RVZC8\(,"PTPL
M998=N3R=*P<Z?E-V--X8?8B/-9*!8:8=+">28F"GHK]U06ZF1/XO2]-3SH#1
M;O;5=R?',UE&_,@Y]^@6N!B&0"QFY 0/RGC??**HDWL%1Y[".E)<23EQ^2U"
M)'P\^[:Y<@A8^Y<W9M6*]#;U7<?SWBF]U]-G(83,FZ$"+R[R1;D@)6QE<#_R
MZL8OQ-;#7^]]M0Z_0>]CWB$_.FQO6%5MUP<C$\C<S-MBF<1!4G)J\#K,UFTP
MI]J'T4S:S8"CO0 M1TA$5ZND2;[7?0L';X/B _?!*)V82GJ<>A&& =Z%\;1A
MA@?3+)8W,+5&&GE.&)_<1M5S;+87M*>4[;IR;71/9;Z>I%DHQX+1TT4)-U<T
MW'&<G(3)@! &^/^S)T_^>A\6^WW$T(VW=771D.Y>/CF 4Q>^0E65[@/:3FYC
M4O/4/<J'J,3O"'L%_6MV9KA,#]M-6XO]"8VWF5FA=7E%>V.#51W.5F2,2=XP
M',]>$*TQ&6[_#I0K&6KA\JGH]\K6HKJ"WR;.V-0[H(OHZG. 7DUF3: Z8^@+
MU?Y95%_39E"5$7@ZX2#B@*UKUHY0[%@)AXC>E-@1;>XN2W5)'W>'XMD*Q$6C
MN*DI3.%P6"G"TJ\TEIGBU/AZZ%1BFW"&2J,N>I,<'8Y(#T]SL ' ]K]F-Q0\
M*':9^4_><XI!&W"$7AE]95B.["-F1W\PC/;["[O^MU4*B6E?K4Z(/>:_^CM?
M(R23K,&!(,#RE+>TG;/W/^?.8'4)W_JX.G;'A<VK1<GPNK$;U<Q?%/($;^20
MW,5EH)Q[[0_KT[\5T'3Y%_^[TG1)/PB"SY!,LT,4))IU<=Y?A+[0*=NAHWN<
M4'A%P9>)16%'U.Z\9/8U[M*.XRUYIHF[RCYD^Q#<-%"+7(!Z, (D1J3>K0OR
MAG2KKR.,'J(HD,GZ;KSK[3O<6KY",!="(!'7UAR] PT1=."Z98SMHH0S,7S[
MJQS:BLIMN<!8(E*+R%$;FMI;?,G!/TJ:(;)R-Q/Y8D4#),AAHA--L6ZKK8/7
MOUM;=G^[AE4&3)"EHE]!;=(^UO5K4$(\!4/XOP:Z>E'^',GGO%_T"@JMP*L5
M[W[_)U@J%,:CQC@6 J RR2[JT96]8L&,WI_V#E)YKM^[DL#+6Y:E#[<!RJQ-
M9U2*0JSMJ"[CAP-NE\(I#4XWNV7VEFHUY:K[PT@ 5JO\UI&-A2!B 09#7FT5
M\C/G* @+A>8-&5+HP5<_#PB22!26TWZCD4<81^[1+^-$,IY-<]I$&2\5\Y!S
MG2$H%<@E*P'0YW3Y'A _BOCYQP/BYP'Q\[DB?B(S7E@K;4*36#H502SBC@I>
M-=9!->%<!"B TN%5R%78?V0&-?BA1;4-,(BFISK=+=$Z17)YV M/["J5T-B_
M9C!HN#8*O6!$14H)(\84\<0$D+T:*>BG%XXF6*_&?=.+B2NH#IGE0)]-+RYF
MT:=8X_3-CZ]>'#W]QPPN% >$DY#H<1_]%=O.\6;/=W=*I!X^:<F)"9!+^J;C
M1%RUV99$[[$%-(]_$42LRO>CN3\2CJ"@"2%KJ$/?-'6S6#?DG6K++R>L",:4
M?PG^9[]P_A'G7![L07$'A'[:$N.W);30$R\,;"6 +/F=T/7-XL-L#5D.&E%"
MS:SM%.1ZF);_%\.V^B@520K<CF<OG'01<MJ&785Q)3!QE5MWI)G,6'2'MK,?
MYX84FN,-C;LS$J.5K!!\JC'='@GHN75^'96(<&)>&)_%TP,-A<Y!B#DL&7+'
M0<*-\A:1:V:V/F0Q_+'O5CMA6+'[W?(8@,DA+K'@VX"14&<H B[**8[/+*P$
M,+9*F+-"-D9BPV]1MNAX]HV@)PBXWRZ);S1M+VE$BY60WKW;RK[<'TW1DO@E
M!>!!W:U<1%$FF#C]K1!T41(CZ:F0(Z%VS.R=<H$D590=MW1.(+N%.P%Z-:C6
MC/2>5!T76+MPTQ-E4","M8TT>$[.A^6(1^D>&/-ZQW6Z4MS9#4P)YCZ-C;<B
M1HCGESPK(?")M"%FUEGZ'=2(/)>R\(P9>+*RX@G8-6A9F66S,<6$.=ZG,EXS
M\M)V#U!H<84U*@B:_#D&_(-K159,]QN0$4%^F4C:I14X<?KS=Y#?.7X&_ ]T
MV+]Y46VW"* 5@7E]0N6,LH&A5PY]__";44J ]N0H!8 E/5KMB<F\80?#)VA<
MDKIL N>X,X6^6Z9[7D;1Y(3K@V==;AK, O@3_F>R@OBIN>0$!&=DVKE"X^!0
M!T,#VV/9H EMT)4S&Z#&;E^3,V*0=N#_PPNF'&K83+A)]+&3;F4^); /C%<E
MA8+\4RC6W^V#Z87R\L^NV4)MB3-;XG'B5N0:3XZ+QS_UO"TW]P( DV0S8!K<
MQXI,RV8JU72KE)5Z+VORHCE/58#WZ\T0WU<+Q+=@?CN(!)N?-'JLE'$9)3P#
MJR>[J8;+*V'\OM$I"T*QD]'4S9)ATYMU7Q;LVGU<R"4LH]2M&@4A_(&F5?@D
M)J"6L_.VN:+":)Q,X\U=D/'@JSQ&C8450I?#_Y>?5HA _=K3L"Y+'TX,72[P
M$Z:.=E.1Q(Q4HJ&_'!1H!D<PCQM9N&AE"1_"Z#=I%A8HLQ3H=*>ESS6[[3$2
M'R"'C+]'9Z_\9NZ]U_SL>';PNJQ+8DIXU,U>4+E406)^2G8,8PKT*Z=ZER&O
M"]=IH%H:DL!_^J^_/WOZ]+D_/7ZZEV+D3\LMW!SP'0JX#EA&P,C_S,$?U+SE
M@K]AUR41O:T2<C0H0P*#6<IK@PZIDNVK:FBYH UA-L'X ,W-L>V#QM&5R^I
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MK@=W@!$/;$@\(JSIX-WRBUT'W)N,4>NA.1=6XL*O#M1J.UMK 3O4@AXBDRW
M2O->]0;> 8/8A5NCFYL^%_L[J@UAK0&3"S,[VR#%%3;/!__0MN$'/P\*4>?G
M< U+2<[;//IC/9#V FS*V<$;?Y9F;SG9<>#'/N^J7EN#B<>K/*?'G[X^X\09
MX7@M'@*O05MB).,,IV#==$,;"QGX(Q>*%O'"J(=J^S'(U$5^<:@9:JJF)'V;
M9"W##(%]D8E6NP/GIP9/P'\.; (\')U;!1O1O\+Q \0P@7"A++.J_#/I'TM_
M2OT+]_2O_%\=-7IV??1;F'")OWZTJ9974)D,K(?D$++C%V(K6W!1DQ:J/"01
MY">'_ +C1!J4/=538:*63F%!-*-F@>Z!Z?@IB,D16!HAR6EY;Z)CEGD6TI*O
MZ"E1YL5;)F&T,57CP+^?7[A)<F,I>>[8BTY$ 2/*C-COIOT"B8YN;1<3C\=4
MV@+:/53S)208#,PWN,&K:BVL$=6"W\MD$G 4!:&$/I@/DG-HK #F;+ J'P$-
M.6%09)M#>)N'"_MYJ 4C^'/R#6$J):&[<4RH<EZM>@8KLH=&?0RA]85^3X=W
M--9K?*[><[5D+((BS.BR8"\_"T!X'J$'R**&/J#8'(*C"*E[_U9'VW(7I!*#
MKQ1)BO-+;8F)##";Q[/7$9_#:$\K&(1IFJZ(<)>?6*AO'1+$J&^=QTQD?D/5
M7!=K5[:2: \B'Q#7T)&"C/*P7H^Z[FRP$V?,QZ5WW*P:JC$S2H@60[^0H"_%
M\?O5 YD3-0PH!J7H-O0+O>-?8L(+,BA'_AE'6-HR#J)TA*D%7T!A?D'SB^U7
M?N']$:@S]$EH=Y@"#K:/6Z*F^7Z4U>=7J__BH5;_4*N_N]H0MV_'N I43=:(
M,VR:?1>,'KB29/T8S>"%="' $9,,=2B@QD)U7"((+L9$:T;D3D5)_P@Q8$Q\
MW$?$EX%M&&/$FBH0*RB/:7GJQ-YGK+FTTG5Q*J^XMS0^/SE#CJNJQ?L6GD+%
M7/\:)*S/6[C[CWCX*_S?\]_J9=Z26_HM%1O.* W^J)M]\9<G7TE3;;0]"8'Q
M>_;B'>#8>#@'A\)%"7'^<@.- [WCO@^$?=*;O8MRMV>2[C_A;S"6X?'!M^_.
M3@X.6<$+,QXQ^/1'R$A#<N)DY<V%]T,>'_SHOS#[6@ RU*5]!HSO@S>1CP^^
M/B.L2C2+P95\WQ( XYV#'+G4L'9 ^HE5K7MP8-[RNY.KCP?#!R<+K>I<0AFC
M7'@;86H3# =GBRBEN[7[&"@G&N\\U#'QA%\<[_9S(1=Y2(O8V,:922%;",OA
MS6(+29DS:@Z)G@<X$.9R0+0UBOT@;3ZVYV!8BL\H0R^?F@79 .#="L$]=S65
M5V5KY(G"=4,U<2*"^-?@=Z&#/C',?S<M8(TPSH3Z+0UKF3:Y(P7!PE!@4J':
MCH3C#[[-),=$55F>D9;A[.B88PUY2Q4XJ*L3]3SZ<=S>A1]KVNJ\0O^>2MG+
MP?&D0K"GF7S:$M%N&'=ZBXB%/UB:]^XO7!9;QJLM:)N]U[$-@*1S%S3*N3"/
MH=^2_EQ) Q4^(("3"%K2];(\R-8+A8/DI3"3A>D,NEAQ8EVU)I, 7X#JEC29
MI3D_"GNC/K+@<5AK>!^LQ>E$>5-@6(CQ)KW.*';N.548,#P!E(#*C5@.ILDV
M77@9@($%!4W]"B;%O>-4=3:C$7B73+Z+#(' /2@-@L.0IP>*4#UTNOHT7CI2
MA@>2Q:":=G* ).ZPI.TA  R)=*E.QQS74FYO4 $'5'S1#D3;\Q@RWC&[R**B
MLD"@4HWL'?H.?%ZTE0%'#%>L*&Q-/,7N::M$ %,0GJ4M#VAP%1\C.7!+PRFM
MHFE17V&/?CK>0G'E*^5H4-#*T'-ZB9-(]^",O1DFLU:?-. )>:<DXF$($^T"
M*: SJ0G3@8900V50$%I8U3'1V2T,/A;^I7Z30$$%(QPERC-W47 4+!]X2-,5
M^%R$P&4?R;V\@0L<?T?*138K=[/8;"+XHD/CYZB%65W1\96B/>'"$>]5THU#
M2D'E!^I_QLY1&5+D.Z2S+ZJJ]@:F-V!SAZ+J'7MC0OP<;08EO$I%!/<NI6EV
MEMH0[9W[<#RC\D9NVLU.1FL:*H#D?XY\/KH%8H>#-W+,4S(%+IIA*WJ4C@=_
M-<;85Y@+XKPN^E$L,32Z?^",D"ODELR[$XP+U6C3WNO=E,^#E<+6"0?+J%2:
M?__N6D,/CX#9+53%$0HL Q:)Z AMX"/9"Y: %/SVLDH1A,G"ET:DCHPGE:01
M?407_Y96,S29TP26X^U$)@5* /_CUQ@6_ND7!6M&X="U.H:6<G;RXMU,! _0
M.5>:B-%*$T-"M'=P]:G&1%*ILE&4:6.^RVVV,G[Z+IY# 973%CHOJ[H#!0:P
MF5R.6@[$[<>J<D.M@9Y0'+1BHJ$8BDJN/LAIAO,+?>FR=NN8=A.\<Q0A!0L&
M$XSW9M @-?VAY+VZ$F7<:BIK*G 4 D_8-F%R'36)1OVHU$H.=7DPI/BQ)2K.
MC&I9H\@F9 _U2'GS#4"L2Q8,>T*"8;SF;&-*<**XP=;_'O5 M(._'$@\5=!,
M\ ^=%F,73-'(MMQLF./9UP0"*] MMQKME"Q,OKIT*T1M,9B1[Y5H/\4&3>\-
M\3XWL-3&>B!R)F;I9\\VD)%G#&8<T-53)S![(1_/IH7'[\Z]]!/;+FNL8SN;
MB7*BFBP'0VI?PWJU!LA]QO'(+DG7R,[P?PO^S/E0+2T'5PBM<\.(EB]A.@QN
M79"4"<-B_[?%PGXX6K=9_GNP^'Y16M':\5;BBR(QT4C-L$5>U94_:UWH!&AI
M#\3**+0%@+HDD,!'+$+^[\6SRWYD JD= CF*78 SDJX9_OUETQ$:!FB6"._
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M;?T?IG%M F12%;-13TEZH*2E$!J*HQS>R)=(P ]@@@CF=.&OMMD:Y&$4LJ$
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M%PST3K$:#O<KF+_D=G1,&:N,H;29P.;*/(!,#O/66(L\'DAA,458KJYZJIX
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MH41BNF$Z/)TT_L66X<>(I28F.4_)8Z>%Z[KQ.P_35?/W%,F_TK%3WH[IYI8
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M@Y_CF!\#87B^^P:7#3_;XQ'M5TZ*"K6_29X.G3%'+@?X":@N@-/C7*8*L 2
MMK 1=\&-G:6]34OI4%Z1WFESR][I+OR$$>M()U*H_E9B,]]"A@C:B:&W"2DF
M4M.FH'0'VD$@'(V[X[RHL@XQ=&=0F+M9Z3M=Z5.=\J-^=N(94X&82T<C?(Q[
MA9K) I\V#2U)J0,<WSE) 3=&#=B2N2"OZJ.IV$52L?NJ"P09^&0YX?Q9;'7
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ML2QBORF$>&=')*:4Y]Q0"0+_'EU^#LN&7L8'E#5HM]K?VX]9$[MR36-.; S
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MQ_"'CA']H@4NXT\7?GSU7U!+ P04    " #9.:16*1AWWKH9  !4\0  %0
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M+3SH][X@<)1',_/=V5N<QF6 5Q8#VN4XW\[FT$$_GX2HM$@ID. -/@52.GP
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M!C A@DJ&*Y("-Z61A",VRE6?,6D,1[][,&UR-ZPQ.2OU>5))''4;3UX=YA5
M)H W' H,#+\DM^B+@;%$"Y6H\=PX7UN/W -G3'T#J_&BUO0/?"([NM5OINWG
M*_[=1:^)53/5-J\Y7<[?/$]N"X>V,H(ZY[@/."N5W..MSOPK)Y-Z*Q(CT:NB
MA@(GE@M/'#5"&E4*<VHWTMX*\+:Z\/H'3[(7T@&3!!*EQ6X[$C1C1.I(O?$N
MVU"[%.TZ@C$YUL_'I)LJ<@NI#+P,M#M_Y;ONK)D=K1*( P2;D@E$E</+)#!#
M0K3H]WDJ8@"C@A[B>7D0V)@\[V_'H_HRW-#HGK]?O@3?PU_^]+]02P,$%
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M/K<&9S(#[HK.+&;RJUJ;(?,G/VM&=Q!>P^Z2"Q3O^B'V!S/3F0R-V?7]E]&
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M[R#MVS9>\)V&;<[4(<N^*.-U'>_BA8J8@M!2**>Y?[AAV[HG-V_1I@UB=CH
MV1CDC;K,(#"&D)(S0@BGF-G(']\E-O.N88NVVB$=7^/\OV^']QNQ?Z07].?1
M^+<PSCW#B_1<(!1RNNE4+AR<5P%L2EPD.J2%Z:!UVS80G\0M_S:ZL22UN#-*
MNFUK>C]9A2>7,KW6P*4C@SR3,+Q-'E)M(<-+0KQ[(![9A(M.R=QF[,4V3'1@
M3J^>PX N9^U3HA>$##S:Z MXGC0PEA3)0FOO6OO#3VCLQ2'UHPT'7?3XN;?D
MGDXQ1E\DE$S&ODJ<5XL_@30U41(UTZK]X7H7Q7&KPYY2[^3RBQ#-YS;=3$"8
M*^DB%1]SO;[#X63F+_123ME)QL 50?M:L F\MAZD=8';G&(0K>OK=H#Y.]"D
M#GGKH"' "LBS68(K$%NCHW7% Q>:;#HN,T2G:A4(<B\<L]:W-GVW1_F[5+16
MK'50CSE_!SZ$?J;U?P[?:@O6+_/T*_K&"LS%BAQJ$WQ4=4IV,AE"EK[.P)7:
M:UYT\Q2\77 >N:YUS5P'Y9\O\G]?3*;5%9U\Q$$=COIYM"ET;PM/EJ"76J2B
M=+ $G3G(9 (ZCM'1:]-8Z?: >]RZ=R@>&Q:HSD*Y-_?GVANR9@$NV:K?G)T/
M1M]Q433]81"&/2<84V1^@O9H";9T9!F$"#X:YFLV5[[K!JX(G>^.X3AUZI#$
M=%#W.D/^$<\OQNE+U?7[!F8ODRD9/%.0A?#DO<8$,4@.K#A2_V*UD\V/RP=1
M':<R=<1*)_,U5R.<Z7HO.I=$+!:D1/) 9$$R"G,&C-H+D7UFHI,0PSI0OU^M
MV9Z3+HID;QR\GT<O<IX)/PRJ%?AV^"J<]Z=A,-/O>/?<_8@DJDE_BI?7HO-5
M?<0T.IU3.%\@9]$61B]$BG4<M3:>Q)<MB,"]Y<I+U7SR=]=K.FZ=?5(:T44]
M[^V*31V"T[6_E\>H0-5Q;"%R1J]BT#XX\J&;M[Y[_)8Q!U.FW66]A/G.2@AO
MEO3T%%,\),6@)$_NA#.2=F2;P :;9931)V</6"CU>$4IA]23YLPL49\&S?;7
M7#=ZF;034@./*8 REKP&DP.87(Q0U@O??)C]YA>_+:\OR?^A5U5$<"+X^NH2
M"S8;$!IY"*9$W7Q:ZX;7ETWNX4I2(A11P-GJ_;$0P$4TP(W/2"I''F#[ J3U
M]W![%U59Q16CM[!.$*Z-J@V]F2P5X"%'E6L?I]Q9XLYC%U7MDYBRAQ@?NZCJ
MWA+NCY6.QMHB!1A1ZPD9TQ"*KQ6J.AJM&8NR_>W."C!/I-QJ*X)7Z<I>@C[,
ME/5-$&U3=+7-F76@:>NK*J\:T_7PN/5=9'T8+4 6R9KR#"2RVKC5*7!T@@.S
MH;9;"M*HYL.X#\3^B@JL@Y._C8@[&2]Y;R2\DEEF:Q*9:V0Y*QX='8PF@E(,
ML_)DOOG6UMM]%$]B!/M6W"Q-/-Q9L!TDI5ZI]-R K*[4:%AC.#.UUM8$%GPM
M4+"UW;@W$%E-$5 I)5W_57965;\,T#&=]WL+O(/\PCN8+C5^$U ='?M+ 3WR
MR;\_<7<[J3:3>@=GP7)PR:)7*.CE\;EV.+*T:W$9B4"9G77%*=N\C_+A5&%3
M,^! FK"-L#NS!F9'X.69E0B'84R =(+.K$B ?*$C+ IFL_/HI6L=%[@'XO"V
M0 -R5M<A["#9#JR!%=<V"W QEN1K^Z<0-"C# P3D&9C.Z'200<36';37 CH&
M%6@G\0[>_(\XI?5A7K3ZOD3EO63)U)&ER#R9/Z6 T\E#484;P4UDS8NZER,Y
M!@5H(.,.#,$7*5V<7<P2ZE9=L5P"%98[J;PCH%C(?T$&P:("@R(Q(6GCBJV5
M86-PQZ ?W3#104W*DLN62V#::6Z"\""-0Z@N<IWY(T'+VJ7 LIBP=>7)2C#'
MH!)M)+VR5J1MU?]E'X1/88"33^D+YHL!CLI[G-[\A]=U$QQ,;D/;K,I_J\]O
M4=6_^X+N5/$3/;5'FTY%,Y6(<L\LO<*<!RN*]MC;ZDG[O;RO^Y-P>DJKG27D
MG)3+#C/7UV%.><9\*/5F4P#!]628)@=**5>\0)F;3X5_"-/^ULWL\Q:3S6HG
MC9HW_NIB,J5-=?SF6QI<U"OQ%Y,)TO_->J$F%[BV*@%C=3 WJWW:;7' ZW";
M(G/&T+I,>P>8A]_DFNK/?1.I6Z(Z<*16R&,>/A0V>I%9J(T959WN'B&D4#NG
M1O+X2K0LM8ZEK\-SJ$OV3G6DF< ?^P*^]@ZZ"C#]%4>GXW#^I9_"8!9<4MF0
M0V@-($=?.[@5\*G02IP5]30Q/F]T^?Y X\.5 !XK -^.WE%K,3=N>OEIKCXW
M(5V:C)N :MCR="60P[<\;434J"LI'TP%4DDL\L (G*)MDGX-0DW]]V37Y\22
M$6ZC IZG1?V:OJ>'9'X;X39D/(TNR*;YWOOU4X\K76@Y$IRL725B<!!%HBTM
M>,PJR9C-NLR*":8_G8Z^_G3YB7.&+_]R3?#U\P[;$*^1X$=[2:UU5]./.)F>
ME+^/R!*X=,'IT/$E6P$E%SJ1D"!Y711H6]"63.O!S9J9WOOHYTQ7 V%UTUSZ
M=D=E(:04J@A(M>V3DBZ RRS7.A,,T62I^48MEIY1Y_A.+*N]A=LPI+V^&><F
MH'Y'?>2WXFBCEN*["/A@?>19EMS:% %++2QB,H#W,4)1/.JL5-"2/S_6M^TC
MWY[T;>3:>1_YK'@1I4ZF474@<<$"T7H$*Y11QL<L6>O0Y9/L([\5*6O[R&\C
MT=86UYOO PQW8N"7L*+62(].-?,&0:4@P/',0+F4D M12C8;F5ZKGW'XR.H>
MDA^U%UO#EW4&Z]W;EY]?_-?)<F#:6AF%J/FUSM>@8)UKQ#Q(%#Z($IVZ.^5C
M!9_KGO)L&6TFNM9]X#^,:[GV<+H<F=?<DYL@@4X5K),G%$1-SIMR] WN.&.,
M;T3JVL<\6U;;":_A%?]\!_GZ#\1_AD7:>N*8<G)@F61U]DSM%B?(!U=HF,F<
MF;O5SJOVVIL?^VQIVUTX#5LVSI"\'9Z%?V)<[ .*.<7KR#]FZ,R7=/!'GBUD
MRU':HEEAF]%TZV.?+4V["V=EQ\/NLB7>AW$=]? 5&V5'W/N\UMD0ZP'?R7ZP
M16!2L62B4,G@HD+.B0)$KHP3O+?VD_?.;JOAP\G[T12KH?QN%(:3CYBP_[6&
M/=Y=W4@*XYPI]/K:7%O$"9D@&E[ &B]DR5H@:][J;T-L#3+\9L^Y_F@Z<EY=
MC.L,VIX-QFMO$'2U"Y6(AM9='&C!JP&1N;X;Q&RV[F5X#K_?=*(A2U+[VE#0
M15W89;[12;DEBID<2!X_]X=AF/K#TVOL\XAACL$&P0+('&OY8PD02I%@2W::
MA:QT:-XR8#>HATI[.(@J'8*NQ\Z,6"K0-2M\^?W&:NFS9[$NM#8%)..9,U6;
M2,4$@8X?"#[0N<D+&6@=I"OOC/?1"AX/H4\KML/.>>VD4N(FHD6E\ :8.JJ;
M7(;G<<HF#\?JO:S!1I0<2EV2\86%&& VN5FYFK(8ZG'@K<W..439NJ/<X=3D
M@9+*IZ4EVS#1R0B@D/&^<;@(+KA@$\,("4L!Y9V%H&M(2.:4E-$EQM;M-]8"
M.KQQOC]G]PHJ6@E\I25^B***5Z-APIH?73]_5#[V)_^(W^N?/X=$&M>\R&+#
MYW57=+'+@N^$(<C 3H4EY2QSRK <E1*.9Q'(&*?_URN*,#9\\KZ%US<>4C_\
MVE?0O%@K68$@JK;'.A2&5>T4)?@8:=<3K3MYKT:S?X'YG4_^0(8J?2.<(N]9
MS3GW.H/TY NII!T$IS0PY5QF)HC2P6"\U7@>H05-&RVX7WO>2.B=3$J\@VWN
M7*3LZ-&64*6:+<9J<SYG%; 46?"H76&MN]$L1W*HT,&AJ-]>O$\E%G!O*2^_
MO\1A^G(6QO^XM T%MSP7X"(A*.4%N.0X.,F]RS+Y4MJWJEB/Z;%\^A:T/Z1)
M^XB_D]8E=_$MT%WY@P_CZZJCX0/8'L==;\OH@^K2@(['4!O+I(H.-11;ZO0%
MA>#0:L Z]U%EHV/S:MC'49<'W/;'U99M6&B=N/37\6@RN?0-+E.F%SU;5(Y>
M: .1UUOEI#5X2]XHD\Z:R'/2<K,K]Y6/> (VZ%Y4C)K+\1 VZ,OO5P$G6>JD
MQ#R+-1$TK00$5118]%YIS$GJUI.8U\ Y;GMB)Z%WT!'G_FJO8T^;0#N4%?'8
M\?YF%#[HM.PG_T.8#3<@.L&LRK7#JRI86X8&B,D8<,5EPTW,JOLPQB/'^!]#
M,[81>Q<:<=FBXA[$RS..T2)=2!G,;/1)-'7X!R+8$)77+ =CFD<TUD-Z K;%
MKO3=58N&LF]H7]0:C5_"?X_&"WSSKJ&I:.&\=6!GS9\=XQ"$$'1JBFB5L04W
M:ZGY0"72_2<?@?700*0-DZ4KFO?A#$_*+4Q7Q;,/@VI8;[@2R.'K#?=E:-25
M>!M7&ZX&APY#B@;K!#/ZPRCR:)3W8$OP##GGKFQD SPMSM=4&QZ$\FVDVCH*
M\++VF_H%<ZV.OSQ6#&U?VEL)O-0.OMHE\$5:<-KDH(+#).XDF*UP_^]_]F$+
M"1M)?-1.7*U+"7])_TZ 1L-7H_'Y:'X0+?H2<)XLNEK P0RARA&\-+J.FF0I
M:Q6,9QN1N/(1SY[+-L);^4*VS9=X-1H0^9<PW_7)\)A@&,X;JKXX'>/L4FKR
MXFR1 %('C_X3<YU<>-E_9E1.R+B9_?[DM_[TRZ<P')7^'BD574-JD75Q4+'=
M2<QPSG,L-AAGHHKD_FG#F9$L84S:1=_K&ES'#36SUJ%X54#3@4B&KF*TYTE-
M?S6^H$_*FP,U 7SWF TU R,7+F0.5GM3.]8Z")K,_^0MD[9$9+9U(LMQ--3<
M1G]:--3<AJA#-]1,6 0/6=+BN:MM:AQ$S0TPVC,T1N,-:QU<>Q8--??1D68"
M?S*I(O/)"O4,>#6:3"<GY=?A^7CT%?.'\8C.@6D?)W/-QUS?##HYZ'O_G"W_
MY??+G_E^,J:O_AO3=#[K18=HM!7@2JZS7@P#GP,#3D=5T2Q*;#ZDOH-E/,G6
M4UNIV-W0WR-3W4U+FPIE4;F\ 9B.+IQN 7FD*Z;'IO=^<YP]N>E<8;(U4D07
M0++(0*58^X'0<9"<-$8S&RVVWJ@.H"@/73@]:3W9AI+6<:NYIW/+@[IRF5X,
MI_TXRM\O84K,PA?O(*N402DNP%>3HDYLSSXXQ\5F_5HV?^:CM)?8E9E1]V)M
M'?=:!_/MV=G%<#0:IM%@=+H 6T30S"A)UF/MM1O(A(S&"*!-C/D02E1WKREW
MT(%E3SY*3=A;Q!V<%O-!0E>1D7?U%RKF60Y?5$[H$"#Q6$.$IH9H0[TW%>01
MQI"+:>U=K8%S=,9J*]%WD/.T MHB=+P!N(Z,T+7 'L<H;4;C9NJQ!P>'VSX6
M61S61&9][=)>IWD(E2#H: &M]2:6G)2USU]!'C!&'T<_MA%]:R/SUNEW.[>7
M*V^<\P:D$A$4&@6A]CL):% $F;14:2.#8O4S#F\Z-&1BU%Z,'<1D/^($Z0._
MO!CFUX1K,#J?#47^=EZO8A9#"44I7AH+,@9;Y]SY6CQM@)LH RU=%-6Z_FH#
M6,>@'%VQT,'Q\ D']$^G?ZWWBV% 0%_D,Y+X9#IOZG:)=='DTI"])+,SM!&*
M4%-$-/@DR..VDMQK3;)PK>W-K0 >D_)TQTSKKK(U@G-2_CH:Y<FGT=4 "9(^
M0Z$C)$TZK;Q4X+ VWD2=LR9/VMSM[;WR(%GR\<? ="/A-4R07*QU=E-_>0,_
M/)VO_/:V56)R.GJL[6Y#'0AGR2G."8R-%:$A9VNC]OQ;[ 0/@CH&G>B&@8:=
M;%>.*HB.>U):!CF0D:QX%N"S*6 RXYR)FB'^NQK0LDO@H8EP&R=,KYY:L FH
MW]& EJTXVFA6QRX"/MB EBR88\Y+B++V$Y3DX7B!F?Y@TJ6DF+T[TN$YL+[M
M@);VI&\CU^:73U_"&$\*@2M].LUJCM';X:O1<(BIBG:6B30Z.Z,=LE\O[VZF
MEB;ME(O"@U&U**A^Y0(OX+&DS%$X'S=+KMX=PU.9YK(5@Z/#B[_]I=4 )R_#
M!/,O??IJ.AKBFS >XL*8M5):[VIK@:!K0QQ7+V:9@U2$BLIFI^*F]Y1K'_3\
M^6\HR-9;PT?LG\6+\61FZ/X\&O\2AA<EI.G%F.S3DW*MEY\NSL\'_2O'%+46
M7$FR2XV+H(J*$%7TD")7/(I2C-TLGK@C@&>O%(<0?.N(P"W,U2Y>$P>;O$?Z
MD9,XZ,_-:%KBY3[X\?6=( =JQ44ND7R<I$&Y&E0-3M8)'LG)+!)3<GM=:H;O
MN%3M<6AK/1KG@;?GS;>5[T_@3'HGR&M#\MI421Z"*R1*3UX<VA*SW'1:[(X0
MCDN?.A-^ZS$]6[T%BYPA'40P*D!R/(,*=7*-C4@G<^0Q!BY"V4%9-GOX<:E)
M!P)?.2"HC8+<,\D_XB!,,=]!')+-02OR%%4UWH1(X)SUH(64"5VQX6X/\<U4
M9+/''YN2="#T^VIB]E23RZJ]R>7!>(WYKC(;YA5*#BQX2W8]DC)+SR':8KCC
M,F7C-U2-#1]Y!.K0A7#OJX!MD,XYAS@J[_IQ&KZ/?OW3IS\M>JN1GW\U0-!Q
MY-P%X-K7M%/CP+/D0#OT*?"L?%0;*<$6#WWV:M"5@.\K@MM+$9;4NMZ.Z_QZ
M_C,I\_1#^#ZKC5UDD; <$\&%P#+))1@)/I%P>$@Z*2E\LIME]^[V_&>O'@<0
M^WU-\?O$VZ_N$O^*H]-Q./]2&S+,(LVT60ENF(5<B@/%I85@A(+LA71.1LO\
M1N.1'HBWKP1P5)=L;<3<^%KUT[R:\B:DRQ=@$U -;]I6 CG\35LCHD9=2;GQ
M==MJ<,ZYF$MBP(05H%(.0 ZR(' 10_"I%+51PL73HG[-==LAF=]&N!TDX;T?
M#7]=G#T%(V>JEAL5*<ECX0J<* *,T\A44JFHUOVK;SS^L"=^(T)&;:1YH %!
MFS5'F1NVB\JT%O.&FSSW<*UKMA' G?XT"5F,TNK(!%.U*M1Z'D209.8[,AG=
MAOUI'D#0=1.:)*.4RH&TH9!E(Q.YK4F!9+0FIY.5K'5V=E=-:&:F^/4,FY/R
M>4QN^JSN]R/^ST5_C/GSZ"7^?%$Y?/G]!CO#TP]A//U.KIM5H: !%U/M<$)>
M0)2%O'FGZ#'(9-C0-]X'Q5/L-+.%DMQRC [&1NM<@YO _^."X.!X\/W2S[\)
M_T/HYY]'XSM1PQOQY-F">[*.$JM+*<K6^*"WM=-L 9MU4$)'A<ELK5C[XSI6
M53LP8ZUS(&XNY5:NSN37VHII=(7]_DM#*[M^SWHB:_0<-0BK;$W91XA!>O#>
MHN2&5F$VRXUOA>A8%>Y@+'50XKM+*S O:\Z'EF =F;K*TBOB9]<?AD7I+7=<
MM)Y >B0]VW;0MD,1U3HGXEW=4R=T\/^&@Z_X"T'^,LL\>S']._E@\Z^O$M 6
MH=&_CRX&^27.1[!B[EG#HXI% 3I6*U2R@,BMA"A2U(D<<8.;W7BW0',D"O4X
M[+3.GZ#]MS^J1_F+]*6/7TGQ9Y@_A_$ISK) [H#_.)H5NKT,D_ZDYP,7.3D!
M.EO:<S/+$)VM(XM"B5AT-&)C2W]G%,>D3@=CHWV6Q4P$'[$*L![0."ZC\5D8
M)KS..OO/0,=U'-!1/IST\V7'V/FM3X]S$S0O""PE A^"!R<QUS'1)+3"C&.;
MYN3LA^28U.F@K#3,R-CH-DD5D3D:!.%%;8_M#$2K/-CH4=-G9:];=[Q]'LU*
M]S".F@G\F)N5LBQ)J"P"9G(W5."6Y" S2#()+7.1I=)\:.7OI%GI5BIV@&:E
MVU#=>>_)3<#\T:RT,WK7-J'<A9O.%8;.Z^"KQ\H5686*EP+!URXWL:!DNG"F
M\_-3E$=H5MI.3[:AY!&;E?JBF,$@P.A9PK;Q0  M"&&$SP49VS#']?DT*]V*
MF1V;E6XCUL:C\CZ&X>GEB,A@M4MTJ 9!:U1*! @Z%W">!26S(ENQ16K:U0./
MQM#878P-X\U7(!8)TQO :)AL=N/1AT\OVU'X=^G;0W*-$\ANP@G.IF)9 !-K
M&BNI(43M,M@4>>3>N\#3<R!P39)86_ZV$5ACWGXA29U=G"V R&"*UP&TUG1R
MD$% BY$6N FTGF)\3!OY@P^-'+WYT,.F?NTL]E$+F34?&OOM!A"C,17/$V2I
M:WJ$3?6&FH,HR>42;#)WXXX[SHO]]JS)VUEFK8W8JPCXU<AKS[))7"6RHC#4
MV<81 LZ&\VB&J+*P8K,Z\WL??3262P/)M;[6O(7F,H]T$SS+;9E-&'V,I/@6
M@E_)X1Y2Z_2M7.#2R%(('%(D-+1+1'#2E-J;69F93R7$TV)QA>ER$!*W$%;[
MN,#-2^K/Q,7BN'!1<T6;.63CZV336N(?ZNQX'XIG2II8-@T#K'C$X8["-J*_
MUP!H;[EUTM_I"M7/_:\+4 D+&L%%G21;@P_.0HA>T6*YR-)S@VRS[,E53S@>
M+G>4VI,:POLI?<%\,<!16:0YO0R#>O,[602E;GU.][4*N^$Y8 U# X'=J6T(
MEMLHD^ Q:(48@V+D]C"=BI %&6Y:V[ ;LHYK'H3P3@I,4%@MU0^&@R=+%(K4
MJ@0FG3>M;Q>Z'KS[(J5%"3+VOU9S^SU.7UV,Q\1"SX6H@\)(F[ISM+?0H>\P
MBCH$E ?D0GG7>OK&.CQ/,$]E&XVX>TW23/0=S&=8EB?ZKA]B?]"??N\5%;,S
M->TJ,EG+*A)X'V--YI/TGL>0TD:ME+=)!U@'Z,@4HYWP.[AO7>NIAUP\UFZS
MW%AR$!C]X>KL"&_1RIQ,HG_^/28H[:,-S01^S E*(6EMR=0 7B?9J*0,>*$"
MR8'$(((L@?^1H+1;]&TK%3M @M(V5'>>;[()F#\2E#JC=VWBR2[<=*XPQ@0O
M+=,0DZQ#@#G25T("<H^9.\.+:UT =9P)2NWT9!M*'C%!B>>@:OP%M,P1E/8%
M(@L>1%3:RB*#QCL%]\\^06DK9G9,4-I&K$^P \=\(O#)Y43@0_?A>.#IA^[&
ML8TP[L2MHJWM%[6QRJ.RV@?-T+.<4C'2Q2"WZLGQ (Z.HU0AF\@).(3 &#F(
M7$!T,4&*"EE)"8/TAW'"]HY2S5[FVSWP/H^6='RPP4@E4QTW$ LM61L(Z PD
M(9)3*M.KO5E5WL//>H*QAFT(O[5--I9L)W-"MR]=ECZD6:VRD5* R@0^>C(4
MK,DUV:H4^E9C_3^.&O-=].A01#4?%S+Z'@;3[VM4_V:;AO<XO>S^.;LUZUFM
M8R&Q0"&#@0R3)(#>DP+,&$-V ]:92QOM-WO!.!(5.C ?'73"6!\_B=885 @A
M$R+E=8+@0ZEY?[88$;1O/HGR6<1$]]EMF@G\F&.B*=3C.F8HNH[<9<9"K"W&
M"T8DD7O-[DXV^B,FVH6*'2 FN@W5G8>X-@'S1TRT,WK7QKIVX:9SA?$I1E>4
M E5R[6-%QF T(4'4Q7/CZ7S C<JSGI:B/$),M)V>;$/)(6.B\\C*Z#*RLBAK
MRC8JRVJ'*J_)^D,+Y#XD*,$Y+H7P0F]FC6_[Y,>.CV[%TJ;QT;U%W#J]\WX>
MLK A\!PMU- $H=$,@I6Q)IM&9K6/] X<4?W#+M9& \FU'KJX+'MU$SQ'4?^P
ME> ?2IW?16J'J'^P3D8=:"NR+I)+)XP'GZ0AEX[\[^RTBW&S<3!/M/ZA*8G;
M"*MY] M/+P;U![Y?(5OT!,#@=&UG[TQ)-=O#@2^F3C?$Z)3-3&#<B,*5CW@"
M.?-;B7[47&Z=U#_<'LM\<@4L)\PY,@3GZP!X2=H;2M)@+$=K;<"H].8U$"N>
M\IPY;2:]3HJ4;@/[_-MH :QH\FF,!B$2V02Q&*B]$,'$$!-S2K*[8S@VI_7J
M*4=&ZV[2:VT&+0%V-0I0!9UU-J!-B:!RE."E8A"C]9AMEI%O5M>[^AE'1NDN
MDFM8UYNQWWM'1OO@S7#:GWZ?&0G1H#8R(XB:OJ]H]X<@8@*>0LR,B<3YNL$8
M$TQ_.AU]_8D^>A[(H"^NXQ=+'G@T+LN^PFS,ZQS%I<YN@F.#F.;#Y-Y\ZF$=
ME[W%/VHHNX9GZ7T\:!A/KO:@(BM-B;KYZZ"!-@T194@JBW7W(D^!PQ5N2W<4
M;B&R;L*!UWTXI.=!062F9@36W$!+EIE1UM(N@[6GV!:AOD.?B?L)]GX$;P>I
M-&XM\ZJ6L.'XO-[0OP]GEWYRR4I8\HY9D+G.0*'='WT&E*[DK*4M=J,,M <Z
MS"Q[]M&<ADV$V[!U_JRO#IY?C-,7LL"NHL5W(2XB5!N ;-FC;5-@A^_@MC^'
MHT,1T+K5V\9@O43)<C+@:G61JH,@ F9!3G<.F4<7E-FHK_G3UI(U;>(>24FV
MD7NGQSJS/CG,#IA.M-1$&Z1+G,XS[Y6BHS!9P9_PL=ZAU%>>^=N([$G5+=R;
M>=X?7HW2'963\\MQ#)/?^M,O+\-W''=>R[ SHL/5-[01VIV:!^&,S2'Z%+12
MV6<G9++.(SD&UD85-ZQYV!E;QW40*L?$> A0G/3TAL0,(18.5I;")1;/RW/K
MUK'3)"_F@G:" ;D2AL3@R0R- 0$QU]+S0OY'ZW*0XTB'WT9_FHQ<VX*H#DHM
MUGLPQO.H=0:A#'DPHHXTUZ$V,+"H#?<*[][L_CZ2F/?1D68"/^8D9BVT]87>
M G*3+2C-!;G.I4"205GAZ1^U;JQXOYLDYFU4[ !)S-M0W7E.ZB9@_DAB[HS>
MM<FINW#3?6.'X&Q$ST$'0: LO5>^G@2<+&K+$_V]M.Z)=9Q)S.WT9!M*6H<W
M9H[.\@3;2W3%&Y95]* 3<E!9!XB!ULDQ,69$Y*QLUISTP4<]=IKR5CR,.A-B
MXYN/*Q_WKS@Z'8?S+_T4!O,K-V0E&*9)@S.2!EL.(7,/Q%K6"FM?B8V,Y0?"
MF2L!'(VUT4[,#9-X9J#F!O--2%<7>@^#:GCQL1+(X2\Z&A$UZDK*C6\W5H-C
MI4C%F -IT(&*PD!@2=)7:"VRG&W:J.#W:5&_YO;BD,QO(]P.;+[WH^&OBYPS
M9JQ@O#;"#S6/318$QW@&5%FY(+/.=U,P][;X;CS^L+<;C0@9M9%F!]&OM\,T
M.L,K37Y7?Z%*LVHQ1YDY+02\J$L4U7[168/TEGD670FY=01U#9RC.=U;B[YA
M_M\#T"Y5?Q-P'<4(U@)[G)A!,QHW4X\]..C@7%@/LJ"4(D@$B2AH@V,1H@H2
M9))9%1%-Q-9SVQ]!01Z(%3R.?FPC^M8Q@%N>Z^5VN0AA263(#6V0IM3NE<%!
MC+1TG93U2CERC#?+8US]C,-[_0V9&+478^NJJX\X0?JT+R^&^36!&HS.ZZ+?
M?#NOM^03^NY'K V*+L_*-3^[F*"3"E=.!;#,8KU*8N!CU!#(%"JR1(=QT\J[
MIL".1H\>D[#&SN=E\ZN3\2<<?^VG>;Z8JWVN&,O 4MU$/7E<#I6AO]I80O12
MN(VNRA[P.Y<]^VALTB;";9QU>XFG:N@EHLGEJ[ )J(;!II5 #A]LVI^C^X0W
M$G WK_H2<$+J9)P2D)G/H-!)\(P7B+DFETN>N=VHE?C38GU-G.E I&\CU]8F
MX[RQ8>E/WPY?C89#G!U'L\RAT=D9[8O]>MDVV^P6%E!-WY,8@:<Z#8;7I*%<
M,E@E%=<\YB+=1E;#MD\^;/RI$5NC0XFZO;'9/XL7X\G,(/IY-/XE#"]*2-.+
M<7]X>E*N(7^Z.#\?]*_J8DL2)L6@P6 B SEX78=WT!*D,1)5SN6N3;#2J-P)
MP+/7DD,(OO4F<C+$S[2A7O92O:?>7^IT[+?#_Q/. _$PKG^[<:.*9+@&H20D
M1 VJ& +N.8/ 6;":-%WJS<8,[(/BV:O-P2AHW9W@XR)#?7(2!_UKNWJ=ZT0[
M:?V1&R_*0[^QF+W@DM%89PEE%LA"MP*"TK9.&O48/(N1;S8O^9"HG[UN/EF*
M5P;PG]8PV?M9*8\X278UF*<P1G9#4=VI2U%61@PV!"NBPF"<2"9:40(/-DMF
M]YXANQI6QR4I,63'$RJ061=0QA=Z&Z(%IADRE;P7OFSBLCVADI2U4TRU8:H(
MCB#0)MJC.(=8I 0>"HH@(M/8N@3GF0V0W48CMAH@NXWH#SY -COI.)DRX*TB
MI]VX!,$P Z8PQ[@@ESXT']?XS ;([J,8[81_\ &R 9-6K #&4J,Y(4/PAD'V
M4@;F"^-,'&:#?%IU1OMH0S.!'W.=D3?6:_22G*PLZC0*>CVRY""D+)S9Y#13
MK7>DWTN=T38J=H ZHVVH[K[W_09@_J@SZHS>]4WP=^"F<X5QY-<'DR,8*3RH
M$NK8'.& O'TFG908=.NI+L=99]1.3[:AY/!U1IP9[61F=6&Y#C@E=#Q+L+$8
ME#JF&#=+-7KR=49;\;!=G=$V0GRVW58^CM*7[B?'[HSH:79;62VT.U$MVFL2
M9UZF@E*9HAR3/&;!R#1"R57IH-O*+6P=A[:T"2(8'R!SG4!E%2 XIL&Z4JPR
M/-MT(,^M66AKER8> 06W(BOPHK;ZRQHA(HN@++>)=@R#IG7$ZSBZK6RC/RVZ
MK6Q#U*&[K20N$K<Z@#=8TUI1@_=^UKA5Y&R#5+_/;BO[Z$@S@3]V%&1E)A1Y
MV2S6,05:6EJ$81XBBPRB-"5Y'[6-+;JN/IO\SZU(?2C_<QOA'BP#<!-0OZ/\
MSZTXVB@5<!<!'XQ]J6W2Z I!\K7>DGR>("T"1^.\S0%UVJCCR--B?=O\S_:D
M;R/7YH.91L-P/J9=[#H5B!FK"(O-!E0=F!&5M#6'702GA77*/^26+?O@IY+$
MLI6L1XT$U<5U9Q?3/ N7#GD"XUVJ7<-I<;%&J:1,R1263?KC2N)PIL%3H;IA
MQM_R,-HF8/ZXDNB,WO7SFW?@IO,K">2.!98$^6'(")1!<LNB HV)-O?BG+I;
M@_ <%.4QYC<WTY-M*&EOPZ0ON#::+K3.P5L+HI0ZIYHK\%HXL QS*-F7Z#>;
M<_;@HQ[[2F(K'D:="?'0#5.R,:Y.H9'::3+&3 1?O*]#3Y!),NUR\S3'Y]8P
M91\+I)7H#]\P90-P?S1,V9K&[1JF[,#!P1NF\,BL]U: -+J.FY<</":$&)22
M].+$G%KGASZSABG=Z<<6HC]@PQ3AK8DR%$"9;4V I)TSU"-5IB P9I?X9J/%
MGT_#E*V8V+!ARC9B?%)Y#*N+.0Z3M;#A\Y]"T<W&&0F)D\4ALB);)"KC7.!"
MF:"X]MXHTI2]ZVP.F7]@69+!64]O2XI ;T@&)X.OG2>#4($)SI_;M)>U]1U2
MH39(;W(Q6<^;)H;(,]2VBT$S&16WO^_2FFTT8JO2FFU$?_A!+48K810YG)G\
M"DX ZQ11R-H(3"ZGT+RRYEFD#NRC#,T$_MBI UW&KGB.CH42P#EE:K<E!4X@
M25D)=)Y9[O4?MQ6[Q0JV4K$#W%9L0W7GP>=-P/QQ6]$9O6NCT+MPT[G"2#JA
MO?!F,8PY)7*!O 5G"FI72BJR=7#R.&\KVNG)-I0<_K;"R1K$MQ)R$370KC1$
MLO] %1M39M;8N&&7DJ=^6[$5#]O=5FPCQ*<5>!@-290O^Z/Z[7".%]-^FKP=
MIO=A7'_SZP%"#YLB.&#P82>AW D_! RHO0_!H52L;AG>UDY^Z(MC);I-PP^;
M8NDX %%,_5^/(!USY&$41PXAEV"8XB9@EBB>2V^/V3O]ZSD=!,/I90NKSZ,;
M; Q//]29UCV4D4DF'+BH)"@=-'AM!63C,&>3BPMVHYWQX6<]P?C"-H3?VBT;
M2[:#$,,EM,GGT8OT/Q?],;ZM@\QQ,GT[_'01)_W<#^/^K&?RBU+Z@WZ8XJ2G
M0O$VL@#)5A<[L5Q'FA?(D1MA@\LNMHY([8+S2#3I8%1U8)#O-!W9EBAJI6X4
MD6P3%ACX%!5PS0(J(XW"UO,5CZ.P:A_EZIJH#G(9UT92C&-2%)8@UDF!*I7:
ME3,[*%E;Q8.@-V&CT5S'%AW=1T>:"?RQHZ,U4_U5C?KC^+P>PN_#V;S$P+-L
M&>DT2&T]J!S)02(=!ZY06!MH56ZCTM8'"BV6/?M)QB.W(G744+B-2VL^XOG%
M.'T)$[SR)NY"O+R*WP1DPT*KC8$=OO!J?PY'AR+@T;3%N21T'5Z,WG!0D1EP
M21/VI$(,4NDH-[J#>]I:LJ90ZY&49!NYMPXCKHI"+"+A%I/.20&C'1*4, &"
M=!'J[.(<<W)ZPWE/ZY]SV+*NCI@9=2/6YU+U)61T(<\ZQ9,IQIT%5^L9G;%&
M9/K_U+SV__=RC[J+W?)4J.Z^ZFL#,'_<HW9&[_JJKQVXZ?P>E6DA$X^R]I^O
M%0S9@].TIQMGHQ%>^5R:A_N.\AZUG9YL0\FA#*"UMX(HF6562D@^ICHEQ=/>
M["1]E=#%PH*):2^SZ"G?MF[%UB9&43-1MYY>]$M_@)/I:(B?Z:=G.E^X$E'5
M+GHEUO$X/(*S-?Z4>$Z<>\W-9E-F[GWTT5@>#237L,#K/IK%.,X-\"RW&S9A
M]#'"'"T$OY+#/:36>L=>ALNA9:PVSK1&6E!.68BF%A=YYUAV*1'(I\7BB@/[
M$"1N(ZS6Y-V8N',%;9'%HZ(36B=PSN7:!I76B(G7N3LR(T'5VFS$X>IG'.[H
M;"/\47O)=1!.J/>U^#\7=8C2UYH8<*6T0N7D,YF%5I/2BI+ "\Y 1XE:H*=O
M;]38;0M+>P64HSE<6XJ\X;C?-; 6!\<&P#IRTU>">AR7O0EU#ZO#'G+OP 5?
M#9"GDI@5'$H,Y$4&(\%Y]'535*H8>B-$Z_JW RO$ Z[Y8?5A&W%WKP<+CY+;
MD#)MJ8:16ZF2J>W0Z/Q2+ ?M2H[!MN[!O!3(X3WK1D2MIW\'*1\HE?D]3N>U
MY!]P_.E+&.-U3>[+,.FG,,RO^X.+*>9[/[E'^G*#I[9(66Z]^#MIRBA#TL89
M:[VB_Y'>)6&PD(TI95+&]!H\?[_-X$T8#_O#T\G5I\Z?]NZZ;W(DJ$8%H&74
M+3#2%LAU@<*Y+)D'^F_K.Z6',.V[ 5Z)\MUH,ND9$7GBBH$(DA88K:P5<@RR
M8);>?FG1MC[\;@$X_(;7E/.[^][NPNW *_H[]D^_T-)>?,5Q.,7W%U4P)V6V
MZLG)Q70RI1>,1#%[UWH^1Y-"]""2I,W9Y "1]NN:/>VU=P&=:'T$;@7PR#2E
M.W*ZZ3DTGH7$PZ#.;1\-YS!?3*?C?KR85F?R\VCV/8*+^3*S^L9\[DD/B_!8
M7 %/?B4H%31$)A P\^A-9,9HV5B]]D=]9#IW8!H[N'E?\=9<2NG>R]/C)@A3
MO 7C.;TWJ!-9G)9L6,N$84;PY%O7UF\)\<A4K$N".NBZ=U<6\]U6T,EL"  8
M6>_YG.?@22(S35<V:7ZO=WASJ^\8C[S]A=U!P'#%BGN)?-3"HP7)@P?%M808
M"P*+6*03*F33NAW,"BA'K@6["/R^'NB]XT*7KN=)60'PY??YF?EJ$":3>?Q<
M,1VL90E";;\_BY\'+0+0IB:UEMHZT?QZ87N8AZJ5Z51KNJ;GL4MH%NM\\5L8
MYZL(K"VV:%18C?T:@K.,]D9M(#F6(JV%7I+6X8=; ![KUJISMN\V+=M9ZEU$
MJ*\,<%KC.8EJGI5TPPI_^?V^D5Y7<+V,8?XP",,;>>2;K*FKVZ\.UO,X%V=[
MJ,G=[>RI</Q<]%=F*[P.#K)7M9-7R1"UH[]F&ZWCF3S/UL.;GX_>/G"_]\35
M=AMJ.U#7-V?G@]%WQ$_34?K'R7E=T*)&1C&?K$3043$"EAPX70*$'+.0/&5C
M6^=IKP3S"!>#C\[U7<>A"5$=Q-D_XF0Z[J<:WZC0%FG#(FB?I ://(.RVM9.
M$19T[1@MK<O1M(ZG+P7RA^8T(&CEOG.PV^@7PVD_5^.W_Q4_8;H8]^]63%1A
M7TSG?= [N9K>"4+']]3[B^7.I;45(D875)(AJ6*\=U[3^1B-CZ6.PEMW:;T3
MF#W]Q6T>>=^=NG;.<];!&$5.4TE8JQQF/0D#"!T+9R9;9*V;<+7"OK?/O1^.
M^5SYGC7,)609Z+\%E&:R)L-*H.TJL*1-D9L-$3Z< .? #W\^/(K.WG/Y#TYZ
M%WG/5W&2/9<S#Z$(;9-$KL$J8T%YQB$PIX!GKH5/Z)&%UDY6TQ4<*M3Y)#3X
M$<E_,M'2_1;^\OOR#YCYR4SYHES1D(HDIR+Y C$(LA%#(!,TIU!XZX2%#I?S
M^)'<PRMIVQV_F;)T$,-8CNR&][0)OH["OP]A>Z10[E-1AHV4=$\F'T/C=.".
M)RQ@I8SD76<&WDDRE+1B/.?DA&I^=?4HFO90\/6Y*MHV!!XT+"N#M-[&#*E.
M 55>>G"('K@SAEQUID7S6_<G%)9MR]O&(=9MA'Z@THU?PO@?.$M:O);#=2SF
M[? K3J:S:&-_^.)KZ _J3_X\&G\* WR-<7K]2WM$RYIC:!$NZU8P=^)E1HND
ME</,@E5*.A\C1D%.<9$6T85><S3-7.8[3[M^TK5_YDPRI/4(I/"N3GTD3PWU
M; P#<SID+9KW3MX*X-['^%J)7_;@F7?LJ=EZDUXB"]M)CI 42E 9+?@H!5BN
M.)>*)RE,ZV-]2XR/<.'1F4[=.[6[Y*N# -4#>%.Z.+L8A"GFOXY'D\FOPS'.
M6T3]E<3^$LNH^GW?>BK;9"2=-F8VSS4&A"B5!ETX=U+HHF7KR_\FP'_'FM@!
MLUUX,3LNHE9W72^"F^0M2@6&U6)6)1%<#F0;:9YXU,@E<T]$/6\!_T,]6S+;
M0;7+:B'=7DY/.!-5=A:BTIEP)@F!7B8H6K,@LD\L_?_M75US&S>R?;__I:OP
M_?&R578VWO668[N<[*VZ3RI\-&SN*J27I+3QO[\-4I1EBI2&&LR0H?226+9J
MYJ#/&:#1Z&X,/4'NP_:<1-:$GP&J7+;$OX5Z'5G-+F#((8,UFJ1N)%_;(=L<
MT%B,/#6_A.EQ6&,=Z(RGF=9<G,I1S)O)-$S3)%R^G2[H?:N4GAJCTIX\4.LX
MR%7/!VX0ZAC L^Q\,3E(WEI7>Z <K053:\9G[2T_@&_UVSQ,%P7G]0*E7W%^
M/4F3Z></90?:1<WX6NS^ITU0J\-8!CJ_:#F.XYQU-!'([,38/77%*L8\0QY!
M9EU[W3@'3O ,IL@L4"C)FM_J??I*?>2LY.2%>@BI PCTI]G\:VU2C*]G=3";
M)6737<D9'T,*8'5MUZ5R@L!5!N^*MKD4Z6SK[)T' 8WO^1^/Z^T[#YH1-4!,
M[I^__D:[W<75_!N9Z6^S:YQ/[W2[CDHX9CF"C4G4C"0!0:,%(93+W,A2FI^N
M/0CH&:NH'5%#5'E5/#CY//W1O;T!IZQ)+AD#:&M>6S&U0SMM>%%GIQRW+/'6
MU?,/ GK&*FI'U  1KEK%2SLI&O3'0%NJ&U!:1H.&<7"8(RAT-$$Z[2$6S7FP
MA?OFK:AV GG&JNE/S !QK)_J-2%EDNI-O!_*7_'K;#'93(?!L>+KYMDQ4QO)
M9-I!^^R!(:/9T'OF7>N3V@?@/&?E-")I@%XO];+=Y>N0_HWWG;*8&%-(6G:I
MI%H-5CO=)P66IR"=](85W3J$OA_.,]9/*Y+V]H@9,POI39C,_S=<7F&8YA\/
MF7 Q*R.E(3T%Q/!Y2+U-LY6()'4I!9/%DI+B&J/@Y-J0#Y.885:K1Q*1G@)G
MS$PDX[CDAE3/8ZB)'"Z"U\D#IH(8T+'\Y\Y$>CA*7N]0GTRO9E=;1[4?Z^)2
ME8F+Q6]?PI2+7^@WORPNI+3&9D9^;8QV?6F31T5;;I6#B Y-P'&/LPX=P:F?
MFQZBQ\/.P ;E>H!X2MO1W$E-6/40UEA/%%D].K:9[.S)92HJT0@S1V&88,W[
MT TZH!==CZ&$ 0(^_0:W&=2'^;O9]#.Y<C;E*.M]4B'7S"_E ] [-5C,&GGQ
MG&M^4KK>'L&+D ?A>H @4]O1;'^6,DJI43% PR(HD1T$(3(XIP(M/$DEW?K8
M9= !O>AZ#"6,GN6U>T@7F:Q56"R 7M0F.-: 5SD#"\P;#-8ZU[K'U5-P/E]1
M-N!M@$C:4S!O?RY1:VTL&K)9S:*S-)A0;Y0LD3O+A.,&6V=(-(#]HL1VK [0
MQKE+LEWQPBB3#&0M:M&!DQ #V<D4%8TDI\0W;W7TITUU'4Y.AW-QZJFN27@A
MM2K@Z]WDJI#5@C2T04LNJXQ(KD'K(X0_8:KK08QW3'4]Q/*GGCC892POJ:Y[
M!-A$($-F$#Z%W5-7K!&)>\$D:$ZKO7*U\RJ-! 3*P&2Q4936K3Y.7ZE/3'4]
M&:$>0NKHJ:[9<R[J\F%"2*"\8S4HZLG=Y-(@-S:'YLD>9YSJ>A#7!Z6Z'D+4
MZ*FN1A$R<F0A%BY U8[1$36"+UAXS%DSVWH?<,ZIKGU4U(ZHT5-=+6V14O0>
MG%0UI\G*NN$5@ Z=(7R*V^8W$YQQJFL?%;4C:K145Q:9,SK7F]7K!(G20X@J
M@I:T3]+".)HM7U)=!U[!^A(S<JIK5"(+'6J76$G38>TW[.SJ7#A$:1UCXB75
M=1SE-")IY%37P(4MSEI(LM8?65/O@F$.?,X>N?"\J-;Z.=]4US[Z:4722*FN
MMRF2OZQ<M?55'G=N/ZBC6=S\6P[+VU^?3<.G.KSYS776?3)=FV-HD>@ZK&&V
M\ERUL\EX9*EF/FN4CEQ@;5 ;%35F[B^:H^D9+=\\?_UB^N;>34*<7-Z(?0WC
MP_3VU?0+[V?3^0](OI]'9&-D<)E#S/2EJ:($1&,=F"A1%NVC:WZK3M,!]/8+
MPN(+O:#^[^?_7$VNPV5E]Q;B7R>+>A)"B"X\(LL9.>V2:G-8KB-XJSEH'Y0J
MM5$VMMZ7= 8W_IQ_/!7><QH&87"$WGU[NQLY%; H*VCXY" K:1/$D 0(<IW)
M-%B":9W*=[K=ITY':(/P-T2G9_H*EM^^XWES_7YRD:4),2D/DG0/BIRLFDOE
M0-K .:URAMRBQIK:A>,YZZ<W+T-TQ%L99==D:46)/K,$PB#MU[.TX(K71#-&
ME0D:AD'J]UZ6MR$8&B"BTL)$-Y>0^! *EIJ_K!R9)Q4(K+;=5VB\%SKQYCV0
MFX$?*\OH= 1Y'-Y/)E=I,_K7W^YL!]_,\3]7.$W?UNV5C+3%UJ.Y(FE<'@M$
MD1/03R*1L0/FUB5&'6 =*X?I2'K9I]I&O W@M^V*,]P"W'1VZP!QH&2F#O".
ME*/4FMI]TFG,RY$D1!^1S6@SB!K^5-S7MJM* 4N6TQJ0@A&MXQA'D\YC24,G
MH)Q#Z!A),8O;N7AS=L>S\8XGR)()4,9:"#)IX.A\,CH*)EL?JG;!=<1M02M"
M.PBF%QL#A+'N?#2W?_S[!.?TDB_?WN$U7JZ^FUQ\X,P8X#8K4$[18JV"@N1R
M*4*+*%3K0JANR%[\H,;L#1"6V/D=W,=[\\5U 3NB4[07Z-'=HV:,=YFVFM(U
MULJW%W21LN3 )& @7T!)5L!'(R#3UQ>%5MJYUC'Y$]!6=__I-*1U"$M#2NKM
M].O5<K&R +_-ELN!QWIYH#><C! D>$<VR28:1"EH11_LH/4^G--PG1H1N4\R
M/5D8TG>Z TUL.H>F)+G@@AQ%I%6]=N8.@G'P++KDI22?<C"'Z3Z<YR:0I[ P
MQ RRIXQ%%9U$/:O.K,(*PH#'&,"6F)--";-H71)T8J60)^(^-^!G@+.8MLTF
M.XSEI6!RGTQ;"&30*Q>>P.ZI%TR2-YERY@;,JL@O" ?.:P59NQ+ID^8H6Q^X
MG+Y2GU@P>3)"/834T0LFE>!&2YE 1<S532 /03@-R42F@ZM7.+<^LC[G@LF#
MN#ZH8/(0HD8OF$S:JV1T (>.P&E;FX%$"S9[5;QE)8C6K<[.N6"RCXK:$35Z
MP20W/B5.>Q_)$^F<,PO!<E85;W1A@8;_<C?(."IJ1]1H!9/2,)>ST(#ULAOE
MZGJ?"V$,AFMNG5>\=6#S' LF^ZU@?8D9N6"2!LH(08%L-0DY!%&O(Q 08Q8L
M.(_"-M?,V19,]E).(Y)&+IAT";U(0D"BA96F/T;2#G%U/L"\RTI(V?R"][,M
MF.RCGU8D-6P\6$L4+WZZ#(O%6MA$Q(?R=GJ-B^7M'M5Q5Y2C/2KSB?:H-0?:
MY11H765,\%ARC(\6/G9XS_,,=;8FH.'<\@BTFP^B"[C=\<N#57*,2&-S?KKQ
MWL.X#7=$W4#:P$.=%LE7JHVC+4,(JOK=@B8UFSSZJ$Z8^3V1N^,2?XA-6Q->
M.^72LC=)2\PWJY.7R7@7-116[RAAPE?'1@%7PCO#:B<CWXGB^\\>SQ\8P/*S
M=F9K& Y;P?FT#2;1P$I*!@*2<Z$L5Q!D49"BR#6)T9#CVHG#[2>?#8.]3+;W
M*VS;Q>+7Y2S]^\OLDMZP6)<XO@_S.9GB&GOTI>CPU!:=)@X%O]4[HE:->\=U
MT=$I+W,0E4V9BLZ1:<\O.CR_YS:]:N]#6;WGW6U]E]0QLZ(UT): EH&4/-!'
MG\GO*Z2^0MY@\U;P.X'T#GS6IWW"KU?S]"4L\.-\]GD>?G]UM?PRF]?&Z:]^
MGUU-E_PBUWL1BZL?@Z5I3:.&Z&AN*YX9+ZS5.>36(=!NT,;?7/97Q+VHY@ L
M#'#6LAOF)ZQ6J[ND6[S??V>#W$G+>.TW9*QBH%RF?5*4"D2(M%^*J!UKG9SW
M=+3G*ZGF7 UQ%G/;[G\UAM??5L99;[<EBU'J@%!</6PL!,UE[P!CX)I^C(FU
M/A5^ ,Y8I<D#J*.1C4^E:/C7+V&.]R?0=;I%*"%7(4<30/ED(>3H0/"DD#,:
M$6]^>+<7S;$"7LWXWM91&[L/,8OL1':;HO4XMH$2\!["=9R$NE8<=I)&#P+&
M%DG.KG!:\D#38KB^^MT%E:"(XKE2O 36.G=D?'$\DL-V#&T<8O?6<;#=P-[/
MKE?^&_&U*7-P)F=K"%H]ZB,?R62(206@S6G07LL4V=8![9[(2M<W'N$6KV8D
MS8:V<.M VFZ0_PC3JS#_5CG<M,SUW#"T')@2G*R@+<1 *RES0G&C1&';:;$'
MJ>#>"\];!/WL.U(P[AU^#I>_A.42YWVZPNYZ3(MPVZ/PMN)K":/WQ4<I8E&9
MQ> CHO#*VIR\UNYBUP/[+;KUTKWUQ:6$/OUP=YN50M,.,X.168!2*,$)1Z3S
MS!QB)+"MTQ;VH^DU@_SXV&\___$QS)>D,_PC_#Z9KL+8;R:7F-]?K3L.E%1R
MQ@#,)DDK*D?P*9%+KHK+G-;5H+J=MQ_VWO'GDT;D_S";#&CKU@O+&D(]P*#O
MJ<(D"WS"ZPG^]^W'3Q]QN;+^8H7VPLO"/,^1-O2\5E+ZVN32TW;?!F^X069R
MM\.; UYZ'H(8RLH#[$#N#7^])X]1I\Q*!%0Y@=+U#A!K+-#P#;.:"Y9;'R_L
M1C)6B*NQ#!J:]U1"7/>&\OK;^["\FN.'<F?RNVD'8- [)<$X7T!)I<%;DT 4
MB>2RI>!MZY!7=W3'"H&UD,)CZFI#R>#3S W*VVXACT,;*!CV *SCQ,*&8O1!
MX?2G8V3%2&."=38 ]YIFY!(DA$2?D$,>//,J9BW_[$IY)#!V D(YA(76<;)7
M0IB/85F3XJ;9>['^\R:%QCGRHV(!QJVLYX>Q]F?+$+WR40D,9KN5PA[']:&W
M'-M3[<'%; A#MMZIO)+2W0)CQO\ 3">-@A<#T8J:N2X5N*)K.WXM,XHL@[3=
M&'[@+>?"<"M#-O^&C>0_@)%HBO2F@,%L::**NL+B(+@AT@(/+'9D=>O)Y\)D
M'X,U+#=<S)<7'^>S?)66'^;KZA9<K30L(Y>%UA=F2$C*EPQ>2P2MM1>Y1)=5
MI^MAZ05WUF3ZZ?MZO._=9^#5-S'K,#1_+V/"35%2%U"'>.W=.+\/9%P_O0U'
M]PEO9."&4_3#X(JOZK862NW0I9A#\$X@U'MQO(D\.-GI;/JT6-_C<X](^B%V
M;;T>__Q_[WY^]:I<3FAI2?AU^7;Z+TS5J)MRTR(<^F! U$M>50X*@F86--,V
M2N9XS*+3\OS(B\9;K1MR,1O(D W=ZCK:GVJ&)<Z_AGG-4_]]+6,I2\),ND56
M[PI)GD%@+-- &6T;4\ 4.B4U/O(Q[WKWF2S;O<W:L+R_XKF34_MYCJLX\#;$
MC3/: 63#9;PSL/&7]?X<SL8BH/$RWQTLMPYIR<O #>T956(&0@XT<Q6/R<3:
M@J!3X.VT5?* &W DD1QB]^:UN'AYN9R38=Y.TZ;'KE?:BI0!>;V?0!H!(6H)
M3*)B,N1$$V<G3^#^L\==_ =B8-;.?,W#:E]G2_SC#I;D;&1! Q>IWDX8'$2E
M"B"-SJ%64N?2B<JM!Y\=CWT,=VAJV,U?U_]$&M-?_N?_ 5!+ P04    " #9
M.:16<&O1YP:P   <)@< %0   ')E9VXM,C R,S S,S%?;&%B+GAM;-2]:W/D
M-K(F_/W\"KS>B!T[0K )$KS-GG,VU+?9WFVWM-WRF9UUO%&!J\3C$JDAJ]2M
M^?4+D*Q[%0M@@13G@]LJB41F/B@\2 ")S'_][]\?Y^!9E%56Y/_V _K9^P&(
MG!4\R^__[8??[C[ Y(?__N__\B__^O]!^'_>?/D$WA5L^2CR!7A;"K(0''S+
M%@_@KUQ4?P!9%H_@KT7Y1_9,(/SW^J6WQ=-+F=T_+(#O^<'^7\L_^S[CJ4@9
M3%@D( YX"@E+4R@X3SF7Q.>,7]W_.>&<$2HC*"5-($84P92D'D188)QZQ LE
MJAN=9_D??];_4%()H(S+J_KCO_WPL%@\_?F77[Y]^_;S=UK.?R[*^U]\SPM^
M63W]0_OX]X/GOP7UTRA-TU_JOZX?K;)C#ZIFT2__Y]=/7]F#>"0PRZL%R9D6
M4&5_KNI??BH86=28G]4+G'Q"?X*KQZ#^%40^#-#/WRO^P[__"P -'&4Q%U^$
M!/K_OWWY>%)D^HM^XI=<W.N>O15E5O"O"U(N/A$JYDK[NK7%RY/XMQ^J[/%I
M+E:_>RB%/-[LO"QW6M5:IEI+%&DM_\LI8;]<H+XC?1>'NCI0KC;WLRL=NS#]
M[$S=.\4/8GB%M\1<K'+SA7J?\[&^NVM1%ZL^O,:NOA;%@LQ'^%ILQ&RI/->_
M^*1^:L7HACK(M);34O>6JN+[0N1<-&RYTS3(^+_]H'Z:+2MX3\C3['.1,U(]
MW)2WBJ3:#]?L[\NLRC21?\P5Q]]G="ZNJTHLJOI/I>!HAD4J211PB'T_AC@*
M(TBE#&'(2,(\/TZ\V)LMUM_]F<CA;U]7:M:ZN%'D!PND%B=&?"FJ8EFRS5SY
M.#\V :JY3\^6R2\Y>135$VE?4-9HMZ(Q\-^O&2N7RH-@1;Y0[H9V*M2/5<9%
M64^-0!8E^)31!7DI0+:V"A!MUK_^LH%GP+Z;3Z9'YL-V1JLU4)!K(\#J\Y89
M5V!C"&@L 2M33G9'P794GFNWIRCWL2R8,RPW=%,I&&H@):EHC40K0Z'J^[^(
M^:):_0;JW]2<<[$:OQQ\&Z_+%0:D9&>ZNGWB%S40F'A:P)U>U_ZU6[ 6A=LO
M<M/)RH@?U!=)C6.UHC@"R,'PO'XFF?H\%Q^*\BN9BZ^"+4LE453O!%W\2A;M
MI[^JM4:6W^3B;X*4'TA6_@>9+\4LX%%( @]!BAB"F,<!I(E>0TB!9> S&0HK
M@KU,G:G1[$;?>JV6Y:#(!7A1*MMQZ(6=9,:DXT$_,)]J=<%&^RNPM@RJ:0UJ
MVZZ 5AS4FE^!UK87]>2\9DDU,Y*<@Z]J:E1\N_HS>*?^<@6TV4"9[XYWW2#O
MB'TO5&94#G8#W#X3.VJU'Q]_713LCR_B20V&!U()_DX)R^_;-?H#4>-DAJD?
MA9)*&.A_,%7^+(W] "+N<QXQ'#(>S@[6=6?'_WG)1F/<;/GJ<KQO=*Y (<';
MXO%1>;"U.>!'Q;E5K?Q/=I1KT ]FM.H(UG&HLP%M2UO0J L:?:] H[$[ZC-'
MQQ&]&0@<E<+, =BG*8LW>[J&_#^7U4+O.%=WQ1>A#<KFXK-8?,Q9\2@^%97Z
M_5OEIMZ6Q;-:.O(W+[\I/3[F-T_U,C*_OV:+[+GFRFM:+4K"%C.9>B+V(@:]
MF(00(T5>)(T%C/S(]R(12<:PE<,X@))3<R.W; 2+ I0K*T$N%FIUKNW4O]>?
MZH7C4VLJH"^@6)D)R-K./UMZGT-\#PQ]TE?NW8'I=J]CUP8"92%H3 0_:B-_
MTG_6=H+;K;[]4=NJO@ _@;6Y8&,O^'UE\?_OT%4=L$-<.;!#J#BN6SL@R ?.
M[I"R^LT[2G(IU(SV3C3__YC74]U#,5=M5.__OE1KL2_%?*[<\V^DY+-(TH1(
MCT ATP!B3GQ(1$Q@)),X43^$4L:S9U'2PG12L=3 AE&V]1B.6%8&@!]7)ORD
M> )L6_$GT-@!?M>6@-:4TU3AI*O,6'] ^ <F] %PMZ;HGN@Y8E];Z:,2:T]H
M]CFS;S,]=P38@^#+N;B1FH:O<Z[_IX4\DWE-VWJKXDY\7[Q1IOXQPUB&@1^E
M, F1A#BEB@U#S&'L^QBC1$8TC&P<;#OQ4W.=5]K7&P/:?]+[>O4/6R98[@S8
M]8?A+L%@* ^]8V ",/B]UA]H T!M@4.^ZP>=J^T$.^'C;BWT N9@FZ%?*W9<
M5XK[?/9;KKZ8BS)C"\%_%8]4E#-*B!!)C"%+8@HQ%0(22@FD'DI\(0F.D-%N
MP8GVI\96VQJ:D=(IX+I9QP$< ]/*MG+@]T8]0]_T%"2\#9^L QR&A&9'T)"^
MYK-8;1Y\>U!K"K!4_V45R(L%V$)/^9_JSYJA2_WS$RD75WKW0,=^Z-7:DLP!
MN2^%:)I23RD,EG/-NB_JQ_J8N?[3SY=S]AET&U+6#VFF#;R@B:?\+Z=>&X5.
MS^B\XLMSC_5>"ZM5^!WY_O[[D\@K\4;D0F:+F?+QTI@D,>019VK-ZX<P132
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M;(T.A./ A+,%H=8;M(J#1G/PH]+])[#6'GP8$&.+3=*!L!YIG]0IYG:;ICV
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M<-]T3J%#R1YO,AX8O9UI?6A9_4)B[LHZ,^!+77CK;?'XJ,\$=*E#EJ:<$99
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MN(Q2ED"I$WMBH@]X:<(A\KGT_2#VD&^4W?.LI*E11[M\M%CI=.)HL$YTA<[
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MAZ+<*6ZEF>%9S(LG_:$^XYEQCBC"OIKT*=*E$+'.D*$^RL /TS3P!#([AAE
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MYR%\(%E9YY'[51"=>5MO %?K7_Z/3)2JR8>7=\4CR?)9( /$8D4L49!$RGG
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MMUO@_OC;"O*U\N#Z/,S69&>/F".:LQ \*L'9 [)/;3U:Z%LR<QT/^R%[7AU
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M3)D-_5B-/C<JV@@?T%;Z8-6('50[N0,0,"UZ\%-1=K_^V8Z;+.<G)VF6)1%
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MG2PE:] \VDSF8T]N/5G#<LJ.LG^)@P-QKP]]=Y/:.4>@Q Q2FH $QSE D1"
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M/=3T\8O4H8GJ$'G[O/Y6U<5_2['[S.UC]5RNHX5(6<H8U>WR!-4U!CC 0B+
ML7:$X(0(:95TYB[*_*SD3N: ;H56++:1.J"-V+:EAITGRHSBIH%_9-9K@S%W
M$@:=&C?!;DYVFO0_>#L\)P[%BJ^%TUL)8V=!)BYL?"U@Q^6.KW[C%?W(FF/(
MLN_ N%VOZX(]-_TJ[JM=:&(7QMB+3]5.Y22D+,]!2F ,D)0Q8 DE($N)3'":
M1"FT+!AUK4AS(]GW>2YYXX,0Q?)Y77R7O0Y![JY.#W-GQK?3SLC(O-M39AL7
MWZ@3]/71B2;O-I.UF[\+P=J^6Z=YP=QG7[7K!)J^Z9H7 $]V9//S9M=&/P.%
M2Q<")>I$GH> IRD!2.048!(S@".9Q1G/&&56F=2#H\V-:K<5>74(LMB):]O=
M9PA@,]+T!MOH#ML>8B=J&/OLVV. B+=F/4-C3=RAQT#MX[8\)@^YT8<ZD?^^
M]8C'42KR! &)XQ2@C&*@BWPJ,XXD*8LX%[E5\>'>N^=&#9^?UZM"R.#WLM#>
M[J:XJF6>6Q\Y,Q9PQ&/D-:^D4G^.4%OEA+J>%G3_S9,NWQ,J'2[64Q]Q6YJ?
MZP=:=K[]MU6YJI:%:/ZA>.!.?0,V]T6]KCC;3CFK7DG-+)0P$@"B" ,4R0BH
MU2R50<!#BB%-\]3* O BU>SHH*>4#J'HJ=5LA7W%]CM'[71S+L/I9Y[-*&CR
MV1N9O*::.&OR\PJT)]KT(].DA.L5QD.J]OOR*PMA?2R?E$WR2=MW<&./A3BC
M.5;V6,:U,RW/U>&-9(#@/&:0Y3S.K.RQ@;'F1LB-; %T+'IU DLS>O2$T,BD
MMRMX=1.T@MX$'6 CF'$&F/BN=W5BI->I=G5>Y;.UK@8><4WQ^[BKAO.I*.5'
MQ4"K!8TIRC&) $L% 8CA'# L,MV C$L)92I2RV2_4\/,C1>Z9+>>J,$?6MB@
MD=;0\+J [#!5^,-K9)9PA<HA27 (B2O2!4^^=N+$P2'5CE,(!S_M9B"T]PW%
M=T4LO'J4]_3'%V6"M'7,GXORX?.3;$OVKA8RCY1=('*09S(#B(=<F0HB!H3K
MDIF<Q!Q3&WO!?.C9T<1&\J!H1&\J&BE9+8.Q++ WLR_&071L(MF"V4K=E"W2
M<@=?I%Y'Q;+HSE]W4@WI,QK!'B]/IHC%P)-:)O: '!HJ#F^PMUO>MD%>'XH5
MI\O_E+1^7XIW:IB%IB!"1 *B-(X 2C,"<"XAX#"*(\Z3%"=&WJBA0>9&1IV<
M02MHH"4-WNO[%6,^&H3TLKGB ZB1.<8)(RM+Y1((3G;*V9=.9J5<4JMOHUS\
MK'.,N&;]KG% L?KSS<L;6?)OC[3^\_9'H9-X21YQP4!$=%-+*!# 5!<%$J%(
M2!QE20+MNCH-#S@[ NC+&VB!@ZV\P1]:8NO&31<0-[-&?.(X-C]< :%+,+@1
M+OZBP(>'FSK\VTCY$W'?9L^YD<ROZC6R":?YNHV6Z_AL@1"7)&4YH#'" %$J
M ,E2#&B89[K2MTRH543WP%ASHY:=J+TH0CLR&4+6C$<\X34RA?2@VHEY$[SU
MG4IB@(8GXA@::5+.,%#YD"Y,'G%TF-!:ATFO-EURF\A-*7;^O1A!Q19AJ$@"
M$H 4/0",! 90P#0,E6$"X\S*37)AP+EQQD;>7<_GFZ"3^29@+YM V*8"N+Y@
MX,OGIC##_5]5^\/@5[G^5@D'SZOQ'!FZ4SPB/[8395+0[1TMADCZ<J]<&FY:
MIXJA\D>N%-/GO!+9(D6<TT1*$$H=TQLE$6!QIN@,AW&<\S2&%'G@K[G1EB[J
MU7ESG]0::K(D M!F44C19$X(W<*N7NU^;YE$<0[QJ]CH?P8)C4XETS#(+(C#
MDB^NI(F/Y5K-<:$LJ=O52JYU]^[W/[KMXQ]5)?XJELL%RJ($$:8.1C(3BC-0
MI ]+!' 91S!DDF.[I%>30>=&(#N9 ]H(?1.4TC(9P AL,[KP#>'(W-%#[[9#
M3S/R3UN9@XW0YTG7(?')'"-OJ4T&0TZ<O&0.PG%ZDL6SCNY?NM*9"?H/74?^
M.UWJ\+@3O=\688A()M(8T"R! %&6 IS'(<@3C!B*,D$0L?(#FXX\-R;2$C>=
M)#J1+;V_QH ;NH''@'%L?[!&4 ?X-G_IB7T3G&P'Z=$Y;(N6+R^Q\;C3NHMM
MX3CR&UN_P#&;8OU-UKJ;3BV_R7*UO0#_5*TT*W[.[^F/NZINPG_WDC?OJ'9*
M;>/LL8!)3FD,A*0<((ATD7V8@)C$69RG<1YGN54^A1^YYD9QC5JZS-Y.K\WI
M[2<UGZN?&^-+A^2OZ8__US)APM-4FM'C*TS0R.39SLV>2IO0GI\^M7/S6SLW
M2K6;H%/N*"6^U6^<[ F_F/O*G_ DU;09%'ZA/,JA\/QZAR*I;^B+%F&I?E"U
MUX^W#[5LLC2ZX'_*$YS$*0.QQ-KPU+'2,*< ICS-LCA"*3:J2F(VW-RHN!'8
MHISF93R'B=,_2B/S82-KL"=LL)76I2#I900MBH]Z17*B0J-7(FI76]08H,$Z
MHI??,EW-4&.-]NJ#FC_E9D'?BG\]=ZV:[ZM;(0H]!%W>T4)\+-_2IV)-EXU?
MDQTVKORBS[JK8BV_ROI[P65;45Y'#S^4S5L:4W^1)Q!F29@!%/,$(*&O: 4G
M((L@C;.(QRRUNM@86^"Y$7U3. PTRC26]T:;@"LE'VSC0D:?;C/S>TZ3./(^
M='OW\>W%'L#-Y;"N-2^;GLUOJ]4ZZ.GDSP:?"GA/QOGHXDYJM4\%_J$Y/]FX
MGD*-NXP3^B"C!1-<I# -04HA!HAE!-"0Q""'3$:0"(QCHXQ(D\'F1OW[\;&U
M$O9&WX)WXEX97=P'V="E[ FZL;W(1U'%VQRF(=2N#R@^ <=8P<3]H5XWD/B$
MTA>#B$\]XRU+X5Z]J0F7SU((TYAE0/!$69\198"E,0(1AY# ,,\YMTJ<'!AK
MWL31!-9K47VE)6PA=N0--^ FIPTCS'SD(1RB,5X*PG:DU\X^.%39(/'@Z!'_
M5T;ZONK#LOKK/Z1XD/^@1:E_>)NK):M,'AVO6>0%WQ23N:<_%B&6 L8I!9#E
M,4 \CP 360PHY'%.$(%1;,4Q/H6;&RG]7JH#SK(I=?Z@I _T$5;?\^9*I^";
M5LKR+.MU)J^_-AIS?E[_[JBYDM?J!8U^-X'6</M;JM4,#O5L[O*5IM-<(;GB
M/\$]DK5HL[E,<@75YD;)>0RW#6#3MZ27$<4$33"+='(93@$B(@0,":;^R2(H
M$B$D$HMUI8[)9C1^/(05&6\'&F_%W^LQ@JYM2[#<R6M'P2>P-"/2ZQ :F0Y[
MPHV02G9>=4],=&* 2?GDO(*'K##PR2N,NX_E=_6FJGYIKJIUG>7ZNUPMB* T
MXQD%"8>)6N3J/*A^E ,B>9J$448R:1_C<WJLN9E>V^YEO%K9!B8.06IA-%T/
MU"0VT%;,;;3,1E3/1LPP'CYMDC,C36]B#*M\TF*X\(A#7,G7JJP>Z9NBTJ^G
M3_)Y7?"5LD4&+_9EG,L(9QRD5+$&RC@%C*,0()92*$08\S Q#C5QD6!NA-+J
M$!PHT=QB_7(N0L BU,)IDH;):!+H1Z8H%]1=(EV<X+<(?AE[&B:*A_&Z".RB
M8ZY!<#!@QNG%T\707*/W7EC-52]RV';>RN5R7:MWJC&Z!<.3+!:,9X E&0(H
MI@D@>1B"-*8IB3C!V*S6ZYGWSVW+V$K8+A +.CJ!G0'77X?(V)<-^V"XD/0)
M5"PH^#IT)B)8TZ^,'7>>5WV0&4\\-AWOG9=YC]4&/N::AJS,[39RY&/Y3K+U
M;2EV15YT:L_Z95?J16?\R'I-B_*^ICH9L4U/W&7[W,L?ZS=*J3\7,N$"AUD*
MJ* Q0$) @#.2@#Q,4AA%L;ZSM6LM/I:H-NMBFE[D)VL>V68\CS2O9AZ!.<S5
MR S?4S$HRD KV5R']":OU;,WA\%/3?)CJVO0*=LE9O_<RWL,_M :!XW*'F^F
MQYX5;[G<(XDY<?[WN& ?YXR//-X5W8GI2KZ3[9\?RUO.==OCU1U]T9(I2=1/
MZF==@6?K+%X03@1CDH (,AT52#- 9(X E9B(+(0DE-AV^W 19'Z;PS:.^"?1
M:?*SYA_:*1,\M=K<Z)]H90+9=AQ4YU9-/LUYR/T^R'$Z37>-L:=H]#UA,S?O
M^G.ST2+HU&@FHE,D^&0P%6ZMAYV1]-ENV%Z(Z5L,.P-ULJVP^]N<&;:M"'_*
M7&,B(8DNV@Y%$@)$$ (D37(@DPPABD+.(FG-HV>'FR5;=KT/')CN/*S&?.8%
MJO%9:],?8@(3]#(D_NCG_%!3D\Q%I4]0R>5G'&.JGU=K]>[Z* 2S\S(E*6&4
M$0YHPAE F$% >*:L,!ASC$B>)] H[]IPO-GY,3MQ WZ4G6$96'T!9S,2\8C>
MV#[/#7 G(JW]-[@SQ,57J/6%T:8-MS93_2CDVO Q=T]B<Y/_H2B+U3<I=*&R
MU7XX"95I!A%&(*81!2@-*<!9+H"@*8VR/ V9-+IFMQAS;NRRD31XT*+:._4N
M06SNG_,(W 2NMBYF9PM?(_"(,3P6"'ET>UT:<7(/EB$$IYQ1IH^ZT8WV</7<
M6=]IL=0'K ]5_94N-XVQJN?5+BE!!QW?5:LFJS6"OZI/?%M]KC]5Y8/:BU$F
MTH3@"&0X3P%"J0 $80[2'&)($<-Q+&R8R:]XLR.Q7;$^$$0P:*55\Q?\0ZFS
M-JU;,])<FE'@Z\W0R&S9W$3T>V5L=0-Y50.M7=-SO=,OZ*7M: V#C8HW^S/;
MZNF/8,?!WQ,7>Q9N4MH>!]A#AA]I%(?(FR_RX7FIOVPOOQ9+J4S<4G8'+ 0A
M35C(0)+HXRM/&<""8< 3E))40BB042?VX6'F1LX[08.MI!9A)^?A'.95?R"-
MS(^G\'&)SSD/E$68CA? )HK6L?IBV87L7(1A,'+G_-/3!?!<U& OCN?RIYV(
M<"75$[HN[SO=R+YZTE^*]]WUG_KI%RF>N?Z.M%;XV<]V7V.2DDB$>010KJM[
MZ9K?1&129T$K F69D-RH\/<8PLV-='_Z\F_T\>GO[S:WK3__^U:?YGRZ_ULK
MEO$[J48D_FI3-3KUM](&M[I)[4[>8*-<\XO]F;OPB-O.X7=.K?:;5YO;R78I
M[W/L;9,;!?L+6Z/?,:?<4$=!ZV ;'F<,/YW#WM!5P1<QCD2<A@B$84K5+DQS
M@%/&@4 \3D06(8[#:_J&-:/,;3L]TS6,:5E'Z1G68FWF.;H:P9%WN5/]PAH9
MQ^L6M@?!2+W"VC%>M5/8GIJ7^H3M?]B-$IH7?9%/ZJOQC:[D75T]U/2Q*<V5
M*E+(:<) @@D&".<QH!1AD D1LQPG*2)6_5#/#S4W<F@D#7:B!IVL3M7/!A V
M8P,_N(U,":Z061/#930\L</ 0)-2Q&6%#WG"X DWLOBM*BNU'RK[NGQHPX<Z
MZV3;.H6F4093D8&$PAB@)(P E3$'ZL>1Y!")-(9VT8 7Q[19!-.$!+9U(#9=
M;3;G=<MF-I>Q-F,/K_B-3")]6;?5PSIQ?QZEH8PQ.IY(Y?)XDW*+L?J'%&/^
MH.-)Y2";Y,/WWXK=1<^FPM<B(3"+%;< @4D"$-(MC[%@($SC.&8HH32$BU(^
MT+44]Q8G&*/1C18.:1?.D0SC+2(MFESIVHB/NT2Q76+&JG=O:]WFU'!:#$\Y
M_E">Z-ASF&UW$WSXO^"WCS?]&^Y>44./IR$KJ'P=C\P&G?:\9 7$T0'*[FFW
M&Y+UY_R?5;T4G>LTRW3K/YR#F""A+"+U-\STE4>4RBS/".=,VMQQ[+]^;B>G
M+Y__:>>F/D#+[/+ '8/QW?_KX',>--(Y.NX/$+%SO;LC,YWS?(>0/[?W:;TO
M.:X/GIK4]7Q:XD/G\9E/V3&3D,7B?;E6U'<KA)K,5??'IZ*4T2(*LQ3G6  L
M:080XSF@>0X!1B&)4AJ*C!JY?P='F1M/M8(&G8@WF[\$6MC@LVDXRS"PPUSF
M#:ZQC1Y7I(S7L!$2)VP:9<G^\E!]_W?U?&O.J+_LK)CAMTZRU(T4VZQXLP\[
M.GGY-RF>E[*Y8UK7!5='D=/]E7<)B"())6Q:L<<" B2E(@B4<)!'$B<9YFD.
MK>*5'628&VEL!%<;9'.^.MMLW-)![# [AI[C<3&?P)@R@COXX[XYY(Z23WH%
MAKX<T0X23.NA=H?HR'5]Q:L\]?_134+>58_J,+C +(JII R$881T_Y\(T$1F
M($&Z8X>,LSBUXL"!L>;&=6=[V;3B7ML!J >R&95Y@FYDRG)&[?H>0,=XC-4#
MJ#?2Z_8 .E;Y8@^@$X_8T<:J7B]V5VO;\IYO=0T.63_1>OWRF_J"=-_M,.(D
MBC$',B0$J -5 G 4AH"'N8ZZX2P11@1B->K\J&0G9:#%M"01.\B'Z60T($<G
M%FL,C2G%"9,A<E$O[!&+^M>.5.S&FH1>G-3?$(W;P]>>XC8U?WZKUG+UJ:*E
MCB3\4)2TY$7Y\$5RJ:PD91$W9O&"98*G&') (4T!HC@##&9"F3))+#.<,TFY
MVTG.2HZYT=)&#1V?NU'D)FA4N0D:99K#QE:=8*=/=^"P#01RG#_;L]YHLS(R
MQXTY(5<<^YS@]'[TLY/BE8Y_3E"=/P*ZO<[Y&-C$+?RS6'_;E#'95%![6: 8
M,BKS"$BJG6$Y)P!K8TY*&%',$2;4MH7T^='F1I3;UC^U_"[+9_NNT0/ &A_^
M_, U_O&OD3/X2PD:;"2]V59@?/%Z_KL,B;\3X,!84Y\!+ZM]XA1H\)"C4;:N
M^)_?JJ5Z8M6&%RQ$G/$491%(H;[Q%Q(#+%()"(0Q3[F $4]M6@$>#V'%$).U
M ESUY/Q;(!M)+2VD8S!A(L-$)B' 6%+=<HVJ$W26@$CF.9<\YTRDBR=9%Y7X
MNE;F]A20'@XW'K!OY$-1ZIC_X U5O^"6W'L"3\S2B"<D BR"!""64$#"* ,D
MI22F:8)E)#L\WY=B.C0W@XUYD2E\ FEHE5\%S=@&]]Z"[:+;;M?KNF#/;=C@
MN@KNJ-_>E><1\64S'P\PK3E\5L$C2_?\)^V=DG=UI3,)/]=?9?V]X$V?\T6F
M.XBC2("P:2Y.*0(XSB& (DP%Q9'V2)KZ'T\-,#=3M9.Q.2=V8EKE[)P%\K)7
M\5IX1E[K#LA8.1"'U+_"5WCRM9.Y!8>4ZGL !S_G>![57:L_YPU%=)YMGD@:
M<A(#+G6U#+V.L0@1D$)0CB7,T]BHV-#Y(>:VG!L)M3NHD='U[O$82<-3YU7X
MC'W4M(3&_H!Y5GM?I\KC :8]2IY5\.C\>/Z3;HM;5S=LBAON2F^OMFE=(@U%
M&&%EG$.ICH](1V;&A(,L(C1'&,HTL@HZ&!IL;@N^5_:Q)ZU)YI<]SF8DX N]
MD>G '3AK8C!!Q!-%# XU*5F8*'U(&T;/..28W#Y5:_FCUP4TEJ0I=TW#D&@7
M"5:$ 260"*900I3&B7EKZ8.7SXT@6O%LVW\>(C:\]*_%8>2EWH/ )</D$ N+
M_)(K,)DHN\3DZV&76W)&Y\',DL-GILLK.2/M7E;)N<^X%N57RUZN-F6*%BG'
M/&%"F2LBT4EN601P$NE@ YE+EF=(Y,0A(_=@&*.OWO2IMQLI[:KPG8/2S$!Q
M06:JHOH=&MZ*G%W0V5N9_/VW3UP2_Z1JQ^7O3W_,-3&L>9^R2XKO\AU=T[?/
MM?;Z+I(T3& ,!4ASO9IY)@$AA()$$AYF,E7_,4I>O330W,R,+NFI)VR@I0TZ
M<6VSP\Z@.[S ?6(V\DIWA<LA16P8BRNRQ,Z\>.)$L6'UCG/%+GS>;4]OZM>\
MK1Z?:OE-L8MZ=UOB8Y<J_Q_54E^F;3+F/Y>]0NUUL5*_>J?^63[<-7=[35>.
M>_IC(2,I8I)C$+(H TBR%) TBX'ZBX 999@PJTJ#8PDZ-SKJE9=X:,I++'5Y
M"9T3)70KAI5C"^_1YMG,<IG#[(U,C)_??KP)C-IE]*:XT[I?2>0F8%)]5@:W
MXE_/;0_FFX#FZKNGFRKZ,ZS&GA)/%MIH8DYJZHT-]J'-./IXOOIW?]Y4EGI+
MGXHU76Y=MNH@F68D4_:GR"! (LH!2V "2(32+%6;2)P:F:/V0\]M1WC[3?U+
MKIJ^W$U?]>9BM]=TV[+:G,4DF!Y+QX!V]!/KR>[:6\F#3O11_.KVB(W61?OL
MP*_<.?L2()>[95]\PY6M*;6_OTTVW+1+3+(P1)S&( HC#A"6(6"2Q "%+&2*
MM5()(Z>.E$=#S8VCMI(&WS>B!O6E-HJV\)JRD0_01F>?#5Y;*<=L.WD6"M_=
M)H\'>ITFDV<5/MM;\OP35]+$J8[O*:(Y9YP QG78.(D9P$S;.CR46019QBAU
M(HHK>\-/21761]A!1"VYX4J<)F.'G9S!'Z.4/#%!Q#=)G!KJ=6AB0.FS1#'T
MS#4%<+=&-^,YY90A(,-,D8/D,2!,7ZL1%/*0,20AMNK1L??ZN=%!%XKN&O9S
M@)T9#;@C,K9SW1@,Q[*R(QTK#E[^"F5B+QT/SGS*;<%^D6M:E%)LFG1TX14R
MC.(TYB' :G,'"/(<L!R&.H:7QE&,4T&L%N[I8>:V@#=2!ALQ[1;P&2S-%O+U
M"(V\H(_ N1S&8[VRAT'PM,+/##+I2A]6]'#%7_BT-ZM^N_=D48ZA[@BLOA3J
MS,^0,N]9EH",D5@@'&,86RW_@;'FQ@&G#5;'+7T(8V<S?X:;O2MH/FS\T=R+
MYT=Z;0O_L@/Q\B.N(3?W],='H=Y>Y 5OG R_/3>[7!I"==SG">!"1LIB$"D@
M-(( 0AG&B8 9$<@NYN;,2',CC"Z*1$D;[(L;M/+:1MV< WB8+[S"-O;1P!4Q
MA\";"VA<$7ES[LT3A]Y<4/ X]N;2 ]=6^3IL]_>N6#ZOI7CS\K9Z?*S*)BNI
MK1!%L<@EP1P@DF& 4)H# IG4?XLDI#$1S"HST$&&N9%)OYC4J7:5G2(W 7L)
M6EV"1ID;'3R^?&X",.[_JMH?!K_*];=*7%OVRWQ"S4R:D:=I9/)ZE1FZH@Z8
M-<;>:X"92_!*];^L(3I?^\O^5:YUO_3KFM3.SLN0Q!CS3%_3DE07?=;YEUF6
M 0PQ3E."A4B)70O#HS%L5N$T+0N[!=;(:%O?ZQ# -,,IRT0,!$*YKG\4 49S
M9<]2DD"98!+*=%%*PU(];N!M<S_&KM#C$SA!&(H3&($TACK!/XL!SG,">(:2
MB(LDDI&1Y>_E>S=-96!_X)EMF5=!,O*&V$=C!)?@6=6]58D[?/_$E>'.J'=<
M#>[<!]UV$-,JE6]>>A4KU5!-71F29Y'01GN:HU!Q91@"*L,()#"'B4BR/)>Y
MS9*_1IBYL4.OO&M;1-^A^?95DV-&*5-!/OJMA!7:UO3C R9/3'65*).2F@_0
M#OG/RSNO*);Y<;5ZEJ(?2-X426BL_#=T)84.49?EJDU(QQQ2&B=-RB$&B&8A
M(+J'9A3&*.)0\MBL@X*["'.C12V\KF"HS\U[)D->U5W5S8#^16NQ"AYJ6JI#
M4_!<JCD*EE7Y )2$C[HUN?9;?9?!DWJU;;LJ^TDT=&>,.C5C>S.T@*N@%?^F
M+<5RT[HR0"-W<$=?=-Y.<%O7.G:_G\/SH:IS6:R?:X\YTNYH^JS#:"? ]'4:
MG0 Z6<?1[4UN/'I75_^2?-V=?%"21@QF$"1(9U6&+ ,T102$0N:9C&.>FET8
MG7S[W-BO$\ZQ%MP^<&:TY S'R(QCC(0U=9S4V!,K[+][T@5_4JW#M7SZ0PY5
MFMY6NGGO/ZI*K+Y6VV[.B$81Q,J2$2A) ,KC"%"<2K5JTS#-XERBE!C7:CHY
MQ-P6K!92FRH/6LQ@50UT?38%<7C=^H%F=%]/VP:[D3#0(KK4<CH-CT5%IZMA
MFJBNTS%<GLH[#0(P6.3I])/3E7H:E'ROX-/P)QTMD-:872G+==?^ZG/>\ZTM
MLC@E&'($4*(K]R>( :)C8%DHPR1,$I)EF4,EJ,LCVUT03%8<:B?MZO#H9FG$
M7,;>T++Q ^5$YDXG;'/,W8EK#*6]%62,CB_3Z/* T]I+Q@ <&5'F3[HZDM2J
M;1KM]4KS-CY;'H4DS&$*N+ZS1221@'$&01QAJ PM)C.[@-NS(\W.SCHH".W@
M+#^/JJD#QP-68QM>5C Y>%TN0.#-N7)NG(E]*!?4/7:57'K@2D)HXZ>R*,&$
M8@APFB@6R))09]U(W08CR7C$E"UGE72___JY+?VM=(X!:OO86:[UV865&8/A
MOKA'"?/:?_GK+./AX*S3GW+PC7R1#[*4=56N&O=H:QG(FA=TV16TW*1\<4PC
MFJ$($ [524)GSE$8ID 2F$.1((0BHZ1XNV'GML"W@O]-;5UL63RT0=[:$BZ4
M1;S2VC1[&BVKO CX5JU-(5K#*Q[+R3'PPXP"^<@,TD>[D5I['G9R;\K9&J3M
M70.NA1=G%) G\NR8@NW)WV,-U: /R/QMT_F%K#7<\Q79/^UFK[TK5O3AH98M
MDWW.O[2M99N=95?  \,D)"S'ZO2F.QYQC@&)$08B$C&$69S 1-B%XAJ-:[-,
MI@G/[<?*/W6=O%9T:5LMQ0SU7$0\CA@',HJD.D)C#%C*<H!%S@D)!9$XM3&>
MO6,^=?X(KY9*GTH7#OLNW;H@FR%O9GI[QW/D_71?7@UH)W%GH0>C%+&Q0LF3
M#6\VYJ2FO14,AQ:_W<,.!X'68'V[6U]5>:O&:TX9M^6Z8)5XZ>PA3'(B&=2Y
M!(F.E$V8;EP+098CP5*8Q"0QOSDU'W=VO-2:^'NB!UO9;X*-]!8VJ<4D&%C\
MXT [MM/ $%47D]\"7@N;?QR8)S+Z_<%M9_W;@S9H_EN\;CK[WU['O0. P^.N
M]9*:O>2#DOYM538E%?Y9K+^]?5ZM*W7BV%;W0"(/!4Q3G2&A&\ +"7 H<L )
M5]LOBRF)K#(D#,>=&^]O3"8]V\%&\. O)7FP$=VYN(KI5)B9IR, /+K#QPNV
M#D6:K)#R5K7);-2)RSA907%<U\GN<3?*^I76?\JU-GYW=?%_4_IU[7S2G"4Z
MY$4?E)6%FJ(<T(B%($RI/C9+D2!FPU3#P\V-H';2.O<CN8"O&?WX0VUDUND!
MUF\.LI/5']&88>*)7RX,-BFMF"E^R":&3]D7?GK7F=?_WS.MU9I<OGR13U6]
M7I X95F(0Y#)F '$XP0P'"MK)Q=1*F$>P]"XS=J9,>9&%QLQ@ZV<02NH>96G
M<V@.\X0GC,;VF5G#8U72Z0( 3L6<SKUSLC).%Y3J%W"Z]%&7KLQQC._HNCDF
MB3 E[=\W8?\8I3#/$1"Y2 &*20HP#B%(&691K-8Z1$8I.A='FMLR_YN2-6@%
M5*=Z$?Q-R=O]VZ9G\1"V!CXI7XB-O.@'P'+J]#R$FDW;9T_H3>1<<OG*6?:$
M-@!DN$'TT LF[!9MH,=^ZVB3!QP#^)K\V3M:B ]5?4]_Z./;M[8=F?K!N>1P
M@B,I< QH0I6U!&$&B$@IR(FNAP\13B%R2#%PD<5H(4R?=+"7(*XF2TV(S@=_
M4C^3/_2]?AM!OVI^7SUI3=I68M_EJNEXI7ZI^PS7!=>)Y*M=HOGCT[)ZD3)8
MTQ^]F*15\%-1M@%)JY\MPQ!=O@%F9\+1)G3"W/*A+/(N^;Q12RY%,T&Z*&A/
MS^#S=HX\!D1>@:NOL$D7$:8-KKP"I*,0S&O>Y5C>J&DOV#46WKJ"A<B23/T7
MQ%CFVBL/ <UDJI-94T&ILG9#;E6WZ-0H<S-F._&ZCHN6'19/XVC&7U>C,S)!
MM?+=;/I]C^(L'\3 5V&@DV-,6_%G2,VC4CZ#'[ZV_O"][IGX7+\TQL.;E[;D
MYC96*<HQ5:=:!'BH;2\&0\!X(H&,&964QQEA5O=RAN/.C1/Z<6+=-KQ+>3-,
M=;>%WM#H\0_HR#2RS<W:"+Q)TAHQ3,P2)>\U?8='?:4ZOD90G*_=:_:X'3VM
MZO7BB[9XFWS$A$L"DX2#))00("IRP"0/E0T"<_6CG"?(R&&^]];948OVE*A3
M&*?+X-<&T2ZOR2*U<Q^V8>)P!F/LXX\;#L94<%+OH86N'N@M<O6OW0+??]<D
MR_>D^)O%>?J7;I;!WK)N][I;_E_/12W%(HYI'H4Q!I!#?6\58;4@I001$81R
M'F81LHH9'QAK;LNT[?K0>%':_=_9 S($L-F>[PFVD1?T_O:^<5_<!!M1_>WN
M!GAXVM&'1IIT%S=0^7#G-GG$L;H^77W3_Z\[+7ZG2UT3XLO6FZA_<5N*_1_T
M/ME6T3ONX=XU?WC_0]G8BMF^T+5\G^=2>R5T9& J(A"', 5(( PH;#)7X@RQ
M#))<LU"UIDLS%II6?"MBVRHQ(K')M:X4VHBM_A)PI=]-\[]-F=%.S9O&7=SS
M$>L/6!9SG_9;8D:E\YW[L4]AS33K_PW>]Z=YIVS0?D3/^\$/]Y]H40@V, 0_
M;8#XN=_#90-&H-$(6C@\5KU_E6GT55)_6N&GK=?_*A-SU S@=:3PTV+XEO/G
MQ^>EODM\)_."%^L%C$2<$,+5=XDQ98<G&:"AVA!%F.((QDQ$B56Y[,M#SLT<
MWW;7E5Y:#Y_ V&S_\(O<R)Q_W)+XIYZ\02?P^>/,U?V)SZ,S4J_B$P.^:M_B
M\P!<ZF$\\*1[2ZPVY?^./LEZ$\*&("<LAH E.D8UQ8I9,D1!*)3V%.:1C*VB
MVT^.,C<RZ16B>-)2VC<I.@:2YX1D/)1 \E0 %.<1P E+ <T9D6&:021B^_YB
M5T$Y78\QWV :VO+7 C2VR;U#IA%PI.Y/9R'PV 'J>(S)NT"=5?-4)ZCS'[ZN
M&]2N=XHZ1G<WM N8H%"M<@00EE*' 1/%H2D'B%/.DYC'(C6J9F4RV-RH="-K
M4&^%O0E*:1@&; 2O&1GX FUD3MCB]:6'5]LNY':YK/YJ6L#H0*^WM13%.OA4
MK781&/[;-@VAY;DMT\FA7J7MTI#2Y]HJ#3YS7;'M^ZISRYY*4%KD!"&"\@Q@
M+* Z^BG;#.LKF(RBC),LH7DD-L&P9O1B-*[1DMD/?!V9:>[Z9;8?=UEVVE]5
MK;^I!>2:H&@V$68TY _<B>MOKZO-14UP,H71?P5N(X@\%^$>'O-5ZG ;P7"N
M%+?9P_8IC>_+=;%^>2MUTO7R8RGDC_\C7Q8DS-,\P1# 1,8 980"ENLJGC 3
M@J1<&3U&AL[9$>9FW;1"!IV402-FH.0TSV8\#>0PEWB!9V3>L$;&*I%Q4'NG
M-,;3;YPLB7%0H7X*X_ 'W0R-W[]NKH)O2_&/ZKNLR\==REB.("4DQT 0J@R,
M,,. ,)$ CIGD(M6E6:QB/ 9'F]L"__V7K[\$#ULA&V.B_\\'6?*7?B*,G64Q
MC'R"DB3,$@9$*G459)H!DHL<X)"F1"0LC 6V<QEYPWX:U]&KHJ]/[!E,0Y"Q
M7&]F(00XCR"@8<IEAD3,$3;O9W\]\I/UMG]5U,VL:&_?XY%WP=^_[H*:-8P[
M44?P]1F!XLE>'AYK4CO92.U#^]CL(4=?H-JB1;%\UF5C>Y5$U->D;=FXD"*7
M7/.ZC&4"$,,18&G&0(A8G.1APKA934O3 >>VJ?;EW2^"HQYR;/%Y$71#+Z%'
M*,?V%%Z'HKU+T! :7V[!2\--ZQHT5/[(/6CZW)7];]XW#<!U_F=5ZG-_$_>?
MPY 0"3F N<0 Q8IB&!88\)ADB M&DA0ZM<,Y-=K<2*:5,=@)>5UOK), FW&*
M-]C&/K+;(N;>26<("=^-=4Z.]3I]=H;4/MMV9_ A-]KX0(NZ:5/^YJ676?.A
MEO_UK&W[YKN=YDF4("9 BE-=NRA+ <$<@5@BQ'.8B1!975H:C#DW"NEG'6T%
M=:(1$\#-R,0SC"-3BA."UK1B@8DG<C$9<5**L8#@D&AL'KV2;GKOUQ>FSW5=
ME \;9U<"HRC*D;).D  (L@@0@6*08RR5M9*RB%@9*R:#SI1P1%"5 =41$ZVP
M :.KPM++8H2Y)>5X0G)DSM'B!HV\.GEA Z%_=XL-++YI9VC(U^$= Q#.$H_)
MLXZN&/&OY]6Z>W$3*WM?F=:8DC -"<\C14B< *3,'<#2B /!><[R"%%"J%U@
MQ172S"_<8O(28Y;^H"MFWM!5-/)LSJ3(V":_9;+J8AYP]>6"ND*2:;U3UT-V
MY+CR\$K7/(1>V[7>5_%=L>++2F\4O4Z!!.8LHAPP 1.@SJ4"D!@C0 B+,<U2
M0J+$+CO!>.RYV8Y[O5MN@D\%UVT;VW3-STWXV[:ABR65VDR(&76.!//(5+DG
M=9\D@YW<P1^CE"MR ,Q;<+_YR!.'_%M#<IP(8/\*Q[ZGDJUW[O_;[[18ZE \
M3:%T*77ODJ)\KIY7OY=JKUT6_ZVLMVJUNJM6A5[-G^1J=?^-EA'\57WRVVK!
M<RF2C,: Q3 #B%(*2*8C[@3.9!BCA"&K"T2_XLV-&7<'P@ $6MA@K:0-(ABT
M\EJV]/0[E6:$^7H3-#*G:L7V+B^WN@%E;P*MW4VPTR_8*=AD/@0;%6^L)M:^
MJ^@H^/MJ/^I7N&G[E(X"[%%#TW%&<>\$\T'M,'3YGY+6']1/5@O)*$<<(< R
M# '*TAQ0F2> 4YKEC*=,(FS;">9@C+FQ\K;522MGH 4-&DGM6\$<PCE,JIY
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M%#$ KQE-^ %M9*IH\>I)V9)#*Z<_7KB,A2=N&!AH4GZXK/ A1Q@\X>@<;7>
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M>QU 8_MMCXI6#U_%VWMLSZOORU5[8H1I?;3G53QRS@Y\U&V-GR:.[D*N"X"
MN11Y%&,0R5R7=\ YH%3&((H%Q7D<Q1FU:F9K,.;<K+:?OOP;?7SZ^[O-->_/
M__Y%-HZKJM0!<0>_M>,&DRDPXPK/P([,'>>LA\UU\ @A*!8 >6(7DQ$G91L+
M" [9Q^91-S9Z5ZSHPT,MVX3WS_D7-4SY+#]M^[S@A(<QHA"(&.5-DB=@N;)!
M,BI8*N*(9UEH0T67!IP;#^W+VU!/*_$5[70N@FY&/CZA'-OW>QV*UK1C"HTG
MSKDXW*2$8ZK\(=L8/^=&-<J"JB5=R7>R_?-C^;%4 ZB)+.1J@4)*(4DP@)+%
M "&2 X(3I!/,$Y3 G$B('.+_!P=UN(N>(O9_(W-0E.J_6VGM.&88;3."N1Z\
M:=AE"]A/&TE_UMA]-,#.FEF,,/%$*\-C3<HI1FH?$HK90XXQLOR;.@\LY>?\
M/:U+=4!;W<EZ$VY7<&TQ%<MGO6)UF/6]_+%^H_3Y<P$304G$)9 <)0!A20!.
M< A$$@F"L?HCL0NB=9-C;F9.(VQ[+FC%#71^X9Z+06?/M#5C+$-N'6?*C*,F
MP']D]MIHH*VBC0X[K&^"XZEI"[ &6IF@T<9G!Z'K\/05Z>LHQ;2AP-=!=10K
M?.7K'*X1]RO,OKS_<4?KM?PBY0_Z6)2-&?BA6$K1W6!+"J-4NZ62,.$ B1"K
MLR!)0<X(1C*5-(+FMXEV8\^-+UNI])*5/X(G+7E0]T57__JO9[FR*@EG.1L&
M%XOC83PR)QY4G7ZY"=[_"!KA@SWI;X)&_ANKZ P7L"UN',<#?:*+1]_@V]U!
MNL$W>!5I^<KI;B3==-V[F'1\A9O1W?; VQ7Y^&>Q_E8]K[](*HKERSNIF%</
MJFN";#JLW#Y6S^5ZD>&8IX)*$,(L DAF N"4,[5UI&F6$9'(Q*K%@+,D<]M(
M=BH$U5^E,N[*:JTVCT:-X)'6?\HF3]3.Y':?)S.C>Q+T1]YBNBZ</?S_:K4(
M.C6"OA[!KN/33=#JXL_FOAI.3U:WNQR3VMU7PW5H>5__0E\>T;M:/M%"O).Y
MK&LINIL>9?HW24)=,@E,0\X9(X"2IF@SY(!D" (J)8R9%))AR^)R;H(XN$\G
M])P^M1IL;HA7S0FZ[8Y.AY-3?,Z5JZ/5&_ZOZH'MM-C>+^LI:!,/?><'78?@
M:/Y:(R%>V9%K ]1E#Z_5VYS+NM3/BDMV*9.;U_=^M$!QG$2218!11 "*(P88
M)B' BC[C%(64Y5:]W8U&G9MUV0E]B@2OSI,VFP8S O0.[LA\M\&U)UV/W#X9
M0.I2S,4<(G^%7 S&G+J(BSD,)PJX6#SLQDYMJ;:F:DGCO%U]?EZOUNK+H4[H
M"Y9(*3(L0<2Y.@:G*%=6&^8@X4F*\Q#G%!HE3YD,-C<NZM>PNVF[::@S[T[>
MX"=E,;0_MJPL-0@Y86DJ8):"B$:Z +/(E+4<02!X+I,D%:GDX>*IJ3GV=4WK
M];3 'PX\X@V??"A*?:T0O*'J%UR.A'>61(SS5*K=5L8 ::A)!G63 !@AB3!C
M:=+A_;XT/)_X17LS[(B^A?8+/2[09CNK+^A&WE#WR:&5]";HR>IO(S5!Q-/^
M.3C4I-NFB=*'NZ71,YY*DWPLU18D5^N/Y==GMBI$0>MV=[[-<[4OT[4R)4,!
M)8E%"FB>Y@ )B $CBM,3' HB):5A8A6*ZB+$W#;5NZYVIKZ)?*J[0U>PLJ\3
MZS0C9A0T-LXC4].I2B<;#;23HZ]#VW%[J\6(]4\L,!RK)(J)"*];)<4"I(N%
M4VS>Y1"*\446C^Q9$88>5<?>#D3^KWZ3ZB.?MWWJ= %^3=#JL7>;CW1I+%)*
M+E/"@(B@5 >.+ )4L!"P/$XP#S,2,60<LC&.C'.CU(%>@+HCVK8-8->'\R 3
M25DMI5SKW]=]M$[D+-F$AHST[3 ((7G].1^9WO<4##[GNQSKV]-94KI2GFP^
MN=,T^%!U\7K-&[J)WCS@TKIPI!FWB&-Y_9F?*-YE@F^ I]B8<:=D,(9FI*&G
MB[49%[N]F)R1A[*S+E;U>O&;^O9_SG^E_ZKJM\_J</ HZW?5(RW*191102*9
M QW:"1 3$- TS@!.<LYECG F4Q/[8'"4N>WP&^F"/UKY#'EY&,GAO=0;/F/[
M88RA,68N(]6'SBCJ!;WSB?K7[FPR_.Y)R,5(O0T]F'WXW +OS\4G];?__;\V
M/U'_HRND_^__]?\#4$L#!!0    ( -DYI%;3--P%+'4  /0K!0 5    <F5G
M;BTR,#(S,#,S,5]P<F4N>&UL[+U9=UM)<B[Z[E]1M^_KC:Z<!R_;9U%#M;6L
MDF1)Y3Z^+U@Y1%)P@X ,@"JI?_V)!,&9(#'DQMZL8P\JBB*1,7P9&9$9PS_]
MK^]GDY^^X7PQGDW_^4_\S^Q//^$TS?)X>OK/?_KM\R_@_O2__N4?_N&?_A^
M__WBX]N?7LW2^1E.ES^]G&-88O[I]_'RRT]_S;CXVT]E/CO[Z:^S^=_&WP+
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MYA"YL_)6^%#/#!\'B;=GB%R(Y9?Q!-^=K[QF93U+T62PR1JBV'#P7#,HKN1
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M*CL3,V2+3L6H7<(&52P;5M\.+\_K*K2!G >!E_KX/'\9EG@ZF_\8<9D9T]R
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M!E]W;V4TNA(L.G!8AP0ZVG\A^@+1N4B8L+GPUK</FZGI]ZVW&^UOAM@AJA@
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M'W%)\L!\F?FYYL)[R9*I'5J0^3IGKH#3R4-1A1O!363-.[P_3$F_E]'MP=-
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ME&LMM">A9PLB<&^Y\E+QU@7I7?/4?ZNO/GS1_N$Q !?A=K<A'8+3M2^\QZA
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MF@8>0-MB8R+'B\*$ULDZ'16!7GJ<[\O=%>H-82+<OQI/SFN?VMNH9\P65+Z
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MODZ*=QR<Y-YEF7PIK>_RGJ*I[X'6A^O]*2@=HH1!@NJ2FW4L99E4T:&&8HL
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M7'(K*+EG Z4N!-TW?"[2"R]8FI6WX[@,/V:__?G3GR_;:97Q\FK:H>/(N0O
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MU>*F_VK! ??\V.>(VU^80T# 97:&LZE8%L#$^F1%W$+4+H--D4?NO0L\M<)
MW]>Q>RKKKKKWD%S? T+&T_'9^=DEX3*8XG4 K3790SHBB7EI@9M _!?C8]K*
M7WYJ-LC-17M6^CXJF[607]^*#]]O$&XTIN)Y@BQUO3FSJ8ZTX2!*<KD$FPS;
MRO5\<BC,]QT5WTDA31/%[RV_OMW#JTJ?J_E;GF63N$KDDV"HPY(B!%S=TVJ&
MJ+*P=UOX;YKJ</>C!US@N\^YWD!^@]+^^LG1:V0I! XI$M6$W@A.FE+;4BFS
M\H2%V%W_?;[ MU#41IWO(;6^M;ZJ\[MF@I1X:?]<U%R1=8)L?!UP4JL)0IV6
MYD/Q3$D3R[81X(8EAH* ?=1VKU;R8!D."PF_C+]=36\E8HS@H@ZCJ7&JLQ"B
M5W5HL,C2<X/,[ &$ZQ7Z.>^[QL&>$AS Y>/3S[=)1BF5 VD#A4)&)O 4_H!D
MC(Y+G:QDK?NJ-<FXZ"<#\)"K\*:JZ-O"7(^5>5\^S\=ALKK._8C_?3XF2C[/
M7N OY_4M]L6/&_=GT],/8;[\,?+.JD#;"%Q,U9&.'*(L%I13M PR&;;,?3^$
MBD$^N.P)AED?FAD2!/_]G,C'^>3'.N__)KL?PCC_,IO?J5ZZ41.W$M!(.D=Q
M/;%>E*UU2M[6Z*Z S3HHH:/"M-W1V):N05Z:-H;ID;4W).#>ZNNR^*WF.,VN
M>+V_04D2UWMZ)+)&SU&#L,K6'HA(+JGTX+U%R0UQ?3<#90O('D+1(&\"&H/U
M:!H;@/>X3WZ>E[7'AY9@ZYL;N=P<_*K\T[ HO>6.BZTZB T@J?+8/N9A2#V6
MTOHVGV^K[5^0<_,[3B@L(Q:_K**UD^5?OXS3E]N1VV6%UE]GYY/\ C]B0HKE
M\L@:B@!C48".U7:A64#D5D(4*>HD)!T>VW4=:$'-(%/,&YC-HVNJ;VC2.3&>
M57?EA&2.WVB3K7C\'.:GN.KZ<8?9C[-5M^,785'O+0,7.3D!.ELZ&S++$)U%
M<!A*Q**C$5M'17M3T4]'C*.<X,?13-\07(OL(];[K^J$X+S,YF=AFO"ZN]%_
M!'))XH3<E>EBG-<C/2^*7D><FZ!Y06 I$;,A>' 2Z[1$1T(NS+B[KX0;.QL<
M1DD_O3.ZA^)1-?3<*R#2%\SG$YR52U?F19A422TN$[!N?4[WE1'[T7/4BHD&
M(CMR)47F7C*?,S"3(JAH(G@7!#@65"@EEYA:#UL80B5%R,5C;2[,C:TCX^D/
M5^=I4"QH94XFT3__3R7% 5C9J9)B%VT,(#3O(I,Z)*VM8@%XG1BDDC+@A0HD
M I* "+($_C^5%(<\'^V$L2-44NRB\ %@_G9>MS'!2\LTQ"3KK%F.])60@-QC
MYL[PXEI?-/W!*REV@L.CE12[Z*;OB&F'-'^>@ZJO_*!ECG5T?('(R/T646DK
MBPP:PU:QT?.LI-A)JWM64NPBX@&8I"?#1"&\DP(3%%;[UP7#P4>KH$BM2F#2
M>=.ZWJM)?D4_=1B'')!-53$ :)VD=-F%#,??JGC>X?+E^;P*>>1"U$%AA&R<
M V61!(51U*X+/" 7RKO6\U<?HV>0/M>>FI]UI(8!0.JAR.KM.,3Q9+S\,2HJ
M9F?J-6=DLJ9\)/ ^QGKQ+HN0,:2TU8RH7=S_QP@:I)UJ ZIVBGCN%WPKS^!B
M]OK[]>SU8S<Z>6+UX[<[V44<Q[ZJ"\R9Q!@854.$3 8O<F\@!J$P2*\U;]V@
M:Q!7==$:@PHA9%E >9T@^%!JS9<M1@3MFP]C_ -<U>V E=VNZG;0QA!.W0Y"
M]124TR9F*+I.OF7D(\?:(+M@Q,"8U^SN/*/_N:K;+1+9!6-'N*K;1>$#P/SM
MBP.?8G1%D1$HN::]20'1A 11%\^-#X'A5IT&_N>J;B\X/'I5MXMNAGQ5=^$T
MS=9.T^7T@&RCLJQFLWD-2J(%SXBY$ISCDCQXH;?+D-UUY2%=V^VDX6VO[0X6
M]]Y8^H;S..NF1EK8$'B.%F2=4J>D9A"LC+7&+S*K?:0=MQ5<]JN1[NG.;8^3
MKH'\^K8E#Y4+6B>C#K1)K(L,E# >?)(&4O2%9:==C-L-41AZC?1.BGJJ1GH7
MJ?6M]8]X>CZI/_#CBI/+-E$8G*Z-N)TIJ5X]._#%U&%K&)VRF0F,6^E^XQ)#
M0< ^:ILUEV'?2'A@*N[[*T9RPIPC0W"^SOV6M%-"21J,Y6BM#1B5WM)OV+S*
MP&JE]\9#,TD.$!*??Y]=,E(TQ1A&@Q")CLE8#-2T8# QQ,2<DNSN$(/M(7&U
M2C\%5$>!Q'Z2'" DKB:3J:"SS@:T*1%4CA*\5 QBM!ZSS3+R[1KJ;%ZCGRJE
MH\!A'RGV"(:,X]%;\I\GKZ?+\?+'RHF*!K61&4'4%T!%)QP$$1/P%&)F3"3.
M'VN=L,#TY]/9MY_IHR\N-.B+ZWN,!Q8<9'7E_C'$H2+M&0T75*]W1D3#>'*U
MX2?Y/$I4DZ:#!H*SB#(DE<5CU[%/0^'F:OWXD0>K:]9 =OT?!_5&Y+H?G/0\
M*(C,U'2HFAAER<DQREK: E@[O^YPN=1GD'"84N[?&>TAH9Y;);ZL21XX_UIK
MMM^%LW687+(2EH)C%F2N707(K*'/@-*5G+6TQ?I'MO6V'1,?6GN0!<K[&_LF
M(NZ[;RY^/9^G+^3&7-V"WF7ILNV41,ER,N!J!INJY:H!LZ 8*(?,HPO*;#4C
MXZFNNML2U%_[U<-U/NM: 8,Z4YCUR6%VP'0BT23:6RYQ,J#>*T6V-UG!G\F9
MTJ'&-AXXNXAO *^D3^:8A6PB3Q0EA\ HXG)<0'3D8*6HD)64:AK%$+.'^YF'
M=\B;?5-5]&U2;H\G_CQ[H-.7#:;>_3/P.9*LG"8'#QW%\D(DIU26><L>;$^O
M-<@LCST5.^M.R@.P1_NTCI$^I%6O&".E )6)V>A9 &MR;:=?"GWKN!F!>_?[
MZ2^7>!\,'DMI_3_4?YS]")/ECT<VVLT&7>]PN1X)O[IV'%FM8R%!0E':4Q":
M!-"N+,",,5%IY/[N?+!-#WN'D#'(R[L&1O!XNGGFF>X7S3MJ&<GL=%ISP<;3
MJ_'AL_+^Z[K'Q^)WVKLOP@^<=Y[]OC=%Q\R(;R.V(V?):ZX1'7F>P=46]-YK
M\#%;R)DGSGB,*;3N[#"(+'GC>=0Z@U"&O!U1A][K4"MB+&K#O<*[Z3/_DR6_
M$U9VRY+?01L#\#V[R)+50EM? @(%?Q:4IE,M^%(@R:"L\/2/NG6URO]E6?*[
M8.P(6?*[*'P F+]37A^<C>@YZ""(>$MB];%PX-9YRQ/]O;2NO_R#9\GO!(?'
M&UKLH)N^;W]6;M##6=MK;HHW+*OH02?D%/[I )&"/N"8&#,B<E:VZW7^Y%)#
MRH/?28>SS@3:\RO6E??\%YR=SL/7+^,4)A>O^13I!<,T[9:,M%LLAY"Y!])X
MU@IK_XVMW+<G7JTV$C#(.YK]S[EVPNX;,7AZEX7UHPTK12K&'$B##E04!@)+
MDKY":Y'E;--69;%/(683 ?T];#52[*RUE ?@U+R;37^[S.YCQ@K&:UP3:L:@
M+ B.\0RHLG)!9IWO)LT>[-+<6+Y'>+11YJR-9 < BC?31%'OU:YY6W^AZJ'N
M&(XR<V(<O*@B$?5<UEF#])9Y%ET)N?4CYR/D#/*B]O!HJY4"AHNE]08K**4(
M$D$B"MH=+$)408),,JLBHHFX5>[-X6CJ\XQJKO;MX+2'#OJ.EF[Y]>OMMK:Q
M6B)#;FB#F5+[(08',9*H=%+6*^4H;-@NP7/S&H-$QSY:G+47:=_(^$C*H-6_
MG$SSC7E3K_]/>U_6W-:1I/M^_TM&U+Z\3(3DMOMJPI84DOM.]!.CEBP)TQ2@
M!D"U]>]O%@CN)(@#U,$IRHZ.MK700%;F5[E5+G]\K2\5*_K3#UA?LK9Z>L?/
M7FT0387716I@F27/,)'=]C%J"&2\BRS18=RWP[ I8=/&72-A<$KA31RO;5]8
MWRT_XO+;+%W67+KZF,I8!I:JLO>YKJ]0AGYK8PG12^'V2H4_$ZH]]MT]ES(?
M&-<?S>(^(%+OP?8$J^V%$U(GXY2 S'P&A4Z"9[Q S+64CF)8;O>:JKP?3AX2
M,%W,=KQ,'P+D2 9/;0$ORS7*;/UF_M-B/L>-OMR\8BZ^?,%EFM5\_48X5^8]
M^D3:.@)/=7(A][46LV2P2BJN><Q%NKU,W-!OGAPVQTIZ<2JV3XVI.YL\Z^:E
M,+\H(:TOEK/YIW?EYH@?+[Y^/9]=-XJ6)$R*08/!1)YC\+J.!J8C2V,DJIS+
M?0/VI/=T$ '3>$DC(>P40IB^;O#=''^??;E:Z?7@,GT.\T_X9O[?X6L@&2[K
M[VX]Z2#Y=$$H"0E1@RJ&CNHY@\!9L)KNE=3[S7H_AHIIDE$C@>YDXIA>Q6V+
MW58W"[V>B3)6I//KC]S9<KS[O[@:F.^2T5AGI&<6R(6U H+2ENXEF8'@68Q<
M[*D73T?U-"'!:,JT4W%WD*M]MO!8Y9@8#P&*D[[&U1E"?92WLA0NL7A>NMR/
M,%&'TQ$O $U%T0&T#MISS%S03C#((ADZ8G648T! S'5D>V$\M7YJ&JM99;J&
MJ4$X:;&<>H#07GB3P-/+&Q_6($VX[/)I8OK8=+DGLT[<%2"%=,G%6N0M.;FP
MI5"4GA5HY5(HFS;G$RN?TW0%!$Q:L0(82TVA!5(7WM!M]E(&YNGZLM;;/5]^
M5\ 0K SK"A@@C0Z,_!A5P=Y8K]%+BAVSJ+UNY.AGXK*0LG!FD]-,-0;DGZPK
M8 C&3M 5,$3@'6#^;M6RH[@SF!S!2$'>5@FU,U,XH&B422<E!MVZO_H'[PH8
M!(>=70%#9#-U4NKY(G;.C'8RL\J(7%<OTFEXEF!C,2AU3#'N5^[RHKH"!LEP
M6%? $(9VH'>>#?QBR(XG5""S+J",)Z=$10M,,V04EWGARVD\N6&YFHEZ!HZP
M@DU%T0&T=BY1U(:I(CB"0)M (><0BY3 0T$11&0:6Z< 7_ NRT&2'[++<H@8
M.H#4[A6*V4G'K2;+;A5=/N,2!,,,F,(<XT(C#\U7V;_@79;'@*J=(%YX\F[(
MJ(H/B_1Y_/V6!U/4ZX2/I]EVXER>B"5C\!%X#)%BB(@0+/W6U#6',2FC5&N;
MU4,N+W&1Z#8'\ 9K^39J\-YOICZ+G&V0ZJ\)'T=A95 N;X@T^B@XO5M<2?XQ
MBW4MB):6Z#?,0V21092FD,V)VNZ7$!^K)GF:[-D@J3Y7DSR$Q7U Y)'*#*EM
MTN@*D>YKIR3%Z4%:!([&>9L#ZOT6D_\@-<F#9+I73?(0!D^=Q_JPF ?ZXF]X
M4QC&C%5$N\VF:E=BA)*VED2(X+2P3OGGO*G'/GARH1\KIT4CIO40ZXVQ0;5P
MZ9 G,)YB$N4I[HFQIH*E3(FBDVS2C_(*-$W^ZQ [UHO .\#\W2PU<L<"2P*L
M0T;$&_(A752@,9%&*,ZI^XT5?[T"-83#SE>@(;*9WGI2 +WST4)HG8.W%D0I
M=;,T5^"U<& 9YE"R+]'OM];LV:_JZ15HD P7HS&T [VS<V) -L;5+3Y2.TUN
M@XG@B_=URCXR24Y(;OX ]#(G=1QC^UH)H%\L;;U9'IGUW@J01M=MX9*#QX00
M@U*2^!=S:IVC?ZF3.H:(?="DCB$RF-IV[1@K(;PU488"*#<K[CW=O% 5N4Q!
M8,PN\?T6=[_,21V#I+CGI(XA+.U U3S[Q*5-$*&>(G--_EY6@2P\72GK2K'*
M\&S3B<I0?QU4O##-8(1C#%A3470 K4-Z%@(*;D4F5T_45419TV5$%D%9;A//
MTJ Y\?O0"VPT&823!HTF0X3VPM^JG^Z=.,W+])[?WT<[23>OSCYP%9CV="&\
M(%A*"8X5!I+L=/*"QY1^Q%?G8(Q6PBBZ^'0Y%<\:Z@9:R-H(3"ZGT+R8Y^6_
M.@_!RL"]$OM+HP/K/4;ND.?H6"@!G%.FMN$J< (S."70>6:YUS_*V\%4>R4&
M8.P$;P=#!-X!YN_F-J5FT@MOKM9BID21G+?@3$%-KE0JLG76[@=_.Q@$AYUO
M!T-D,W7^Y?E4MY,UC6XEY")JJEMIB-H@J&)CRLP:&_><1?*2W@X&R7#8V\$0
MAG:@=YZ-Z"Q+,CCK09I$<962=&=D\'56?A#DK@C.NYSV,=76B<.M8%-1= "M
MG:T+4B'=BE"@&.+19B)^B#Q#G:D?Z'9&Q>U?'20'27Y(!\D0,;ST_,EBOO@2
M7L\6]8_#5[Q8S]+JS3R]#<OZ7WX[009E7PI.FD,YB"TGSJ)P'RC\)>_-UGER
MRAI#CILCH\V2#S%H=+GU2T /613CF!2%)8AU/95*I<YNS Y*UE9QNOF)[;6L
MYT^511F"E4%9E"'2F+@P^Z>J\7'YM2YS?AN^7!8A>Y8MBX*#U&1)5([D_I8H
M@"L4I.WI0&ZO2_1,3?9CW]VE>3U JHN&+)X8(A_PZ\4R?0XKO+8%]X^T?:IV
M+@E=MS&B-QQ49'2ADJ8S)O(7@E0ZRKURN<_@9F^"IBOS/E[FB[$%,'7&X2EW
MXFJ^@L6D<U+ Z'(!14H!@G01ZB;&''-R>L_]++N_9SJ(C"35Q3@L[B!*'*50
M6,CH0MX,N784A3L+KK;;.&,I8J+_I^8]CW^N1H%#C&8O N\ \W>3D4P+F7B4
M=8IQ+=S)'IPF16"<C49XY7-IG0KYP9/]@^"P,]D_1#:]FMZ=Z6J4S++ZTIQ\
M3'4]@*<[[2AN"@E=+"R8F(XRR"_E26"0I/<QQ\W8/C6N?IN=(\78<_R=?GIS
MOPI7(JHZ&ZO$NE."1W#6([DN/"?.O>9FOT4+#SZZXP:!0VQ> _YU)?TKUQ4M
M8W7LFC72@G+*0C2UPMT[Q[)+B0XS7/Y31G<M!/6DS _@VM12O[7-X/HH5V^G
M*CJA=0+G7*[3]X@GF'C=:2 STM&T-GL)_^GOZ 4#APANT9Z+'7BL'R_B"O]]
M00?YF53B^N:"")63S^1?64T71)0$7G &%+RB%NCICUL/R'Z"E(XK\X^)EEHP
MOD_\7#7"I)*8%1Q*#.2K!R/!>?3UABE5##%*M*XO>)*8:?W1)J)^'CX'\+T_
M %TY[=R&E"."8>2YJV3J> S2HHKEH%W),=C6[X*/$M(=< X1\F[H',#Q#F#S
M;&5%,?5_U:5SC#BDBH.(7-+Q%/EVF"6*+@?D3K/,Z!A+UE044_O'__CZRW(Q
M7V\7X_V^N!7LSS^]KYE^"O$CDTPX<+&^0^N@P6LK(!N'.9M<7+![^<G/?U>7
MSZL'"G8Q'I<[T$?;HZQ^7[Q*_[Z8+?%-?1JBR.#-O.K;69Z%Y6RS[/Q5*;/S
M65CCZDR%XFUD 9*MU5^)9=+BN4".W @;7':Q>8+X #J[?*\X#H4G$UL'T#QH
MSY<M4=25#%'$0CY 8.!35, U"ZB,- KW&O/70<_LJ9.*;8 YMM"ZK?E\B^O+
M 0OO<?GQ,PGBIA?T=5C-4ICGO\W.+]:8'_SD$76>#;ZU36UGZ^,WJN?\.2SG
MA+;5U7==%^5E0> IMF+<,S+37$.PFGZ5K/5.L^BX::PHGJ+EZ$ATR^EWY?XW
M;#G^^GM=QKV8_W0>5JM+OUDQ':PEOSG4 9 ;OSEH$8#NM]1::NM$\S39<#*G
M=2.;8.=!$#NRL#JPVZ_^$Y;Y.EEDBRT:%4+DMD;\EI2[U :28W4+O.!:MBY]
MN4/ Q)F0L<5]O[?B8-YW )P-7\A:U,*++W5C]59,UWO<5Z^_W_S,U@7>G/CF
MV//\_CS,;U6UR6R%U\%!]JHV0)4,43OZ;;;1.IXC,ZUWGXUQCFEA? 2L[NN_
MJ67< <Y_)L]N\1WQXWJ1_O7N:V7 5:FD8CY9B:"C(GO"DP.G2X"08Q:2IVQL
MZ\#Z26(F5IR3XV0QAM Z0-\')#=FELCV;(YR5?\C@O9):O#(,RBK;<T-6-!U
M5INT+D?3OJ'I$4*FS=ETA[KCA=4!XIYP?6X2#CI*F8P*8)RI#XHQ@>>Z0.%<
MELP#_;NUC_@<31/C\,1N8U,)=8"XZQS#KXO5ZLR(R!-I:1!!$O'1RMH#SR +
M9A.STJ)M_:)_AX"^PMCC9+MHQ>B#4?(-EW'1""?_@[-/GXD9K^A#PR=\>U'5
MZ[NRX=/JW<5ZM0[SFJW<I+#./.G5%*('D:0$97*H'G"H[SM>>Q?0B=8V<A"!
MT^JL47$VGJ"ZP"'=H>7&OPCGEWK]\F"OUF3\X\6ZZO??%P\=CUM^R1D6X;&X
M CX(XJX*&B(3")AY](9\#*-E8W >3_6T#R&C(O;$(NW Z#YQ1[=<?7!5S\@Q
M$:9X"\9SNJ6H$T1K/?V#"<.,X,FWGH WD,1I2SBG4*A-A'4X%A=T6T8).2[M
M@B /Q!#!8&1M;7&>@R<.;FZ5LDGS!WN^FL<9^QOJT0JJ1L75\8SO0),]P:&S
M9%@L/%J0/%"(Q;6$& L"BUBD$RIDTWJ([!.D[(4@\T,@Z!#FO\0J@5?S]2S7
ML\Z^X4=,%\O9_4[3FI.ZN"1BG)*!@T@8O7[@>,:,74S@HK R< %:H:"XMW;V
MIJ @%&5L"DRRT+KJ:/QB@D%L?YBHNDQ*"6V31*[!$B= ><8A,*> 9ZZ%3^B1
MA<:<:7N"OG(W!R'NZ1*$DXNX ]M^Y)E??W_\ S8/HTSYHES1D(JLY2"^0 S"
M@@LA>Y43V;W6,?B(Q^FE<N+T*+U?5-$)9+J]/;<>NW3@CB<L8*6L6T\R ^]D
M!J,5XSDG<M2:E_L\0]/$I1.]@&<O4!\HR0Z0^?3[O S2>ALSI+J,2GGIP2%Z
MX,X8[273HGFM8Z=%%6UEOG>!Q! !=("D(V_L312<LP[&*$U>6<(Z4V4SXC^
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M(TMIGCO=2="T>:EN$-A.:!T@\&.E'V>?YG>]H>UAE#7))6, ;<UA%%/'8,<
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MBN:7)?[[ N?I^^4L>R-ML;4:KD@ZDL<"4>0$=<MX4D4%XOI8>'V:K$Z0>%K
M/ 7;1M+K"9"/'6C[+$L<LQEM!E$?317W=?*)4L"2Y<:Z%(QH756V!UF= +(5
M%)Z"6B.Y= JUU?6-O2I1XMEXQQ-DR00H8RT$F31P=#X9'063K>O(]J&K$["U
M L,>8#M*,CVA[?7WZU_^WQDNB:C/WW_%;WB^N:.Y^,"9H?#.9@7**3('*BA(
M+I<BM(BB>8_T?I1-^Z[6G;UM)<.>D'G[MCT\W_9>%RE+#DP"!K(D2I+#[:,1
MD(F346BEG6O],C:(P$XT8T.$[*,<FXBK)RR^F7^]6*\V'./7=>DY\%A7<'O#
MB6E!@G?$PVRB092"C$'K%N\=Y'2"L_8@> IN1TJD4W")JPTM*4DNN"#_!,DL
MU*UM03 .GD67O)3DRHQF=Q^2TXFQG01<ATBD!W ]T6"KBD[":@Z9U6,$8<!C
M#&!+S,FFA%FT[EH^IF-^M)*03CRX!E+J &Q-J]S)\T@Y<P-FTP(>A /GM8*L
M78G$4(ZR=7[OQ^^K'P2H,?OJATBW V3O;M%6@ALM90(5,5>;0.9 . W)1*:#
M$TFKUD\G?Y:^^D$X&=17/T1H1[Q8KT_04Y^T5\GH  X='47;^O@?+=CL5?&6
ME2!:5\3]67KJC\%?.Z%-CK_=K=G<^)0X.=>2U[FGG%D(EK-ZLXPN+!"S_EK^
M>7K\M1-:%S,='F_6EH:YG(4&K+MSE:L>32YTJF"XYM9YQ5LG_G[TCOKC;.ZQ
M0NH#:SM:M(DUC&@ND*VFBQ."J+L"!<28!0O.H[#-$?>GZ*D_"G>-!-8%^G8U
M:;N$7B0A()$#0<J:T54*<9.R9]YE):1LOESI3]%5?PSZ6@ELZJ'P/YV'U>KR
M&I$(WY6;2:6;[('CKBBG.3"?'*C,$KB< GD0C D>2X[QV<+6/;YG6E,Z;4:P
MM1CZ1=3VVMG 0[UZY O4OAW+$((RFS4A"6WRZ*,Z$E-3)N2:RW,_G!S W*F1
M4OL,2"?/TAKS5G5ZF8ROXXX+JQWQ3/AJLQ5P);PSK$Z?\WMAX^%G=XF&0Z2V
M:,?"J1'PX3[QB1A14C(0D*RFLEQ!D$5!BB+7.BI#_MQ>\K__R=,DJ$:6_E'L
MZR#'WL+P_GK=$)6-D<%E#C&70,97D;]OK ,3)<JB?71FM+*,%@>8-J[KY%ET
M,D1T<!U^"JO/=*#ZK[H>X%LXOU/O<--K<N816<[(P1?)0'$=P=<W/NV#4L4C
M"]BZ\'QOXCJI1SH]@.[G)T:19@<PW7M[CU,!B[*"V*7(KDF;((8D0'@1B)58
M@FF=-FNZ9JGK(N(V(!U%EAU@]/YZE5^^O9V=96E"3,J#I#L&2B1>!T8XD.2
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M=[5#965*Q+CURB5)M!'> "]N_0X+Y<R42L ??E 5%.X!SO[0"NG]V0(ZV1I
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MA%\(Q[!R]7EAIS>PO6C"AVAIY5:;?.*V=/T9[F[[6^1G_P=02P,$%     @
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M,S,Q7V-A;"YX;6Q02P$"% ,4    " #9.:165E ^:-1=  !I  0 %0
M        @ $>]@( <F5G;BTR,#(S,#,S,5]D968N>&UL4$L! A0#%     @
MV3FD5G!KT><&L   '"8' !4              ( !)50# ')E9VXM,C R,S S
M,S%?;&%B+GAM;%!+ 0(4 Q0    ( -DYI%;3--P%+'4  /0K!0 5
M      "  5X$! !R96=N+3(P,C,P,S,Q7W!R92YX;6Q02P$"% ,4    " #9
M.:16E6[56E<&   +%P  &P              @ &]>00 <F5G;BUE>%\Q,#%X
M,S,Q,C R,W@Q,'$N:'1M4$L! A0#%     @ V3FD5OUJ4.UY"   H"X  !L
M             ( !38 $ ')E9VXM97A?,S$Q>#,S,3(P,C)X,3!Q+FAT;5!+
M 0(4 Q0    ( -DYI%:/4[W==0@  +@N   ;              "  ?^(! !R
M96=N+65X7S,Q,G@S,S$R,#(R>#$P<2YH=&U02P$"% ,4    " #9.:1622=K
M!@4%  !6&@  &@              @ &MD00 <F5G;BUE>%\S,G@S,S$R,#(R
>>#$P<2YH=&U02P4&      H "@"M @  ZI8$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
